2021-01-17 14:20:05 | INFO | fairseq_cli.generate | {'_name': None, 'common': {'_name': None, 'no_progress_bar': False, 'log_interval': 100, 'log_format': None, 'tensorboard_logdir': None, 'wandb_project': None, 'azureml_logging': False, 'seed': 1, 'cpu': False, 'tpu': False, 'bf16': False, 'memory_efficient_bf16': False, 'fp16': True, 'memory_efficient_fp16': False, 'fp16_no_flatten_grads': False, 'fp16_init_scale': 128, 'fp16_scale_window': None, 'fp16_scale_tolerance': 0.0, 'min_loss_scale': 0.0001, 'threshold_loss_scale': None, 'user_dir': None, 'empty_cache_freq': 0, 'all_gather_list_size': 16384, 'model_parallel_size': 1, 'quantization_config_path': None, 'profile': False, 'reset_logging': True}, 'common_eval': {'_name': None, 'path': './checkpoint_nl_underscore/checkpoint_last.pt', 'post_process': None, 'quiet': False, 'model_overrides': '{}', 'results_path': './out/nl_underscore_en'}, 'distributed_training': {'_name': None, 'distributed_world_size': 1, 'distributed_rank': 0, 'distributed_backend': 'nccl', 'distributed_init_method': None, 'distributed_port': -1, 'device_id': 0, 'distributed_no_spawn': False, 'ddp_backend': 'c10d', 'bucket_cap_mb': 25, 'fix_batches_to_gpus': False, 'find_unused_parameters': False, 'fast_stat_sync': False, 'heartbeat_timeout': -1, 'broadcast_buffers': False, 'distributed_wrapper': 'DDP', 'slowmo_momentum': None, 'slowmo_algorithm': 'LocalSGD', 'localsgd_frequency': 3, 'nprocs_per_node': 1, 'pipeline_model_parallel': False, 'pipeline_balance': None, 'pipeline_devices': None, 'pipeline_chunks': 0, 'pipeline_encoder_balance': None, 'pipeline_encoder_devices': None, 'pipeline_decoder_balance': None, 'pipeline_decoder_devices': None, 'pipeline_checkpoint': 'never', 'zero_sharding': 'none', 'tpu': False}, 'dataset': {'_name': None, 'num_workers': 1, 'skip_invalid_size_inputs_valid_test': False, 'max_tokens': 768, 'batch_size': None, 'required_batch_size_multiple': 8, 'required_seq_len_multiple': 1, 'dataset_impl': None, 'data_buffer_size': 10, 'train_subset': 'train', 'valid_subset': 'valid', 'validate_interval': 1, 'validate_interval_updates': 0, 'validate_after_updates': 0, 'fixed_validation_seed': None, 'disable_validation': False, 'max_tokens_valid': 768, 'batch_size_valid': None, 'curriculum': 0, 'gen_subset': 'test', 'num_shards': 1, 'shard_id': 0}, 'optimization': {'_name': None, 'max_epoch': 0, 'max_update': 0, 'stop_time_hours': 0.0, 'clip_norm': 0.0, 'sentence_avg': False, 'update_freq': [1], 'lr': [0.25], 'stop_min_lr': -1.0, 'use_bmuf': False}, 'checkpoint': {'_name': None, 'save_dir': 'checkpoints', 'restore_file': 'checkpoint_last.pt', 'finetune_from_model': None, 'reset_dataloader': False, 'reset_lr_scheduler': False, 'reset_meters': False, 'reset_optimizer': False, 'optimizer_overrides': '{}', 'save_interval': 1, 'save_interval_updates': 0, 'keep_interval_updates': -1, 'keep_last_epochs': -1, 'keep_best_checkpoints': -1, 'no_save': False, 'no_epoch_checkpoints': False, 'no_last_checkpoints': False, 'no_save_optimizer_state': False, 'best_checkpoint_metric': 'loss', 'maximize_best_checkpoint_metric': False, 'patience': -1, 'checkpoint_suffix': '', 'checkpoint_shard_count': 1, 'load_checkpoint_on_all_dp_ranks': False, 'model_parallel_size': 1, 'distributed_rank': 0}, 'bmuf': {'_name': None, 'block_lr': 1.0, 'block_momentum': 0.875, 'global_sync_iter': 50, 'warmup_iterations': 500, 'use_nbm': False, 'average_sync': False, 'distributed_world_size': 1}, 'generation': {'_name': None, 'beam': 5, 'nbest': 1, 'max_len_a': 0.0, 'max_len_b': 200, 'min_len': 1, 'match_source_len': False, 'unnormalized': False, 'no_early_stop': False, 'no_beamable_mm': False, 'lenpen': 1.0, 'unkpen': 0.0, 'replace_unk': None, 'sacrebleu': False, 'score_reference': False, 'prefix_size': 0, 'no_repeat_ngram_size': 0, 'sampling': False, 'sampling_topk': -1, 'sampling_topp': -1.0, 'constraints': None, 'temperature': 1.0, 'diverse_beam_groups': -1, 'diverse_beam_strength': 0.5, 'diversity_rate': -1.0, 'print_alignment': None, 'print_step': False, 'lm_path': None, 'lm_weight': 0.0, 'iter_decode_eos_penalty': 0.0, 'iter_decode_max_iter': 10, 'iter_decode_force_max_iter': False, 'iter_decode_with_beam': 1, 'iter_decode_with_external_reranker': False, 'retain_iter_history': False, 'retain_dropout': False, 'retain_dropout_modules': None, 'decoding_format': None, 'no_seed_provided': False}, 'eval_lm': {'_name': None, 'output_word_probs': False, 'output_word_stats': False, 'context_window': 0, 'softmax_batch': 9223372036854775807}, 'interactive': {'_name': None, 'buffer_size': 0, 'input': '-'}, 'model': None, 'task': Namespace(_name='translation_from_pretrained_bart', all_gather_list_size=16384, azureml_logging=False, batch_size=None, batch_size_valid=None, beam=5, best_checkpoint_metric='loss', bf16=False, bpe='sentencepiece', broadcast_buffers=False, bucket_cap_mb=25, checkpoint_shard_count=1, checkpoint_suffix='', constraints=None, cpu=False, criterion='cross_entropy', curriculum=0, data='./postprocessed/en_underscore', data_buffer_size=10, dataset_impl=None, ddp_backend='c10d', decoding_format=None, device_id=0, disable_validation=False, distributed_backend='nccl', distributed_init_method=None, distributed_no_spawn=False, distributed_port=-1, distributed_rank=0, distributed_world_size=1, distributed_wrapper='DDP', diverse_beam_groups=-1, diverse_beam_strength=0.5, diversity_rate=-1.0, empty_cache_freq=0, eos=2, eval_bleu=False, eval_bleu_args=None, eval_bleu_detok='space', eval_bleu_detok_args=None, eval_bleu_print_samples=False, eval_bleu_remove_bpe=None, eval_tokenized_bleu=False, fast_stat_sync=False, find_unused_parameters=False, finetune_from_model=None, fix_batches_to_gpus=False, fixed_validation_seed=None, force_anneal=None, fp16=True, fp16_init_scale=128, fp16_no_flatten_grads=False, fp16_scale_tolerance=0.0, fp16_scale_window=None, gen_subset='test', heartbeat_timeout=-1, iter_decode_eos_penalty=0.0, iter_decode_force_max_iter=False, iter_decode_max_iter=10, iter_decode_with_beam=1, iter_decode_with_external_reranker=False, keep_best_checkpoints=-1, keep_interval_updates=-1, keep_last_epochs=-1, langs='ar_AR,cs_CZ,de_DE,en_XX,es_XX,et_EE,fi_FI,fr_XX,gu_IN,hi_IN,it_IT,ja_XX,kk_KZ,ko_KR,lt_LT,lv_LV,my_MM,ne_NP,nl_XX,ro_RO,ru_RU,si_LK,tr_TR,vi_VN,zh_CN', left_pad_source='True', left_pad_target='False', lenpen=1, lm_path=None, lm_weight=0.0, load_alignments=False, load_checkpoint_on_all_dp_ranks=False, localsgd_frequency=3, log_format=None, log_interval=100, lr_scheduler='fixed', lr_shrink=0.1, match_source_len=False, max_len_a=0, max_len_b=200, max_source_positions=1024, max_target_positions=1024, max_tokens=768, max_tokens_valid=768, maximize_best_checkpoint_metric=False, memory_efficient_bf16=False, memory_efficient_fp16=False, min_len=1, min_loss_scale=0.0001, model_overrides='{}', model_parallel_size=1, nbest=1, no_beamable_mm=False, no_early_stop=False, no_epoch_checkpoints=False, no_last_checkpoints=False, no_progress_bar=False, no_repeat_ngram_size=0, no_save=False, no_save_optimizer_state=False, no_seed_provided=False, nprocs_per_node=1, num_batch_buckets=0, num_shards=1, num_workers=1, optimizer=None, optimizer_overrides='{}', pad=1, path='./checkpoint_nl_underscore/checkpoint_last.pt', patience=-1, pipeline_balance=None, pipeline_checkpoint='never', pipeline_chunks=0, pipeline_decoder_balance=None, pipeline_decoder_devices=None, pipeline_devices=None, pipeline_encoder_balance=None, pipeline_encoder_devices=None, pipeline_model_parallel=False, post_process=None, prefix_size=0, prepend_bos=False, print_alignment=None, print_step=False, profile=False, quantization_config_path=None, quiet=False, replace_unk=None, required_batch_size_multiple=8, required_seq_len_multiple=1, reset_dataloader=False, reset_logging=True, reset_lr_scheduler=False, reset_meters=False, reset_optimizer=False, restore_file='checkpoint_last.pt', results_path='./out/nl_underscore_en', retain_dropout=False, retain_dropout_modules=None, retain_iter_history=False, sacrebleu=False, sampling=False, sampling_topk=-1, sampling_topp=-1.0, save_dir='checkpoints', save_interval=1, save_interval_updates=0, score_reference=False, scoring='bleu', seed=1, sentencepiece_model='../models/mbart.cc25/sentence.bpe.model', shard_id=0, skip_invalid_size_inputs_valid_test=False, slowmo_algorithm='LocalSGD', slowmo_momentum=None, source_lang='src', target_lang='label', task='translation_from_pretrained_bart', temperature=1.0, tensorboard_logdir=None, threshold_loss_scale=None, tokenizer=None, tpu=False, train_subset='train', truncate_source=False, unk=3, unkpen=0, unnormalized=False, upsample_primary=1, user_dir=None, valid_subset='valid', validate_after_updates=0, validate_interval=1, validate_interval_updates=0, wandb_project=None, warmup_updates=0, zero_sharding='none'), 'criterion': {'_name': 'cross_entropy', 'sentence_avg': True}, 'optimizer': None, 'lr_scheduler': {'_name': 'fixed', 'force_anneal': None, 'lr_shrink': 0.1, 'warmup_updates': 0, 'lr': [0.25]}, 'scoring': {'_name': 'bleu', 'pad': 1, 'eos': 2, 'unk': 3}, 'bpe': {'_name': 'sentencepiece', 'sentencepiece_model': '../models/mbart.cc25/sentence.bpe.model'}, 'tokenizer': None}
2021-01-17 14:20:06 | INFO | fairseq.tasks.translation | [src] dictionary: 250001 types
2021-01-17 14:20:06 | INFO | fairseq.tasks.translation | [label] dictionary: 250001 types
2021-01-17 14:20:06 | INFO | fairseq_cli.generate | loading model(s) from ./checkpoint_nl_underscore/checkpoint_last.pt
2021-01-17 14:21:23 | INFO | fairseq.data.data_utils | loaded 2,024 examples from: ./postprocessed/en_underscore/test.src-label.src
2021-01-17 14:21:23 | INFO | fairseq.data.data_utils | loaded 2,024 examples from: ./postprocessed/en_underscore/test.src-label.label
2021-01-17 14:21:23 | INFO | fairseq.tasks.translation | ./postprocessed/en_underscore test src-label 2024 examples
S-228	Clinical comparisons were made between the 2 groups.<unk>
T-228	clinical
H-228	-0.5800408720970154	▁Clinic al
D-228	-0.5800408720970154	Clinical
P-228	-1.6145 -0.0149 -0.6284 -0.0624
S-664	We identified 12 556 patients from 45 practices.<unk>
T-664	patients
H-664	-0.6478471159934998	
D-664	-0.6478471159934998	
P-664	-1.1055 -0.1902
S-1528	Of 402 patients, 48 (12%) had EH.<unk>
T-1528	patients
H-1528	-0.15555573999881744	▁EH
D-1528	-0.15555573999881744	EH
P-1528	-0.1591 -0.1407 -0.1669
S-1451	A nested case-control study design was used.<unk>
T-1451	
H-1451	-1.073075532913208	▁neste d _ case - control ▁study
D-1451	-1.073075532913208	nested_case-control study
P-1451	-3.9768 -0.0741 -0.9898 -1.5692 -0.5399 -0.0224 -1.6830 -0.6226 -0.1799
S-133	The basis for these differences requires further examination.<unk>
T-133	
H-133	-0.2949369549751282	
D-133	-0.2949369549751282	
P-133	-0.5272 -0.0627
S-1685	The young woman and her family adamantly refuse.<unk>
T-1685	
H-1685	-1.045123815536499	
D-1685	-1.045123815536499	
P-1685	-1.7683 -0.3220
S-1916	RESULTS: No adverse events occurred.<unk>
T-1916	adverse_events
H-1916	-0.908502459526062	
D-1916	-0.908502459526062	
P-1916	-1.5575 -0.2595
S-1497	SETTING: Single tertiary referral centre.<unk>
T-1497	
H-1497	-0.9240263104438782	▁tertia ry _ ▁refer ral ▁centre
D-1497	-0.9240263104438782	tertiary_ referral centre
P-1497	-3.9551 -0.6509 -1.1468 -0.5447 -0.0495 -0.5352 -0.2996 -0.2105
S-256	This was associated with lower NO production of EC.<unk>
T-256	
H-256	-0.9560773372650146	▁ec
D-256	-0.9560773372650146	ec
P-256	-2.1574 -0.5791 -0.1317
S-307	Recommendations based on a systematic review.<unk>
T-307	
H-307	-0.8083940148353577	
D-307	-0.8083940148353577	
P-307	-1.4981 -0.1187
S-1607	However, the molecular mechanism is still unclear.<unk>
T-1607	
H-1607	-0.1249963641166687	▁molecular ▁mechanism
D-1607	-0.1249963641166687	molecular mechanism
P-1607	-0.1267 -0.1327 -0.0865 -0.1541
S-1496	DXA results were compared with Australian reference data.<unk>
T-1496	dxa
H-1496	-0.7637698650360107	▁d XA
D-1496	-0.7637698650360107	dXA
P-1496	-1.5544 -0.0293 -1.0972 -0.3742
S-18	No correlation to changes in FM was found.<unk>
T-18	correlation
H-18	-0.6383952498435974	▁FM
D-18	-0.6383952498435974	FM
P-18	-1.7265 -0.1198 -0.0689
S-1897	Playing it safe: exercise and cardiovascular health.<unk>
T-1897	exercise cardiovascular health
H-1897	-1.6239739656448364	
D-1897	-1.6239739656448364	
P-1897	-3.0038 -0.2441
S-1699	Results were similar for HF and PNA.<unk>
T-1699	hf pna
H-1699	-0.6799718141555786	▁ HF ▁p NA
D-1699	-0.6799718141555786	HF pNA
P-1699	-1.1157 -0.2017 -1.4798 -1.0454 -0.0993 -0.1380
S-1066	Contemporary use of devices in heart failure.<unk>
T-1066	heart_failure
H-1066	-1.5257227420806885	▁devices ▁heart ▁failure
D-1066	-1.5257227420806885	devices heart failure
P-1066	-3.9753 -3.3052 -0.1319 -0.0859 -0.1304
S-233	Liver disease in the adults was more advanced.<unk>
T-233	liver_disease
H-233	-0.5401443839073181	▁Live r ▁disease
D-233	-0.5401443839073181	Liver disease
P-233	-1.3577 -0.0587 -0.7539 -0.3427 -0.1877
S-1592	Renal artery stenosis - an update.<unk>
T-1592	renal_artery_stenosis
H-1592	-0.145285964012146	▁Ren al ▁arter y ▁sten osis
D-1592	-0.145285964012146	Renal artery stenosis
P-1592	-0.0818 -0.0827 -0.4446 -0.1658 -0.1613 -0.0143 -0.0932 -0.1185
S-190	The primary end point was inhospital mortality.<unk>
T-190	primary_end_point inhospital mortality
H-190	-0.7218465805053711	▁in hospital ▁mortal ity
D-190	-0.7218465805053711	inhospital mortality
P-190	-2.1646 -0.0315 -0.7539 -1.0982 -0.0975 -0.1854
S-1712	DESIGN: Retrospective cohort study.<unk>
T-1712	retrospective_cohort_study
H-1712	-0.5979541540145874	▁Retro spec tive _ co hor t
D-1712	-0.5979541540145874	Retrospective_cohort
P-1712	-2.7216 -0.0110 -0.4294 -0.7637 -0.2986 -0.0302 -0.3108 -0.6694 -0.1470
S-1279	Acute care surgery in heart transplant recipients.<unk>
T-1279	acute_care_surgery heart_transplant
H-1279	-1.0619500875473022	▁heart ▁transplant ▁recipient s
D-1279	-1.0619500875473022	heart transplant recipients
P-1279	-5.3434 -0.2825 -0.1778 -0.3923 -0.1131 -0.0627
S-1788	The reality of heart failure in Latin America.<unk>
T-1788	heart_failure latin_america
H-1788	-1.022894263267517	▁heart ▁failure ▁Latin ▁America
D-1788	-1.022894263267517	heart failure Latin America
P-1788	-4.1391 -0.8007 -0.7520 -0.1932 -0.1126 -0.1398
S-811	DESIGN: Observational cohort study.<unk>
T-811	observational_cohort_study
H-811	-1.062888503074646	
D-811	-1.062888503074646	
P-811	-1.9596 -0.1662
S-1345	Periodic breathing with no heart beat.<unk>
T-1345	periodic_breathing heart_beat
H-1345	-1.1509085893630981	
D-1345	-1.1509085893630981	
P-1345	-2.2128 -0.0891
S-211	DESIGN: Retrospective cohort.<unk>
T-211	retrospective_cohort
H-211	-0.3783070147037506	▁Retro spec tive _ co hor t
D-211	-0.3783070147037506	Retrospective_cohort
P-211	-1.3182 -0.0086 -0.3123 -0.9127 -0.3378 -0.0182 -0.1986 -0.1451 -0.1534
S-241	Two final multivariate models were developed.<unk>
T-241	multivariate_models
H-241	-0.47503551840782166	
D-241	-0.47503551840782166	
P-241	-0.8153 -0.1348
S-346	He developed HF again 4 years later.<unk>
T-346	hf
H-346	-0.4076751172542572	▁ HF
D-346	-0.4076751172542572	HF
P-346	-1.0797 -0.1321 -0.2160 -0.2029
S-589	The 90-day mortality was 28%.<unk>
T-589	mortality
H-589	-0.6563442349433899	▁90- day ▁mortal ity
D-589	-0.6563442349433899	90-day mortality
P-589	-2.1492 -0.2812 -0.8152 -0.4818 -0.0920 -0.1187
S-796	SETTING: Patients' home environment.<unk>
T-796	patients
H-796	-0.8506881594657898	
D-796	-0.8506881594657898	
P-796	-1.5224 -0.1790
S-1944	Similar results were observed after 6 months.<unk>
T-1944	
H-1944	-0.19168934226036072	
D-1944	-0.19168934226036072	
P-1944	-0.3434 -0.0399
S-1982	Of these, 92 participants completed the trial.<unk>
T-1982	
H-1982	-0.6955745220184326	
D-1982	-0.6955745220184326	
P-1982	-1.2185 -0.1726
S-44	Trials were assessed for quality.<unk>
T-44	
H-44	-0.6589421629905701	
D-44	-0.6589421629905701	
P-44	-1.1797 -0.1382
S-1846	We will extract data in duplicate.<unk>
T-1846	
H-1846	-0.9322373867034912	
D-1846	-0.9322373867034912	
P-1846	-1.5379 -0.3266
S-1686	Should the doctors let her die?<unk>
T-1686	doctors
H-1686	-0.4082857668399811	▁doctor s
D-1686	-0.4082857668399811	doctors
P-1686	-1.0372 -0.1585 -0.3506 -0.0869
S-422	Heart rate was minimally altered.<unk>
T-422	heart_rate
H-422	-0.38776257634162903	▁Heart ▁rate
D-422	-0.38776257634162903	Heart rate
P-422	-0.2334 -0.9308 -0.2249 -0.1620
S-1356	Nutrition in heart failure: an update.<unk>
T-1356	heart_failure
H-1356	-1.184141993522644	▁heart ▁failure
D-1356	-1.184141993522644	heart failure
P-1356	-4.2176 -0.2735 -0.1399 -0.1056
S-1620	SETTING: Northwest United States.<unk>
T-1620	united_states
H-1620	-1.078233003616333	▁North west _ ▁United ▁States
D-1620	-1.078233003616333	Northwest_ United States
P-1620	-4.5363 -0.0097 -1.9780 -0.6487 -0.0961 -0.0992 -0.1795
S-1683	She is going into heart failure.<unk>
T-1683	heart_failure
H-1683	-0.8006884455680847	▁heart ▁failure
D-1683	-0.8006884455680847	heart failure
P-1683	-2.7447 -0.1475 -0.1067 -0.2038
S-363	Therefore, the surgery was successful.<unk>
T-363	surgery
H-363	-0.3226228952407837	
D-363	-0.3226228952407837	
P-363	-0.5692 -0.0760
S-795	DESIGN: Cross-sectional.<unk>
T-795	
H-795	-0.9293004274368286	▁Cross - sec tional
D-795	-0.9293004274368286	Cross-sectional
P-795	-3.9150 -0.2338 -0.7694 -0.0883 -0.3813 -0.1880
S-798	INTERVENTIONS: Not applicable.<unk>
T-798	
H-798	-0.529405415058136	▁INTER ven TIONS
D-798	-0.529405415058136	INTERvenTIONS
P-798	-0.5090 -0.7460 -1.0282 -0.2661 -0.0977
S-1595	It is predominantly unilateral.<unk>
T-1595	
H-1595	-0.4241492748260498	▁unilateral
D-1595	-0.4241492748260498	unilateral
P-1595	-0.6122 -0.4113 -0.2489
S-979	Heart failure in the young.<unk>
T-979	heart_failure
H-979	-0.3433239459991455	▁Heart ▁failure
D-979	-0.3433239459991455	Heart failure
P-979	-0.2706 -0.5487 -0.3975 -0.1565
S-1249	5, 43-47].<unk>
T-1249	
H-1249	-0.23601080477237701	
D-1249	-0.23601080477237701	
P-1249	-0.3559 -0.1162
S-1687	Is there any alternative?<unk>
T-1687	
H-1687	-0.29823872447013855	
D-1687	-0.29823872447013855	
P-1687	-0.5416 -0.0549
S-1246	(2012) Clin.<unk>
T-1246	
H-1246	-0.2911933362483978	▁c lin
D-1246	-0.2911933362483978	clin
P-1246	-0.6739 -0.0979 -0.3082 -0.0848
S-1247	Trans.<unk>
T-1247	
H-1247	-0.5547968745231628	▁trans
D-1247	-0.5547968745231628	trans
P-1247	-0.6912 -0.8643 -0.1090
S-1248	Sci.<unk>
T-1248	
H-1248	-0.461818128824234	▁Sci
D-1248	-0.461818128824234	Sci
P-1248	-0.4917 -0.6699 -0.2238
S-1763	Similar results were obtained for the secondary study end point.<unk>
T-1763	end_point
H-1763	-0.3615332245826721	
D-1763	-0.3615332245826721	
P-1763	-0.6475 -0.0755
S-1005	Intermediate frailty was defined as 1 to 2.<unk>
T-1005	frailty
H-1005	-0.37214210629463196	▁Inter media te _ fra il ty
D-1005	-0.37214210629463196	Intermediate_frailty
P-1005	-0.9441 -0.1650 -0.1491 -0.7783 -0.6209 -0.2442 -0.1457 -0.1555 -0.1465
S-1963	Further large-scale randomised studies are warranted.<unk>
T-1963	randomised
H-1963	-0.7341672778129578	
D-1963	-0.7341672778129578	
P-1963	-1.2871 -0.1813
S-222	These decreases are most likely due to better CHF treatments.<unk>
T-222	chf
H-222	-0.5457674860954285	▁CHF
D-222	-0.5457674860954285	CHF
P-222	-0.2729 -1.2597 -0.1047
S-205	We read the article by Dodson et al with interest.<unk>
T-205	dodson
H-205	-0.43293309211730957	▁do d son
D-205	-0.43293309211730957	dodson
P-205	-0.9354 -0.0727 -0.0161 -1.0470 -0.0934
S-392	A total of 8204 patients were included in the analyses.<unk>
T-392	patients
H-392	-0.5361229181289673	
D-392	-0.5361229181289673	
P-392	-0.9453 -0.1269
S-575	This exercise modality is a promising alternative for this population.<unk>
T-575	exercise
H-575	-0.6485360264778137	
D-575	-0.6485360264778137	
P-575	-1.2184 -0.0786
S-126	RESULTS: The mean age was 55 ± 15 years.<unk>
T-126	
H-126	-0.5200759768486023	
D-126	-0.5200759768486023	
P-126	-0.8687 -0.1715
S-1101	We evaluated temporal trends in HF after MI.<unk>
T-1101	hf mi
H-1101	-1.0235769748687744	▁ HF
D-1101	-1.0235769748687744	HF
P-1101	-2.4178 -0.2277 -1.0148 -0.4340
S-673	The rates and risk factors associated with CHF were evaluated.<unk>
T-673	chf
H-673	-0.6685029864311218	▁CHF
D-673	-0.6685029864311218	CHF
P-673	-1.4618 -0.3352 -0.2085
S-1886	Heart failure affects nearly one million people in the UK.<unk>
T-1886	heart_failure
H-1886	-1.3851351737976074	▁Heart ▁failure
D-1886	-1.3851351737976074	Heart failure
P-1886	-2.2260 -1.0576 -1.8769 -0.3801
S-825	Patients were followed up for 3.0 ± 1.8 years.<unk>
T-825	patients followed_up
H-825	-0.5937271118164062	
D-825	-0.5937271118164062	
P-825	-1.0726 -0.1149
S-1805	Assessing the link between air pollution and heart failure.<unk>
T-1805	air heart_failure
H-1805	-0.544898271560669	▁air ▁pollution ▁heart ▁failure
D-1805	-0.544898271560669	air pollution heart failure
P-1805	-0.2514 -1.3932 -1.2966 -0.0902 -0.0818 -0.1560
S-1296	The extracorporeal support was needed for three days.<unk>
T-1296	extracorporeal_support
H-1296	-0.25457730889320374	▁extra corp o real
D-1296	-0.25457730889320374	extracorporeal
P-1296	-0.1143 -0.0075 -0.2060 -0.0069 -1.0460 -0.1468
S-247	This function is impaired in patients with cardiovascular disease.<unk>
T-247	patients cardiovascular_disease
H-247	-0.6907975673675537	▁cardiovascular ▁disease
D-247	-0.6907975673675537	cardiovascular disease
P-247	-1.8580 -0.6964 -0.0899 -0.1188
S-1073	Heart failure: a disease complex with challenging therapeutics.<unk>
T-1073	heart_failure disease therapeutics
H-1073	-0.6472736597061157	▁Heart ▁failure
D-1073	-0.6472736597061157	Heart failure
P-1073	-0.5246 -0.3688 -1.5782 -0.1175
S-1116	Secondary outcomes included markers of hemostasis.<unk>
T-1116	secondary_outcomes hemostasis
H-1116	-1.153043508529663	▁hemos tas is
D-1116	-1.153043508529663	hemostasis
P-1116	-4.9766 -0.2279 -0.2291 -0.1608 -0.1708
S-53	Remote ischemic conditioning for patients with heart failure?<unk>
T-53	remote_ischemic_conditioning patients heart_failure
H-53	-1.03559410572052	▁ ische mic _ ▁condition ing ▁patients ▁heart ▁failure
D-53	-1.03559410572052	ischemic_ conditioning patients heart failure
P-53	-1.9773 -0.0784 -0.4950 -0.9953 -0.9588 -0.0611 -3.2953 -3.1318 -0.1882 -0.0976 -0.1126
S-1584	Heart rate variability in risk stratification of cardiac patients.<unk>
T-1584	heart_rate_variability risk_stratification cardiac patients
H-1584	-1.3683890104293823	▁Heart ▁rate _ ▁variabil ity
D-1584	-1.3683890104293823	Heart rate_ variability
P-1584	-0.3996 -1.0086 -2.8278 -0.8446 -1.0392 -2.9666 -0.4924
S-1619	DESIGN: Retrospective matched cohort study.<unk>
T-1619	retrospective_matched_cohort_study
H-1619	-0.7999548316001892	
D-1619	-0.7999548316001892	
P-1619	-1.5093 -0.0906
S-1754	We evaluated whether this finding has a prognostic meaning.<unk>
T-1754	prognostic
H-1754	-0.7793202996253967	
D-1754	-0.7793202996253967	
P-1754	-1.3354 -0.2232
S-749	Compliance with treatment had a more remarkable role.<unk>
T-749	compliance
H-749	-1.100337028503418	
D-749	-1.100337028503418	
P-749	-2.1359 -0.0648
S-312	We made policy recommendations on the basis of our systematic review.<unk>
T-312	policy
H-312	-0.7608888149261475	
D-312	-0.7608888149261475	
P-312	-1.4311 -0.0907
S-311	Data were, however, limited to 2-3 studies per outcome.<unk>
T-311	outcome
H-311	-0.24789443612098694	
D-311	-0.24789443612098694	
P-311	-0.4231 -0.0727
S-885	A total of 1483 patients were included in this study.<unk>
T-885	patients
H-885	-0.47308820486068726	
D-885	-0.47308820486068726	
P-885	-0.8406 -0.1055
S-1339	Sham-operated animals were used as a control group.<unk>
T-1339	
H-1339	-0.938090980052948	▁Sham - opera ted _ animal
D-1339	-0.938090980052948	Sham-operated_animal
P-1339	-0.8651 -0.1361 -0.0065 -0.8346 -1.5686 -1.8938 -1.5867 -0.6133
S-1399	A retrospective descriptive research design was used.<unk>
T-1399	
H-1399	-0.6090667247772217	▁retro spec tive ▁de script ive _ onderzoek
D-1399	-0.6090667247772217	retrospective descriptive_onderzoek
P-1399	-1.3211 -0.0246 -0.1645 -0.6885 -0.0404 -0.0595 -0.3798 -2.0172 -1.2598 -0.1352
S-1125	These reasons were classified using a published taxonomy.<unk>
T-1125	
H-1125	-1.38340425491333	▁tax ono my
D-1125	-1.38340425491333	taxonomy
P-1125	-6.0693 -0.0392 -0.5296 -0.1539 -0.1250
S-364	However, this patient developed HF 4 years later.<unk>
T-364	patient hf
H-364	-0.6506110429763794	▁ HF
D-364	-0.6506110429763794	HF
P-364	-2.0185 -0.1218 -0.1828 -0.2793
S-1900	The benefits of exercise extend well beyond the cardiovascular system.<unk>
T-1900	exercise cardiovascular
H-1900	-0.9776272177696228	▁benefits ▁cardiovascular ▁system
D-1900	-0.9776272177696228	benefits cardiovascular system
P-1900	-2.7512 -1.1595 -0.7674 -0.1290 -0.0810
S-1037	Now, reporting in Cell, Anand et al.<unk>
T-1037	reporting cell anand
H-1037	-0.26167890429496765	▁Cell ▁Anand
D-1037	-0.26167890429496765	Cell Anand
P-1037	-0.6205 -0.1023 -0.1719 -0.1520
S-1988	There were no study-related serious adverse events.<unk>
T-1988	adverse_events
H-1988	-0.7344013452529907	
D-1988	-0.7344013452529907	
P-1988	-1.3660 -0.1028
S-949	No major complications occurred during follow-up.<unk>
T-949	complications follow-up
H-949	-0.45708322525024414	
D-949	-0.45708322525024414	
P-949	-0.8527 -0.0615
S-957	Doxorubicin was injected i.p.<unk>
T-957	doxorubicin injected
H-957	-0.40432459115982056	▁do xor ubi cin ▁inject ed
D-957	-0.40432459115982056	doxorubicin injected
P-957	-0.9235 -0.0071 -0.0189 -0.1863 -0.8753 -0.3833 -0.5708 -0.2695
S-1684	Her doctors urgently recommend blood transfusions.<unk>
T-1684	doctors blood_transfusions
H-1684	-2.440695285797119	▁डॉक्टर ▁ब्लड ▁trans fusion
D-1684	-2.440695285797119	डॉक्टर ब्लड transfusion
P-1684	-3.8046 -6.0940 -0.3281 -0.0249 -3.8264 -0.5661
S-1534	Heart failure in patients treated with bisphosphonates.<unk>
T-1534	heart_failure patients bisphosphonates
H-1534	-0.6451674103736877	▁Heart ▁failure ▁bis phos phon ates
D-1534	-0.6451674103736877	Heart failure bisphosphonates
P-1534	-0.8746 -2.5716 -0.8031 -0.0143 -0.1053 -0.2805 -0.3887 -0.1233
S-1198	Diuretic use in heart failure and outcomes.<unk>
T-1198	diuretic heart_failure outcomes
H-1198	-1.045009970664978	▁di ure tic
D-1198	-1.045009970664978	diuretic
P-1198	-1.1857 -0.1477 -0.5890 -3.0791 -0.2236
S-169	Caspase-3 gene expression increased in heart failure.<unk>
T-169	caspase-3 gene_expression heart_failure
H-169	-1.596801996231079	▁Cas pas e
D-169	-1.596801996231079	Caspase
P-169	-1.9601 -0.0020 -0.3264 -5.3569 -0.3387
S-712	Two Cox proportional hazards models were developed.<unk>
T-712	cox_proportional_hazards_models
H-712	-0.6456171274185181	▁co x ▁proportion al _ ▁hazard s
D-712	-0.6456171274185181	cox proportional_ hazards
P-712	-0.4018 -0.0120 -0.3654 -0.0446 -0.2156 -2.4287 -0.6637 -1.4106 -0.2683
S-1090	Acute right heart failure in pulmonary hypertension.<unk>
T-1090	acute_right_heart_failure pulmonary_hypertension
H-1090	-0.6616538166999817	▁right _ heart ▁failure ▁pulmonar y ▁hyper tension
D-1090	-0.6616538166999817	right_heart failure pulmonary hypertension
P-1090	-3.7720 -0.8071 -1.3711 -0.2067 -0.0011 -0.0113 -0.2834 -0.0248 -0.0673 -0.0717
S-1843	We will use American, Canadian and European HF guidelines as our reference.<unk>
T-1843	american hf
H-1843	-1.0419199466705322	▁ europe se _ HF
D-1843	-1.0419199466705322	europese_HF
P-1843	-1.5907 -2.8995 -0.2982 -0.2689 -1.5594 -0.5525 -0.1242
S-1889	Patients are likely to be older women with a history of hypertension.<unk>
T-1889	patients hypertension
H-1889	-1.3149802684783936	▁hyper tension
D-1889	-1.3149802684783936	hypertension
P-1889	-4.8092 -0.1534 -0.1376 -0.1598
S-1616	Besides, these genes can be targets to develop treatments.<unk>
T-1616	genes
H-1616	-0.6500621438026428	
D-1616	-0.6500621438026428	
P-1616	-1.2035 -0.0966
S-32	Literature was reassessed in April 2013, and additional studies were included.<unk>
T-32	
H-32	-0.3569846749305725	▁Literatur e
D-32	-0.3569846749305725	Literature
P-32	-0.8605 -0.1553 -0.2513 -0.1609
S-786	Internal reliability was assessed with Cronbach's α.<unk>
T-786	
H-786	-0.9874014258384705	▁Cro n bach
D-786	-0.9874014258384705	Cronbach
P-786	-3.0295 -0.0503 -0.0306 -1.6424 -0.1842
S-804	The third trial added little or no information to the first 2 trials.<unk>
T-804	
H-804	-0.6275127530097961	
D-804	-0.6275127530097961	
P-804	-1.1283 -0.1267
S-0	National trends in patient safety for four common conditions, 2005-2011.<unk>
T-0	patient conditions
H-0	-1.4923962354660034	▁patient ▁safety
D-0	-1.4923962354660034	patient safety
P-0	-3.0187 -2.0923 -0.4799 -0.3786
S-1759	AT was identified in 1935 out of 2137 patients (90.54%).<unk>
T-1759	patients
H-1759	-0.6406993269920349	▁AT
D-1759	-0.6406993269920349	AT
P-1759	-1.2459 -0.4171 -0.2591
S-156	No trial of implanted monitoring devices met the inclusion criteria.<unk>
T-156	implanted
H-156	-0.8033968806266785	▁implant ed ▁monitoring ▁devices
D-156	-0.8033968806266785	implanted monitoring devices
P-156	-1.5691 -0.1835 -2.1541 -0.7099 -0.1224 -0.0815
S-1469	Few treatments have been investigated in clinical trials.<unk>
T-1469	clinical
H-1469	-0.7714247107505798	
D-1469	-0.7714247107505798	
P-1469	-1.5042 -0.0387
S-518	HR modulates Ea, and, therefore, afterload burden.<unk>
T-518	ea afterload
H-518	-2.3179032802581787	▁HR
D-518	-2.3179032802581787	HR
P-518	-4.3804 -2.1602 -0.4131
S-778	There were no periprocedural deaths or strokes.<unk>
T-778	deaths strokes
H-778	-0.47771158814430237	▁per i pro ced ural
D-778	-0.47771158814430237	periprocedural
P-778	-0.4992 -0.1790 -0.0605 -0.0172 -0.0178 -2.5106 -0.0598
S-1594	The most common cause of RAS is atherosclerosis.<unk>
T-1594	ras atherosclerosis
H-1594	-0.923784077167511	▁ RAS ▁at hero sc ler osis
D-1594	-0.923784077167511	RAS atherosclerosis
P-1594	-1.2424 -0.0193 -3.7386 -0.4087 -0.0431 -2.5620 -0.0286 -0.0949 -0.1765
S-1000	Measuring frailty in heart failure: a community perspective.<unk>
T-1000	frailty heart_failure
H-1000	-0.8763430714607239	▁fra il ty ▁heart ▁failure ▁community
D-1000	-0.8763430714607239	frailty heart failure community
P-1000	-2.1013 -0.8454 -0.0813 -1.9487 -0.1642 -1.1877 -0.5154 -0.1667
S-1932	PSSS did not impact the effect of exercise training on outcomes.<unk>
T-1932	psss exercise training outcomes
H-1932	-0.6266589164733887	▁PS SS
D-1932	-0.6266589164733887	PSSS
P-1932	-1.1311 -0.0797 -1.0949 -0.2009
S-1479	MicroRNAs in heart failure: new targets in disease management.<unk>
T-1479	micrornas heart_failure disease
H-1479	-0.4296877980232239	▁micro RNA s ▁heart ▁failure ▁disease ▁management
D-1479	-0.4296877980232239	microRNAs heart failure disease management
P-1479	-0.3004 -0.0025 -0.1641 -1.3846 -0.5824 -0.8762 -0.2673 -0.1440 -0.1457
S-612	Using exercise to improve quality of life for people with heart failure.<unk>
T-612	exercise quality_of_life heart_failure
H-612	-2.0980794429779053	
D-612	-2.0980794429779053	
P-612	-4.0429 -0.1532
S-1770	Hazard ratios were computed with Cox regression analysis.<unk>
T-1770	hazard_ratios cox_regression_analysis
H-1770	-0.6256344318389893	▁co x ▁re gression
D-1770	-0.6256344318389893	cox regression
P-1770	-1.1804 -0.0244 -0.5495 -0.0895 -1.5834 -0.3266
S-1033	Cardiology: Bromodomain inhibition halts heart failure.<unk>
T-1033	cardiology bromodomain halts heart_failure
H-1033	-0.6958839893341064	▁Card i ology ▁bro modo main ▁inhibi tion ▁halt s ▁heart ▁failure
D-1033	-0.6958839893341064	Cardiology bromodomain inhibition halts heart failure
P-1033	-0.7758 -0.2004 -0.1469 -2.6997 -0.0018 -0.0980 -0.8888 -0.1860 -3.5579 -0.2422 -0.5354 -0.2228 -0.1253 -0.0613
S-1885	Management of heart failure with preserved ejection fraction.<unk>
T-1885	heart_failure_with_preserved_ejection_fraction
H-1885	-0.7301246523857117	▁heart ▁failure ▁pres er ved ▁e je ction ▁ fraction
D-1885	-0.7301246523857117	heart failure preserved ejection fraction
P-1885	-3.1607 -0.3724 -1.9903 -0.0631 -0.4579 -1.1174 -0.0330 -0.0209 -1.3251 -0.0005 -0.0959 -0.1243
S-677	Median age of the entire cohort was 71 years old.<unk>
T-677	
H-677	-1.0046370029449463	▁media n _ âge
D-677	-1.0046370029449463	median_âge
P-677	-1.3822 -0.1290 -1.0774 -2.3232 -0.9498 -0.1663
S-1688	Composite quality measures for common inpatient medical conditions.<unk>
T-1688	inpatient medical conditions
H-1688	-1.186797022819519	
D-1688	-1.186797022819519	
P-1688	-2.1906 -0.1830
S-1679	A young adult Jehovah's Witness with severe anemia.<unk>
T-1679	witness anemia
H-1679	-1.1360445022583008	▁Jehovah ' s ▁Wit ness
D-1679	-1.1360445022583008	Jehovah's Witness
P-1679	-0.6607 -2.4713 -0.3275 -0.3413 -2.1401 -1.8273 -0.1841
S-812	SETTING: Department of cardiology in a university hospital.<unk>
T-812	cardiology hospital
H-812	-0.9933629035949707	▁card i ology
D-812	-0.9933629035949707	cardiology
P-812	-1.5557 -0.7933 -0.1321 -2.3927 -0.0931
S-1078	However, treatment of HFpEF still poses significant challenges.<unk>
T-1078	hfpef
H-1078	-0.21951009333133698	▁ HF p EF
D-1078	-0.21951009333133698	HFpEF
P-1078	-0.8307 -0.0907 -0.0446 -0.1206 -0.1620 -0.0685
S-1309	Concurrent HF comprised 75% of incident HF cases.<unk>
T-1309	hf hf
H-1309	-0.522518515586853	▁ HF
D-1309	-0.522518515586853	HF
P-1309	-0.9137 -0.2878 -0.7288 -0.1597
S-1375	We examined several markers indicative of autonomic balance.<unk>
T-1375	autonomic_balance
H-1375	-0.822127103805542	▁autonomi c _ ▁balance
D-1375	-0.822127103805542	autonomic_ balance
P-1375	-1.8768 -0.0666 -1.6647 -0.8579 -0.1584 -0.3083
S-624	Impact of frailty on HF risk is not known.<unk>
T-624	frailty hf
H-624	-0.5752367377281189	▁fra il ty ▁ HF
D-624	-0.5752367377281189	frailty HF
P-624	-1.7251 -0.7383 -0.1338 -0.7032 -0.0403 -0.5245 -0.1615
S-1960	No patient was admitted to hospital for worsening heart failure.<unk>
T-1960	patient hospital heart_failure
H-1960	-1.366180419921875	
D-1960	-1.366180419921875	
P-1960	-2.5070 -0.2253
S-702	ST2 was modestly associated with measures of functional capacity.<unk>
T-702	st2 functional_capacity
H-702	-1.2304408550262451	
D-702	-1.2304408550262451	
P-702	-2.3211 -0.1398
S-204	Heart failure and cognitive impairment: relationships with mortality.<unk>
T-204	heart_failure mortality
H-204	-0.39962607622146606	▁Heart ▁failure ▁cognitive ▁im pair ment ▁mortal ity
D-204	-0.39962607622146606	Heart failure cognitive impairment mortality
P-204	-0.3812 -0.5241 -0.4771 -1.3875 -0.0053 -0.1193 -0.6407 -0.3075 -0.0513 -0.1023
S-280	Severe LV fibrosis was found in ANS mice.<unk>
T-280	lv_fibrosis
H-280	-0.4498382806777954	▁LV ▁fibro sis
D-280	-0.4498382806777954	LV fibrosis
P-280	-0.1902 -0.2840 -0.1047 -1.5399 -0.1305
S-495	The median follow-up duration was 20.8 mo.<unk>
T-495	follow-up_duration
H-495	-0.36587050557136536	▁media n ▁follow - up
D-495	-0.36587050557136536	median follow-up
P-495	-0.1682 -0.2253 -1.1097 -0.1610 -0.0153 -0.7133 -0.1682
S-511	Dynamic and competitive collateral growth patterns were observed.<unk>
T-511	collateral_growth
H-511	-1.3404184579849243	▁competitive _ col lateral
D-511	-1.3404184579849243	competitive_collateral
P-511	-2.9023 -1.8431 -1.0546 -0.0092 -2.0828 -0.1505
S-325	Indices were correlated against CO with mixed linear models.<unk>
T-325	correlated mixed_linear_models
H-325	-0.7798268795013428	▁CO ▁mix ed _ ▁linear ▁models
D-325	-0.7798268795013428	CO mixed_ linear models
P-325	-1.3700 -2.5041 -0.0453 -1.1818 -0.0756 -0.6688 -0.1809 -0.2120
S-410	Similar results were found for heart failure hospitalization and cardiovascular death.<unk>
T-410	heart_failure hospitalization cardiovascular_death
H-410	-0.8386357426643372	▁heart ▁failure ▁hospital ization ▁cardiovascular ▁death
D-410	-0.8386357426643372	heart failure hospitalization cardiovascular death
P-410	-1.6750 -0.3302 -2.1886 -0.9093 -0.0197 -1.4333 -0.0589 -0.0941
S-1654	Key secondary outcomes include cognitive function and quality of life.<unk>
T-1654	secondary_outcomes quality_of_life
H-1654	-0.8884024024009705	▁cognitive ▁function
D-1654	-0.8884024024009705	cognitive function
P-1654	-0.4595 -1.3997 -1.4617 -0.2327
S-633	The role of vasopressin in congestive heart failure.<unk>
T-633	vasopressin congestive_heart_failure
H-633	-0.4037443995475769	▁vaso press in ▁con ges tive _ heart ▁failure
D-633	-0.4037443995475769	vasopressin congestive_heart failure
P-633	-0.0649 -0.1898 -0.3456 -0.1684 -0.0690 -1.3364 -0.2038 -1.6884 -0.1884 -0.0954 -0.0911
S-707	Ten-year experience with extended criteria cardiac transplantation.<unk>
T-707	extended_criteria_cardiac_transplantation
H-707	-0.777998149394989	▁cardiac ▁transplant ation
D-707	-0.777998149394989	cardiac transplantation
P-707	-2.1573 -1.3192 -0.1371 -0.1821 -0.0942
S-332	Mitral stenosis reversed by medical treatment for heart failure.<unk>
T-332	mitral_stenosis medical_treatment heart_failure
H-332	-1.2515591382980347	▁mit ral ▁sten osis
D-332	-1.2515591382980347	mitral stenosis
P-332	-1.8413 -0.0363 -2.1496 -0.0444 -3.2646 -0.1733
S-1211	However, the role of PDE2 in HF is poorly understood.<unk>
T-1211	pde2 hf
H-1211	-0.30950334668159485	▁p de 2 ▁ HF
D-1211	-0.30950334668159485	pde2 HF
P-1211	-1.0391 -0.4230 -0.0271 -0.4659 -0.0226 -0.0458 -0.1430
S-958	over 2 weeks to obtain a cumulative dose of 18 mg/kg.<unk>
T-958	
H-958	-1.1278098821640015	
D-958	-1.1278098821640015	
P-958	-2.1698 -0.0858
S-1837	Results from the 1:1 propensity score-matched analyses were similar.<unk>
T-1837	
H-1837	-0.5899568796157837	▁pro pens ity
D-1837	-0.5899568796157837	propensity
P-1837	-0.7456 -0.0076 -0.5415 -1.5397 -0.1154
S-1998	RESULTS: Fifty patients were enrolled at 10 centers.<unk>
T-1998	patients
H-1998	-0.7797626256942749	
D-1998	-0.7797626256942749	
P-1998	-1.4297 -0.1298
S-1634	RESULTS: There were 749 self-identified black patients (33%).<unk>
T-1634	patients
H-1634	-1.577741265296936	▁black
D-1634	-1.577741265296936	black
P-1634	-1.7794 -2.5735 -0.3804
S-1261	RESULTS: Twenty-seven studies with 1887 patients were included.<unk>
T-1261	patients
H-1261	-0.4460375905036926	
D-1261	-0.4460375905036926	
P-1261	-0.7744 -0.1177
S-134	Implications of metric choice for common applications of readmission metrics.<unk>
T-134	readmission
H-134	-0.8060768842697144	▁ metric _ ▁choice ▁read mission _ ▁metri cs
D-134	-0.8060768842697144	metric_ choice readmission_ metrics
P-134	-0.3866 -0.0171 -1.1588 -1.0266 -0.6249 -3.3384 -1.2302 -0.8137 -0.0510 -0.0963 -0.1233
S-261	This may be one mechanism how ET exerts beneficial effects in CHF.<unk>
T-261	chf
H-261	-2.1779069900512695	
D-261	-2.1779069900512695	
P-261	-4.1609 -0.1949
S-145	Careful consideration should be placed on readmission metric choice for these applications.<unk>
T-145	readmission
H-145	-1.1400270462036133	▁read mission ▁ metric
D-145	-1.1400270462036133	readmission metric
P-145	-1.7965 -2.7377 -0.9097 -0.0083 -1.2746 -0.1135
S-1726	We examined physician volume within strata of hospital volume and physician specialty.<unk>
T-1726	physician hospital physician
H-1726	-1.4412480592727661	▁physician ▁volume
D-1726	-1.4412480592727661	physician volume
P-1726	-1.7224 -0.6092 -2.9403 -0.4930
S-1839	LIMITATION: Residual confounding and short follow-up.<unk>
T-1839	follow-up
H-1839	-0.971676766872406	▁li MIT ATION ▁Res idu al ▁con found ing
D-1839	-0.971676766872406	liMITATION Residual confounding
P-1839	-3.2102 -0.8965 -1.2605 -2.3527 -0.0853 -0.0548 -0.8546 -0.0164 -0.0214 -1.8540 -0.0820
S-1758	Median follow-up was 3.01 (1.39-4.98) years.<unk>
T-1758	follow-up
H-1758	-0.39989015460014343	▁media n ▁follow - up
D-1758	-0.39989015460014343	median follow-up
P-1758	-1.1065 -0.1716 -0.8505 -0.2144 -0.0069 -0.2862 -0.1631
S-1238	Arrhythmia-related costs accounted for 45% of total expenditures.<unk>
T-1238	costs expenditures
H-1238	-1.0849659442901611	▁ar rhythm ia - related
D-1238	-1.0849659442901611	arrhythmia-related
P-1238	-1.6156 -0.2791 -0.9743 -0.1652 -0.3231 -3.9965 -0.2410
S-403	Medication regimen and sST2 values were obtained during 10 months.<unk>
T-403	medication sst2
H-403	-0.4515061378479004	▁Medica tion ▁regime n ▁s ST 2
D-403	-0.4515061378479004	Medication regimen sST2
P-403	-0.5009 -0.1816 -0.9823 -0.4983 -0.0147 -0.5675 -0.1035 -0.9372 -0.2777
S-481	The objective of this study was to test its reliability in stable HF.<unk>
T-481	stable_hf
H-481	-0.830403745174408	▁ HF
D-481	-0.830403745174408	HF
P-481	-2.3695 -0.6582 -0.1864 -0.1075
S-159	No beneficial effect on mortality was observed with STS HM.<unk>
T-159	mortality sts
H-159	-1.005053162574768	▁s ts ▁ HM
D-159	-1.005053162574768	sts HM
P-159	-3.4900 -0.8174 -1.2195 -0.0533 -0.1239 -0.3262
S-150	STUDY DESIGN: Systematic review and network meta-analysis.<unk>
T-150	meta-analysis
H-150	-1.2548803091049194	▁system a tic _ review ▁network ▁meta - analyse
D-150	-1.2548803091049194	systematic_review network meta-analyse
P-150	-5.0671 -0.1892 -0.7626 -0.4013 -0.5459 -1.6228 -0.2400 -0.1447 -3.3556 -1.2930 -0.1817
S-598	Surgical tactics included a brief hypothermic circulatory arrest.<unk>
T-598	surgical hypothermic_circulatory_arrest
H-598	-0.829047441482544	▁Sur g ical _ ▁tac tics ▁circula tory _ ▁arrest
D-598	-0.829047441482544	Surgical_ tactics circulatory_ arrest
P-598	-3.1568 -0.3671 -0.5500 -1.1759 -0.1201 -0.3508 -2.0354 -0.4707 -1.3040 -0.1125 -0.1466 -0.1585
S-616	Primary outcomes were improvements in functional capacity and quality of life.<unk>
T-616	primary_outcomes functional_capacity quality_of_life
H-616	-1.1257092952728271	▁functional ▁capacity ▁quality
D-616	-1.1257092952728271	functional capacity quality
P-616	-0.8326 -2.1292 -1.6916 -0.8626 -0.1125
S-64	We meta-analyzed mortality using random-effects models.<unk>
T-64	meta-analyzed mortality random-effects_models
H-64	-0.8373627662658691	▁mortal ity ▁random - effect s ▁models
D-64	-0.8373627662658691	mortality random-effects models
P-64	-2.5670 -1.3521 -1.8297 -0.1243 -0.0008 -0.0875 -1.2162 -0.1260 -0.2327
S-194	Ejection fraction and sex were independently associated with BNP.<unk>
T-194	ejection_fraction bnp
H-194	-0.7248973846435547	▁e je ction ▁ fraction ▁sex
D-194	-0.7248973846435547	ejection fraction sex
P-194	-1.4169 -0.0331 -0.0024 -0.6778 -0.0045 -1.2479 -2.2554 -0.1612
S-1009	Over a mean follow-up of 2.4 years, 63 patients died.<unk>
T-1009	follow-up patients
H-1009	-0.4373704195022583	
D-1009	-0.4373704195022583	
P-1009	-0.7969 -0.0779
S-1796	Chronic HF is the cause of death in 6.3% of cases.<unk>
T-1796	chronic_hf death
H-1796	-0.25579383969306946	▁Chro nic _ HF
D-1796	-0.25579383969306946	Chronic_HF
P-1796	-0.0479 -0.0173 -0.6367 -0.2713 -0.4083 -0.1533
S-352	The etiology of the MR and MS was diagnosed as functional.<unk>
T-352	etiology diagnosed
H-352	-0.48526397347450256	▁MR ▁MS
D-352	-0.48526397347450256	MR MS
P-352	-0.6100 -1.0860 -0.1619 -0.0831
S-787	Among 849 patients, 200 (24%) had HFpEF.<unk>
T-787	patients hfpef
H-787	-0.34936606884002686	▁ HF p EF
D-787	-0.34936606884002686	HFpEF
P-787	-1.3023 -0.2672 -0.0899 -0.0999 -0.1256 -0.2113
S-997	Cardiac amyloidosis, about an atypical case.<unk>
T-997	cardiac_amyloidosis
H-997	-0.15448935329914093	▁Card iac ▁a my lo idos is
D-997	-0.15448935329914093	Cardiac amyloidosis
P-997	-0.1341 -0.0234 -0.2682 -0.1132 -0.0294 -0.0865 -0.5435 -0.1537 -0.0385
S-507	Pigs were given antiarrhythmic medication to prevent sudden death.<unk>
T-507	antiarrhythmic medication death
H-507	-0.9626957774162292	▁Pig s ▁anti ar rhythm ic
D-507	-0.9626957774162292	Pigs antiarrhythmic
P-507	-1.4799 -0.2493 -0.7326 -0.0886 -0.0713 -0.1624 -4.4309 -0.4866
S-1911	Robot-assisted training for heart failure patients - a small pilot study.<unk>
T-1911	training heart_failure patients
H-1911	-0.979037880897522	▁Robot - assist ed _ training ▁heart ▁failure
D-1911	-0.979037880897522	Robot-assisted_training heart failure
P-1911	-1.3967 -0.1802 -0.0119 -0.1284 -1.1955 -0.6136 -3.6187 -0.4316 -1.9406 -0.2731
S-550	Of the 6 patients, 5 experienced significant improvement in functional capacity and symptoms.<unk>
T-550	patients functional_capacity symptoms
H-550	-1.0214420557022095	
D-550	-1.0214420557022095	
P-550	-1.9414 -0.1015
S-219	Of the CHF patients, 778 (2.4%) were intubated.<unk>
T-219	chf patients intubated
H-219	-0.8903285264968872	▁CHF
D-219	-0.8903285264968872	CHF
P-219	-0.0195 -2.4885 -0.1630
S-266	The end point was survival from the time of inclusion through 4 years.<unk>
T-266	end_point
H-266	-0.5125026106834412	
D-266	-0.5125026106834412	
P-266	-0.9605 -0.0646
S-424	Heart rate was unchanged, and arterial pressure declined modestly.<unk>
T-424	heart_rate arterial_pressure
H-424	-0.6050880551338196	▁Heart ▁rate ▁arterial ▁pressure
D-424	-0.6050880551338196	Heart rate arterial pressure
P-424	-0.4160 -1.4743 -0.1225 -1.4396 -0.0824 -0.0958
S-1736	Very few of these patients were on standard therapy with beta blockade.<unk>
T-1736	patients therapy beta_blockade
H-1736	-1.297852635383606	▁beta ▁block ade
D-1736	-1.297852635383606	beta blockade
P-1736	-5.6901 -0.5109 -0.0137 -0.1542 -0.1205
S-840	Hgb level was not significantly correlated with baseline HRQoL.<unk>
T-840	hgb correlated baseline hrqol
H-840	-1.1098082065582275	▁h gb
D-840	-1.1098082065582275	hgb
P-840	-0.9793 -0.0007 -3.2489 -0.2103
S-1914	Patients underwent testing of cardiac and inflammatory biomarkers.<unk>
T-1914	patients cardiac inflammatory biomarkers
H-1914	-0.6868932247161865	▁cardiac _ ▁infla mma tory ▁bio mark ers
D-1914	-0.6868932247161865	cardiac_ inflammatory biomarkers
P-1914	-0.2685 -2.1471 -2.9883 -0.0939 -0.1427 -0.6891 -0.0081 -0.1548 -0.1219 -0.2544
S-1069	Most data have been collected in patients with systolic dysfunction.<unk>
T-1069	collected patients systolic_dysfunction
H-1069	-0.3743669390678406	▁sy sto lic _ ▁dys function
D-1069	-0.3743669390678406	systolic_ dysfunction
P-1069	-0.6175 -0.1350 -0.1606 -1.5624 -0.1716 -0.1037 -0.1609 -0.0833
S-1464	A preserved ejection fraction outcomes trial is beginning.<unk>
T-1464	preserved_ejection_fraction outcomes
H-1464	-0.5717822313308716	▁pres er ved _ e je ction ▁ fraction
D-1464	-0.5717822313308716	preserved_ejection fraction
P-1464	-0.3189 -0.1613 -0.7137 -0.8557 -0.7795 -0.1927 -0.0214 -1.0205 -0.0014 -1.9616 -0.2629
S-1797	Decompensated HF is the main cause of cardiovascular hospitalization.<unk>
T-1797	decompensated_hf cardiovascular hospitalization
H-1797	-0.8291840553283691	▁ HF ▁cardiovascular _ hospital ization
D-1797	-0.8291840553283691	HF cardiovascular_hospitalization
P-1797	-1.6316 -0.2279 -1.3010 -2.5168 -0.1905 -0.5756 -0.0739 -0.1162
S-1471	Therapeutic implications of biomarkers in chronic heart failure.<unk>
T-1471	therapeutic biomarkers chronic_heart_failure
H-1471	-0.3505856394767761	▁bio mark ers ▁chronic _ heart ▁failure
D-1471	-0.3505856394767761	biomarkers chronic_heart failure
P-1471	-0.1048 -0.0207 -0.1938 -0.9167 -0.3684 -0.9888 -0.3675 -0.0920 -0.1027
S-461	Do outcomes for patients with heart failure vary by emergency department volume?<unk>
T-461	outcomes patients heart_failure emergency_department
H-461	-1.7237800359725952	▁heart ▁failure ▁emergency ▁department
D-461	-1.7237800359725952	heart failure emergency department
P-461	-4.8273 -1.0176 -2.0891 -0.7117 -1.5504 -0.1465
S-1255	VO2max increased (~24%) but did not reach statistical significance.<unk>
T-1255	vo2max significance
H-1255	-0.5173949003219604	▁VO 2 max
D-1255	-0.5173949003219604	VO2max
P-1255	-1.4449 -0.0424 -0.0212 -0.8757 -0.2028
S-1204	An estimated 5.1 million Americans aged 20 years and older have heart failure.<unk>
T-1204	heart_failure
H-1204	-1.561020851135254	▁heart ▁failure
D-1204	-1.561020851135254	heart failure
P-1204	-5.2190 -0.7220 -0.2117 -0.0914
S-799	MAIN OUTCOME MEASURE: Time to complete the TUG test.<unk>
T-799	outcome tug_test
H-799	-1.3717706203460693	▁m AIN ▁o UTC OME
D-799	-1.3717706203460693	mAIN oUTCOME
P-799	-4.5567 -0.4129 -1.8431 -0.0035 -0.0634 -2.6367 -0.0861
S-608	The HR was also not elevated in subjects with a history of HF.<unk>
T-608	elevated hf
H-608	-0.3952614963054657	▁HR ▁ HF
D-608	-0.3952614963054657	HR HF
P-608	-0.1967 -1.4299 -0.0366 -0.1498 -0.1632
S-70	Further research is needed to study other potential predictors, particularly biomarkers.<unk>
T-70	biomarkers
H-70	-0.2637331485748291	▁bio mark ers
D-70	-0.2637331485748291	biomarkers
P-70	-1.0098 -0.0189 -0.0683 -0.1047 -0.1170
S-394	Forty-one patients developed ESRD (1.3/1000 patient-years).<unk>
T-394	patients esrd
H-394	-1.4584983587265015	▁ES RD
D-394	-1.4584983587265015	ESRD
P-394	-5.1987 -0.1192 -0.1968 -0.3193
S-591	Previously documented prognostic factors were also confirmed in this cohort.<unk>
T-591	prognostic
H-591	-0.889235258102417	
D-591	-0.889235258102417	
P-591	-1.6062 -0.1723
S-603	METHODS: We used data from four different US healthcare programmes.<unk>
T-603	healthcare
H-603	-1.6412938833236694	
D-603	-1.6412938833236694	
P-603	-3.2123 -0.0703
S-1028	Appropriately designed clinical trials will be needed to confirm these potential benefits.<unk>
T-1028	clinical
H-1028	-0.43556058406829834	
D-1028	-0.43556058406829834	
P-1028	-0.8326 -0.0385
S-1197	Our review of this newly introduced drug is based on our experience in Japan.<unk>
T-1197	drug japan
H-1197	-0.9039167165756226	
D-1197	-0.9039167165756226	
P-1197	-1.6837 -0.1241
S-746	Abnormal cardiac T2* values determined changes in treatment in most subjects.<unk>
T-746	cardiac
H-746	-0.8824501633644104	▁ab normal ▁cardiac _ t 2
D-746	-0.8824501633644104	abnormal cardiac_t2
P-746	-1.8241 -0.0017 -0.5776 -0.9563 -1.3709 -0.0511 -2.1577 -0.1202
S-800	Three trials were performed on the same day and by the same assessors.<unk>
T-800	
H-800	-0.6778069734573364	
D-800	-0.6778069734573364	
P-800	-1.2669 -0.0887
S-1923	Results can only be considered as preliminary and need further validation in larger studies.<unk>
T-1923	
H-1923	-0.4454655349254608	
D-1923	-0.4454655349254608	
P-1923	-0.8089 -0.0820
S-1854	We will explore why some interventions may succeed in one setting and fail in another.<unk>
T-1854	
H-1854	-0.5328208208084106	
D-1854	-0.5328208208084106	
P-1854	-0.9471 -0.1185
S-1206	Determination of risk and associated treatment strategies is the subject of this brief review.<unk>
T-1206	
H-1206	-1.0277059078216553	▁risk
D-1206	-1.0277059078216553	risk
P-1206	-1.9587 -1.0093 -0.1151
S-1299	Heart failure with preserved left ventricular ejection fraction.<unk>
T-1299	heart_failure_with_preserved_left_ventricular_ejection_fraction
H-1299	-0.7710500955581665	▁Heart ▁failure ▁left ▁vent ri cular ▁e je ction
D-1299	-0.7710500955581665	Heart failure left ventricular ejection
P-1299	-0.1869 -1.5845 -3.7138 -0.6825 -0.2592 -0.3106 -0.5614 -0.0624 -0.0504 -0.9583 -0.1114
S-1919	The quality of life assessment indicated better well-being in all participants.<unk>
T-1919	quality_of_life
H-1919	-1.2952783107757568	
D-1919	-1.2952783107757568	
P-1919	-2.4290 -0.1616
S-785	Covariate adjustment was made using Cox proportional hazards models.<unk>
T-785	covariate_adjustment cox_proportional_hazards_models
H-785	-0.4517330229282379	▁co x ▁proportion al _ ▁hazard s ▁models
D-785	-0.4517330229282379	cox proportional_ hazards models
P-785	-0.3135 -0.1148 -0.1095 -0.0510 -0.2872 -1.1340 -0.7500 -1.4737 -0.0938 -0.1897
S-1195	Tolvaptan is a vasopressin type 2 receptor antagonist.<unk>
T-1195	tolvaptan vasopressin_type_2_receptor_antagonist
H-1195	-0.5702447891235352	▁Tol va p tan ▁vaso press in ▁receptor
D-1195	-0.5702447891235352	Tolvaptan vasopressin receptor
P-1195	-0.0620 -0.0582 -0.6824 -0.0199 -0.0589 -0.1218 -0.8432 -0.1729 -3.4022 -0.2809
S-645	Epidemiology and treatment of chronic heart failure; use of bisoprolol.<unk>
T-645	epidemiology chronic_heart_failure bisoprolol
H-645	-0.9560933113098145	▁Epidemi ology ▁chronic _ heart ▁failure ▁bis o pro lol
D-645	-0.9560933113098145	Epidemiology chronic_heart failure bisoprolol
P-645	-5.3241 -0.1843 -3.3295 -0.3853 -1.2177 -0.3507 -0.2222 -0.1582 -0.0106 -0.0145 -0.1893 -0.0865
S-437	Effectiveness and safety of spironolactone for systolic heart failure.<unk>
T-437	spironolactone systolic_heart_failure
H-437	-0.5540841817855835	▁spi rono lac tone ▁sy sto lic ▁heart ▁failure
D-437	-0.5540841817855835	spironolactone systolic heart failure
P-437	-0.2376 -0.0085 -0.0080 -0.0231 -0.0307 -0.0257 -0.0313 -5.3163 -0.1277 -0.1094 -0.1764
S-1034	Heart failure (HF) is the leading cause of mortality in modern society.<unk>
T-1034	heart_failure hf leading mortality society
H-1034	-0.7865657210350037	▁Heart ▁failure _ HF
D-1034	-0.7865657210350037	Heart failure_HF
P-1034	-0.6110 -0.3359 -2.2920 -0.1350 -1.1368 -0.2087
S-339	Functional MS has not been reported in patients with degenerative MR.<unk>
T-339	functional_ms reported patients degenerative_mr
H-339	-0.18846087157726288	▁Fun ction al ▁MS ▁de genera tive ▁MR
D-339	-0.18846087157726288	Functional MS degenerative MR
P-339	-0.2608 -0.0019 -0.0082 -0.5354 -0.1270 -0.0007 -0.1881 -0.5557 -0.1331 -0.0738
S-989	Key role of ERK1/2 molecular scaffolds in heart pathology.<unk>
T-989	molecular_scaffolds heart pathology
H-989	-1.0572195053100586	▁e RK 1/2 ▁molecular _ sc af fold s ▁heart ▁path ology
D-989	-1.0572195053100586	eRK1/2 molecular_scaffolds heart pathology
P-989	-2.5342 -0.0227 -3.6068 -0.8507 -0.6783 -0.9851 -2.2863 -0.4521 -0.0830 -0.5597 -1.9107 -0.5241 -0.1002 -0.2072
S-1067	Devices have become a cornerstone of heart failure (HF) therapy.<unk>
T-1067	heart_failure hf therapy
H-1067	-1.6086878776550293	▁heart ▁failure HF ▁ therapy
D-1067	-1.6086878776550293	heart failureHF therapy
P-1067	-6.4930 -0.7322 -1.0340 -2.6170 -0.0223 -0.1700 -0.1923
S-581	LVET was measured from the reconstructed aortic pressure curve.<unk>
T-581	lvet aortic_pressure
H-581	-0.8416004180908203	▁l VET ▁a or tic _ ▁pressure ▁cur ve
D-581	-0.8416004180908203	lVET aortic_ pressure curve
P-581	-3.4417 -0.1259 -1.4129 -0.3264 -0.6092 -0.0738 -2.3887 -0.5418 -0.0513 -0.0702 -0.2157
S-983	Cardiac symptoms in children are usually the result of congenital lesions.<unk>
T-983	cardiac symptoms congenital lesions
H-983	-0.5873407125473022	▁Card iac
D-983	-0.5873407125473022	Cardiac
P-983	-0.4431 -0.0397 -1.7109 -0.1557
S-1651	Nights spent in hospital will be counted as a coprimary outcome.<unk>
T-1651	hospital coprimary_outcome
H-1651	-1.124133586883545	▁Night s
D-1651	-1.124133586883545	Nights
P-1651	-1.8774 -0.0542 -2.2759 -0.2891
S-669	Trastuzumab-related cardiotoxicity among older patients with breast cancer.<unk>
T-669	cardiotoxicity patients breast_cancer
H-669	-0.6549762487411499	▁Tras tuz um ab - related _ ▁cardio toxic ity ▁breast ▁cancer
D-669	-0.6549762487411499	Trastuzumab-related_ cardiotoxicity breast cancer
P-669	-0.8775 -0.0453 -0.0203 -0.3286 -0.1230 -1.0161 -1.0520 -0.2536 -0.6833 -2.6618 -1.2037 -0.6062 -0.1665 -0.1317
S-1606	OBJECTIVES: Heart failure is a major public health problem worldwide.<unk>
T-1606	heart_failure public health
H-1606	-1.8793352842330933	
D-1606	-1.8793352842330933	
P-1606	-3.6476 -0.1111
S-1414	We explored whether physician continuity further influences outcomes after discharge.<unk>
T-1414	physician outcomes discharge
H-1414	-0.5190293788909912	▁physician ▁continu ity
D-1414	-0.5190293788909912	physician continuity
P-1414	-0.4159 -0.1801 -0.3294 -1.3938 -0.2759
S-539	Postoperative normalization of albumin level is associated with improved survival.<unk>
T-539	postoperative albumin
H-539	-0.4356546998023987	▁album in ▁level
D-539	-0.4356546998023987	albumin level
P-539	-1.4208 -0.1781 -0.3277 -0.1347 -0.1168
S-1276	In addition to prognosis, the pathophysiological origin is also discussed.<unk>
T-1276	prognosis pathophysiological
H-1276	-0.49304524064064026	▁prognos is ▁pat ho phy si ological
D-1276	-0.49304524064064026	prognosis pathophysiological
P-1276	-0.9867 -0.0808 -0.5437 -0.1569 -0.2604 -0.7646 -0.2752 -1.3039 -0.0654
S-545	METHODS: From 2005 to 2011, 271 patients underwent LVAD implantation.<unk>
T-545	patients lvad implantation
H-545	-0.8688111305236816	▁l VAD ▁implant ation
D-545	-0.8688111305236816	lVAD implantation
P-545	-2.4108 -0.1325 -2.1296 -0.1493 -0.2250 -0.1656
S-1821	Overall management of patients with heart failure requires the collaboration of professionals from multiple disciplines.<unk>
T-1821	patients heart_failure
H-1821	-1.7317242622375488	▁patients ▁heart ▁failure
D-1821	-1.7317242622375488	patients heart failure
P-1821	-4.2171 -3.8298 -0.2711 -0.2489 -0.0918
S-1792	LA countries have reduced gross income and lower total expenditure on health per capita.<unk>
T-1792	income expenditure health
H-1792	-2.412632703781128	▁gross _ ▁income
D-1792	-2.412632703781128	gross_ income
P-1792	-5.3310 -1.4824 -0.4315 -4.3806 -0.4376
S-1908	The AHA and the ESC advocate pre-participation screening of young athletes.<unk>
T-1908	aha esc
H-1908	-1.0336261987686157	▁ AHA ▁ESC
D-1908	-1.0336261987686157	AHA ESC
P-1908	-0.6261 -0.0083 -2.0561 -2.2489 -0.2287
S-709	There is a paucity of data examining long-term outcomes with this strategy.<unk>
T-709	paucity outcomes
H-709	-1.4485197067260742	
D-709	-1.4485197067260742	
P-709	-2.7443 -0.1528
S-1732	Our findings suggest that clinician expertise may play an important role in HF care.<unk>
T-1732	clinician hf
H-1732	-0.9293585419654846	▁ HF
D-1732	-0.9293585419654846	HF
P-1732	-1.4963 -0.8001 -1.2869 -0.1340
S-1072	In addition, stand-alone diagnostic devices are now also being developed for HF.<unk>
T-1072	diagnostic hf
H-1072	-0.9642069339752197	▁stand - a lone _ Diagnos ▁devices
D-1072	-0.9642069339752197	stand-alone_Diagnos devices
P-1072	-1.7229 -0.0699 -0.1564 -0.0042 -0.1176 -2.3208 -0.4455 -3.7429 -0.0975
S-1848	We will assess the impact of the intervention on adherence to the CPGs.<unk>
T-1848	cpgs
H-1848	-0.8916693329811096	▁c PG s
D-1848	-0.8916693329811096	cPGs
P-1848	-3.9204 -0.0531 -0.1432 -0.0976 -0.2441
S-75	Enrollment occurred from September 2010 to March 2013 across 26 sites in North America.<unk>
T-75	north_america
H-75	-0.7758825421333313	▁en roll ment
D-75	-0.7758825421333313	enrollment
P-75	-2.0681 -0.0052 -0.1278 -1.6080 -0.0704
S-1824	Hence, progress has yet to be made regarding appropriate referrals and patient circulation.<unk>
T-1824	patient circulation
H-1824	-0.7883591651916504	
D-1824	-0.7883591651916504	
P-1824	-1.4521 -0.1246
S-1965	Despite that, no major development has occurred in the therapy in recent years.<unk>
T-1965	therapy
H-1965	-0.4692458510398865	▁ therapy
D-1965	-0.4692458510398865	therapy
P-1965	-1.6284 -0.1126 -0.0695 -0.0664
S-1576	DESIGN: Prospective, non-randomized, two-center pilot project.<unk>
T-1576	prospective
H-1576	-0.8398796916007996	
D-1576	-0.8398796916007996	
P-1576	-1.5452 -0.1346
S-1881	RESULTS: There were no significant difference between two groups patients (P > 0.05).<unk>
T-1881	patients
H-1881	-0.5309196710586548	
D-1881	-0.5309196710586548	
P-1881	-0.9669 -0.0949
S-372	At this point, insignificant MS can be considered as not indicative for surgery.<unk>
T-372	surgery
H-372	-0.36641669273376465	▁insigni fica nt ▁MS
D-372	-0.36641669273376465	insignificant MS
P-372	-1.3398 -0.0448 -0.0159 -0.1785 -0.5602 -0.0594
S-675	Analyses included descriptive statistics and Cox proportional hazards models.<unk>
T-675	descriptive_statistics cox_proportional_hazards_models
H-675	-0.6657385230064392	▁de script ive _ ▁statistic s ▁co x ▁proportion al _ ▁hazard s
D-675	-0.6657385230064392	descriptive_ statistics cox proportional_ hazards
P-675	-3.4091 -0.0048 -0.0134 -0.5478 -0.2081 -0.1720 -0.3263 -0.0135 -0.1950 -0.0409 -0.2085 -1.7793 -0.7560 -2.0692 -0.2422
S-913	Certain dialysis patients demonstrated compelling improvement after device implantation.<unk>
T-913	dialysis patients implantation
H-913	-0.8563969731330872	▁di al ysis ▁patients ▁device ▁implant ation
D-913	-0.8563969731330872	dialysis patients device implantation
P-913	-0.6454 -0.1472 -0.0250 -4.9929 -1.2982 -0.1798 -0.1066 -0.1692 -0.1433
S-1503	Psychometric testing of the Self-Care of Heart Failure Index Version 6.2.<unk>
T-1503	psychometric self-care_of_heart_failure_index_version_6.2
H-1503	-0.7892961502075195	▁psycho metric _ ▁testing ▁Self - Car e _ of _ ▁Heart ▁Fail ure ▁Index
D-1503	-0.7892961502075195	psychometric_ testing Self-Care_of_ Heart Failure Index
P-1503	-1.3685 -0.0135 -1.3478 -2.2500 -1.3520 -0.0739 -1.0680 -0.0522 -0.2136 -1.1724 -0.2785 -0.5278 -0.3913 -1.3319 -1.6406 -0.1660 -0.1701
S-1537	The risk of heart failure was estimated by Cox proportional hazard analyses.<unk>
T-1537	heart_failure cox_proportional_hazard_analyses
H-1537	-0.7969787120819092	▁co x ▁proportion al _ ▁hazard analyse s
D-1537	-0.7969787120819092	cox proportional_ hazardanalyses
P-1537	-3.1678 -0.0035 -1.2110 -0.0089 -0.2125 -1.2984 -1.1611 -0.3801 -0.2310 -0.2955
S-253	Endothelial function was assessed by flow-mediated dilatation.<unk>
T-253	endothelial_function flow-mediated_dilatation
H-253	-0.5387965440750122	▁en dot heli al ▁function ▁flow - media ted ▁di la tation
D-253	-0.5387965440750122	endothelial function flow-mediated dilatation
P-253	-1.2379 -0.1966 -0.0320 -0.0122 -2.8216 -0.4697 -0.0139 -0.0526 -0.5254 -1.7034 -0.2040 -0.0068 -0.1320 -0.1351
S-975	In total, 17% of patients developed acute kidney injury postoperatively.<unk>
T-975	patients acute_kidney_injury postoperatively
H-975	-0.5750895738601685	▁ki dne y ▁injury ▁post operativ ely
D-975	-0.5750895738601685	kidney injury postoperatively
P-975	-1.2830 -0.5129 -0.0621 -1.0111 -0.9070 -0.0344 -1.0044 -0.2453 -0.1156
S-1465	Pharmacological treatment of acute heart failure: current treatment and new targets.<unk>
T-1465	pharmacological acute_heart_failure
H-1465	-1.0633163452148438	▁Pharma c ological ▁a cute _ heart ▁failure
D-1465	-1.0633163452148438	Pharmacological acute_heart failure
P-1465	-2.4918 -0.0090 -0.7086 -4.8124 -0.0364 -0.0722 -1.4162 -0.6530 -0.3426 -0.0909
S-551	One patient died postoperatively secondary to multiorgan failure and sepsis.<unk>
T-551	patient postoperatively multiorgan_failure sepsis
H-551	-0.5050755143165588	▁multi organ ▁failure ▁se psis
D-551	-0.5050755143165588	multiorgan failure sepsis
P-551	-2.8608 -0.0070 -0.4214 -0.0624 -0.0004 -0.0537 -0.1299
S-567	Randomized trial of Nordic walking in patients with moderate to severe heart failure.<unk>
T-567	randomized walking patients severe_heart_failure
H-567	-2.224705219268799	▁Nordic _ ▁walking
D-567	-2.224705219268799	Nordic_ walking
P-567	-2.1286 -1.9504 -3.9132 -2.8933 -0.2381
S-1059	T1-mapping values were compared between the baseline and heart failure scans.<unk>
T-1059	t1-mapping baseline heart_failure
H-1059	-1.5462089776992798	
D-1059	-1.5462089776992798	
P-1059	-2.9404 -0.1520
S-2011	Survival projections are based on a modified Seattle Heart Failure Model.<unk>
T-2011	seattle_heart_failure_model
H-2011	-1.0318769216537476	▁Seattle _ ▁Heart ▁Fail ure ▁Model
D-2011	-1.0318769216537476	Seattle_ Heart Failure Model
P-2011	-3.1241 -0.5276 -1.2622 -0.8771 -0.8157 -1.4313 -0.0886 -0.1283
S-223	Hemodynamic phenotype of the failing Fontan in an adult population.<unk>
T-223	hemodynamic_phenotype fontan
H-223	-0.48856380581855774	▁Hem o dynamic _ ▁ph eno type ▁fail ing _ ▁Font an
D-223	-0.48856380581855774	Hemodynamic_ phenotype failing_ Fontan
P-223	-1.8137 -0.0822 -0.0006 -0.3274 -0.6968 -0.0186 -0.0026 -0.8112 -0.1198 -0.2542 -1.5189 -0.2832 -0.8396 -0.0710
S-358	In this patient there was no MS before the surgery by echocardiography.<unk>
T-358	patient surgery echocardiography
H-358	-0.2687424123287201	▁MS ▁e cho card i ography
D-358	-0.2687424123287201	MS echocardiography
P-358	-0.3340 -1.0975 -0.0142 -0.1491 -0.3384 -0.0866 -0.0885 -0.0417
S-349	Coronary angiography revealed no significant lesions in the major branches.<unk>
T-349	coronary_angiography lesions
H-349	-0.7692314982414246	▁Corona ry _ ang i ography
D-349	-0.7692314982414246	Coronary_angiography
P-349	-0.0461 -0.6427 -0.4086 -1.8340 -2.5508 -0.0934 -0.5100 -0.0682
S-826	Univariate and multivariate analyses were used for factors predicting survival.<unk>
T-826	multivariate_analyses
H-826	-1.1202398538589478	
D-826	-1.1202398538589478	
P-826	-2.1569 -0.0836
S-1902	Individuals who exercise regularly extend their life expectancy by three to seven years.<unk>
T-1902	exercise life_expectancy
H-1902	-0.6907245516777039	
D-1902	-0.6907245516777039	
P-1902	-1.3032 -0.0783
S-772	Safe, effective off-pump sternal sparing approach for HeartMate II exchange.<unk>
T-772	sternal heartmate_ii
H-772	-0.6635236144065857	▁off - pump _ ster nal _ ▁spar ing _ ▁approach ▁Heart Mate ▁II ▁exchange
D-772	-0.6635236144065857	off-pump_sternal_ sparing_ approach HeartMate II exchange
P-772	-0.0248 -0.0603 -0.1177 -1.9021 -1.0106 -0.3581 -0.1536 -0.8369 -0.0419 -1.5435 -1.5179 -0.0899 -0.0794 -3.1346 -0.1545 -0.0994 -0.1547
S-1263	Most adverse events observed in the studies were not severe and resolved without special treatment.<unk>
T-1263	adverse_events
H-1263	-0.5326398611068726	
D-1263	-0.5326398611068726	
P-1263	-1.0182 -0.0471
S-888	Furthermore, there was continuous relationship between QRS duration and extent of benefit.<unk>
T-888	qrs_duration
H-888	-0.9395416975021362	▁QR s
D-888	-0.9395416975021362	QRs
P-888	-0.7655 -2.0251 -0.7652 -0.2023
S-1640	There was no interaction between race and exercise training on outcomes (P > .5).<unk>
T-1640	exercise training outcomes
H-1640	-1.2677348852157593	▁race _ training
D-1640	-1.2677348852157593	race_training
P-1640	-1.4690 -3.0865 -1.2376 -0.4273 -0.1182
S-1397	Using standardized nursing terminologies makes it possible to measure aspects of nursing care.<unk>
T-1397	nursing nursing
H-1397	-1.4043322801589966	▁nur sing _ ▁terminologi es
D-1397	-1.4043322801589966	nursing_ terminologies
P-1397	-5.0305 -0.1636 -3.3706 -0.5488 -0.0399 -0.5362 -0.1407
S-547	The patients were examined for new-onset severe AI requiring surgical intervention.<unk>
T-547	patients surgical
H-547	-1.77742600440979	
D-547	-1.77742600440979	
P-547	-3.4332 -0.1217
S-1165	Over a median follow-up of 541 days, there were 150 events (37%).<unk>
T-1165	follow-up
H-1165	-0.4266361594200134	▁media n ▁follow - up
D-1165	-0.4266361594200134	median follow-up
P-1165	-0.8636 -0.0537 -1.5062 -0.1004 -0.0039 -0.4032 -0.0554
S-3	The analysis included a large study sample with more than 60,000 patients across 4372 hospitals.<unk>
T-3	patients hospitals
H-3	-0.8128532767295837	
D-3	-0.8128532767295837	
P-3	-1.5261 -0.0996
S-1006	The deficit index was defined as the proportion of deficits present out of 32 deficits.<unk>
T-1006	deficit_index
H-1006	-0.49381959438323975	▁deficit ▁index
D-1006	-0.49381959438323975	deficit index
P-1006	-0.1369 -0.3525 -1.2873 -0.1986
S-1696	We repeated this analysis using 2005-2008 performance on existing quality indicators, including mortality.<unk>
T-1696	mortality
H-1696	-1.4457191228866577	
D-1696	-1.4457191228866577	
P-1696	-2.6688 -0.2226
S-810	This study sought to examine the ability of GLS in predicting CV events in AF.<unk>
T-810	gls
H-810	-0.7904435396194458	▁g LS
D-810	-0.7904435396194458	gLS
P-810	-1.0676 -0.1306 -1.8500 -0.1135
S-370	According to the guideline, the MS at that time could be considered indicative for surgery.<unk>
T-370	surgery
H-370	-1.0138682126998901	▁MS
D-370	-1.0138682126998901	MS
P-370	-2.6247 -0.3182 -0.0988
S-1855	We will disseminate our findings through briefing reports, publications and presentations.<unk>
T-1855	
H-1855	-0.5384362936019897	
D-1855	-0.5384362936019897	
P-1855	-0.9676 -0.1092
S-1752	Prognostic value of indeterminable anaerobic threshold in heart failure.<unk>
T-1752	prognostic anaerobic_threshold heart_failure
H-1752	-0.5207898020744324	▁ana ero bic _ ▁thre s hold ▁heart ▁failure
D-1752	-0.5207898020744324	anaerobic_ threshold heart failure
P-1752	-1.9156 -0.9782 -0.3541 -0.9323 -0.1702 -0.0945 -0.1097 -0.6338 -0.3842 -0.0680 -0.0880
S-1486	Renin-angiotensin-aldosterone system inhibitors in heart failure.<unk>
T-1486	renin-angiotensin-aldosterone_system_inhibitors heart_failure
H-1486	-0.33831971883773804	▁re nin - angi oten sin - al do ster one ▁system ▁inhibi tors ▁heart ▁failure
D-1486	-0.33831971883773804	renin-angiotensin-aldosterone system inhibitors heart failure
P-1486	-0.7085 -0.1875 -0.0532 -0.0057 -0.0507 -0.5274 -0.1609 -0.0602 -0.5458 -0.0202 -0.4464 -1.6748 -0.2276 -0.2615 -0.4066 -0.5239 -0.1073 -0.1216
S-1372	We hypothesized in CHF, unilateral renal DNx would improve cardiac autonomic balance.<unk>
T-1372	chf unilateral_renal_dnx cardiac autonomic_balance
H-1372	-0.4285587966442108	▁CHF ▁unilateral ▁renal ▁DN x ▁cardiac ▁autonomi c ▁balance
D-1372	-0.4285587966442108	CHF unilateral renal DNx cardiac autonomic balance
P-1372	-0.0931 -0.3173 -0.2405 -0.7975 -0.0146 -0.3540 -0.5887 -0.2378 -1.7646 -0.1382 -0.1678
S-1491	Skeletal muscle abnormalities and exercise capacity in adults with a Fontan circulation.<unk>
T-1491	skeletal_muscle exercise_capacity fontan_circulation
H-1491	-0.8034999966621399	▁s kelet al ▁muscle ▁ab normal ities ▁exercise ▁capacity ▁Font an ▁circulation
D-1491	-0.8034999966621399	skeletal muscle abnormalities exercise capacity Fontan circulation
P-1491	-2.5969 -0.0017 -0.0295 -1.9995 -0.2659 -0.0273 -0.2932 -2.7951 -1.4767 -0.2762 -0.0733 -1.1633 -0.1617 -0.0887
S-1014	Learning from recent trials and shaping the future of acute heart failure trials.<unk>
T-1014	acute_heart_failure
H-1014	-0.785797119140625	▁a cute _ heart ▁failure
D-1014	-0.785797119140625	acute_heart failure
P-1014	-2.1156 -0.0102 -0.0756 -1.2063 -0.6441 -1.3517 -0.0971
S-898	9/10 patients were Stage 3 chronic kidney disease (CKD) or worse.<unk>
T-898	patients chronic_kidney_disease ckd
H-898	-0.7396565079689026	▁chronic ▁ki dne y ▁disease CK D
D-898	-0.7396565079689026	chronic kidney diseaseCKD
P-898	-2.4453 -1.0167 -0.4635 -0.1327 -0.9618 -0.7812 -0.4960 -0.1931 -0.1666
S-362	Mitral regurgitation as well as HF symptoms disappeared after the surgery.<unk>
T-362	mitral_regurgitation hf symptoms surgery
H-362	-0.4870489835739136	▁mit ral ▁re gur gi tation ▁ HF
D-362	-0.4870489835739136	mitral regurgitation HF
P-362	-2.2083 -0.1055 -1.0511 -0.3334 -0.2273 -0.2559 -0.1779 -0.0329 -0.3057 -0.1725
S-1598	This progressive disease can lead to resistant hypertension and end stage kidney failure.<unk>
T-1598	disease lead hypertension kidney_failure
H-1598	-0.8884993195533752	▁progressive ▁hyper tension ▁ki dne y ▁failure
D-1598	-0.8884993195533752	progressive hypertension kidney failure
P-1598	-1.3511 -6.1009 -0.0727 -0.0562 -0.0447 -0.0333 -0.1432 -0.0921 -0.1023
S-1669	In this article, we describe current strategies for the treatment of end stage heart failure.<unk>
T-1669	end_stage_heart_failure
H-1669	-1.735268473625183	
D-1669	-1.735268473625183	
P-1669	-3.4188 -0.0517
S-147	CONTEXT: Readmission to hospital for heart failure is common after recent discharge.<unk>
T-147	readmission hospital heart_failure discharge
H-147	-1.2235978841781616	▁hospital _ voor _ heart ▁failure
D-147	-1.2235978841781616	hospital_voor_heart failure
P-147	-4.1968 -1.0829 -1.9743 -0.0487 -1.1822 -0.7609 -0.4203 -0.1227
S-1798	The prevalence of systolic HF varies from 64% to 69%.<unk>
T-1798	prevalence systolic_hf
H-1798	-0.18054339289665222	▁sy sto lic _ HF
D-1798	-0.18054339289665222	systolic_HF
P-1798	-0.1549 -0.0764 -0.0115 -0.3342 -0.4317 -0.1478 -0.1074
S-143	Correlations among metrics were modest when measuring hospital longitudinal change.<unk>
T-143	correlations hospital longitudinal change
H-143	-0.8381361365318298	
D-143	-0.8381361365318298	
P-143	-1.5620 -0.1143
S-1580	MAIN OUTCOME MEASURE: 30-day all-cause readmissions.<unk>
T-1580	outcome all-cause_readmissions
H-1580	-1.0080726146697998	▁m AIN _ o UTC OME
D-1580	-1.0080726146697998	mAIN_oUTCOME
P-1580	-3.4544 -0.6414 -0.4473 -1.6259 -0.0061 -0.1781 -1.6301 -0.0813
S-1589	Abnormal HR variability predicts both sudden and non-sudden cardiac death.<unk>
T-1589	hr_variability cardiac_death
H-1589	-1.2810146808624268	▁ab normal _ HR _ ▁variabil ity
D-1589	-1.2810146808624268	abnormal_HR_ variability
P-1589	-1.9560 -0.0025 -1.0819 -1.3405 -2.4905 -0.0529 -0.4944 -3.7264 -0.3841
S-1048	Importantly, no toxicity or effects on systemic blood pressure were observed.<unk>
T-1048	systemic_blood_pressure
H-1048	-0.9330869317054749	▁ toxic ity ▁system ic _ ▁blood ▁pressure
D-1048	-0.9330869317054749	toxicity systemic_ blood pressure
P-1048	-0.2118 -0.0524 -2.1729 -1.6566 -0.2278 -0.2581 -2.9813 -1.5441 -0.0924 -0.1334
S-828	These groups were not significantly different in terms of medication and resting hemodynamics.<unk>
T-828	medication resting_hemodynamics
H-828	-1.1639904975891113	▁medication ▁rest ing ▁hem o dynamic s
D-828	-1.1639904975891113	medication resting hemodynamics
P-828	-2.4110 -2.8102 -0.1971 -4.2008 -0.3358 -0.0016 -0.1889 -0.2629 -0.0677
S-1720	Physician volume, specialty, and outcomes of care for patients with heart failure.<unk>
T-1720	physician outcomes patients heart_failure
H-1720	-1.9722328186035156	▁Physic ian _ ▁volume
D-1720	-1.9722328186035156	Physician_ volume
P-1720	-4.3718 -0.2886 -2.4546 -0.7155 -3.6211 -0.3817
S-331	Lack of correlation of remaining indices may reflect postsystolic function.<unk>
T-331	correlation postsystolic_function
H-331	-1.2285284996032715	▁post y sto lic
D-331	-1.2285284996032715	postystolic
P-331	-5.3331 -0.4168 -0.0642 -0.0385 -1.3707 -0.1479
S-1782	Mice subjected to AAC demonstrated a progressive development of cardiac hypertrophy.<unk>
T-1782	aac cardiac_hypertrophy
H-1782	-0.6920155882835388	▁a ac ▁cardiac ▁hyper trop hy
D-1782	-0.6920155882835388	aac cardiac hypertrophy
P-1782	-1.1336 -0.6154 -1.0922 -1.9379 -0.0047 -0.5702 -0.0673 -0.1148
S-617	Secondary outcome measures related to patient satisfaction and sustainability of the intervention post study.<unk>
T-617	secondary_outcome patient post
H-617	-0.8844197392463684	▁patient ▁satisfaction
D-617	-0.8844197392463684	patient satisfaction
P-617	-2.3451 -0.3083 -0.7655 -0.1187
S-1582	This represented a net economic savings, even accounting for the added cost of the intervention.<unk>
T-1582	economic accounting cost
H-1582	-0.8054633736610413	▁net _ economic _ ▁sav ings
D-1582	-0.8054633736610413	net_economic_ savings
P-1582	-0.7000 -1.9024 -0.5453 -1.6911 -0.6412 -0.0463 -0.7440 -0.1733
S-582	RESULTS: Overall ICU mortality (median stay, 5 days) was 17%.<unk>
T-582	icu mortality
H-582	-0.5455957055091858	▁ ICU ▁mortal ity
D-582	-0.5455957055091858	ICU mortality
P-582	-0.2162 -0.0200 -1.9880 -0.4999 -0.4456 -0.1039
S-2020	Nurses in all settings have an essential role in supporting patients in managing this disease.<unk>
T-2020	nurses patients disease
H-2020	-1.1369526386260986	
D-2020	-1.1369526386260986	
P-2020	-2.1427 -0.1312
S-905	We therefore studied our center's experience with CRT in dialysis-dependent patients.<unk>
T-905	crt patients
H-905	-0.6950470209121704	▁c RT ▁di al ysis - dependent ▁patients
D-905	-0.6950470209121704	cRT dialysis-dependent patients
P-905	-1.5791 -1.4430 -1.3376 -0.1437 -0.0358 -0.1325 -0.1319 -1.8275 -0.1678 -0.1517
S-217	The mean age of the CHF patients was 76 ± 14 years, and 57% were female.<unk>
T-217	chf patients
H-217	-0.5970454216003418	▁CHF
D-217	-0.5970454216003418	CHF
P-217	-0.3998 -1.3018 -0.0895
S-163	Where 'usual' care is less good, the impact of RM is likely to be greater.<unk>
T-163	rm
H-163	-1.3155800104141235	
D-163	-1.3155800104141235	
P-163	-2.5612 -0.0700
S-556	BACKGROUND: Few studies have focused on young and very young adults with HF.<unk>
T-556	hf
H-556	-0.6068300008773804	▁ HF
D-556	-0.6068300008773804	HF
P-556	-1.8270 -0.3463 -0.1812 -0.0729
S-529	Hypoalbuminemia has been recognized as a prognostic indicator in patients with heart failure.<unk>
T-529	hypoalbuminemia prognostic patients heart_failure
H-529	-0.6488757133483887	▁Hypo album in emia
D-529	-0.6488757133483887	Hypoalbuminemia
P-529	-1.6175 -0.0218 -0.0740 -0.0108 -1.9121 -0.2571
S-1461	First-in-class angiotensin receptor neprilysin inhibitor in heart failure.<unk>
T-1461	angiotensin_receptor_neprilysin_inhibitor heart_failure
H-1461	-0.5187948942184448	▁ang io ten sin ▁receptor ▁nepri ly sin ▁inhibi tor ▁heart ▁failure
D-1461	-0.5187948942184448	angiotensin receptor neprilysin inhibitor heart failure
P-1461	-2.3644 -1.3984 -0.0395 -0.7938 -0.4254 -0.0100 -0.2086 -0.5847 -0.3687 -0.0184 -0.3852 -0.4505 -0.1188 -0.0967
S-1079	Unfolded protein response regulates cardiac sodium current in systolic human heart failure.<unk>
T-1079	unfolded_protein_response cardiac_sodium systolic heart_failure
H-1079	-1.2159994840621948	▁un fold ed _ ▁protein ▁response _ regula tes ▁cardiac ▁so dium _ ▁current ▁sy sto lic _ heart ▁failure
D-1079	-1.2159994840621948	unfolded_ protein response_regulates cardiac sodium_ current systolic_heart failure
P-1079	-3.8581 -0.0001 -0.0268 -1.9347 -1.8328 -1.9832 -2.4099 -5.2270 -0.0386 -0.0713 -0.0595 -0.0067 -1.0697 -2.4984 -0.0302 -0.0066 -0.0160 -0.1847 -4.5347 -0.5283 -0.2147 -0.2200
S-1566	Presence of diastolic dysfunction in patients with peripheral artery disease.<unk>
T-1566	diastolic_dysfunction patients peripheral_artery_disease
H-1566	-0.2729743421077728	▁dia sto lic ▁dys function ▁per i pher al ▁arter y ▁disease
D-1566	-0.2729743421077728	diastolic dysfunction peripheral artery disease
P-1566	-0.0103 -0.0294 -0.0860 -0.8504 -0.0534 -0.1167 -0.1626 -0.0057 -0.1213 -1.2767 -0.3774 -0.5425 -0.0932 -0.0961
S-1252	Western blot analysis, immunohistochemistry and electron microscopy were used.<unk>
T-1252	western_blot immunohistochemistry electron_microscopy
H-1252	-0.4594111144542694	▁blot _ analyse ▁immun oh isto che mist ry ▁electro n ▁micro s copy
D-1252	-0.4594111144542694	blot_analyse immunohistochemistry electron microscopy
P-1252	-1.1408 -2.7430 -0.1635 -0.0451 -0.0505 -0.4444 -0.1042 -0.2456 -1.4383 -0.0015 -0.0196 -0.2879 -0.2860 -0.1387 -0.1316 -0.1099
S-1741	However, limited evidence is available specifically on idiopathic dilated cardiomyopathy.<unk>
T-1741	evidence idiopathic_dilated_cardiomyopathy
H-1741	-0.22114664316177368	▁ idio pathi c ▁dil ated _ ▁cardio my o pathy
D-1741	-0.22114664316177368	idiopathic dilated_ cardiomyopathy
P-1741	-0.7843 -0.0089 -0.0065 -0.0299 -0.4336 -0.2385 -0.2463 -0.1340 -0.6601 -0.1268 -0.0163 -0.1177 -0.0721
S-67	Ischemic cardiomyopathy and male sex were not independent predictors of mortality.<unk>
T-67	ischemic_cardiomyopathy mortality
H-67	-0.4403272271156311	▁i sche mic _ ▁cardio my o pathy ▁male _ ▁sex
D-67	-0.4403272271156311	ischemic_ cardiomyopathy male_ sex
P-67	-1.1700 -0.0008 -0.0713 -0.4095 -0.1299 -0.4644 -0.1489 -0.0178 -0.4512 -1.0424 -0.3873 -1.2725 -0.1583
S-350	The patient was diagnosed as hypertensive LV dysfunction with mild MR and significant MS.<unk>
T-350	patient diagnosed hypertensive_lv_dysfunction
H-350	-0.4325351119041443	▁hyper tensi ve _ ▁LV ▁dys function ▁mild ▁MR
D-350	-0.4325351119041443	hypertensive_ LV dysfunction mild MR
P-350	-0.5332 -0.0332 -0.0237 -0.3662 -0.2772 -0.1008 -0.0188 -0.8729 -0.1782 -2.2904 -0.0633
S-1036	At the molecular level, HF has been associated with chromatin hyperacetylation.<unk>
T-1036	hf chromatin_hyperacetylation
H-1036	-0.28067275881767273	▁ HF ▁chr omat in ▁hyper ace ty lation
D-1036	-0.28067275881767273	HF chromatin hyperacetylation
P-1036	-0.6514 -0.0336 -0.4885 -0.0280 -0.9366 -0.4153 -0.0827 -0.2608 -0.0468 -0.0837 -0.0600
S-1724	We divided physicians into quintiles according to their volume of patients with HF.<unk>
T-1724	physicians patients hf
H-1724	-1.0699468851089478	▁physician s ▁ HF
D-1724	-1.0699468851089478	physicians HF
P-1724	-3.6103 -0.0600 -2.3541 -0.1755 -0.1335 -0.0863
S-1701	Race influences the safety and efficacy of spironolactone in severe heart failure.<unk>
T-1701	spironolactone severe_heart_failure
H-1701	-0.7175422310829163	▁spi rono lac tone
D-1701	-0.7175422310829163	spironolactone
P-1701	-1.6384 -0.0092 -0.0200 -0.0744 -2.2769 -0.2864
S-1644	Conceptually, maintenance of sinus rhythm could prevent adverse outcomes related to AF.<unk>
T-1644	sinus_rhythm adverse_outcomes
H-1644	-0.5844358801841736	▁sinus ▁ rhythm
D-1644	-0.5844358801841736	sinus rhythm
P-1644	-1.3842 -0.2785 -0.0315 -1.1439 -0.0841
S-875	This included significant amelioration of all the ingenuity pathway analysis noted above.<unk>
T-875	ingenuity_pathway_analysis
H-875	-0.5372880101203918	▁ingen u ity _ path way
D-875	-0.5372880101203918	ingenuity_pathway
P-875	-0.6256 -0.2326 -0.7014 -0.8891 -0.5279 -0.4376 -0.7127 -0.1714
S-568	BACKGROUND: Patients with heart failure are a growing population within cardiac rehabilitation.<unk>
T-568	patients heart_failure cardiac_rehabilitation
H-568	-1.1317592859268188	▁heart ▁failure ▁cardiac ▁rehabilita tion
D-568	-1.1317592859268188	heart failure cardiac rehabilitation
P-568	-3.9364 -0.9705 -1.2874 -1.1106 -0.3997 -0.1152 -0.1025
S-1795	The prognosis of C'D HF is worse than for other etiologies.<unk>
T-1795	prognosis hf etiologies
H-1795	-0.7612974643707275	▁prognos is ▁c ' d ▁ HF
D-1795	-0.7612974643707275	prognosis c'd HF
P-1795	-1.6406 -0.0262 -1.4565 -1.4919 -0.5742 -1.0713 -0.0244 -0.4935 -0.0732
S-1137	Myocardial infarction was elicited in adult male Wistar rats.<unk>
T-1137	myocardial_infarction
H-1137	-0.5017232894897461	▁My o card ial ▁in far ction ▁Wi star ▁rat s
D-1137	-0.5017232894897461	Myocardial infarction Wistar rats
P-1137	-0.4536 -0.0648 -0.0811 -0.3589 -0.6991 -0.1317 -0.1042 -3.5243 -0.4286 -0.2136 -0.0712 -0.1420 -0.2493
S-490	E/e'septal showed good diagnostic performance for detecting normal filling pressures.<unk>
T-490	septal diagnostic filling_pressures
H-490	-1.6275923252105713	
D-490	-1.6275923252105713	
P-490	-3.1026 -0.1526
S-39	Background: The benefits of anemia treatment in patients with heart disease are uncertain.<unk>
T-39	anemia patients heart_disease
H-39	-1.5205954313278198	▁an emia
D-39	-1.5205954313278198	anemia
P-39	-1.0629 -0.1122 -4.7473 -0.1599
S-468	Interventions to improve management of acute heart failure are required at low-volume sites.<unk>
T-468	acute_heart_failure
H-468	-0.5101357698440552	▁a cute _ heart ▁failure
D-468	-0.5101357698440552	acute_heart failure
P-468	-1.4904 -0.0102 -0.0491 -1.2642 -0.4287 -0.1934 -0.1350
S-1689	BACKGROUND: Public reporting on quality aims to help patients select better hospitals.<unk>
T-1689	public_reporting patients hospitals
H-1689	-1.6324845552444458	
D-1689	-1.6324845552444458	
P-1689	-3.1772 -0.0878
S-1617	Effects of care management and telehealth: a longitudinal analysis using medicare data.<unk>
T-1617	telehealth longitudinal medicare
H-1617	-1.1948707103729248	▁care ▁management ▁tele health ▁medica re
D-1617	-1.1948707103729248	care management telehealth medicare
P-1617	-6.4229 -0.2907 -1.2432 -0.5021 -0.0715 -0.0118 -0.9089 -0.1078
S-299	Preoperative demographics, operative outcomes, and survival were analyzed.<unk>
T-299	preoperative operative outcomes
H-299	-0.5201171636581421	
D-299	-0.5201171636581421	
P-299	-0.9889 -0.0513
S-543	Treatment algorithms for de novo, post-LVAD AI have not been well defined.<unk>
T-543	post-lvad_ai
H-543	-0.8665746450424194	▁algorithm s ▁post - L VAD
D-543	-0.8665746450424194	algorithms post-LVAD
P-543	-2.5218 -0.1531 -0.2383 -0.0089 -1.8670 -0.0131 -1.9482 -0.1822
S-1829	DESIGN: Population-based, retrospective, new-user cohort study.<unk>
T-1829	cohort_study
H-1829	-1.0078909397125244	
D-1829	-1.0078909397125244	
P-1829	-1.9484 -0.0674
S-1232	Rhythm- and rate-control strategies are associated with similar efficacy outcomes.<unk>
T-1232	rate-control outcomes
H-1232	-1.0034984350204468	▁ Rhythm - _ control ▁strategie s
D-1232	-1.0034984350204468	Rhythm-_control strategies
P-1232	-0.1945 -0.0500 -0.0389 -4.9826 -1.9119 -1.0747 -0.1336 -0.4266 -0.2185
S-1711	OBJECTIVES: To analyze the relationship between length of stay and rehospitalization.<unk>
T-1711	rehospitalization
H-1711	-1.2282689809799194	
D-1711	-1.2282689809799194	
P-1711	-2.3503 -0.1062
S-872	We found that 538 proteins significantly changed after TAC, which mapped to 53 pathways.<unk>
T-872	proteins tac
H-872	-0.992017924785614	▁protein s ▁ TAC
D-872	-0.992017924785614	proteins TAC
P-872	-4.4680 -0.0515 -0.8382 -0.1696 -0.2995 -0.1252
S-361	However, the degree of MS early after surgery was not significant, with an MVA of 1.8 cm2.<unk>
T-361	surgery mva
H-361	-0.47491753101348877	▁MS ▁m VA
D-361	-0.47491753101348877	MS mVA
P-361	-0.6915 -1.0352 -0.3691 -0.2336 -0.0452
S-1769	Participants were divided into age-specific low, moderate, and high CRF categories.<unk>
T-1769	crf
H-1769	-0.5160298347473145	▁c RF
D-1769	-0.5160298347473145	cRF
P-1769	-1.7484 -0.1033 -0.1724 -0.0401
S-688	Mediterranean and DASH diet scores were calculated from food-frequency questionnaires.<unk>
T-688	dash
H-688	-0.7995346188545227	▁Mediterrane an ▁DAS h ▁die t ▁score s
D-688	-0.7995346188545227	Mediterranean DASh diet scores
P-688	-2.2251 -0.0195 -0.1973 -0.2200 -2.5100 -0.1613 -0.4731 -0.1276 -1.8869 -0.1745
S-1931	CONCLUSIONS: Poor social support and high barriers to exercise were associated with lower exercise time.<unk>
T-1931	exercise exercise
H-1931	-1.8186486959457397	
D-1931	-1.8186486959457397	
P-1931	-3.5531 -0.0842
S-132	In patients with diabetes, lower EO-CFUs were associated with improved functional capacity.<unk>
T-132	patients diabetes eo-cfus functional_capacity
H-132	-0.6293200850486755	▁diabetes ▁ EO - C FU s
D-132	-0.6293200850486755	diabetes EO-CFUs
P-132	-0.3495 -1.9513 -0.0062 -0.0157 -0.8072 -0.0229 -1.8835 -0.4764 -0.1513
S-377	Risk stratification for death and all-cause hospitalization in heart failure clinic outpatients.<unk>
T-377	risk_stratification death all-cause_hospitalization heart_failure clinic outpatients
H-377	-2.0863986015319824	▁risk
D-377	-2.0863986015319824	risk
P-377	-2.8317 -3.1357 -0.2919
S-844	Cardiac-resynchronization therapy in heart failure with a narrow QRS complex.<unk>
T-844	cardiac-resynchronization_therapy heart_failure narrow_qrs_complex
H-844	-0.6142008900642395	▁Card iac - re syn chron ization _ therapy ▁heart ▁failure
D-844	-0.6142008900642395	Cardiac-resynchronization_therapy heart failure
P-844	-0.4382 -0.1831 -0.1092 -0.1114 -0.1030 -0.0051 -1.2806 -2.2319 -0.2384 -1.8462 -0.6318 -0.7248 -0.0809
S-1573	Hospital-to-Home: a hospital readmission reduction program for congestive heart failure.<unk>
T-1573	hospital-to-home hospital readmission congestive_heart_failure
H-1573	-1.0341284275054932	▁hospital ▁read mission _ ▁re duction _ programm ▁con ges tive _ heart ▁failure
D-1573	-1.0341284275054932	hospital readmission_ reduction_programm congestive_heart failure
P-1573	-1.3783 -2.7620 -2.7755 -1.3786 -0.8211 -0.0579 -1.3754 -0.8424 -0.7112 -0.2152 -1.6836 -0.1223 -1.4818 -0.5248 -0.2071 -0.2089
S-1636	Blacks had shorter 6-minute walk distance and lower peak VO2 at baseline.<unk>
T-1636	6-minute_walk_distance peak_vo2 baseline
H-1636	-1.0908803939819336	▁Black s
D-1636	-1.0908803939819336	Blacks
P-1636	-1.2409 -0.0792 -2.4302 -0.6133
S-191	Multivariate models were used to compute odds ratios while accounting for hospital clustering.<unk>
T-191	multivariate_models odds_ratios accounting hospital
H-191	-0.7103220820426941	▁odds ▁ratio s ▁hospital ▁cluster ing
D-191	-0.7103220820426941	odds ratios hospital clustering
P-191	-3.2556 -0.3347 -0.1775 -1.5078 -0.0270 -0.0802 -0.1387 -0.1610
S-497	HFrEF and HFpEF patients exhibited a similar distribution along the regression line.<unk>
T-497	hfref hfpef patients regression_line
H-497	-0.49380046129226685	▁H Fr EF ▁ HF p EF
D-497	-0.49380046129226685	HFrEF HFpEF
P-497	-2.4222 -0.0846 -0.1052 -0.1568 -0.0380 -0.0905 -0.1060 -1.2466 -0.1943
S-412	Nitroxyl (HNO): A novel approach for the acute treatment of heart failure.<unk>
T-412	nitroxyl hno acute heart_failure
H-412	-0.8435148596763611	▁ni tro x yl h no
D-412	-0.8435148596763611	nitroxylhno
P-412	-0.6234 -0.0018 -0.0583 -0.1307 -2.6006 -0.4952 -2.7249 -0.1132
S-1412	Impact of physician continuity on death or urgent readmission after discharge among patients with heart failure.<unk>
T-1412	physician death readmission discharge patients heart_failure
H-1412	-1.6454732418060303	▁physician ▁continu ity _ van _ ▁death ▁urgent _ ▁read mission
D-1412	-1.6454732418060303	physician continuity_van_ death urgent_ readmission
P-1412	-1.4170 -0.9176 -0.2744 -4.9926 -3.1380 -0.6417 -1.6337 -1.2876 -0.1083 -1.3380 -0.4039 -5.0639 -0.1743
S-322	Heart block was induced, the pulmonary artery snared, and BiVP initiated.<unk>
T-322	heart_block pulmonary_artery bivp
H-322	-0.2910686433315277	▁Heart ▁block ▁pulmonar y ▁arter y ▁snar ed ▁Bi VP
D-322	-0.2910686433315277	Heart block pulmonary artery snared BiVP
P-322	-1.5926 -0.6582 -0.0072 -0.0189 -0.0520 -0.1727 -0.5170 -0.0407 -0.3092 -0.0008 -0.0442 -0.0795
S-1319	Feasibility was assessed in terms of recruitment, intervention compliance, and attrition.<unk>
T-1319	compliance attrition
H-1319	-1.0223987102508545	
D-1319	-1.0223987102508545	
P-1319	-2.0036 -0.0412
S-940	These results further implicate resistin as a link between inflammation, metabolism, and heart disease.<unk>
T-940	resistin inflammation metabolism heart_disease
H-940	-1.2192012071609497	▁resist in ▁ inflammation ▁metabolism
D-940	-1.2192012071609497	resistin inflammation metabolism
P-940	-1.2981 -0.4320 -2.0892 -0.0158 -0.2654 -3.8951 -0.5389
S-974	During 90 days of follow-up, there were 2,462 cardiovascular events and 617 deaths.<unk>
T-974	follow-up cardiovascular_events deaths
H-974	-0.9198914766311646	▁cardiovascular ▁events
D-974	-0.9198914766311646	cardiovascular events
P-974	-1.3513 -1.8330 -0.4464 -0.0489
S-588	The change in LVET between admission and follow-up measurement was not associated with outcome.<unk>
T-588	change lvet admission follow-up outcome
H-588	-0.9802973866462708	▁l VET ▁ad mission ▁follow - up
D-588	-0.9802973866462708	lVET admission follow-up
P-588	-2.7949 -0.1211 -2.1068 -1.5822 -0.0586 -0.0339 -0.0064 -1.7809 -0.3377
S-1605	Bioinformatic analysis of microarray data reveals several key genes related to heart failure.<unk>
T-1605	microarray genes heart_failure
H-1605	-0.8374670743942261	▁bio informati c ▁micro arra y
D-1605	-0.8374670743942261	bioinformatic microarray
P-1605	-0.4791 -0.0452 -0.0850 -1.9549 -0.0322 -0.0632 -3.8233 -0.2169
S-1183	Identifying CAD as a cause of systolic HF has prognostic and treatment implications.<unk>
T-1183	cad systolic_hf prognostic
H-1183	-0.29067960381507874	▁CAD ▁sy sto lic _ HF
D-1183	-0.29067960381507874	CAD systolic_HF
P-1183	-1.1520 -0.0620 -0.0254 -0.0072 -0.3960 -0.1681 -0.4468 -0.0680
S-1202	Herein, we review the current knowledge on diuretic use and outcomes in HF.<unk>
T-1202	diuretic outcomes hf
H-1202	-1.2815531492233276	▁ HF
D-1202	-1.2815531492233276	HF
P-1202	-3.8147 -0.7880 -0.4064 -0.1170
S-373	Therefore, the surgical indications need to be carefully evaluated in patients with functional MS.<unk>
T-373	surgical patients functional_ms
H-373	-0.6572099328041077	▁functional ▁MS
D-373	-0.6572099328041077	functional MS
P-373	-2.2868 -0.1947 -0.0772 -0.0701
S-813	PATIENTS: 196 persistent AF patients referred for echocardiographic examination.<unk>
T-813	patients patients echocardiographic
H-813	-1.1070802211761475	▁af ▁patients ▁e cho car dio graphic
D-813	-1.1070802211761475	af patients echocardiographic
P-813	-2.1263 -3.0065 -0.3050 -0.0163 -0.0123 -0.6749 -1.4969 -2.2238 -0.1018
S-161	Care packages generally improved health-related quality-of-life and were acceptable to patients.<unk>
T-161	quality-of-life patients
H-161	-0.8057923913002014	
D-161	-0.8057923913002014	
P-161	-1.4598 -0.1518
S-985	It is not appropriate to expand on the management of congenital heart lesions in this review.<unk>
T-985	congenital heart lesions
H-985	-0.7558969259262085	▁con geni tal _ heart ▁les ions
D-985	-0.7558969259262085	congenital_heart lesions
P-985	-1.9396 -0.0286 -0.0292 -0.2254 -2.4476 -1.8919 -0.0478 -0.1136 -0.0792
S-1349	PVF and its recovery had no effect on PB characteristics (period or amplitude).<unk>
T-1349	pvf pb
H-1349	-0.41058266162872314	▁PV F ▁ PB
D-1349	-0.41058266162872314	PVF PB
P-1349	-0.0436 -0.4608 -0.8790 -0.1082 -0.8854 -0.0865
S-401	It remains unclear whether sST2 concentrations identify benefit of BB therapy, however.<unk>
T-401	sst2 therapy
H-401	-1.585366129875183	▁s ST 2 ▁concentration s
D-401	-1.585366129875183	sST2 concentrations
P-401	-1.0541 -2.4837 -0.1259 -2.7125 -0.2132 -4.1899 -0.3182
S-1143	Cardiac function was assessed by means of the pressure-volume conductance catheter system.<unk>
T-1143	cardiac_function catheter
H-1143	-0.6847609281539917	▁Card iac ▁function ▁pressure - volu me _ ▁conduct ance ▁cat heter ▁system
D-1143	-0.6847609281539917	Cardiac function pressure-volume_ conductance catheter system
P-1143	-0.3309 -0.0427 -3.2794 -0.3013 -0.0378 -0.0073 -0.2550 -0.7611 -1.9280 -0.3250 -1.6986 -0.0053 -1.1045 -0.1290 -0.0655
S-353	As significant MS was associated with HF, surgical indication for MS was discussed.<unk>
T-353	hf surgical
H-353	-0.6993646621704102	▁MS
D-353	-0.6993646621704102	MS
P-353	-0.3363 -1.6856 -0.0762
S-865	General use of beta-blockers (93%) and adherence in this study was high.<unk>
T-865	beta-blockers
H-865	-0.2748592495918274	▁beta - block ers ▁ad her ence
D-865	-0.2748592495918274	beta-blockers adherence
P-865	-0.8635 -0.0526 -0.0652 -0.1048 -0.3041 -0.4040 -0.4702 -0.0933 -0.1160
S-1872	The primary safety end point was system- and procedure-related major adverse neurological and cardiovascular events.<unk>
T-1872	end_point neurological cardiovascular_events
H-1872	-1.5990549325942993	
D-1872	-1.5990549325942993	
P-1872	-3.0571 -0.1410
S-342	He had grade 4/6 holosystolic murmur and a third heart sound in the apex.<unk>
T-342	grade holosystolic_murmur third_heart_sound apex
H-342	-0.41879355907440186	▁holo sy sto lic _ ▁mur mur
D-342	-0.41879355907440186	holosystolic_ murmur
P-342	-0.0509 -0.0139 -0.0879 -0.0372 -0.5230 -1.2926 -0.0099 -1.6500 -0.1038
S-306	Should eligibility for heart transplantation be a requirement for left ventricular assist device use?<unk>
T-306	heart_transplantation left_ventricular_assist_device
H-306	-0.8950474262237549	▁e ligi bility ▁heart ▁transplant ation ▁left ▁vent ri cular _ assist ▁device
D-306	-0.8950474262237549	eligibility heart transplantation left ventricular_assist device
P-306	-2.0509 -0.0046 -0.2931 -3.2273 -0.9314 -0.1405 -0.6095 -0.4008 -0.8218 -0.3539 -0.8134 -0.5645 -2.4848 -0.6410 -0.0883
S-1157	Relationships between right ventricular function, body composition, and prognosis in advanced heart failure.<unk>
T-1157	right_ventricular_function prognosis heart_failure
H-1157	-1.5406931638717651	▁right ▁vent ri cular _ function
D-1157	-1.5406931638717651	right ventricular_function
P-1157	-3.5723 -0.7309 -0.6505 -0.3644 -2.0530 -1.4555 -3.3233 -0.1756
S-1039	The remodelling that precedes HF is induced by haemodynamic and neuronal stressors.<unk>
T-1039	remodelling hf haemodynamic neuronal_stressors
H-1039	-0.4116963744163513	▁ HF ▁ha emo dynamic ▁neuron al ▁stress ors
D-1039	-0.4116963744163513	HF haemodynamic neuronal stressors
P-1039	-1.7651 -0.0491 -0.0204 -0.0531 -0.0013 -0.3857 -0.0172 -1.8264 -0.2122 -0.1044 -0.0939
S-1557	Adjusted means were calculated for subclinical atherosclerosis using general linear models.<unk>
T-1557	subclinical atherosclerosis linear_models
H-1557	-0.9061632752418518	▁sub clin ical _ at hero sc ler osis
D-1557	-0.9061632752418518	subclinical_atherosclerosis
P-1557	-2.2825 -0.0941 -0.2225 -0.1923 -0.4924 -1.0220 -0.0553 -3.3635 -0.0566 -1.9525 -0.2342
S-1273	Exercise intolerance is a hallmark feature of chronic heart failure and is associated with poor prognosis.<unk>
T-1273	exercise_intolerance chronic_heart_failure prognosis
H-1273	-0.8597596883773804	▁Exerci se ▁in tolerance ▁chronic _ heart ▁failure
D-1273	-0.8597596883773804	Exercise intolerance chronic_heart failure
P-1273	-3.9425 -0.0096 -0.2421 -0.0156 -1.2312 -0.3724 -1.1840 -0.7594 -0.7404 -0.1002
S-538	In conclusion, preoperative hypoalbuminemia is associated with poor prognosis after LVAD surgery.<unk>
T-538	preoperative hypoalbuminemia prognosis lvad surgery
H-538	-0.5423593521118164	▁pre operativ e ▁hypo album in emia
D-538	-0.5423593521118164	preoperative hypoalbuminemia
P-538	-0.5332 -0.0277 -0.0115 -1.2573 -0.0501 -0.0578 -0.0404 -2.7712 -0.1320
S-981	In children, where coronary disease is not the leading cause of heart failure, it is less common.<unk>
T-981	coronary_disease leading heart_failure
H-981	-0.6610737442970276	▁corona ry _ ▁disease ▁heart ▁failure
D-981	-0.6610737442970276	coronary_ disease heart failure
P-981	-0.1495 -0.6280 -1.5976 -0.7125 -1.8836 -0.1728 -0.0749 -0.0697
S-929	Recent clinical studies have connected elevated resistin levels with the development and severity of heart failure.<unk>
T-929	clinical connected elevated resistin heart_failure
H-929	-1.5812147855758667	
D-929	-1.5812147855758667	
P-929	-3.0857 -0.0768
S-1012	CONCLUSION: The deficit index and the biological phenotype equally predict mortality.<unk>
T-1012	deficit_index biological_phenotype mortality
H-1012	-0.6678236126899719	▁deficit ▁index ▁bi ological _ ▁ph eno type
D-1012	-0.6678236126899719	deficit index biological_ phenotype
P-1012	-1.5491 -1.0092 -1.3389 -0.2308 -0.5408 -0.2703 -0.0263 -0.0005 -1.5329 -0.1793
S-1231	BACKGROUND: Atrial fibrillation (AF) is common in patients with heart failure.<unk>
T-1231	atrial_fibrillation patients heart_failure
H-1231	-0.8369835615158081	▁At rial ▁fi bril lation AF ▁heart ▁failure
D-1231	-0.8369835615158081	Atrial fibrillationAF heart failure
P-1231	-2.8699 -0.0116 -2.0966 -0.0096 -0.0387 -1.3054 -1.6642 -0.2232 -0.0859 -0.0649
S-1457	Fat, cachexia, and the right ventricle in heart failure: a web of complicity.<unk>
T-1457	cachexia right_ventricle heart_failure
H-1457	-1.0123109817504883	▁cache xia ▁vent ric le ▁heart ▁failure
D-1457	-1.0123109817504883	cachexia ventricle heart failure
P-1457	-1.4341 -0.0168 -3.0794 -1.3559 -0.2449 -1.2685 -0.5788 -0.9679 -0.1645
S-992	Specific signalling pathways activating either adaptive or maladaptive cardiac remodelling have been identified.<unk>
T-992	signalling_pathways cardiac_remodelling
H-992	-0.7947758436203003	▁signal ling ▁path ways ▁mal adapt ive _ ▁cardiac ▁remodel ling
D-992	-0.7947758436203003	signalling pathways maladaptive_ cardiac remodelling
P-992	-3.2404 -0.2949 -2.5818 -0.0778 -1.4558 -0.0099 -0.0166 -0.6246 -0.3273 -1.3105 -0.0847 -0.1659 -0.1419
S-884	All baseline ECGs were reviewed by a panel of 3 experienced electrocardiographers.<unk>
T-884	baseline ecgs electrocardiographers
H-884	-0.7252720594406128	▁e CG s ▁electro car dio graph ers
D-884	-0.7252720594406128	eCGs electrocardiographers
P-884	-2.3769 -0.0809 -1.7189 -0.3278 -0.0060 -1.1180 -1.2087 -0.1918 -0.1579 -0.0659
S-328	During AVD and VVD variations, CO was associated with free wall RS (P < 0.008).<unk>
T-328	avd vvd free_wall_rs
H-328	-1.2100664377212524	▁AV D ▁VVD ▁free _ ▁wall ▁RS
D-328	-1.2100664377212524	AVD VVD free_ wall RS
P-328	-0.7904 -0.7216 -2.7258 -3.1473 -0.3779 -1.5717 -1.3663 -0.1103 -0.0794
S-1446	This appears to be a genuine effect that is not solely a consequence of heart rate variation.<unk>
T-1446	heart_rate
H-1446	-1.3620532751083374	
D-1446	-1.3620532751083374	
P-1446	-2.5706 -0.1535
S-388	Therefore, we examined incidence and predictors of ESRD in outpatients with HF.<unk>
T-388	incidence esrd outpatients hf
H-388	-1.292907953262329	▁ES RD ▁ HF
D-388	-1.292907953262329	ESRD HF
P-388	-3.4360 -0.2088 -3.7229 -0.1736 -0.1086 -0.1075
S-1153	A left bundle branch block electrical activation sequence was simulated in all models.<unk>
T-1153	left_bundle_branch_block
H-1153	-0.8990030288696289	▁bund le _ ▁bran ch _ ▁block ▁electric al ▁activa tion
D-1153	-0.8990030288696289	bundle_ branch_ block electrical activation
P-1153	-0.7552 -1.5169 -0.5866 -3.1204 -0.1160 -0.9904 -1.4947 -0.6280 -0.0534 -0.3542 -0.1994 -1.7399 -0.1320
S-1834	The risk for hHF was not higher with DPP-4 inhibitors than with the other study drugs.<unk>
T-1834	dpp-4_inhibitors drugs
H-1834	-0.3640076518058777	▁h HF ▁d PP -4 ▁inhibi tors
D-1834	-0.3640076518058777	hHF dPP-4 inhibitors
P-1834	-0.2232 -0.4210 -1.3009 -0.0827 -0.1784 -0.1216 -0.1376 -0.7276 -0.0831
S-718	CONCLUSIONS: ECCT is an acceptable alternative for advanced heart failure therapy in select patients.<unk>
T-718	ecct heart_failure therapy patients
H-718	-0.8288272023200989	▁EC CT ▁advanced _ heart ▁failure ▁ therapy
D-718	-0.8288272023200989	ECCT advanced_heart failure therapy
P-718	-1.1243 -0.3265 -2.7529 -0.1576 -1.5414 -0.7843 -1.1576 -0.0134 -0.3353 -0.0951
S-815	CV events were defined as CV death, non-fatal stroke and hospitalisation for heart failure.<unk>
T-815	death stroke hospitalisation heart_failure
H-815	-0.6342098116874695	▁CV ▁death ▁non - fa tal _ stro t ▁hospital isation ▁heart ▁failure
D-815	-0.6342098116874695	CV death non-fatal_strot hospitalisation heart failure
P-815	-0.0469 -3.3954 -1.1372 -0.0090 -0.0109 -0.0043 -0.1813 -0.4411 -1.9545 -0.3139 -0.0123 -1.6285 -0.1804 -0.0635 -0.1339
S-248	Protective effects of exercise training (ET) on endothelial function have been demonstrated.<unk>
T-248	exercise training endothelial_function
H-248	-0.7595112919807434	▁ Protect ive _ effect ▁exercise _ training ET ▁en dot heli al ▁function
D-248	-0.7595112919807434	Protective_effect exercise_trainingET endothelial function
P-248	-1.3279 -0.2726 -0.0160 -1.0501 -0.0740 -3.2756 -1.3450 -0.2228 -1.4737 -0.5721 -0.5278 -0.0190 -0.0129 -1.8266 -0.0537 -0.0822
S-714	Among the 454 patients who underwent heart transplant, 84 (18.5%) were ECCT.<unk>
T-714	patients heart_transplant ecct
H-714	-1.1583690643310547	▁heart ▁transplant ▁EC CT
D-714	-1.1583690643310547	heart transplant ECCT
P-714	-4.7074 -0.5421 -1.4929 -0.0601 -0.0618 -0.0861
S-20	Prospectively, FFM decreased but FM increased, despite stable body weight in CC.<unk>
T-20	prospectively ffm stable
H-20	-1.0239096879959106	▁f FM
D-20	-1.0239096879959106	fFM
P-20	-0.6680 -0.3065 -3.0386 -0.0826
S-908	No periprocedural or long-term complications were observed among dialysis patients.<unk>
T-908	complications dialysis patients
H-908	-0.8299605846405029	▁per i pro ced ural
D-908	-0.8299605846405029	periprocedural
P-908	-2.2732 -0.1602 -0.0214 -0.0124 -0.0206 -3.1561 -0.1657
S-943	BACKGROUND: AF is a precipitating factor for clinical deterioration of HFPEF.<unk>
T-943	clinical hfpef
H-943	-1.9555044174194336	▁af _ factor ▁clinic al _ ▁deteriora tion
D-943	-1.9555044174194336	af_factor clinical_ deterioration
P-943	-2.8942 -4.3397 -4.6506 -2.1148 -0.0373 -0.5061 -0.5795 -0.9975 -3.3141 -0.1213
S-84	Participating in a multihospital study to promote adoption of heart failure guidelines: lessons for nurse leaders.<unk>
T-84	heart_failure nurse
H-84	-1.5951563119888306	▁multi hospital _ ▁study ▁heart ▁failure
D-84	-1.5951563119888306	multihospital_ study heart failure
P-84	-3.5664 -0.0202 -2.7069 -1.0919 -2.8952 -0.2448 -2.0281 -0.2078
S-1003	METHODS: Southeastern Minnesota residents with HF were recruited from 2007 to 2011.<unk>
T-1003	minnesota hf
H-1003	-0.9405817985534668	▁South e a stern ▁Minnesota ▁residents ▁ HF
D-1003	-0.9405817985534668	Southeastern Minnesota residents HF
P-1003	-6.3308 -0.0545 -0.0867 -0.0217 -0.3534 -1.9345 -0.2526 -0.0294 -0.2163 -0.1258
S-9	OBJECTIVES: Cardiac cachexia (CC) is associated with changes in body composition.<unk>
T-9	cardiac_cachexia
H-9	-0.42182305455207825	▁Card iac ▁cache xia cc
D-9	-0.42182305455207825	Cardiac cachexiacc
P-9	-0.5205 -0.0103 -0.3085 -0.0723 -1.4536 -0.5186 -0.0689
S-632	CONCLUSIONS: Frailty is independently associated with risk of HF in older adults.<unk>
T-632	frailty hf
H-632	-0.6507025957107544	▁fra il ty ▁ HF
D-632	-0.6507025957107544	frailty HF
P-632	-1.1683 -0.7870 -0.0620 -1.9365 -0.1677 -0.3699 -0.0635
S-254	The proteome of HDL particles was profiled by shotgun LC-MS/MS.<unk>
T-254	proteome hdl
H-254	-0.6623340845108032	▁prote ome ▁HD L _ parti cles ▁shot gun ▁ LC - MS
D-254	-0.6623340845108032	proteome HDL_particles shotgun LC-MS
P-254	-1.7774 -0.0756 -2.1769 -1.5258 -1.2687 -0.9331 -0.0691 -0.3679 -0.0157 -0.8659 -0.0139 -0.0325 -0.0119 -0.6372 -0.1635
S-566	Fatal and nonfatal outcomes were discordant, with better survival despite higher hospitalization rates.<unk>
T-566	outcomes hospitalization
H-566	-1.1717382669448853	
D-566	-1.1717382669448853	
P-566	-2.2652 -0.0783
S-532	Preoperative clinical characteristics and laboratory variables associated with mortality were analyzed.<unk>
T-532	preoperative clinical mortality
H-532	-0.700223982334137	▁pre operativ e ▁clinic al _ karakter istic s ▁laborator y _ ▁variable s ▁mortal ity
D-532	-0.700223982334137	preoperative clinical_karakteristics laboratory_ variables mortality
P-532	-2.8996 -0.0046 -0.0362 -3.1657 -0.0339 -0.7032 -1.7141 -0.1736 -0.0968 -0.2512 -0.0373 -0.7171 -0.6220 -0.6533 -0.0594 -1.3136 -0.0356 -0.0869
S-1484	Here, we give an overview of these miRNAs and their role in cardiac pathogenesis.<unk>
T-1484	mirnas cardiac pathogenesis
H-1484	-0.7758641839027405	▁mi RNA s ▁cardiac
D-1484	-0.7758641839027405	miRNAs cardiac
P-1484	-1.5059 -0.0032 -0.3469 -0.1384 -2.5625 -0.0984
S-61	We conducted a meta-analysis to identify factors associated with mortality in ICD-HF patients.<unk>
T-61	meta-analysis mortality patients
H-61	-0.9352484941482544	▁i CD - HF
D-61	-0.9352484941482544	iCD-HF
P-61	-3.5160 -0.1374 -0.0592 -0.0560 -1.4055 -0.4375
S-777	The patients were extubated within 3 to 6 hours, and blood loss and transfusion requirements were nominal.<unk>
T-777	patients extubated blood transfusion
H-777	-1.542016863822937	▁patients ▁trans fusion
D-777	-1.542016863822937	patients transfusion
P-777	-2.9970 -3.5550 -0.0730 -0.9576 -0.1275
S-984	Most of these lesions, such as septal defects, are amenable to surgical intervention.<unk>
T-984	lesions septal surgical
H-984	-0.279838889837265	▁sept al ▁defect s
D-984	-0.279838889837265	septal defects
P-984	-0.6670 -0.0397 -0.1639 -0.0335 -0.6846 -0.0903
S-730	Only 13% of patients had no discrepancy between the discharge and follow-up medication lists.<unk>
T-730	patients discharge follow-up medication
H-730	-1.2866019010543823	
D-730	-1.2866019010543823	
P-730	-2.4868 -0.0864
S-1030	Measuring heart failure care by 30-day readmission: Rethinking the quality of outcome measures.<unk>
T-1030	heart_failure readmission outcome
H-1030	-1.034367561340332	▁heart ▁failure _ care
D-1030	-1.034367561340332	heart failure_care
P-1030	-1.7317 -0.2409 -1.5703 -1.5882 -0.9496 -0.1256
S-1042	However, the role of 'readers' (bromodomain proteins) was less well defined.<unk>
T-1042	bromodomain_proteins
H-1042	-0.6996952891349792	bro modo main _ ▁protein s
D-1042	-0.6996952891349792	bromodomain_ proteins
P-1042	-3.6838 -0.0217 -0.0165 -1.1548 -0.4663 -0.0179 -0.1543 -0.0821
S-1667	This patient population has a 1-year mortality rate of approximately 50% and requires special therapeutic interventions.<unk>
T-1667	patient mortality therapeutic
H-1667	-1.2382937669754028	
D-1667	-1.2382937669754028	
P-1667	-2.3517 -0.1249
S-315	We found that BTT and DT as implantation strategies tend to be no longer mutually exclusive.<unk>
T-315	btt dt implantation
H-315	-0.6956291198730469	▁B TT ▁ DT
D-315	-0.6956291198730469	BTT DT
P-315	-2.2955 -0.1294 -0.5731 -0.0201 -1.0810 -0.0747
S-1970	The treatment was safe, typical adverse event was hypotension, however without a need to interrupt the treatment.<unk>
T-1970	adverse_event hypotension
H-1970	-0.6725547909736633	▁hypo tension
D-1970	-0.6725547909736633	hypotension
P-1970	-2.2172 -0.1806 -0.2215 -0.0709
S-948	Multiple procedures and pharmaceutically assisted success rate was 73% (n = 54).<unk>
T-948	pharmaceutically
H-948	-0.47480466961860657	▁ pharma ce ut ically
D-948	-0.47480466961860657	pharmaceutically
P-948	-0.2138 -0.2648 -0.7108 -0.1014 -0.2416 -1.6774 -0.1137
S-288	RESULTS: Over a mean follow-up of 10.4 years, 970 participants developed incident HF.<unk>
T-288	follow-up hf
H-288	-0.8601939082145691	▁ HF
D-288	-0.8601939082145691	HF
P-288	-1.7900 -1.4159 -0.1463 -0.0886
S-1475	However, the use of biomarkers in the treatment of HF remains in its infancy.<unk>
T-1475	biomarkers hf
H-1475	-0.1962738186120987	▁bio mark ers ▁ HF
D-1475	-0.1962738186120987	biomarkers HF
P-1475	-0.0213 -0.0149 -0.1245 -0.9750 -0.0529 -0.1097 -0.0757
S-1498	RESULTS: Peak VO2 was 1.9±0.1 L/min (66±3% of predicted values).<unk>
T-1498	peak_vo2
H-1498	-0.5640391111373901	▁Peak _ vo 2
D-1498	-0.5640391111373901	Peak_vo2
P-1498	-1.0800 -0.7616 -0.4470 -0.2026 -0.6387 -0.2543
S-699	ST2 was analyzed in a subset of 910 patients with evaluable plasma samples.<unk>
T-699	st2 patients plasma
H-699	-0.669683039188385	▁ evalua ble _ ▁plasma ▁sample s
D-699	-0.669683039188385	evaluable_ plasma samples
P-699	-3.2943 -0.3518 -0.1183 -0.4625 -0.7013 -0.7434 -0.0923 -0.1764 -0.0869
S-1575	In addition to indicating possible suboptimal care of patients with this condition, there are significant economic considerations.<unk>
T-1575	patients condition economic
H-1575	-1.3283823728561401	
D-1575	-1.3283823728561401	
P-1575	-2.5055 -0.1513
S-1690	However, individual quality measures are suboptimal in identifying superior and inferior hospitals based on outcome performance.<unk>
T-1690	hospitals outcome
H-1690	-1.511919617652893	
D-1690	-1.511919617652893	
P-1690	-2.8474 -0.1765
S-671	The rates and risk factors associated with trastuzumab-related CHF among older patients are unknown.<unk>
T-671	chf patients
H-671	-0.8553079962730408	▁tras tuz um ab - related ▁CHF
D-671	-0.8553079962730408	trastuzumab-related CHF
P-671	-1.7006 -0.1180 -0.1200 -1.3237 -0.2318 -1.8947 -1.7361 -0.4072 -0.1658
S-2000	At 6 months, 88% of patients continued on support, 4% received transplants, and 8% died.<unk>
T-2000	patients transplants
H-2000	-0.8496062159538269	▁patients ▁transplant s
D-2000	-0.8496062159538269	patients transplants
P-2000	-2.6491 -1.2636 -0.1059 -0.1844 -0.0450
S-1903	Healthy individuals should engage in 150 minutes of moderate-intensity, aerobic exercise per week.<unk>
T-1903	healthy engage exercise
H-1903	-1.6873451471328735	▁aero bic
D-1903	-1.6873451471328735	aerobic
P-1903	-4.3651 -0.0792 -2.1664 -0.1387
S-1694	We ranked hospitals on the basis of their July 2005 to June 2008 performance on the composite.<unk>
T-1694	hospitals
H-1694	-0.8404248356819153	▁rank ed ▁hospital s
D-1694	-0.8404248356819153	ranked hospitals
P-1694	-2.6094 -0.0836 -1.6116 -0.0985 -0.5681 -0.0714
S-1955	FINDINGS: Between Oct 10, 2013, and March 27, 2015, we enrolled ten patients.<unk>
T-1955	patients
H-1955	-1.1094677448272705	
D-1955	-1.1094677448272705	
P-1955	-2.1151 -0.1039
S-1	The effects of more than a decade of national efforts dedicated to improve patient safety remain largely unclear.<unk>
T-1	patient
H-1	-1.4100799560546875	
D-1	-1.4100799560546875	
P-1	-2.7322 -0.0880
S-125	We recorded mortality, HF hospital admissions, transplant, and ventricular assist device.<unk>
T-125	mortality hf hospital admissions transplant ventricular_assist_device
H-125	-0.46670880913734436	▁ HF ▁hospital ▁ad missions ▁transplant ▁vent ri cular _ assist ▁device
D-125	-0.46670880913734436	HF hospital admissions transplant ventricular_assist device
P-125	-1.1738 -0.0326 -1.9315 -0.2247 -0.1014 -0.1858 -0.2021 -0.4910 -0.2513 -0.6701 -0.4216 -0.6200 -0.1119 -0.1161
S-1182	Coronary artery disease (CAD) is a major cause of systolic heart failure (HF).<unk>
T-1182	coronary_artery_disease cad systolic_heart_failure hf
H-1182	-0.25099459290504456	▁Corona ry ▁arter y ▁disease CAD ▁sy sto lic _ heart ▁failure HF
D-1182	-0.25099459290504456	Coronary artery diseaseCAD systolic_heart failureHF
P-1182	-0.3501 -0.2029 -0.2999 -0.0367 -0.4814 -0.4411 -0.0578 -0.0035 -0.0351 -0.1536 -0.9629 -0.2179 -0.3460 -0.1245 -0.0515
S-600	Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist.<unk>
T-600	heart_failure patients rheumatoid_arthritis tnf_antagonist
H-600	-0.715842068195343	▁Heart ▁failure ▁rhe um ato id _ ar thri tis ▁T NF ▁anta gon ist
D-600	-0.715842068195343	Heart failure rheumatoid_arthritis TNF antagonist
P-600	-1.0882 -2.2388 -4.3503 -0.0792 -0.1989 -0.2074 -0.6828 -0.8693 -0.6143 -0.2767 -0.7670 -0.0030 -0.2397 -0.0080 -0.1345 -0.2718 -0.1394
S-1593	Renal artery stenosis (RAS) is a common form of peripheral arterial disease.<unk>
T-1593	renal_artery_stenosis ras peripheral_arterial_disease
H-1593	-0.33602654933929443	▁Ren al ▁arter y ▁sten osis RAS ▁per i pher al _ ▁arterial ▁disease
D-1593	-0.33602654933929443	Renal artery stenosisRAS peripheral_ arterial disease
P-1593	-0.2832 -0.0243 -0.4246 -0.0927 -0.3068 -0.0195 -0.8140 -0.3799 -0.0738 -0.0072 -0.0793 -1.0656 -0.2612 -1.1946 -0.1705 -0.1791
S-923	Wilcoxon matched-pairs signed-rank tests were used for pre-post comparisons.<unk>
T-923	wilcoxon_matched-pairs_signed-rank_tests
H-923	-0.35344263911247253	▁Wil co xon
D-923	-0.35344263911247253	Wilcoxon
P-923	-0.1261 -0.0009 -0.0824 -1.3595 -0.1983
S-293	Survival after left ventricular assist device with and without temporary right ventricular support.<unk>
T-293	left_ventricular_assist_device right_ventricular_support
H-293	-0.7070844173431396	▁vent ri cular _ assist ▁device ▁right ▁vent ri cular _ support
D-293	-0.7070844173431396	ventricular_assist device right ventricular_support
P-293	-0.8765 -0.2075 -0.1144 -1.1045 -0.2369 -0.7672 -2.9614 -0.6451 -0.1702 -0.0889 -1.9940 -0.4720 -0.1624 -0.0981
S-1554	Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study.<unk>
T-1554	psoriasis atherosclerosis cardiovascular_events rotterdam_study
H-1554	-1.2246367931365967	▁p sori asis
D-1554	-1.2246367931365967	psoriasis
P-1554	-1.0355 -0.0635 -0.0157 -4.9156 -0.0929
S-1713	SETTING: Six thousand five hundred thirty-seven hospitals nationwide from January 1999 through September 2005.<unk>
T-1713	hospitals
H-1713	-0.9757246971130371	
D-1713	-0.9757246971130371	
P-1713	-1.8842 -0.0672
S-154	DATA EXTRACTION: Data were extracted and validity was assessed independently by two reviewers.<unk>
T-154	
H-154	-1.0448963642120361	
D-154	-1.0448963642120361	
P-154	-2.0444 -0.0454
S-1227	Eplerenone was effective in reducing the primary composite endpoint in all subgroups.<unk>
T-1227	eplerenone primary_composite_endpoint
H-1227	-0.27115532755851746	▁e pler en one
D-1227	-0.27115532755851746	eplerenone
P-1227	-0.3902 -0.0006 -0.0579 -0.2076 -0.8457 -0.1249
S-1280	Orthotopic heart transplantation (OHT) is the optimal treatment for end-stage heart failure.<unk>
T-1280	orthotopic_heart_transplantation oht end-stage_heart_failure
H-1280	-0.46746501326560974	▁Ort ho topic _ heart ▁transplant ation ▁o HT
D-1280	-0.46746501326560974	Orthotopic_heart transplantation oHT
P-1280	-0.6942 -0.0215 -0.0590 -0.2319 -1.0233 -0.7315 -0.0635 -0.0490 -0.1588 -2.0393 -0.0701
S-592	Right atrial myxoma complicated by pulmonary embolism and revealed by right heart failure.<unk>
T-592	right_atrial_myxoma pulmonary_embolism right_heart_failure
H-592	-0.42606258392333984	▁Right _ at rial _ my xo ma ▁pulmonar y ▁e mbol ism ▁right _ ▁heart ▁failure
D-592	-0.42606258392333984	Right_atrial_myxoma pulmonary embolism right_ heart failure
P-592	-1.4652 -0.3594 -0.7588 -0.0436 -0.2457 -1.6910 -0.0164 -0.2511 -0.0014 -0.0117 -0.1855 -0.0005 -0.3859 -0.1598 -0.1177 -1.3940 -0.8657 -0.0836 -0.0582
S-1369	Unilateral renal denervation improves autonomic balance in conscious rabbits with chronic heart failure.<unk>
T-1369	unilateral_renal_denervation autonomic_balance chronic_heart_failure
H-1369	-0.7833184599876404	▁Uni lateral _ ▁renal _ ▁den er va tion ▁autonomi c _ ▁balance ▁ conscious ▁rabbi ts ▁chronic _ heart ▁failure
D-1369	-0.7833184599876404	Unilateral_ renal_ denervation autonomic_ balance conscious rabbits chronic_heart failure
P-1369	-3.6489 -0.0043 -1.2316 -0.5833 -0.9796 -1.0432 -0.4393 -0.5836 -0.3403 -0.1372 -0.0824 -0.3537 -0.6820 -0.6127 -0.0509 -0.1008 -0.0283 -3.8738 -0.1910 -1.6180 -1.0908 -0.1349 -0.2058
S-594	Myxomas in the right atrium may rarely embolize to the pulmonary arterial vasculature.<unk>
T-594	myxomas right_atrium embolize pulmonary_arterial_vasculature
H-594	-0.42815595865249634	▁My xo mas ▁pulmonar y ▁arterial _ vas cula ture
D-594	-0.42815595865249634	Myxomas pulmonary arterial_vasculature
P-594	-0.5760 -0.0016 -0.4052 -0.0865 -0.0314 -0.7530 -1.8140 -0.9252 -0.1347 -0.1087 -0.1692 -0.1324
S-1203	The high-risk patient with heart failure with reduced ejection fraction: treatment options and challenges.<unk>
T-1203	patient heart_failure_with_reduced_ejection_fraction
H-1203	-1.2792726755142212	▁high - risk _ patient ▁heart ▁failure
D-1203	-1.2792726755142212	high-risk_patient heart failure
P-1203	-3.0078 -0.0325 -0.0154 -1.2872 -0.9621 -2.4627 -0.2744 -3.3537 -0.1177
S-638	Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure.<unk>
T-638	nfat mir-25 transcription_factor hand2 heart_failure
H-638	-0.7560805082321167	▁N fat ▁mi r -25 ▁tran scription ▁factor ▁Hand 2
D-638	-0.7560805082321167	Nfat mir-25 transcription factor Hand2
P-638	-3.7468 -0.0440 -1.1798 -1.0257 -0.0316 -0.0898 -0.1163 -0.2331 -0.7173 -0.2021 -1.3994 -0.2868
S-1429	Further, the expression of type I regulatory subunit (RI) was increased in HF.<unk>
T-1429	expression type_i_regulatory_subunit ri hf
H-1429	-1.0413655042648315	▁regulator y _ sub un it ▁ HF
D-1429	-1.0413655042648315	regulatory_subunit HF
P-1429	-5.5025 -0.0183 -1.1564 -1.0217 -0.6893 -0.0533 -1.3075 -0.4743 -0.0627 -0.1276
S-1564	The results were similar when coronary heart disease, stroke, and heart failure were analyzed separately.<unk>
T-1564	coronary_heart_disease stroke heart_failure
H-1564	-0.4415939450263977	▁corona ry _ heart ▁disease ▁stroke ▁heart ▁failure
D-1564	-0.4415939450263977	coronary_heart disease stroke heart failure
P-1564	-0.0827 -0.3575 -0.5975 -1.3620 -0.8111 -0.0657 -0.8284 -0.1936 -0.0556 -0.0618
S-458	Moreover, VEGF inhibition counteracted the positive effects of B on cardiac function and remodeling.<unk>
T-458	vegf_inhibition cardiac_function remodeling
H-458	-0.6550456881523132	▁VE GF ▁inhibi tion ▁b ▁cardiac ▁function ▁remodel ing
D-458	-0.6550456881523132	VEGF inhibition b cardiac function remodeling
P-458	-0.2805 -0.0119 -0.3864 -0.0328 -3.3479 -0.8509 -1.7745 -0.3057 -0.0274 -0.1269 -0.0607
S-400	We recently found changing doses of β-blocker (BB) may affect sST2 concentrations.<unk>
T-400	changing β-blocker sst2
H-400	-0.6164974570274353	▁β - block er bb ▁s ST 2
D-400	-0.6164974570274353	β-blockerbb sST2
P-400	-1.7792 -0.0368 -0.0653 -0.1386 -2.0818 -0.1875 -0.4609 -0.1555 -0.9505 -0.3089
S-720	Change in readmissions and follow-up visits as part of a heart failure readmission quality improvement initiative.<unk>
T-720	change readmissions follow-up heart_failure readmission
H-720	-1.7600655555725098	▁read missions ▁heart ▁failure
D-720	-1.7600655555725098	readmissions heart failure
P-720	-3.2606 -0.0656 -3.7579 -0.3265 -3.0216 -0.1283
S-1991	Neither intervention had a significant effect on quality of life as measured by the MLHF Questionnaire.<unk>
T-1991	quality_of_life mlhf_questionnaire
H-1991	-0.5950207114219666	▁ ML HF
D-1991	-0.5950207114219666	MLHF
P-1991	-0.8650 -0.4016 -0.4409 -1.0936 -0.1739
S-199	Pediatric heart failure (HF) is an important cause of morbidity and mortality in childhood.<unk>
T-199	heart_failure hf morbidity mortality
H-199	-0.5956804156303406	▁Pediatri c _ heart ▁failure HF ▁morbi d ity ▁mortal ity
D-199	-0.5956804156303406	Pediatric_heart failureHF morbidity mortality
P-199	-1.1631 -0.0022 -0.5354 -1.5507 -0.3546 -2.2179 -0.1889 -0.0097 -0.5423 -0.2281 -0.4425 -0.4040 -0.1045
S-938	Further, elevation in resistin correlated with decline in ejection fraction in these women.<unk>
T-938	elevation resistin correlated ejection_fraction
H-938	-0.6507186889648438	▁resist in ▁e je ction
D-938	-0.6507186889648438	resistin ejection
P-938	-0.1174 -0.2442 -1.3954 -0.0281 -0.0556 -2.4889 -0.2255
S-732	Patients with heart failure were complex and often had diagnostic testing and medication changes at follow-up visits.<unk>
T-732	patients heart_failure diagnostic medication follow-up
H-732	-1.2522848844528198	▁heart ▁failure
D-732	-1.2522848844528198	heart failure
P-732	-3.1241 -0.5850 -1.0814 -0.2187
S-711	Baseline characteristics and outcomes were compared between ECCT and standard criteria cardiac transplant recipients.<unk>
T-711	baseline outcomes ecct cardiac_transplant
H-711	-0.4703531861305237	▁EC CT ▁cardiac ▁transplant ▁recipient s
D-711	-0.4703531861305237	ECCT cardiac transplant recipients
P-711	-1.2922 -0.3361 -0.4913 -0.8998 -0.2514 -0.1986 -0.1258 -0.1676
S-1884	CONCLUSION: The CPET guiding exercise rehabilitation is safe and effective for patients with CHF.<unk>
T-1884	cpet exercise_rehabilitation patients chf
H-1884	-0.6083412766456604	▁c PET _ ▁gu iding _ ▁exercise ▁rehabilita tion ▁CHF
D-1884	-0.6083412766456604	cPET_ guiding_ exercise rehabilitation CHF
P-1884	-0.4727 -0.8304 -2.1386 -0.3916 -0.0422 -0.1361 -1.4977 -1.1357 -0.1111 -0.3781 -0.0933 -0.0726
S-1121	Reasons for not prescribing guideline-recommended medications to adults with heart failure.<unk>
T-1121	prescribing medications heart_failure
H-1121	-2.4965105056762695	
D-1121	-2.4965105056762695	
P-1121	-4.7877 -0.2053
S-1074	Heart failure (HF) is the most common cause of cardiovascular hospitalization, especially among the elderly.<unk>
T-1074	heart_failure hf cardiovascular hospitalization
H-1074	-0.9881685972213745	▁Heart ▁failure HF ▁cardiovascular ▁hospital ization
D-1074	-0.9881685972213745	Heart failureHF cardiovascular hospitalization
P-1074	-0.7254 -0.1580 -2.1975 -1.2479 -2.4563 -0.6097 -0.4054 -0.1050
S-776	We have used this technique to exchange malfunctioning HeartMate II LVADs in 14 consecutive patients.<unk>
T-776	heartmate_ii lvads patients
H-776	-1.0923607349395752	▁mal function ing ▁Heart Mate _ II _ L VAD s
D-776	-1.0923607349395752	malfunctioning HeartMate_II_LVADs
P-776	-6.4308 -0.2798 -0.0452 -0.3291 -0.0669 -0.8060 -2.2561 -0.5147 -2.3529 -0.0199 -0.4843 -0.3412 -0.2739
S-599	The patient had an uneventful recovery and was asymptomatic after 6 months of follow-up.<unk>
T-599	patient asymptomatic follow-up
H-599	-1.0069656372070312	▁patient
D-599	-1.0069656372070312	patient
P-599	-2.2792 -0.6724 -0.0693
S-1381	Renal DNx also prevented the increase in circulating plasma NE seen in CHF-INV rabbits.<unk>
T-1381	renal_dnx plasma
H-1381	-0.5283008813858032	▁Ren al ▁DN x ▁circula ting _ ▁plasma ▁CHF - IN v ▁rabbi ts
D-1381	-0.5283008813858032	Renal DNx circulating_ plasma CHF-INv rabbits
P-1381	-0.3150 -0.0123 -1.4144 -0.0140 -0.0041 -0.9672 -1.0803 -0.0887 -2.5382 -0.0409 -0.8378 -0.6075 -0.0435 -0.0653 -0.1422 -0.2816
S-1525	However, clinical characteristics and outcomes of EH have not been well described in HFpEF.<unk>
T-1525	clinical outcomes hfpef
H-1525	-0.537996232509613	▁EH
D-1525	-0.537996232509613	EH
P-1525	-0.2077 -1.3051 -0.1012
S-774	When dysfunction is due to pump failure or driveline injury, isolated pump replacement can be curative.<unk>
T-774	dysfunction pump driveline pump curative
H-774	-0.6047501564025879	▁pump ▁failure ▁drive line ▁injury ▁isola ted ▁pump ▁replace ment
D-774	-0.6047501564025879	pump failure driveline injury isolated pump replacement
P-774	-2.4245 -0.4830 -0.0646 -0.0047 -0.4722 -0.4439 -0.0322 -2.4528 -0.4098 -0.1467 -0.2430 -0.0798
S-1333	Given the lack of effective evidence-based therapies in these patients, FES warrants further investigation.<unk>
T-1333	evidence-based therapies patients fes
H-1333	-0.9958215951919556	
D-1333	-0.9958215951919556	
P-1333	-1.9276 -0.0640
S-1828	OBJECTIVE: To examine the associations of hHF with saxagliptin and sitagliptin.<unk>
T-1828	saxagliptin sitagliptin
H-1828	-0.3206692039966583	▁h HF ▁sax ag lip tin ▁si tag lip tin
D-1828	-0.3206692039966583	hHF saxagliptin sitagliptin
P-1828	-0.0327 -0.6587 -0.4735 -0.0072 -0.2829 -1.2420 -0.1724 -0.0476 -0.0266 -0.6949 -0.1506 -0.0590
S-171	No band of activated Caspase was found in the normal nor in the paced myocardium.<unk>
T-171	caspase myocardium
H-171	-0.7171036005020142	▁band ▁activa ted ▁Cas pas e ▁pace d _ my o car dium
D-171	-0.7171036005020142	band activated Caspase paced_myocardium
P-171	-2.5714 -2.5707 -0.3503 -0.9678 -0.0097 -0.6232 -0.5981 -0.0604 -0.5832 -2.0094 -0.0345 -0.0009 -0.1232 -0.1080 -0.1457
S-1285	All but one of the seven ischemic/inflammatory abdominal problems occurred in the MT group.<unk>
T-1285	ischemic inflammatory abdominal
H-1285	-0.7810903191566467	▁ ische mic _ in flam ma tory _ ▁abdominal _ problem
D-1285	-0.7810903191566467	ischemic_inflammatory_ abdominal_problem
P-1285	-1.0074 -0.1542 -0.5412 -0.3453 -0.0129 -0.0601 -1.3646 -0.4058 -0.3242 -2.3985 -2.2308 -0.7896 -1.1546 -0.1460
S-719	Age and renal dysfunction are important determinants of long-term survival and post-transplant morbidity.<unk>
T-719	renal_dysfunction morbidity
H-719	-0.41377755999565125	▁renal ▁dys function ▁post - trans plant ▁morbi d ity
D-719	-0.41377755999565125	renal dysfunction post-transplant morbidity
P-719	-0.2477 -2.1750 -0.1070 -0.9950 -0.0139 -0.0053 -0.0349 -0.1245 -0.0326 -1.0588 -0.0630 -0.1077
S-62	METHODS: We searched in MedLine, EMBASE, and CINAHL in May 2012.<unk>
T-62	medline embase cinahl
H-62	-0.5311020016670227	▁med Line ▁ EMBA se ▁c INA HL
D-62	-0.5311020016670227	medLine EMBAse cINAHL
P-62	-0.8351 -0.8982 -0.4506 -0.0322 -2.1506 -0.3975 -0.1299 -0.2514 -0.0917 -0.0739
S-140	Correlations between the ACR and CMS metrics were highest (r = 0.67-0.84).<unk>
T-140	correlations acr cms
H-140	-0.5040097832679749	▁a cr ▁CMS ▁metri cs
D-140	-0.5040097832679749	acr CMS metrics
P-140	-0.6303 -0.4761 -0.4582 -1.6680 -0.1412 -0.0926 -0.0617
S-1771	During a mean follow-up of 19.8±10.4 years, 153 HF deaths occurred.<unk>
T-1771	follow-up hf deaths
H-1771	-0.3533083200454712	▁ HF
D-1771	-0.3533083200454712	HF
P-1771	-0.5206 -0.1268 -0.6043 -0.1615
S-40	Purpose: To evaluate the benefits and harms of treatments for anemia in adults with heart disease.<unk>
T-40	anemia heart_disease
H-40	-1.6337157487869263	▁an emia _ van _ heart ▁disease
D-40	-1.6337157487869263	anemia_van_heart disease
P-40	-2.5527 -0.1676 -4.8072 -1.7811 -0.4370 -3.9063 -0.8651 -0.0874 -0.0990
S-302	Survival to hospital discharge was not different between groups (95.2 versus 88.2%; p = 0.2).<unk>
T-302	hospital discharge
H-302	-1.112898826599121	
D-302	-1.112898826599121	
P-302	-2.1743 -0.0515
S-2008	BACKGROUND: Heart failure disease management programs can influence medical resource use and quality-adjusted survival.<unk>
T-2008	heart_failure disease medical
H-2008	-1.2569074630737305	▁Heart ▁failure ▁disease ▁management
D-2008	-1.2569074630737305	Heart failure disease management
P-2008	-0.6039 -0.6125 -2.2444 -0.9611 -3.0131 -0.1065
S-252	HDL-bound malondialdehyde and HDL-induced NO production by EC were quantified.<unk>
T-252	malondialdehyde
H-252	-0.4587452709674835	▁HD L - bound ▁malo ndi alde hy de ▁HD L - indu ced ▁ec
D-252	-0.4587452709674835	HDL-bound malondialdehyde HDL-induced ec
P-252	-0.8916 -0.6473 -0.0243 -0.0970 -0.2306 -0.0839 -0.0093 -0.8572 -0.0679 -0.1521 -0.6692 -0.0196 -0.0165 -0.3428 -3.3595 -0.1612 -0.1687
S-627	During a median follow up of 11.4 (7.1-11.7) years, 466 participants developed HF.<unk>
T-627	follow_up hf
H-627	-0.5809597969055176	▁ HF
D-627	-0.5809597969055176	HF
P-627	-1.3686 -0.6969 -0.1633 -0.0951
S-1021	Studies and subsequent meta-analyses are mixed on the absolute value of routine NP assessment of ED patients.<unk>
T-1021	meta-analyses patients
H-1021	-1.1668601036071777	▁ NP
D-1021	-1.1668601036071777	NP
P-1021	-0.9779 -0.2771 -3.2188 -0.1937
S-676	In total, 9,535 patients were included, of whom 2,203 (23.1%) received trastuzumab.<unk>
T-676	patients trastuzumab
H-676	-0.3700547218322754	▁tras tuz um ab
D-676	-0.3700547218322754	trastuzumab
P-676	-1.3331 -0.2079 -0.0412 -0.3103 -0.2118 -0.1160
S-531	We studied 272 consecutive patients undergoing LVAD implantation from 2000 to 2010 at our institution.<unk>
T-531	patients lvad implantation
H-531	-0.7474684119224548	▁l VAD ▁implant ation
D-531	-0.7474684119224548	lVAD implantation
P-531	-1.8750 -0.0836 -1.6334 -0.0619 -0.6863 -0.1445
S-1454	Seventy-seven cases with pre-HCT germline DNA and 178 controls were genotyped.<unk>
T-1454	dna genotyped
H-1454	-0.2959265112876892	▁pre - h CT ▁germ line _ DNA ▁geno type d
D-1454	-0.2959265112876892	pre-hCT germline_DNA genotyped
P-1454	-0.8672 -0.0167 -0.8604 -0.3903 -0.0638 -0.0428 -0.3617 -0.2039 -0.1906 -0.0011 -0.5251 -0.2540 -0.0695
S-1468	The treatment aims are to stabilize the patient, improve clinical symptoms, and increase long-term survival rates.<unk>
T-1468	patient clinical symptoms
H-1468	-1.0899105072021484	
D-1468	-1.0899105072021484	
P-1468	-2.1226 -0.0572
S-1874	RESULTS: One hundred forty-six patients were randomized, 70 to control and 76 to treatment.<unk>
T-1874	patients randomized
H-1874	-0.6428270936012268	
D-1874	-0.6428270936012268	
P-1874	-1.1943 -0.0914
S-1189	Of the 124 patients in the derivation cohort, 27% had CAD, including 15% with severe CAD.<unk>
T-1189	patients cad cad
H-1189	-1.8109604120254517	▁CAD
D-1189	-1.8109604120254517	CAD
P-1189	-4.7437 -0.5965 -0.0927
S-729	Fifty-one percent of patients had blood work drawn, and 26% had a medication dose changed.<unk>
T-729	patients blood medication
H-729	-1.3290607929229736	▁blood ▁work ▁draw n ▁medication
D-729	-1.3290607929229736	blood work drawn medication
P-729	-4.5766 -1.9688 -1.0758 -0.1750 -0.7180 -0.6470 -0.1421
S-123	We evaluated CPCs and functional capacity (peak VO2) every 6 months for up to 2 years.<unk>
T-123	cpcs functional_capacity peak_vo2
H-123	-0.6300361156463623	▁c PC s ▁functional ▁capacity pe ak ▁VO 2
D-123	-0.6300361156463623	cPCs functional capacitypeak VO2
P-123	-0.5789 -0.4213 -0.3832 -0.1843 -2.1481 -1.6444 -0.0183 -0.5621 -0.5145 -0.1793 -0.2961
S-502	The bottleneck stent model for chronic myocardial ischemia and heart failure in pigs.<unk>
T-502	bottleneck_stent chronic_myocardial_ischemia heart_failure
H-502	-0.6106019020080566	▁bottle ne ck _ ▁sten t ▁model ▁chronic _ my o card ial _ ische mia ▁heart ▁failure ▁pig s
D-502	-0.6106019020080566	bottleneck_ stent model chronic_myocardial_ischemia heart failure pigs
P-502	-0.5495 -0.0116 -0.0100 -0.6667 -2.4608 -0.0348 -1.3897 -2.2472 -0.3947 -3.0247 -0.1059 -0.3749 -0.1324 -0.2521 -0.0814 -0.4356 -0.6376 -0.3166 -0.0389 -0.0425 -0.1106 -0.1151
S-1656	Gastrointestinal bleeding in patients with ventricular assist devices: what every cardiac nurse should know.<unk>
T-1656	gastrointestinal_bleeding patients ventricular_assist_devices cardiac nurse
H-1656	-0.5414584875106812	▁Gastro inte stin al _ ▁ble ed ing ▁vent ri cular _ assist ▁devices ▁cardiac ▁nurse
D-1656	-0.5414584875106812	Gastrointestinal_ bleeding ventricular_assist devices cardiac nurse
P-1656	-0.3188 -0.0979 -0.5507 -0.3431 -1.4655 -0.1551 -0.8306 -0.1543 -0.1646 -0.5840 -0.4846 -0.4101 -0.4193 -1.7724 -0.0415 -1.6186 -0.1992 -0.1360
S-489	In conclusion, e' is useful for estimating LV filling pressure in stable severe systolic HF.<unk>
T-489	lv_filling_pressure stable severe_systolic_hf
H-489	-0.8601759672164917	▁LV ▁fill ing ▁pressure ▁sy sto lic _ HF
D-489	-0.8601759672164917	LV filling pressure systolic_HF
P-489	-1.5868 -2.2901 -0.0615 -1.6119 -2.7876 -0.0280 -0.0058 -0.9102 -0.0400 -0.0599 -0.0802
S-1899	Exercise is generally associated with a 50% reduction in adverse events from coronary artery disease (CAD).<unk>
T-1899	exercise adverse_events coronary_artery_disease cad
H-1899	-0.6959914565086365	▁corona ry ▁arter y ▁disease CAD
D-1899	-0.6959914565086365	coronary artery diseaseCAD
P-1899	-3.3156 -0.3880 -0.5143 -0.0896 -0.7148 -0.4016 -0.0620 -0.0821
S-146	Remote monitoring after recent hospital discharge in patients with heart failure: a systematic review and network meta-analysis.<unk>
T-146	remote_monitoring hospital discharge patients heart_failure meta-analysis
H-146	-1.1346018314361572	▁remote _ monitor ing _ van _ de _ hospital _ ▁dis charge _ in _ ▁patients ▁heart ▁failure
D-146	-1.1346018314361572	remote_monitoring_van_de_hospital_ discharge_in_ patients heart failure
P-146	-1.8416 -0.5510 -0.6148 -0.7841 -1.7400 -2.6921 -0.0807 -3.9670 -0.3384 -0.6272 -0.8191 -0.4063 -0.1146 -2.0821 -1.6932 -0.9381 -0.6946 -2.8471 -0.5029 -0.4235 -0.0684
S-695	Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes.<unk>
T-695	st2 ambulatory patients heart_failure functional_capacity outcomes
H-695	-1.042905330657959	▁Solu ble _ ▁ST 2 ▁ambula tory _ ▁patients ▁heart ▁failure
D-695	-1.042905330657959	Soluble_ ST2 ambulatory_ patients heart failure
P-695	-0.8866 -0.0227 -0.2618 -2.5177 -0.1614 -4.2886 -0.2075 -0.9269 -0.6812 -2.7599 -0.3327 -0.3749 -0.1359
S-1809	Cardiac overexpression of Mammalian enabled (Mena) exacerbates heart failure in mice.<unk>
T-1809	cardiac_overexpression mammalian_enabled mena heart_failure
H-1809	-0.8192093968391418	▁Card iac ▁Mamma lian ▁men a ▁heart ▁failure
D-1809	-0.8192093968391418	Cardiac Mammalian mena heart failure
P-1809	-1.1158 -0.0108 -1.0236 -0.1307 -2.4378 -0.1253 -1.9408 -0.1663 -1.1592 -0.0817
S-771	Titin hypophosphorylation importantly contributed to the underlying myocardial DD.<unk>
T-771	titin_hypophosphorylation myocardial_dd
H-771	-0.41688674688339233	▁Tit in ▁hypo phos phor y lation ▁my o card ial ▁ DD
D-771	-0.41688674688339233	Titin hypophosphorylation myocardial DD
P-771	-0.0296 -0.4012 -0.3857 -0.0312 -0.1694 -0.6722 -0.1422 -1.3566 -0.1206 -0.0958 -0.3413 -2.1625 -0.0045 -0.1225 -0.2181
S-907	Baseline and 6-month echocardiograms were assessed for evidence of reverse remodeling.<unk>
T-907	baseline echocardiograms evidence reverse_remodeling
H-907	-0.5151116251945496	▁e cho card i ogram s
D-907	-0.5151116251945496	echocardiograms
P-907	-1.3467 -0.0152 -0.1691 -0.1939 -0.0025 -0.4920 -1.8161 -0.0853
S-1999	The indications for LVAS support were bridge to transplantation (54%) or destination therapy (46%).<unk>
T-1999	lvas bridge_to_transplantation destination_therapy
H-1999	-0.5541848540306091	▁l VAS ▁ bridge ▁to ▁transplant ation ▁destination ▁ therapy
D-1999	-0.5541848540306091	lVAS bridge to transplantation destination therapy
P-1999	-1.0462 -0.0923 -2.9652 -0.3201 -0.4161 -0.6333 -0.0257 -0.2937 -0.6525 -0.0063 -0.1240 -0.0749
S-164	Investigation of apoptosis in a canine model of chronic heart failure induced by tachycardia.<unk>
T-164	apoptosis chronic_heart_failure tachycardia
H-164	-1.2412229776382446	▁apo pto sis ▁can ine _ model ▁chronic _ heart ▁failure ▁ta chy car dia
D-164	-1.2412229776382446	apoptosis canine_model chronic_heart failure tachycardia
P-164	-7.3549 -0.1480 -0.2903 -4.5411 -0.2628 -0.5271 -0.3784 -2.8337 -0.2033 -2.2624 -1.2881 -0.6632 -0.0654 -0.0038 -0.0046 -0.1299 -0.1439
S-399	BACKGROUND: Concentrations of soluble (s)ST2 predict prognosis in heart failure.<unk>
T-399	st2 prognosis heart_failure
H-399	-1.8295221328735352	
D-399	-1.8295221328735352	
P-399	-3.6178 -0.0412
S-183	No benefit of RAS- or β-blocker uptitration was observed in HFpEF.<unk>
T-183	β-blocker uptitration hfpef
H-183	-0.800550103187561	▁ RAS - ▁β - block er ▁ HF p EF
D-183	-0.800550103187561	RAS- β-blocker HFpEF
P-183	-0.8562 -0.0389 -0.1353 -5.0212 -0.0364 -0.0785 -0.1051 -2.9114 -0.7864 -0.0275 -0.1051 -0.0513 -0.2539
S-1103	Framingham Heart Study criteria were used to define HF, which was further classified according to EF.<unk>
T-1103	framingham_heart_study hf ef
H-1103	-0.3298187553882599	▁Fram ing ham ▁Heart ▁Study ▁criteri a ▁ HF
D-1103	-0.3298187553882599	Framingham Heart Study criteria HF
P-1103	-0.0234 -0.0384 -0.0251 -1.1028 -0.0892 -0.9097 -0.0701 -0.2096 -0.0421 -1.0594 -0.0583
S-35	This guideline grades the evidence and recommendations using the ACP's clinical practice guidelines grading system.<unk>
T-35	evidence acp clinical_practice_guidelines
H-35	-0.8479313850402832	▁a CP ▁clinic al _ ▁practice ▁guidelines
D-35	-0.8479313850402832	aCP clinical_ practice guidelines
P-35	-1.2980 -0.0342 -2.2742 -0.0239 -0.3394 -1.4695 -1.1173 -0.8825 -0.1924
S-1199	Diuretics are frequently administered to relieve congestive symptoms in patients with heart failure (HF).<unk>
T-1199	diuretics symptoms patients heart_failure hf
H-1199	-0.9738264679908752	▁di ure tics
D-1199	-0.9738264679908752	diuretics
P-1199	-0.6203 -0.2956 -0.1151 -3.7503 -0.0878
S-208	Rates of ED visits and of intubations for congestive heart failure declined from 1996 to 2008.<unk>
T-208	intubations congestive_heart_failure
H-208	-0.4679737389087677	▁ED ▁in tuba tions ▁con ges tive _ heart ▁failure
D-208	-0.4679737389087677	ED intubations congestive_heart failure
P-208	-1.2306 -0.3476 -0.0269 -0.3329 -0.6054 -0.1197 -0.9643 -0.1142 -1.4851 -0.2491 -0.0636 -0.0762
S-1648	The EAST will test whether an early, modern rhythm control therapy can reduce cardiovascular complications in AF.<unk>
T-1648	east rhythm_control_therapy cardiovascular complications
H-1648	-0.6390429139137268	▁e ast ▁ rhythm ▁control ▁ therapy ▁cardiovascular ▁complica tions ▁AF
D-1648	-0.6390429139137268	east rhythm control therapy cardiovascular complications AF
P-1648	-1.1707 -0.6936 -0.7030 -1.0122 -1.1636 -0.6558 -0.0090 -0.7449 -0.2312 -0.4989 -1.2036 -0.0462 -0.1749
S-1778	BACKGROUND: Cardiac hypertrophy is accompanied by significant alterations in energy metabolism.<unk>
T-1778	cardiac_hypertrophy energy_metabolism
H-1778	-0.443974107503891	▁Card iac ▁hyper trop hy ▁energie ▁metabolism
D-1778	-0.443974107503891	Cardiac hypertrophy energie metabolism
P-1778	-0.8040 -0.0940 -0.9247 -0.0081 -0.7994 -1.0521 -0.1144 -0.1405 -0.0585
S-560	The youngest patients were less likely to have clinical and radiological signs of HF during hospitalization.<unk>
T-560	patients clinical radiological hf hospitalization
H-560	-0.5548532605171204	▁ HF
D-560	-0.5548532605171204	HF
P-560	-1.4295 -0.1291 -0.5226 -0.1381
S-959	Nicorandil (3 mg/kg/day) was given orally with or without doxorubicin treatment.<unk>
T-959	nicorandil orally doxorubicin
H-959	-0.19255736470222473	▁Nico rand il ▁do xor ubi cin
D-959	-0.19255736470222473	Nicorandil doxorubicin
P-959	-0.0031 -0.0016 -0.1563 -0.7438 -0.0216 -0.0214 -0.2040 -0.4864 -0.0948
S-621	Frailty and risk for heart failure in older adults: the health, aging, and body composition study.<unk>
T-621	frailty heart_failure health
H-621	-1.0392595529556274	▁fra il ty _ risk _ van _ heart ▁failure
D-621	-1.0392595529556274	frailty_risk_van_heart failure
P-621	-1.3504 -0.0535 -0.0482 -2.4229 -1.9055 -0.5414 -1.4431 -0.0845 -1.3029 -1.0516 -2.1656 -0.1015
S-747	Heart T2* was confirmed to be highly predictive over 1 year for heart failure and arrhythmias.<unk>
T-747	heart heart_failure arrhythmias
H-747	-1.2535970211029053	▁Heart _ t 2
D-747	-1.2535970211029053	Heart_t2
P-747	-0.5295 -1.9791 -1.3668 -0.0371 -3.4965 -0.1125
S-1611	Interactors of the DEGs were retrieved with Osprey and then networks were constructed.<unk>
T-1611	degs osprey
H-1611	-0.5185533165931702	▁DE G s ▁o spre y ▁network s
D-1611	-0.5185533165931702	DEGs osprey networks
P-1611	-2.7138 -1.4411 -0.2859 -0.0829 -0.0007 -0.0403 -0.4478 -0.0974 -0.0465 -0.0292
S-843	In addition, the beneficial effects of HRQoL from exercise training were not modulated by baseline Hgb.<unk>
T-843	hrqol exercise training baseline hgb
H-843	-0.9045981168746948	▁HR Qo L
D-843	-0.9045981168746948	HRQoL
P-843	-1.1237 -0.0188 -0.4543 -2.8846 -0.0416
S-1401	All top 10 NOC outcomes demonstrated statistically significant improvement in outcome ratings from admission to discharge.<unk>
T-1401	noc outcomes outcome admission discharge
H-1401	-1.075361967086792	▁NO c
D-1401	-1.075361967086792	NOc
P-1401	-0.9804 -0.4349 -2.6781 -0.2080
S-945	AF-free probability after catheter ablation and factors relating to maintenance of sinus rhythm were investigated.<unk>
T-945	catheter_ablation sinus_rhythm
H-945	-1.6214240789413452	▁AF - free _ ▁probabil ity ▁cat heter ▁ab lation
D-945	-1.6214240789413452	AF-free_ probability catheter ablation
P-945	-2.8051 -0.0763 -0.1162 -1.5496 -5.6112 -0.5216 -3.7374 -0.0146 -0.1257 -0.0690 -4.6029 -0.2276
S-982	It is, however, an important disease, accounting for 10% of paediatric cardiac transplants in children.<unk>
T-982	disease accounting cardiac_transplants
H-982	-0.40698811411857605	▁pa e dia tric ▁cardiac ▁transplant s
D-982	-0.40698811411857605	paediatric cardiac transplants
P-982	-0.3141 -0.1612 -0.0140 -0.0786 -0.9850 -0.4011 -0.1651 -1.4157 -0.1280
S-1400	Data were obtained from 268 inpatient records of patients discharged with HF during a 1-year period.<unk>
T-1400	inpatient patients discharged hf
H-1400	-0.35297879576683044	▁in patient ▁records ▁ HF
D-1400	-0.35297879576683044	inpatient records HF
P-1400	-0.3829 -0.0099 -0.2574 -1.2450 -0.2346 -0.2465 -0.0944
S-68	CONCLUSIONS: This meta-analysis identified strong reliable mortality predictors in ICD-HF patients.<unk>
T-68	meta-analysis mortality patients
H-68	-0.9286085963249207	▁i CD - HF
D-68	-0.9286085963249207	iCD-HF
P-68	-3.4646 -0.2146 -0.0526 -0.0501 -1.6102 -0.1796
S-5	However, there were no measurable overall improvements for patients admitted with pneumonia or surgical conditions.<unk>
T-5	patients pneumonia surgical conditions
H-5	-1.1185190677642822	▁pneu monia
D-5	-1.1185190677642822	pneumonia
P-5	-2.1920 -0.7947 -1.3981 -0.0893
S-1223	Patients were receiving optimal therapy and most had been hospitalized for a cardiovascular reason within 180 days of inclusion.<unk>
T-1223	patients therapy hospitalized cardiovascular
H-1223	-1.4611451625823975	
D-1223	-1.4611451625823975	
P-1223	-2.7741 -0.1482
S-290	Interestingly, the simpler laboratory report model was statistically no different than the ARIC HF model.<unk>
T-290	report aric hf
H-290	-0.5670812726020813	▁a RIC _ HF
D-290	-0.5670812726020813	aRIC_HF
P-290	-1.3256 -0.2550 -0.7275 -0.2966 -0.6755 -0.1222
S-848	All patients underwent device implantation and were randomly assigned to have CRT capability turned on or off.<unk>
T-848	patients implantation crt
H-848	-0.5393094420433044	▁device ▁implant ation ▁c RT
D-848	-0.5393094420433044	device implantation cRT
P-848	-1.2364 -0.3059 -0.0795 -0.4926 -0.3327 -1.2449 -0.0832
S-1467	It is a life-threatening situation in which diagnosis and initiation of therapy are crucial.<unk>
T-1467	diagnosis therapy
H-1467	-0.6068676710128784	▁ therapy
D-1467	-0.6068676710128784	therapy
P-1467	-1.2952 -0.9920 -0.0518 -0.0884
S-1852	We will synthesise the results narratively and, if appropriate, will pool results for meta-analysis.<unk>
T-1852	meta-analysis
H-1852	-0.9624852538108826	
D-1852	-0.9624852538108826	
P-1852	-1.8579 -0.0671
S-792	Future studies should extend and replicate our findings, including the establishment of its responsiveness to clinical change.<unk>
T-792	clinical change
H-792	-0.9405729174613953	
D-792	-0.9405729174613953	
P-792	-1.8558 -0.0254
S-1008	The deficit index ranged from 0.02-0.75, with a mean (SD) of 0.25 (0.13).<unk>
T-1008	deficit_index
H-1008	-0.6177313327789307	▁deficit ▁index
D-1008	-0.6177313327789307	deficit index
P-1008	-0.5759 -0.8772 -0.8071 -0.2108
S-1716	RESULTS: Medicare's post-acute care transfer policy led to immediate declines in length of stay.<unk>
T-1716	medicare policy
H-1716	-0.9089993238449097	▁Medica re ▁post - a cute _ care ▁transfer
D-1716	-0.9089993238449097	Medicare post-acute_care transfer
P-1716	-0.3431 -0.0081 -1.2040 -0.0163 -0.0246 -0.0092 -0.1289 -2.9699 -1.5101 -3.5350 -0.2498
S-892	There may be some delayed benefit when the QRS is ≥160 ms, but this needs further investigation.<unk>
T-892	qrs
H-892	-0.7898703813552856	▁QR S
D-892	-0.7898703813552856	QRS
P-892	-1.1222 -1.7312 -0.2407 -0.0653
S-216	RESULTS: Of the 2,374,428 ED visits, 32,036 (1.3%) were for CHF.<unk>
T-216	chf
H-216	-1.2567243576049805	▁ED ▁visit s ▁CHF
D-216	-1.2567243576049805	ED visits CHF
P-216	-4.3088 -2.8795 -0.0997 -0.0733 -0.0659 -0.1133
S-692	Diet score components, vegetables, nuts, and whole grain intake, were inversely associated with mortality.<unk>
T-692	mortality
H-692	-1.441166639328003	▁vegetables ▁nu ts ▁whole _ ▁grain ▁in take
D-692	-1.441166639328003	vegetables nuts whole_ grain intake
P-692	-7.1624 -1.3459 -0.0244 -1.8001 -1.6823 -0.0602 -0.3197 -0.1714 -1.5159 -0.3293
S-619	CONCLUSIONS: Anecdotal evidence of perceived benefit was expressed in participant satisfaction responses.<unk>
T-619	evidence
H-619	-0.8381455540657043	
D-619	-0.8381455540657043	
P-619	-1.6266 -0.0497
S-1508	Contrasting groups validity, internal consistency, and test-retest reliability were supported as well.<unk>
T-1508	
H-1508	-0.7548418045043945	▁contra s ting _ groep ▁interne _ ▁consiste ncy ▁test - re test
D-1508	-0.7548418045043945	contrasting_groep interne_ consistency test-retest
P-1508	-2.9298 -0.0565 -0.0642 -1.6445 -1.6981 -2.6631 -0.3912 -0.4273 -0.0207 -0.0562 -0.0220 -0.0160 -0.0629 -1.1756 -0.0946
S-49	Data supporting iron use come mainly from 1 large trial, and long-term effects are unknown.<unk>
T-49	
H-49	-0.8497143387794495	▁ir on
D-49	-0.8497143387794495	iron
P-49	-1.5271 -0.0896 -1.6819 -0.1003
S-821	Assessment and prognostic relevance of right ventricular contractile reserve in patients with severe pulmonary hypertension.<unk>
T-821	prognostic right_ventricular_contractile_reserve patients pulmonary_hypertension
H-821	-0.42247167229652405	▁vent ri cular _ contract ile ▁reserve ▁pulmonar y ▁hyper tension
D-821	-0.42247167229652405	ventricular_contractile reserve pulmonary hypertension
P-821	-1.4695 -0.4578 -0.1850 -0.5833 -0.7616 -0.1878 -0.1041 -0.3896 -0.0470 -1.1262 -0.0307 -0.0807 -0.0690
S-1439	Variability in QT intervals was expressed as the SD of all QT intervals (SDQT).<unk>
T-1439	qt_intervals sd_of_all_qt_intervals sdqt
H-1439	-0.39248448610305786	▁ QT ▁interval s ▁SD QT
D-1439	-0.39248448610305786	QT intervals SDQT
P-1439	-0.4579 -0.1032 -0.1766 -0.0401 -0.1222 -1.8654 -0.1792 -0.1952
S-1297	Seven days after the emergency cardiac catheterization the patient was extubated and transferred to our intermediate care.<unk>
T-1297	cardiac_catheterization patient extubated transferred
H-1297	-0.9686732888221741	▁emergency ▁cardiac _ ▁cat heter ization
D-1297	-0.9686732888221741	emergency cardiac_ catheterization
P-1297	-1.0768 -0.2817 -2.2063 -1.5337 -0.0276 -0.8792 -1.6912 -0.0527
S-245	Exercise training in patients with chronic heart failure promotes restoration of high-density lipoprotein functional properties.<unk>
T-245	exercise training patients chronic_heart_failure high-density_lipoprotein
H-245	-1.4593368768692017	▁chronic _ heart ▁failure ▁lipo prote in ▁functional ▁properties
D-245	-1.4593368768692017	chronic_heart failure lipoprotein functional properties
P-245	-5.1238 -0.2934 -1.3205 -0.7718 -4.8737 -0.1561 -0.3474 -1.0809 -1.8067 -0.1872 -0.0912
S-931	Specifically, we explored whether resistin underlies acute anthracycline-induced cardiotoxicity.<unk>
T-931	resistin acute anthracycline-induced_cardiotoxicity
H-931	-0.4828336834907532	▁resist in ▁a cute ▁an thra cycli ne - indu ced ▁cardio toxic ity
D-931	-0.4828336834907532	resistin acute anthracycline-induced cardiotoxicity
P-931	-0.2900 -0.1355 -1.4203 -0.0177 -0.7046 -0.0307 -0.1401 -1.2077 -0.4819 -0.0290 -0.3742 -0.8673 -0.1278 -1.6778 -0.0967 -0.1241
S-1869	BAT results in centrally mediated reduction of sympathetic outflow and increased parasympathetic activity.<unk>
T-1869	bat sympathetic_outflow parasympathetic_activity
H-1869	-0.5178355574607849	▁BAT ▁sympa the tic _ out flow ▁para sy mpa the tic ▁activity
D-1869	-0.5178355574607849	BAT sympathetic_outflow parasympathetic activity
P-1869	-0.4173 -2.6052 -0.1307 -0.3378 -0.3168 -0.1352 -0.0281 -0.0147 -0.0195 -0.0314 -0.9202 -0.2574 -2.2674 -0.1288 -0.1569
S-1065	T1 mapping may be a useful technique for detecting early but clinically significant myocardial fibrosis.<unk>
T-1065	t1_mapping clinically myocardial_fibrosis
H-1065	-1.7693452835083008	
D-1065	-1.7693452835083008	
P-1065	-3.4555 -0.0832
S-1447	The effect of acute autonomic nervous system modulation on QTV appears to be limited in HF patients.<unk>
T-1447	acute autonomic_nervous_system qtv hf patients
H-1447	-0.8112267851829529	▁a cute _ ▁autonomi c _ ▁ner vous ▁system ▁modul ation ▁Q TV
D-1447	-0.8112267851829529	acute_ autonomic_ nervous system modulation QTV
P-1447	-1.1776 -0.0027 -0.1768 -1.7852 -0.0739 -0.1801 -2.9487 -1.3982 -1.1286 -0.3273 -0.0563 -0.5494 -0.1139 -2.1812 -0.0685
S-960	Heart rate and aortic blood flow were recorded 24 h after receiving the last dose of doxorubicin.<unk>
T-960	heart_rate aortic blood_flow doxorubicin
H-960	-0.3354232609272003	▁Heart ▁rate ▁a or tic _ ▁blood ▁flow ▁do xor ubi cin
D-960	-0.3354232609272003	Heart rate aortic_ blood flow doxorubicin
P-960	-1.3236 -1.4075 -0.3969 -0.0386 -0.4032 -0.1371 -0.3460 -0.1864 -0.1676 -0.0059 -0.0232 -0.1344 -0.0577 -0.0679
S-327	During RVPO with BiVP, CO only correlated with RS synchrony and CS (P < 0.05).<unk>
T-327	rvpo bivp correlated rs_synchrony
H-327	-0.5562519431114197	▁ RV PO ▁Bi VP ▁RS ▁synchron y ▁CS
D-327	-0.5562519431114197	RVPO BiVP RS synchrony CS
P-327	-0.2937 -0.3321 -0.3259 -0.7360 -0.0120 -4.1687 -0.0042 -0.0335 -0.0243 -0.0483 -0.1400
S-903	Usefulness and consequences of cardiac resynchronization therapy in dialysis-dependent patients with heart failure.<unk>
T-903	cardiac_resynchronization_therapy patients heart_failure
H-903	-0.5554319620132446	▁cardiac ▁re syn chron ization ▁ therapy ▁di al ysis - dependent _ ▁patients ▁heart ▁failure
D-903	-0.5554319620132446	cardiac resynchronization therapy dialysis-dependent_ patients heart failure
P-903	-0.3001 -0.4154 -0.0279 -0.0145 -1.3268 -1.8966 -0.0166 -0.2500 -0.0551 -0.0175 -0.1356 -0.0870 -1.6563 -1.4225 -1.8979 -0.2716 -0.0750 -0.1315
S-1933	However, for cardiovascular death or HF hospitalization, exercise training had a greater impact on patients with lower BTES.<unk>
T-1933	cardiovascular_death hf hospitalization exercise training patients btes
H-1933	-0.8482295870780945	▁cardiovascular ▁death ▁ HF ▁hospital ization ▁exercise ▁training
D-1933	-0.8482295870780945	cardiovascular death HF hospitalization exercise training
P-1933	-0.6364 -1.4548 -0.2195 -0.0016 -1.5316 -0.6009 -0.8776 -1.3867 -1.7244 -0.0488
S-1500	Low skeletal muscle mass correlated with poorer VO2 max (r=0.67, p=0.004).<unk>
T-1500	skeletal_muscle correlated vo2_max
H-1500	-0.8763154745101929	▁skelet al _ ▁muscle ▁mass
D-1500	-0.8763154745101929	skeletal_ muscle mass
P-1500	-1.1674 -0.0606 -1.1311 -0.4401 -0.7731 -2.4618 -0.1001
S-526	Because Ees is unaltered, improved ventricular-arterial coupling is responsible for increased SV.<unk>
T-526	ees ventricular-arterial_coupling
H-526	-0.3561131954193115	▁vent ri cular - arte rial _ ▁coup ling ▁SV
D-526	-0.3561131954193115	ventricular-arterial_ coupling SV
P-526	-1.1351 -0.4042 -0.0841 -0.1330 -0.0147 -0.0150 -0.8248 -0.7982 -0.2582 -0.3938 -0.0616 -0.1505
S-77	Within each strategy, participants were randomized in a double-blind, 2:1 ratio to active treatment or placebo.<unk>
T-77	randomized double-blind active placebo
H-77	-1.653012752532959	
D-77	-1.653012752532959	
P-77	-3.1352 -0.1708
S-1213	RESULTS: Myocardial PDE2 expression and activity were ~2-fold higher in advanced human HF.<unk>
T-1213	myocardial pde2 expression activity hf
H-1213	-0.8941883444786072	▁My o card ial _ p de 2
D-1213	-0.8941883444786072	Myocardial_pde2
P-1213	-1.3846 -0.0839 -0.1072 -0.1252 -0.4563 -2.8057 -1.2645 -0.0444 -2.5750 -0.0950
S-986	There is a small subgroup of children that have diastolic failure from cardiomyopathic restriction to flow.<unk>
T-986	diastolic_failure cardiomyopathic
H-986	-0.5392693877220154	▁dia sto lic _ ▁failure ▁cardio my o pathi c
D-986	-0.5392693877220154	diastolic_ failure cardiomyopathic
P-986	-0.6308 -0.0188 -0.0405 -1.4275 -0.1188 -0.2012 -0.5784 -0.1569 -0.0050 -0.0345 -3.1785 -0.0804
S-1850	We will include clinical outcomes such as hospitalisations, readmissions and mortality, if data is available.<unk>
T-1850	clinical outcomes hospitalisations readmissions mortality
H-1850	-0.7172148823738098	▁hospital isation s ▁read missions ▁mortal ity
D-1850	-0.7172148823738098	hospitalisations readmissions mortality
P-1850	-5.1121 -0.0361 -0.1161 -0.1631 -0.2026 -0.2141 -0.4365 -0.0948 -0.0796
S-1925	BACKGROUND: Psychosocial factors may influence adherence with exercise training for heart failure (HF) patients.<unk>
T-1925	psychosocial exercise training heart_failure hf patients
H-1925	-1.618883728981018	▁psycho social _ ▁factors
D-1925	-1.618883728981018	psychosocial_ factors
P-1925	-1.4460 -0.2771 -2.6815 -1.0803 -4.1391 -0.0893
S-1436	The aim of the present study was to investigate the role of autonomic nervous system activity on QTV.<unk>
T-1436	autonomic_nervous_system activity qtv
H-1436	-0.8418740630149841	▁autonomi c _ ▁ner vous ▁system ▁activity ▁Q TV
D-1436	-0.8418740630149841	autonomic_ nervous system activity QTV
P-1436	-0.3653 -0.0319 -0.3455 -2.3071 -0.6934 -1.2459 -3.7755 -0.3052 -0.0583 -0.0416 -0.0910
S-2004	There were no pump exchanges, pump malfunctions, pump thrombosis, or hemolysis events.<unk>
T-2004	pump pump pump_thrombosis hemolysis
H-2004	-0.6289005279541016	▁pump ▁exchange s ▁pump ▁mal function s ▁pump ▁ thro mbo sis ▁hem ol ysis
D-2004	-0.6289005279541016	pump exchanges pump malfunctions pump thrombosis hemolysis
P-2004	-0.0278 -4.2040 -0.1625 -0.3639 -1.7573 -0.0831 -0.2895 -0.1578 -0.9099 -0.1247 -0.2312 -1.0455 -0.1180 -0.2313 -0.0786 -0.8297 -0.0764
S-883	For this substudy, we excluded patients in atrial fibrillation and those with a previous pacemaker.<unk>
T-883	patients atrial_fibrillation pacemaker
H-883	-0.9236148595809937	▁at rial _ fi bril lation ▁pace maker
D-883	-0.9236148595809937	atrial_fibrillation pacemaker
P-883	-6.1125 -0.0274 -0.8652 -0.9209 -0.0218 -0.0706 -1.0011 -0.0454 -0.1094 -0.0619
S-1768	Measures included body mass index and CRF quantified as duration of maximal treadmill exercise testing.<unk>
T-1768	body_mass_index crf exercise
H-1768	-0.40860944986343384	▁body ▁mass ▁index ▁c RF ▁tre ad m ill
D-1768	-0.40860944986343384	body mass index cRF treadmill
P-1768	-0.3770 -0.5623 -0.0141 -0.2107 -0.0123 -0.6894 -0.0031 -0.4556 -0.0542 -2.0144 -0.1015
S-1426	In this study, human myocardial tissue was used to examine the state of PKA subunits.<unk>
T-1426	myocardial_tissue pka
H-1426	-0.8245472311973572	▁human ▁my o card ial _ ▁tissu e ▁p ka
D-1426	-0.8245472311973572	human myocardial_ tissue pka
P-1426	-2.5226 -3.3443 -0.1806 -0.1449 -0.1319 -1.5019 -0.0534 -0.0913 -0.2736 -0.7315 -0.8285 -0.0900
S-1791	A systematic search of the electronic databases and the World Health Organization website was undertaken for HF in LA.<unk>
T-1791	world_health_organization hf
H-1791	-1.0591273307800293	▁electronic _ ▁database s ▁World _ Health ▁Organization ▁ HF
D-1791	-1.0591273307800293	electronic_ databases World_Health Organization HF
P-1791	-3.8750 -0.4455 -0.6915 -0.0300 -1.8319 -0.1566 -3.2539 -0.2199 -1.5651 -0.2589 -0.2562 -0.1251
S-1321	RESULTS: Attrition was 30% but with 100% compliance to exercise and injections in patients who completed the study.<unk>
T-1321	attrition compliance exercise injections patients
H-1321	-0.885403037071228	
D-1321	-0.885403037071228	
P-1321	-1.7352 -0.0356
S-626	RESULTS: Mean age of participants was 74 ± 3 years; 48% were men and 59% were white.<unk>
T-626	
H-626	-0.7637452483177185	
D-626	-0.7637452483177185	
P-626	-1.4284 -0.0991
S-1219	This may constitute an important defense mechanism during cardiac stress, for example, by antagonizing excessive β-AR drive.<unk>
T-1219	cardiac_stress β-ar drive
H-1219	-2.2503774166107178	▁defense ▁mechanism ▁cardiac _ ▁stress
D-1219	-2.2503774166107178	defense mechanism cardiac_ stress
P-1219	-8.0189 -0.2078 -1.9949 -1.4892 -1.1747 -2.6683 -0.1989
S-1681	This month's "Ethics Rounds" presents a case in which these 2 complexities overlapped.<unk>
T-1681	ethics_rounds
H-1681	-0.38356560468673706	▁e thi cs ▁Round s
D-1681	-0.38356560468673706	ethics Rounds
P-1681	-1.4228 -0.0204 -0.0912 -0.7388 -0.0702 -0.2920 -0.0496
S-1928	Higher PSSS indicated higher levels of social support, whereas higher BTES indicated more barriers to exercise.<unk>
T-1928	psss btes exercise
H-1928	-1.1430596113204956	▁PS SS ▁social _ support
D-1928	-1.1430596113204956	PSSS social_support
P-1928	-2.3625 -0.3658 -2.1631 -1.1399 -0.6661 -1.1458 -0.1583
S-650	The effectiveness of bisoprolol in reducing mortality has also also been documented in a number of studies.<unk>
T-650	bisoprolol mortality
H-650	-0.7648962736129761	▁bis o pro lol
D-650	-0.7648962736129761	bisoprolol
P-650	-0.9771 -0.3829 -0.0337 -0.3258 -2.7202 -0.1497
S-623	BACKGROUND: Frailty is common in the elderly and is associated with adverse health outcomes.<unk>
T-623	frailty health outcomes
H-623	-0.5713717341423035	▁fra il ty
D-623	-0.5713717341423035	frailty
P-623	-0.6717 -0.5946 -0.1633 -1.3813 -0.0460
S-221	CONCLUSION: The rates of annual ED visits for CHF and intubation rates declined from 1996 to 2008.<unk>
T-221	chf intubation
H-221	-0.718245267868042	▁ED ▁visit s ▁CHF ▁in tub ation ▁rates
D-221	-0.718245267868042	ED visits CHF intubation rates
P-221	-3.5479 -2.6606 -0.0587 -0.0960 -0.0173 -0.0307 -0.1036 -0.3648 -0.2451 -0.0578
S-1422	Research is needed to explore whether physician continuity is important for other conditions and in settings other than recent hospital discharge.<unk>
T-1422	physician conditions hospital discharge
H-1422	-0.5517961978912354	▁physician ▁continu ity
D-1422	-0.5517961978912354	physician continuity
P-1422	-0.6796 -0.2383 -0.2108 -1.4944 -0.1358
S-1714	PARTICIPANTS: Medicare fee-for-service beneficiaries associated with 2,101,481 hospitalizations.<unk>
T-1714	medicare hospitalizations
H-1714	-0.43193918466567993	▁Medica re ▁fee - for - service
D-1714	-0.43193918466567993	Medicare fee-for-service
P-1714	-0.3034 -0.0179 -1.1899 -0.0441 -0.0669 -0.0633 -0.1919 -1.8041 -0.2060
S-1368	However, clinical and therapeutic implications are indistinct and need to be elucidated in further studies.<unk>
T-1368	clinical therapeutic
H-1368	-0.42442333698272705	▁ therapeut ic
D-1368	-0.42442333698272705	therapeutic
P-1368	-1.5385 -0.0208 -0.0626 -0.4469 -0.0534
S-1315	Increased attention to these high-risk patients is needed given the lack of improvement in their long-term prognosis.<unk>
T-1315	patients prognosis
H-1315	-1.1063419580459595	
D-1315	-1.1063419580459595	
P-1315	-2.1633 -0.0494
S-1983	Exercise attendance was 84% (SD, 14%) and diet adherence was 99% (SD, 1%).<unk>
T-1983	exercise
H-1983	-0.8589852452278137	▁die t ▁ad her ence SD
D-1983	-0.8589852452278137	diet adherenceSD
P-1983	-4.6580 -0.0372 -0.3717 -0.3318 -0.9090 -0.2020 -0.2925 -0.0696
S-1862	RESULTS: The sample (n = 25) was predominately male (76%) with an average age of 62 years.<unk>
T-1862	
H-1862	-0.6376836895942688	
D-1862	-0.6376836895942688	
P-1862	-1.2157 -0.0597
S-2013	The model can be used to evaluate parallel-group and single-cohort study designs and hypothetical programs.<unk>
T-2013	
H-2013	-0.3991679847240448	▁parallel - group ▁single - co hor t
D-2013	-0.3991679847240448	parallel-group single-cohort
P-2013	-1.9195 -0.0254 -0.0810 -0.6750 -0.0145 -0.0061 -0.0084 -0.0364 -1.1453 -0.0801
S-1382	These results suggest renal DNx improves cardiac autonomic balance in CHF by a reduction of sympathetic tone.<unk>
T-1382	renal_dnx cardiac autonomic_balance chf sympathetic_tone
H-1382	-0.31474199891090393	▁renal ▁DN x ▁cardiac ▁autonomi c ▁balance ▁CHF ▁sympa the tic ▁tone
D-1382	-0.31474199891090393	renal DNx cardiac autonomic balance CHF sympathetic tone
P-1382	-0.0278 -0.4581 -0.0163 -0.0806 -0.5270 -0.1226 -1.8299 -0.0124 -0.0116 -0.2516 -0.3102 -0.5031 -0.1620 -0.0931
S-29	Treatment of anemia in patients with heart disease: a clinical practice guideline from the American College of Physicians.<unk>
T-29	anemia patients heart_disease clinical_practice_guideline american_college_of_physicians
H-29	-1.2719504833221436	▁an emia ▁heart ▁disease ▁clinic al _ ▁practice ▁guide line
D-29	-1.2719504833221436	anemia heart disease clinical_ practice guideline
P-29	-0.6722 -0.0153 -5.7033 -1.2136 -2.5578 -0.0178 -0.1764 -1.0393 -0.8669 -0.0058 -2.9394 -0.0556
S-386	Incidence and predictors of end-stage renal disease in outpatients with systolic heart failure.<unk>
T-386	incidence end-stage_renal_disease outpatients systolic_heart_failure
H-386	-0.4750705063343048	▁end - s tage ▁renal ▁disease ▁sy sto lic _ heart ▁failure
D-386	-0.4750705063343048	end-stage renal disease systolic_heart failure
P-386	-1.9178 -0.0597 -0.3091 -0.0034 -0.4078 -0.5783 -1.3644 -0.0138 -0.1318 -0.1972 -1.3103 -0.1937 -0.0687 -0.0952
S-1135	The parasympathetic neurotransmission can be improved by acetylcholinesterase inhibition.<unk>
T-1135	parasympathetic_neurotransmission acetylcholinesterase_inhibition
H-1135	-0.33845317363739014	▁para sy mpa the tic ▁neuro trans mission ▁a ce tyl cho line ster ase ▁inhibi tion
D-1135	-0.33845317363739014	parasympathetic neurotransmission acetylcholinesterase inhibition
P-1135	-0.0027 -0.0190 -0.0541 -0.4885 -0.4022 -1.5585 -0.0013 -1.3606 -0.0875 -0.1314 -0.1026 -0.1570 -0.1140 -0.0433 -1.2068 -0.1902 -0.2838 -0.1696 -0.0575
S-515	Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients.<unk>
T-515	heart_rate_reduction ivabradine left_ventricle heart_failure patients
H-515	-0.7993532419204712	▁i va bra dine ▁left ▁vent ric le ▁heart ▁failure
D-515	-0.7993532419204712	ivabradine left ventricle heart failure
P-515	-0.7915 -0.1033 -0.1036 -0.0914 -1.3341 -0.8295 -1.7220 -0.7481 -1.4725 -0.5709 -1.5209 -0.3045
S-2018	Heart Failure: Pathophysiology, Diagnosis, Medical Treatment Guidelines, and Nursing Management.<unk>
T-2018	heart_failure pathophysiology diagnosis medical_treatment nursing
H-2018	-0.40175870060920715	▁Heart ▁Fail ure ▁Path o phy si ology ▁Medical ▁Treatment ▁Guide lines ▁Nur sing ▁Management
D-2018	-0.40175870060920715	Heart Failure Pathophysiology Medical Treatment Guidelines Nursing Management
P-2018	-0.3063 -0.7265 -0.5105 -0.4504 -0.6550 -0.0250 -1.0627 -0.0885 -1.5704 -0.1783 -0.2490 -0.2761 -0.2196 -0.0082 -0.4128 -0.0315 -0.0592
S-198	Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society guidelines.<unk>
T-198	diagnosis medical heart_failure canadian_cardiovascular_society
H-198	-1.053657054901123	▁medical _ management _ van _ heart ▁failure ▁Canadian _ ▁Card io vas cular ▁Society
D-198	-1.053657054901123	medical_management_van_heart failure Canadian_ Cardiovascular Society
P-198	-4.8301 -0.6950 -0.1015 -1.4170 -1.0522 -0.1537 -0.8742 -0.7764 -2.2105 -0.4064 -2.9488 -0.3886 -0.1729 -0.1412 -0.8877 -0.7521 -0.1038
S-13	Biomarkers of neurohormonal stimulation, inflammation, and endothelial dysfunction were measured.<unk>
T-13	biomarkers neurohormonal_stimulation inflammation endothelial_dysfunction
H-13	-0.13517503440380096	▁bio mark ers ▁neuro hormon al ▁stimul ation ▁ inflammation ▁en dot heli al ▁dys function
D-13	-0.13517503440380096	biomarkers neurohormonal stimulation inflammation endothelial dysfunction
P-13	-0.2752 -0.0247 -0.0471 -0.0492 -0.0179 -0.0691 -0.6392 -0.0791 -0.1028 -0.0020 -0.0701 -0.5063 -0.0242 -0.0081 -0.3651 -0.0485 -0.0399 -0.0648
S-426	Echocardiographic predictors of reverse remodeling after cardiac resynchronization therapy and subsequent events.<unk>
T-426	echocardiographic reverse_remodeling cardiac_resynchronization_therapy
H-426	-0.36987796425819397	▁e cho car dio graphic ▁rever se _ ▁remodel ing ▁cardiac ▁re syn chron ization
D-426	-0.36987796425819397	echocardiographic reverse_ remodeling cardiac resynchronization
P-426	-0.6805 -0.0068 -0.0050 -0.5736 -0.3392 -1.5578 -0.0105 -0.3339 -0.0524 -0.0344 -0.0668 -0.3142 -0.0018 -0.0015 -0.6880 -1.5587 -0.0631
S-634	Neurohormonal abnormalities contribute to the pathophysiology of congestive heart failure (CHF).<unk>
T-634	neurohormonal pathophysiology congestive_heart_failure chf
H-634	-0.5528948307037354	▁neuro hormon al ▁ab normal ities ▁pat ho phy si ology ▁con ges tive _ heart ▁failure CH F
D-634	-0.5528948307037354	neurohormonal abnormalities pathophysiology congestive_heart failureCHF
P-634	-1.5349 -0.0064 -0.0150 -0.5944 -0.0115 -0.4662 -2.1707 -0.0419 -0.1206 -0.9052 -0.4317 -0.1629 -0.0876 -1.1723 -0.0855 -2.3385 -0.5395 -0.4748 -0.3135 -0.0897 -0.0481
S-1485	In addition, we provide brief insight into the potential of miRNAs as novel therapeutic targets for heart failure.<unk>
T-1485	mirnas therapeutic heart_failure
H-1485	-0.9261623620986938	▁mi RNA s
D-1485	-0.9261623620986938	miRNAs
P-1485	-1.7339 -0.0022 -0.2145 -2.5814 -0.0988
S-1164	The extent of RV dysfunction correlated with greater antecedent weight loss and a lower fat/lean body mass ratio.<unk>
T-1164	rv_dysfunction correlated lean_body_mass
H-1164	-1.0940802097320557	▁ RV _ ▁dys function
D-1164	-1.0940802097320557	RV_ dysfunction
P-1164	-0.2020 -0.2620 -2.8797 -0.9699 -0.0654 -2.9912 -0.2884
S-2023	Such an understanding can ultimately reduce morbidity and mortality and optimize quality of life in patients with HF.<unk>
T-2023	morbidity mortality quality_of_life patients hf
H-2023	-0.5425364375114441	▁morbi d ity ▁mortal ity
D-2023	-0.5425364375114441	morbidity mortality
P-2023	-0.4845 -0.0244 -0.6858 -0.4618 -0.3670 -1.6737 -0.1005
S-1274	This review provides an update on cardiopulmonary exercise variables, proven to be prognostically important in heart failure.<unk>
T-1274	cardiopulmonary exercise prognostically heart_failure
H-1274	-1.263776183128357	▁cardio pul mon ary _ ▁exercise
D-1274	-1.263776183128357	cardiopulmonary_ exercise
P-1274	-0.8552 -0.1105 -1.7718 -0.4239 -0.9036 -2.8526 -3.0978 -0.0948
S-1670	Potent inhibition of L-type Ca2+ currents by a Rad variant associated with congestive heart failure.<unk>
T-1670	rad_variant congestive_heart_failure
H-1670	-0.9923321604728699	▁l - type _ ca 2 _ current s ▁Rad ▁con ges tive _ heart ▁failure
D-1670	-0.9923321604728699	l-type_ca2_currents Rad congestive_heart failure
P-1670	-3.0043 -0.0373 -0.0012 -0.8624 -0.0368 -0.1333 -1.9895 -4.4571 -0.1959 -0.7054 -2.8961 -0.0918 -0.5811 -0.1129 -2.2153 -0.3817 -0.1070 -0.0527
S-565	Clinical and radiological signs of HF were less common, yet quality of life was more significantly impaired.<unk>
T-565	clinical radiological hf quality_of_life
H-565	-0.4723514914512634	▁ HF
D-565	-0.4723514914512634	HF
P-565	-1.1355 -0.1134 -0.5701 -0.0704
S-1091	The right ventricle (RV) is integral to normal cardiac function, but receives little attention in the medical literature.<unk>
T-1091	right_ventricle rv cardiac_function medical
H-1091	-1.2946430444717407	▁right ▁vent ric le ▁ RV ▁cardiac
D-1091	-1.2946430444717407	right ventricle RV cardiac
P-1091	-2.4673 -0.5188 -0.6147 -0.2859 -3.6894 -0.3630 -1.1541 -2.4277 -0.1309
S-1682	An 18-year-old Jehovah's Witness with sickle cell disease has life-threatening anemia.<unk>
T-1682	witness sickle_cell_disease anemia
H-1682	-0.8404130935668945	▁Jehovah ' s ▁Wit ness ▁sick le _ ▁cell ▁disease ▁an emia
D-1682	-0.8404130935668945	Jehovah's Witness sickle_ cell disease anemia
P-1682	-0.4485 -2.2388 -0.6233 -0.5881 -1.5856 -0.1915 -0.2903 -0.3520 -2.3312 -0.5962 -1.8451 -0.0516 -0.2508 -0.3728
S-1057	Animals were scanned twice with a 1.5-T MRI scanner, once at baseline and once at heart failure.<unk>
T-1057	mri_scanner baseline heart_failure
H-1057	-1.6433073282241821	▁m RI ▁scanner
D-1057	-1.6433073282241821	mRI scanner
P-1057	-4.8475 -0.7759 -0.4995 -1.8432 -0.2503
S-209	OBJECTIVE: Many advances have been made recently in the treatment of congestive heart failure (CHF).<unk>
T-209	congestive_heart_failure chf
H-209	-0.5596573948860168	▁con ges tive _ heart ▁failure CH F
D-209	-0.5596573948860168	congestive_heart failureCHF
P-209	-1.7257 -0.0931 -0.5011 -0.1044 -1.4149 -0.5247 -0.7933 -0.3517 -0.0437 -0.0441
S-1721	BACKGROUND: There is an urgent need to improve outcomes and reduce costs for patients with heart failure (HF).<unk>
T-1721	outcomes costs patients heart_failure hf
H-1721	-2.0439982414245605	
D-1721	-2.0439982414245605	
P-1721	-4.0495 -0.0385
S-99	This study reports the quantitative analysis of a new chromatin subproteome in the normal and diseased mouse heart.<unk>
T-99	chromatin_subproteome diseased heart
H-99	-0.9703512787818909	▁chr omat in _ sub prote ome
D-99	-0.9703512787818909	chromatin_subproteome
P-99	-2.0396 -0.0357 -1.1173 -0.8562 -0.7308 -0.1285 -0.0246 -3.6543 -0.1461
S-1493	A muscle-wasting syndrome exists in acquired heart failure but has not been assessed in Fontan subjects.<unk>
T-1493	syndrome heart_failure fontan
H-1493	-0.3261719048023224	▁muscle - was ting ▁syndrome ▁acquire d _ heart ▁failure ▁Font an
D-1493	-0.3261719048023224	muscle-wasting syndrome acquired_heart failure Fontan
P-1493	-1.1930 -0.0815 -0.0580 -0.0471 -1.1151 -0.2704 -0.0091 -0.0917 -0.9160 -0.4045 -0.0917 -0.0424 -0.1720 -0.0738
S-684	Mediterranean and DASH diet scores and mortality in women with heart failure: The Women's Health Initiative.<unk>
T-684	dash mortality heart_failure health
H-684	-1.0411864519119263	▁mediterrane an ▁DAS h ▁die t ▁score s ▁mortal ity ▁heart ▁failure ▁Women _ s _ Health ▁Initiative
D-684	-1.0411864519119263	mediterranean DASh diet scores mortality heart failure Women_s_Health Initiative
P-684	-4.5581 -0.0290 -0.1738 -0.2709 -1.8176 -0.0560 -0.2300 -0.0947 -0.4218 -0.4460 -3.9496 -1.6790 -2.1000 -1.3855 -0.9538 -0.8583 -1.4607 -0.1357 -0.0595 -0.1436
S-118	The differential effect of LVEF on long-term mortality is significantly attenuated in the older age group.<unk>
T-118	differential_effect lvef mortality
H-118	-0.5845438838005066	▁LV EF ▁long - term _ ▁mortal ity
D-118	-0.5845438838005066	LVEF long-term_ mortality
P-118	-0.7038 -0.0804 -3.2136 -0.0849 -0.0879 -0.2724 -0.4961 -0.5390 -0.2173 -0.1500
S-291	CONCLUSIONS: cTnT and NT-proBNP have significant value in HF risk prediction.<unk>
T-291	ctnt nt-probnp hf
H-291	-0.33984580636024475	▁c t n t ▁NT - pro b NP ▁ HF
D-291	-0.33984580636024475	ctnt NT-probNP HF
P-291	-0.0588 -0.4737 -0.0449 -0.3332 -0.4045 -0.0196 -0.0076 -0.5464 -0.0393 -0.5524 -0.2447 -1.5483 -0.1445
S-195	Inhospital mortality was 2.7%, and patients above the median BNP level had higher mortality than those below.<unk>
T-195	inhospital mortality patients bnp mortality
H-195	-0.5144953727722168	▁in hospital ▁mortal ity ▁b NP
D-195	-0.5144953727722168	inhospital mortality bNP
P-195	-0.5348 -0.0105 -0.1544 -0.2315 -1.9054 -0.1568 -1.0473 -0.0753
S-1626	No relationship was found between the Health Buddy Program and ED use or number of hospital days for participants who were hospitalized.<unk>
T-1626	health_buddy_program hospital hospitalized
H-1626	-1.0410321950912476	▁Health ▁Budd y ▁Program ▁ED
D-1626	-1.0410321950912476	Health Buddy Program ED
P-1626	-2.6149 -0.0995 -0.0493 -2.5660 -0.2013 -1.6146 -0.1416
S-936	We also examined resistin levels in anthracycline-treated breast cancer patients with and without cardiotoxicity.<unk>
T-936	resistin breast_cancer patients cardiotoxicity
H-936	-0.5245329141616821	▁resist in ▁levels ▁an thra cycli ne - tre ated ▁breast ▁cancer ▁patients ▁cardio toxic ity
D-936	-0.5245329141616821	resistin levels anthracycline-treated breast cancer patients cardiotoxicity
P-936	-1.3918 -0.2958 -1.4528 -0.0404 -0.0142 -0.1988 -1.0250 -0.3055 -0.0222 -0.6656 -0.1385 -0.5080 -1.1754 -0.0210 -0.0705 -1.8661 -0.1262 -0.1238
S-1622	INTERVENTION: The Health Buddy Program, which integrates a content-driven telehealth system with care management.<unk>
T-1622	health_buddy_program telehealth
H-1622	-1.0130348205566406	▁Health ▁Budd y _ ▁Program ▁content - driv en _ ▁tele health ▁system ▁care ▁management
D-1622	-1.0130348205566406	Health Buddy_ Program content-driven_ telehealth system care management
P-1622	-2.8523 -0.2195 -0.0439 -2.7284 -2.4185 -2.6061 -0.0145 -0.0066 -0.0357 -1.1289 -1.0996 -0.4447 -1.9610 -0.7938 -0.4769 -0.2090 -0.1820
S-1287	Mortality was 24 per cent with five deaths occurring within 30 days of ACS consultation and/or operation.<unk>
T-1287	mortality deaths acs consultation operation
H-1287	-0.5525664687156677	▁Mor t ality
D-1287	-0.5525664687156677	Mortality
P-1287	-1.0925 -0.0560 -0.0105 -1.5214 -0.0824
S-1740	BACKGROUND: Contemporary therapeutic options have led to substantial improvement in survival of patients with heart failure.<unk>
T-1740	therapeutic patients heart_failure
H-1740	-1.3794180154800415	▁con tempor ary _ therapeut ic
D-1740	-1.3794180154800415	contemporary_therapeutic
P-1740	-5.9698 -0.0746 -0.1625 -0.3933 -0.2647 -0.0408 -4.0658 -0.0639
S-586	Dobutamine requirement, higher furosemide dose, and higher oxygen flow were associated with unfavorable outcome.<unk>
T-586	dobutamine furosemide outcome
H-586	-1.0114599466323853	▁do bu tamine ▁fur os em ide ▁dose ▁oxygen
D-586	-1.0114599466323853	dobutamine furosemide dose oxygen
P-586	-0.5063 -0.0039 -0.0672 -4.1534 -0.1641 -0.0102 -0.0134 -1.2682 -0.2470 -4.6038 -0.0884
S-130	CONCLUSIONS: We noted differential relations between CPCs and outcomes in patients with vs without diabetes.<unk>
T-130	cpcs outcomes patients diabetes
H-130	-0.9794689416885376	▁c PC s
D-130	-0.9794689416885376	cPCs
P-130	-1.1392 -0.3582 -0.8362 -2.3710 -0.1928
S-727	Frequency of 7-day follow-up visits increased from 19.6% to 46.9% (P < .01).<unk>
T-727	follow-up
H-727	-0.6573870182037354	
D-727	-0.6573870182037354	
P-727	-1.2722 -0.0426
S-1284	Patients undergoing MT were more likely to require consultation for abdominal problems (88 vs 27%; P = 0.004).<unk>
T-1284	patients consultation abdominal
H-1284	-1.4625651836395264	
D-1284	-1.4625651836395264	
P-1284	-2.7817 -0.1434
S-1661	This article describes the possible causes of, the array of diagnostic procedures for, and treatments for this complication.<unk>
T-1661	diagnostic complication
H-1661	-1.0244333744049072	▁diagnostic ▁procedure s
D-1661	-1.0244333744049072	diagnostic procedures
P-1661	-3.8123 -0.3423 -0.0251 -0.8561 -0.0864
S-2001	Thirty-day mortality was 2% and 6-month survival 92%, which exceeded the 88% performance goal.<unk>
T-2001	mortality
H-2001	-0.6664777994155884	▁Thi r ty - day ▁mortal ity
D-2001	-0.6664777994155884	Thirty-day mortality
P-2001	-2.6559 -0.0294 -0.1268 -0.0167 -0.1699 -1.7291 -0.2264 -0.9390 -0.1049
S-850	RESULTS: On March 13, 2013, the study was stopped for futility on the recommendation of the data and safety monitoring board.<unk>
T-850	
H-850	-1.5768452882766724	▁fut ility ▁data
D-850	-1.5768452882766724	futility data
P-850	-2.4576 -0.1112 -0.8027 -4.4197 -0.0930
S-1092	The etiologic causes of acute RV failure often differ from those encountered in left ventricular dysfunction.<unk>
T-1092	etiologic acute_rv_failure left_ventricular_dysfunction
H-1092	-0.8030778169631958	▁et i ologic _ ▁causes ▁a cute _ RV _ ▁failure ▁left ▁vent ri cular ▁dys function
D-1092	-0.8030778169631958	etiologic_ causes acute_RV_ failure left ventricular dysfunction
P-1092	-2.0227 -0.1113 -0.0530 -1.0965 -2.1127 -2.0091 -0.0061 -0.1533 -1.1335 -2.0824 -0.1242 -0.3069 -1.2298 -1.1189 -0.3963 -1.0393 -0.0653 -0.1059 -0.0912
S-576	Left ventricular ejection time in acute heart failure complicating precapillary pulmonary hypertension.<unk>
T-576	left_ventricular_ejection_time acute_heart_failure precapillary_pulmonary_hypertension
H-576	-0.4433046281337738	▁vent ri cular ▁e je ction ▁a cute _ heart ▁failure ▁pre cap illa ry ▁pulmonar y ▁hyper tension
D-576	-0.4433046281337738	ventricular ejection acute_heart failure precapillary pulmonary hypertension
P-576	-1.0085 -0.4168 -0.0957 -1.1731 -0.0309 -0.0097 -3.2290 -0.0283 -0.2455 -1.1205 -0.3447 -0.0905 -0.0166 -0.0213 -0.0924 -0.6647 -0.0258 -0.4219 -0.0152 -0.1206 -0.1377
S-541	Surgical correction of aortic valve insufficiency after left ventricular assist device implantation.<unk>
T-541	surgical aortic_valve_insufficiency left_ventricular_assist_device implantation
H-541	-0.4276650846004486	▁a or tic _ ▁val ve ▁insu ffi cie ncy ▁left ▁vent ri cular _ assist ▁device ▁implant ation
D-541	-0.4276650846004486	aortic_ valve insufficiency left ventricular_assist device implantation
P-541	-0.5073 -0.0334 -0.5417 -0.2931 -0.4927 -0.0400 -0.4834 -0.0672 -0.5982 -0.0333 -0.4800 -0.2680 -0.3123 -0.0847 -0.5210 -0.8459 -2.8157 -0.2830 -0.0767 -0.1388 -0.0648
S-750	Impact of ejection fraction on the clinical response to cardiac resynchronization therapy in mild heart failure.<unk>
T-750	ejection_fraction clinical cardiac_resynchronization_therapy mild_heart_failure
H-750	-0.34052878618240356	▁e je ction ▁ fraction ▁cardiac ▁re syn chron ization ▁ therapy ▁mild _ heart ▁failure
D-750	-0.34052878618240356	ejection fraction cardiac resynchronization therapy mild_heart failure
P-750	-0.2201 -0.0092 -0.0034 -0.5264 -0.0005 -0.2856 -0.7672 -0.0212 -0.0098 -0.6913 -1.7199 -0.0122 -0.3879 -0.2036 -0.8410 -0.3042 -0.0486 -0.0775
S-318	Effects of biventricular pacing on left heart twist and strain in a porcine model of right heart failure.<unk>
T-318	biventricular_pacing left_heart_twist strain right_heart_failure
H-318	-0.7692681550979614	▁bi ven tri cular _ ▁pa cing ▁left _ ▁heart ▁twist _ ▁strain ▁por cine _ model ▁right _ ▁heart ▁failure
D-318	-0.7692681550979614	biventricular_ pacing left_ heart twist_ strain porcine_model right_ heart failure
P-318	-1.4195 -0.0263 -0.0368 -0.4565 -0.5229 -1.0420 -0.0338 -2.0962 -0.2469 -1.7207 -0.7534 -2.7280 -0.6781 -1.0092 -0.0100 -0.6798 -0.7355 -1.5363 -0.0932 -1.3920 -0.2887 -0.0585 -0.1289
S-761	They contribute to myocardial diastolic dysfunction (DD) through collagen deposition or titin modification.<unk>
T-761	myocardial_diastolic_dysfunction dd collagen_deposition titin
H-761	-0.27507948875427246	▁my o card ial ▁dia sto lic ▁dys function ▁collage n ▁de position ▁titi n
D-761	-0.27507948875427246	myocardial diastolic dysfunction collagen deposition titin
P-761	-0.5056 -0.1108 -0.0997 -0.0878 -1.1773 -0.0239 -0.0400 -0.5166 -0.0644 -0.8982 -0.0364 -0.0655 -0.0707 -0.0031 -0.0275 -0.8898 -0.0590
S-832	Stress Doppler echocardiography may be a useful tool for prognostic assessment in pulmonary hypertension patients.<unk>
T-832	stress_doppler_echocardiography prognostic pulmonary_hypertension patients
H-832	-0.4086368680000305	▁Stress ▁do pp ler ▁e cho card i ography ▁pulmonar y ▁hyper tension
D-832	-0.4086368680000305	Stress doppler echocardiography pulmonary hypertension
P-832	-0.5053 -1.2698 -0.0085 -0.8137 -0.5319 -0.1807 -0.2722 -0.4244 -0.2152 -0.0341 -0.0325 -0.8091 -0.2728 -0.6387 -0.1209
S-329	CO correlated with septal wall CS during AVD variation and free wall CS during VVD variation (P < 0.008).<unk>
T-329	correlated septal wall avd free_wall_cs vvd
H-329	-0.918371856212616	▁sept al _ ▁wall ▁CS ▁free _ ▁wall ▁VVD
D-329	-0.918371856212616	septal_ wall CS free_ wall VVD
P-329	-1.1400 -0.0184 -0.4480 -0.8578 -1.5045 -2.9995 -0.1679 -2.1842 -0.5688 -0.1150 -0.0981
S-418	Neither inhibition of protein kinase A nor soluble guanylate cyclase altered this contractile response.<unk>
T-418	protein_kinase_a guanylate_cyclase contractile_response
H-418	-0.6827819347381592	▁protein ▁kina se ▁solu ble _ ▁gua ny late _ ▁cy cla se ▁contract ile
D-418	-0.6827819347381592	protein kinase soluble_ guanylate_ cyclase contractile
P-418	-1.5897 -0.1503 -0.0581 -3.1619 -0.4154 -0.6661 -0.1193 -0.6347 -1.0390 -1.1001 -0.0291 -0.0131 -0.4993 -0.0144 -0.0946 -1.8697 -0.1525
S-1162	Subjects were followed up for adverse events (defined as death, transplantation, or circulatory assist device).<unk>
T-1162	followed_up adverse_events death transplantation circulatory_assist_device
H-1162	-0.9584835767745972	▁circula tory _ assist ▁device
D-1162	-0.9584835767745972	circulatory_assist device
P-1162	-4.6947 -0.1045 -0.1582 -0.3635 -1.1910 -0.1260 -0.0715
S-351	Both systolic and diastolic mitral leaflet motions were restricted without any clear organic lesion.<unk>
T-351	systolic diastolic_mitral_leaflet_motions organic lesion
H-351	-0.6455879211425781	▁sy sto lic ▁dia sto lic _ met ral _ met ral _ le a flet _ ▁motion s
D-351	-0.6455879211425781	systolic diastolic_metral_metral_leaflet_ motions
P-351	-0.0163 -0.0089 -0.0067 -1.3760 -0.0279 -0.0101 -0.6155 -0.6228 -0.1815 -0.5618 -2.5268 -0.1989 -0.4297 -2.4282 -0.2084 -0.0019 -2.4856 -0.4730 -0.1236 -1.1405 -0.1132
S-119	Changes in circulating progenitor cells are associated with outcome in heart failure patients: a longitudinal study.<unk>
T-119	circulating_progenitor_cells outcome heart_failure patients longitudinal
H-119	-0.8475582599639893	▁circula ting _ pro gen itor _ ▁cell s ▁heart ▁failure
D-119	-0.8475582599639893	circulating_progenitor_ cells heart failure
P-119	-0.0062 -0.8004 -0.2077 -1.5447 -0.0445 -0.0798 -1.7213 -1.6358 -0.0685 -3.0670 -0.3807 -1.3193 -0.1426
S-1115	Primary outcome was sympathetic activity as measured by (123)I-MIBG myocardial washout.<unk>
T-1115	primary_outcome sympathetic_activity myocardial_washout
H-1115	-0.9387447834014893	▁sympa the tic _ ▁activity ▁i - MI BG ▁my o card ial ▁was hout
D-1115	-0.9387447834014893	sympathetic_ activity i-MIBG myocardial washout
P-1115	-3.2104 -0.1783 -0.1676 -1.5941 -1.2860 -1.6040 -0.3296 -0.4140 -0.6270 -1.5687 -0.2777 -0.4010 -0.0806 -3.7215 -0.0712 -0.1688 -0.2582
S-215	We used the Student t test, calculated 95% confidence intervals (CIs), and performed regression analyses.<unk>
T-215	student_t_test confidence_intervals cis regression_analyses
H-215	-1.107230305671692	▁student ▁t ▁test ▁ci s
D-215	-1.107230305671692	student t test cis
P-215	-2.1060 -0.2601 -1.6145 -2.5414 -0.0347 -1.0864 -0.1077
S-597	The left pulmonary artery was completed occluded and the right pulmonary artery was partially obstructed.<unk>
T-597	left_pulmonary_artery right_pulmonary_artery
H-597	-0.21152399480342865	▁pulmonar y ▁arter y
D-597	-0.21152399480342865	pulmonary artery
P-597	-0.5170 -0.0208 -0.1446 -0.1024 -0.3973 -0.0870
S-1951	METHODS: We did this proof-of-principle cohort study at one centre in Canada.<unk>
T-1951	proof-of-principle_cohort_study canada
H-1951	-0.3501007854938507	▁ proof - of - princip le _ co hor t
D-1951	-0.3501007854938507	proof-of-principle_cohort
P-1951	-0.7144 -0.3599 -0.0407 -0.1814 -0.0835 -0.0046 -0.4107 -0.3540 -0.5539 -0.0403 -0.0984 -1.5894 -0.1202
S-1937	This study assessed the impact of HR reduction with beta blockers on exercise capacity in recent onset HFrEF.<unk>
T-1937	hr_reduction beta_blockers exercise_capacity hfref
H-1937	-0.5260265469551086	▁HR ▁re duction ▁beta ▁block ers ▁exercise ▁capacity ▁h Fr EF
D-1937	-0.5260265469551086	HR reduction beta blockers exercise capacity hFrEF
P-1937	-0.8900 -1.7727 -0.0266 -0.4299 -0.5631 -0.0172 -0.1972 -0.8166 -1.8032 -0.1196 -0.0993 -0.0467 -0.0563
S-946	LV strain and strain rate were assessed by echocardiography at baseline and over 12 months after ablation.<unk>
T-946	lv_strain strain echocardiography baseline ablation
H-946	-0.5962627530097961	▁LV ▁e cho card i ography
D-946	-0.5962627530097961	LV echocardiography
P-946	-0.6685 -2.6956 -0.0091 -0.1336 -0.2007 -0.1311 -0.8547 -0.0767
S-121	We evaluated the association between serial measurements of CPCs and functional capacity and outcomes in heart failure (HF).<unk>
T-121	cpcs functional_capacity outcomes heart_failure hf
H-121	-0.5831877589225769	▁c PC s ▁functional ▁capacity ▁heart ▁failure HF
D-121	-0.5831877589225769	cPCs functional capacity heart failureHF
P-121	-0.8727 -0.2023 -0.7326 -0.0836 -1.8261 -0.9682 -0.1054 -0.8655 -0.0642 -0.1112
S-6	Some events, such as pressure ulcers in surgical patients, actually increased despite considerable national attention to these problems.<unk>
T-6	pressure_ulcers surgical patients
H-6	-1.1766440868377686	▁pressure ▁ul cer s ▁sur g ical ▁patients
D-6	-1.1766440868377686	pressure ulcers surgical patients
P-6	-2.0150 -1.2265 -0.0461 -0.2473 -4.2607 -0.1764 -0.2324 -2.7081 -0.6483 -0.2057
S-1527	We compared clinical, laboratory, echocardiographic, invasive hemodynamic, and outcome data among groups.<unk>
T-1527	clinical echocardiographic invasive hemodynamic outcome
H-1527	-0.3024452030658722	▁e cho car dio graphic ▁invasi ve _ hem o dynamic
D-1527	-0.3024452030658722	echocardiographic invasive_hemodynamic
P-1527	-0.7021 -0.0076 -0.0085 -0.4572 -0.1487 -0.0509 -0.0333 -0.4160 -1.6486 -0.1946 -0.0003 -0.2036 -0.0605
S-1341	Here, we found that CHF atrial explants produced less c-Kit+ cells than sham explants.<unk>
T-1341	chf atrial_explants cells explants
H-1341	-0.4905412495136261	▁CHF _ at rial _ ▁ex plant s ▁c - K it _ ▁cell s ▁sham ▁ex plant s
D-1341	-0.4905412495136261	CHF_atrial_ explants c-Kit_ cells sham explants
P-1341	-0.0115 -2.6395 -1.1533 -0.0276 -0.2378 -0.9077 -0.0021 -0.2572 -0.0710 -0.0502 -0.2489 -0.0040 -0.4221 -2.2665 -0.1745 -0.1649 -1.3185 -0.0011 -0.1810 -0.0881 -0.0738
S-886	Of these, 1175 had left bundle-branch block (LBBB) and 308 had non-LBBB.<unk>
T-886	left_bundle-branch_block lbbb
H-886	-0.4076969623565674	▁bund le - bran ch ▁block LB bb
D-886	-0.4076969623565674	bundle-branch blockLBbb
P-886	-0.1233 -0.0485 -0.0335 -0.0096 -0.1178 -1.0801 -0.4860 -1.0026 -1.0760 -0.0996
S-1811	We have previously demonstrated that cardiac Mena deletion produced cardiac dysfunction with conduction abnormalities and hypertrophy.<unk>
T-1811	cardiac mena_deletion cardiac_dysfunction hypertrophy
H-1811	-0.47276434302330017	▁cardiac ▁Men a ▁dele tion ▁cardiac ▁dys function ▁hyper trop hy
D-1811	-0.47276434302330017	cardiac Mena deletion cardiac dysfunction hypertrophy
P-1811	-0.0446 -1.8251 -0.1112 -0.1463 -0.0794 -0.0901 -1.9285 -0.0967 -0.7291 -0.0037 -0.9848 -0.0407 -0.0658
S-902	PD appears to be a viable option in refractory, end-stage congestive heart failure (CHF).<unk>
T-902	pd congestive_heart_failure chf
H-902	-0.7873879671096802	▁PD ▁re frac tory _ ▁end - s tage _ ▁con ges tive _ heart ▁failure CH F
D-902	-0.7873879671096802	PD refractory_ end-stage_ congestive_heart failureCHF
P-902	-1.6081 -1.8414 -0.0129 -0.0404 -1.3307 -4.8616 -0.0331 -0.1108 -0.0009 -0.5212 -1.0686 -0.1683 -0.4900 -0.0853 -1.9657 -0.3618 -0.8004 -0.3136 -0.0670 -0.0660
S-649	However, during the past decades several studies have demonstrated that beta blockers decrease mortality in patients with heart failure.<unk>
T-649	beta_blockers mortality patients heart_failure
H-649	-1.2863749265670776	▁beta ▁block ers
D-649	-1.2863749265670776	beta blockers
P-649	-1.9663 -0.8626 -0.1515 -3.3628 -0.0886
S-1233	We compared the economic impact of the 2 treatment strategies in patients with AF and heart failure from the province of Québec, Canada.<unk>
T-1233	economic patients heart_failure québec canada
H-1233	-1.9999068975448608	▁economische _ impact
D-1233	-1.9999068975448608	economische_impact
P-1233	-2.2476 -3.1934 -0.2575 -4.1650 -0.1360
S-682	Among patients treated with trastuzumab, those with cardiac comorbidities and older age may be at higher risk.<unk>
T-682	patients trastuzumab cardiac comorbidities
H-682	-0.5396035313606262	▁tras tuz um ab ▁cardiac ▁como rbi di ties
D-682	-0.5396035313606262	trastuzumab cardiac comorbidities
P-682	-0.4363 -0.0389 -0.0082 -0.3302 -0.0598 -4.0788 -0.0019 -0.2331 -0.1167 -0.5270 -0.1047
S-279	This phenotype was reproducible, and there were few perioperative or early deaths in the experimental procedures.<unk>
T-279	phenotype perioperative deaths
H-279	-0.5443354845046997	
D-279	-0.5443354845046997	
P-279	-1.0322 -0.0565
S-369	At the time of second HF 4 years after valve plasty, MS was significant with an MVA of 1.2 cm2.<unk>
T-369	hf valve_plasty mva
H-369	-0.415272057056427	▁ HF ▁val ve ▁plast y ▁MS ▁m VA
D-369	-0.415272057056427	HF valve plasty MS mVA
P-369	-0.5862 -0.0206 -2.1925 -0.0146 -0.4260 -0.1772 -0.5238 -0.3320 -0.0588 -0.1778 -0.0585
S-662	Multivariable hierarchical regression models were adjusted for demographics, insurance status, and comorbidities.<unk>
T-662	regression_models comorbidities
H-662	-1.3512665033340454	▁hier archi cal _ ▁re gression
D-662	-1.3512665033340454	hierarchical_ regression
P-662	-5.4113 -0.0472 -0.1061 -0.5834 -0.6994 -0.0043 -3.8692 -0.0892
S-1893	The duration and extent of the symptoms are relevant and it is useful to classify patients according to the NYHA functional assessment.<unk>
T-1893	symptoms patients nyha
H-1893	-0.9731038808822632	▁NY HA ▁functional ▁assessment
D-1893	-0.9731038808822632	NYHA functional assessment
P-1893	-4.1891 -0.1099 -0.9267 -0.5016 -0.0456 -0.0657
S-701	The median baseline ST2 level was 23.7 ng/mL (interquartile range, 18.6-31.8).<unk>
T-701	baseline st2 interquartile_range
H-701	-1.418778896331787	▁media n ▁base line ▁ST 2
D-701	-1.418778896331787	median baseline ST2
P-701	-2.4912 -0.2269 -2.5267 -0.0054 -2.7281 -0.0898 -3.0785 -0.2036
S-927	Human resistin in chemotherapy-induced heart failure in humanized male mice and in women treated for breast cancer.<unk>
T-927	resistin heart_failure breast_cancer
H-927	-0.5148027539253235	▁Human ▁resist in ▁che mo therapy - indu ced _ heart ▁failure ▁human ized _ male _ mi ce ▁breast ▁cancer
D-927	-0.5148027539253235	Human resistin chemotherapy-induced_heart failure humanized_male_mice breast cancer
P-927	-2.0724 -1.6742 -0.1302 -0.1088 -0.2487 -0.0316 -0.3789 -0.0066 -0.2204 -0.4530 -1.0129 -0.2054 -0.7249 -0.1077 -0.2191 -2.1310 -0.2998 -0.6156 -0.0839 -0.3519 -0.5504 -0.0849 -0.1282
S-849	The primary efficacy outcome was the composite of death from any cause or first hospitalization for worsening heart failure.<unk>
T-849	outcome death hospitalization heart_failure
H-849	-1.5505671501159668	
D-849	-1.5505671501159668	
P-849	-2.9680 -0.1331
S-1402	Findings from this study provide insight on the possible contribution of nursing to outcomes of hospitalized older adults with HF.<unk>
T-1402	nursing outcomes hospitalized hf
H-1402	-1.6679092645645142	▁ HF
D-1402	-1.6679092645645142	HF
P-1402	-3.2350 -2.8340 -0.4805 -0.1221
S-1071	Besides therapeutic functions, devices can have add-on diagnostic features such as early detection of fluid overload.<unk>
T-1071	therapeutic diagnostic fluid_overload
H-1071	-0.881705105304718	▁ therapeut ic _ ▁function s
D-1071	-0.881705105304718	therapeutic_ functions
P-1071	-0.5734 -0.0138 -0.0410 -1.4089 -1.5981 -0.0697 -3.2706 -0.0782
S-1395	Nursing-sensitive outcome change scores for hospitalized older adults with heart failure: a preliminary descriptive study.<unk>
T-1395	outcome change hospitalized heart_failure
H-1395	-1.1717606782913208	▁Nur sing - sensitiv e _ ▁outcome ▁change ▁score s ▁hospital ized _ ▁older _ ▁adults ▁heart ▁failure
D-1395	-1.1717606782913208	Nursing-sensitive_ outcome change scores hospitalized_ older_ adults heart failure
P-1395	-2.8742 -0.0061 -0.0382 -0.0018 -0.1125 -1.5747 -3.2704 -3.7299 -0.5101 -0.0513 -1.9182 -0.1021 -0.6478 -3.3806 -1.0103 -1.7710 -1.6052 -0.5770 -0.0945 -0.1593
S-793	Within-day test-retest reliability of the Timed Up & Go test in patients with advanced chronic organ failure.<unk>
T-793	patients chronic_organ_failure
H-793	-1.3104252815246582	▁Time d _ up _ go
D-793	-1.3104252815246582	Timed_up_go
P-793	-4.0146 -0.1483 -0.3302 -0.3468 -0.2757 -0.9681 -4.1594 -0.2402
S-1637	Over a median follow-up of 2.5 years, black race was associated with increased risk for all outcomes except mortality.<unk>
T-1637	follow-up outcomes mortality
H-1637	-0.7816454172134399	▁black _ ▁race
D-1637	-0.7816454172134399	black_ race
P-1637	-0.0321 -0.8870 -0.9188 -1.8844 -0.1859
S-553	Various transcatheter approaches to these difficult problems are also available and offer less invasive alternatives to conventional surgery.<unk>
T-553	transcatheter invasive surgery
H-553	-0.4755166172981262	▁trans cat heter
D-553	-0.4755166172981262	transcatheter
P-553	-0.0881 -0.1309 -0.0172 -2.0508 -0.0906
S-748	The choice of chelation regimens known to remove heart iron efficiently was not sufficient by itself to influence the risk.<unk>
T-748	chelation heart_iron
H-748	-1.2493172883987427	▁che lation ▁regime ns
D-748	-1.2493172883987427	chelation regimens
P-748	-0.3951 -0.0525 -1.3926 -0.2466 -5.2957 -0.1133
S-1926	We aimed to describe the association between social support and barriers to participation with exercise adherence and clinical outcomes.<unk>
T-1926	exercise clinical outcomes
H-1926	-1.593630313873291	
D-1926	-1.593630313873291	
P-1926	-3.0866 -0.1007
S-1257	Effectiveness of Chinese herbal medicine as an adjunctive treatment for dilated cardiomyopathy in patients with heart failure.<unk>
T-1257	medicine dilated_cardiomyopathy patients heart_failure
H-1257	-0.6100559830665588	▁Chinese ▁herbal ▁medicine ▁dil ated _ ▁cardio my o pathy ▁heart ▁failure
D-1257	-0.6100559830665588	Chinese herbal medicine dilated_ cardiomyopathy heart failure
P-1257	-1.1913 -1.3140 -1.2076 -0.5600 -0.2456 -0.1423 -0.4151 -1.3285 -0.2108 -0.0318 -1.1083 -0.4488 -0.1436 -0.1930
S-1856	Patient perceptions of implantable cardioverter-defibrillator deactivation discussions: A qualitative study.<unk>
T-1856	patient implantable_cardioverter-defibrillator
H-1856	-0.26368749141693115	▁implant able _ ▁cardio ver ter - de fi br illa tor ▁de activa tion
D-1856	-0.26368749141693115	implantable_ cardioverter-defibrillator deactivation
P-1856	-0.9642 -0.0207 -0.2725 -1.0725 -0.0059 -0.2401 -0.3129 -0.0118 -0.1602 -0.1556 -0.0957 -0.0316 -0.2073 -0.0064 -0.2496 -0.5149 -0.1608
S-167	We evaluated protein levels of these genes by Western blot and DNA fragmentation by TUNEL method from autopsy samples.<unk>
T-167	protein genes western_blot dna_fragmentation tunel
H-167	-0.9785687923431396	▁protein ▁levels ▁Western ▁blot _ DNA ▁fragment ation ▁TU NEL ▁auto psy
D-167	-0.9785687923431396	protein levels Western blot_DNA fragmentation TUNEL autopsy
P-167	-2.2740 -0.5275 -1.7004 -0.3891 -3.0625 -2.2767 -0.4834 -0.0409 -0.9440 -0.6814 -0.4350 -0.0125 -0.7545 -0.1181
S-1480	Heart failure is the leading cause of mortality in Western society and represents the fastest growing subclass of cardiovascular diseases.<unk>
T-1480	heart_failure leading mortality western society cardiovascular_diseases
H-1480	-1.61835515499115	▁Heart _ ▁failure
D-1480	-1.61835515499115	Heart_ failure
P-1480	-1.7541 -1.8598 -1.0405 -3.2361 -0.2012
S-917	In HFPEF animal models, dietary sodium restriction improves ventricular and vascular stiffness and function.<unk>
T-917	hfpef sodium ventricular vascular_stiffness
H-917	-0.6159820556640625	▁H FP EF ▁dieta ry ▁so dium ▁restriction ▁vent ri cular ▁vas cular ▁sti ff ness
D-917	-0.6159820556640625	HFPEF dietary sodium restriction ventricular vascular stiffness
P-917	-0.7224 -0.0218 -0.1731 -3.2941 -0.1214 -0.1023 -0.0604 -0.5741 -0.0136 -0.5235 -0.1709 -1.4422 -0.4151 -0.5940 -0.0502 -1.9617 -0.7378 -0.1091
S-1532	Despite these differences, EH and CH had similarly elevated cardiac filling pressures and equivalent adverse outcomes.<unk>
T-1532	elevated cardiac_filling_pressures adverse_outcomes
H-1532	-0.916496753692627	▁EH ▁cardiac ▁fill ing _ ▁pressure s
D-1532	-0.916496753692627	EH cardiac filling_ pressures
P-1532	-0.1313 -2.3540 -2.3420 -0.0802 -1.9651 -0.6340 -0.3022 -0.3441 -0.0955
S-1146	Mechanistic insight into prolonged electromechanical delay in dyssynchronous heart failure: a computational study.<unk>
T-1146	electromechanical_delay dyssynchronous_heart_failure
H-1146	-0.6529673933982849	▁electro me chan ical ▁de lay ▁dys syn chron ous _ heart ▁failure ▁computa tional
D-1146	-0.6529673933982849	electromechanical delay dyssynchronous_heart failure computational
P-1146	-3.5085 -0.0144 -0.0025 -0.2438 -1.2940 -0.0596 -0.1696 -0.0030 -0.0022 -1.4372 -0.3484 -1.7047 -0.4546 -0.0477 -0.0026 -1.6191 -0.1885
S-165	Participation of apoptosis during the development of pacing-induced dilated cardiomyopathy is not fully understood.<unk>
T-165	apoptosis pacing-induced_dilated_cardiomyopathy
H-165	-0.6432740092277527	▁pa cing - indu ced _ ▁dil ated _ ▁cardio my o pathy
D-165	-0.6432740092277527	pacing-induced_ dilated_ cardiomyopathy
P-165	-1.4256 -1.1576 -0.1030 -0.0118 -0.3385 -0.1586 -3.8180 -0.6762 -0.2021 -0.4614 -0.8546 -0.2393 -0.0387 -0.0477 -0.1159
S-1370	A hallmark of chronic heart failure (CHF) is an increased sympathetic tone resulting in autonomic imbalance.<unk>
T-1370	chronic_heart_failure chf sympathetic_tone autonomic_imbalance
H-1370	-0.5548163652420044	▁chronic _ heart ▁failure CH F ▁sympa the tic _ ▁tone ▁autonomi c
D-1370	-0.5548163652420044	chronic_heart failureCHF sympathetic_ tone autonomic
P-1370	-0.6663 -0.4004 -1.3781 -0.4078 -1.2909 -0.7964 -0.1958 -0.0777 -0.2257 -0.9476 -0.0639 -0.0004 -0.1158 -1.6525 -0.1027
S-596	The right atrium mass presented with prolapse through the tricuspid valve causing a stenotic physiology.<unk>
T-596	right_atrium prolapse tricuspid_valve stenotic_physiology
H-596	-0.5614073276519775	▁right _ at rium _ ▁mass ▁tri cus pid _ ▁val ve ▁ste no tic ▁physio log y
D-596	-0.5614073276519775	right_atrium_ mass tricuspid_ valve stenotic physiology
P-596	-3.0550 -0.2833 -0.3443 -0.0014 -0.8678 -1.0133 -0.7202 -0.0312 -0.0177 -0.4313 -0.3454 -0.1025 -0.0014 -0.0764 -0.4835 -2.6443 -0.0527 -0.6218 -0.0843 -0.0504
S-571	The primary outcome, measured after 12 weeks, was functional capacity assessed by a 6-minute walk test (6MWT).<unk>
T-571	primary_outcome functional_capacity 6-minute_walk_test 6mwt
H-571	-1.3666685819625854	▁functional _ capaci
D-571	-1.3666685819625854	functional_capaci
P-571	-0.8732 -1.7004 -0.7732 -3.4067 -0.0798
S-224	Fontan failure can occur even with normal systolic ventricular function and often in the context of significant liver disease.<unk>
T-224	fontan_failure systolic_ventricular_function liver_disease
H-224	-0.7591173052787781	▁Font an ▁failure ▁sy sto lic _ ▁vent ri cular
D-224	-0.7591173052787781	Fontan failure systolic_ ventricular
P-224	-0.3490 -0.2889 -3.7219 -0.1104 -0.0056 -0.0569 -1.1998 -0.0336 -0.2170 -0.0868 -2.9183 -0.1213
S-1431	Western blots with site-specific monoclonal antibodies showed increased Ser83 phosphorylation in HF.<unk>
T-1431	western_blots monoclonal_antibodies ser83 phosphorylation hf
H-1431	-0.40018725395202637	▁Western ▁blot s ▁mono clo nal ▁anti bo dies ▁Ser 83 ▁ phos phor y lation ▁ HF
D-1431	-0.40018725395202637	Western blots monoclonal antibodies Ser83 phosphorylation HF
P-1431	-0.4986 -0.4380 -0.0473 -0.0196 -0.0074 -0.7553 -0.7068 -0.0541 -1.7804 -0.3865 -0.5085 -0.2404 -0.0047 -0.5041 -1.0097 -0.1109 -0.7396 -0.0011 -0.0734 -0.1175
S-1292	INVESTIGATIONS: The cardiac catheterization showed a thrombotic obstruction of the right coronary artery.<unk>
T-1292	cardiac_catheterization thrombotic_obstruction right_coronary_artery
H-1292	-0.5768514275550842	▁cardiac _ ▁cat heter ization ▁ thro mbo tic _ ob struct ion ▁right ▁corona ry ▁arter y
D-1292	-0.5768514275550842	cardiac_ catheterization thrombotic_obstruction right coronary artery
P-1292	-0.3668 -1.8957 -0.8416 -0.0320 -0.8124 -0.5345 -0.0661 -0.1573 -1.9800 -0.2643 -0.6087 -0.0293 -0.0442 -1.8407 -0.9341 -0.2529 -0.1230 -0.4971 -0.1328 -0.1235
S-528	Relation of preoperative serum albumin levels to survival in patients undergoing left ventricular assist device implantation.<unk>
T-528	preoperative serum_albumin patients left_ventricular_assist_device implantation
H-528	-0.8396903872489929	▁pre operativ e _ se rum ▁album in
D-528	-0.8396903872489929	preoperative_serum albumin
P-528	-2.2854 -0.0732 -0.0130 -0.8038 -0.6089 -0.0541 -0.3355 -0.0434 -4.0412 -0.1385
S-1992	Fully Magnetically Levitated Left Ventricular Assist System for Treating Advanced HF: A Multicenter Study.<unk>
T-1992	fully_magnetically_levitated_left_ventricular_assist_system hf
H-1992	-0.6659227013587952	▁magnet ically _ ▁Lev itate d _ le ft _ ▁Vent ri cular _ ▁Assist ▁System ▁Tre ating ▁Advanced _ HF
D-1992	-0.6659227013587952	magnetically_ Levitated_left_ Ventricular_ Assist System Treating Advanced_HF
P-1992	-1.0347 -0.3563 -0.4916 -1.0063 -0.6227 -0.0170 -0.4954 -1.0409 -0.0114 -0.0614 -2.0496 -1.4394 -0.3240 -1.1699 -0.3916 -0.5339 -2.3573 -0.0177 -0.8379 -0.6471 -0.0368 -0.2617 -0.1114
S-614	The challenge is to deliver cost-effective, participatory, population-specific health interventions that result in measurable benefits.<unk>
T-614	health
H-614	-1.1925603151321411	
D-614	-1.1925603151321411	
P-614	-2.3473 -0.0379
S-851	At study closure, the 809 patients who had undergone randomization had been followed for a mean of 19.4 months.<unk>
T-851	patients randomization
H-851	-0.9567694664001465	
D-851	-0.9567694664001465	
P-851	-1.8489 -0.0646
S-1662	It is critical to develop an understanding of this topic so cardiac nurses can partner with other subspecialty groups to manage this population.<unk>
T-1662	cardiac nurses
H-1662	-0.3720996677875519	▁cardiac ▁nurse s
D-1662	-0.3720996677875519	cardiac nurses
P-1662	-0.2498 -0.9316 -0.0353 -0.5725 -0.0713
S-1282	In total, 28 consultations were required in 21 patients (9%) and 16 procedures were performed in 11 patients (5%).<unk>
T-1282	consultations patients patients
H-1282	-0.7168846726417542	
D-1282	-0.7168846726417542	
P-1282	-1.3850 -0.0487
S-50	Conclusion: Higher transfusion thresholds do not consistently improve mortality rates, but large trials are needed.<unk>
T-50	transfusion mortality
H-50	-0.7985775470733643	▁trans fusion ▁thre s hold s
D-50	-0.7985775470733643	transfusion thresholds
P-50	-0.9312 -0.8039 -1.6283 -0.1648 -0.1720 -0.2291 -2.3116 -0.1477
S-1539	The absolute risk of heart failure was 4.4% in the exposed group and 3.7% in the control group (P < 0.01).<unk>
T-1539	heart_failure
H-1539	-0.8680828213691711	▁absolute _ risk _ van _ heart ▁failure
D-1539	-0.8680828213691711	absolute_risk_van_heart failure
P-1539	-3.0432 -0.2764 -1.6706 -0.4016 -0.8742 -0.0431 -1.1745 -0.5079 -0.6052 -0.0841
S-383	The concordance c statistics in the UM/VA/VA-RT cohorts were 0.71/0.68/0.74.<unk>
T-383	c_statistics
H-383	-0.8232868909835815	▁concorda nce _ ▁c ▁statistic s ▁UM / VA / VA - RT
D-383	-0.8232868909835815	concordance_ c statistics UM/VA/VA-RT
P-383	-2.7939 -0.3131 -1.3577 -1.1543 -0.4308 -0.0292 -0.2472 -0.7369 -0.1717 -1.6215 -0.7434 -0.2249 -2.1025 -0.2515 -0.1706
S-1875	The major adverse neurological and cardiovascular event-free rate was 97.2% (lower 95% confidence bound 91.4%).<unk>
T-1875	neurological cardiovascular bound
H-1875	-1.5410891771316528	▁neurologi cal ▁cardiovascular _ event - free
D-1875	-1.5410891771316528	neurological cardiovascular_event-free
P-1875	-2.3033 -0.1371 -4.4659 -1.1964 -3.1155 -0.2444 -0.0716 -2.2559 -0.0798
S-1050	Importantly, the targets of BETs in the mouse TAC model were also found to be relevant in human HF.<unk>
T-1050	bets tac hf
H-1050	-0.3597829341888428	▁ BET s ▁mouse ▁ TAC ▁model ▁human ▁ HF
D-1050	-0.3597829341888428	BETs mouse TAC model human HF
P-1050	-0.4907 -0.3352 -0.4612 -0.3682 -0.1093 -0.0069 -0.8813 -0.4320 -1.0498 -0.0108 -0.0292 -0.1429
S-1972	Czech Republic significantly contributed to this study and all study sites should be congratulated and thanked for their high-quality work provided.<unk>
T-1972	czech_republic
H-1972	-0.4959898889064789	▁Czech ▁Republic
D-1972	-0.4959898889064789	Czech Republic
P-1972	-0.7779 -0.1355 -0.8755 -0.1951
S-414	Its clinical usefulness is limited by chemical instability and cogeneration of nitrite which itself has vascular effects.<unk>
T-414	clinical nitrite vascular
H-414	-0.7431735992431641	▁chemical ▁in st ability ▁nit rite
D-414	-0.7431735992431641	chemical instability nitrite
P-414	-3.0259 -0.1111 -0.0315 -0.0546 -0.2358 -0.5210 -1.9034 -0.0620
S-858	METHODS: All patients in the MADIT-CRT study who received a device (N = 1,790) were identified.<unk>
T-858	patients madit-crt
H-858	-0.7953886389732361	▁MAD it - c RT
D-858	-0.7953886389732361	MADit-cRT
P-858	-0.5028 -1.4716 -0.0243 -1.0820 -0.9094 -1.5139 -0.0637
S-1106	Over the 5-year follow-up period, 715 patients developed HF, 475 of whom developed it during the first week.<unk>
T-1106	follow-up patients hf
H-1106	-0.34499451518058777	▁ HF
D-1106	-0.34499451518058777	HF
P-1106	-0.7959 -0.1084 -0.3979 -0.0777
S-76	INTERVENTIONS: Participants were randomized in an open, 1:1 allocation ratio to the dopamine or nesiritide strategy.<unk>
T-76	randomized dopamine nesiritide
H-76	-0.8119218349456787	▁dop amine ▁nesi riti de
D-76	-0.8119218349456787	dopamine nesiritide
P-76	-3.0913 -0.1170 -0.5814 -0.0013 -0.0791 -1.7300 -0.0832
S-1290	Extracorporeal membrane oxygenation as bridge to recovery in infarction-related refractory right heart failure.<unk>
T-1290	extracorporeal_membrane_oxygenation refractory_right_heart_failure
H-1290	-0.5570685863494873	▁extra corp o real _ ▁membran e ▁oxygen ation ▁in far ction - related _ ▁re frac tory _ ▁right _ heart ▁failure
D-1290	-0.5570685863494873	extracorporeal_ membrane oxygenation infarction-related_ refractory_ right_heart failure
P-1290	-0.6094 -0.0014 -0.1435 -0.0054 -0.7866 -0.1292 -0.0203 -1.4638 -0.0324 -2.0459 -0.1423 -0.0405 -0.3685 -0.1300 -0.8438 -1.1287 -0.0045 -0.1995 -0.3338 -2.7540 -0.4211 -1.5893 -0.4430 -0.1609 -0.1291
S-136	DATA SOURCES: 2000-2009 California Office of Statewide Health Planning and Development Patient Discharge Data Nonpublic file.<unk>
T-136	california_office_of_statewide_health_planning_and_development_patient_discharge_data_nonpublic_file
H-136	-1.0667901039123535	▁California _ office _ of _ ▁State wide _ Health plan ning _ ▁Development ▁Patient _ Dis charge
D-136	-1.0667901039123535	California_office_of_ Statewide_Healthplanning_ Development Patient_Discharge
P-136	-2.4080 -1.0165 -0.9915 -0.5293 -1.5803 -0.1645 -3.1612 -0.2200 -0.0124 -1.8581 -0.9403 -0.0134 -0.7097 -3.2605 -0.8313 -1.1592 -1.6804 -0.0349 -0.6995 -0.0647
S-368	Because functional MS is dynamic and proportional to LV dilatation, the degree of functional MS can potentially vary considerably.<unk>
T-368	functional_ms lv_dilatation functional_ms
H-368	-0.5125928521156311	▁functional ▁MS
D-368	-0.5125928521156311	functional MS
P-368	-0.1955 -0.3437 -1.4347 -0.0765
S-838	Treatment group effects on HRQoL were estimated using linear mixed models according to the intention-to-treat principle.<unk>
T-838	hrqol linear_mixed_models intention-to-treat
H-838	-1.2275209426879883	▁HR Qo L
D-838	-1.2275209426879883	HRQoL
P-838	-4.8872 -0.0070 -0.5256 -0.6573 -0.0605
S-648	Because of their negative inotropic effect, beta blockers were neglected for a long time from the treatment of heart failure.<unk>
T-648	inotropic_effect beta_blockers heart_failure
H-648	-0.8211901187896729	▁in o tropi c ▁effect ▁beta ▁block ers
D-648	-0.8211901187896729	inotropic effect beta blockers
P-648	-1.8352 -0.3699 -0.0115 -0.0585 -2.3133 -0.2158 -0.3895 -0.0971 -2.8178 -0.1033
S-1954	Patients had clinical and echocardiography evaluations at baseline and months 1 and 3 after shunt implantation.<unk>
T-1954	patients clinical echocardiography baseline shunt implantation
H-1954	-0.25692617893218994	▁e cho card i ography ▁shu nt ▁implant ation
D-1954	-0.25692617893218994	echocardiography shunt implantation
P-1954	-0.6699 -0.0083 -0.2008 -0.3644 -0.1586 -0.7857 -0.0467 -0.3455 -0.0689 -0.0859 -0.0916
S-1779	Whether these changes in energy metabolism precede and contribute to the development of heart failure in the hypertrophied heart is not clear.<unk>
T-1779	energy_metabolism heart_failure hypertrophied heart
H-1779	-0.687939465045929	▁energie ▁metabolism ▁hyper trop hi ed _ heart
D-1779	-0.687939465045929	energie metabolism hypertrophied_heart
P-1779	-1.2256 -0.2720 -3.2042 -0.0147 -0.0205 -0.3276 -0.7148 -0.9174 -0.0485 -0.1342
S-2012	Projections of resource use and quality of life are modeled using relationships with time-varying Seattle Heart Failure Model scores.<unk>
T-2012	quality_of_life seattle_heart_failure_model
H-2012	-1.2584304809570312	▁resource ▁use ▁Seattle _ ▁Heart ▁Fail ure
D-2012	-1.2584304809570312	resource use Seattle_ Heart Failure
P-2012	-1.0289 -2.4769 -4.0430 -0.3159 -1.3522 -1.2978 -0.4746 -0.2393 -0.0973
S-1652	Usual care will consist of anticoagulation, therapy of underlying heart disease, and rate control as an initial approach.<unk>
T-1652	anticoagulation therapy heart_disease rate_control
H-1652	-0.4863857924938202	▁antico ag ulation ▁ therapy ▁under ly ing _ heart ▁disease ▁rate
D-1652	-0.4863857924938202	anticoagulation therapy underlying_heart disease rate
P-1652	-0.4183 -0.0282 -0.0550 -1.4406 -0.0104 -1.7417 -0.0692 -0.0480 -0.3641 -0.7697 -0.9466 -0.0143 -0.8414 -0.0619
S-212	SETTING: consecutive patients seen by ED physicians in 4 suburban hospitals in New Jersey and New York from 1996 to 2008.<unk>
T-212	patients physicians hospitals new_jersey new_york
H-212	-0.9836068749427795	▁ED ▁physician s ▁subur ban _ hospital s ▁New ▁Jersey
D-212	-0.9836068749427795	ED physicians suburban_hospitals New Jersey
P-212	-3.7775 -1.6374 -0.0629 -1.1408 -0.0905 -1.1933 -0.2916 -0.1581 -1.0185 -0.0494 -2.2653 -0.1179
S-2021	This article describes the pathophysiology of HF, diagnosis, medical management, and nursing interventions.<unk>
T-2021	pathophysiology hf diagnosis medical nursing
H-2021	-0.7675844430923462	▁pat ho phy si ology ▁ HF
D-2021	-0.7675844430923462	pathophysiology HF
P-2021	-2.0637 -0.3510 -0.4509 -1.2141 -0.2250 -0.3125 -0.0380 -2.2045 -0.0485
S-1350	This occurred despite a profound change in Paco2, cerebral blood flow, and perfusion of the carotid bodies.<unk>
T-1350	change paco2 cerebral blood_flow perfusion carotid
H-1350	-0.3890853822231293	▁Paco 2 ▁cerebral _ ▁blood ▁flow ▁caro tid ▁bo dies
D-1350	-0.3890853822231293	Paco2 cerebral_ blood flow carotid bodies
P-1350	-0.7709 -0.1155 -0.1320 -0.6254 -1.1428 -0.5194 -0.4323 -0.0185 -0.6003 -0.2146 -0.0340 -0.0634
S-1388	Comparison of baseline characteristics, duration of mechanical cardiac support, and renal function was made between the three groups.<unk>
T-1388	baseline mechanical_cardiac_support renal_function
H-1388	-1.042661190032959	▁mechanic al _ ▁cardiac _ support ▁renal
D-1388	-1.042661190032959	mechanical_ cardiac_support renal
P-1388	-2.5857 -0.0187 -0.4936 -1.5635 -1.4806 -1.0140 -0.0130 -2.0900 -0.1249
S-1423	Human heart failure is accompanied by altered protein kinase A subunit expression and post-translational state.<unk>
T-1423	heart_failure protein_kinase_a expression
H-1423	-1.467980980873108	▁human _ heart ▁failure ▁protein ▁kina se
D-1423	-1.467980980873108	human_heart failure protein kinase
P-1423	-5.3093 -0.6632 -2.1329 -0.9665 -1.8294 -0.0493 -0.0424 -2.0505 -0.1681
S-1390	The patients in the ECMO group were significantly younger and smaller than the patients in the VAD and ECMO+VAD groups.<unk>
T-1390	patients ecmo patients vad ecmo vad
H-1390	-0.9020854234695435	▁EC mo _ groep ▁ VAD ▁ec mo + VAD
D-1390	-0.9020854234695435	ECmo_groep VAD ecmo+VAD
P-1390	-1.0928 -0.6186 -2.7587 -0.3236 -0.7090 -0.1054 -2.2066 -0.7892 -1.1933 -0.1641 -0.6245 -0.2392
S-1558	Using Cox regression, the hazards of cardiovascular events for psoriasis, as a time-dependent variable, were calculated.<unk>
T-1558	cox_regression cardiovascular_events psoriasis
H-1558	-0.3966600000858307	▁co x ▁re gression ▁cardiovascular _ ▁events ▁psoriasis
D-1558	-0.3966600000858307	cox regression cardiovascular_ events psoriasis
P-1558	-0.3819 -0.0099 -0.5573 -0.0197 -0.9686 -1.0288 -0.7296 -0.0402 -0.0978 -0.1328
S-1568	We investigated 120 consecutive patients with PAD, defined by an ankle-brachial index ≤ 0.9.<unk>
T-1568	patients pad ankle-brachial_index
H-1568	-0.24401745200157166	▁ PAD ▁an kle - bra chi al ▁index
D-1568	-0.24401745200157166	PAD ankle-brachial index
P-1568	-0.8061 -0.0648 -0.4328 -0.0587 -0.1944 -0.1641 -0.4161 -0.0967 -0.0688 -0.1856 -0.1960
S-160	Reductions were also observed in all-cause hospitalisations for TM interventions but not for STS interventions.<unk>
T-160	all-cause_hospitalisations sts
H-160	-1.320744514465332	
D-160	-1.320744514465332	
P-160	-2.5572 -0.0843
S-525	CONCLUSIONS: Isolated HR reduction by ivabradine improves TAC, thus reducing Ea.<unk>
T-525	hr_reduction ivabradine tac ea
H-525	-0.7444199323654175	▁i va bra dine ▁ TAC
D-525	-0.7444199323654175	ivabradine TAC
P-525	-1.4074 -1.8886 -0.0947 -0.0897 -1.6993 -0.0557 -0.5458 -0.1742
S-1845	We will include prospective studies evaluating implementation interventions aimed at improving uptake of class I CPG recommendations in HF.<unk>
T-1845	prospective_studies cpg hf
H-1845	-1.2050517797470093	▁c PG
D-1845	-1.2050517797470093	cPG
P-1845	-3.0191 -0.0558 -1.6463 -0.0990
S-1075	It has a higher mortality and morbidity than several cancers and consumes a significant portion of the health-care budget.<unk>
T-1075	mortality morbidity health-care budget
H-1075	-0.8907931447029114	▁mortal ity ▁morbi d ity ▁cancer s
D-1075	-0.8907931447029114	mortality morbidity cancers
P-1075	-2.7227 -0.7826 -0.4561 -0.0156 -0.8651 -0.9304 -0.2305 -1.7999 -0.2143
S-1513	We aimed to characterize and quantify the various forms of NT-proBNP in the circulation of HF patients.<unk>
T-1513	nt-probnp circulation hf patients
H-1513	-0.805229902267456	▁NT - pro b NP ▁ HF
D-1513	-0.805229902267456	NT-probNP HF
P-1513	-2.1158 -0.0543 -0.0108 -1.0740 -0.0643 -2.0790 -0.2800 -1.2288 -0.3399
S-1070	Data in patients with preserved systolic function are scarce, but interesting therapeutic concepts are evolving.<unk>
T-1070	patients systolic_function therapeutic
H-1070	-0.7761236429214478	▁patients ▁pres er ved ▁sy sto lic _ ▁function
D-1070	-0.7761236429214478	patients preserved systolic_ function
P-1070	-3.1793 -1.1939 -0.0511 -0.3085 -0.7596 -0.0340 -0.0423 -0.8987 -0.6986 -1.2754 -0.0961
S-259	A correlation between changes in HDL-induced NO production and flow-mediated dilatation improvement by ET was evident.<unk>
T-259	correlation flow-mediated_dilatation
H-259	-0.5087858438491821	▁HD L - indu ced _ no ▁production ▁flow - media ted _ di la tation ▁ET
D-259	-0.5087858438491821	HDL-induced_no production flow-mediated_dilatation ET
P-259	-2.6403 -1.0736 -0.0767 -0.0020 -0.0459 -0.3475 -1.7059 -0.5982 -0.1884 -0.0183 -0.0995 -0.3633 -0.1150 -1.0001 -0.0739 -0.0054 -1.1868 -0.0340 -0.0921
S-271	Furthermore, the optimal cutoff level of NT-proBNP used to predict 4-year survival had high sensitivity.<unk>
T-271	nt-probnp sensitivity
H-271	-0.4642041325569153	▁cut off ▁level ▁NT - pro b NP
D-271	-0.4642041325569153	cutoff level NT-probNP
P-271	-1.6785 -0.0330 -0.6422 -0.6633 -0.0199 -0.0160 -0.6744 -0.0364 -0.7059 -0.1723
S-58	However, patients with AHF are highly heterogeneous, and appropriate risk stratification is essential in conducting studies in this area.<unk>
T-58	patients ahf risk_stratification
H-58	-0.796593189239502	▁patients ▁a HF
D-58	-0.796593189239502	patients aHF
P-58	-1.4198 -1.3748 -0.0447 -1.0057 -0.1380
S-267	RESULTS: The mean age of the patients in this study was 71.1 ± 10.3 years; 50 of these patients were female.<unk>
T-267	patients patients
H-267	-0.6920657157897949	
D-267	-0.6920657157897949	
P-267	-1.3111 -0.0730
S-1002	Each method has strengths and limitations, but their utility has never been evaluated in the same community HF cohort.<unk>
T-1002	hf
H-1002	-0.6149235367774963	▁ HF ▁co hor t
D-1002	-0.6149235367774963	HF cohort
P-1002	-1.4899 -0.2870 -2.4172 -0.0062 -0.0240 -0.0386 -0.0415
S-65	RESULTS: Of 10,420 studies reviewed, 72 studies evaluating 63 predictors on 257,692 ICD patients proved eligible.<unk>
T-65	icd patients
H-65	-0.8586091995239258	▁i CD
D-65	-0.8586091995239258	iCD
P-65	-2.0305 -0.2803 -0.9611 -0.1625
S-144	CONCLUSIONS: Different approaches to computing readmissions can produce different hospital rankings and impact pay-for-performance.<unk>
T-144	readmissions hospital
H-144	-0.5774622559547424	▁computing _ ▁read missions ▁hospital ▁ranking s ▁pay - for - per form ance
D-144	-0.5774622559547424	computing_ readmissions hospital rankings pay-for-performance
P-144	-1.4525 -0.9332 -2.4411 -0.1427 -1.7383 -0.5769 -0.1794 -0.6159 -0.0277 -0.1808 -0.0646 -0.0597 -0.5291 -0.0758 -0.1027 -0.1190
S-1124	Reasons for nontreatment were identified from clinic notes and from interviews with 62 primary care clinicians caring for these patients.<unk>
T-1124	clinic clinicians patients
H-1124	-1.2175860404968262	
D-1124	-1.2175860404968262	
P-1124	-2.3523 -0.0829
S-700	Correlations and Cox models were used to assess the relationship among ST2, functional capacity, and long-term outcomes.<unk>
T-700	correlations cox_models st2 functional_capacity outcomes
H-700	-0.9511289596557617	▁co x ▁models
D-700	-0.9511289596557617	cox models
P-700	-0.4084 -0.0038 -2.1267 -2.1421 -0.0746
S-1272	Exercise intolerance in heart failure: update on exercise parameters for diagnosis, prognosis and therapeutic interventions.<unk>
T-1272	exercise_intolerance heart_failure exercise diagnosis prognosis therapeutic
H-1272	-0.7454789876937866	▁Exerci se ▁in tolerance _ in _ heart ▁failure
D-1272	-0.7454789876937866	Exercise intolerance_in_heart failure
P-1272	-2.6389 -0.0321 -0.1055 -0.0051 -1.7916 -0.5605 -0.8049 -0.7389 -0.3463 -1.0544 -0.1220
S-1560	Psoriasis patients were significantly younger, smoked more, and had higher diastolic blood pressure and body mass index levels.<unk>
T-1560	psoriasis patients diastolic_blood_pressure body_mass_index
H-1560	-0.5590126514434814	▁p sori asis ▁patients ▁dia sto lic _ ▁blood ▁pressure ▁body ▁mass ▁index
D-1560	-0.5590126514434814	psoriasis patients diastolic_ blood pressure body mass index
P-1560	-0.5576 -0.0144 -0.0469 -1.9615 -2.5493 -0.0245 -0.1030 -0.3111 -0.5386 -1.0669 -0.3309 -0.3655 -0.0164 -0.3627 -0.1359
S-1365	Both BNP and NT-proBNP have proven to be reliable diagnostic and prognostic biomarkers in patients with heart failure.<unk>
T-1365	bnp nt-probnp diagnostic prognostic biomarkers patients heart_failure
H-1365	-0.691665530204773	▁b NP ▁NT - pro b NP
D-1365	-0.691665530204773	bNP NT-probNP
P-1365	-1.3770 -0.1127 -1.7273 -0.0229 -0.0058 -0.4448 -0.0432 -2.3754 -0.1158
S-366	There have been reports demonstrating development of functional MS following ring annuloplasty for ischemic MR with LV dilatation.<unk>
T-366	functional_ms ring_annuloplasty ischemic_mr lv_dilatation
H-366	-0.28262048959732056	▁functional ▁MS ▁ring ▁ann ulo plast y ▁ ische mic ▁MR ▁LV ▁di la tation
D-366	-0.28262048959732056	functional MS ring annuloplasty ischemic MR LV dilatation
P-366	-0.1979 -0.5494 -0.0282 -0.6555 -0.0368 -0.0167 -0.1331 -0.5671 -0.0215 -0.0431 -1.5818 -0.0954 -0.6980 -0.0207 -0.0008 -0.1145 -0.0440
S-1194	Experience of a vasopressin receptor antagonist, tolvaptan, under the unique indication in Japanese heart failure patients.<unk>
T-1194	vasopressin_receptor_antagonist tolvaptan heart_failure patients
H-1194	-0.4221930205821991	▁vaso press in ▁receptor ▁anta gon ist ▁to lv ap tan ▁Japanese _ heart ▁failure
D-1194	-0.4221930205821991	vasopressin receptor antagonist tolvaptan Japanese_heart failure
P-1194	-0.0185 -0.0429 -0.3631 -0.3235 -0.5331 -0.0294 -0.3890 -0.0052 -0.0798 -0.1539 -0.0126 -1.7115 -0.6422 -1.3836 -0.5817 -0.8156 -0.0919
S-15	An inverse correlation was observed between pro-adrenomedullin (MR-proADM) and FFM.<unk>
T-15	inverse_correlation pro-adrenomedullin mr-proadm ffm
H-15	-0.25101399421691895	▁pro - ad re nom edu llin MR - pro AD m ▁f FM
D-15	-0.25101399421691895	pro-adrenomedullinMR-proADm fFM
P-15	-0.5254 -0.0120 -0.0040 -0.0816 -0.0680 -0.4685 -0.1113 -0.0870 -0.0079 -0.0110 -0.4927 -1.1118 -0.7344 -0.2172 -0.0341 -0.0494
S-398	Soluble concentrations of the interleukin receptor family member ST2 and beta-blocker therapy in chronic heart failure.<unk>
T-398	interleukin_receptor st2 beta-blocker therapy chronic_heart_failure
H-398	-0.8215734362602234	▁inter le u kin ▁receptor ▁family ▁member ▁ST 2 ▁beta - block er _ therapy ▁chronic _ heart ▁failure
D-398	-0.8215734362602234	interleukin receptor family member ST2 beta-blocker_therapy chronic_heart failure
P-398	-0.0071 -0.2471 -0.0468 -4.2320 -0.3250 -0.8889 -2.5292 -0.7664 -0.0586 -0.0581 -0.0207 -0.0235 -0.0352 -2.1852 -0.0406 -2.1342 -0.3798 -1.9707 -1.1414 -0.0866 -0.0761
S-2005	New York Heart Association classification, 6-min walk test, and quality-of-life scores showed progressive and sustained improvement.<unk>
T-2005	new_york_heart_association_classification 6-min_walk_test quality-of-life
H-2005	-1.6586905717849731	▁New _ York _ heart _ association
D-2005	-1.6586905717849731	New_York_heart_association
P-2005	-5.1230 -0.8565 -2.1464 -0.3179 -1.6849 -1.1413 -1.1298 -2.3910 -0.1375
S-1383	Comparative effects of ventricular assist device and extracorporeal membrane oxygenation on renal function in pediatric heart failure.<unk>
T-1383	ventricular_assist_device extracorporeal_membrane_oxygenation renal_function heart_failure
H-1383	-0.43614739179611206	▁vent ri cular _ assist ▁device ▁extra corp o real _ ▁membran e ▁oxygen ation ▁pediatr ic _ heart ▁failure
D-1383	-0.43614739179611206	ventricular_assist device extracorporeal_ membrane oxygenation pediatric_heart failure
P-1383	-0.0042 -0.3959 -0.1264 -0.6753 -0.2783 -1.0960 -0.0395 -0.0058 -0.1668 -0.0074 -0.1556 -0.2302 -0.0247 -0.9348 -0.0823 -0.5189 -0.1312 -0.4434 -2.7143 -1.3124 -0.1068 -0.1451
S-1765	Cardiorespiratory fitness, body mass index, and heart failure mortality in men: Cooper Center Longitudinal Study.<unk>
T-1765	cardiorespiratory_fitness body_mass_index heart_failure mortality cooper_center_longitudinal_study
H-1765	-0.6269493699073792	▁Card i ore spira tory _ ▁fitness ▁body ▁mass ▁index ▁heart ▁failure _ ▁mortal ity ▁Cooper ▁Center
D-1765	-0.6269493699073792	Cardiorespiratory_ fitness body mass index heart failure_ mortality Cooper Center
P-1765	-0.6298 -0.3058 -1.6790 -0.0201 -0.0903 -1.1327 -0.8155 -0.3453 -0.2375 -0.0150 -1.0814 -0.6951 -2.3012 -0.6805 -0.4255 -0.2303 -0.7199 -0.3633 -0.1436
S-806	CONCLUSIONS: The TUG test is reliable in patients with advanced COPD, CHF, or CRF after 2 trials.<unk>
T-806	tug_test patients copd chf crf
H-806	-1.6803460121154785	▁TU G ▁test
D-806	-1.6803460121154785	TUG test
P-806	-1.3878 -2.0100 -1.6338 -3.3226 -0.0476
S-1898	Regular physical activity controls acquired cardiovascular risk factors such as obesity, diabetes mellitus, hypertension and hyperlipidaemia.<unk>
T-1898	physical activity cardiovascular obesity diabetes_mellitus hypertension hyperlipidaemia
H-1898	-0.735738217830658	▁cardiovascular _ risk ▁factors ▁diabetes ▁mell itus ▁hyper tension ▁hyper li pida emia
D-1898	-0.735738217830658	cardiovascular_risk factors diabetes mellitus hypertension hyperlipidaemia
P-1898	-2.5033 -1.8612 -1.8494 -1.7408 -1.6798 -0.0046 -0.0707 -0.1155 -0.2976 -0.3983 -0.2501 -0.0690 -0.0132 -0.1187 -0.0638
S-419	Unlike isoproterenol, CXL-1020 was equally effective in myocytes from normal or failing hearts.<unk>
T-419	isoproterenol cxl-1020 myocytes hearts
H-419	-0.5954813957214355	▁iso prot eren ol ▁c XL -10 20
D-419	-0.5954813957214355	isoproterenol cXL-1020
P-419	-0.0384 -0.0724 -0.1475 -0.3904 -0.9338 -0.0728 -1.0451 -0.0397 -3.0464 -0.1683
S-1445	In conclusion, patients with HF and spontaneous VT have larger fluctuations in beat-to-beat QT intervals.<unk>
T-1445	patients hf spontaneous_vt qt_intervals
H-1445	-0.2971731424331665	▁ HF ▁spontane ous _ VT ▁beat - to - beat _ QT ▁interval s
D-1445	-0.2971731424331665	HF spontaneous_VT beat-to-beat_QT intervals
P-1445	-0.2922 -0.0291 -1.1410 -0.0456 -0.9660 -0.1301 -0.0732 -0.0403 -0.0279 -0.0496 -0.0882 -0.9855 -0.1661 -0.6595 -0.0595 -0.1345 -0.1636
S-725	RESULTS: The average age of patients with heart failure was 79.9 years in 2011, with 45.9% having systolic heart failure.<unk>
T-725	patients heart_failure systolic_heart_failure
H-725	-0.766379177570343	▁heart ▁failure ▁sy sto lic _ heart ▁failure
D-725	-0.766379177570343	heart failure systolic_heart failure
P-725	-5.2885 -0.3065 -0.0703 -0.0086 -0.0504 -0.2892 -1.3690 -0.1157 -0.0935 -0.0719
S-305	However biventricular dysfunction does not have a favorable outcome at 1 year when compared with patients requiring isolated HeartMate II.<unk>
T-305	biventricular_dysfunction outcome patients heartmate_ii
H-305	-0.7264153957366943	▁bi ven tri cular _ ▁dys function ▁isola ted _ ▁Heart Mate
D-305	-0.7264153957366943	biventricular_ dysfunction isolated_ HeartMate
P-305	-1.0125 -0.0779 -0.3034 -1.8579 -2.1445 -0.2993 -0.3156 -1.7259 -0.0623 -0.2971 -0.5941 -0.0343 -1.3001 -0.1451
S-356	His HF symptom as well as cardiac murmurs disappeared with a reduction in blood pressure to 140/80 mm Hg.<unk>
T-356	hf symptom cardiac_murmurs blood_pressure
H-356	-0.7842007875442505	▁ HF ▁cardiac _ ▁mur mur s ▁blood ▁pressure
D-356	-0.7842007875442505	HF cardiac_ murmurs blood pressure
P-356	-0.2707 -0.0202 -1.8610 -1.1379 -0.6715 -0.0076 -0.1798 -2.2845 -1.5203 -0.5430 -0.1297
S-376	Functional MS can potentially be reversed by medical treatment and thus requires careful evaluation of the surgical indications.<unk>
T-376	functional_ms medical_treatment surgical
H-376	-0.37904709577560425	▁Fun ction al ▁MS
D-376	-0.37904709577560425	Functional MS
P-376	-0.3011 -0.0014 -0.0051 -0.5730 -1.3316 -0.0621
S-203	This work does not include Recommendations for advanced management involving ventricular assist devices, or other device therapies.<unk>
T-203	ventricular_assist_devices therapies
H-203	-0.5114651918411255	▁vent ri cular _ assist ▁devices ▁device ▁ therapie s
D-203	-0.5114651918411255	ventricular_assist devices device therapies
P-203	-2.4886 -0.5485 -0.1527 -0.5282 -0.4320 -1.2682 -0.2890 -0.0750 -0.0352 -0.1255 -0.0949 -0.1000
S-1394	CONCLUSIONS: On the basis of these data, we demonstrate that renal dysfunction improves early after mechanical cardiac support.<unk>
T-1394	renal_dysfunction mechanical_cardiac_support
H-1394	-1.0699416399002075	▁renal ▁dys function ▁mechanic al _ ▁cardiac
D-1394	-1.0699416399002075	renal dysfunction mechanical_ cardiac
P-1394	-0.9285 -4.1538 -0.1874 -1.0026 -0.0380 -0.3625 -0.6353 -2.2707 -0.0506
S-1956	The device was successfully implanted in all patients; no device-related or procedural adverse events occurred during follow-up.<unk>
T-1956	implanted patients adverse_events follow-up
H-1956	-0.8166825771331787	▁device
D-1956	-0.8166825771331787	device
P-1956	-0.6300 -1.7231 -0.0969
S-1746	There was a trend toward enrollment of older patients with less severe left ventricular dilatation and dysfunction during the years.<unk>
T-1746	patients left_ventricular_dilatation dysfunction
H-1746	-1.0385680198669434	▁vent ri cular _ di la tation
D-1746	-1.0385680198669434	ventricular_dilatation
P-1746	-4.7911 -0.6850 -0.3014 -0.7832 -1.2242 -0.2346 -0.0176 -1.2479 -0.0621
S-1351	It is concluded that PB in patients with HF could be produced by primary oscillations originating from the central pattern generator.<unk>
T-1351	pb patients hf
H-1351	-1.0099557638168335	▁ PB ▁ PB ▁ HF
D-1351	-1.0099557638168335	PB PB HF
P-1351	-0.5366 -0.0177 -0.9344 -1.6345 -0.8924 -1.0928 -2.7493 -0.2219
S-38	(Grade: strong recommendation; moderate-quality evidence) Treatment of anemia in patients with heart disease: a systematic review.<unk>
T-38	grade evidence anemia patients heart_disease
H-38	-1.5472897291183472	▁an emia ▁patients ▁heart ▁disease
D-38	-1.5472897291183472	anemia patients heart disease
P-38	-4.1532 -0.0531 -2.7231 -3.0437 -0.5996 -0.1478 -0.1105
S-548	RESULTS: During follow-up, 6 CF LVAD patients developed new, severe AI that was accompanied by heart failure.<unk>
T-548	follow-up lvad patients heart_failure
H-548	-1.2951290607452393	▁CF ▁l VAD
D-548	-1.2951290607452393	CF lVAD
P-548	-0.0544 -2.3559 -0.0356 -3.9343 -0.0954
S-1396	Nursing has a social mandate to ensure effective practice within its domain and to be accountable for the outcomes of nursing care.<unk>
T-1396	nursing mandate accountable outcomes nursing
H-1396	-1.513512372970581	▁social _ ▁mandat e
D-1396	-1.513512372970581	social_ mandate
P-1396	-5.0500 -1.6662 -0.2106 -0.0300 -1.8670 -0.2574
S-1294	TREATMENT AND CLINICAL COURSE: The patient became again hemodynamically unstable and a CPR was required.<unk>
T-1294	clinical patient hemodynamically cpr
H-1294	-1.3551818132400513	▁hem o dynamic ally _ ▁uns table
D-1294	-1.3551818132400513	hemodynamically_ unstable
P-1294	-5.5727 -0.0975 -0.0007 -0.3079 -1.1177 -1.0657 -0.3670 -3.6311 -0.0364
S-1506	We then used exploratory factor analysis to determine the presence of separate scale dimensions, followed by CFA in a separate sub-sample.<unk>
T-1506	exploratory_factor_analysis cfa
H-1506	-1.069630742073059	▁c fa
D-1506	-1.069630742073059	cfa
P-1506	-3.3445 -0.6516 -0.1708 -0.1116
S-1237	Baseline characteristics were similar in rhythm-control (n = 149) and rate-control (n = 155) groups.<unk>
T-1237	baseline rhythm-control rate-control
H-1237	-0.3597392737865448	▁ rhythm - control ▁rate - control
D-1237	-0.3597392737865448	rhythm-control rate-control
P-1237	-0.3042 -0.3589 -0.1656 -0.0030 -1.3702 -0.1728 -0.0032 -0.6742 -0.1855
S-2019	Heart failure (HF) is a debilitating chronic disease and is expected to increase in upcoming years due to demographic changes.<unk>
T-2019	heart_failure hf chronic disease
H-2019	-0.8100118041038513	▁Heart ▁failure ▁ HF
D-2019	-0.8100118041038513	Heart failure HF
P-2019	-0.7135 -0.1592 -2.9263 -0.0257 -0.9182 -0.1172
S-555	OBJECTIVES: This study sought to determine the characteristics and outcomes of young adults with heart failure (HF).<unk>
T-555	outcomes heart_failure hf
H-555	-1.7208632230758667	
D-555	-1.7208632230758667	
P-555	-3.3757 -0.0660
S-43	Data Extraction: Data on study design, population characteristics, hemoglobin levels, and health outcomes were extracted.<unk>
T-43	hemoglobin health outcomes
H-43	-1.416635513305664	▁hem o glob in
D-43	-1.416635513305664	hemoglobin
P-43	-4.4003 -0.1769 -0.1012 -0.4835 -3.2521 -0.0858
S-1790	The HF epidemiology and the adequacy of relevant health service provision related to HF in LA are not well delineated.<unk>
T-1790	hf epidemiology health hf
H-1790	-1.0337961912155151	▁ HF ▁ HF
D-1790	-1.0337961912155151	HF HF
P-1790	-0.1216 -0.0418 -1.8754 -0.4517 -3.4089 -0.3033
S-1113	Second, we assessed whether that response correlates with levels of various serum factors that serve as markers for coagulability.<unk>
T-1113	correlates coagulability
H-1113	-1.2226998805999756	▁se rum ▁factors
D-1113	-1.2226998805999756	serum factors
P-1113	-3.0562 -0.0403 -0.6008 -2.2959 -0.1202
S-1719	CONCLUSION: A 1-day reduction in hospital length of stay was not consistently associated with a higher rate of rehospitalization.<unk>
T-1719	hospital rehospitalization
H-1719	-1.036598801612854	▁re hospital ization
D-1719	-1.036598801612854	rehospitalization
P-1719	-2.6051 -1.6651 -0.7257 -0.1061 -0.0811
S-1905	Sudden cardiac death in athletes under 35 is rare with.estimates ranging from 1 in 50,000 to 1 in 200,000.<unk>
T-1905	cardiac_death
H-1905	-1.152213215827942	▁cardiac _ ▁death
D-1905	-1.152213215827942	cardiac_ death
P-1905	-1.7090 -2.1578 -0.7799 -0.9849 -0.1295
S-1692	To assess how well the composite measure predicts future high and low performers, and explains variance in future hospital mortality.<unk>
T-1692	hospital mortality
H-1692	-1.3962329626083374	
D-1692	-1.3962329626083374	
P-1692	-2.7121 -0.0804
S-683	Further studies need to confirm the role that the frequency of administration plays in the development of trastuzumab-related CHF.<unk>
T-683	administration chf
H-683	-0.8930665254592896	▁tras tuz um ab - related ▁CHF
D-683	-0.8930665254592896	trastuzumab-related CHF
P-683	-6.1380 -0.1233 -0.0401 -0.3404 -0.4849 -0.3981 -0.2586 -0.1464 -0.1077
S-272	However, especially in the case of long-term survival, additional prospective, large, and multicenter studies are required to confirm our results.<unk>
T-272	prospective
H-272	-0.3862864375114441	▁long - term _ ▁survival
D-272	-0.3862864375114441	long-term_ survival
P-272	-1.0972 -0.0916 -0.0280 -0.6618 -0.4380 -0.3199 -0.0675
S-142	Between 47 and 75 percent of hospitals in an extreme decile according to one metric remained when using a different metric.<unk>
T-142	hospitals
H-142	-0.9891667366027832	▁ metric
D-142	-0.9891667366027832	metric
P-142	-3.3014 -0.2039 -0.2357 -0.2156
S-1476	This is partly a result of shortcomings in research studies and a dearth of biomarker-guided clinical trials.<unk>
T-1476	clinical
H-1476	-0.19457583129405975	▁bio mark er - guide d ▁clinic al ▁trial s
D-1476	-0.19457583129405975	biomarker-guided clinical trials
P-1476	-0.3414 -0.0298 -0.0502 -0.1269 -0.0015 -0.0661 -0.7704 -0.0555 -0.5980 -0.0786 -0.0847 -0.1318
S-1131	The structure of medical records should be improved to facilitate documentation of contextual reasons for not providing guideline-recommended care.<unk>
T-1131	medical
H-1131	-1.3851227760314941	▁medical ▁records
D-1131	-1.3851227760314941	medical records
P-1131	-3.3306 -1.2817 -0.8224 -0.1057
S-1979	INTERVENTIONS: Twenty weeks of diet, exercise, or both; attention control consisted of telephone calls every 2 weeks.<unk>
T-1979	exercise
H-1979	-1.4408022165298462	▁die t
D-1979	-1.4408022165298462	diet
P-1979	-2.8075 -0.0389 -2.8152 -0.1016
S-454	Moreover, B treatment was associated with increased cardiac angiogenesis and in vivo coronary perfusion and reduced cardiac fibrosis.<unk>
T-454	cardiac_angiogenesis in_vivo_coronary_perfusion cardiac_fibrosis
H-454	-0.4660659730434418	▁cardiac ▁ang io gene sis ▁in ▁vivo _ ▁corona ry _ per fusion ▁cardiac ▁fibro sis
D-454	-0.4660659730434418	cardiac angiogenesis in vivo_ coronary_perfusion cardiac fibrosis
P-454	-1.1213 -4.2289 -0.3853 -0.0281 -0.2181 -0.3191 -0.0012 -0.8170 -0.1255 -0.1253 -0.2019 -0.4793 -0.0034 -0.1231 -0.0315 -0.0599 -0.0841 -0.0361
S-1300	Half of patients with heart failure (HF) have a preserved left ventricular ejection fraction (HFpEF).<unk>
T-1300	patients heart_failure hf preserved_left_ventricular_ejection_fraction hfpef
H-1300	-0.9290521740913391	▁heart ▁failure ▁ HF ▁vent ri cular ▁e je ction ▁ fraction HF p EF
D-1300	-0.9290521740913391	heart failure HF ventricular ejection fractionHFpEF
P-1300	-2.5051 -0.2448 -3.8052 -0.0131 -4.3176 -0.4549 -0.5540 -2.6909 -0.1115 -0.0630 -0.5064 -0.0218 -0.2327 -0.0893 -0.0147 -0.1030 -0.0659
S-1510	Circulating fragments of N-terminal pro-B-type natriuretic peptides in plasma of heart failure patients.<unk>
T-1510	n-terminal_pro-b-type_natriuretic_peptides plasma heart_failure patients
H-1510	-0.9042693972587585	▁n - termin al _ pro - B - type ▁na tri ure tic _ pe pti des ▁plasma _ van _ heart ▁failure
D-1510	-0.9042693972587585	n-terminal_pro-B-type natriuretic_peptides plasma_van_heart failure
P-1510	-5.2583 -0.0231 -0.0331 -0.0176 -1.6115 -1.4577 -0.0210 -1.0614 -0.0602 -0.0093 -0.1477 -0.0114 -0.4863 -2.2512 -0.4554 -0.3433 -0.1205 -0.4101 -0.5588 -2.6291 -2.9233 -0.3863 -1.4894 -0.2078 -1.2921 -0.2451
S-1141	Pyridostigmine reduced the myocyte diameter and collagen density of the surviving left ventricle.<unk>
T-1141	pyridostigmine myocyte collagen left_ventricle
H-1141	-0.4561300277709961	▁Pyr ido stig mine ▁my o cy te ▁collage n ▁den s ity ▁left ▁vent ric le
D-1141	-0.4561300277709961	Pyridostigmine myocyte collagen density left ventricle
P-1141	-0.0137 -0.0034 -0.0001 -0.0113 -0.9443 -0.0369 -0.0111 -0.0191 -0.6788 -0.0321 -1.0590 -0.2702 -0.8450 -2.7345 -0.5837 -0.5574 -0.7024 -0.0840 -0.0795
S-506	Ejection fraction (EF), infarct size, collateral growth, and myocardial perfusion were assessed.<unk>
T-506	ejection_fraction ef infarct collateral_growth myocardial_perfusion
H-506	-0.3654366135597229	▁e je ction ▁ fraction EF ▁col lateral _ ▁growth ▁my o card ial _ per fusion
D-506	-0.3654366135597229	ejection fractionEF collateral_ growth myocardial_perfusion
P-506	-0.5840 -0.0134 -0.0032 -0.5110 -0.0027 -0.6690 -1.2516 -0.0005 -1.5941 -0.2813 -0.3200 -0.1113 -0.1471 -0.3307 -0.4134 -0.5549 -0.0127 -0.0631 -0.0792
S-1133	Heart failure (HF) is characterized by elevated sympathetic activity and reduced parasympathetic control of the heart.<unk>
T-1133	heart_failure hf elevated sympathetic_activity parasympathetic_control heart
H-1133	-1.1949818134307861	▁Heart ▁failure HF
D-1133	-1.1949818134307861	Heart failureHF
P-1133	-0.7178 -0.1981 -2.4397 -2.5289 -0.0905
S-1230	Atrial fibrillation and congestive heart failure: a cost analysis of rhythm-control vs. rate-control strategies.<unk>
T-1230	atrial_fibrillation congestive_heart_failure cost rhythm-control rate-control
H-1230	-0.47670355439186096	▁At rial ▁fi bril lation ▁con ges tive _ heart ▁failure ▁ rhythm - control ▁rate - control ▁strategie s
D-1230	-0.47670355439186096	Atrial fibrillation congestive_heart failure rhythm-control rate-control strategies
P-1230	-3.1257 -0.0057 -1.5536 -0.0149 -0.0170 -0.1570 -0.2224 -0.8004 -0.1254 -1.2621 -0.2212 -0.4294 -0.2496 -0.0496 -0.0026 -1.6322 -0.1483 -0.0012 -0.2248 -0.0408 -0.1419 -0.0617
S-1657	Patients with end-stage heart failure are increasingly being treated with implantation of a long-term ventricular assist device.<unk>
T-1657	patients end-stage_heart_failure implantation ventricular_assist_device
H-1657	-0.8387336730957031	▁end - s tage _ heart ▁failure ▁long - term _ ▁vent ri cular _ assist ▁device
D-1657	-0.8387336730957031	end-stage_heart failure long-term_ ventricular_assist device
P-1657	-3.9081 -0.0616 -0.5400 -0.0029 -0.2046 -1.1445 -0.6522 -4.6362 -0.0613 -0.0317 -0.2149 -1.5219 -0.6789 -0.1910 -0.3122 -0.2861 -1.1294 -0.1706 -0.1879
S-471	In the setting of increased ATP demand, XO-mediated ROS can decrease mitochondrial respiration and contractile function.<unk>
T-471	atp xo-mediated_ros mitochondrial_respiration contractile_function
H-471	-0.25164294242858887	▁ATP ▁demand ▁ XO - media ted ▁ ROS ▁mito cho ndri al _ ▁respira tion ▁contract ile
D-471	-0.25164294242858887	ATP demand XO-mediated ROS mitochondrial_ respiration contractile
P-471	-0.4740 -1.0066 -0.3613 -0.0045 -0.0075 -0.0665 -0.0158 -0.9359 -0.0138 -0.0438 -0.0285 -0.1449 -0.0255 -0.5802 -0.1410 -0.0565 -0.0020 -0.0099 -0.9755 -0.1391
S-1406	These 2 receptors have opposing actions on adenylyl cyclase because of differential G-protein coupling.<unk>
T-1406	receptors adenylyl_cyclase g-protein_coupling
H-1406	-0.34173691272735596	▁a den yl yl ▁cy cla se ▁g - prote in ▁coup ling
D-1406	-0.34173691272735596	adenylyl cyclase g-protein coupling
P-1406	-0.6504 -0.0184 -0.0207 -0.4441 -0.2356 -0.0022 -0.2157 -2.3394 -0.0900 -0.0645 -0.3143 -0.2517 -0.2093 -0.1452 -0.1245
S-59	Predictors of mortality in patients with an implantable cardiac defibrillator: a systematic review and meta-analysis.<unk>
T-59	mortality patients implantable_cardiac_defibrillator meta-analysis
H-59	-0.6056547164916992	▁implant able _ ▁cardiac ▁de fi br illa tor
D-59	-0.6056547164916992	implantable_ cardiac defibrillator
P-59	-4.5199 -0.0304 -0.2390 -0.0748 -1.0230 -0.0454 -0.0336 -0.0573 -0.0276 -0.5316 -0.0795
S-1975	Exercise intolerance is the primary symptom of chronic HFPEF and a major determinant of reduced quality of life (QOL).<unk>
T-1975	exercise_intolerance symptom chronic_hfpef quality_of_life qol
H-1975	-0.7628106474876404	▁Exerci se ▁in tolerance ▁chronic _ h FP EF
D-1975	-0.7628106474876404	Exercise intolerance chronic_hFPEF
P-1975	-3.2999 -0.0056 -0.2142 -0.0055 -0.6471 -1.2294 -0.4882 -0.3762 -0.2428 -1.7826 -0.0993
S-877	CONCLUSIONS: This study elucidates the signaling pathways significantly changed in pressure-overload-induced heart failure.<unk>
T-877	signaling_pathways pressure-overload-induced_heart_failure
H-877	-0.9247139096260071	▁pressure - over load - indu ced _ heart ▁failure
D-877	-0.9247139096260071	pressure-overload-induced_heart failure
P-877	-7.7564 -0.0922 -0.0018 -0.0944 -0.2333 -0.0595 -0.6010 -0.5559 -0.6765 -0.6922 -0.1351 -0.1982
S-1434	Autonomic modulation of repolarization instability in patients with heart failure prone to ventricular tachycardia.<unk>
T-1434	repolarization patients heart_failure ventricular_tachycardia
H-1434	-0.772807240486145	▁auto no mic _ modul ation ▁repo lar ization ▁in st ability ▁heart ▁failure ▁vent ri cular _ ta chy car dia
D-1434	-0.772807240486145	autonomic_modulation repolarization instability heart failure ventricular_tachycardia
P-1434	-4.3026 -0.0190 -0.7151 -2.0413 -0.2425 -0.0840 -1.3844 -0.4719 -0.2711 -0.7616 -0.1237 -0.2015 -1.9187 -0.1828 -0.6857 -1.0543 -0.4008 -1.3978 -1.9160 -0.1317 -0.0033 -0.0101 -0.1458 -0.0817
S-1184	Whether all patients with systolic HF of unclear etiology should undergo coronary angiography has been controversial.<unk>
T-1184	patients systolic_hf etiology coronary_angiography
H-1184	-0.5003081560134888	▁sy sto lic _ HF ▁un clear _ ▁et i ology ▁corona ry _ ang i ography
D-1184	-0.5003081560134888	systolic_HF unclear_ etiology coronary_angiography
P-1184	-0.0267 -0.0095 -0.0085 -0.6039 -0.0755 -2.8832 -0.0289 -0.6958 -0.1926 -0.0389 -0.1045 -0.0065 -0.3539 -0.4163 -2.3639 -1.1034 -0.0697 -0.4467 -0.0773
S-1509	This evidence provides a new understanding of the structure of the SCHFI v.6.2 and supports its use in clinical practice and research.<unk>
T-1509	evidence schfi_v.6.2 clinical
H-1509	-0.6691486835479736	▁ SCH FI
D-1509	-0.6691486835479736	SCHFI
P-1509	-0.7720 -0.3691 -1.3305 -0.8057 -0.0684
S-1781	The rates of energy substrate metabolism were assessed in isolated working hearts obtained 1, 2, and 3 weeks after AAC.<unk>
T-1781	energy_substrate_metabolism hearts aac
H-1781	-0.547016441822052	▁energie ▁substrat e ▁metabolism
D-1781	-0.547016441822052	energie substrate metabolism
P-1781	-1.3391 -0.0523 -0.0633 -0.5261 -1.2244 -0.0769
S-630	Results were comparable across age, sex, and race, and in sub-groups based on diabetes mellitus or cardiovascular disease at baseline.<unk>
T-630	diabetes_mellitus cardiovascular_disease baseline
H-630	-0.7044830322265625	▁diabetes ▁mell itus ▁cardiovascular ▁disease
D-630	-0.7044830322265625	diabetes mellitus cardiovascular disease
P-630	-3.0320 -0.0110 -0.0333 -0.0908 -1.6181 -0.0510 -0.0950
S-1134	Experimental evidence suggests that the increase in parasympathetic function can be a therapeutic alternative to slow HF evolution.<unk>
T-1134	evidence parasympathetic therapeutic hf
H-1134	-0.5908203721046448	▁para sy mpa the tic _ ▁function ▁slow _ HF
D-1134	-0.5908203721046448	parasympathetic_ function slow_HF
P-1134	-0.3397 -0.0273 -0.0694 -0.2462 -0.2306 -0.9069 -0.7633 -2.4769 -0.8918 -0.1831 -0.8737 -0.0809
S-237	An ability to identify patients with HFpEF who are at increased risk for adverse outcomes can facilitate their more careful management.<unk>
T-237	patients hfpef adverse_outcomes
H-237	-0.3464723825454712	▁ HF p EF
D-237	-0.3464723825454712	HFpEF
P-237	-0.4684 -0.0494 -0.0300 -0.0263 -1.3279 -0.1768
S-1603	Surgical revascularization is considered only if catheter-based revascularization is unsuitable or unsuccessful.<unk>
T-1603	surgical revascularization revascularization
H-1603	-1.0615448951721191	▁Sur g ical _ re vas cular ization
D-1603	-1.0615448951721191	Surgical_revascularization
P-1603	-1.8227 -0.7217 -2.0702 -1.3169 -1.1046 -0.4461 -0.2835 -0.5995 -2.1578 -0.0926
S-607	The HR for the TNF antagonists compared with nbDMARD was 0.85 (95% CI 0.63 to 1.14).<unk>
T-607	tnf_antagonists nbdmard
H-607	-0.593276858329773	▁HR ▁t NF ▁anta gon ists ▁n b DM ARD
D-607	-0.593276858329773	HR tNF antagonists nbDMARD
P-607	-0.0610 -2.4278 -0.1025 -3.5394 -0.0097 -0.4382 -0.0196 -0.0053 -0.0843 -0.0570 -0.2879 -0.0868
S-1563	The risk of incident CVD was not increased in psoriasis (adjusted hazard ratio 0.73, 95% confidence interval 0.50-1.06).<unk>
T-1563	cvd psoriasis hazard_ratio confidence_interval
H-1563	-1.1421146392822266	▁CV d ▁psoriasis
D-1563	-1.1421146392822266	CVd psoriasis
P-1563	-3.9620 -1.0981 -0.2508 -0.2615 -0.1381
S-1572	The prevalence of high BNP levels in patients with PAD suggests that routine BNP measurements might be useful to detect HF.<unk>
T-1572	prevalence bnp patients pad bnp hf
H-1572	-1.274731993675232	▁ PAD ▁ PAD ▁B NP
D-1572	-1.274731993675232	PAD PAD BNP
P-1572	-1.6827 -0.0468 -2.4627 -0.4449 -3.1871 -0.0057 -2.2953 -0.0727
S-96	Morpholino-based knockdown of nucleolin nearly abolished protein expression but surprisingly had little impact on gross morphological development.<unk>
T-96	morpholino-based nucleolin protein_expression
H-96	-0.9310674667358398	▁Mor pho lino - based _ ▁knock down ▁nucleo lin ▁protein ▁expression
D-96	-0.9310674667358398	Morpholino-based_ knockdown nucleolin protein expression
P-96	-1.0671 -0.0116 -0.0752 -0.2659 -0.1469 -1.9032 -2.5423 -0.2127 -1.3616 -2.5305 -1.8726 -0.2642 -0.6863 -0.0948
S-1185	We sought to derive and validate a clinical prediction rule to exclude CAD as a cause of systolic HF.<unk>
T-1185	clinical rule cad systolic_hf
H-1185	-0.4089629054069519	▁clinic al _ ▁predict ion ▁rule ▁sy sto lic _ HF
D-1185	-0.4089629054069519	clinical_ prediction rule systolic_HF
P-1185	-1.3136 -0.0087 -0.3195 -0.9220 -0.0362 -1.4013 -0.7431 -0.0546 -0.0072 -0.2423 -0.0799 -0.0829 -0.1050
S-1556	In this study, embedded within the population-based Rotterdam Study, we aimed to assess the association between psoriasis and cardiovascular outcomes.<unk>
T-1556	rotterdam_study psoriasis cardiovascular outcomes
H-1556	-1.1191188097000122	▁ europe se _ studie ▁psoriasis ▁cardiovascular
D-1556	-1.1191188097000122	europese_studie psoriasis cardiovascular
P-1556	-3.5368 -1.2206 -0.0318 -0.2507 -1.4775 -1.8394 -0.1720 -1.4808 -0.0624
S-207	Subsequently, the authors analyzed the association of cognitive impairment with 6-month mortality or readmission.<unk>
T-207	mortality readmission
H-207	-0.9011116623878479	▁cognitive ▁im pair ment
D-207	-0.9011116623878479	cognitive impairment
P-207	-0.3880 -2.3837 -0.1097 -0.2067 -2.2436 -0.0750
S-1631	We aimed to investigate the association between race and outcomes and to explore interactions with exercise training in patients with ambulatory HF.<unk>
T-1631	outcomes exercise training patients ambulatory hf
H-1631	-1.4715962409973145	▁race ▁ HF
D-1631	-1.4715962409973145	race HF
P-1631	-1.9043 -3.6970 -1.2857 -0.2748 -0.1962
S-841	Baseline Hgb did not moderate the beneficial effect of exercise training on KCCQ overall or subscales relative to usual care.<unk>
T-841	baseline hgb exercise training kccq
H-841	-0.9231263995170593	▁base line _ h gb ▁k cc q
D-841	-0.9231263995170593	baseline_hgb kccq
P-841	-3.3580 -0.0185 -0.6901 -0.3735 -0.0004 -3.5618 -0.1540 -0.6630 -0.2693 -0.1426
S-1359	This review provides an overview of the sonographic, histological, and functional abnormalities of different gastrointestinal regions.<unk>
T-1359	sonographic histological gastrointestinal
H-1359	-2.3142075538635254	▁sono graphic ▁his t ological
D-1359	-2.3142075538635254	sonographic histological
P-1359	-6.8358 -1.3292 -3.8543 -0.1307 -0.2252 -3.6472 -0.1771
S-1286	Complications occurred after five ACS procedures (31%) in two patients undergoing MT and three patients undergoing VAD.<unk>
T-1286	complications acs patients patients vad
H-1286	-0.8312422633171082	▁a CS ▁procedure s ▁MT
D-1286	-0.8312422633171082	aCS procedures MT
P-1286	-0.3978 -0.8170 -0.9957 -0.0657 -1.7150 -1.6995 -0.1279
S-1577	SETTING: General hospital and cardiac specialty hospital, both located in a community of 150,000 population in predominantly rural South Dakota.<unk>
T-1577	hospital cardiac hospital south_dakota
H-1577	-1.0983400344848633	▁hospital ▁cardiac _ special ty _ hospital
D-1577	-1.0983400344848633	hospital cardiac_specialty_hospital
P-1577	-4.9313 -1.0207 -1.5444 -0.4900 -0.0303 -0.8354 -0.0878 -0.8072 -0.1379
S-1277	Different mechanisms underlie these exercise variables with an important contribution of haemodynamic, pulmonary and peripheral abnormalities.<unk>
T-1277	exercise haemodynamic pulmonary
H-1277	-0.14417918026447296	▁ha emo dynamic ▁pulmonar y ▁per i pher al ▁ab normal ities
D-1277	-0.14417918026447296	haemodynamic pulmonary peripheral abnormalities
P-1277	-0.1707 -0.0375 -0.0005 -0.0260 -0.0216 -0.0823 -0.1800 -0.0040 -0.0697 -0.9403 -0.0128 -0.2451 -0.0963 -0.1316
S-1392	In the ECMO group, the improvement in eGFR continued until day 28 after which there was a steady decline in eGFR.<unk>
T-1392	ecmo egfr egfr
H-1392	-0.9636390805244446	▁ec mo ▁e G FR
D-1392	-0.9636390805244446	ecmo eGFR
P-1392	-1.2451 -0.6534 -2.2268 -1.4752 -0.1169 -0.8916 -0.1366
S-1159	BACKGROUND: Previous studies investigating HF-related cachexia have not examined the impact of RV function on body composition.<unk>
T-1159	cachexia rv_function
H-1159	-0.5649235248565674	▁ HF - related ▁cache xia ▁ RV
D-1159	-0.5649235248565674	HF-related cachexia RV
P-1159	-0.4900 -0.3068 -0.0509 -0.8718 -0.8808 -0.1146 -0.1635 -0.1258 -2.5560 -0.0890
S-1191	A prediction rule of having ≥1 independent predictor identified 97% of the patients with CAD and 100% of the patients with severe CAD.<unk>
T-1191	rule patients cad patients cad
H-1191	-1.5205992460250854	▁CAD
D-1191	-1.5205992460250854	CAD
P-1191	-3.8777 -0.5935 -0.0906
S-1188	The diagnostic performance of the defined prediction rule was prospectively validated in a separate cohort recruited from 2 institutions.<unk>
T-1188	diagnostic rule prospectively
H-1188	-1.5214663743972778	▁diagnostic _ ▁performance
D-1188	-1.5214663743972778	diagnostic_ performance
P-1188	-1.4279 -2.1658 -0.9779 -2.9084 -0.1273
S-1018	We describe lessons learned from recent trials in acute HF and outline strategies to improve the potential for success in future trials.<unk>
T-1018	acute_hf
H-1018	-0.4960332214832306	▁a cute _ HF
D-1018	-0.4960332214832306	acute_HF
P-1018	-2.1616 -0.0025 -0.1063 -0.1158 -0.5086 -0.0815
S-1487	Heart failure (HF) is a very common condition that, despite advances in treatment, carries significant morbidity and mortality.<unk>
T-1487	heart_failure hf condition morbidity mortality
H-1487	-0.8273699879646301	▁Heart ▁failure HF
D-1487	-0.8273699879646301	Heart failureHF
P-1487	-0.8291 -0.1481 -2.4305 -0.6518 -0.0773
S-775	We have developed a quick, safe pump-exchange technique that avoids a redo sternotomy and cardiopulmonary bypass.<unk>
T-775	redo_sternotomy cardiopulmonary_bypass
H-775	-1.008827805519104	▁pump - ex change ▁techniek ▁redo _ ster no to my ▁cardio pul mon ary
D-775	-1.008827805519104	pump-exchange techniek redo_sternotomy cardiopulmonary
P-775	-6.2119 -0.0607 -0.0408 -0.0275 -1.6355 -1.2292 -1.1959 -1.7100 -0.0420 -0.0703 -0.6518 -0.0287 -0.1254 -1.4401 -0.4305 -2.0519 -0.1979
S-371	After aggressive medical treatment for HF, the HF symptom disappeared and the MS was reversed to an MVA of 1.7 cm2.<unk>
T-371	medical_treatment hf hf symptom mva
H-371	-0.6839745044708252	▁ HF ▁ HF ▁MS ▁m VA
D-371	-0.6839745044708252	HF HF MS mVA
P-371	-1.5519 -0.1340 -1.9314 -0.1364 -1.0204 -1.0718 -0.0787 -0.1575 -0.0739
S-1868	BACKGROUND: Increased sympathetic and decreased parasympathetic activity contribute to HF symptoms and disease progression.<unk>
T-1868	sympathetic parasympathetic_activity hf symptoms disease
H-1868	-0.6509515643119812	▁sympa the tic ▁para sy mpa the tic ▁ HF
D-1868	-0.6509515643119812	sympathetic parasympathetic HF
P-1868	-1.2191 -0.1421 -0.2460 -0.4328 -0.0375 -0.0466 -0.4405 -0.2360 -3.4508 -0.0545 -1.4436 -0.0621
S-354	The possibility of MS to improve after medical treatment for HF was considered because functional MS is highly dynamic and can potentially respond to medical treatment.<unk>
T-354	medical_treatment hf functional_ms medical_treatment
H-354	-0.8465006351470947	▁MS ▁ HF
D-354	-0.8465006351470947	MS HF
P-354	-0.5815 -2.0308 -0.0783 -1.4769 -0.0650
S-283	This might be a novel and useful mouse HF model to study the transition from compensated LV hypertrophy to HF in HHD.<unk>
T-283	hf transition compensated_lv_hypertrophy hf hhd
H-283	-0.729847252368927	▁mouse ▁ HF _ model ▁compensa ted _ ▁LV ▁hyper trop hy ▁ HF ▁h HD
D-283	-0.729847252368927	mouse HF_model compensated_ LV hypertrophy HF hHD
P-283	-1.5903 -0.4309 -0.0291 -3.5968 -0.7466 -0.2366 -0.0839 -0.1494 -1.1509 -1.9545 -0.0051 -0.4749 -0.6490 -0.0056 -1.7655 -0.1010 -0.0715 -0.0958
S-503	A large animal model of chronic myocardial ischemia and heart failure is crucial for the development of novel therapeutic approaches.<unk>
T-503	chronic_myocardial_ischemia heart_failure therapeutic
H-503	-1.1150561571121216	▁chronic _ my o card ial _ ische mia ▁heart ▁failure
D-503	-1.1150561571121216	chronic_myocardial_ischemia heart failure
P-503	-6.1119 -0.2865 -5.0646 -0.1864 -0.2746 -0.1531 -0.2485 -0.1533 -0.4700 -0.5967 -0.3231 -0.5430 -0.0841
S-445	Spironolactone was independently associated with a 3.5-fold increased risk of hyperkalemia but not with acute kidney injury.<unk>
T-445	spironolactone hyperkalemia acute_kidney_injury
H-445	-0.252647340297699	▁Spir ono lac tone ▁hyper kal emia ▁a cute ▁ki dne y ▁injury
D-445	-0.252647340297699	Spironolactone hyperkalemia acute kidney injury
P-445	-0.1180 -0.0458 -0.0067 -0.0349 -1.0094 -0.3581 -0.0726 -0.2789 -0.0135 -1.1251 -0.3127 -0.0470 -0.1930 -0.0742 -0.0998
S-1529	Compared with CH, patients with EH had lower systolic blood pressure and less renal impairment despite similar rates of hypertension.<unk>
T-1529	patients systolic_blood_pressure renal_impairment hypertension
H-1529	-0.5163231492042542	▁EH ▁sy sto lic _ ▁blood ▁pressure ▁renal ▁im pair ment ▁hyper tension
D-1529	-0.5163231492042542	EH systolic_ blood pressure renal impairment hypertension
P-1529	-0.1930 -3.7418 -0.0138 -0.0608 -0.2166 -0.3703 -0.6560 -0.0083 -0.5730 -0.0013 -0.0783 -1.5587 -0.0830 -0.0639 -0.1260
S-1895	Estimating the jugular venous pressure and the presence of peripheral oedema allows assessment of the patient's volume status.<unk>
T-1895	jugular_venous_pressure peripheral_oedema patient
H-1895	-0.2460920810699463	▁jugu lar _ ve nous _ ▁pressure ▁per i pher al _ ▁oed ema ▁volume
D-1895	-0.2460920810699463	jugular_venous_ pressure peripheral_ oedema volume
P-1895	-0.0019 -0.0491 -0.7442 -0.6573 -0.0849 -0.5221 -0.1901 -0.0255 -0.0306 -0.0007 -0.0416 -0.3460 -0.7732 -0.0161 -0.1367 -0.4978 -0.0658
S-1023	Natriuretic peptide levels, like other biomarkers, can now be measured at the point of care (POC).<unk>
T-1023	natriuretic_peptide biomarkers point_of_care poc
H-1023	-0.6940620541572571	▁na tri ure _ pe pti de ▁bio mark ers
D-1023	-0.6940620541572571	natriure_peptide biomarkers
P-1023	-0.3275 -0.0019 -0.2262 -4.9516 -0.8474 -0.0355 -0.0697 -0.1211 -0.0108 -0.1365 -1.5553 -0.0452
S-1384	BACKGROUND: Effects of mechanical cardiac support on renal function in children with end-stage heart failure are unknown.<unk>
T-1384	mechanical_cardiac_support renal_function end-stage_heart_failure
H-1384	-0.9075065851211548	▁mechanic al _ ▁cardiac _ support ▁renal _ ▁function ▁end - s tage _ heart ▁failure
D-1384	-0.9075065851211548	mechanical_ cardiac_support renal_ function end-stage_heart failure
P-1384	-0.8819 -0.0197 -0.6010 -1.9613 -0.8240 -1.4414 -0.2653 -1.1971 -0.8849 -4.5850 -0.0914 -0.2739 -0.0017 -0.0997 -1.6325 -1.3415 -0.0782 -0.1545
S-1352	Do anticoagulants or antiplatelet drugs have a role in treating heart failure in the absence of atrial fibrillation?<unk>
T-1352	anticoagulants antiplatelet_drugs heart_failure atrial_fibrillation
H-1352	-0.5635607838630676	▁antico a gul ants ▁anti plate let ▁drugs ▁heart ▁failure ▁at rial ▁fi bril lation
D-1352	-0.5635607838630676	anticoagulants antiplatelet drugs heart failure atrial fibrillation
P-1352	-0.3122 -0.0722 -0.0912 -0.0159 -0.0175 -0.1121 -0.0579 -0.3891 -5.4163 -0.4099 -0.8812 -0.0219 -1.6225 -0.0034 -0.0253 -0.0711 -0.0608
S-333	It is reported that functional mitral stenosis frequently develops after ring annuloplasty for ischemic mitral regurgitation.<unk>
T-333	reported functional_mitral_stenosis ring_annuloplasty ischemic_mitral_regurgitation
H-333	-0.34300169348716736	▁functional ▁mit ral ▁sten osis ▁ring ▁ann ulo plast y ▁ ische mic _ met ral ▁re gur gi tation
D-333	-0.34300169348716736	functional mitral stenosis ring annuloplasty ischemic_metral regurgitation
P-333	-0.1387 -2.5608 -0.0193 -0.6094 -0.0023 -0.0119 -0.6051 -0.0271 -0.0418 -0.1055 -0.6663 -0.0155 -0.0504 -0.2424 -1.6480 -0.2295 -0.2379 -0.0143 -0.0463 -0.0141 -0.2048 -0.0546
S-434	During follow-up, there were 134 deaths, 18 heart transplantations/LV assist device implantations, and 93 heart failure admissions.<unk>
T-434	follow-up deaths heart_transplantations lv_assist_device_implantations heart_failure admissions
H-434	-0.956274151802063	▁heart ▁transplant ations LV _ assist _ ▁device ▁implant ations
D-434	-0.956274151802063	heart transplantationsLV_assist_ device implantations
P-434	-2.7473 -0.4895 -0.0160 -1.5423 -1.0785 -0.6259 -1.2365 -0.8143 -0.7407 -0.0074 -2.0627 -0.1142
S-21	Diagnosis of heart failure with preserved ejection fraction: role of clinical Doppler echocardiography.<unk>
T-21	diagnosis heart_failure_with_preserved_ejection_fraction clinical doppler_echocardiography
H-21	-0.5550960302352905	▁heart ▁failure ▁pres er ved _ e je ction _ fraction ▁clinic al _ do pp ler ▁e cho card i ography
D-21	-0.5550960302352905	heart failure preserved_ejection_fraction clinical_doppler echocardiography
P-21	-1.9365 -0.6760 -2.1559 -0.0448 -0.2272 -0.4423 -1.1822 -0.0691 -0.0222 -1.3665 -0.0023 -0.2314 -0.0255 -1.5219 -0.4752 -0.0031 -0.7479 -1.2406 -0.0419 -0.1082 -0.4252 -0.1672 -0.1118 -0.0972
S-7	This study suggests that national patient safety initiatives have led to real progress in some areas but have not created across-the-board improvements.<unk>
T-7	patient
H-7	-1.6656136512756348	▁national _ ▁patient _ ▁safety ▁initiative s
D-7	-1.6656136512756348	national_ patient_ safety initiatives
P-7	-4.2717 -0.3143 -3.9370 -1.2994 -2.3707 -2.3208 -0.0173 -0.3225 -0.1370
S-1473	As a result, the focus of research investigations and clinical care has shifted to measurement and modification of maladaptive molecular processes.<unk>
T-1473	clinical
H-1473	-0.9118347764015198	▁mal adapt ive ▁molecular _ process es
D-1473	-0.9118347764015198	maladaptive molecular_processes
P-1473	-3.1059 -0.0161 -0.0113 -3.7780 -1.1020 -0.0599 -0.0229 -0.0713 -0.0392
S-2009	Because projecting long-term costs and survival is challenging, a consistent and valid approach to extrapolating short-term outcomes would be valuable.<unk>
T-2009	costs outcomes
H-2009	-1.256747841835022	▁long - term _ kosten
D-2009	-1.256747841835022	long-term_kosten
P-2009	-4.3944 -0.0386 -0.0208 -0.9140 -1.4087 -1.9116 -0.1091
S-1104	Both early-onset (0-7 days after MI) and late-onset (8 days to 5 years after MI) HF were examined.<unk>
T-1104	mi mi hf
H-1104	-0.981593906879425	▁MI ▁ HF
D-1104	-0.981593906879425	MI HF
P-1104	-2.1629 -2.4241 -0.0831 -0.0837 -0.1542
S-1151	The goal of this study was to determine the individual and combined contributions of HF-induced remodeling aspects to EMD prolongation.<unk>
T-1151	remodeling emd
H-1151	-0.45794689655303955	▁ HF - indu ced _ ▁remodel ing ▁aspects ▁EM D ▁prolong ation
D-1151	-0.45794689655303955	HF-induced_ remodeling aspects EMD prolongation
P-1151	-0.4889 -0.2093 -0.0978 -0.0048 -0.1053 -0.4253 -0.2258 -0.0232 -4.0196 -0.1028 -0.6718 -0.2978 -0.0865 -0.0344 -0.0760
S-694	These data provide support for the concept that dietary recommendations developed for other cardiovascular conditions or general populations may also be appropriate in patients with HF.<unk>
T-694	cardiovascular conditions patients hf
H-694	-0.917181670665741	▁ HF
D-694	-0.917181670665741	HF
P-694	-2.4929 -0.6389 -0.4390 -0.0978
S-620	Secondary outcomes were met in relation to sustainability with commissioning of hospital- and community-based programmes on completion of the study.<unk>
T-620	secondary_outcomes
H-620	-0.9502429962158203	▁sustain ability
D-620	-0.9502429962158203	sustainability
P-620	-0.7332 -0.1410 -2.8191 -0.1076
S-85	Many multisite studies in practice settings focus on improving processes of care, adopting evidence-based practices, and improving patient outcomes.<unk>
T-85	evidence-based patient outcomes
H-85	-1.623335599899292	
D-85	-1.623335599899292	
P-85	-3.1672 -0.0795
S-303	However, 1-year survival was significantly greater in patients who required isolated HeartMate II LVAD (87% versus 77%; p = 0.03).<unk>
T-303	patients heartmate_ii lvad
H-303	-1.0290508270263672	▁isola ted _ ▁Heart Mate _ II _ L VAD
D-303	-1.0290508270263672	isolated_ HeartMate_II_LVAD
P-303	-3.6376 -0.0828 -0.8372 -1.3567 -0.0632 -0.4861 -1.6258 -0.3773 -3.6299 -0.0173 -0.1472 -0.0874
S-536	Furthermore, the impact of normalization of albumin levels during LVAD support on postoperative survival was analyzed in both groups.<unk>
T-536	albumin lvad postoperative
H-536	-1.1073977947235107	▁album in ▁levels ▁l VAD
D-536	-1.1073977947235107	albumin levels lVAD
P-536	-2.5272 -0.2319 -0.7659 -1.2673 -0.0295 -2.6797 -0.2503
S-994	A notable example is the Raf-MEK1/2-ERK1/2 signalling pathway that can control both adaptive and maladaptive remodelling.<unk>
T-994	signalling_pathway remodelling
H-994	-0.46228858828544617	▁Raf - MEK 1/2 - ER k 1/2 ▁signal ling _ path way
D-994	-0.46228858828544617	Raf-MEK1/2-ERk1/2 signalling_pathway
P-994	-0.0208 -0.0483 -0.0067 -0.2737 -0.0539 -0.3670 -0.2420 -0.2631 -0.9096 -0.0991 -1.4349 -0.9393 -0.4721 -1.6920 -0.1117
S-1906	Hereditary and congenital abnormalities of the heart are the most common cause of nontraumatic death during sport in young athletes.<unk>
T-1906	hereditary congenital heart death
H-1906	-0.8545377254486084	▁her edit ary ▁con geni tal _ ▁ab normal ities ▁heart
D-1906	-0.8545377254486084	hereditary congenital_ abnormalities heart
P-1906	-2.0888 -0.0505 -0.2634 -0.8858 -0.0262 -0.0158 -0.4273 -0.4231 -0.0738 -1.1051 -2.3866 -3.1101 -0.2525
S-1830	SETTING: 18 health insurance and health system data partners in the U.S. Food and Drug Administration's Mini-Sentinel program.<unk>
T-1830	health health u.s. drug administration
H-1830	-1.8183128833770752	▁health _ in _ health ▁system ▁data ▁partners ▁u . s . ▁Food _ and _ ▁Drug ▁Administration
D-1830	-1.8183128833770752	health_in_health system data partners u.s. Food_and_ Drug Administration
P-1830	-1.9046 -3.3372 -3.7344 -2.0367 -1.3517 -1.0275 -3.2343 -1.8696 -3.8349 -0.1331 -0.9297 -1.3617 -0.7313 -0.9038 -4.9870 -0.6922 -2.6934 -0.0259 -1.3337 -0.2437
S-1544	CONCLUSIONS: Bisphosphonate users were at increased risk of heart failure compared to age- and gender-matched control subjects.<unk>
T-1544	bisphosphonate heart_failure
H-1544	-1.648850917816162	▁bis phos phon ate
D-1544	-1.648850917816162	bisphosphonate
P-1544	-1.9673 -0.0124 -0.2218 -2.3949 -5.2399 -0.0568
S-808	Global left ventricular longitudinal systolic strain as a major predictor of cardiovascular events in patients with atrial fibrillation.<unk>
T-808	global_left_ventricular_longitudinal_systolic_strain cardiovascular_events patients atrial_fibrillation
H-808	-0.5961556434631348	▁left ▁vent ri cular ▁longitud in al _ ▁sy sto lic _ ▁strain ▁cardiovascular _ ▁events ▁at rial _ ▁fi bril lation
D-808	-0.5961556434631348	left ventricular longitudinal_ systolic_ strain cardiovascular_ events atrial_ fibrillation
P-808	-1.4334 -0.4317 -0.4741 -0.2845 -0.3955 -0.0712 -0.0900 -0.9332 -0.6554 -0.0211 -0.0135 -1.3175 -0.3262 -0.6656 -1.8615 -0.8975 -2.1699 -0.0354 -0.6825 -1.2288 -0.0093 -0.0635 -0.1106 -0.1360
S-469	Xanthine oxidase inhibition preserves left ventricular systolic but not diastolic function in cardiac volume overload.<unk>
T-469	xanthine_oxidase_inhibition left_ventricular systolic diastolic_function cardiac_volume_overload
H-469	-0.6677740812301636	▁Xan thi ne ▁oxid ase ▁inhibi tion ▁left ▁vent ri cular ▁sy sto lic ▁dia sto lic ▁cardiac ▁volume ▁over load
D-469	-0.6677740812301636	Xanthine oxidase inhibition left ventricular systolic diastolic cardiac volume overload
P-469	-0.0019 -0.1234 -0.4332 -0.4604 -2.8349 -1.2752 -0.2864 -3.6674 -0.2407 -1.6765 -0.8350 -1.4216 -0.0527 -0.0410 -0.6313 -0.0397 -0.0279 -0.4657 -0.1535 -0.0870 -0.0245 -0.4149 -0.1640
S-1521	Immunodetection of NT-proBNP was significantly improved with the use of antibodies that did not target these terminal regions.<unk>
T-1521	immunodetection nt-probnp antibodies terminal
H-1521	-0.36544162034988403	▁immun o det ection ▁NT - pro b NP ▁anti bo dies
D-1521	-0.36544162034988403	immunodetection NT-probNP antibodies
P-1521	-0.2845 -0.0266 -0.0356 -0.0486 -2.2289 -0.0403 -0.0105 -0.9904 -0.0366 -0.1309 -0.0203 -0.7122 -0.4607 -0.0900
S-895	We examined the impact of PD on clinical status hospitalizations, and complications of therapy in severe end-stage HF.<unk>
T-895	pd clinical hospitalizations complications therapy end-stage_hf
H-895	-0.9644412994384766	▁PD ▁clinic al ▁status ▁hospital ization s ▁complica tions ▁ therapy
D-895	-0.9644412994384766	PD clinical status hospitalizations complications therapy
P-895	-0.3297 -4.7979 -0.0082 -0.4983 -0.3302 -0.5258 -0.1960 -1.2094 -0.6330 -1.5397 -0.0351 -2.3583 -0.0762
S-439	We studied the effectiveness and safety of spironolactone in adults with newly diagnosed systolic heart failure in clinical practice.<unk>
T-439	spironolactone diagnosed systolic_heart_failure clinical
H-439	-0.5964984893798828	▁spi rono lac tone ▁sy sto lic _ heart
D-439	-0.5964984893798828	spironolactone systolic_heart
P-439	-0.2309 -0.0083 -0.0118 -0.0539 -0.2153 -0.0308 -0.0575 -0.1882 -1.1396 -4.5601 -0.0653
S-574	CONCLUSIONS: Nordic walking was superior to standard cardiac rehabilitation care in improving functional capacity and other important outcomes in patients with heart failure.<unk>
T-574	walking cardiac_rehabilitation functional_capacity outcomes patients heart_failure
H-574	-1.5511722564697266	▁Nordic _ walk ▁cardiac ▁rehabilita tion
D-574	-1.5511722564697266	Nordic_walk cardiac rehabilitation
P-574	-1.1006 -1.1916 -3.6039 -1.7306 -0.8751 -0.1390 -3.6793 -0.0893
S-544	In the present report, we have described 6 patients who underwent aortic valve surgery for new-onset post-LVAD AI.<unk>
T-544	report patients aortic_valve surgery post-lvad_ai
H-544	-0.5986290574073792	▁a or tic _ ▁val ve ▁surgery ▁post - L VAD
D-544	-0.5986290574073792	aortic_ valve surgery post-LVAD
P-544	-0.6271 -0.0173 -0.6374 -0.1535 -0.5134 -0.0129 -0.4236 -4.0519 -0.0128 -1.0020 -0.0084 -0.2581 -0.0637
S-658	Practice-level variation in use of recommended medications among outpatients with heart failure: Insights from the NCDR PINNACLE program.<unk>
T-658	medications outpatients heart_failure ncdr_pinnacle
H-658	-1.3393136262893677	▁ nc DR _ PIN NA CLE
D-658	-1.3393136262893677	ncDR_PINNACLE
P-658	-3.6858 -0.5076 -1.2611 -1.0773 -2.9145 -1.0025 -0.5060 -0.9401 -0.1589
S-980	Heart failure is an enormous clinical burden in adult medicine, largely because of the prevalence of atheromatous coronary disease.<unk>
T-980	heart_failure clinical medicine prevalence coronary_disease
H-980	-0.6686267256736755	▁Heart ▁failure ▁a ther omat ous _ ▁corona ry ▁disease
D-980	-0.6686267256736755	Heart failure atheromatous_ coronary disease
P-980	-1.2472 -0.9046 -2.1901 -0.0310 -0.0557 -1.5720 -0.2461 -0.2247 -0.6040 -0.7476 -0.1102 -0.0905
S-1891	Clinical symptoms and signs in HFpEF are often nonspecific although the primary symptoms are breathlessness, fatigue and fluid retention.<unk>
T-1891	clinical symptoms hfpef symptoms breathlessness fluid_retention
H-1891	-0.462490051984787	▁ HF p EF
D-1891	-0.462490051984787	HFpEF
P-1891	-0.4343 -0.2476 -0.1051 -0.2054 -1.6911 -0.0913
S-1892	There is still no single diagnostic test for HFpEF and the cornerstone in the assessment remains a thorough medical history and physical examination.<unk>
T-1892	diagnostic hfpef medical_history physical_examination
H-1892	-0.3712807893753052	▁ HF p EF
D-1892	-0.3712807893753052	HFpEF
P-1892	-0.6828 -0.1400 -0.0585 -0.0753 -1.1713 -0.0999
S-527	Therefore, unloading of the heart may contribute to the beneficial effect of isolated HR reduction in patients with systolic heart failure.<unk>
T-527	heart hr_reduction patients systolic_heart_failure
H-527	-0.6437684893608093	▁un load ing _ de _ heart ▁isola ted _ HR ▁re duction ▁sy sto lic _ heart ▁failure
D-527	-0.6437684893608093	unloading_de_heart isolated_HR reduction systolic_heart failure
P-527	-1.0242 -0.0096 -0.0095 -2.0716 -3.0813 -0.3787 -0.5500 -1.0229 -0.0099 -0.1578 -0.7565 -2.2791 -0.0263 -0.0542 -0.0144 -0.0967 -0.2196 -1.3592 -0.1999 -0.0686 -0.1291
S-1612	The overlapping part of the network was selected out using Cytoscape, for which functional enrichment analysis was applied with DAVID tools.<unk>
T-1612	cytoscape functional_enrichment_analysis david
H-1612	-0.7135521769523621	▁Cy to scape ▁functional ▁en rich ment analyse ▁DA VID
D-1612	-0.7135521769523621	Cytoscape functional enrichmentanalyse DAVID
P-1612	-2.2078 -0.0178 -0.0244 -1.0941 -1.1861 -0.0170 -0.1098 -3.2568 -0.3502 -0.0011 -0.2199 -0.0775
S-928	Resistin is a circulating mediator of insulin resistance mainly expressed in human monocytes and responsive to inflammatory stimuli.<unk>
T-928	resistin insulin_resistance monocytes inflammatory
H-928	-0.29266804456710815	▁circula ting ▁media tor ▁insulin ▁resist ance ▁mono cy tes ▁infla mma tory ▁stimul i
D-928	-0.29266804456710815	circulating mediator insulin resistance monocytes inflammatory stimuli
P-928	-0.8658 -0.3169 -1.0528 -0.0530 -0.6500 -0.1129 -0.0792 -0.0684 -0.0059 -0.0055 -0.3981 -0.1249 -0.0825 -0.6525 -0.1797 -0.1818 -0.1453
S-1635	Blacks were younger with significantly more hypertension and diabetes, less ischemic etiology, and lower socioeconomic status versus whites.<unk>
T-1635	hypertension diabetes ischemic etiology
H-1635	-0.41664692759513855	▁black s ▁hyper tension ▁diabetes ▁ ische mic _ ▁et i ology ▁socio economic
D-1635	-0.41664692759513855	blacks hypertension diabetes ischemic_ etiology socioeconomic
P-1635	-0.5440 -0.2021 -0.2175 -0.0592 -0.2710 -0.0891 -0.0149 -0.0379 -0.8853 -0.4034 -0.0923 -0.2479 -1.3118 -0.0052 -2.1873 -0.0974
S-262	Determination of a predictive cutoff value of NT-proBNP testing for long-term survival in ED patients with acute heart failure.<unk>
T-262	nt-probnp patients acute_heart_failure
H-262	-0.86222243309021	▁NT - pro b NP
D-262	-0.86222243309021	NT-probNP
P-262	-1.8199 -0.0240 -0.0078 -0.6500 -0.0530 -3.3765 -0.1044
S-281	Oxidative stress was enhanced and small GTPase Rac1 activity was upregulated in the hearts of ANS mice.<unk>
T-281	oxidative_stress gtpase rac1 activity hearts
H-281	-0.6718049049377441	▁o xi da tive _ stress ▁small ▁GT Pas e ▁Rac 1
D-281	-0.6718049049377441	oxidative_stress small GTPase Rac1
P-281	-0.9069 -0.0181 -0.0093 -0.1106 -1.0875 -0.7543 -2.2350 -0.4546 -0.0630 -0.0334 -0.5753 -0.3890 -2.6092 -0.1589
S-1789	Heart failure (HF) data in Latin America (LA) were reviewed to guide health service planning in the prevention and treatment of HF.<unk>
T-1789	heart_failure hf latin_america health hf
H-1789	-1.479078769683838	▁Heart ▁failure _ HF ▁la
D-1789	-1.479078769683838	Heart failure_HF la
P-1789	-2.3086 -0.3740 -2.0502 -0.3386 -2.7628 -2.4190 -0.1004
S-1459	We first propose fundamental definitions of the distinctive components of the right heart circulation and provide consensus on a universal definition of right heart failure.<unk>
T-1459	right_heart_circulation right_heart_failure
H-1459	-2.024238348007202	▁right _ heart _ ▁circulation
D-1459	-2.024238348007202	right_heart_ circulation
P-1459	-6.4414 -0.6072 -3.7339 -1.1201 -0.3916 -1.7614 -0.1141
S-1494	We sought to investigate whether adults with the Fontan circulation exhibit reduced skeletal muscle mass and/or metabolic abnormalities.<unk>
T-1494	fontan_circulation skeletal_muscle metabolic
H-1494	-0.8185071349143982	▁Font an _ ▁circulation
D-1494	-0.8185071349143982	Fontan_ circulation
P-1494	-0.6479 -0.1537 -0.4926 -0.2161 -3.2737 -0.1271
S-1709	These hypothesis-generating findings suggest that safety and efficacy of mineralocorticoid receptor antagonists may differ by race.<unk>
T-1709	mineralocorticoid_receptor_antagonists
H-1709	-0.7494035363197327	▁mineral o cor tico id ▁receptor ▁anta gon ists ▁race
D-1709	-0.7494035363197327	mineralocorticoid receptor antagonists race
P-1709	-4.6647 -0.1131 -0.2249 -0.5525 -0.1667 -1.2625 -0.3684 -0.0243 -0.5098 -0.9293 -0.0586 -0.1181
S-232	In conclusion, adult patients with failing Fontan circulation had a lower SVR index and similar cardiac index compared with the pediatric cohort.<unk>
T-232	patients fontan_circulation svr cardiac_index
H-232	-0.7710793018341064	▁fail ing _ ▁Font an _ ▁circulation ▁s VR ▁index ▁cardiac _ ▁index ▁pediatr ic _ ▁co hor t
D-232	-0.7710793018341064	failing_ Fontan_ circulation sVR index cardiac_ index pediatric_ cohort
P-232	-4.1394 -0.1227 -0.6217 -2.3681 -0.2378 -0.2438 -0.1420 -1.2633 -0.0193 -1.1850 -0.0538 -1.9169 -1.1199 -0.2713 -0.0421 -1.5306 -0.7640 -0.0017 -0.0143 -0.0917 -0.0434
S-755	The time to death or first HF hospitalization was significantly prolonged with CRT (hazard ratio, 0.26; P=0.012).<unk>
T-755	death hf hospitalization crt hazard_ratio
H-755	-0.9440661668777466	▁ HF ▁c RT haz ard ▁ratio
D-755	-0.9440661668777466	HF cRThazard ratio
P-755	-0.9836 -0.1635 -4.0908 -0.8299 -0.6008 -0.0044 -1.4455 -0.2968 -0.0812
S-1820	In addition to palliative care of patients in the terminal phase, accurate recognition of advanced disease is vital in the determination of therapeutic options.<unk>
T-1820	palliative_care patients terminal disease therapeutic
H-1820	-1.1127166748046875	▁palli ative _ care
D-1820	-1.1127166748046875	palliative_care
P-1820	-0.0495 -0.0151 -1.1702 -1.4378 -3.9318 -0.0719
S-1710	Does reducing length of stay increase rehospitalization of medicare fee-for-service beneficiaries discharged to skilled nursing facilities?<unk>
T-1710	rehospitalization medicare discharged nursing
H-1710	-0.8116996884346008	▁re hospital ization ▁medica re ▁fee - for - service
D-1710	-0.8116996884346008	rehospitalization medicare fee-for-service
P-1710	-5.6408 -0.0262 -0.1739 -0.0332 -0.0039 -0.1900 -0.0397 -0.0454 -0.0343 -0.0340 -3.3621 -0.1569
S-297	The purpose of this study was to determine the 1-year survival in patients requiring isolated LVAD and patients requiring biventricular support.<unk>
T-297	patients lvad patients biventricular_support
H-297	-1.1569395065307617	▁l VAD
D-297	-1.1569395065307617	lVAD
P-297	-2.6652 -0.0647 -1.7827 -0.1151
S-158	Exclusion of one trial that provided better-than-usual support to the control group rendered each of the above comparisons statistically significant.<unk>
T-158	
H-158	-0.7585786581039429	
D-158	-0.7585786581039429	
P-158	-1.4381 -0.0791
S-86	While specific research questions may be the focus, it is the implementation issues and strategies that reveal how individuals and organizations are profoundly transformed.<unk>
T-86	
H-86	-0.7987487316131592	
D-86	-0.7987487316131592	
P-86	-1.5336 -0.0639
S-1757	Primary study end point was a composite of cardiovascular death and urgent cardiac transplant, and secondary end point was all-cause death.<unk>
T-1757	end_point cardiovascular_death cardiac_transplant secondary_end_point death
H-1757	-0.7291368842124939	▁cardiovascular _ ▁death ▁urgent _ ▁cardiac ▁transplant
D-1757	-0.7291368842124939	cardiovascular_ death urgent_ cardiac transplant
P-1757	-1.7678 -1.6073 -1.2432 -0.1492 -0.8247 -0.0356 -0.5240 -0.2957 -0.1147
S-26	Hence, the diagnosis of clinical (prognostic) diastolic dysfunction leading to HFPEF is of critical importance.<unk>
T-26	diagnosis clinical prognostic diastolic_dysfunction leading hfpef
H-26	-0.37803342938423157	▁clinic al _ prog nosti c ▁dia sto lic _ ▁dys function ▁H FP EF
D-26	-0.37803342938423157	clinical_prognostic diastolic_ dysfunction HFPEF
P-26	-2.4439 -0.0142 -0.6203 -0.0215 -0.0655 -0.0066 -1.4174 -0.0531 -0.0852 -0.6935 -0.2157 -0.0282 -0.5744 -0.0228 -0.0329 -0.0542 -0.0774
S-1076	HF with preserved ejection fraction (HFpEF) is commoner among women who may have underlying hypertension.<unk>
T-1076	hf_with_preserved_ejection_fraction hfpef hypertension
H-1076	-0.5460389256477356	▁ HF ▁pres er ved _ e je ction _ fraction HF p EF ▁hyper tension
D-1076	-0.5460389256477356	HF preserved_ejection_fractionHFpEF hypertension
P-1076	-1.3348 -0.0053 -4.1871 -0.0407 -0.4526 -0.0983 -0.8059 -0.1142 -0.0405 -1.0244 -0.0352 -0.3573 -0.0669 -0.0281 -1.0306 -0.0595 -0.0546 -0.0925
S-101	Risk factors and outcomes associated with the development of myocardial ischemic events in patients who receive cardiac resynchronization therapy.<unk>
T-101	outcomes myocardial_ischemic_events patients cardiac_resynchronization_therapy
H-101	-0.6681873798370361	▁my o card ial _ ische mic _ ▁events ▁cardiac ▁re syn chron ization ▁ therapy
D-101	-0.6681873798370361	myocardial_ischemic_ events cardiac resynchronization therapy
P-101	-3.5224 -0.2506 -0.0867 -0.2681 -1.1481 -0.0768 -0.2140 -1.6160 -1.7446 -0.0537 -0.6009 -0.0023 -0.0038 -0.6938 -1.5398 -0.0076 -0.0689 -0.1291
S-1132	Increase in parasympathetic tone by pyridostigmine prevents ventricular dysfunction during the onset of heart failure.<unk>
T-1132	parasympathetic_tone pyridostigmine ventricular_dysfunction heart_failure
H-1132	-0.4132469594478607	▁para sy mpa the tic _ ▁tone ▁py rido stig mine ▁vent ri cular ▁dys function ▁heart ▁failure
D-1132	-0.4132469594478607	parasympathetic_ tone pyridostigmine ventricular dysfunction heart failure
P-1132	-0.0480 -0.1745 -0.0373 -0.9026 -0.2672 -0.7762 -0.1323 -0.0572 -0.0080 -0.0008 -0.0713 -0.0096 -0.9365 -0.6612 -1.1125 -0.0529 -2.0932 -0.7703 -0.0732 -0.0802
S-1515	NT-proBNP was enriched from HF patient plasma by use of immunoprecipitation followed by mass spectrometric analysis.<unk>
T-1515	nt-probnp hf patient plasma immunoprecipitation mass_spectrometric_analysis
H-1515	-0.508795976638794	▁NT - pro b NP ▁ HF ▁patient ▁plasma ▁immun o preci pit ation ▁mass ▁spec tro metric
D-1515	-0.508795976638794	NT-probNP HF patient plasma immunoprecipitation mass spectrometric
P-1515	-0.6002 -0.0443 -0.0128 -0.7730 -0.0497 -1.2161 -0.1296 -3.2087 -0.6468 -0.0123 -0.1922 -0.1949 -0.0063 -0.1433 -0.0661 -0.6526 -0.0210 -0.1290 -1.9146 -0.1624
S-459	CONCLUSIONS: β-Blockade promotes cardiac angiogenesis in heart failure via activation of VEGF signaling pathway.<unk>
T-459	β-blockade cardiac_angiogenesis heart_failure vegf_signaling_pathway
H-459	-0.6303346157073975	▁β - Block ade ▁cardiac _ ▁ang io gene sis ▁heart ▁failure ▁VE GF ▁signal ing ▁path way
D-459	-0.6303346157073975	β-Blockade cardiac_ angiogenesis heart failure VEGF signaling pathway
P-459	-1.2836 -0.0779 -0.2350 -0.3599 -0.4579 -2.5291 -2.2543 -1.3755 -0.1498 -0.7369 -0.3978 -0.3823 -0.3310 -0.0046 -0.9879 -0.1838 -0.3343 -0.0991 -0.2701 -0.1561
S-1873	The primary efficacy end points were changes in NYHA functional class, quality-of-life score, and 6-minute hall walk distance.<unk>
T-1873	end_points nyha_functional_class quality-of-life 6-minute_hall_walk
H-1873	-0.574524998664856	▁NY HA ▁functional _ class ▁quality - of - life ▁score
D-1873	-0.574524998664856	NYHA functional_class quality-of-life score
P-1873	-2.1217 -0.2400 -1.1169 -1.0691 -0.7409 -0.2735 -0.0259 -0.0018 -0.0528 -0.1426 -0.8345 -0.6059 -0.2430
S-90	Chromatin-associated proteins alter chromatin structure by changing their association with DNA, thereby altering the gene expression profile.<unk>
T-90	chromatin-associated_proteins chromatin_structure changing dna gene_expression_profile
H-90	-0.5238142609596252	▁Chro mat in - as soci ated _ ▁protein s ▁chr omat in ▁structure ▁DNA
D-90	-0.5238142609596252	Chromatin-associated_ proteins chromatin structure DNA
P-90	-1.1088 -0.0092 -1.1238 -0.1659 -0.0129 -0.0004 -0.3169 -0.9163 -1.4526 -0.0434 -0.1234 -0.0460 -1.1477 -0.8584 -0.6049 -0.8639 -0.1104
S-238	We studied the patients having heart failure (HF) using data from the Heart Failure Adherence and Retention Trial (HART).<unk>
T-238	patients heart_failure hf heart_failure_adherence_and_retention_trial hart
H-238	-0.9022883176803589	▁patients ▁heart ▁failure _ HF ▁Heart ▁Fail ure _ ad her ence _ re tention ▁tri al HAR T
D-238	-0.9022883176803589	patients heart failure_HF Heart Failure_adherence_retention trialHART
P-238	-2.0232 -0.8802 -0.1313 -3.3314 -0.2964 -1.1336 -0.8130 -1.1834 -0.9886 -0.2440 -0.1149 -0.2664 -1.3551 -3.0831 -0.2056 -1.9420 -0.0605 -0.0263 -0.7588 -0.0530 -0.0570
S-1110	Differential effects of nonselective versus selective beta-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure.<unk>
T-1110	selective_beta-blockers cardiac_sympathetic_activity hemostasis patients heart_failure
H-1110	-0.9318992495536804	▁non sel ective ▁beta - block ers ▁cardiac _ ▁sympa the tic _ activ iteit ▁hemos tas is ▁heart ▁failure
D-1110	-0.9318992495536804	nonselective beta-blockers cardiac_ sympathetic_activiteit hemostasis heart failure
P-1110	-2.2809 -0.0061 -0.0077 -6.4678 -0.0733 -0.0953 -0.1781 -0.1127 -1.6048 -0.9539 -0.2658 -1.4774 -1.6530 -0.4383 -1.4183 -0.2504 -0.0344 -0.9725 -1.7620 -0.2799 -0.0990 -0.0702
S-578	Major right ventricle overload leads to decreased stroke volume, which shortens left ventricular ejection time (LVET).<unk>
T-578	right_ventricle leads stroke_volume shortens left_ventricular_ejection_time lvet
H-578	-0.737784206867218	▁vent ric le ▁over load ▁stroke ▁volume ▁left ▁vent ri cular ▁e je ction ▁time ▁l VET
D-578	-0.737784206867218	ventricle overload stroke volume left ventricular ejection time lVET
P-578	-0.7248 -1.5882 -0.4519 -0.1363 -0.0074 -1.0617 -0.2442 -1.6219 -1.0989 -0.8146 -0.2422 -0.8810 -0.2624 -0.0334 -2.9747 -1.6386 -0.0095 -0.1353 -0.0909
S-1338	METHODS AND RESULTS: Myocardial infarction was created by left anterior descending coronary artery occlusion.<unk>
T-1338	myocardial_infarction left_anterior_descending_coronary_artery_occlusion
H-1338	-0.6462429165840149	▁My o card ial ▁in far ction ▁left _ ▁anterior _ ▁descend ing _ ▁corona ry ▁arter y ▁oc clusi on
D-1338	-0.6462429165840149	Myocardial infarction left_ anterior_ descending_ coronary artery occlusion
P-1338	-1.8943 -0.2099 -0.1820 -0.2062 -1.3371 -0.1782 -0.0406 -2.7569 -1.0606 -3.6622 -0.2936 -0.0611 -0.0181 -1.1648 -0.2236 -0.1765 -0.1594 -0.6840 -0.0026 -0.0011 -0.2937 -0.1450 -0.1119
S-1424	β-Adrenergic receptor blockade reduces total mortality and all-cause hospitalizations in patients with heart failure (HF).<unk>
T-1424	β-adrenergic_receptor_blockade mortality all-cause_hospitalizations patients heart_failure hf
H-1424	-0.7887109518051147	▁β - Ad r energi c _ ▁receptor ▁block ade
D-1424	-0.7887109518051147	β-Adrenergic_ receptor blockade
P-1424	-1.0334 -0.0391 -0.8366 -0.2220 -0.8719 -0.0279 -0.9154 -0.0955 -1.3001 -0.0729 -3.8890 -0.1606
S-609	But, it was elevated prior to 2002 (HR 2.17, 95% CI 0.45 to 10.50, test for interaction p=0.036).<unk>
T-609	elevated
H-609	-0.9837571978569031	
D-609	-0.9837571978569031	
P-609	-1.8987 -0.0688
S-1581	RESULTS: A statistically significant 42 percent relative reduction in 30-day readmission rate was documented for those patients participating in the pilot program.<unk>
T-1581	readmission patients
H-1581	-1.1515918970108032	
D-1581	-1.1515918970108032	
P-1581	-2.1422 -0.1610
S-1559	A total of 262 psoriasis (24% systemic/UV treatment) and 8,009 reference subjects were followed up for a mean of 11 years.<unk>
T-1559	psoriasis systemic followed_up
H-1559	-0.6864672303199768	▁psoriasis ▁system ic _ UV
D-1559	-0.6864672303199768	psoriasis systemic_UV
P-1559	-0.2729 -0.9120 -0.0401 -0.5330 -0.9550 -1.9933 -0.0990
S-991	While certain stimuli mediate a beneficial adaptation to stress conditions, others result in maladaptive remodelling, ultimately leading to heart failure.<unk>
T-991	conditions remodelling leading heart_failure
H-991	-0.8704351186752319	▁stress ▁conditions ▁mal adapt ive ▁remodel ling ▁heart ▁failure
D-991	-0.8704351186752319	stress conditions maladaptive remodelling heart failure
P-991	-4.6321 -1.7086 -0.2402 -0.0086 -0.0134 -1.6716 -0.0486 -0.8316 -0.3048 -0.0447 -0.0706
S-513	The mortality was 32 and 37% in the LCX and LAD models but very (71%) high in the two-vessel disease model.<unk>
T-513	mortality lcx lad disease
H-513	-0.746961772441864	▁mortal ity ▁ LC X ▁ LAD
D-513	-0.746961772441864	mortality LCX LAD
P-513	-1.7474 -0.3802 -0.1878 -0.0035 -0.8691 -0.1503 -0.0179 -3.2161 -0.1505
S-141	Rates calculated using the PPR and either ACR or CMS metrics were moderately correlated (r = 0.50-0.67).<unk>
T-141	ppr acr cms correlated
H-141	-0.34873849153518677	▁p PR ▁a cr ▁CMS
D-141	-0.34873849153518677	pPR acr CMS
P-141	-0.4630 -0.2343 -0.1426 -0.2959 -0.2788 -0.9452 -0.0814
S-51	Intravenous iron may help to alleviate symptoms in patients with heart failure and iron deficiency and also warrants further study.<unk>
T-51	intravenous symptoms patients heart_failure
H-51	-1.019041657447815	▁Intra ven ous _ ▁ir on
D-51	-1.019041657447815	Intravenous_ iron
P-51	-0.3083 -0.0022 -1.4115 -0.2596 -1.8319 -0.2794 -3.9208 -0.1387
S-1160	We hypothesized that RV dysfunction is linked to weight loss, abnormal body composition, and worsened prognosis in advanced HF.<unk>
T-1160	rv_dysfunction prognosis hf
H-1160	-1.042454481124878	▁ RV ▁dys function
D-1160	-1.042454481124878	RV dysfunction
P-1160	-0.2002 -0.1909 -2.5227 -0.0895 -3.0394 -0.2121
S-584	The LVET at entry (237 milliseconds) had 73% sensitivity and 89% specificity for identifying death in the ICU.<unk>
T-584	lvet sensitivity specificity death icu
H-584	-1.248732328414917	▁l VET ▁ sensitiv ity
D-584	-1.248732328414917	lVET sensitivity
P-584	-1.6702 -0.2160 -1.4984 -1.9676 -0.4043 -2.8073 -0.1773
S-1613	RESULTS: A total of 293 and 133 DEGs were obtained for non-ischemic and ischemic heart failure, respectively.<unk>
T-1613	degs ischemic_heart_failure
H-1613	-0.9730671048164368	▁non - ische mic ▁ ische mic _ heart ▁failure
D-1613	-0.9730671048164368	non-ischemic ischemic_heart failure
P-1613	-4.3122 -0.0318 -0.0297 -0.2686 -3.4665 -0.0569 -0.2154 -0.3582 -1.9236 -0.8537 -0.0750 -0.0853
S-1179	Because this patient population is symptomatic on exertion, therapeutic treatments targeting abnormal exercise hemodynamic status may prove useful.<unk>
T-1179	patient symptomatic therapeutic exercise hemodynamic
H-1179	-1.071885347366333	▁ex er tion ▁ therapeut ic
D-1179	-1.071885347366333	exertion therapeutic
P-1179	-2.1850 -0.0254 -0.1008 -1.2789 -0.0158 -0.0549 -4.8510 -0.0633
S-1912	OBJECTIVE: The objective of this study was assess robot-assisted gait therapy with the Lokomat® system in heart failure patients.<unk>
T-1912	gait therapy lokomat heart_failure patients
H-1912	-0.5628448128700256	▁robot - assist ed _ ▁ga it ▁ therapy ▁Lok omat _ system ▁heart ▁failure
D-1912	-0.5628448128700256	robot-assisted_ gait therapy Lokomat_system heart failure
P-1912	-2.1142 -0.0756 -0.0098 -0.0518 -0.4048 -0.7339 -0.0710 -0.4407 -0.0066 -0.0699 -0.0121 -1.8289 -1.4844 -0.8865 -0.1083 -1.1391 -0.1307
S-210	We hypothesize that this should have resulted in fewer CHF patients presenting to the emergency department (ED) and fewer being intubated.<unk>
T-210	chf patients emergency_department intubated
H-210	-0.9365105032920837	▁CHF ▁patients ▁in tuba ted
D-210	-0.9365105032920837	CHF patients intubated
P-210	-0.1475 -2.9990 -3.0870 -0.0100 -0.0434 -0.1800 -0.0887
S-1363	SUMMARY: The gut and its role for inflammation and dietary interventions in heart failure patients are a crucial target of further heart failure research.<unk>
T-1363	gut inflammation heart_failure patients heart_failure
H-1363	-1.4365540742874146	▁gut ▁ inflammation ▁dieta ry _ intervention s
D-1363	-1.4365540742874146	gut inflammation dietary_interventions
P-1363	-1.3336 -1.1264 -0.0902 -4.1079 -0.4776 -1.5190 -0.2541 -0.1992 -5.0611 -0.1966
S-462	Background—Heart failure is a common Emergency Department (ED) presentation but whether ED volume influences patient outcomes is unknown.<unk>
T-462	heart_failure emergency_department patient outcomes
H-462	-0.565731942653656	▁he art ▁failure ▁Emer gen cy ▁Department ED ▁ED ▁volume
D-462	-0.565731942653656	heart failure Emergency DepartmentED ED volume
P-462	-0.8285 -0.3590 -0.3115 -1.3786 -0.0112 -0.0179 -1.3697 -0.4226 -0.6934 -0.1584 -1.1112 -0.1266
S-1578	PARTICIPANTS: All patients admitted between June 7, 2010 and June 6, 2011 with a diagnosis of congestive heart failure.<unk>
T-1578	patients diagnosis congestive_heart_failure
H-1578	-0.6506528258323669	▁con ges tive _ heart ▁failure
D-1578	-0.6506528258323669	congestive_heart failure
P-1578	-1.9050 -0.0824 -0.8822 -0.1371 -1.6893 -0.3844 -0.0825 -0.0424
S-1250	We hypothesized that an improved mitochondrial structure may facilitate the reversal of detrimental alterations in sarcomeric microstructure.<unk>
T-1250	mitochondrial_structure sarcomeric_microstructure
H-1250	-0.49370869994163513	▁mito cho ndri al ▁structure
D-1250	-0.49370869994163513	mitochondrial structure
P-1250	-0.1671 -0.0634 -0.1032 -0.0230 -0.6655 -2.3510 -0.0827
S-258	In healthy individuals, ET had no effect on HDL function, whereas ET of CHF-NYHA-IIIb significantly improved HDL function.<unk>
T-258	healthy hdl chf-nyha-iiib hdl
H-258	-1.113392949104309	▁ET ▁ET ▁CHF - NY HA - III b
D-258	-1.113392949104309	ET ET CHF-NYHA-IIIb
P-258	-1.3543 -5.0098 -2.8535 -0.0650 -0.0151 -0.5061 -0.1316 -0.1149 -0.0310 -2.0359 -0.1301
S-1413	BACKGROUND: Early physician follow-up after discharge is associated with lower rates of death and readmission among patients with heart failure.<unk>
T-1413	physician follow-up discharge death readmission patients heart_failure
H-1413	-1.2606301307678223	▁e ar ly _ ▁physician _ ▁follow - up _ de _ ▁dis charge
D-1413	-1.2606301307678223	early_ physician_ follow-up_de_ discharge
P-1413	-6.3740 -0.0949 -0.0805 -0.2839 -1.0683 -1.2261 -1.2837 -0.0273 -0.0025 -0.8428 -2.7308 -0.5502 -1.9665 -0.1105 -3.4557 -0.0725
S-635	Successful approaches to improving the prognosis of patients with CHF are based largely on therapeutic interruption of activated neurohormonal systems.<unk>
T-635	prognosis patients chf therapeutic neurohormonal_systems
H-635	-0.47854816913604736	▁ therapeut ic _ ▁interrupt ion ▁activa ted _ ▁neuro hormon al ▁systems
D-635	-0.47854816913604736	therapeutic_ interruption activated_ neurohormonal systems
P-635	-3.0070 -0.3099 -0.0815 -0.3763 -0.2719 -0.0867 -0.0615 -0.0362 -0.1443 -1.6113 -0.0195 -0.0312 -0.8999 -0.1877 -0.0534
S-180	Patients who received uptitration were significantly younger, with a higher heart rate and better renal function, and received spironolactone more often.<unk>
T-180	patients uptitration heart_rate renal_function spironolactone
H-180	-1.0789871215820312	▁spi rono lac tone
D-180	-1.0789871215820312	spironolactone
P-180	-6.1281 -0.0162 -0.0143 -0.0315 -0.1288 -0.1550
S-1481	An increasing body of evidence indicates an important role for microRNAs (miRNAs) in the pathogenesis and progression of heart failure.<unk>
T-1481	evidence micrornas mirnas pathogenesis heart_failure
H-1481	-0.6148188710212708	▁micro RNA s mi RNA s
D-1481	-0.6148188710212708	microRNAsmiRNAs
P-1481	-0.2092 -0.0021 -0.1558 -1.5795 -0.0012 -0.0483 -2.8061 -0.1164
S-1859	AIM: To determine patient awareness, preferences and timing of implantable cardioverter-defibrillator deactivation discussions.<unk>
T-1859	patient implantable_cardioverter-defibrillator
H-1859	-0.5393160581588745	▁implant able _ ▁cardio ver ter - de fi br illa tor ▁de activa tion
D-1859	-0.5393160581588745	implantable_ cardioverter-defibrillator deactivation
P-1859	-4.9003 -0.0207 -0.2343 -1.8822 -0.0092 -0.2142 -0.2646 -0.0112 -0.2486 -0.2073 -0.0800 -0.0241 -0.4777 -0.0053 -0.1304 -0.3800 -0.0782
S-577	BACKGROUND: Novel noninvasive tools may improve the management of patients with pulmonary hypertension (PH) experiencing heart failure.<unk>
T-577	noninvasive patients pulmonary_hypertension heart_failure
H-577	-1.1040468215942383	▁non in va sive _ ▁tools ▁pulmonar y ▁hyper tension PH
D-577	-1.1040468215942383	noninvasive_ tools pulmonary hypertensionPH
P-577	-5.7615 -0.0253 -0.0680 -0.1764 -1.0408 -1.7655 -0.1862 -0.0218 -1.2443 -0.0807 -1.3063 -2.5954 -0.0804
S-122	METHODS: We included 156 consecutive consenting ambulatory HF patients (left ventricular ejection fraction < 40%).<unk>
T-122	ambulatory hf patients left_ventricular_ejection_fraction
H-122	-0.8338978290557861	▁consenti ng ▁ambula tory ▁ HF ▁patients ▁le ft ▁vent ri cular ▁e je ction
D-122	-0.8338978290557861	consenting ambulatory HF patients left ventricular ejection
P-122	-3.8002 -0.0112 -0.3553 -0.0909 -1.7163 -0.0299 -2.6003 -1.2166 -0.0103 -0.6111 -0.7245 -0.7716 -0.6649 -0.0457 -0.0715 -1.3766 -0.0792
S-1941	Beta-blocker dose after 12 months was comparable in patients with resting HR<70 versus ≥70 bpm (P value=0.631).<unk>
T-1941	beta-blocker patients resting_hr bpm p_value
H-1941	-0.8847209811210632	▁Beta - block er
D-1941	-0.8847209811210632	Beta-blocker
P-1941	-0.3424 -0.0107 -0.0125 -0.1371 -4.7057 -0.1000
S-1435	QT variability (QTV) signifies repolarization lability, and increased QTV is a risk predictor for sudden cardiac death.<unk>
T-1435	qt_variability qtv repolarization qtv cardiac_death
H-1435	-0.6262400150299072	▁ QT _ ▁variabil ity Q TV ▁repo lar ization ▁la bility ▁Q TV
D-1435	-0.6262400150299072	QT_ variabilityQTV repolarization lability QTV
P-1435	-0.9890 -0.0349 -2.2897 -0.1222 -0.4556 -1.4261 -0.3335 -0.7266 -0.2368 -0.1891 -0.0701 -0.0059 -0.3170 -0.1968 -2.4591 -0.1675
S-668	Addressing practice-level differences may be an important component of improving quality of care for patients with heart failure and reduced ejection fraction.<unk>
T-668	patients heart_failure_and_reduced_ejection_fraction
H-668	-1.466596007347107	▁heart ▁failure ▁e je ction ▁ fraction
D-668	-1.466596007347107	heart failure ejection fraction
P-668	-7.9053 -0.4166 -3.0463 -0.0839 -0.0328 -1.4392 -0.0019 -0.1034 -0.1700
S-914	Compared with matched controls, dialysis patients were at increased risk for adverse events and worsened echocardiographic outcomes.<unk>
T-914	dialysis patients adverse_events echocardiographic outcomes
H-914	-0.7652252912521362	▁di al ysis ▁patients
D-914	-0.7652252912521362	dialysis patients
P-914	-0.5478 -0.0956 -0.0279 -1.8670 -1.9676 -0.0855
S-641	In line, mutant mice overexpressing Hand2 in otherwise healthy heart muscle cells developed a phenotype of pathological hypertrophy.<unk>
T-641	hand2 healthy heart_muscle cells phenotype pathological hypertrophy
H-641	-0.7161378264427185	▁mu tant _ mi ce ▁over express ing ▁Hand 2 ▁heart ▁muscle ▁cell s ▁path ological ▁hyper trop hy
D-641	-0.7161378264427185	mutant_mice overexpressing Hand2 heart muscle cells pathological hypertrophy
P-641	-0.3411 -0.2843 -1.3131 -0.3279 -0.1321 -0.0290 -0.1048 -0.0162 -0.9081 -1.3479 -5.2923 -1.4952 -0.7114 -0.1734 -0.2548 -0.3079 -1.4420 -0.0012 -0.3866 -0.0785 -0.0911
S-1373	The present study used conscious, chronically instrumented New Zealand White rabbits undergoing renal DNx prior to pacing-induced CHF.<unk>
T-1373	new_zealand renal_dnx pacing-induced_chf
H-1373	-0.6341147422790527	▁ conscious _ instrument ed ▁New ▁Zealand ▁White ▁rabbi ts ▁renal ▁DN x ▁pa cing - indu ced ▁CHF
D-1373	-0.6341147422790527	conscious_instrumented New Zealand White rabbits renal DNx pacing-induced CHF
P-1373	-2.4178 -0.2129 -2.8837 -4.0217 -0.1215 -0.6759 -0.0176 -1.7906 -0.6531 -0.0333 -0.0497 -0.0272 -0.0047 -0.0153 -0.0302 -0.0491 -0.0005 -0.0195 -0.1148 -0.0691 -0.1083
S-1647	Furthermore, catheter ablation and new antiarrhythmic drugs have enhanced the potential effectiveness and safety of rhythm control therapy.<unk>
T-1647	catheter_ablation antiarrhythmic_drugs rhythm_control_therapy
H-1647	-0.38959673047065735	▁anti ar rhythm ic ▁drugs ▁ rhythm ▁control ▁ therapy
D-1647	-0.38959673047065735	antiarrhythmic drugs rhythm control therapy
P-1647	-1.1500 -0.1044 -0.2974 -0.0636 -0.4085 -0.4286 -0.1620 -1.2659 -0.5200 -0.0049 -0.1022 -0.1677
S-1029	It is also important that processes of care delivery are redesigned to take full advantage of the faster turnaround times provided by POC technology.<unk>
T-1029	advantage poc
H-1029	-1.7603894472122192	▁PO c ▁technologie
D-1029	-1.7603894472122192	POc technologie
P-1029	-5.4097 -0.8219 -2.3399 -0.0843 -0.1460
S-185	RAS-blocker uptitration independently predicts clinical outcome in patients with HFrEF but not in those with HFpEF.<unk>
T-185	ras-blocker uptitration clinical outcome patients hfref hfpef
H-185	-0.5915762782096863	RAS - block er ▁up tit ration ▁clinic al _ ▁outcome ▁h Fr EF ▁ HF p EF
D-185	-0.5915762782096863	RAS-blocker uptitration clinical_ outcome hFrEF HFpEF
P-185	-1.0277 -0.0409 -0.0606 -0.1203 -3.3833 -0.2455 -0.0770 -1.1833 -0.0359 -1.4990 -0.6977 -2.3625 -0.2121 -0.1547 -0.4259 -0.0744 -0.0587 -0.0358 -0.0498 -0.0864
S-652	Cardiac failure is a major cause of death in patients with type 2 diabetes, but the molecular mechanism that links diabetes to heart failure remains unclear.<unk>
T-652	cardiac_failure death patients type_2_diabetes diabetes heart_failure
H-652	-1.3069225549697876	▁Card iac ▁failure ▁diabetes
D-652	-1.3069225549697876	Cardiac failure diabetes
P-652	-4.2153 -0.0372 -0.2975 -0.9292 -2.2702 -0.0922
S-1957	Transoesophageal echocardiography at 1 month showed that all shunts were patent, with no thrombosis or migration.<unk>
T-1957	transoesophageal_echocardiography shunts thrombosis
H-1957	-0.3441787362098694	▁trans o es op hage al _ e cho card i ography ▁patent ▁ thro mbo sis ▁migration
D-1957	-0.3441787362098694	transoesophageal_echocardiography patent thrombosis migration
P-1957	-0.2278 -0.4331 -0.3629 -0.1935 -0.8609 -0.1363 -0.9861 -0.9793 -0.0687 -0.1933 -0.3285 -0.1816 -0.3547 -0.4342 -0.0738 -0.0603 -0.8394 -0.0143 -0.0929 -0.0620
S-579	Our arterial tonometry study tested the hypothesis that LVET carries prognostic value in patients with precapillary PH with heart failure.<unk>
T-579	arterial_tonometry lvet prognostic patients precapillary_ph heart_failure
H-579	-0.9139741659164429	▁arterial _ ▁ton ometr y ▁l VET _ car ries ▁pre cap illa ry _ ▁PH ▁heart ▁failure
D-579	-0.9139741659164429	arterial_ tonometry lVET_carries precapillary_ PH heart failure
P-579	-1.0292 -0.6346 -0.5797 -0.0371 -0.0450 -5.2548 -0.0789 -3.3542 -0.1817 -0.0924 -2.1263 -0.0257 -0.0449 -0.1219 -0.3274 -1.4296 -2.2957 -0.3494 -0.0994 -0.1713
S-1964	Study PARADIGM-HF - a paradigm shift in the treatment of chronic heart failure Chronic heart failure is a crucial problem of current cardiology.<unk>
T-1964	paradigm-hf shift chronic_heart_failure chronic_heart_failure cardiology
H-1964	-1.441576600074768	▁para dig m - HF ▁chronic _ heart ▁failure
D-1964	-1.441576600074768	paradigm-HF chronic_heart failure
P-1964	-3.3040 -1.5203 -0.7650 -0.1011 -0.0271 -4.6108 -0.3300 -1.1676 -0.4905 -3.3782 -0.1629
S-833	Hemoglobin, exercise training, and health status in patients with chronic heart failure (from the HF-ACTION randomized controlled trial).<unk>
T-833	hemoglobin exercise training health patients chronic_heart_failure hf-action randomized
H-833	-0.8844155073165894	▁Hem o glob in ▁ HF - ac TION
D-833	-0.8844155073165894	Hemoglobin HF-acTION
P-833	-0.4296 -0.0604 -0.0069 -0.2729 -3.7477 -1.1567 -0.1861 -1.0150 -1.0629 -1.6761 -0.1143
S-770	CONCLUSIONS: Obese ZSF1 rats developed heart failure with preserved ejection fraction during a 20-week time span.<unk>
T-770	obese zsf1 heart_failure_with_preserved_ejection_fraction
H-770	-0.6657621264457703	▁z SF 1 ▁rat s ▁heart ▁failure ▁pres er ved _ e je ction _ fraction
D-770	-0.6657621264457703	zSF1 rats heart failure preserved_ejection_fraction
P-770	-0.6008 -0.2831 -1.6817 -1.1882 -0.1375 -3.3368 -0.4474 -0.2562 -0.0463 -0.4131 -0.6848 -1.1483 -0.0780 -0.0490 -1.3011 -0.0096 -0.2110 -0.1107
S-8	Cross-talk between the heart and adipose tissue in cachectic heart failure patients with respect to alterations in body composition: a prospective study.<unk>
T-8	cross-talk heart adipose_tissue cachectic_heart_failure patients prospective_study
H-8	-0.8392550349235535	▁heart ▁adi pose _ ▁tissu e ▁cache ctic _ heart ▁failure
D-8	-0.8392550349235535	heart adipose_ tissue cachectic_heart failure
P-8	-3.5570 -1.9170 -0.1241 -0.6883 -0.2302 -0.0293 -0.0079 -0.2939 -0.1193 -1.4395 -0.4302 -1.9677 -0.1062
S-88	Systems proteomics of cardiac chromatin identifies nucleolin as a regulator of growth and cellular plasticity in cardiomyocytes.<unk>
T-88	systems_proteomics cardiac_chromatin nucleolin cellular_plasticity cardiomyocytes
H-88	-1.2668659687042236	▁systems ▁prote o mics ▁cardiac ▁chr omat in ▁nucleo lin
D-88	-1.2668659687042236	systems proteomics cardiac chromatin nucleolin
P-88	-4.7575 -1.5120 -0.9301 -0.0017 -0.3720 -1.3144 -0.0230 -0.9108 -0.0877 -1.5556 -3.6467 -0.0910
S-1546	Reversal of cardiac dysfunction and subcellular alterations by metoprolol in heart failure due to myocardial infarction.<unk>
T-1546	cardiac_dysfunction subcellular metoprolol heart_failure myocardial_infarction
H-1546	-0.36467811465263367	▁cardiac ▁dys function ▁sub cel lular _ ▁altera tions ▁met o pro lol ▁heart ▁failure ▁my o card ial ▁in far ction
D-1546	-0.36467811465263367	cardiac dysfunction subcellular_ alterations metoprolol heart failure myocardial infarction
P-1546	-0.1800 -1.5437 -0.0801 -0.5211 -0.0157 -0.0119 -1.8463 -0.3133 -0.1667 -0.1224 -0.1246 -0.0043 -0.0328 -1.3327 -0.1730 -0.4853 -0.1201 -0.1675 -0.1700 -1.0756 -0.0289 -0.0555 -0.0913 -0.0894
S-1054	Multiacquisition T1-mapping MRI during tidal respiration for quantification of myocardial T1 in swine with heart failure.<unk>
T-1054	t1-mapping mri tidal_respiration myocardial_t1 heart_failure
H-1054	-0.7597358226776123	▁m RI ▁tid al _ ▁respira tion ▁my o card ial _ t 1 ▁s win e ▁heart ▁failure
D-1054	-0.7597358226776123	mRI tidal_ respiration myocardial_t1 swine heart failure
P-1054	-2.5664 -1.2189 -4.0334 -0.0130 -0.3931 -0.1570 -0.0185 -0.9101 -0.1169 -0.0366 -0.0089 -0.5103 -1.8311 -0.3549 -0.0389 -0.0018 -0.1319 -3.2122 -0.1823 -0.0887 -0.1294
S-764	Myocardial collagen, collagen cross-linking, titin isoforms, and phosphorylation were also determined.<unk>
T-764	myocardial_collagen collagen_cross-linking titin isoforms phosphorylation
H-764	-0.47369566559791565	▁My o card ial ▁collage n ▁collage n ▁ phos phor y lation
D-764	-0.47369566559791565	Myocardial collagen collagen phosphorylation
P-764	-1.8918 -0.0216 -0.0442 -0.1336 -0.1215 -0.1413 -0.1820 -0.0436 -3.3549 -0.4267 -0.1963 -0.3704 -0.0607 -0.0728 -0.0440
S-744	Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.<unk>
T-744	heart_magnetic_resonance_imaging chelation compliance heart_disease patients thalassaemia_major
H-744	-0.8294475674629211	▁heart ▁magnetic _ ▁res on ance _ ▁imagin g ▁che lation ▁choice s ▁cardiovascular ▁disease ▁tha lassa emia
D-744	-0.8294475674629211	heart magnetic_ resonance_ imaging chelation choices cardiovascular disease thalassaemia
P-744	-0.9101 -0.4333 -0.4418 -1.7371 -0.4748 -0.9400 -0.5257 -2.6163 -0.1786 -0.0266 -0.0132 -0.6458 -0.0341 -4.0281 -2.8848 -0.0420 -0.1497 -0.1087 -0.3354 -0.0627
S-28	LV diastolic dysfunction and filling pressures can be assessed non-invasively using Doppler echocardiography.<unk>
T-28	lv_diastolic_dysfunction filling_pressures non-invasively doppler_echocardiography
H-28	-0.48851293325424194	▁LV ▁dia sto lic _ ▁dys function ▁fill ing _ ▁pressure s ▁do pp ler ▁e cho card i ography
D-28	-0.48851293325424194	LV diastolic_ dysfunction filling_ pressures doppler echocardiography
P-28	-1.8594 -0.5070 -0.0426 -0.0666 -1.7908 -0.3430 -0.0404 -0.2704 -0.0359 -0.9029 -0.4584 -0.0879 -1.1480 -0.0048 -1.3631 -0.8333 -0.0370 -0.1050 -0.3737 -0.1583 -0.1246 -0.1943
S-733	Cardiac magnetic resonance postcontrast T1 time is associated with outcome in patients with heart failure and preserved ejection fraction.<unk>
T-733	cardiac_magnetic_resonance_postcontrast_t1_time outcome patients heart_failure preserved_ejection_fraction
H-733	-0.6834571361541748	▁Card iac _ ▁magnetic _ ▁res on ance ▁post contra st
D-733	-0.6834571361541748	Cardiac_ magnetic_ resonance postcontrast
P-733	-0.1425 -0.0261 -1.1200 -0.7070 -0.4300 -1.0166 -0.1900 -0.3949 -0.5424 -0.0051 -0.0189 -4.2307 -0.0608
S-2015	RESULTS: The model demonstrated acceptable internal and external validity in replicating resource use, costs, and survival estimates from 3 clinical trials.<unk>
T-2015	costs clinical
H-2015	-1.7501041889190674	
D-2015	-1.7501041889190674	
P-2015	-3.4327 -0.0675
S-94	Our study identified 321 proteins in this subproteome, demonstrating it to have modest conservation (37%) with that revealed using strong acid.<unk>
T-94	proteins subproteome
H-94	-1.4221891164779663	▁protein s
D-94	-1.4221891164779663	proteins
P-94	-3.2595 -0.0548 -2.3308 -0.0436
S-861	RESULTS: Inappropriate therapy occurred in 253 (14%) of 1,790 patients during a follow-up period of 3.4 ± 1.1 years.<unk>
T-861	therapy patients follow-up
H-861	-0.2859935760498047	▁in appropria te _ therapy
D-861	-0.2859935760498047	inappropriate_therapy
P-861	-0.9908 -0.0268 -0.0394 -0.4538 -0.0455 -0.3648 -0.0809
S-1645	Rhythm control therapy has been only moderately effective in published trials, and its potential benefit was offset by side effects of repeated interventions.<unk>
T-1645	rhythm_control_therapy
H-1645	-0.40537020564079285	▁ Rhythm ▁control ▁ therapy
D-1645	-0.40537020564079285	Rhythm control therapy
P-1645	-0.0479 -0.0677 -0.8478 -0.5723 -0.0108 -1.1756 -0.1155
S-200	This article presents guidelines for the recognition, diagnosis, and early medical management of HF in infancy, childhood, and adolescence.<unk>
T-200	diagnosis medical hf
H-200	-1.4450372457504272	▁ diagnos is ▁ HF
D-200	-1.4450372457504272	diagnosis HF
P-200	-1.3014 -4.1729 -0.0274 -1.6371 -0.8129 -2.0692 -0.0944
S-1417	A familiar physician was defined as one who had seen the patient at least twice in the year before the index admission or once during the index admission.<unk>
T-1417	physician patient admission admission
H-1417	-1.1845614910125732	▁physician ▁index ▁ad mission
D-1417	-1.1845614910125732	physician index admission
P-1417	-5.7519 -0.1173 -0.0436 -0.3810 -0.5276 -0.2859
S-1514	METHODS: Plasma samples were collected from HF patients (n = 20) at rest and stored at -80 °C.<unk>
T-1514	plasma collected hf patients
H-1514	-1.448520302772522	▁Plas ma ▁sample s
D-1514	-1.448520302772522	Plasma samples
P-1514	-0.8306 -0.9429 -1.3612 -0.0419 -5.4603 -0.0542
S-1767	METHODS AND RESULTS: A total of 44 674 men without a history of cardiovascular disease underwent a baseline examination between 1971 and 2010.<unk>
T-1767	cardiovascular_disease baseline
H-1767	-1.8114689588546753	
D-1767	-1.8114689588546753	
P-1767	-3.5494 -0.0736
S-1697	RESULTS: The composite (vs. Hospital Compare) explained 68% (vs. 39%) of variation in future AMI mortality rates.<unk>
T-1697	hospital_compare ami mortality
H-1697	-0.7738333344459534	▁ AMI ▁mortal ity
D-1697	-0.7738333344459534	AMI mortality
P-1697	-0.4817 -0.8594 -2.0508 -0.3627 -0.7520 -0.1364
S-726	Thirty-day all-cause readmissions decreased from 27.5% to 19.1% after our quality improvement initiative (P = .024).<unk>
T-726	all-cause_readmissions
H-726	-1.1746814250946045	
D-726	-1.1746814250946045	
P-726	-2.3144 -0.0350
S-1939	Patients participated in a quality of care programme aiming to achieve guideline-recommended target doses for beta-blocker therapy.<unk>
T-1939	patients beta-blocker therapy
H-1939	-1.4753108024597168	▁eu - block er ▁ therapy
D-1939	-1.4753108024597168	eu-blocker therapy
P-1939	-7.5918 -0.5126 -0.3551 -0.2788 -2.3632 -0.0349 -0.1484 -0.5177
S-1288	In summary, this is one of the largest series of ACS problems in patients undergoing OHT bridged to transplant with MT or VAD.<unk>
T-1288	acs patients oht transplant vad
H-1288	-0.7612780332565308	▁a CS ▁o HT ▁ bridge d _ to ▁transplant ▁MT ▁ VAD
D-1288	-0.7612780332565308	aCS oHT bridged_to transplant MT VAD
P-1288	-0.3897 -1.3597 -2.7822 -0.1249 -0.6766 -0.0004 -0.0246 -1.6582 -1.4648 -0.1961 -2.0837 -0.5542 -0.0032 -0.0304 -0.0705
S-1555	Psoriasis has been suggested to be an independent risk factor for cardiovascular disease (CVD); however, available studies have shown inconsistent results.<unk>
T-1555	psoriasis cardiovascular_disease cvd
H-1555	-0.5933354496955872	▁p sori asis ▁cardiovascular ▁disease CV D
D-1555	-0.5933354496955872	psoriasis cardiovascular diseaseCVD
P-1555	-1.2469 -0.0495 -0.0194 -0.6648 -1.8060 -0.3325 -1.0507 -0.1097 -0.0607
S-487	Using a cutoff of 8, negative predictive value of E/e'septal was 89% and negative likelihood ratio of 0.15.<unk>
T-487	septal likelihood_ratio
H-487	-1.235818862915039	▁cut off ▁e / e ' sept al
D-487	-1.235818862915039	cutoff e/e'septal
P-487	-2.5489 -0.0363 -1.9019 -2.7134 -0.0773 -3.7640 -0.0196 -0.0270 -1.0672 -0.2026
S-139	PRINCIPAL FINDINGS: Average hospital rates for HF patients and the CMS metric were generally higher than for other conditions and metrics.<unk>
T-139	principal hospital hf patients cms conditions
H-139	-1.4765993356704712	▁hospital ▁rates ▁ HF ▁CMS
D-139	-1.4765993356704712	hospital rates HF CMS
P-139	-6.6865 -0.9342 -0.4105 -0.0211 -0.7294 -1.4056 -0.1488
S-1838	Results were also similar in subgroups of patients with and without prior cardiovascular disease and in a subgroup defined by the 2 highest DRS deciles.<unk>
T-1838	patients cardiovascular_disease drs
H-1838	-1.179663896560669	▁cardiovascular ▁disease ▁d RS
D-1838	-1.179663896560669	cardiovascular disease dRS
P-1838	-3.8385 -1.6492 -0.7962 -0.0929 -0.6441 -0.0571
S-1217	Importantly, PDE2-overexpressing cardiomyocytes showed marked protection from norepinephrine-induced hypertrophic responses.<unk>
T-1217	cardiomyocytes hypertrophic
H-1217	-0.24890738725662231	▁p de 2- over express ing ▁cardio my o cy tes ▁no re pine ph rine - indu ced ▁hyper trop hic
D-1217	-0.24890738725662231	pde2-overexpressing cardiomyocytes norepinephrine-induced hypertrophic
P-1217	-1.1636 -0.2900 -0.1008 -0.0039 -0.1145 -0.0240 -0.4491 -0.3460 -0.2783 -0.1057 -0.1162 -0.0389 -0.0768 -0.0462 -0.6188 -0.0468 -0.1606 -0.0206 -0.3530 -0.7054 -0.0016 -0.1329 -0.6918 -0.0882
S-622	OBJECTIVE: The aim of this study was to assess the association between frailty and risk for heart failure (HF) in older adults.<unk>
T-622	frailty heart_failure hf
H-622	-0.669791042804718	▁fra il ty ▁risk _ van _ heart ▁failure
D-622	-0.669791042804718	frailty risk_van_heart failure
P-622	-0.4630 -0.2617 -0.0879 -1.4247 -0.8265 -1.4944 -0.0660 -1.0355 -0.5836 -1.0749 -0.0495
S-1940	At baseline, 6 and 12 months, 36%, 70% and 62% of patients, respectively, had a resting HR<70 bpm.<unk>
T-1940	baseline patients resting_hr bpm
H-1940	-1.1633694171905518	
D-1940	-1.1633694171905518	
P-1940	-2.2765 -0.0502
S-1535	OBJECTIVES: The aim of this study was to investigate the occurrence of heart failure in patients treated with bisphosphonates.<unk>
T-1535	heart_failure patients bisphosphonates
H-1535	-1.1900568008422852	▁heart ▁failure ▁bis phos phon ates
D-1535	-1.1900568008422852	heart failure bisphosphonates
P-1535	-7.1458 -0.8602 -1.0583 -0.0137 -0.1187 -0.1390 -0.1103 -0.0744
S-1871	They were randomly assigned to receive ongoing GDMT alone (control group) or ongoing GDMT plus BAT (treatment group) for 6 months.<unk>
T-1871	gdmt gdmt bat
H-1871	-1.0669187307357788	▁GD MT ▁BAT
D-1871	-1.0669187307357788	GDMT BAT
P-1871	-1.0271 -0.0144 -4.0333 -0.2203 -0.0395
S-179	Patients with a RAS- and β-blocker dose increase of ≥10% of the recommended target dose were compared with patients without uptitration.<unk>
T-179	patients β-blocker patients uptitration
H-179	-0.7376611232757568	▁ RAS - ▁β - block er ▁dose
D-179	-0.7376611232757568	RAS- β-blocker dose
P-179	-0.1416 -0.0030 -0.0648 -3.4360 -0.0166 -0.0359 -0.1001 -1.6175 -1.7545 -0.2065
S-170	Compared to the control group, expression of Bax and Bcl-2 proteins and their ratio were increased in dogs only after 4 weeks of pacing.<unk>
T-170	expression bax bcl-2 proteins pacing
H-170	-0.36026453971862793	▁Bax ▁b cl -2 ▁protein s
D-170	-0.36026453971862793	Bax bcl-2 proteins
P-170	-0.3789 -1.2415 -0.0489 -0.2146 -0.3077 -0.0394 -0.5159 -0.1352
S-1483	To date, many miRNAs (and their targets) that play a role in diverse aspects of cardiac remodeling and heart failure development have been identified.<unk>
T-1483	mirnas cardiac_remodeling heart_failure
H-1483	-0.33877530694007874	▁mi RNA s ▁cardiac ▁remodel ing ▁heart ▁failure
D-1483	-0.33877530694007874	miRNAs cardiac remodeling heart failure
P-1483	-0.6318 -0.0004 -0.2187 -0.0930 -0.5077 -0.0225 -1.3920 -0.2777 -0.2009 -0.0430
S-1545	However, users of alendronate showed a dose-dependent reduction in this risk, suggesting that alendronate may reduce the risk of heart failure.<unk>
T-1545	alendronate alendronate heart_failure
H-1545	-1.09158456325531	▁ale ndr onate
D-1545	-1.09158456325531	alendronate
P-1545	-1.4242 -0.0263 -0.2263 -3.6254 -0.1558
S-1804	This novel finding could partly explain the reported greater risk of heart failure linked to the CLCNKA SNP, but requires confirmation on other populations.<unk>
T-1804	reported heart_failure clcnka snp
H-1804	-1.4612152576446533	▁c cn ka _ s NP
D-1804	-1.4612152576446533	ccnka_sNP
P-1804	-6.0185 -1.2820 -0.4746 -1.8197 -1.2133 -0.0590 -0.6795 -0.1430
S-1362	The regulation of feeding is discussed, as are nutritional strategies with potentially anti-inflammatory effects in the treatment of CHF.<unk>
T-1362	regulation anti-inflammatory chf
H-1362	-0.7214069962501526	▁regula tion _ of _ ▁feed ing ▁nutrition al _ strategi s ▁anti - in flam ma tory _ effect ▁CHF
D-1362	-0.7214069962501526	regulation_of_ feeding nutritional_strategis anti-inflammatory_effect CHF
P-1362	-2.9929 -0.0623 -0.5285 -1.6555 -0.4220 -0.8868 -0.0320 -1.2022 -0.0373 -1.6271 -0.1740 -1.6149 -0.0550 -0.0377 -0.1717 -0.0061 -2.2437 -0.3640 -1.5394 -0.2032 -0.6091 -0.0441 -0.0830
S-25	In the general population, the presence of even mild clinical diastolic dysfunction has been associated with pronounced increases in all cause mortality.<unk>
T-25	clinical diastolic_dysfunction mortality
H-25	-0.6133970618247986	▁clinic al ▁dia sto lic _ ▁dys function
D-25	-0.6133970618247986	clinical diastolic_ dysfunction
P-25	-2.6162 -0.0049 -0.8955 -0.0415 -0.1075 -1.3382 -0.3565 -0.0561 -0.6709 -0.0468
S-993	Paradoxically, however, in a number of cases, the transduction pathways involved in such opposing responses engage the same signalling proteins.<unk>
T-993	transduction_pathways engage signalling_proteins
H-993	-0.7421690225601196	▁trans duction ▁path ways ▁signal ling ▁protein s
D-993	-0.7421690225601196	transduction pathways signalling proteins
P-993	-0.1738 -1.1517 -2.7011 -0.0467 -1.9542 -0.1677 -1.0788 -0.0534 -0.0452 -0.0491
S-602	We studied the risk of new or recurrent HF among a group of patients receiving these agents to treat rheumatoid arthritis (RA).<unk>
T-602	hf patients rheumatoid_arthritis ra
H-602	-0.8921642899513245	▁ HF ▁rhe um ato id _ ▁ar thri tis RA
D-602	-0.8921642899513245	HF rheumatoid_ arthritisRA
P-602	-0.8407 -0.5357 -5.9239 -0.0863 -0.1494 -0.2215 -0.7888 -1.4359 -0.0875 -0.0815 -1.2319 -0.0957 -0.1192
S-1516	Customized homogeneous sandwich AlphaLISA® immunoassays were developed and validated to quantify 6 fragments of NT-proBNP.<unk>
T-1516	alphalisa immunoassays nt-probnp
H-1516	-0.6683156490325928	▁Alpha LIS a ▁immun o assa ys ▁NT - pro b NP
D-1516	-0.6683156490325928	AlphaLISa immunoassays NT-probNP
P-1516	-3.3932 -0.2452 -0.8888 -2.6097 -0.0986 -0.0171 -0.2424 -0.6279 -0.0188 -0.0044 -1.0441 -0.0047 -0.0983 -0.0633
S-460	β-Blocker-induced enhancement of cardiac angiogenesis is essential for the favorable effects of this therapy on cardiac function and remodeling.<unk>
T-460	cardiac_angiogenesis therapy cardiac_function remodeling
H-460	-0.715793788433075	▁β - Block er - indu ced _ ▁enhance ment ▁cardiac _ ▁ang io gene sis ▁cardiac ▁function ▁remodel ing
D-460	-0.715793788433075	β-Blocker-induced_ enhancement cardiac_ angiogenesis cardiac function remodeling
P-460	-0.8180 -0.0276 -0.2487 -0.0511 -0.1497 -0.0089 -0.6897 -0.6959 -3.2046 -0.1495 -0.3081 -0.8522 -2.8488 -0.6964 -0.0986 -0.2029 -1.3999 -2.7233 -0.3081 -0.0327 -0.1425 -0.0904
S-226	Twenty-seven symptomatic adult Fontan (SAF) patients who underwent catheterization from 2001 to 2011 constituted our study group.<unk>
T-226	symptomatic_adult_fontan saf patients catheterization
H-226	-1.1726694107055664	▁symptom a tic _ adult _ ▁Font an SAF
D-226	-1.1726694107055664	symptomatic_adult_ FontanSAF
P-226	-4.9040 -0.0805 -0.2358 -0.4147 -0.3866 -0.1659 -1.4379 -0.2442 -3.7908 -1.0712 -0.1677
S-63	Two reviewers selected citations that included ambulatory ICD patients and addressed the association between any predictor and mortality using multivariable regression.<unk>
T-63	ambulatory icd patients mortality multivariable_regression
H-63	-0.36986133456230164	▁ambula tory ▁I CD ▁patients ▁predict or ▁mortal ity ▁multi vari able _ ▁re gression
D-63	-0.36986133456230164	ambulatory ICD patients predictor mortality multivariable_ regression
P-63	-0.5825 -0.0444 -1.6137 -0.0210 -1.0243 -0.3225 -0.0098 -0.3245 -0.2474 -0.1043 -0.0347 -0.0428 -0.7191 -1.0278 -0.0006 -0.0564 -0.1118
S-1328	We sought to investigate the effects of FES on the above parameters in patients with preserved ejection fraction (HFpEF).<unk>
T-1328	fes patients preserved_ejection_fraction hfpef
H-1328	-0.5620993971824646	▁f es ▁pres er ved _ e je ction _ fraction HF p EF
D-1328	-0.5620993971824646	fes preserved_ejection_fractionHFpEF
P-1328	-1.1122 -1.4779 -2.9039 -0.0464 -0.3057 -0.0870 -1.1586 -0.2924 -0.0716 -1.0753 -0.0409 -0.1954 -0.0206 -0.0207 -0.0995 -0.0853
S-955	Despite of its known cardiotoxicity, doxorubicin is still a highly effective anti-neoplastic agent in the treatment of several cancers.<unk>
T-955	cardiotoxicity doxorubicin anti-neoplastic_agent
H-955	-0.4645994305610657	▁do xor ubi cin ▁anti - neo plast ic
D-955	-0.4645994305610657	doxorubicin anti-neoplastic
P-955	-1.5108 -0.0049 -0.0185 -0.0995 -0.4664 -0.0360 -0.0572 -0.0860 -0.0466 -2.7107 -0.0740
S-1289	With similar incidence in MT and VAD groups, ACS consultations and operations are infrequent with high mortality and morbidity.<unk>
T-1289	incidence vad acs consultations operations mortality morbidity
H-1289	-0.9363133311271667	▁MT ▁ VAD ▁groups ▁a CS
D-1289	-0.9363133311271667	MT VAD groups aCS
P-1289	-1.7195 -0.4906 -0.0286 -2.5704 -0.5410 -0.5145 -1.5090 -0.1169
S-1421	INTERPRETATION: Early physician follow-up after discharge and physician continuity were both associated with better outcomes among patients with heart failure.<unk>
T-1421	physician follow-up discharge physician outcomes patients heart_failure
H-1421	-1.0639623403549194	▁physician _ follow - up _ van _ ▁dis charge ▁physician ▁continu ity
D-1421	-1.0639623403549194	physician_follow-up_van_ discharge physician continuity
P-1421	-2.4231 -2.0117 -1.2131 -0.0792 -0.0026 -1.4954 -4.1504 -0.0946 -0.9272 -0.1079 -0.0896 -0.0843 -0.1390 -3.0041 -0.1374
S-1354	Patients in sinus rhythm may benefit from antiplatelet agents or anticoagulants, but much work remains to establish efficacy and safety.<unk>
T-1354	patients sinus_rhythm antiplatelet_agents anticoagulants
H-1354	-0.16037113964557648	▁sinus ▁ rhythm ▁anti plate let ▁agents ▁antico a gul ants
D-1354	-0.16037113964557648	sinus rhythm antiplatelet agents anticoagulants
P-1354	-0.4894 -0.2404 -0.0356 -0.0157 -0.0563 -0.1556 -0.5708 -0.0190 -0.0421 -0.0791 -0.0229 -0.2649 -0.0928
S-1011	Both measures predicted death equally (C-statistics: 0.687 for biological phenotype and 0.700 for deficit index).<unk>
T-1011	death c-statistics biological_phenotype deficit_index
H-1011	-0.39557263255119324	▁c - stat istic s ▁bi ological _ ▁ph eno type ▁deficit ▁index
D-1011	-0.39557263255119324	c-statistics biological_ phenotype deficit index
P-1011	-2.1074 -0.1319 -0.0055 -0.0030 -0.0159 -1.5773 -0.1989 -1.0032 -0.2265 -0.0105 -0.0014 -0.0547 -0.2516 -0.1738 -0.1719
S-22	In developed countries, at least 38–54% of patients with heart failure show preserved left ventricular (LV) ejection fraction.<unk>
T-22	patients heart_failure left_ventricular ejection_fraction
H-22	-0.9602691531181335	▁heart ▁failure ▁pres er ved _ ▁left _ ▁vent ri cular LV
D-22	-0.9602691531181335	heart failure preserved_ left_ ventricularLV
P-22	-5.5596 -0.6269 -1.5218 -0.0351 -0.3126 -0.4754 -1.2481 -0.2473 -1.1436 -0.5047 -0.1459 -0.3049 -1.1701 -0.1476
S-966	Interestingly, nicorandil did not interfere with cytotoxic effect of doxorubicin against the growth of solid Ehrlich carcinoma.<unk>
T-966	nicorandil cytotoxic doxorubicin ehrlich_carcinoma
H-966	-0.4161469638347626	▁nic oran dil ▁cy to toxic ▁effect ▁do xor ubi cin ▁eh r lich _ car cino ma
D-966	-0.4161469638347626	nicorandil cytotoxic effect doxorubicin ehrlich_carcinoma
P-966	-0.1287 -0.0069 -0.0324 -0.1538 -0.0080 -0.0123 -2.2371 -0.1019 -0.0021 -0.0057 -0.0565 -3.2099 -0.0376 -0.0401 -0.6741 -0.6716 -0.0698 -0.6186 -0.1583 -0.0977
S-1858	Few studies have reported the patient's perspective on the timing of implantable cardioverter-defibrillator deactivation discussions.<unk>
T-1858	reported patient implantable_cardioverter-defibrillator
H-1858	-0.4905015528202057	▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion
D-1858	-0.4905015528202057	implantable cardioverter-defibrillator deactivation
P-1858	-3.2863 -0.0168 -2.9261 -0.0100 -0.1702 -0.2845 -0.0098 -0.1767 -0.1266 -0.0678 -0.0243 -0.2589 -0.0052 -0.1904 -0.2353 -0.0590
S-1371	Renal denervation (DNx) in CHF patients has resulted in symptomatic improvement, but the protective mechanisms remain unclear.<unk>
T-1371	renal_denervation dnx chf patients symptomatic
H-1371	-1.2409242391586304	▁Ren al _ ▁den er va tion DN x ▁CHF
D-1371	-1.2409242391586304	Renal_ denervationDNx CHF
P-1371	-2.2669 -0.2369 -0.8428 -3.2531 -1.2964 -1.2779 -0.6457 -2.8568 -0.0396 -0.3096 -1.7366 -0.1286
S-24	LV diastolic dysfunction, either alone or in combination with other factors (figure 1), is the major underlying mechanism of HFPEF.<unk>
T-24	lv_diastolic_dysfunction combination figure hfpef
H-24	-0.4955523908138275	▁LV ▁dia sto lic ▁dys function ▁H FP EF
D-24	-0.4955523908138275	LV diastolic dysfunction HFPEF
P-24	-0.6675 -0.6342 -0.0308 -0.0761 -1.2525 -0.0498 -2.4254 -0.0456 -0.1221 -0.0473 -0.0998
S-1019	Measurement of natriuretic peptides at the point of care in the emergency and ambulatory setting: current status and future perspectives.<unk>
T-1019	natriuretic_peptides point_of_care ambulatory
H-1019	-0.5628693103790283	▁na tri ure tic _ pe pti des
D-1019	-0.5628693103790283	natriuretic_peptides
P-1019	-0.0342 -0.0090 -0.6998 -2.0606 -0.3888 -0.2983 -0.0282 -0.2333 -1.8242 -0.0522
S-593	Myxomas are the most common type of cardiac benign tumors and most of them are located in the left atrium, followed by the right atrium.<unk>
T-593	myxomas cardiac benign_tumors left_atrium right_atrium
H-593	-0.547067403793335	▁My xo mas ▁cardiac ▁benign ▁tumor s
D-593	-0.547067403793335	Myxomas cardiac benign tumors
P-593	-2.3887 -0.0013 -0.1473 -0.4374 -0.1988 -0.5304 -0.0838 -1.0068 -0.1291
S-1077	Significant progress has been achieved in the development of lifesaving drugs for HF with reduced ejection fraction (HFrEF).<unk>
T-1077	drugs hf_with_reduced_ejection_fraction hfref
H-1077	-1.7744289636611938	▁life sa ving ▁drugs ▁ HF
D-1077	-1.7744289636611938	lifesaving drugs HF
P-1077	-3.5552 -2.4823 -0.0241 -2.1869 -1.7746 -0.0102 -4.1188 -0.0434
S-766	At 20 weeks, the lean ZSF1 group was hypertensive, whereas both obese ZSF1 groups were hypertensive and diabetic.<unk>
T-766	zsf1 hypertensive obese zsf1 hypertensive diabetic
H-766	-0.972205638885498	▁lean ▁z SF 1 ▁group ▁hyper tensi ve ▁obes e ▁z SF 1
D-766	-0.972205638885498	lean zSF1 group hypertensive obese zSF1
P-766	-0.1045 -1.1895 -0.0674 -1.2578 -3.9868 -1.2337 -0.0186 -0.0220 -0.5417 -0.0252 -1.7728 -0.0451 -0.7646 -3.4523 -0.1011
S-1659	Gastrointestinal bleeding is not uncommon and is reported to occur in 13% to 44% of patients treated with ventricular assist devices.<unk>
T-1659	gastrointestinal_bleeding reported patients ventricular_assist_devices
H-1659	-0.44034868478775024	▁Gastro inte stin al ▁ble ed ing ▁vent ri cular _ assist ▁devices
D-1659	-0.44034868478775024	Gastrointestinal bleeding ventricular_assist devices
P-1659	-0.3962 -0.1701 -0.4717 -0.1246 -1.2026 -0.9687 -0.2427 -0.0683 -0.4517 -0.2468 -0.6019 -0.4435 -1.0363 -0.0688 -0.1114
S-444	Crude rates of severe hyperkalemia and acute kidney injury during spironolactone use were similar to that seen in clinical trials.<unk>
T-444	hyperkalemia acute_kidney_injury spironolactone clinical
H-444	-0.5510249137878418	▁hyper kal emia ▁a cute _ ▁ki dne y ▁injury ▁spi rono lac tone
D-444	-0.5510249137878418	hyperkalemia acute_ kidney injury spironolactone
P-444	-5.8011 -0.1042 -0.0108 -0.6836 -0.0065 -0.5645 -0.1915 -0.1401 -0.0313 -0.6578 -0.0015 -0.0050 -0.0071 -0.0275 -0.5273 -0.0567
S-1949	BACKGROUND: In patients with heart failure, interventions to reduce elevated left atrial pressure improve symptoms and reduce the risk of hospital admission.<unk>
T-1949	patients heart_failure elevated left_atrial_pressure symptoms hospital admission
H-1949	-1.5152316093444824	▁heart ▁failure
D-1949	-1.5152316093444824	heart failure
P-1949	-2.6490 -0.2455 -3.0996 -0.0669
S-1366	Recently, the diagnostic roles of BNP and NT-proBNP in patients with coronary artery disease (CAD) have been investigated.<unk>
T-1366	diagnostic bnp nt-probnp patients coronary_artery_disease cad
H-1366	-0.5308644771575928	▁b NP ▁NT - pro b NP ▁corona ry ▁arter y ▁disease CAD
D-1366	-0.5308644771575928	bNP NT-probNP coronary artery diseaseCAD
P-1366	-2.0588 -0.2951 -1.0683 -0.0115 -0.0070 -0.9624 -0.0464 -0.1066 -0.5088 -1.2257 -0.2507 -1.0981 -0.2168 -0.0528 -0.0540
S-1220	Thus, activating myocardial PDE2 may represent a novel intracellular antiadrenergic therapeutic strategy in HF.<unk>
T-1220	myocardial pde2 intracellular antiadrenergic therapeutic hf
H-1220	-0.7551233768463135	▁activa ting ▁my o card ial _ ▁P DE 2 ▁intra cel lular _ ▁anti ad r energi c _ strategi e ▁ HF
D-1220	-0.7551233768463135	activating myocardial_ PDE2 intracellular_ antiadrenergic_strategie HF
P-1220	-2.2583 -1.1532 -1.2045 -0.1729 -0.0445 -0.1018 -0.5050 -3.5034 -0.7610 -0.0729 -1.8162 -0.0465 -0.0111 -1.0842 -0.5710 -0.0689 -0.1797 -0.3571 -0.0673 -1.8313 -0.2467 -2.6042 -0.6819 -0.0093 -0.0938 -0.1865
S-235	Comparison of predictors of heart failure-related hospitalization or death in patients with versus without preserved left ventricular ejection fraction.<unk>
T-235	heart hospitalization death patients preserved_left_ventricular_ejection_fraction
H-235	-1.174606442451477	▁predict ors ▁heart ▁failure - related _ hospital ization
D-235	-1.174606442451477	predictors heart failure-related_hospitalization
P-235	-3.9402 -0.5225 -1.6356 -0.4870 -0.2058 -0.1656 -1.0217 -0.0888 -0.4365 -4.1676 -0.2493
S-590	CONCLUSIONS: Shortened LVET at ICU admission was a prognostic factor in patients with precapillary PH with heart failure.<unk>
T-590	shortened lvet icu admission prognostic patients precapillary_ph heart_failure
H-590	-0.7228106260299683	▁l VET ▁ ICU ▁ad mission ▁pre cap illa ry _ PH ▁heart ▁failure
D-590	-0.7228106260299683	lVET ICU admission precapillary_PH heart failure
P-590	-3.8071 -0.2287 -1.3565 -0.0813 -0.7223 -0.3762 -0.6361 -0.0185 -0.0383 -0.1087 -0.6499 -1.1063 -2.0489 -0.1312 -0.0869 -0.1681
S-1810	Mammalian enabled (Mena) is a key regulator of cytoskeletal actin dynamics, which has been implicated in heart failure (HF).<unk>
T-1810	mammalian_enabled mena cytoskeletal_actin_dynamics heart_failure hf
H-1810	-0.768421471118927	▁Mamma lian _ ▁enabled ▁men a ▁cy tos kelet al _ ▁act in ▁dynamic s ▁heart ▁failure
D-1810	-0.768421471118927	Mammalian_ enabled mena cytoskeletal_ actin dynamics heart failure
P-1810	-0.7877 -0.0254 -2.0460 -3.2449 -1.5205 -0.0294 -1.5526 -0.4982 -0.0808 -0.0210 -0.3868 -1.6975 -0.2498 -0.5650 -0.0250 -0.4058 -0.3633 -1.0462 -0.0543
S-893	Reduced hospitalizations in severe, refractory congestive heart failure with peritoneal dialysis: a consecutive case series.<unk>
T-893	hospitalizations refractory_congestive_heart_failure peritoneal_dialysis
H-893	-0.60953688621521	▁re frac tory _ con ges tive _ heart ▁failure ▁per ito ne al _ di al ysis
D-893	-0.60953688621521	refractory_congestive_heart failure peritoneal_dialysis
P-893	-1.7807 -0.0217 -0.8993 -0.1557 -1.8770 -0.7114 -1.7160 -0.0345 -1.4883 -0.5492 -0.1001 -0.3371 -0.1337 -0.0530 -0.1780 -1.9087 -0.0428 -0.0589 -0.0873 -0.0572
S-916	BACKGROUND: Heart failure with preserved ejection fraction (HFPEF) involves failure of cardiovascular reserve in multiple domains.<unk>
T-916	heart_failure_with_preserved_ejection_fraction hfpef cardiovascular_reserve
H-916	-0.5003593564033508	▁Heart ▁failure ▁pres er ved _ e je ction _ fraction h FP EF ▁cardiovascular ▁reserve
D-916	-0.5003593564033508	Heart failure preserved_ejection_fractionhFPEF cardiovascular reserve
P-916	-1.2055 -1.0006 -2.2440 -0.0477 -0.3063 -0.0934 -0.7975 -0.1709 -0.0269 -0.4499 -0.0062 -1.0858 -0.2245 -0.3926 -0.2296 -0.6066 -0.0598 -0.0583
S-23	The prevalence of heart failure with preserved ejection fraction (HFPEF) is steadily increasing and its prognosis is poor.<unk>
T-23	prevalence heart_failure_with_preserved_ejection_fraction hfpef prognosis
H-23	-0.5815836191177368	▁heart ▁failure ▁pres er ved _ e je ction _ fraction h FP EF
D-23	-0.5815836191177368	heart failure preserved_ejection_fractionhFPEF
P-23	-1.6936 -0.3902 -1.9478 -0.0546 -0.3703 -0.0753 -1.0125 -0.2047 -0.0306 -0.6305 -0.0145 -0.9344 -0.2209 -0.1995 -1.4688 -0.0570
S-337	Functional mitral stenosis (MS) frequently develops after ring annuloplasty for ischemic mitral regurgitation (MR).<unk>
T-337	functional_mitral_stenosis ring_annuloplasty ischemic_mitral_regurgitation
H-337	-0.38930991291999817	▁Fun ction al _ met ral _ ▁sten osis ▁m ▁ring ▁ann ulo plast y ▁ ische mic _ met ral ▁re gur gi tation MR
D-337	-0.38930991291999817	Functional_metral_ stenosis m ring annuloplasty ischemic_metral regurgitationMR
P-337	-0.9927 -0.0056 -0.0561 -1.1076 -1.0139 -0.1012 -0.7419 -1.4660 -0.0087 -1.5074 -0.1810 -0.3843 -0.0234 -0.0310 -0.0731 -0.5510 -0.0260 -0.0598 -0.1586 -1.4106 -0.1176 -0.4706 -0.0442 -0.0421 -0.0124 -0.0680 -0.1815 -0.0644
S-1966	In this regard, first results of studies with ARNI inhibitors (angiotensin-receptor neprilysin inhibitors) may be considered hopeful.<unk>
T-1966	arni_inhibitors angiotensin-receptor_neprilysin_inhibitors
H-1966	-0.2699090838432312	▁AR NI ▁inhibi tors angi oten sin - recept or ▁nepri ly sin ▁inhibi tors
D-1966	-0.2699090838432312	ARNI inhibitorsangiotensin-receptor neprilysin inhibitors
P-1966	-1.8542 -0.5535 -0.2694 -0.0946 -0.0820 -0.0771 -0.5303 -0.1982 -0.0202 -0.0353 -0.0502 -0.1246 -0.2378 -0.1944 -0.0938 -0.0998 -0.0730
S-651	Myocardial loss of IRS1 and IRS2 causes heart failure and is controlled by p38alpha MAPK during insulin resistance.<unk>
T-651	myocardial irs1 irs2 heart_failure p38alpha mapk insulin_resistance
H-651	-0.5741934776306152	▁My o card ial _ ▁loss ▁I RS 1 ▁i RS 2 ▁heart ▁failure ▁p 38 al pha ▁MA PK ▁insulin ▁resist ance
D-651	-0.5741934776306152	Myocardial_ loss IRS1 iRS2 heart failure p38alpha MAPK insulin resistance
P-651	-4.5909 -0.0496 -0.0972 -0.0602 -2.0959 -0.2265 -0.6415 -0.0078 -1.3863 -0.9943 -0.0434 -0.1880 -1.5926 -0.1120 -0.0584 -0.8019 -0.0762 -0.0002 -0.9091 -0.0043 -0.0189 -0.1884 -0.0043 -0.0552 -0.1516
S-236	Heart failure with preserved ejection fraction (HFpEF) is recognized as a major cause of cardiovascular morbidity and mortality.<unk>
T-236	heart_failure_with_preserved_ejection_fraction hfpef cardiovascular_morbidity mortality
H-236	-0.46819940209388733	▁Heart ▁failure ▁pres er ved _ e je ction _ fraction HF p EF ▁cardiovascular ▁morbi d ity ▁mortal ity
D-236	-0.46819940209388733	Heart failure preserved_ejection_fractionHFpEF cardiovascular morbidity mortality
P-236	-0.6263 -1.2229 -3.1962 -0.0788 -0.5789 -0.0717 -0.9047 -0.2488 -0.0190 -0.6549 -0.0265 -0.3650 -0.0290 -0.0990 -0.2487 -0.5003 -0.0161 -0.6983 -0.2324 -0.3895 -0.0328 -0.0606
S-1851	We will identify the common elements of successful and failing interventions, and examine the context in which they were applied, using the Process Redesign contextual framework.<unk>
T-1851	
H-1851	-0.9977955222129822	▁Process ▁Re design ▁context ual ▁framework
D-1851	-0.9977955222129822	Process Redesign contextual framework
P-1851	-4.5587 -1.5160 -0.2588 -0.6553 -0.0185 -0.8707 -0.0379 -0.0665
S-573	No significant differences were found for peak aerobic capacity, left-hand grip strength, body weight, waist circumference, or symptoms of anxiety.<unk>
T-573	symptoms
H-573	-0.5809425115585327	▁pe ak ▁aero bic _ ▁capacity ▁left - hand _ grip _ ▁strength ▁body ▁weight ▁wa ist ▁circum ferenc e ▁anxiety
D-573	-0.5809425115585327	peak aerobic_ capacity left-hand_grip_ strength body weight waist circumference anxiety
P-573	-2.6533 -0.0326 -1.1160 -0.1056 -1.8283 -0.9692 -0.4210 -0.0370 -0.0016 -0.3074 -1.8594 -1.1369 -0.4790 -0.6261 -1.0241 -0.0239 -0.0388 -0.0353 -0.0022 -0.0410 -0.4748 -0.0556 -0.0926
S-713	The first to identify clinical variables contributing to survival between the 2 groups, and the second to determine the additional risk associated with assignment to ECCT.<unk>
T-713	clinical ecct
H-713	-1.199920654296875	▁ec CT
D-713	-1.199920654296875	ecCT
P-713	-3.8939 -0.7242 -0.0707 -0.1109
S-1883	However, there were nosignificant changes in control group (P>0.05) and their changes were smaller than those in exercise group (P < 0.01).<unk>
T-1883	nosignificant exercise
H-1883	-0.6610056161880493	▁control ▁group
D-1883	-0.6610056161880493	control group
P-1883	-1.1674 -0.6002 -0.8297 -0.0467
S-1512	Moreover, there is yet to be established a common consensus regarding the circulating forms of NT-proBNP being used in current assays.<unk>
T-1512	nt-probnp
H-1512	-0.5189178586006165	▁circula ting _ form s ▁NT - pro B NP
D-1512	-0.5189178586006165	circulating_forms NT-proBNP
P-1512	-0.3061 -0.1020 -0.3201 -1.0743 -0.1065 -2.1097 -0.0336 -0.0110 -1.2111 -0.0326 -0.8518 -0.0681
S-1348	The 8- to 9-s PVF was incidentally produced during the ascending phase of a PB cycle, followed by another 12-s recovery period of low BP.<unk>
T-1348	pvf pb bp
H-1348	-0.5612495541572571	▁PV F ▁ PB
D-1348	-0.5612495541572571	PVF PB
P-1348	-0.2478 -0.6121 -0.4856 -0.0633 -1.8941 -0.0646
S-881	The interaction between these 2 simple ECG parameters and their effect on CRT has not been systematically assessed in a large-scale clinical trial.<unk>
T-881	ecg crt clinical
H-881	-0.725166380405426	▁e CG ▁parameter s ▁c RT
D-881	-0.725166380405426	eCG parameters cRT
P-881	-1.9065 -0.0265 -2.3735 -0.0746 -0.5288 -0.5121 -0.3041 -0.0751
S-407	Patients with high sST2 treated with low-dose BB had the highest cardiovascular event rate (2.08 events) and the highest cumulative hazard.<unk>
T-407	patients sst2 cardiovascular_event
H-407	-1.124662160873413	▁s ST 2 ▁low - dos e _ bb ▁cardiovascular _ event
D-407	-1.124662160873413	sST2 low-dose_bb cardiovascular_event
P-407	-0.2123 -1.0326 -0.7708 -4.7084 -0.0054 -1.2271 -0.0785 -1.2080 -0.6920 -0.9783 -1.2445 -1.1249 -2.2475 -0.2150
S-690	For a median of 4.6 years of follow-up, 1385 of 3215 (43.1%) participants who experienced a HF hospitalization died.<unk>
T-690	follow-up hf hospitalization
H-690	-0.5604966282844543	▁ HF
D-690	-0.5604966282844543	HF
P-690	-0.3707 -0.1740 -1.6236 -0.0736
S-1985	The combination of exercise + diet was additive (complementary) for peak VO2 (joint effect, 2.5 mL/kg/min).<unk>
T-1985	combination exercise peak_vo2 joint
H-1985	-1.7937968969345093	▁exercise _ comp lement ary ▁pe ak _ vo 2
D-1985	-1.7937968969345093	exercise_complementary peak_vo2
P-1985	-6.0393 -4.9933 -3.7957 -0.0006 -0.1142 -3.1454 -0.0105 -0.4048 -0.4175 -0.2209 -2.1605 -0.2228
S-447	Our findings suggest that the benefits of spironolactone in clinical practice may be reduced compared with other guideline-recommended medications.<unk>
T-447	spironolactone clinical medications
H-447	-0.6297042369842529	▁spi rono lac tone
D-447	-0.6297042369842529	spironolactone
P-447	-1.7311 -0.0122 -0.0156 -0.0431 -1.8369 -0.1393
S-48	Limitations: Few trials have examined transfusions in patients with heart disease, and observational studies are potentially confounded by indication.<unk>
T-48	transfusions patients heart_disease
H-48	-0.5672312378883362	▁trans fusion s ▁heart ▁disease
D-48	-0.5672312378883362	transfusions heart disease
P-48	-0.7296 -0.0534 -0.1796 -2.2111 -0.5676 -0.1415 -0.0878
S-681	In this large cohort of older breast cancer patients, the rates of trastuzumb-related CHF are higher than those reported in clinical trials.<unk>
T-681	breast_cancer patients chf reported clinical
H-681	-0.8203505277633667	▁breast ▁cancer ▁patients ▁tras tuz um b - related ▁CHF
D-681	-0.8203505277633667	breast cancer patients trastuzumb-related CHF
P-681	-5.1098 -0.8787 -1.1122 -0.3512 -0.0142 -0.0250 -0.0136 -0.2707 -0.3583 -1.0903 -0.5538 -0.0663
S-779	Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction.<unk>
T-779	kansas_city_cardiomyopathy_questionnaire patients heart_failure reduced_ejection_fraction
H-779	-0.8963238000869751	▁Kansas ▁City _ car i om yo pathy _ ▁Question naire ▁heart ▁failure
D-779	-0.8963238000869751	Kansas City_cariomyopathy_ Questionnaire heart failure
P-779	-0.1197 -1.1193 -0.9009 -2.5947 -0.1406 -0.0125 -1.8841 -0.1691 -3.0011 -0.4245 -0.0011 -1.1854 -0.1435 -1.6328 -0.1158
S-479	Usefulness of tissue Doppler imaging for assessing left ventricular filling pressure in patients with stable severe systolic heart failure.<unk>
T-479	tissue_doppler left_ventricular_filling_pressure patients stable severe_systolic_heart_failure
H-479	-0.8625955581665039	▁tissu e ▁do pp ler _ ▁imagin g ▁left _ ▁vent ri cular _ ▁fill ing _ ▁pressure ▁sy sto lic _ heart ▁failure
D-479	-0.8625955581665039	tissue doppler_ imaging left_ ventricular_ filling_ pressure systolic_heart failure
P-479	-0.6401 -0.1116 -0.9047 -0.0043 -1.1669 -2.1834 -1.5609 -0.0993 -1.1529 -1.8024 -0.8132 -1.1016 -0.4619 -1.4326 -1.4587 -0.1383 -1.9262 -1.6073 -0.7527 -0.0271 -0.0674 -0.3328 -1.8908 -0.5130 -0.1604 -0.1168
S-273	A novel heart failure mice model of hypertensive heart disease by angiotensin II infusion, nephrectomy, and salt loading.<unk>
T-273	heart_failure hypertensive_heart_disease angiotensin_ii infusion nephrectomy salt_loading
H-273	-0.3674629330635071	▁heart ▁failure ▁mi ce ▁model ▁hyper tensi ve _ heart ▁disease ▁ang io ten sin _ ▁II ▁in fusion ▁nep hr ecto my ▁salt ▁load ing
D-273	-0.3674629330635071	heart failure mice model hypertensive_heart disease angiotensin_ II infusion nephrectomy salt loading
P-273	-1.0948 -0.0999 -1.1161 -0.0125 -0.4391 -0.0618 -0.1058 -0.1241 -0.1613 -2.3042 -1.1754 -0.0603 -0.1489 -0.0178 -0.2113 -0.9970 -1.1164 -0.0420 -0.0026 -0.0038 -0.0854 -0.1043 -0.2859 -0.0011 -0.1025 -0.0099 -0.2921 -0.1126
S-1218	CONCLUSIONS: PDE2 is markedly up-regulated in failing hearts and desensitizes against acute β-AR stimulation.<unk>
T-1218	pde2 hearts acute β-ar
H-1218	-0.6361754536628723	▁p de 2 ▁fail ing ▁heart s ▁desen siti zes ▁β - AR
D-1218	-0.6361754536628723	pde2 failing hearts desensitizes β-AR
P-1218	-0.8481 -0.2426 -0.0721 -1.0707 -0.0457 -1.0733 -0.0491 -2.1392 -0.0576 -0.4695 -1.8835 -0.0072 -0.2626 -1.1486 -0.1731
S-148	Remote monitoring (RM) strategies have the potential to deliver specialised care and management and may be one way to meet the growing needs of the heart failure population.<unk>
T-148	remote_monitoring rm heart_failure
H-148	-0.8539034724235535	▁remote _ monitor ing _ RM
D-148	-0.8539034724235535	remote_monitoring_RM
P-148	-1.3248 -0.5865 -0.1153 -0.7698 -1.5245 -0.2121 -2.2294 -0.0687
S-1470	This review summarizes the principles of pharmacologic treatment, the underlying clinical trials, and new pharmacologic targets.<unk>
T-1470	pharmacologic clinical pharmacologic
H-1470	-0.4526052176952362	▁ pharma c ologic
D-1470	-0.4526052176952362	pharmacologic
P-1470	-0.0983 -0.2343 -0.0292 -0.0500 -2.2326 -0.0713
S-646	The prevalence of chronic heart failure in Hungary is 1.6% in the adult population, but it occurs in 15-20% of subjects over 80 years of age.<unk>
T-646	prevalence chronic_heart_failure hungary
H-646	-1.684227466583252	▁chronic _ heart ▁failure ▁Hungary
D-646	-1.684227466583252	chronic_heart failure Hungary
P-646	-4.0077 -0.3571 -3.6231 -1.1489 -1.9076 -0.5697 -0.1756
S-397	A low eGFR, age <60 years, need of diuretics, and uncontrolled hypertension identify patients with an increased risk for ESRD.<unk>
T-397	egfr diuretics hypertension patients esrd
H-397	-0.40498268604278564	▁e G FR ▁di ure tics ▁un control led _ ▁hyper tension ▁ES RD
D-397	-0.40498268604278564	eGFR diuretics uncontrolled_ hypertension ESRD
P-397	-0.4838 -0.5036 -0.0154 -1.6954 -0.2507 -0.1078 -0.0375 -0.0033 -0.1177 -0.7464 -0.2766 -0.0483 -2.0290 -0.0373 -0.0328 -0.0941
S-1168	CONCLUSIONS: RV dysfunction and cardiac cachexia often coexist, have additive adverse impact, and might be mechanistically interrelated.<unk>
T-1168	rv_dysfunction cardiac_cachexia
H-1168	-0.30688217282295227	▁ RV ▁dys function ▁cardiac ▁cache xia
D-1168	-0.30688217282295227	RV dysfunction cardiac cachexia
P-1168	-0.3488 -0.3914 -0.4292 -0.0374 -0.0146 -0.3936 -0.0549 -0.9838 -0.1083
S-105	Time-dependent analysis was performed to identify the effect of IE on the risk for subsequent heart failure (HF) or death in CRT-D recipients.<unk>
T-105	heart_failure hf death crt-d
H-105	-1.2539606094360352	▁i ▁risk _ van _ heart ▁failure HF ▁c RT - D
D-105	-1.2539606094360352	i risk_van_heart failureHF cRT-D
P-105	-2.2229 -4.6676 -2.3975 -0.9888 -0.2968 -2.8014 -0.4387 -1.8475 -0.9001 -0.1095 -0.0318 -0.4617 -0.2519 -0.1392
S-1664	Because of its age-dependent increase in incidence and prevalence, heart failure is one of the leading causes of death and hospitalisation among the elderly.<unk>
T-1664	incidence prevalence heart_failure leading death hospitalisation
H-1664	-0.799422562122345	▁heart ▁failure
D-1664	-0.799422562122345	heart failure
P-1664	-1.1599 -0.6388 -1.3086 -0.0905
S-846	Mechanical dyssynchrony also occurs in patients with a narrow QRS complex, which suggests the potential usefulness of CRT in such patients.<unk>
T-846	patients narrow_qrs_complex crt patients
H-846	-0.42598506808280945	▁Mechanic al _ ▁dys syn chron y ▁n arrow ▁QR S ▁complex ▁c RT
D-846	-0.42598506808280945	Mechanical_ dyssynchrony narrow QRS complex cRT
P-846	-0.4789 -0.0063 -0.9614 -1.5563 -0.0017 -0.0005 -0.1500 -0.8378 -0.0002 -0.5953 -0.6142 -0.4077 -0.5190 -0.3408 -0.2083 -0.1373
S-34	The target audience for this guideline includes all clinicians, and the target patient population is anemic or iron-deficient adult patients with heart disease.<unk>
T-34	clinicians patient anemic patients heart_disease
H-34	-1.3340107202529907	▁a ne mic _ ▁ir on - d eficient _ adult _ ▁patients
D-34	-1.3340107202529907	anemic_ iron-deficient_adult_ patients
P-34	-6.6310 -0.0836 -0.3737 -1.6289 -2.4590 -0.0697 -0.0653 -0.0971 -0.2776 -0.5554 -1.0680 -1.9230 -1.2597 -3.3905 -0.1274
S-1561	The adjusted carotid intima-media thickness was 1.02±0.18 mm for psoriasis and 1.02±0.16 mm for reference subjects.<unk>
T-1561	carotid_intima-media_thickness psoriasis
H-1561	-0.5075637698173523	▁caro tid ▁intim a - media ▁thi ck ness ▁psoriasis
D-1561	-0.5075637698173523	carotid intima-media thickness psoriasis
P-1561	-0.5457 -0.0452 -1.0007 -0.0265 -0.0277 -0.0592 -2.1539 -0.0105 -1.9866 -0.0274 -0.0925 -0.1151
S-1565	Psoriasis patients with predominantly mild disease from the general population are as likely to develop atherosclerosis and cardiovascular events as subjects without psoriasis.<unk>
T-1565	psoriasis patients disease atherosclerosis cardiovascular_events psoriasis
H-1565	-1.0388903617858887	▁psoriasis
D-1565	-1.0388903617858887	psoriasis
P-1565	-0.4933 -2.4450 -0.1784
S-510	Complete coronary occlusion was necessary for significant collateral growth, which mostly had occurred already during the first wk after the stent occlusion.<unk>
T-510	coronary_occlusion collateral_growth stent
H-510	-0.49660027027130127	▁corona ry ▁oc clusi on ▁col lateral _ ▁growth
D-510	-0.49660027027130127	coronary occlusion collateral_ growth
P-510	-0.1590 -0.4521 -0.2031 -0.0081 -0.1164 -0.3593 -0.0003 -1.8768 -0.2041 -2.0297 -0.0536
S-1947	However, despite aggressive dose uptitration, many patients did not achieve this target as they had little HR reduction with beta-blocker therapy.<unk>
T-1947	uptitration patients hr_reduction beta-blocker therapy
H-1947	-1.4140963554382324	▁aggressiv e _ ▁dose ▁up tit ration
D-1947	-1.4140963554382324	aggressive_ dose uptitration
P-1947	-4.7908 -0.0281 -1.4606 -0.1231 -1.7134 -0.1166 -0.0590 -4.3508 -0.0845
S-678	Among trastuzumab users, the rate of CHF was 29.4% compared with 18.9% in nontrastuzumab users (P < .001).<unk>
T-678	trastuzumab chf nontrastuzumab_users
H-678	-0.9241059422492981	▁tras tuz um ab ▁CHF
D-678	-0.9241059422492981	trastuzumab CHF
P-678	-0.9560 -0.0429 -0.0209 -0.3454 -1.1789 -3.8333 -0.0913
S-1026	Point-of-care systems could be used to assess NP levels in the ED and community outpatient settings to monitor the risk of acute heart failure.<unk>
T-1026	point-of-care outpatient acute_heart_failure
H-1026	-0.8024047613143921	▁Point - of - care ▁systems ▁ NP
D-1026	-0.8024047613143921	Point-of-care systems NP
P-1026	-1.6689 -0.0447 -0.0067 -0.0268 -0.0315 -0.9987 -0.8965 -0.0514 -4.0742 -0.2248
S-129	Higher EO-CFUs were associated with reduced mortality (hazard ratio, 0.25; 95% confidence interval, 0.09-0.69).<unk>
T-129	eo-cfus mortality hazard_ratio confidence_interval
H-129	-0.8542323112487793	▁ EO - c FU s ▁reduc d _ ▁mortal ity haz ard ▁ratio
D-129	-0.8542323112487793	EO-cFUs reducd_ mortalityhazard ratio
P-129	-1.1676 -0.0263 -0.0172 -1.2181 -0.5176 -1.6271 -3.5890 -1.4008 -0.3794 -0.3594 -0.6084 -0.0659 -0.0019 -2.0525 -0.5267 -0.1099
S-1443	Compared with baseline, isoprenaline infusion increased SDQT in HNorm subjects (P = 0.02) but not in HF patients.<unk>
T-1443	baseline isoprenaline infusion sdqt hf patients
H-1443	-0.4311802387237549	▁iso pren a line ▁in fusion ▁SD QT ▁h Nor m ▁ HF
D-1443	-0.4311802387237549	isoprenaline infusion SDQT hNorm HF
P-1443	-0.0435 -0.0675 -0.1085 -0.0498 -2.1303 -0.0321 -0.0715 -0.3396 -1.8448 -0.5422 -0.0460 -0.6834 -0.0487 -0.3381 -0.1217
S-1150	However, the contributions of the four major HF remodeling aspects in extending EMD in the dyssynchronous failing heart remain unknown.<unk>
T-1150	hf remodeling emd dyssynchronous_failing_heart
H-1150	-0.7448395490646362	▁ HF ▁remodel ing ▁EM d ▁dys syn chron ous _ ▁fail ing ▁heart
D-1150	-0.7448395490646362	HF remodeling EMd dyssynchronous_ failing heart
P-1150	-0.1782 -0.0550 -2.7489 -0.0070 -3.6414 -1.0234 -0.0286 -0.0008 -0.0029 -1.0212 -0.8594 -0.0971 -0.0505 -2.0557 -0.0392 -0.1083
S-355	Consequently, surgery was not performed and aggressive medical treatment for HF and hypertension with vasodilators and diuretics was started.<unk>
T-355	surgery medical_treatment hf hypertension vasodilators diuretics
H-355	-0.4899599552154541	▁ HF ▁hyper tension ▁vaso dila tors ▁di ure tics
D-355	-0.4899599552154541	HF hypertension vasodilators diuretics
P-355	-1.7080 -0.1464 -2.7241 -0.1192 -0.1875 -0.0016 -0.1360 -0.2408 -0.4050 -0.0604 -0.1096 -0.0411
S-1466	Acute heart failure (AHF) is defined as the rapid onset of, or changes in, the symptoms and signs of heart failure (HF).<unk>
T-1466	acute_heart_failure ahf symptoms heart_failure hf
H-1466	-0.5440307259559631	▁a cute _ heart ▁failure ▁a HF
D-1466	-0.5440307259559631	acute_heart failure aHF
P-1466	-0.3864 -0.0499 -0.0947 -0.8745 -0.1716 -2.0780 -0.1818 -0.9988 -0.0607
S-1734	Major clinical trials designed to analyze clinical outcomes using an aldosterone antagonist have been done in two groups with heart failure.<unk>
T-1734	clinical clinical outcomes aldosterone_antagonist heart_failure
H-1734	-0.9312623143196106	▁al do ster one ▁anta gon ist
D-1734	-0.9312623143196106	aldosterone antagonist
P-1734	-2.0126 -0.1667 -0.0205 -0.1394 -1.5699 -0.0127 -0.2698 -4.1378 -0.0518
S-449	BACKGROUND: Impaired angiogenesis in the post-myocardial infarction heart contributes to the progression to heart failure.<unk>
T-449	angiogenesis post-myocardial_infarction heart heart_failure
H-449	-0.7422008514404297	▁ang io gene sis ▁post - my o card ial _ in far ction ▁heart
D-449	-0.7422008514404297	angiogenesis post-myocardial_infarction heart
P-449	-3.7911 -1.8269 -0.0412 -0.6860 -0.0446 -0.0230 -1.0453 -0.4990 -0.6218 -0.2120 -0.4989 -0.4200 -0.0558 -0.1818 -1.0748 -1.5152 -0.0801
S-520	Ea, total arterial compliance (TAC), and end-systolic elastance (Ees) were calculated at baseline and after 8 months of treatment.<unk>
T-520	ea total_arterial_compliance tac end-systolic_elastance ees baseline
H-520	-0.6121838688850403	▁arterial ▁compliance ▁ TAC ▁end - sy sto lic ▁elastan ce ▁e es
D-520	-0.6121838688850403	arterial compliance TAC end-systolic elastance ees
P-520	-2.3843 -0.7017 -1.4387 -0.0025 -2.4053 -0.0124 -0.0380 -0.0330 -0.0173 -1.1365 -0.1969 -0.5771 -0.0125 -0.1284 -0.0984
S-1098	Contemporary trends in heart failure with reduced and preserved ejection fraction after myocardial infarction: a community study.<unk>
T-1098	heart_failure preserved_ejection_fraction myocardial_infarction
H-1098	-0.6698088049888611	▁heart ▁failure ▁e je ction ▁ fraction ▁my o card ial _ in far ction
D-1098	-0.6698088049888611	heart failure ejection fraction myocardial_infarction
P-1098	-1.2644 -0.3222 -3.5343 -0.0249 -0.0114 -1.6482 -0.0006 -1.1547 -0.1818 -0.3293 -0.2482 -1.1879 -0.4385 -0.0232 -0.0582 -0.8732 -0.0856
S-978	Renal dysfunction was associated with all-cause mortality but not with cardiovascular events during the first 3 postoperative months after primary isolated CABG.<unk>
T-978	renal_dysfunction all-cause_mortality cardiovascular_events postoperative cabg
H-978	-0.92127925157547	▁Ren al ▁dys function ▁cardiovascular ▁events
D-978	-0.92127925157547	Renal dysfunction cardiovascular events
P-978	-0.9189 -0.0565 -1.4415 -0.0543 -0.4153 -2.5318 -1.8657 -0.0862
S-304	CONCLUSIONS: Biventricular support using a HeartMate II LVAD and CentriMag RVAD resulted in limited mortality at hospital discharge.<unk>
T-304	biventricular_support heartmate_ii lvad centrimag rvad mortality hospital discharge
H-304	-0.8585765361785889	▁Bi ven tri cular _ support ▁Heart Mate _ ▁II ▁l VAD ▁Centri Mag _ r VAD
D-304	-0.8585765361785889	Biventricular_support HeartMate_ II lVAD CentriMag_rVAD
P-304	-3.6319 -0.0673 -0.0853 -1.1374 -1.1847 -0.6816 -1.6856 -0.0328 -0.8317 -1.8026 -2.0731 -0.0168 -0.0464 -0.0600 -0.3322 -1.7501 -0.2009 -0.5493 -0.1433
S-1448	Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation.<unk>
T-1448	genetic congestive_heart_failure haematopoietic_cell_transplantation
H-1448	-0.3928941786289215	▁an thra cycli ne - related ▁con ges tive _ heart ▁failure ▁ha e mato po ie tic _ cell ▁transplant ation
D-1448	-0.3928941786289215	anthracycline-related congestive_heart failure haematopoietic_cell transplantation
P-1448	-0.1824 -0.0426 -0.1588 -0.1572 -0.6543 -0.5184 -1.0243 -0.0647 -1.0356 -0.1913 -1.0494 -0.1953 -0.0074 -0.1250 -0.0133 -0.1173 -0.1983 -0.7285 -0.5601 -2.1100 -0.0587 -0.0539 -0.1073 -0.0755
S-1181	A simple validated clinical tool to predict the absence of coronary artery disease in patients with systolic heart failure of unclear etiology.<unk>
T-1181	clinical coronary_artery_disease patients systolic_heart_failure etiology
H-1181	-0.32230836153030396	▁corona ry ▁arter y ▁disease ▁sy sto lic _ heart ▁failure ▁un clear ▁et i ology
D-1181	-0.32230836153030396	coronary artery disease systolic_heart failure unclear etiology
P-1181	-0.6991 -0.3675 -0.5983 -0.0932 -0.7697 -0.0098 -0.0071 -0.0323 -0.2024 -1.1947 -0.1621 -0.8507 -0.0146 -0.4010 -0.1741 -0.0961 -0.0621 -0.0666
S-1890	Other cardiovascular risk factors, such as diabetes mellitus, atrial fibrillation and coronary artery disease are prevalent in the HFpEF population.<unk>
T-1890	cardiovascular diabetes_mellitus atrial_fibrillation coronary_artery_disease hfpef
H-1890	-0.38385874032974243	▁diabetes ▁mell itus ▁at rial ▁fi bril lation ▁corona ry ▁arter y ▁disease ▁ HF p EF
D-1890	-0.38385874032974243	diabetes mellitus atrial fibrillation coronary artery disease HFpEF
P-1890	-1.9539 -0.0121 -0.0331 -0.3345 -0.0045 -0.6937 -0.0048 -0.0160 -0.0147 -0.4176 -0.4343 -0.5203 -2.0577 -0.2974 -0.0183 -0.0327 -0.0498 -0.2765 -0.1212
S-969	Renal dysfunction is related to long-term mortality and myocardial infarction after coronary artery bypass grafting (CABG).<unk>
T-969	renal_dysfunction mortality myocardial_infarction coronary_artery_bypass_grafting cabg
H-969	-0.6298463344573975	▁Ren al ▁dys function ▁my o card ial ▁in far ction ▁corona ry ▁arter y _ by pass ▁graf ting CA BG
D-969	-0.6298463344573975	Renal dysfunction myocardial infarction coronary artery_bypass graftingCABG
P-969	-0.5695 -0.0409 -1.4848 -0.0429 -4.3772 -0.0888 -0.0827 -0.0497 -1.0870 -0.0116 -0.0478 -0.2058 -0.3878 -0.3935 -0.5906 -1.6714 -1.9084 -0.0506 -0.0264 -0.3032 -1.3857 -0.0401 -0.1557 -0.1144
S-1953	Shunt implants were done after transseptal catheterisation with transoesophageal echocardiographic guidance under general anaesthesia.<unk>
T-1953	shunt implants transseptal_catheterisation transoesophageal_echocardiographic general_anaesthesia
H-1953	-0.4648079574108124	▁Shu nt ▁implant s ▁trans sept al _ ▁cat heter isation ▁trans o es op hage al ▁e cho car dio graphic
D-1953	-0.4648079574108124	Shunt implants transseptal_ catheterisation transoesophageal echocardiographic
P-1953	-0.0556 -0.0117 -0.9051 -0.0382 -0.0238 -0.0761 -0.3244 -1.3926 -0.3712 -0.0061 -0.0514 -0.0037 -1.6135 -0.2207 -0.0177 -0.1895 -0.1214 -0.9242 -0.0080 -0.0052 -0.4527 -1.7514 -2.4724 -0.1188
S-1995	OBJECTIVES: The aim of this single-arm, prospective, multicenter study was to evaluate the performance and safety of this LVAS.<unk>
T-1995	prospective lvas
H-1995	-1.0670323371887207	▁l VAS
D-1995	-1.0670323371887207	lVAS
P-1995	-3.8786 -0.2161 -0.0818 -0.0917
S-260	CONCLUSIONS: These results demonstrate that HDL function is impaired in CHF and that ET improved the HDL-mediated vascular effects.<unk>
T-260	hdl chf vascular
H-260	-0.6927064061164856	▁HD L ▁function ▁CHF ▁ET ▁HD L - media ted _ vas cular
D-260	-0.6927064061164856	HDL function CHF ET HDL-mediated_vascular
P-260	-1.4075 -0.8033 -1.0517 -0.1204 -1.3696 -1.5628 -0.8615 -0.0428 -0.0652 -0.0711 -0.1859 -0.7492 -0.0475 -1.9755 -0.0764
S-1774	Within men matched for the same number of HF risk factors, fit men had significantly lower HF mortality than unfit men (P≤0.02).<unk>
T-1774	hf hf mortality
H-1774	-0.8465075492858887	▁ HF _ risk ▁factors ▁fit _ men ▁ HF _ ▁mortal ity ▁un fit _ ▁men
D-1774	-0.8465075492858887	HF_risk factors fit_men HF_ mortality unfit_ men
P-1774	-0.2211 -0.0367 -2.4696 -1.2870 -0.5349 -1.5752 -1.4279 -1.6425 -1.1547 -0.1219 -1.1945 -0.2984 -0.9982 -0.3455 -0.0114 -1.6514 -0.7954 -0.1969 -0.1205
S-1853	Discussion and dissemination In this review, we will assess the impact of implementation strategies and contextual factors on physician adherence to HF CPGs.<unk>
T-1853	physician hf cpgs
H-1853	-1.0692245960235596	▁ HF ▁c PG s
D-1853	-1.0692245960235596	HF cPGs
P-1853	-2.4987 -1.3751 -2.9689 -0.0331 -0.1926 -0.1020 -0.3141
S-522	RESULTS: At baseline Ea, TAC, HR, and Ees did not differ significantly between ivabradine- and placebo-treated patients.<unk>
T-522	baseline ea tac ees patients
H-522	-0.7061024308204651	▁e es ▁i va bra dine - ▁place bo - tre ated
D-522	-0.7061024308204651	ees ivabradine- placebo-treated
P-522	-4.1772 -0.1637 -0.2006 -0.0277 -0.0490 -0.0137 -1.0218 -3.3429 -0.0030 -0.0165 -0.0038 -0.1684 -0.5991 -0.0980
S-1256	These initial results warrant further rigorous investigation, since the use of ERC (or pure epicatechin) may represent a safe and novel means of improving muscle function.<unk>
T-1256	warrant erc epicatechin muscle
H-1256	-0.5547257661819458	▁ ERC ▁pure _ ▁epi cate chin
D-1256	-0.5547257661819458	ERC pure_ epicatechin
P-1256	-0.2932 -0.0259 -1.1540 -0.5830 -1.2118 -0.0025 -0.0431 -1.5756 -0.1034
S-736	METHODS AND RESULTS: Patients with suspected HFPEF (n=100) were enrolled in this prospective, observational study.<unk>
T-736	patients hfpef prospective
H-736	-1.1498711109161377	▁H FP EF
D-736	-1.1498711109161377	HFPEF
P-736	-5.0174 -0.1735 -0.2522 -0.2133 -0.0929
S-1628	CONCLUSION: Care management coupled with content-driven telehealth technology has potential to improve health outcomes in high-cost Medicare beneficiaries.<unk>
T-1628	telehealth health outcomes medicare
H-1628	-1.4634325504302979	▁Care ▁management ▁content - driv en ▁tele health ▁technologie
D-1628	-1.4634325504302979	Care management content-driven telehealth technologie
P-1628	-5.2834 -0.4284 -2.4998 -0.0074 -0.0097 -0.0123 -3.0369 -0.2707 -2.5294 -1.9522 -0.0675
S-78	The dopamine (n = 122) and nesiritide (n = 119) groups were independently compared with the pooled placebo group (n = 119).<unk>
T-78	dopamine nesiritide placebo
H-78	-0.4357055425643921	▁dop amine ▁nesi riti de
D-78	-0.4357055425643921	dopamine nesiritide
P-78	-0.0081 -0.0110 -0.1410 -0.0005 -0.0129 -2.8118 -0.0647
S-1127	Clinician interviews identified twice as many reasons for nonprescribing as chart review (mean 1.6 vs. 0.8 reasons per patient, P<0.001).<unk>
T-1127	clinician nonprescribing patient
H-1127	-0.8861211538314819	▁non pre scribi ng ▁chart ▁review
D-1127	-0.8861211538314819	nonprescribing chart review
P-1127	-5.5960 -0.0620 -0.0326 -0.0151 -0.6740 -0.3883 -0.2076 -0.1134
S-1128	In these interviews, biomedical reasons for nonprescribing were cited in 50%-70% of patients, and contextual reasons in 64%-70%.<unk>
T-1128	biomedical nonprescribing patients
H-1128	-0.6979845762252808	▁bio medic al ▁reasons ▁non pre scribi ng
D-1128	-0.6979845762252808	biomedical reasons nonprescribing
P-1128	-0.0164 -0.0148 -0.0033 -2.5768 -2.6839 -0.0572 -0.0604 -0.0544 -1.4134 -0.0993
S-1639	The hazard associated with black race was largely caused by increased HF hospitalization (HR 1.58, 95% CI 1.27-1.96), given similar cardiovascular mortality.<unk>
T-1639	hf hospitalization cardiovascular_mortality
H-1639	-0.5857332348823547	▁black _ ▁race ▁ HF _ hospital ization ▁cardiovascular ▁mortal ity
D-1639	-0.5857332348823547	black_ race HF_hospitalization cardiovascular mortality
P-1639	-0.0440 -0.9703 -0.7375 -0.5039 -0.0237 -2.5155 -0.2017 -0.4722 -1.0252 -0.3984 -0.4976 -0.0802 -0.1442
S-1393	Improvement in eGFR in the VAD group and the ECMO+VAD group was much higher than in the ECMO group in the first 7 days.<unk>
T-1393	egfr vad ecmo vad ecmo
H-1393	-0.8865562081336975	▁e G FR ▁ VAD _ groep ▁EC MO _ groep
D-1393	-0.8865562081336975	eGFR VAD_groep ECMO_groep
P-1393	-0.1255 -1.0163 -0.1420 -0.7128 -0.1645 -2.6582 -1.0220 -0.2423 -1.4774 -1.3516 -2.2977 -0.1433 -0.1718
S-41	Data Sources: MEDLINE, EMBASE, and Cochrane databases; clinical trial registries; reference lists; and technical advisors.<unk>
T-41	medline embase cochrane clinical
H-41	-0.5263603925704956	▁MED line ▁ EMBA se ▁co ch rane _ ▁database s ▁clinic al _ ▁trial ▁registri es
D-41	-0.5263603925704956	MEDline EMBAse cochrane_ databases clinical_ trial registries
P-41	-0.3904 -1.1772 -0.2237 -0.0009 -0.9133 -0.5587 -0.0358 -0.0090 -1.0332 -0.4828 -0.2356 -0.1952 -0.0285 -0.1258 -2.3643 -0.2300 -0.0186 -1.8440 -0.1339
S-1764	CONCLUSIONS: The inability to identify AT most often occurs in patients with severe HF, and it has an independent prognostic role in HF.<unk>
T-1764	patients severe_hf prognostic hf
H-1764	-0.5482768416404724	▁ HF
D-1764	-0.5482768416404724	HF
P-1764	-1.1162 -0.3132 -0.6309 -0.1329
S-1142	Pyridostigmine also increased vascular endothelial growth factor protein in the left ventricle, suggesting myocardial angiogenesis.<unk>
T-1142	pyridostigmine vascular_endothelial_growth_factor protein left_ventricle myocardial_angiogenesis
H-1142	-0.7017669081687927	▁Pyr ido stig mine ▁vas cular ▁en dot heli al _ ▁growth ▁factor ▁protein ▁left ▁vent ric le ▁my o card ial _ ang io gene sis
D-1142	-0.7017669081687927	Pyridostigmine vascular endothelial_ growth factor protein left ventricle myocardial_angiogenesis
P-1142	-0.0351 -0.0051 -0.0001 -0.0502 -0.2484 -0.0549 -0.4934 -0.9158 -0.0160 -0.0314 -1.3004 -1.0010 -0.4707 -2.4024 -1.4263 -0.4189 -0.9852 -0.7115 -0.6805 -0.1082 -0.3647 -0.4377 -0.6654 -4.7323 -2.1306 -0.0689 -0.2525 -0.2403 -0.1034
S-1775	CONCLUSIONS: Higher baseline CRF is associated with lower HF mortality risk in men, regardless of the number of HF risk factors present.<unk>
T-1775	baseline crf hf mortality hf
H-1775	-0.8808936476707458	▁base line _ c RF ▁ HF _ ▁mortal ity
D-1775	-0.8808936476707458	baseline_cRF HF_ mortality
P-1775	-3.1934 -0.0162 -0.6072 -0.9130 -0.2408 -0.2666 -0.3461 -1.7255 -0.1741 -0.2319 -2.7985 -0.0573
S-1904	Recent studies have demonstrated that even lower volumes of exercise below these recommendations confer health benefits, which is highly relevant to individuals with established cardiac disease including heart failure.<unk>
T-1904	exercise health cardiac_disease heart_failure
H-1904	-1.995181918144226	
D-1904	-1.995181918144226	
P-1904	-3.9561 -0.0342
S-1921	CONCLUSIONS: Robot-assisted gait therapy with the Lokomat® System is feasible in heart failure patients and was safe in this trial.<unk>
T-1921	gait therapy lokomat heart_failure patients
H-1921	-0.5148256421089172	▁Robot - assist ed _ ▁ga it ▁ therapy ▁Lok omat _ system ▁heart ▁failure
D-1921	-0.5148256421089172	Robot-assisted_ gait therapy Lokomat_system heart failure
P-1921	-0.8281 -0.0664 -0.0096 -0.0860 -0.4627 -1.0345 -0.0960 -0.4004 -0.0067 -0.0981 -0.0282 -1.8575 -1.0830 -1.5438 -0.1268 -0.9298 -0.0945
S-769	The latter occurred specifically at the S3991 site of the elastic N2Bus segment and at the S12884 site of the PEVK segment.<unk>
T-769	s3991 n2bus s12884 pevk
H-769	-0.6909705400466919	▁elastic _ n 2 bu s ▁segment ▁PE v k
D-769	-0.6909705400466919	elastic_n2bus segment PEvk
P-769	-0.9077 -0.4654 -2.0711 -0.1656 -0.4802 -0.5926 -1.1772 -0.2129 -0.7367 -1.0849 -0.1843 -0.2133
S-92	The present study tests the fundamental hypothesis that cardiac growth and plasticity in the setting of disease recapitulates conserved developmental chromatin remodeling events.<unk>
T-92	tests cardiac_growth disease chromatin remodeling
H-92	-0.506381094455719	▁cardiac _ ▁growth ▁plastic ity ▁disease ▁recap it ulat es ▁chr omat in ▁remodel ing
D-92	-0.506381094455719	cardiac_ growth plasticity disease recapitulates chromatin remodeling
P-92	-0.2399 -1.7525 -0.8528 -1.8837 -0.5130 -0.5993 -0.0019 -0.0136 -0.0007 -0.1996 -0.8616 -0.0124 -0.3440 -0.0531 -0.0174 -1.2182 -0.0448
S-1433	Therefore, failing myocardium displays altered expression and post-translational modification of PKA subunits that may impact downstream signaling.<unk>
T-1433	myocardium expression pka downstream_signaling
H-1433	-0.5792703032493591	▁my o car dium ▁display s ▁post - trans la tional _ ▁modification ▁p ka
D-1433	-0.5792703032493591	myocardium displays post-translational_ modification pka
P-1433	-0.8960 -0.0559 -0.0014 -0.0262 -0.4859 -0.0902 -1.5709 -0.0032 -0.0010 -0.1546 -0.0005 -1.2655 -1.0787 -1.4821 -0.7326 -1.8195 -0.1834
S-416	METHODS AND RESULTS: CXL-1020 converts solely to HNO and inactive CXL-1051 with a t1/2 of 2 minutes.<unk>
T-416	cxl-1020 hno cxl-1051 t1
H-416	-0.5538055896759033	▁c XL -10 20 ▁h no ▁in active ▁c XL -10 51
D-416	-0.5538055896759033	cXL-1020 hno inactive cXL-1051
P-416	-1.0631 -0.1362 -0.2691 -0.0908 -3.1875 -0.4645 -0.1969 -0.2445 -1.1804 -0.0914 -0.4042 -0.1645 -0.1653 -0.0950
S-93	We used quantitative proteomics to identify chromatin-associated proteins extracted via detergent and to quantify changes in their abundance during disease.<unk>
T-93	proteomics chromatin-associated_proteins disease
H-93	-0.3352321982383728	▁quantitat ive _ prote o mics ▁chr omat in - as soci ated _ ▁protein s ▁detergent
D-93	-0.3352321982383728	quantitative_proteomics chromatin-associated_ proteins detergent
P-93	-0.2340 -0.0399 -0.7140 -1.0407 -0.6293 -0.0008 -0.1612 -0.0163 -0.4866 -0.0601 -0.0068 -0.0002 -0.2370 -0.4938 -0.4445 -0.0328 -0.6755 -0.9763 -0.1196
S-213	OBJECTIVE: PROTOCOL: We classified patients as having CHF based on International Classification of Diseases, Ninth Revision, codes.<unk>
T-213	patients chf international_classification_of_diseases
H-213	-0.6423949003219604	▁CHF ▁international ▁Classifica tion _ of _ ▁Disease s ▁Nin th _ re vision ▁code s
D-213	-0.6423949003219604	CHF international Classification_of_ Diseases Ninth_revision codes
P-213	-1.0714 -5.9826 -0.7431 -0.0222 -0.3739 -0.8112 -0.6460 -0.0445 -0.0052 -0.0521 -0.0147 -0.2684 -1.2191 -0.0161 -0.0940 -0.0261 -0.0797 -0.0928
S-1742	We thus examined changes in prognosis of a large idiopathic dilated cardiomyopathy cohort systematically followed during the past 30 years.<unk>
T-1742	prognosis idiopathic_dilated_cardiomyopathy
H-1742	-0.423250287771225	▁ idio pathi c _ ▁dil ated _ ▁cardio my o pathy
D-1742	-0.423250287771225	idiopathic_ dilated_ cardiomyopathy
P-1742	-0.9384 -0.0579 -0.0273 -0.0567 -0.6190 -0.8230 -0.2050 -0.0587 -0.2867 -1.4343 -0.2608 -0.0573 -1.0112 -0.0890
S-867	Inappropriate therapy due to atrial fibrillation was associated with a 50% lower rate in patients receiving carvedilol compared with those receiving metoprolol.<unk>
T-867	therapy atrial_fibrillation patients carvedilol metoprolol
H-867	-0.5450168251991272	▁at rial _ fi bril lation ▁car vedi lol ▁met o pro lol
D-867	-0.5450168251991272	atrial_fibrillation carvedilol metoprolol
P-867	-5.3760 -0.0413 -0.9465 -0.7279 -0.0145 -0.0257 -0.1698 -0.0090 -0.0091 -0.4549 -0.1718 -0.0033 -0.0105 -0.1409 -0.0740
S-1163	RESULTS: Subjects with RV dysfunction (51%) had lower body mass index, lower fat mass index, and were more likely to display cachexia (19%).<unk>
T-1163	rv_dysfunction body_mass_index fat_mass cachexia
H-1163	-0.561867892742157	▁ RV _ ▁dys function ▁lower _ ▁body ▁mass ▁index _ index ▁cache xia
D-1163	-0.561867892742157	RV_ dysfunction lower_ body mass index_index cachexia
P-1163	-0.1145 -0.2018 -2.0896 -0.2890 -0.0486 -1.0615 -0.1584 -0.9649 -0.3948 -0.0198 -2.4822 -0.2301 -0.7300 -0.0292 -0.0802 -0.0953
S-300	RESULTS: A total of 139 patients required HeartMate II insertion; 34 (24%) required biventricular support at the time of HeartMate II implantation.<unk>
T-300	patients heartmate_ii biventricular_support heartmate_ii implantation
H-300	-1.0639530420303345	▁Heart Mate ▁II ▁ insertion
D-300	-1.0639530420303345	HeartMate II insertion
P-300	-1.8105 -0.0863 -1.7740 -1.4085 -0.0098 -2.2242 -0.1344
S-1016	As a result, pharmacologic management for acute HF has changed little in recent years, and adverse event rates remain higher than in chronic HF.<unk>
T-1016	pharmacologic acute_hf adverse_event chronic_hf
H-1016	-0.4374781847000122	▁ pharma c ologic ▁management ▁a cute _ HF ▁advers e _ event ▁rates ▁chronic _ HF
D-1016	-0.4374781847000122	pharmacologic management acute_HF adverse_event rates chronic_HF
P-1016	-0.2319 -0.1622 -0.0123 -0.0510 -2.0502 -0.2935 -0.0050 -0.2781 -0.1195 -1.1035 -0.0101 -0.2239 -2.1122 -0.3930 -0.2329 -0.9282 -0.0177 -0.0438 -0.0432
S-611	CONCLUSIONS: TNF antagonists were not associated with a risk of HF hospital admissions compared with nbDMARDs in this RA population.<unk>
T-611	tnf_antagonists hf hospital admissions nbdmards ra
H-611	-0.4315834939479828	▁t NF ▁anta gon ists ▁ HF ▁hospital ▁ad missions ▁n b DM ARD s ▁RA
D-611	-0.4315834939479828	tNF antagonists HF hospital admissions nbDMARDs RA
P-611	-1.4395 -0.0197 -0.3154 -0.0249 -0.3755 -0.7260 -0.1129 -3.5788 -0.1006 -0.2959 -0.0084 -0.0072 -0.0240 -0.0086 -0.0864 -0.4136 -0.1502 -0.0810
S-954	Nicorandil ameliorates mitochondrial dysfunction in doxorubicin-induced heart failure in rats: possible mechanism of cardioprotection.<unk>
T-954	nicorandil mitochondrial_dysfunction heart_failure cardioprotection
H-954	-0.26367297768592834	▁Nico rand il ▁mito cho ndri al ▁dys function ▁do xor ubi cin - indu ced _ heart ▁failure ▁rat s ▁cardio protec tion
D-954	-0.26367297768592834	Nicorandil mitochondrial dysfunction doxorubicin-induced_heart failure rats cardioprotection
P-954	-0.0128 -0.0141 -0.1877 -0.0169 -0.2645 -0.1131 -0.0201 -0.4722 -0.0207 -0.0238 -0.0019 -0.0046 -0.2667 -0.0784 -0.0242 -0.5423 -0.1998 -1.0998 -0.5743 -1.8858 -0.0161 -0.3195 -0.3445 -0.1012 -0.1709 -0.0796
S-367	This patient showed that functional MS could develop even in a patient with successful valve plasty for degenerative MR, if the LV is dilated by another disease.<unk>
T-367	patient functional_ms patient valve_plasty degenerative_mr dilated disease
H-367	-0.4415507912635803	▁functional ▁MS ▁val ve ▁plast y ▁de genera tive ▁MR ▁LV
D-367	-0.4415507912635803	functional MS valve plasty degenerative MR LV
P-367	-0.0327 -0.0775 -1.5450 -0.0038 -0.3198 -0.1026 -0.0856 -0.0001 -0.0797 -2.6727 -0.4025 -0.3777 -0.0406
S-1105	Changes in patient presentation were noted, including fewer ST-segment-elevation MIs, lower Killip class, and more comorbid conditions.<unk>
T-1105	patient st-segment-elevation_mis killip_class comorbid conditions
H-1105	-0.6026264429092407	▁ST - seg ment - elevat ion ▁MI s ▁Kill ip ▁class
D-1105	-0.6026264429092407	ST-segment-elevation MIs Killip class
P-1105	-5.2200 -0.0375 -0.0009 -0.0306 -0.0093 -0.0012 -0.0170 -1.4437 -0.0123 -0.9168 -0.0140 -0.5606 -0.0799 -0.0929
S-1993	BACKGROUND: The HeartMate 3 left ventricular assist system (LVAS) is intended to provide long-term support to patients with advanced heart failure.<unk>
T-1993	heartmate left_ventricular_assist_system lvas patients heart_failure
H-1993	-0.7113950252532959	▁Heart Mate ▁left _ ▁vent ri cular _ assist ▁system ▁l VAS
D-1993	-0.7113950252532959	HeartMate left_ ventricular_assist system lVAS
P-1993	-0.2856 -0.1956 -3.4151 -0.3835 -0.5076 -0.5604 -0.5034 -0.4511 -0.3348 -1.2628 -0.3482 -0.0353 -1.5771 -0.0989
S-1860	DESIGN: Grounded theory was used to collect and analyze interview data from 25 heart failure patients with an implantable cardioverter-defibrillator.<unk>
T-1860	collect heart_failure patients implantable_cardioverter-defibrillator
H-1860	-2.344754934310913	
D-1860	-2.344754934310913	
P-1860	-4.6378 -0.0517
S-17	The latter correlated inversely to baseline NT-proBNP, MR-proANP, and MR-proADM (p<0.05).<unk>
T-17	correlated baseline nt-probnp mr-proanp mr-proadm
H-17	-0.457543283700943	▁NT - pro b NP ▁MR - pro AN P ▁MR - pro AD m
D-17	-0.457543283700943	NT-probNP MR-proANP MR-proADm
P-17	-2.5156 -0.0277 -0.0104 -0.9509 -0.0416 -0.0170 -0.0121 -0.0144 -0.4573 -1.4795 -0.0303 -0.0092 -0.0484 -1.0861 -0.9080 -0.0456 -0.1243
S-517	BACKGROUND: The effective arterial elastance (Ea) represents resistive and pulsatile afterload of the heart derived from the pressure volume relation.<unk>
T-517	arterial_elastance ea pulsatile_afterload heart pressure_volume_relation
H-517	-0.999613881111145	▁arterial ▁elastan ce ▁pulsa tile _ ▁after load _ van _ the _ heart ▁pressure ▁volume
D-517	-0.999613881111145	arterial elastance pulsatile_ afterload_van_the_heart pressure volume
P-517	-0.7980 -1.4151 -0.2787 -1.9875 -0.0045 -0.2113 -4.3456 -0.0034 -1.9148 -1.9350 -0.1549 -2.1747 -0.3843 -0.9737 -0.0898 -0.4124 -0.8558 -0.0535
S-1099	Major changes have recently occurred in the epidemiology of myocardial infarction (MI) that could possibly affect outcomes such as heart failure (HF).<unk>
T-1099	epidemiology myocardial_infarction mi outcomes heart_failure hf
H-1099	-0.6534547805786133	▁epidemi ology ▁my o card ial _ in far ction MI ▁heart ▁failure HF
D-1099	-0.6534547805786133	epidemiology myocardial_infarctionMI heart failureHF
P-1099	-1.0992 -0.4810 -0.9164 -0.1274 -0.3210 -0.1083 -0.5279 -0.4314 -0.0224 -0.0502 -4.2038 -1.1154 -0.1968 -0.7486 -0.0643 -0.0411
S-585	Other prognostic factors at admission were higher serum levels of brain natriuretic peptide (BNP) and creatinine and lower natremia.<unk>
T-585	prognostic admission brain_natriuretic_peptide bnp creatinine natremia
H-585	-0.7096604108810425	▁na tri ure tic _ pe pti de ▁creati nine ▁na trem ia
D-585	-0.7096604108810425	natriuretic_peptide creatinine natremia
P-585	-5.7078 -0.0326 -0.1805 -1.3146 -0.3902 -0.2017 -0.0429 -0.1287 -0.6124 -0.0531 -0.5431 -0.0086 -1.2473 -0.1013 -0.0798
S-1663	Management of end stage heart failure Heart failure is a major public health problem, with a patient population of at least 10 million in Europe and approximately 5 million in North America.<unk>
T-1663	end_stage_heart_failure heart_failure public health patient europe north_america
H-1663	-1.7077062129974365	▁management _ de _ de _ de _ de _ de _ de _ de _ de _ heart _ ▁failure
D-1663	-1.7077062129974365	management_de_de_de_de_de_de_de_de_heart_ failure
P-1663	-5.0432 -1.6610 -2.3751 -0.1166 -3.5149 -0.0570 -3.5484 -0.0493 -3.2937 -0.0495 -3.0528 -0.0477 -2.7624 -0.0461 -2.6318 -0.0467 -2.4378 -0.0444 -3.9173 -1.1035 -0.2203 -3.1336 -0.1242
S-1597	Even though the majority of patients with RAS are asymptomatic, it can clinically present with hypertension, nephropathy and congestive heart failure.<unk>
T-1597	patients ras asymptomatic clinically hypertension nephropathy congestive_heart_failure
H-1597	-0.2797471284866333	▁ RAS ▁hyper tension ▁nep hro pathy ▁con ges tive _ heart ▁failure
D-1597	-0.2797471284866333	RAS hypertension nephropathy congestive_heart failure
P-1597	-0.9216 -0.0066 -1.0568 -0.0463 -0.1048 -0.0044 -0.0378 -0.0151 -0.0444 -0.5819 -0.1593 -0.9843 -0.0929 -0.0602 -0.0796
S-1430	Isoelectric focusing of RIα demonstrated up to three variants, consistent with reports that Ser77 and Ser83 are in vivo phosphorylation sites.<unk>
T-1430	isoelectric_focusing riα ser77 ser83 in_vivo phosphorylation
H-1430	-0.6495685577392578	▁iso electric _ ▁focus ing ▁RI α ▁ser 77 ▁ser 83 ▁vivo _ phos phor y lation ▁sites
D-1430	-0.6495685577392578	isoelectric_ focusing RIα ser77 ser83 vivo_phosphorylation sites
P-1430	-0.9726 -0.2685 -1.6269 -0.1087 -0.0251 -0.5370 -0.0474 -1.2374 -0.6525 -1.3967 -1.3273 -0.3646 -0.9648 -0.0077 -0.3704 -1.0781 -0.1818 -1.5991 -0.1366 -0.0882
S-1504	The Self-Care of Heart Failure Index Version 6.2 (SCHFI v.6.2) is widely used, but its psychometric profile is still questioned.<unk>
T-1504	self-care_of_heart_failure_index_version_6.2 schfi_v.6.2 psychometric
H-1504	-0.5380993485450745	▁Self - car e _ of _ heart _ ▁Fail ure _ index ▁ SCH FI ▁psycho metric ▁profile
D-1504	-0.5380993485450745	Self-care_of_heart_ Failure_index SCHFI psychometric profile
P-1504	-0.1500 -0.0339 -1.1596 -0.2619 -0.1644 -0.6520 -0.2499 -0.9428 -0.7648 -0.5413 -1.1817 -1.3091 -0.2637 -2.2334 -0.1095 -0.7558 -0.0678 -0.0071 -0.3132 -0.0813 -0.0570
S-1440	The ratio of the SDQT to SD of RR intervals (SDRR) was calculated as an index of QTV normalized to heart rate variability.<unk>
T-1440	sdqt sd_of_rr_intervals sdrr qtv heart_rate_variability
H-1440	-0.8551373481750488	▁SD QT ▁ RR _ ▁interval s SD RR ▁Q TV ▁heart ▁rate ▁variabil ity
D-1440	-0.8551373481750488	SDQT RR_ intervalsSDRR QTV heart rate variability
P-1440	-0.0555 -0.0789 -3.7960 -0.9119 -2.0085 -0.0626 -0.0076 -3.5619 -0.5249 -0.6090 -0.1238 -1.4329 -0.3976 -0.2266 -0.3139 -0.0958 -0.3302
S-1935	Heart rate reduction and exercise performance in recent onset heart failure with reduced ejection fraction: arguments for beta-blocker hypo-response.<unk>
T-1935	heart_rate_reduction exercise heart_failure_with_reduced_ejection_fraction beta-blocker
H-1935	-0.8787333965301514	▁Heart ▁rate ▁re duction ▁exercise ▁performance ▁heart ▁failure ▁e je ction ▁ fraction ▁beta - block er
D-1935	-0.8787333965301514	Heart rate reduction exercise performance heart failure ejection fraction beta-blocker
P-1935	-0.7745 -1.3401 -0.4927 -0.0809 -2.4504 -0.1548 -4.1998 -0.2757 -1.9010 -0.0148 -0.0089 -1.2767 -0.0005 -0.2760 -0.0158 -0.0341 -0.0440 -3.2179 -0.1372
S-1818	Future of advanced heart failure and mechanical support devices: A Cardiology-Cardiovascular Surgery Consensus Report Heart failure is a progressive disease.<unk>
T-1818	heart_failure cardiology-cardiovascular_surgery_consensus_report heart_failure disease
H-1818	-0.6532468795776367	▁advanced _ heart ▁failure ▁mechanic al _ support ▁devices ▁Card i ology - car dio vas cular _ Sur ger y ▁Cons en sus _ report ▁Heart ▁failure
D-1818	-0.6532468795776367	advanced_heart failure mechanical_support devices Cardiology-cardiovascular_Surgery Consensus_report Heart failure
P-1818	-3.7967 -0.9719 -0.8056 -0.4655 -0.7792 -0.0068 -0.1689 -0.4192 -0.2897 -0.4070 -0.0915 -0.1714 -0.3159 -0.5160 -1.0405 -0.2267 -0.1497 -0.1661 -1.2827 -1.2104 -0.1969 -1.3709 -0.0039 -0.0462 -0.7868 -1.8840 -0.6682 -0.3811 -0.9026 -0.0752
S-1271	Newly diagnosed patients with HF under drug treatment have an affected profile of PAF biosynthetic enzymes and especially lyso-PAF-AT.<unk>
T-1271	diagnosed patients hf drug_treatment paf biosynthetic_enzymes lyso-paf-at
H-1271	-0.4752262830734253	▁ HF ▁bio syn the tic ▁enzym es ▁lys o - PA F - AT
D-1271	-0.4752262830734253	HF biosynthetic enzymes lyso-PAF-AT
P-1271	-0.2994 -0.0124 -4.0360 -0.0076 -0.1831 -0.3345 -1.0933 -0.0401 -0.0017 -0.0375 -0.0123 -0.8168 -0.5956 -0.1046 -0.0645 -0.2934 -0.1460
S-1842	We will conduct a systematic review to identify implementation strategies that improve physician adherence to class I recommendations, those with clear evidence that benefits outweigh the risks.<unk>
T-1842	physician evidence
H-1842	-0.9380875825881958	▁physician ▁ad her ence
D-1842	-0.9380875825881958	physician adherence
P-1842	-3.0846 -0.0282 -0.2257 -0.4748 -1.7287 -0.0865
S-87	Utilizing voluntary testimonies and conversations with participating nurses, the benefits of involvement in a multisite study extend beyond meeting Magnet(®) research requirements.<unk>
T-87	nurses magnet
H-87	-1.6949143409729004	
D-87	-1.6949143409729004	
P-87	-3.3179 -0.0719
S-1981	RESULTS: Of the 100 enrolled participants, 26 participants were randomized to exercise; 24 to diet; 25 to exercise + diet; 25 to control.<unk>
T-1981	randomized exercise exercise
H-1981	-1.3109591007232666	
D-1981	-1.3109591007232666	
P-1981	-2.5702 -0.0517
S-1695	We then estimated the odds of future (July to December 2009) 30-day, risk-adjusted mortality at the worst versus best quintile of hospitals.<unk>
T-1695	mortality hospitals
H-1695	-0.653139054775238	▁risk - ad just ed _ ▁mortal ity ▁best ▁quin tile
D-1695	-0.653139054775238	risk-adjusted_ mortality best quintile
P-1695	-3.9365 -0.0370 -0.0038 -0.0200 -0.0415 -0.2217 -0.1730 -0.4770 -0.8751 -0.4997 -0.0011 -2.0564 -0.1481
S-1236	RESULTS: In all, 304 patients were included, aged 68 ± 9 years; 86% male; ejection fraction, 26% ± 6%.<unk>
T-1236	patients ejection_fraction
H-1236	-0.55744469165802	▁e je ction ▁ fraction
D-1236	-0.55744469165802	ejection fraction
P-1236	-2.2609 -0.0764 -0.0272 -1.0493 -0.0017 -0.3274 -0.1592
S-1314	CONCLUSIONS: Despite encouraging declines in the incidence of HF complicating AMI, it remains a common problem with high mortality.<unk>
T-1314	incidence hf ami mortality
H-1314	-0.44654542207717896	▁ HF ▁complicat ing ▁ AMI
D-1314	-0.44654542207717896	HF complicating AMI
P-1314	-0.4070 -0.0714 -1.6646 -0.0346 -0.2619 -0.0145 -1.0669 -0.0515
S-1731	CONCLUSIONS: Physician volume is associated with lower mortality for HF, particularly in low-volume institutions and among noncardiologist physicians.<unk>
T-1731	physician mortality hf physicians
H-1731	-0.95641028881073	▁Physic ian ▁volume ▁ HF
D-1731	-0.95641028881073	Physician volume HF
P-1731	-1.9372 -0.2476 -0.3488 -1.2858 -0.0700 -2.7575 -0.0479
S-406	Those with low sST2/low-dose BB, or high sST2/high-dose BB had intermediate outcomes (0.92 and 1.19 events).<unk>
T-406	sst2 sst2 outcomes
H-406	-0.6545107960700989	▁s ST 2/ low - dos e ▁BB ▁s ST 2/ high - dos e ▁BB
D-406	-0.6545107960700989	sST2/low-dose BB sST2/high-dose BB
P-406	-0.2335 -0.8797 -0.7562 -0.8970 -0.0135 -1.3209 -0.0767 -0.4070 -0.6169 -0.7551 -0.5668 -1.1879 -0.0234 -0.8696 -0.0673 -2.8127 -0.1420 -0.1552
S-817	Multivariate analysis showed worsening GLS (HR 1.121; 95% CI 1.023 to 1.228, p=0.014) was independently associated with increased CV events.<unk>
T-817	multivariate_analysis gls
H-817	-1.2810417413711548	▁g LS
D-817	-1.2810417413711548	gLS
P-817	-2.9065 -0.5265 -1.5016 -0.1895
S-214	For each year of the study, we determined CHF visit rates (as a percentage of total ED visits) and calculated the percentage of CHF patients intubated.<unk>
T-214	chf chf patients intubated
H-214	-1.2472732067108154	▁CHF ▁in tuba ted
D-214	-1.2472732067108154	CHF intubated
P-214	-0.5681 -6.5108 -0.0026 -0.0093 -0.3332 -0.0596
S-483	Mean age was 56 ± 11 years and mean LV ejection fraction was 28 ± 8%; 48% had PCWP of >15 mm Hg.<unk>
T-483	lv_ejection_fraction pcwp
H-483	-0.45146626234054565	▁LV ▁e je ction ▁ fraction ▁pc WP
D-483	-0.45146626234054565	LV ejection fraction pcWP
P-483	-0.3599 -1.4058 -0.0464 -0.0204 -1.4520 -0.0035 -0.7271 -0.1443 -0.2638 -0.0914
S-740	Patients with T1 times below the median (<388.3 ms) were at greater risk of cardiac events than the rest of the group (P<0.01).<unk>
T-740	patients t1_times cardiac_events
H-740	-1.3636125326156616	▁cardiac ▁events
D-740	-1.3636125326156616	cardiac events
P-740	-2.6411 -2.2903 -0.4784 -0.0446
S-100	Validation studies in the complementary model system of zebrafish examine the role of Nucleolin to orchestrate genomic reprogramming events shared between development and disease.<unk>
T-100	nucleolin genomic_reprogramming disease
H-100	-0.5163706541061401	▁zebra fish ▁nu cle olin ▁genom ic _ ▁re programm ing
D-100	-0.5163706541061401	zebrafish nucleolin genomic_ reprogramming
P-100	-1.5935 -0.0233 -0.4433 -0.0005 -0.0055 -0.5640 -0.0453 -0.9303 -0.6700 -0.0118 -0.0182 -2.3102 -0.0971
S-1391	There was a steady improvement in eGFR in the VAD group and the ECMO+VAD group until day 7 after which there was a decline in renal function.<unk>
T-1391	egfr vad ecmo vad renal_function
H-1391	-0.9561223983764648	▁e G FR ▁ VAD _ groep ▁ec mo + VAD
D-1391	-0.9561223983764648	eGFR VAD_groep ecmo+VAD
P-1391	-0.0876 -0.6601 -0.0778 -0.8785 -0.0254 -3.5360 -0.6779 -0.8975 -1.3375 -0.6628 -0.0701 -3.2912 -0.2272
S-737	Confirmatory diagnostic tests, cardiac magnetic resonance imaging including T1 mapping, and invasive hemodynamic assessments were performed at baseline.<unk>
T-737	diagnostic tests cardiac_magnetic_resonance_imaging t1_mapping invasive_hemodynamic_assessments baseline
H-737	-0.538520097732544	▁cardiac _ ▁magnetic _ ▁res on ance ▁imagin g ▁T 1 ▁ma pping ▁invasi ve _ hem o dynamic ▁assessment s
D-737	-0.538520097732544	cardiac_ magnetic_ resonance imaging T1 mapping invasive_hemodynamic assessments
P-737	-0.0582 -1.4488 -0.6857 -0.2061 -0.7984 -0.2405 -0.6957 -1.9259 -0.0883 -1.7675 -0.1544 -0.0805 -0.0080 -0.0596 -0.0698 -0.0792 -2.0464 -0.3246 -0.0008 -0.9341 -0.5487 -0.1239 -0.0409
S-868	(MADIT-CRT: Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy; NCT00180271).<unk>
T-868	madit-crt multicenter_automatic_defibrillator_implantation_with_cardiac_resynchronization_therapy
H-868	-0.45744645595550537	▁m ADI t - c RT ▁multi center _ automat ic _ de ib rilla tor ▁Implant ation ▁Card iac _ re syn chron ization ▁Therapy
D-868	-0.45744645595550537	mADIt-cRT multicenter_automatic_deibrillator Implantation Cardiac_resynchronization Therapy
P-868	-1.0237 -0.0372 -0.2811 -0.0119 -0.6771 -0.3882 -0.9154 -0.0189 -1.4211 -0.1940 -0.0292 -0.1465 -1.8688 -0.0440 -0.6668 -0.0161 -0.7480 -0.1060 -0.4861 -0.0323 -0.9332 -1.0241 -0.0101 -0.0015 -0.8511 -0.3550 -0.4555 -0.0653
S-486	AUCs of E/eseptal and E/emean did not vary with s'septal, QRS width, or resynchronization.<unk>
T-486	aucs septal qrs resynchronization
H-486	-0.6195729374885559	▁e / e sept al ▁e / eme an ▁QR s ▁re syn chron ization
D-486	-0.6195729374885559	e/eseptal e/emean QRs resynchronization
P-486	-0.6355 -3.4374 -0.1106 -0.0286 -0.0165 -0.7122 -1.2217 -0.0075 -0.0207 -1.0774 -1.2260 -1.1329 -0.0052 -0.0011 -0.7414 -0.0828 -0.0753
S-1200	Despite their widespread use, prospective data on the potential of diuretics to modulate HF-related morbidity and mortality are scarce.<unk>
T-1200	prospective diuretics morbidity mortality
H-1200	-0.7660178542137146	▁di ure tics ▁ HF - related
D-1200	-0.7660178542137146	diuretics HF-related
P-1200	-0.3673 -0.4423 -0.1573 -2.2079 -0.0967 -0.4828 -0.8472 -2.2436 -0.0490
S-1808	Physicians and professionals in public health should be aware that the air pollution experienced in most urban and industrial areas can aggravate cardiovascular health and lead to hospitalisation and death.<unk>
T-1808	physicians public health air cardiovascular health lead hospitalisation death
H-1808	-1.9435827732086182	▁public ▁health ▁air ▁pollution
D-1808	-1.9435827732086182	public health air pollution
P-1808	-3.4200 -3.9838 -0.8477 -0.6233 -2.6456 -0.1410
S-731	CONCLUSIONS: Our hospital's 30-day readmission rate for patients with heart failure decreased in parallel with an increase in 7-day follow-up visits.<unk>
T-731	hospital readmission patients heart_failure follow-up
H-731	-2.0406157970428467	▁hospital _ in _ patient _ with _ heart ▁failure
D-731	-2.0406157970428467	hospital_in_patient_with_heart failure
P-731	-4.5325 -3.1422 -4.3352 -2.0060 -2.8011 -1.2248 -3.7496 -0.3060 -0.5877 -1.0522 -0.6583 -0.0919
S-1658	As the use of these devices has grown, health care providers have been faced with managing clinically significant gastrointestinal bleeding in this population.<unk>
T-1658	health_care clinically gastrointestinal_bleeding
H-1658	-1.0558961629867554	▁gastro inte stin al ▁ble ed ing
D-1658	-1.0558961629867554	gastrointestinal bleeding
P-1658	-6.7220 -0.3170 -0.3257 -0.1068 -0.9483 -0.6153 -0.1191 -0.2993 -0.0497
S-857	BACKGROUND: The impact of carvedilol and metoprolol on inappropriate therapy in heart failure patients with devices has not yet been investigated.<unk>
T-857	carvedilol metoprolol therapy heart_failure patients
H-857	-0.4707641899585724	▁car vedi lol ▁met o pro lol
D-857	-0.4707641899585724	carvedilol metoprolol
P-857	-0.0691 -0.0061 -0.0093 -0.1803 -0.1482 -0.0051 -0.0369 -3.7105 -0.0715
S-326	RESULTS: During IVC occlusion, CO correlated with twist, apical rotation, RS, RS synchrony, and CS (P < 0.05).<unk>
T-326	ivc_occlusion correlated rs rs_synchrony
H-326	-0.2457108348608017	▁IV c ▁oc clusi on ▁twist ▁ap ical ▁ro tation ▁RS ▁synchron y ▁CS
D-326	-0.2457108348608017	IVc occlusion twist apical rotation RS synchrony CS
P-326	-1.1548 -0.6618 -0.0230 -0.0005 -0.0831 -0.7579 -0.6604 -0.0148 -0.3887 -0.0024 -0.0068 -0.0052 -0.0297 -0.0400 -0.0305 -0.0719
S-973	Logistic regression models were used to estimate the risk for the primary outcome and the secondary outcome of death from any cause, while adjusting for confounders.<unk>
T-973	logistic_regression primary_outcome secondary_outcome death
H-973	-0.8277063369750977	▁Log istic _ ▁re gression ▁models
D-973	-0.8277063369750977	Logistic_ regression models
P-973	-0.7606 -0.0058 -0.9005 -1.0821 -0.0019 -1.1656 -2.6252 -0.0798
S-378	BACKGROUND: Most heart failure (HF) risk stratification models were developed for inpatient use, and available outpatient models use a complex set of variables.<unk>
T-378	heart_failure hf risk_stratification inpatient outpatient
H-378	-1.0970444679260254	▁heart ▁failure HF
D-378	-1.0970444679260254	heart failureHF
P-378	-0.9363 -0.3866 -1.6799 -2.4173 -0.0651
S-1301	Morbidity and mortality in HFpEF are similar to values observed in patients with HF and reduced EF, yet no effective treatment has been identified.<unk>
T-1301	morbidity mortality hfpef patients hf reduced_ef
H-1301	-0.42182743549346924	▁Morbi d ity ▁mortal ity ▁ HF p EF
D-1301	-0.42182743549346924	Morbidity mortality HFpEF
P-1301	-0.2364 -0.0087 -0.7332 -1.0036 -0.3546 -0.1378 -0.0051 -0.0688 -0.0188 -2.0123 -0.0608
S-1574	OBJECTIVE: To decrease the 30-day readmission rate following hospital stay for congestive heart failure, which in the United States approaches 30 percent nationally.<unk>
T-1574	readmission hospital congestive_heart_failure united_states
H-1574	-0.790463387966156	▁con ges tive _ heart ▁failure
D-1574	-0.790463387966156	congestive_heart failure
P-1574	-4.0624 -0.0981 -0.4224 -0.0669 -0.8333 -0.5439 -0.2280 -0.0687
S-1045	Similar results were achieved through knockdown of the BET bromodomain-containing protein 4 (BRD4), which is highly expressed in cardiac tissues.<unk>
T-1045	bet bromodomain-containing_protein_4 brd4 cardiac
H-1045	-0.44369983673095703	▁ BET ▁bro modo main - conta ining _ ▁protein br d 4 ▁cardiac ▁tissu es
D-1045	-0.44369983673095703	BET bromodomain-containing_ proteinbrd4 cardiac tissues
P-1045	-0.9843 -0.0184 -0.0958 -0.0077 -0.0183 -0.1197 -0.0007 -0.0894 -0.7685 -0.1305 -1.5819 -0.3732 -1.7237 -0.0626 -1.7167 -0.0980 -0.1062 -0.0913
S-1474	Accumulating evidence shows that molecular biomarkers provide a window into the pathophysiology of chronic HF and therefore have important therapeutic implications.<unk>
T-1474	evidence biomarkers pathophysiology chronic_hf therapeutic
H-1474	-0.4275348484516144	▁molecular ▁bio mark ers ▁pat ho phy si ology ▁chronic ▁ HF
D-1474	-0.4275348484516144	molecular biomarkers pathophysiology chronic HF
P-1474	-0.4715 -0.1424 -0.0188 -0.0585 -1.9738 -0.1610 -0.2616 -0.8115 -0.2218 -0.2378 -0.7905 -0.0053 -0.7465 -0.0845
S-56	Comments on "the role of the emergency department in acute heart failure clinical trials-Enriching patient identification and enrollment" by Collins et al.<unk>
T-56	emergency_department acute_heart_failure clinical patient collins
H-56	-0.8092389106750488	▁emergency ▁department ▁a cute _ heart ▁failure ▁clinic al _ ▁trial s ▁en roll ment
D-56	-0.8092389106750488	emergency department acute_heart failure clinical_ trials enrollment
P-56	-3.0301 -1.5685 -0.1711 -0.0065 -0.0216 -2.0443 -1.2799 -1.5664 -0.0269 -0.6005 -0.7615 -0.0243 -1.6642 -0.5054 -0.1043 -0.3117 -0.0698
S-46	Moderate-strength evidence from 3 trials of intravenous iron found improved short-term exercise tolerance and quality of life in patients with heart failure.<unk>
T-46	evidence intravenous exercise_tolerance quality_of_life patients heart_failure
H-46	-1.1952084302902222	▁intra ven ous _ ▁ir on
D-46	-1.1952084302902222	intravenous_ iron
P-46	-2.9548 -0.0052 -1.3059 -0.1364 -2.0630 -0.0929 -2.9453 -0.0582
S-1723	METHODS AND RESULTS: We used Medicare inpatient data in 2009 to examine all HF admissions to acute care hospitals in the United States.<unk>
T-1723	medicare inpatient hf admissions acute hospitals united_states
H-1723	-0.6948416233062744	▁Medica re ▁in patient ▁data ▁ HF
D-1723	-0.6948416233062744	Medicare inpatient data HF
P-1723	-0.0433 -0.0021 -0.2153 -0.0019 -1.6756 -0.2587 -0.6026 -3.3091 -0.1449
S-1909	The ECG has the ability to detect congenital accessory pathways and ion channelopathies, and is frequently abnormal in individuals with cardiomyopathy.<unk>
T-1909	ecg congenital accessory ion_channelopathies cardiomyopathy
H-1909	-0.4287627935409546	▁e CG ▁con geni tal _ accesso ry _ path ways ▁ion ▁channel o pathi es ▁cardio my o pathy
D-1909	-0.4287627935409546	eCG congenital_accessory_pathways ion channelopathies cardiomyopathy
P-1909	-0.5246 -0.0494 -4.0627 -0.0237 -0.0150 -0.7684 -0.9483 -0.2081 -0.1840 -0.8364 -0.0222 -0.0345 -0.7037 -0.1883 -0.0152 -0.0228 -0.1150 -0.4791 -0.0882 -0.0444 -0.0388 -0.0599
S-275	This study aimed to develop a novel mouse HF model of HHD by combining salt loading and uninephrectomy with ANG II infusion.<unk>
T-275	hf hhd salt_loading uninephrectomy ang_ii_infusion
H-275	-0.46930596232414246	▁mouse ▁ HF ▁model ▁H HD ▁salt ▁load ing ▁un ine ph r ecto my ▁ANG ▁II ▁in fusion
D-275	-0.46930596232414246	mouse HF model HHD salt loading uninephrectomy ANG II infusion
P-275	-0.4203 -0.2580 -0.0063 -1.6527 -1.9588 -0.5789 -0.2949 -0.0780 -0.0121 -0.0824 -0.5205 -0.9704 -0.0763 -0.0670 -0.6440 -0.0470 -1.8762 -0.1313 -0.0021 -0.1010 -0.0771
S-335	We report the case of a 57-year-old man who had a history of successful mitral valve plasty for degenerative mitral regurgitation.<unk>
T-335	report mitral_valve_plasty degenerative_mitral_regurgitation
H-335	-0.40435609221458435	▁mit ral _ ▁val ve ▁plast y ▁de genera tive _ met ral _ ▁re gur gi tation
D-335	-0.40435609221458435	mitral_ valve plasty degenerative_metral_ regurgitation
P-335	-0.8981 -0.0122 -0.6254 -0.9522 -0.0503 -0.8248 -0.1102 -0.0811 -0.0003 -0.3409 -0.2350 -1.9174 -0.2077 -0.9041 -0.6636 -0.0398 -0.0480 -0.0296 -0.0726 -0.0739
S-52	Erythropoiesis-stimulating agents do not seem to benefit patients with mild to moderate anemia and heart disease and may be associated with serious harms.<unk>
T-52	erythropoiesis-stimulating_agents patients anemia heart_disease
H-52	-0.8888502717018127	▁er y thro po ies is - stimul ating _ agent
D-52	-0.8888502717018127	erythropoiesis-stimulating_agent
P-52	-0.7506 -0.2293 -0.6191 -0.5180 -1.2400 -0.2304 -0.1263 -0.0255 -0.3049 -3.2503 -0.5590 -3.5941 -0.1075
S-1739	Improving survival rates of patients with idiopathic dilated cardiomyopathy in Tuscany over 3 decades: impact of evidence-based management.<unk>
T-1739	patients idiopathic_dilated_cardiomyopathy tuscany evidence-based
H-1739	-0.3754023015499115	▁ idio pathi c _ ▁dil ated _ ▁cardio my o pathy ▁tu sca ny
D-1739	-0.3754023015499115	idiopathic_ dilated_ cardiomyopathy tuscany
P-1739	-0.7185 -0.0481 -0.0269 -0.0485 -0.2813 -1.5017 -0.3010 -0.0345 -0.6794 -1.2446 -0.2616 -0.0551 -0.2166 -0.0001 -0.2283 -0.6904 -0.0454
S-1235	In-trial resource utilization and unit costs were estimated from Québec Health Insurance Board databases supplemented by disease-specific costs from the Ontario Case Costing Initiative.<unk>
T-1235	costs québec_health_insurance_board costs ontario_case_costing_initiative
H-1235	-0.6275456547737122	▁in - t rial ▁resource ▁utiliza tion ▁unit ▁costs ▁Québec ▁Health ▁Insurance ▁Board
D-1235	-0.6275456547737122	in-trial resource utilization unit costs Québec Health Insurance Board
P-1235	-0.4248 -0.0972 -0.1750 -0.0092 -0.9651 -0.2162 -0.0235 -1.1245 -0.6228 -0.1367 -1.7498 -0.4344 -0.3486 -3.0433 -0.0421
S-176	Benefits in HF with preserved ejection fraction (pEF), as well as uptitration after a hospitalization, remain uncertain.<unk>
T-176	hf_with_preserved_ejection_fraction pef uptitration hospitalization
H-176	-0.5101076364517212	▁ HF ▁pres er ved _ e je ction _ fraction ▁p EF
D-176	-0.5101076364517212	HF preserved_ejection_fraction pEF
P-176	-0.8422 -0.0469 -1.3912 -0.0425 -0.4039 -0.2969 -1.0964 -0.2799 -0.1437 -0.9687 -0.0136 -0.2611 -0.0134 -1.7333 -0.1181
S-1244	HF (heart failure) and T2D (Type 2 diabetes) associate with detrimental alterations in SkM (skeletal muscle) structure/function.<unk>
T-1244	hf heart_failure t2d type_2_diabetes skm skeletal_muscle
H-1244	-0.6851567625999451	▁ HF heart ▁failure ▁T 2 d ▁type ▁2 ▁diabetes ▁Sk m ▁s kelet al _ ▁muscle
D-1244	-0.6851567625999451	HFheart failure T2d type 2 diabetes Skm skeletal_ muscle
P-1244	-1.0396 -0.0097 -1.8283 -0.0113 -1.8918 -0.0102 -1.2512 -1.0049 -0.8492 -0.0469 -0.3673 -0.6798 -1.7039 -0.0443 -0.0250 -1.5761 -0.1538 -0.4512 -0.0736
S-1971	Dual RAS and neprilysin inhibition might thus after long time become a change in stable chronic heart failure with systolic dysfunction treatment "paradigm".<unk>
T-1971	ras neprilysin_inhibition change stable chronic_heart_failure systolic_dysfunction
H-1971	-0.8523832559585571	▁ RAS ▁nepri ly sin ▁inhibi tion
D-1971	-0.8523832559585571	RAS neprilysin inhibition
P-1971	-1.2039 -0.0056 -1.1956 -0.1469 -0.3075 -0.2534 -0.0665 -4.2301 -0.2620
S-1058	A T1-mapping sequence was performed during tidal respiration before and 5 minutes after the administration of a gadolinium-chelate contrast agent.<unk>
T-1058	t1-mapping tidal_respiration administration gadolinium-chelate_contrast_agent
H-1058	-0.7427924275398254	▁tid al _ ▁respira tion ▁ gado lini um - che late _ ▁contrast ▁agent
D-1058	-0.7427924275398254	tidal_ respiration gadolinium-chelate_ contrast agent
P-1058	-5.2029 -0.0327 -0.7072 -0.2953 -0.0689 -0.3158 -0.0120 -0.0971 -0.1174 -0.0741 -0.0076 -1.0655 -0.0672 -4.1786 -0.1582 -0.1120 -0.1152
S-1140	In conscious HF rats, pyridostigmine reduced the basal heart rate, increased vagal, and reduced sympathetic control of heart rate.<unk>
T-1140	hf pyridostigmine basal_heart_rate sympathetic_control_of_heart_rate
H-1140	-0.43461430072784424	▁ conscious ▁ HF ▁rat s ▁py rido stig mine ▁bas al _ ▁heart ▁rate ▁va gal ▁sympa the tic _ control
D-1140	-0.43461430072784424	conscious HF rats pyridostigmine basal_ heart rate vagal sympathetic_control
P-1140	-0.4732 -0.6000 -0.2811 -0.0183 -2.4505 -0.1699 -0.0034 -0.0011 -0.0003 -0.0500 -0.9523 -0.0186 -0.2945 -1.3454 -0.1548 -0.0007 -0.0027 -0.0204 -0.0929 -0.1395 -0.3241 -0.0312 -2.7858 -0.2200
S-1253	We report severe perturbations in components of the DAPC (dystrophin-associated protein complex) as well as sarcomeric microstructure at baseline.<unk>
T-1253	report dapc dystrophin-associated_protein_complex sarcomeric_microstructure baseline
H-1253	-0.31884047389030457	▁DAP c dys trop hin - as soci ated _ ▁protein ▁complex ▁sar come ric ▁micro structure
D-1253	-0.31884047389030457	DAPcdystrophin-associated_ protein complex sarcomeric microstructure
P-1253	-0.3261 -0.5681 -1.7119 -0.0169 -0.8346 -0.0805 -0.0148 -0.0001 -0.3690 -0.1307 -0.5739 -0.0491 -0.0131 -0.2167 -0.5962 -0.3824 -0.0326 -0.0838 -0.0575
S-1915	A cardiopulmonary exercise test, a quality of life score and an evaluation of the muscular strength by measuring the peak quadriceps force was performed.<unk>
T-1915	cardiopulmonary_exercise_test quality_of_life muscular peak_quadriceps_force
H-1915	-1.1105709075927734	▁cardio pul mon ary _ ▁exercise ▁test ▁muscular _ ▁strength ▁pe ak ▁quadri cep s ▁force
D-1915	-1.1105709075927734	cardiopulmonary_ exercise test muscular_ strength peak quadriceps force
P-1915	-0.0649 -0.0795 -0.9120 -0.8727 -1.4252 -3.7328 -2.8684 -3.4596 -1.5222 -1.6091 -0.1483 -0.0357 -0.6941 -0.0541 -0.0278 -2.2611 -0.0793 -0.1436
S-71	Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial.<unk>
T-71	dopamine nesiritide acute_heart_failure renal_dysfunction rose acute_heart_failure randomized
H-71	-0.46835458278656006	▁dop amine ▁nesi riti de ▁a cute _ heart ▁failure ▁renal ▁dys function ▁a cute _ heart ▁failure
D-71	-0.46835458278656006	dopamine nesiritide acute_heart failure renal dysfunction acute_heart failure
P-71	-0.4028 -0.0247 -2.2095 -0.0022 -0.0271 -0.1230 -0.0147 -0.1139 -1.1130 -0.3151 -0.1699 -0.5703 -0.0423 -1.1803 -0.1315 -0.0212 -1.1704 -0.9114 -0.7619 -0.0617
S-941	Efficacy, safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction.<unk>
T-941	outcomes catheter_ablation atrial_fibrillation patients heart_failure_with_preserved_ejection_fraction
H-941	-0.6466949582099915	▁cat heter ▁ab lation ▁at rial _ fi bril lation ▁heart ▁failure ▁pres er ved _ e je ction _ fraction
D-941	-0.6466949582099915	catheter ablation atrial_fibrillation heart failure preserved_ejection_fraction
P-941	-3.4430 -0.1208 -0.5077 -0.0950 -3.0403 -0.0603 -0.4697 -1.0482 -0.0236 -0.0115 -0.9691 -0.2527 -0.3133 -0.1122 -0.9294 -0.3992 -1.0160 -0.1052 -0.0334 -1.7199 -0.0029 -0.1081 -0.0925
S-759	Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model.<unk>
T-759	myocardial titin_hypophosphorylation heart_failure_with_preserved_ejection_fraction metabolic
H-759	-0.6278297305107117	▁My o card ial ▁titi n ▁hypo phos phor y lation ▁heart ▁failure
D-759	-0.6278297305107117	Myocardial titin hypophosphorylation heart failure
P-759	-1.9312 -0.0317 -0.0271 -0.1257 -0.8707 -0.0887 -0.6865 -0.1321 -0.2958 -0.5813 -0.0785 -0.9839 -0.1406 -3.2921 -0.1515
S-953	However, the current study was a single-arm analysis; therefore, larger randomized control studies are needed to verify the benefit of AF ablation in this cohort.<unk>
T-953	randomized af_ablation
H-953	-1.4887906312942505	▁AF ▁ab lation
D-953	-1.4887906312942505	AF ablation
P-953	-6.6351 -0.4587 -0.0790 -0.1966 -0.0745
S-909	Heterogenous improvement in ejection fraction (+3.1 ± 9.2%) was noted and 2 patients derived absolute improvements of 8% and 22%, respectively.<unk>
T-909	ejection_fraction patients
H-909	-0.6492893099784851	▁e je ction ▁ fraction
D-909	-0.6492893099784851	ejection fraction
P-909	-2.6979 -0.2420 -0.2083 -0.6447 -0.0028 -0.6545 -0.0949
S-317	However, evidence gaps, limitations in economic models, and the lack of Canadian data point to the importance of mandatory, systematic monitoring of LVAD use and outcomes.<unk>
T-317	evidence economic lvad outcomes
H-317	-1.327279806137085	▁economische _ model
D-317	-1.327279806137085	economische_model
P-317	-1.1926 -2.7212 -0.3541 -2.3006 -0.0679
S-428	We hypothesized that combining parameters would be more robust and sought to develop a multiparametric echocardiographic score for predicting CRT response.<unk>
T-428	echocardiographic crt
H-428	-0.6839480996131897	▁e cho car dio graphic ▁score ▁c RT
D-428	-0.6839480996131897	echocardiographic score cRT
P-428	-2.8273 -0.0258 -0.0082 -0.3072 -0.1387 -1.8428 -0.8014 -0.4736 -0.2760 -0.1386
S-724	We quantified the change in 30-day readmission rate after the initiative, frequency of 7-day follow-up visits, and events at follow-up visits.<unk>
T-724	change readmission follow-up follow-up
H-724	-1.499817967414856	
D-724	-1.499817967414856	
P-724	-2.9298 -0.0699
S-1100	Data describing trends in HF after MI are scarce and conflicting and do not distinguish between preserved and reduced ejection fraction (EF).<unk>
T-1100	hf mi reduced_ejection_fraction ef
H-1100	-1.413803219795227	▁trend s ▁ HF _ van _ mi
D-1100	-1.413803219795227	trends HF_van_mi
P-1100	-3.2769 -0.1009 -0.4485 -0.0115 -2.9371 -2.8257 -0.1945 -1.5563 -2.6557 -0.1308
S-298	METHODS: All patients who underwent HeartMate II LVAD alone or in conjunction with a temporary CentriMag RVAD were examined from 2006 to 2011.<unk>
T-298	patients heartmate_ii lvad centrimag rvad
H-298	-0.6717303991317749	▁Heart Mate _ II _ ▁l VAD ▁temporar y ▁Centri Mag _ r VAD
D-298	-0.6717303991317749	HeartMate_II_ lVAD temporary CentriMag_rVAD
P-298	-1.2936 -0.0407 -0.7747 -1.8435 -0.6129 -3.2187 -0.0106 -0.2957 -0.0464 -0.5648 -0.0868 -0.2502 -1.3733 -0.0227 -0.2302 -0.0831
S-791	CONCLUSIONS: Among patients with HFpEF, the KCCQ seems to be a valid and reliable measure of health status and offers excellent prognostic ability.<unk>
T-791	patients hfpef kccq health prognostic
H-791	-0.3889627158641815	▁ HF p EF ▁k cc q
D-791	-0.3889627158641815	HFpEF kccq
P-791	-0.4551 -0.0469 -0.0326 -0.0496 -0.8913 -0.1597 -0.4562 -1.3576 -0.0514
S-1334	Chronic heart failure is associated with transforming growth factor beta-dependent yield and functional decline in atrial explant-derived c-Kit+ cells.<unk>
T-1334	chronic_heart_failure yield atrial cells
H-1334	-0.6638777256011963	▁Chro nic _ heart ▁failure ▁transform ing ▁growth ▁factor ▁beta - dependent _ ▁yi eld
D-1334	-0.6638777256011963	Chronic_heart failure transforming growth factor beta-dependent_ yield
P-1334	-0.2771 -0.0150 -0.3291 -1.3288 -0.4118 -1.6419 -0.0161 -1.3999 -0.1782 -0.7863 -0.0034 -0.0422 -0.8195 -0.6713 -0.0000 -3.2815 -0.0837
S-1623	MEASUREMENTS: Mortality, inpatient admissions, hospital days, and emergency department (ED) visits during the 2-year study period were measured.<unk>
T-1623	mortality inpatient admissions hospital emergency_department
H-1623	-0.32028064131736755	▁Mor t ality ▁in patient ▁ad missions ▁hospital ▁days ▁emergency ▁department ED
D-1623	-0.32028064131736755	Mortality inpatient admissions hospital days emergency departmentED
P-1623	-0.7369 -0.0543 -0.0475 -0.1153 -0.0372 -0.1542 -0.1127 -0.2109 -0.5698 -0.1552 -0.8764 -1.1858 -0.1415 -0.0863
S-1093	Thus, RV failure frequently requires diagnostic procedures and management strategies that differ from those routinely used in the management of intrinsic left ventricular dysfunction.<unk>
T-1093	rv_failure diagnostic left_ventricular_dysfunction
H-1093	-1.3401635885238647	▁ RV _ ▁failure
D-1093	-1.3401635885238647	RV_ failure
P-1093	-0.1138 -0.2376 -3.4224 -0.3375 -3.8099 -0.1199
S-441	We excluded patients with baseline serum creatinine level of >2.5 mg/dl or a serum potassium level of >5.0 mEq/L.<unk>
T-441	patients baseline serum_creatinine serum_potassium
H-441	-0.6075102090835571	▁base line ▁se rum ▁creati nine ▁level ▁se rum _ po tas s ium ▁level
D-441	-0.6075102090835571	baseline serum creatinine level serum_potassium level
P-441	-2.8128 -0.0317 -0.9942 -0.1025 -1.1930 -0.1201 -0.1734 -0.2476 -0.0837 -1.1056 -0.6944 -0.3436 -0.3283 -0.0867 -1.2058 -0.6742 -0.1303
S-899	After PD initiation, average weight loss was almost 7 kg (p = 0.016) with improvement in diuretic response, peripheral edema, and functional class.<unk>
T-899	pd diuretic peripheral_edema functional_class
H-899	-0.5544165372848511	▁PD _ ▁initiat ion ▁di ure tic _ ▁response ▁per i pher al _ ▁ed ema ▁functional
D-899	-0.5544165372848511	PD_ initiation diuretic_ response peripheral_ edema functional
P-899	-0.2156 -2.8348 -1.3668 -0.0111 -2.0494 -0.1736 -0.2534 -0.9051 -0.3547 -0.0095 -0.0588 -0.0033 -0.0274 -0.3522 -0.9406 -0.0008 -0.0075 -0.8673 -0.1019
S-834	Anemia is common in patients with chronic heart failure (HF), with a prevalence ranging from 10% to 56%, and may be a risk factor for poor outcomes.<unk>
T-834	anemia patients chronic_heart_failure hf prevalence outcomes
H-834	-0.538887619972229	▁an emia ▁chronic _ heart ▁failure HF
D-834	-0.538887619972229	anemia chronic_heart failureHF
P-834	-0.9046 -0.0018 -1.3982 -0.2705 -1.0068 -0.2267 -0.5176 -0.4648 -0.0589
S-1170	Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.<unk>
T-1170	if-channel_inhibition hemodynamic exercise_tolerance heart_failure_with_preserved_ejection_fraction randomized
H-1170	-0.47957998514175415	▁If - chan nel _ ▁inhibi tion ▁hem o dynamic ▁status ▁exercise ▁ tolerance ▁heart ▁failure ▁pres er ved _ e je ction _ fraction
D-1170	-0.47957998514175415	If-channel_ inhibition hemodynamic status exercise tolerance heart failure preserved_ejection_fraction
P-1170	-2.4690 -0.0614 -0.0027 -0.0115 -1.6979 -0.7658 -0.3060 -0.4992 -0.2324 -0.0011 -0.7513 -0.3163 -0.1321 -0.0013 -0.2627 -0.1410 -0.1713 -0.1442 -0.9527 -0.4888 -1.2635 -0.1158 -0.0262 -1.8776 -0.0075 -0.1911 -0.0583
S-1777	Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy.<unk>
T-1777	cardiac insulin-resistance mitochondrial_energy_production systolic_heart_failure pressure-overload_hypertrophy
H-1777	-0.31519436836242676	▁Card iac ▁insulin - re si stance ▁mito cho ndri al ▁energy ▁production ▁sy sto lic _ ▁heart ▁failure ▁pressure - over load ▁hyper trop hy
D-1777	-0.31519436836242676	Cardiac insulin-resistance mitochondrial energy production systolic_ heart failure pressure-overload hypertrophy
P-1777	-0.5761 -0.0078 -0.6678 -0.0224 -0.0134 -0.3289 -0.0020 -0.0082 -0.0584 -0.0501 -0.0264 -2.6533 -1.3459 -0.0053 -0.0038 -0.0265 -0.1792 -1.6873 -0.2397 -0.0308 -0.0730 -0.0027 -0.0596 -0.2713 -0.0008 -0.3571 -0.0590 -0.0688
S-427	BACKGROUND: Studies of echocardiographic predictors of response after cardiac resynchronization therapy (CRT) have largely involved single parameters.<unk>
T-427	echocardiographic cardiac_resynchronization_therapy crt
H-427	-0.5739102959632874	▁e cho car dio graphic _ ▁predict ors ▁cardiac ▁re syn chron ization ▁ therapy ▁c RT
D-427	-0.5739102959632874	echocardiographic_ predictors cardiac resynchronization therapy cRT
P-427	-0.0334 -0.0100 -0.0075 -0.6463 -0.1529 -1.6000 -1.2076 -0.2024 -2.2145 -1.0321 -0.0129 -0.0052 -0.6721 -1.7533 -0.0198 -1.0849 -0.1568 -0.0504 -0.0421
S-1519	The apparent circulating NT-proBNP concentration was increased with antibodies targeting nonglycosylated and nonterminal epitopes (P < 0.05).<unk>
T-1519	nt-probnp antibodies nonterminal_epitopes
H-1519	-0.24660125374794006	▁circula ting ▁NT - pro b NP ▁anti bo dies ▁non gly cos yla ted ▁non termin al ▁e pito pes
D-1519	-0.24660125374794006	circulating NT-probNP antibodies nonglycosylated nonterminal epitopes
P-1519	-0.4388 -0.0572 -0.1131 -0.0163 -0.0074 -1.1879 -0.0375 -0.0749 -0.0117 -1.2007 -0.3822 -0.1905 -0.0706 -0.0716 -0.0650 -0.3545 -0.2210 -0.0063 -0.9754 -0.0104 -0.0288 -0.0745 -0.0757
S-615	METHODOLOGY: A mixed-methods study was undertaken to assess the benefits of participation in a structured exercise programme for patients with heart failure.<unk>
T-615	mixed-methods_study exercise patients heart_failure
H-615	-2.014036178588867	▁ MET HOD OLO GY
D-615	-2.014036178588867	METHODOLOGY
P-615	-3.7649 -2.4417 -1.8599 -1.6719 -0.0851 -4.1493 -0.1254
S-1946	CONCLUSIONS: In recent onset HFrEF, exercise performance was better when resting HR was controlled <70 bpm with beta-blocker therapy.<unk>
T-1946	hfref exercise resting_hr bpm beta-blocker therapy
H-1946	-0.7017940878868103	▁H Fr EF ▁exercise ▁performance ▁rest ing ▁HR ▁beta - block er
D-1946	-0.7017940878868103	HFrEF exercise performance resting HR beta-blocker
P-1946	-1.8318 -0.2565 -0.2363 -1.7777 -0.1086 -2.0698 -0.0291 -0.1016 -0.6232 -0.0136 -0.0162 -0.0426 -2.6375 -0.0808
S-1386	METHODS: We performed a single center retrospective observational study in children with end-stage heart failure supported on pediatric mechanical cardiac support.<unk>
T-1386	end-stage_heart_failure mechanical_cardiac_support
H-1386	-1.7839163541793823	▁wind _ ▁failure ▁pediatr ic ▁mechanic al _ ▁cardiac
D-1386	-1.7839163541793823	wind_ failure pediatric mechanical_ cardiac
P-1386	-7.6462 -3.0656 -2.0927 -1.2248 -0.1733 -1.8011 -0.0210 -0.3728 -0.1999 -2.9327 -0.0931
S-606	RESULTS: We compared 8656 new users of a nbDMARD with 11 587 new users of a TNF antagonist with similar baseline covariates.<unk>
T-606	nbdmard tnf_antagonist baseline covariates
H-606	-0.35562846064567566	▁n b DM ARD ▁t NF ▁anta gon ist
D-606	-0.35562846064567566	nbDMARD tNF antagonist
P-606	-0.0626 -0.0119 -0.0501 -0.1321 -2.4556 -0.1021 -0.5948 -0.0146 -0.0894 -0.3081 -0.0905
S-934	Hum-Retn mice showed increased cardiac mRNA levels of inflammatory and cell adhesion genes compared with Retn(-/-) mice.<unk>
T-934	cardiac_mrna inflammatory cell_adhesion_genes retn
H-934	-0.6889026165008545	▁Hum - Re t n _ mi ce ▁cardiac ▁m RNA ▁infla mma tory ▁cell ▁a dhe sion _ ▁gene s ▁Ret n ( - / -
D-934	-0.6889026165008545	Hum-Retn_mice cardiac mRNA inflammatory cell adhesion_ genes Retn(-/-
P-934	-0.1945 -0.0541 -0.6188 -0.0368 -0.0215 -1.3893 -0.5180 -0.1649 -0.3425 -0.0198 -0.0013 -2.9974 -0.0714 -0.0411 -3.7533 -0.0620 -0.0040 -0.2598 -2.0296 -0.2656 -0.1236 -0.0345 -0.0538 -1.4428 -0.1690 -1.9301 -0.2396 -3.0258 -0.1130
S-1266	Baseline and 6-Week follow-up levels of PAF and activity of its metabolic enzymes in patients with heart failure and healthy volunteers--a pilot study.<unk>
T-1266	baseline follow-up paf activity metabolic enzymes patients heart_failure healthy
H-1266	-0.8393262028694153	▁pa f ▁metabol ic _ ▁enzym es ▁heart ▁failure
D-1266	-0.8393262028694153	paf metabolic_ enzymes heart failure
P-1266	-2.7161 -1.3818 -0.1417 -0.0332 -0.9104 -0.1267 -0.0502 -2.3625 -0.4869 -0.8586 -0.1645
S-91	Little is known about the global changes in chromatin subproteomes that accompany heart failure, and the mechanisms by which these proteins alter chromatin structure.<unk>
T-91	chromatin_subproteomes heart_failure proteins chromatin_structure
H-91	-0.9423904418945312	▁chr omat in _ sub prote om es ▁heart ▁failure ▁protein s
D-91	-0.9423904418945312	chromatin_subproteomes heart failure proteins
P-91	-2.3112 -0.0279 -0.5691 -0.9019 -1.2180 -0.1840 -0.0404 -0.3474 -1.2284 -1.5358 -2.1337 -0.0508 -2.5419 -0.1031
S-1896	Patients with heart failure should be referred to heart failure nurses and have follow-up with local cardiology services as these have both been shown to reduce mortality.<unk>
T-1896	patients heart_failure heart_failure nurses follow-up cardiology mortality
H-1896	-0.4515063166618347	▁heart ▁failure ▁nurse s ▁card i ology
D-1896	-0.4515063166618347	heart failure nurses cardiology
P-1896	-0.8727 -0.0855 -0.7946 -0.0144 -0.9100 -0.1092 -0.1165 -1.0302 -0.1303
S-1138	After 4 wk of pyridostigmine administration, per os, methylatropine and propranolol were used to evaluate the cardiac sympathovagal balance.<unk>
T-1138	pyridostigmine administration methylatropine propranolol cardiac sympathovagal_balance
H-1138	-0.590862512588501	▁py rido stig mine _ administration ▁met hy la tropi ne ▁propra no lol ▁cardiac ▁sympa t hova gal _ ▁balance
D-1138	-0.590862512588501	pyridostigmine_administration methylatropine propranolol cardiac sympathovagal_ balance
P-1138	-0.0236 -0.0076 -0.0003 -0.0363 -4.0418 -1.2979 -0.4151 -0.0844 -0.2602 -0.0035 -1.7112 -0.0038 -0.0061 -0.0081 -0.0358 -2.7535 -0.2376 -0.0949 -0.2645 -1.5604 -0.5321 -0.1292 -0.0820
S-970	We aimed to investigate the association between preoperative renal dysfunction and early risk of stroke, myocardial infarction, or heart failure after CABG.<unk>
T-970	preoperative renal_dysfunction stroke myocardial_infarction heart_failure cabg
H-970	-0.5997092723846436	▁pre operativ e ▁renal ▁dys function ▁stroke ▁my o card ial _ in far ction ▁heart ▁failure
D-970	-0.5997092723846436	preoperative renal dysfunction stroke myocardial_infarction heart failure
P-970	-1.9166 -0.0194 -0.0126 -0.1231 -0.2560 -0.0260 -3.9064 -1.0533 -0.2801 -0.1170 -0.1559 -0.7517 -0.4931 -0.0235 -0.0675 -0.6148 -0.1490 -1.3590 -0.0697
S-1427	As expected, total myosin binding protein-C phosphorylation and Ser23/24 troponin I phosphorylation significantly decreased in HF.<unk>
T-1427	myosin protein-c phosphorylation troponin_i phosphorylation hf
H-1427	-0.5283041596412659	▁my os in ▁ binding _ ▁protein - C ▁ phos phor y lation ▁Ser 23 /24 ▁trop onin ▁I ▁ phos phor y lation ▁ HF
D-1427	-0.5283041596412659	myosin binding_ protein-C phosphorylation Ser23/24 troponin I phosphorylation HF
P-1427	-3.7680 -0.0436 -0.7246 -1.0784 -0.0022 -1.2501 -0.4967 -0.0463 -1.5510 -0.2191 -0.0030 -0.2561 -1.0693 -0.0978 -0.5242 -0.1431 -0.0168 -0.0793 -0.0242 -2.0356 -0.3516 -0.0010 -0.1487 -0.6445 -0.1021 -0.4849 -0.0027 -0.0492 -0.1066
S-670	The use of trastuzumab in the adjuvant setting improves outcomes but is associated with cardiotoxicity manifested as congestive heart failure (CHF).<unk>
T-670	trastuzumab adjuvant outcomes cardiotoxicity congestive_heart_failure chf
H-670	-0.49415087699890137	▁tras tuz um ab ▁cardio toxic iteit ▁con ges tive _ heart ▁failure CH F
D-670	-0.49415087699890137	trastuzumab cardiotoxiciteit congestive_heart failureCHF
P-670	-0.0715 -0.0206 -0.0064 -0.4045 -0.7147 -0.1671 -1.5492 -0.0705 -0.0632 -1.1452 -0.1741 -2.0820 -0.2750 -1.2166 -0.3351 -0.0466 -0.0583
S-1207	Phosphodiesterase-2 is up-regulated in human failing hearts and blunts beta-adrenergic responses in cardiomyocytes.<unk>
T-1207	phosphodiesterase-2 hearts beta-adrenergic_responses cardiomyocytes
H-1207	-0.6401863694190979	▁Pho s pho dies tera se -2 ▁fail ing _ heart s ▁blu nts ▁beta - ad r energi c ▁cardio my o cy tes
D-1207	-0.6401863694190979	Phosphodiesterase-2 failing_hearts blunts beta-adrenergic cardiomyocytes
P-1207	-0.6212 -0.2170 -0.7779 -3.4493 -0.0126 -0.0618 -0.8605 -4.9926 -0.0417 -1.1636 -0.6398 -0.2180 -0.0315 -0.0580 -0.1223 -0.0112 -0.0223 -0.3390 -1.0421 -0.0595 -1.4876 -0.4056 -0.1327 -0.0554 -0.1225 -0.1739 -0.1655
S-391	Cox hazard models for time to ESRD, to death, and the composite end point of ESRD or death were constructed and predictors of ESRD identified.<unk>
T-391	cox_hazard_models esrd death composite_end_point esrd death esrd
H-391	-1.3191649913787842	▁co x _ ▁hazard ▁models ▁eu RD
D-391	-1.3191649913787842	cox_ hazard models euRD
P-391	-0.4732 -0.0008 -1.6209 -1.4772 -0.5633 -4.0753 -1.2356 -2.2781 -0.1482
S-557	METHODS: Patients were categorized into 5 age groups: 20 to 39, 40 to 49, 50 to 59, 60 to 69, and ≥70 years.<unk>
T-557	patients
H-557	-0.9559624791145325	
D-557	-0.9559624791145325	
P-557	-1.8718 -0.0402
S-1864	Most patients (n = 17, 68%) said they would consider deactivation, six (24%) were undecided and two (8%) were adamant they would never turn it off.<unk>
T-1864	patients
H-1864	-0.2552184462547302	▁de activa tion
D-1864	-0.2552184462547302	deactivation
P-1864	-0.4857 -0.0069 -0.0590 -0.6640 -0.0604
S-1729	Finally, costs were higher for the high-volume physicians ($8982 versus $8731; P=0.002, a difference that was consistent across hospital volume groups).<unk>
T-1729	costs physicians hospital
H-1729	-0.49575963616371155	▁kosten ▁high - volu me _ ▁physician s
D-1729	-0.49575963616371155	kosten high-volume_ physicians
P-1729	-0.7837 -1.9562 -0.0230 -0.0769 -0.0419 -0.4461 -0.7836 -0.0186 -0.7744 -0.0532
S-1361	This review highlights the current knowledge of nutritional abnormalities that may occur in CHF, including fat, carbohydrates, proteins, water, and micronutrients.<unk>
T-1361	chf proteins
H-1361	-1.6383962631225586	▁nutrition al ▁ab normal ities ▁CHF
D-1361	-1.6383962631225586	nutritional abnormalities CHF
P-1361	-5.7683 -0.0167 -2.0915 -0.0086 -0.2803 -0.9444 -3.9262 -0.0711
S-932	Remarkably, doxorubicin (25mg/kg ip) led to a 4-fold induction of serum resistin levels in Hum-Retn mice.<unk>
T-932	doxorubicin resistin
H-932	-0.8113006353378296	▁do xor ubi cin ▁i p ▁se rum ▁resist in ▁levels ▁Hum - Re t n
D-932	-0.8113006353378296	doxorubicin ip serum resistin levels Hum-Retn
P-932	-0.0046 -0.0050 -0.0142 -0.0546 -4.2945 -0.0144 -1.0946 -0.0868 -0.4116 -0.5639 -3.3210 -0.0852 -0.1110 -1.6948 -0.3806 -0.1167 -2.1837 -0.1663
S-321	MATERIALS AND METHODS: In nine pigs, the inferior vena cava (IVC) was snared to decrease CO and establish a control model.<unk>
T-321	inferior_vena_cava ivc
H-321	-1.1377419233322144	▁pig s ▁inferior ▁ve na ▁ca va ▁v c
D-321	-1.1377419233322144	pigs inferior vena cava vc
P-321	-5.9260 -0.0659 -0.8313 -1.1957 -0.0553 -0.1436 -0.0620 -1.6759 -0.4324 -2.0095 -0.1175
S-359	Direct observation at the time of surgery also confirmed no findings of rheumatic or other causes of MS. After the surgery, MVA was reduced but only modestly.<unk>
T-359	surgery rheumatic surgery mva
H-359	-1.1507391929626465	▁m VA
D-359	-1.1507391929626465	mVA
P-359	-3.1374 -0.9680 -0.4026 -0.0950
S-728	Eighty-one percent of 7-day visits occurred in the University of Connecticut Heart Failure Center with a cardiologist or heart failure nurse practitioner.<unk>
T-728	university_of_connecticut_heart_failure_center heart_failure nurse_practitioner
H-728	-0.9306386113166809	▁University _ Connect i cut _ ▁Heart ▁Fail ure ▁Center ▁cardio logist ▁heart ▁failure
D-728	-0.9306386113166809	University_Connecticut_ Heart Failure Center cardiologist heart failure
P-728	-3.8113 -1.2379 -2.1574 -0.0185 -0.0522 -1.1165 -0.9195 -0.5037 -0.7767 -0.9328 -0.0276 -0.0067 -0.6657 -0.1292 -2.4669 -0.0676
S-472	Thus, we tested the hypothesis that XO inhibition improves cardiomyocyte bioenergetics and LV function in chronic ACF in the rat.<unk>
T-472	xo_inhibition cardiomyocyte_bioenergetics lv_function chronic_acf
H-472	-0.37117642164230347	▁ XO ▁inhibi tion ▁cardio my o cy te ▁bio ener ge tics ▁LV ▁chronic ▁A CF
D-472	-0.37117642164230347	XO inhibition cardiomyocyte bioenergetics LV chronic ACF
P-472	-0.3041 -0.0121 -0.6564 -0.1235 -0.0567 -0.2565 -0.2997 -0.1337 -0.2018 -0.0981 -0.0435 -0.8621 -0.1028 -0.4203 -1.0264 -0.9738 -0.0518 -1.3655 -0.0636
S-1753	BACKGROUND: In patients with heart failure (HF), during maximal cardiopulmonary exercise test, anaerobic threshold (AT) is not always identified.<unk>
T-1753	patients heart_failure hf cardiopulmonary_exercise_test anaerobic_threshold
H-1753	-0.7456650137901306	▁heart ▁failure HF ▁cardio pul mon ary _ ▁exercise ▁test ▁ana ero bic _ ▁thre s hold AT
D-1753	-0.7456650137901306	heart failureHF cardiopulmonary_ exercise test anaerobic_ thresholdAT
P-1753	-1.8757 -0.2313 -1.4885 -2.6443 -0.0559 -0.8362 -0.3289 -0.4380 -2.7840 -1.9892 -0.0126 -0.0434 -0.0512 -0.3152 -0.1178 -0.0634 -0.2152 -1.2486 -0.1324 -0.0415
S-1084	UPR effectors, protein kinase R-like ER kinase (PERK), calreticulin, and CHOP, were increased in human HF tissues.<unk>
T-1084	upr protein_kinase_r-like_er_kinase perk calreticulin chop hf
H-1084	-0.647756814956665	▁protein ▁kina se ▁r - like _ er ▁kina se per k ▁cal ret icul in ▁CHO p
D-1084	-0.647756814956665	protein kinase r-like_er kinaseperk calreticulin CHOp
P-1084	-1.8445 -0.0812 -0.0332 -2.3264 -0.0840 -0.8405 -0.3568 -2.1163 -1.6220 -0.0200 -0.9495 -0.3381 -0.0059 -0.0744 -0.0004 -0.2096 -0.0371 -0.6786 -1.2152 -0.1214
S-1120	Therefore, carvedilol may reduce the risk of thromboembolic events in patients with heart failure, irrespective of β2-receptor haplotype status.<unk>
T-1120	carvedilol thromboembolic_events patients heart_failure β2-receptor_haplotype
H-1120	-0.43983781337738037	▁car vedi lol ▁ thro mbo e mbol ic _ ▁events ▁heart ▁failure ▁β 2- recept or ▁ha plo type
D-1120	-0.43983781337738037	carvedilol thromboembolic_ events heart failure β2-receptor haplotype
P-1120	-0.0168 -0.0033 -0.0353 -1.1591 -0.1917 -0.8439 -0.2904 -0.0092 -0.3597 -2.8555 -0.9374 -1.9256 -0.2036 -0.0201 -0.0673 -0.0551 -0.0168 -0.0176 -0.0027 -0.0098 -0.5865 -0.0690
S-1144	HF rats treated with pyridostigmine exhibited a higher stroke volume, ejection fraction, cardiac output, and contractility of the left ventricle.<unk>
T-1144	hf pyridostigmine stroke_volume ejection_fraction cardiac_output contractility left_ventricle
H-1144	-0.5705124735832214	▁py rido stig mine ▁e je ction ▁ fraction ▁cardiac ▁output ▁contract ility
D-1144	-0.5705124735832214	pyridostigmine ejection fraction cardiac output contractility
P-1144	-3.2091 -0.0052 -0.0007 -0.1099 -0.5927 -0.0260 -0.0064 -0.3782 -0.0002 -0.0052 -0.0216 -0.1375 -0.6167 -3.4027 -0.0455
S-1324	Echocardiographic measures, N-terminal pro-brain natriuretic peptide, and inflammatory markers were mostly unchanged.<unk>
T-1324	echocardiographic n-terminal_pro-brain_natriuretic_peptide inflammatory
H-1324	-0.398649662733078	▁e cho car dio graphic _ ▁measure s ▁N - termin al _ ▁pro - bra in ▁na tri ure tic _ pe pti de ▁infla mma tory ▁marker s
D-1324	-0.398649662733078	echocardiographic_ measures N-terminal_ pro-brain natriuretic_peptide inflammatory markers
P-1324	-0.7961 -0.0594 -0.0131 -0.2725 -0.2348 -3.0934 -1.2088 -0.0360 -1.2370 -0.0133 -0.0747 -0.0065 -0.4924 -1.2891 -0.0200 -0.0649 -0.0667 -0.0785 -0.0027 -0.1507 -1.2612 -0.3690 -0.4099 -0.0363 -0.0864 -0.0032 -0.2177 -0.1398 -0.8150 -0.0575 -0.0531 -0.0972
S-152	STUDY SELECTION: All randomised-controlled trials (RCTs) or observational cohort studies with a contemporaneous control group were included.<unk>
T-152	randomised-controlled_trials rcts observational_cohort_studies contemporaneous_control_group
H-152	-0.5432343482971191	▁random ised - control led _ ▁trial s RC T s ▁observation al _ co hor t ▁studies
D-152	-0.5432343482971191	randomised-controlled_ trialsRCTs observational_cohort studies
P-152	-2.6655 -1.1543 -0.2173 -0.0013 -0.3888 -0.4362 -0.7530 -0.0321 -0.2439 -1.0732 -0.1214 -0.5360 -0.0048 -0.4143 -0.9300 -0.0216 -0.0691 -0.4519 -1.2690 -0.0808
S-438	Aldosterone receptor antagonists have been shown in randomized trials to reduce morbidity and mortality in adults with symptomatic systolic heart failure.<unk>
T-438	aldosterone_receptor_antagonists randomized morbidity mortality symptomatic_systolic_heart_failure
H-438	-0.5816818475723267	▁al do ster one ▁receptor ▁anta gon ists ▁morbi d ity ▁sy sto lic _ heart ▁failure
D-438	-0.5816818475723267	aldosterone receptor antagonists morbidity systolic_heart failure
P-438	-0.6249 -0.0815 -0.0175 -0.1272 -0.4032 -0.1921 -0.0228 -1.1650 -2.0708 -0.0072 -1.1904 -2.9691 -0.0545 -0.1048 -0.2778 -1.1555 -0.4579 -0.0828 -0.0468
S-613	Abstract In the current economic climate within the NHS, behavioural-change interventions in chronic disease such as exercise programmes will be time-limited within acute hospital facilities.<unk>
T-613	economic nhs chronic disease exercise acute hospital
H-613	-1.2791954278945923	▁economische _ ▁climate ▁NH s ▁behaviour al - change _ intervention s ▁chronic _ ▁disease ▁exercise
D-613	-1.2791954278945923	economische_ climate NHs behavioural-change_interventions chronic_ disease exercise
P-613	-3.0007 -2.8698 -1.7065 -2.2406 -0.8724 -1.3688 -0.0251 -0.0299 -0.0246 -2.8889 -1.9636 -0.1645 -0.3679 -0.9611 -0.8052 -0.9441 -2.6112 -0.1805
S-912	In conclusion, at our center, the dialysis-dependent patients with HF who underwent CRT implantation did so safely and no serious complications were observed.<unk>
T-912	patients hf crt implantation complications
H-912	-0.4426512122154236	▁di al ysis - dependent ▁patients ▁ HF ▁c RT
D-912	-0.4426512122154236	dialysis-dependent patients HF cRT
P-912	-0.7398 -0.0215 -0.0128 -0.0208 -0.0464 -1.3157 -0.5136 -0.0039 -0.6823 -0.1324 -1.7838 -0.0389
S-1389	RESULTS: During the study period, there were 23 patients in the VAD group, 16 patients in the ECMO+VAD group, and 37 patients in the ECMO group.<unk>
T-1389	patients vad patients ecmo vad patients ecmo
H-1389	-1.0348329544067383	▁ VAD _ groep ▁EC mo + VAD
D-1389	-1.0348329544067383	VAD_groep ECmo+VAD
P-1389	-0.6074 -0.0703 -3.2991 -0.4272 -0.5009 -1.2857 -1.1154 -0.0434 -2.8339 -0.1650
S-687	METHODS AND RESULTS: Women's Health Initiative participants were followed up from the date of HF hospitalization through the date of death or last participant contact before August 2009.<unk>
T-687	health followed_up hf hospitalization death contact
H-687	-1.057756781578064	▁Women _ Health ▁Initiative ▁ HF _ hospital ization
D-687	-1.057756781578064	Women_Health Initiative HF_hospitalization
P-687	-2.7901 -1.2479 -2.7195 -0.5092 -0.7116 -0.2404 -2.0381 -0.2608 -0.2972 -0.7135 -0.1068
S-1452	Cases (post-HCT CHF) were identified from 2950 patients who underwent HCT between 1988 and 2007 at City of Hope and had survived ≥1 year.<unk>
T-1452	chf patients hct city_of_hope
H-1452	-0.9083070158958435	▁post - h CT _ ▁CHF
D-1452	-0.9083070158958435	post-hCT_ CHF
P-1452	-2.8101 -0.0115 -0.3420 -0.4500 -0.8696 -1.2852 -1.4525 -0.0457
S-1094	In this summary, the structure and function of the RV will be reviewed, concentrating on the pathophysiologic mechanisms behind the development of RV dysfunction.<unk>
T-1094	rv pathophysiologic rv_dysfunction
H-1094	-0.7463792562484741	▁ RV
D-1094	-0.7463792562484741	RV
P-1094	-0.4373 -0.4482 -1.9629 -0.1371
S-1918	Peak oxygen consumption (range: –3% to + 61%) increased in three, and oxygen pulse (range: –7% to + 44%) in four of five patients.<unk>
T-1918	peak_oxygen_consumption pulse patients
H-1918	-0.527240514755249	▁oxygen _ ▁consum p tion ▁oxygen ▁puls e
D-1918	-0.527240514755249	oxygen_ consumption oxygen pulse
P-1918	-1.0889 -1.6378 -0.4628 -0.0076 -0.1689 -1.3721 -0.0333 -0.1631 -0.2484 -0.0895
S-816	RESULTS: There were 19 CV deaths, 12 non-fatal stroke and 28 hospitalisations for heart failure during an average follow-up of 21 ± 10 months.<unk>
T-816	deaths stroke hospitalisations heart_failure follow-up
H-816	-0.6747325658798218	▁CV ▁death s ▁non - fa tal _ stro t ▁hospital isation s ▁heart ▁failure
D-816	-0.6747325658798218	CV deaths non-fatal_strot hospitalisations heart failure
P-816	-0.5329 -4.3944 -0.1486 -0.1306 -0.0099 -0.0208 -0.0105 -0.2167 -0.5973 -1.9100 -0.5265 -0.0220 -0.1461 -2.1576 -0.4571 -0.1178 -0.0717
S-1907	In middle-aged recreational athletes more than 90% of sudden cardiac deaths occur in males and more than 90% are caused by atherosclerotic CAD.<unk>
T-1907	cardiac_deaths atherosclerotic_cad
H-1907	-0.8525734543800354	▁a ther os cle ro tic _ CAD
D-1907	-0.8525734543800354	atherosclerotic_CAD
P-1907	-5.4702 -0.2455 -0.2458 -0.1293 -0.0347 -0.3757 -0.6273 -1.1371 -0.1282 -0.1320
S-1477	In this review, we summarize the potential therapeutic implications of promising biomarkers that uniquely capture the molecular dysfunction that occurs in chronic HF.<unk>
T-1477	therapeutic biomarkers molecular_dysfunction chronic_hf
H-1477	-0.2599962055683136	▁bio mark ers ▁molecular ▁dys function ▁chronic ▁ HF
D-1477	-0.2599962055683136	biomarkers molecular dysfunction chronic HF
P-1477	-1.1842 -0.0206 -0.0693 -0.2039 -0.3387 -0.0305 -0.1450 -0.7412 -0.0041 -0.0683 -0.0543
S-1806	Ambient air pollution is a well-recognised risk factor for cardiovascular health, and it has been shown to be an important trigger of acute myocardial infarction.<unk>
T-1806	air cardiovascular health acute_myocardial_infarction
H-1806	-1.1829034090042114	▁Ambient _ air ▁pollution ▁cardiovascular _ health ▁a cute _ in far ction
D-1806	-1.1829034090042114	Ambient_air pollution cardiovascular_health acute_infarction
P-1806	-0.4132 -1.1354 -2.8872 -2.1053 -0.9696 -1.4733 -1.7285 -1.4953 -0.0246 -0.0698 -4.7332 -0.2194 -0.2285 -0.1356 -0.1246
S-1655	CONCLUSION: EAST will determine whether rhythm control therapy, when applied early after the initial diagnosis of AF, can prevent cardiovascular complications associated with AF.<unk>
T-1655	east rhythm_control_therapy diagnosis cardiovascular complications
H-1655	-0.5819442868232727	▁e ast ▁ rhythm ▁control ▁ therapy ▁AF ▁cardiovascular ▁complica tions
D-1655	-0.5819442868232727	east rhythm control therapy AF cardiovascular complications
P-1655	-1.8284 -0.5918 -0.0478 -0.1390 -0.5239 -0.2883 -0.0066 -1.6786 -0.6041 -0.1316 -0.3876 -1.2644 -0.0732
S-1089	Because the effect is not entirely specific to the SCN5A transcript, the UPR may play an important role in downregulation of multiple cardiac genes in HF.<unk>
T-1089	scn5a upr downregulation cardiac genes hf
H-1089	-0.8762561678886414	▁s cn 5 a ▁tran script ▁u PR
D-1089	-0.8762561678886414	scn5a transcript uPR
P-1089	-1.8809 -0.5307 -0.2275 -0.3498 -0.1809 -0.0031 -0.6599 -0.0808 -4.7533 -0.0956
S-379	We hypothesized that routinely collected clinical data could predict the 6-month risk of death and all-cause medical hospitalization in HF clinic outpatients.<unk>
T-379	collected clinical death medical hospitalization hf clinic outpatients
H-379	-1.1251366138458252	▁ HF
D-379	-1.1251366138458252	HF
P-379	-1.9256 -0.8506 -1.5436 -0.1807
S-1192	In the prospective validation cohort of 143 patients, the prediction rule had 98% sensitivity and 18% specificity for CAD but 100% sensitivity for severe CAD.<unk>
T-1192	prospective patients rule sensitivity specificity cad sensitivity cad
H-1192	-0.7526488900184631	▁ sensitiv ity ▁CAD
D-1192	-0.7526488900184631	sensitivity CAD
P-1192	-2.1283 -0.0561 -0.5370 -0.8069 -0.9293 -0.0582
S-540	Attention to albumin levels by correcting nutrition, inflammation, and hepatic function could be an effective way to improve prognosis in patients evaluated for LVAD implantation.<unk>
T-540	albumin inflammation hepatic prognosis patients lvad implantation
H-540	-0.6666112542152405	▁album in ▁levels ▁ inflammation ▁he pati c ▁function ▁l VAD
D-540	-0.6666112542152405	albumin levels inflammation hepatic function lVAD
P-540	-0.1395 -0.0391 -1.8794 -1.6125 -0.0176 -0.0191 -0.0231 -0.0400 -1.4594 -2.0722 -0.0267 -1.1719 -0.1655
S-496	TAPSE vs. PASP relationship showed a downward regression line shift in nonsurvivors who were more frequently presenting with higher PASP and lower TAPSE.<unk>
T-496	tapse pasp downward regression_line shift pasp tapse
H-496	-1.593963861465454	▁pas p
D-496	-1.593963861465454	pasp
P-496	-3.0065 -1.6028 -1.6846 -0.0819
S-814	MAIN OUTCOME MEASURES: The risk of GLS measured by index beat method for CV events was assessed by Cox proportional hazards analyses.<unk>
T-814	outcome gls beat cox_proportional_hazards_analyses
H-814	-0.588290274143219	▁g LS ▁index ▁beat _ methode ▁CV _ ▁events ▁co x ▁proportion al _ ▁hazard s ▁analyse s
D-814	-0.588290274143219	gLS index beat_methode CV_ events cox proportional_ hazards analyses
P-814	-1.7463 -0.6227 -0.0731 -0.0571 -0.7320 -1.0400 -0.1810 -2.7807 -2.0601 -0.1967 -0.0011 -0.0743 -0.0057 -0.1696 -0.5929 -0.0836 -0.9858 -0.1562 -0.0840 -0.1231
S-1817	These findings indicate that hearts with increased levels of Mena fare worse when subjected to cardiac injury and suggest that Mena contributes to HF pathophysiology.<unk>
T-1817	hearts mena cardiac_injury mena hf pathophysiology
H-1817	-0.848185658454895	▁heart s ▁men a ▁cardiac ▁injury ▁ HF
D-1817	-0.848185658454895	hearts mena cardiac injury HF
P-1817	-2.8961 -0.1500 -0.6180 -0.1086 -1.2173 -0.5664 -1.5922 -0.3014 -0.9601 -0.0717
S-1102	All residents of Olmsted County, Minnesota (n = 2,596) who had a first-ever MI diagnosed in 1990-2010 and no prior HF were followed-up through 2012.<unk>
T-1102	olmsted_county minnesota mi diagnosed hf followed-up
H-1102	-0.6655402779579163	▁Ol m sted ▁County ▁Minnesota
D-1102	-0.6655402779579163	Olmsted County Minnesota
P-1102	-1.2785 -0.0402 -0.0042 -0.1312 -0.6683 -2.4392 -0.0971
S-1340	CHF-developed infarcted animals were selected on the basis of left ventricle end-diastolic pressure ≥ 20 mm Hg and scar size ≥ 30%.<unk>
T-1340	infarcted left_ventricle_end-diastolic_pressure
H-1340	-0.787260890007019	▁CHF - develop ed _ in far cted _ animal ▁left ▁vent ric le _ ▁end - dia sto lic _ ▁pressure ▁scar
D-1340	-0.787260890007019	CHF-developed_infarcted_animal left ventricle_ end-diastolic_ pressure scar
P-1340	-0.0353 -1.5351 -0.3546 -0.0309 -1.4179 -0.6999 -0.0029 -2.2747 -1.0659 -1.2305 -0.5975 -0.6479 -0.5555 -0.8129 -0.5652 -3.8620 -0.1069 -0.0092 -0.0590 -0.0386 -0.5042 -0.7617 -1.0575 -1.3967 -0.0591
S-1615	CONCLUSIONS: Genes differentially expressed in non-ischemic and ischemic heart failure can be biomarkers to distinguish the two types of heart failure.<unk>
T-1615	genes ischemic_heart_failure biomarkers heart_failure
H-1615	-0.9440232515335083	▁bio mark ers ▁heart ▁failure
D-1615	-0.9440232515335083	biomarkers heart failure
P-1615	-2.4763 -0.0592 -0.0972 -3.4378 -0.3622 -0.1098 -0.0656
S-10	Lipolysis and increased energy expenditure caused by A- and B natriuretic peptides (NPs) have been suggested to play a role in CC.<unk>
T-10	lipolysis expenditure b_natriuretic_peptides nps
H-10	-0.342874139547348	▁li poly sis ▁energie ▁ex pendi ture ▁na tri ure tic _ pe pti des NP s ▁CC
D-10	-0.342874139547348	lipolysis energie expenditure natriuretic_peptidesNPs CC
P-10	-0.7619 -0.0012 -0.0669 -0.8305 -0.1007 -0.0083 -0.2043 -0.7377 -0.0137 -0.2568 -1.2595 -0.5459 -0.3852 -0.0394 -0.1975 -0.8079 -0.0490 -0.4693 -0.0332 -0.0887
S-184	In conclusion, uptitration of neurohumoral blockers after an HF hospitalization is more frequently performed in younger patients with low co-morbidity burden.<unk>
T-184	uptitration neurohumoral_blockers hf hospitalization patients co-morbidity
H-184	-0.5848044753074646	▁neuro hu moral ▁block ers ▁ HF
D-184	-0.5848044753074646	neurohumoral blockers HF
P-184	-0.4611 -0.0038 -0.6426 -1.4328 -0.1030 -0.2824 -0.0065 -2.2900 -0.0410
S-784	Predictive validity of the KCCQ Overall Summary scores was assessed with Kaplan-Meier curves for death and all-cause hospitalization.<unk>
T-784	kccq kaplan-meier_curves death all-cause_hospitalization
H-784	-0.8965689539909363	▁k cc q ▁ka plan - me ier _ ▁cur ves
D-784	-0.8965689539909363	kccq kaplan-meier_ curves
P-784	-1.8992 -0.0704 -0.4760 -1.7258 -0.0210 -0.0138 -1.1527 -0.0733 -0.4491 -1.5523 -1.4793 -2.5930 -0.1495
S-294	BACKGROUND: Right ventricular (RV) failure after the insertion of a left ventricular assist device (LVAD) historically results in poor outcomes.<unk>
T-294	right_ventricular rv left_ventricular_assist_device lvad outcomes
H-294	-0.8025524020195007	▁Right ▁vent ri cular _ RV ▁ insertion ▁left _ ▁vent ri cular _ assist ▁device ▁l VAD
D-294	-0.8025524020195007	Right ventricular_RV insertion left_ ventricular_assist device lVAD
P-294	-2.1197 -0.4260 -0.2155 -0.0751 -2.3692 -1.1351 -3.4044 -0.1398 -0.6068 -0.9380 -0.7058 -0.5385 -0.1360 -0.3769 -0.3620 -1.9905 -0.3498 -0.0050 -0.0751 -0.0819
S-1308	We assessed the temporal incidence of and adjusted odds ratio/hazard ratio for death associated with HF concurrent with AMI admission and within 1 year after discharge.<unk>
T-1308	incidence adjusted_odds_ratio hazard_ratio death hf ami admission discharge
H-1308	-0.7450338006019592	▁odds _ haz ard ▁ratio ▁ HF ▁ AMI
D-1308	-0.7450338006019592	odds_hazard ratio HF AMI
P-1308	-2.7605 -2.0696 -0.0438 -0.0047 -1.2372 -0.6625 -0.1308 -0.5821 -0.1999 -0.3833 -0.1210
S-1316	Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: a double-blind randomized controlled feasibility study.<unk>
T-1316	testosterone_therapy exercise_rehabilitation patients chronic_heart_failure testosterone double-blind randomized
H-1316	-1.1134438514709473	▁test o ster one ▁ therapy ▁exercise ▁rehabilita tion ▁patients ▁chronic _ heart ▁failure ▁testosteron e ▁status
D-1316	-1.1134438514709473	testosterone therapy exercise rehabilitation patients chronic_heart failure testosterone status
P-1316	-2.2133 -0.4686 -0.0109 -0.1584 -1.6703 -0.0156 -5.5592 -0.2397 -0.1479 -4.7175 -1.7484 -0.1876 -1.1747 -0.7808 -1.0286 -0.0185 -0.7713 -0.1717 -0.0724
S-689	Cox proportional hazards models adjusted for demographics, health behaviors, and health status were used to calculate hazard ratios and 95% confidence intervals (CI).<unk>
T-689	cox_proportional_hazards_models health health hazard_ratios confidence_intervals
H-689	-0.7483013272285461	▁co x ▁proportion al _ ▁hazard s ▁models
D-689	-0.7483013272285461	cox proportional_ hazards models
P-689	-0.0798 -0.0026 -0.3988 -0.0070 -0.0765 -1.9864 -0.1372 -1.5378 -3.1801 -0.0769
S-1718	Individuals hospitalized for AMI without major complications, heart failure, or kidney infection or UTI with major complications had no increase in 30-day rehospitalization.<unk>
T-1718	hospitalized ami complications heart_failure kidney_infection uti complications rehospitalization
H-1718	-0.46969863772392273	▁ AMI ▁heart ▁failure ▁ki dne y ▁infection ▁ UTI
D-1718	-0.46969863772392273	AMI heart failure kidney infection UTI
P-1718	-0.4353 -0.0167 -4.4369 -0.0249 -0.0316 -0.0377 -0.0147 -0.1482 -0.1618 -0.0008 -0.2477 -0.0800
S-705	However, ST2 did not add significantly to reclassification of risk as assessed by changes in the C statistic, net reclassification improvement, and integrated discrimination improvement.<unk>
T-705	st2 c_statistic net_reclassification_improvement integrated_discrimination_improvement
H-705	-0.8755062222480774	▁re class ification _ ▁risk ▁c ▁statistic ▁integrat ed _ ▁discrimina tion
D-705	-0.8755062222480774	reclassification_ risk c statistic integrated_ discrimination
P-705	-3.2076 -0.0255 -0.1378 -1.5734 -1.5568 -1.2394 -0.1062 -1.8556 -0.0331 -0.2755 -0.9053 -0.2872 -0.9271 -0.1265
S-1599	Screening patients for RAS with either Doppler ultrasonography, computed tomographic angiography, or magnetic resonance angiography is preferred.<unk>
T-1599	patients ras doppler_ultrasonography tomographic_angiography magnetic_resonance_angiography
H-1599	-0.36049985885620117	▁ RAS ▁do pp ler ▁ultra son ography ▁com put ed ▁to mo graphic _ ang i ography ▁magnetic _ ▁res on ance _ ang i ography
D-1599	-0.36049985885620117	RAS doppler ultrasonography computed tomographic_angiography magnetic_ resonance_angiography
P-1599	-1.5507 -0.0072 -0.4629 -0.0048 -0.6428 -0.5269 -0.0515 -0.1006 -0.1047 -0.0055 -0.0857 -0.0548 -0.0649 -0.1381 -0.2076 -0.9556 -0.3702 -0.0621 -0.0081 -0.6601 -0.8560 -0.1040 -0.4552 -0.6873 -1.3002 -0.6626 -0.0491 -0.1602 -0.1151
S-107	Treatment with CRT-D did not have a significant effect on IE risk compared with defibrillator-only therapy (HR 0.87, p = 0.51).<unk>
T-107	crt-d therapy
H-107	-0.3963048756122589	▁c RT - D ▁de fi br illa tor - on ly _ therapy
D-107	-0.3963048756122589	cRT-D defibrillator-only_therapy
P-107	-0.5482 -0.1764 -0.0321 -0.8763 -2.3264 -0.0137 -0.0246 -0.0998 -0.0109 -0.0664 -0.0989 -0.3488 -0.9459 -0.0478 -0.6135 -0.1112
S-1819	A considerable number of patients eventually reach an advanced or terminal phase, in spite of developments in diagnostic procedure, alternative treatments that can slow progression, management, and follow-up.<unk>
T-1819	patients terminal diagnostic follow-up
H-1819	-1.1101211309432983	▁diagnose s
D-1819	-1.1101211309432983	diagnoses
P-1819	-3.0626 -0.7350 -0.5945 -0.0484
S-316	We conclude that evidence is sufficient to support LVAD use, regardless of transplantation eligibility status, as long as patients are carefully selected and program infrastructure and budget are adequate.<unk>
T-316	evidence lvad transplantation patients budget
H-316	-0.9561132192611694	▁l VAD ▁transplant ation ▁e ligi bility
D-316	-0.9561132192611694	lVAD transplantation eligibility
P-316	-1.7952 -0.0696 -3.5841 -0.0718 -0.3408 -0.0059 -0.1416 -2.5432 -0.0527
S-530	We aimed to investigate the association of hypoalbuminemia with postoperative mortality in patients undergoing left ventricular assist device (LVAD) implantation.<unk>
T-530	hypoalbuminemia postoperative mortality patients left_ventricular_assist_device lvad implantation
H-530	-0.4258055090904236	▁hypo album in emia ▁post operativ e _ ▁mortal ity ▁left ▁vent ri cular _ assist ▁device ▁l VAD
D-530	-0.4258055090904236	hypoalbuminemia postoperative_ mortality left ventricular_assist device lVAD
P-530	-0.0730 -0.0347 -0.0485 -0.0213 -0.0704 -0.0545 -0.0422 -1.4799 -0.0232 -0.3374 -0.2460 -0.6356 -1.1151 -0.1991 -0.3768 -0.4984 -2.8298 -0.4972 -0.0047 -0.2177 -0.1364
S-110	Age-dependent effect of left ventricular ejection fraction on long-term mortality in patients with heart failure (from the Heart Failure Survey in ISrael).<unk>
T-110	left_ventricular_ejection_fraction mortality patients heart_failure heart_failure_survey israel
H-110	-0.9871312379837036	▁left _ ▁vent ri cular _ e je ction _ fraction ▁long - term _ ▁mortal ity ▁Heart _ ▁Fail ure ▁Survey
D-110	-0.9871312379837036	left_ ventricular_ejection_fraction long-term_ mortality Heart_ Failure Survey
P-110	-1.7238 -1.8056 -0.4215 -0.6243 -0.7804 -0.8219 -1.2559 -0.0903 -0.0897 -1.8302 -0.1376 -4.7695 -0.0811 -0.1050 -0.2196 -0.4819 -0.4050 -2.7225 -1.0561 -0.5759 -1.1264 -0.6166 -1.7848 -0.1655
S-1596	The pathophysiologic mechanism stems from renal underperfusion resulting in the activation of the renin- angiotensin-aldosterone pathway.<unk>
T-1596	pathophysiologic renal_underperfusion renin-_angiotensin-aldosterone_pathway
H-1596	-0.7348482608795166	▁renal _ ▁under per fusion ▁re nin - ▁ang io ten sin - al do ster one
D-1596	-0.7348482608795166	renal_ underperfusion renin- angiotensin-aldosterone
P-1596	-1.8762 -1.3160 -2.7345 -0.0202 -0.0842 -0.0666 -0.1930 -0.0265 -3.8469 -0.5837 -0.0280 -0.5439 -0.4149 -0.0798 -0.9849 -0.0108 -0.5456 -0.4032 -0.2033
S-860	Secondary endpoints were inappropriate therapy due to atrial fibrillation and atrial tachyarrhythmias, also evaluated as ATP or shock therapy.<unk>
T-860	secondary_endpoints therapy atrial_fibrillation atrial_tachyarrhythmias atp shock_therapy
H-860	-0.5389193892478943	▁ therapy ▁at rial ▁fi bril lation ▁at rial _ ta chy ar rhythm ias ▁ATP ▁shock ▁ therapy
D-860	-0.5389193892478943	therapy atrial fibrillation atrial_tachyarrhythmias ATP shock therapy
P-860	-3.0227 -0.1644 -0.7451 -0.0035 -0.7172 -0.0016 -0.0136 -0.3890 -0.0057 -0.9863 -3.4874 -0.2631 -0.0103 -0.0419 -0.6875 -0.1226 -0.2474 -0.2973 -0.0032 -0.0576 -0.0500
S-1293	After percutaneous coronary revascularization a hemodynamically stable situation could be achieved and the patient was admitted to the intensive care unit (ICU).<unk>
T-1293	percutaneous coronary_revascularization hemodynamically stable patient intensive_care_unit icu
H-1293	-0.4143129587173462	▁per cuta ne ous _ ▁corona ry _ ▁re vas cular ization ▁hem o dynamic ally
D-1293	-0.4143129587173462	percutaneous_ coronary_ revascularization hemodynamically
P-1293	-0.0352 -0.0007 -0.0673 -1.4557 -0.6313 -0.2627 -0.3927 -1.2001 -0.7023 -0.1203 -0.2410 -0.6448 -0.1605 -0.0379 -0.0005 -0.2447 -1.2257 -0.0345
S-965	Moreover, nicorandil provided a significant cardioprotection via inhibition of apoptotic signaling pathway, DNA fragmentation and mitochondrial ultrastructural changes.<unk>
T-965	nicorandil cardioprotection apoptotic_signaling_pathway dna_fragmentation mitochondrial
H-965	-0.28140395879745483	▁nic oran dil ▁cardio protec tion ▁apo pto tic _ ▁signal ing ▁path way ▁DNA ▁fragment ation ▁mito cho ndri al ▁ultra struct ural
D-965	-0.28140395879745483	nicorandil cardioprotection apoptotic_ signaling pathway DNA fragmentation mitochondrial ultrastructural
P-965	-0.0910 -0.0068 -0.0281 -0.7632 -0.0910 -0.0635 -0.6014 -0.0052 -0.3280 -0.3656 -1.2934 -0.0551 -0.1094 -0.1005 -0.4088 -1.5441 -0.0546 -0.0005 -0.0555 -0.0159 -0.0202 -0.5217 -0.0107 -0.0062 -0.7055 -0.0704
S-760	BACKGROUND: Obesity and diabetes mellitus are important metabolic risk factors and frequent comorbidities in heart failure with preserved ejection fraction.<unk>
T-760	obesity diabetes_mellitus metabolic comorbidities heart_failure_with_preserved_ejection_fraction
H-760	-0.868493378162384	▁diabetes ▁mell itus ▁metabol ic _ ▁risk ▁factors ▁heart ▁failure ▁pres er ved ▁e je ction _ fraction
D-760	-0.868493378162384	diabetes mellitus metabolic_ risk factors heart failure preserved ejection_fraction
P-760	-2.6010 -0.0420 -0.0680 -1.9509 -0.0181 -0.6760 -1.0983 -0.1892 -4.3646 -0.7026 -0.1073 -0.1660 -0.5813 -2.8303 -0.0894 -0.0627 -1.5887 -0.0051 -0.0995 -0.1289
S-869	Global proteomics and pathway analysis of pressure-overload-induced heart failure and its attenuation by mitochondrial-targeted peptides.<unk>
T-869	proteomics pressure-overload-induced_heart_failure mitochondrial-targeted_peptides
H-869	-0.2879633903503418	▁prote o mics ▁pressure - over load - indu ced _ heart ▁failure ▁mito cho ndri al - tar get ed _ pe pti des
D-869	-0.2879633903503418	proteomics pressure-overload-induced_heart failure mitochondrial-targeted_peptides
P-869	-2.2472 -0.3843 -0.0009 -0.4502 -0.0331 -0.0012 -0.0277 -0.1510 -0.1099 -0.2525 -0.2588 -1.0959 -0.4450 -0.0006 -0.0786 -0.1871 -0.0209 -0.0504 -0.0271 -0.0047 -0.0167 -1.2107 -0.4014 -0.0207 -0.1042 -0.0773 -0.1167
S-450	The inhibition of vascular endothelial growth factor (VEGF) signaling has been shown to be crucial for the transition from compensatory hypertrophy to cardiac failure.<unk>
T-450	vascular_endothelial_growth_factor vegf transition compensatory_hypertrophy cardiac_failure
H-450	-0.6028190851211548	▁inhibi tion ▁vas cular _ ▁en dot heli al _ ▁growth ▁factor ve GF ▁compensa tory _ ▁hyper trop hy ▁cardiac ▁failure
D-450	-0.6028190851211548	inhibition vascular_ endothelial_ growth factorveGF compensatory_ hypertrophy cardiac failure
P-450	-1.1682 -0.1780 -1.2321 -0.1817 -1.3624 -0.8708 -1.5852 -0.0239 -0.0135 -0.4412 -1.0363 -0.4729 -1.0843 -0.0306 -1.1158 -0.0461 -0.4689 -1.0780 -0.0019 -0.5691 -0.0032 -1.3781 -0.0617 -0.0638
S-103	The present study population comprised 1,045 patients with IC enrolled in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy.<unk>
T-103	patients ic multicenter_automatic_defibrillator_implantation_trial-cardiac_resynchronization_therapy
H-103	-0.45753204822540283	▁IC ▁multi center _ automat ic _ de ib rilla tor ▁Implant ation ▁tri al - Card iac _ re syn chron ization ▁Therapy
D-103	-0.45753204822540283	IC multicenter_automatic_deibrillator Implantation trial-Cardiac_resynchronization Therapy
P-103	-1.4319 -0.5954 -0.0297 -0.4145 -0.4183 -0.0261 -0.0310 -2.2477 -0.0524 -0.8911 -0.0279 -0.5430 -0.0987 -0.8580 -0.0910 -0.1230 -0.0951 -0.0955 -1.3073 -1.4669 -0.0034 -0.0006 -0.5061 -0.4123 -0.0659 -0.0631
S-320	Accordingly, we used speckle tracking echocardiography (STE) to analyze BiVP during acute right ventricular pressure overload (RVPO).<unk>
T-320	speckle_tracking_echocardiography ste bivp acute right_ventricular_pressure_overload rvpo
H-320	-0.634118378162384	▁spec kle ▁track ing ▁e cho card i ography ▁ STE ▁Bi VP ▁vent ri cular _ ▁pressure ▁over load RV PO
D-320	-0.634118378162384	speckle tracking echocardiography STE BiVP ventricular_ pressure overloadRVPO
P-320	-0.3221 -0.0744 -0.1656 -0.0628 -0.3904 -0.0154 -0.0924 -0.4216 -0.0783 -3.2247 -0.0321 -1.1075 -0.0158 -4.8905 -0.3885 -0.6692 -0.8448 -0.6231 -1.2134 -0.2096 -0.1060 -0.1282 -0.0659 -0.0764
S-1174	Cardiopulmonary exercise testing with echocardiographic assessment of myocardial function and left ventricular filling were undertaken at rest and after exercise.<unk>
T-1174	cardiopulmonary_exercise_testing echocardiographic myocardial_function left_ventricular_filling exercise
H-1174	-0.5911686420440674	▁Card io pul mon ary ▁e cho car dio graphic _ ▁assessment ▁my o card ial _ ▁function ▁left ▁vent ri cular ▁fill ing
D-1174	-0.5911686420440674	Cardiopulmonary echocardiographic_ assessment myocardial_ function left ventricular filling
P-1174	-0.5966 -1.3942 -0.0473 -0.6044 -0.4728 -2.3710 -0.0062 -0.0019 -0.1354 -0.4441 -2.4048 -2.5365 -0.7384 -0.0529 -0.0986 -0.1173 -1.1716 -0.8886 -0.1812 -0.1219 -0.2354 -0.1427 -0.3461 -0.0168 -0.2007 -0.0428
S-1627	The Health Buddy Program was most strongly associated with fewer admissions for individuals with chronic obstructive pulmonary disease and mortality for those with congestive heart failure.<unk>
T-1627	health_buddy_program admissions chronic_obstructive_pulmonary_disease mortality congestive_heart_failure
H-1627	-0.8212867379188538	▁Health ▁Budd y _ programm ▁chronic _ ob struct ive _ ▁pulmonar y ▁disease ▁mortal ity ▁con ges tive _ heart ▁failure
D-1627	-0.8212867379188538	Health Buddy_programm chronic_obstructive_ pulmonary disease mortality congestive_heart failure
P-1627	-2.3203 -0.2395 -0.0187 -3.3587 -1.7884 -2.3061 -0.8357 -0.8745 -0.2178 -0.0993 -0.3924 -0.1107 -0.0704 -1.6591 -1.0749 -0.3179 -0.1574 -0.0572 -0.4490 -0.0813 -2.3912 -0.7023 -0.1030 -0.0850
S-1587	Various measures of HR dynamics, such as time-domain, spectral, and non-linear measures of HR variability have been used in risk stratification.<unk>
T-1587	hr_variability risk_stratification
H-1587	-1.1490089893341064	▁HR ▁dynamic s
D-1587	-1.1490089893341064	HR dynamics
P-1587	-0.4787 -1.9163 -0.0768 -3.0824 -0.1909
S-1313	Occurrence of HF within 90 days of the index AMI was associated with an adjusted hazard ratio of 2.7 for 1-year mortality in 90-day survivors.<unk>
T-1313	hf ami hazard_ratio mortality
H-1313	-0.5827322006225586	▁ HF ▁index ▁ AMI
D-1313	-0.5827322006225586	HF index AMI
P-1313	-1.8197 -0.1920 -0.0726 -0.1008 -0.0154 -1.7352 -0.1435
S-114	Among the study patients, 30% had preserved LVEF and 20%, 25%, and 25%, had mild, moderate, and severe reductions in LVEF, respectively.<unk>
T-114	patients preserved_lvef lvef
H-114	-0.5124809741973877	▁LV EF
D-114	-0.5124809741973877	LVEF
P-114	-1.7495 -0.0499 -0.2044 -0.0461
S-1088	CONCLUSIONS: UPR can be initiated by Na+ channel mRNA splice variants and is involved in the reduction of cardiac Na+ current during human HF.<unk>
T-1088	upr mrna_splice cardiac hf
H-1088	-0.6979954838752747	▁u PR ▁na + ▁channel ▁m RNA ▁sp lice
D-1088	-0.6979954838752747	uPR na+ channel mRNA splice
P-1088	-1.3335 -0.1985 -0.8569 -0.8653 -0.2883 -0.0311 -0.0399 -0.0117 -0.0320 -3.9490 -0.0717
S-1201	Diuretic efficacy may be limited by adverse neurohormonal activation and by "congestion-like" symptoms that may occur in the absence of fluid overload.<unk>
T-1201	diuretic neurohormonal symptoms fluid_overload
H-1201	-0.6167985200881958	▁di ure tic _ ef fica cy ▁neuro hormon al ▁activa tion
D-1201	-0.6167985200881958	diuretic_efficacy neurohormonal activation
P-1201	-0.5274 -0.1322 -1.0868 -1.0785 -1.1558 -0.1204 -0.1198 -0.9513 -0.0154 -0.0675 -0.5229 -0.0716 -2.7354 -0.0501
S-173	Our results are not in favour of apoptosis in the pathogenesis of heart failure in this model and may be it could be attributed to activation of other systems.<unk>
T-173	apoptosis pathogenesis heart_failure
H-173	-1.6886883974075317	▁apo pto sis
D-173	-1.6886883974075317	apoptosis
P-173	-2.4518 -0.0518 -0.1758 -5.6057 -0.1583
S-1052	Moreover, BETs were found to function, in part, by promoting transcriptional pause release (and thereby re-activating transcription) during pathological stress.<unk>
T-1052	bets transcriptional_pause_release pathological
H-1052	-0.5898265242576599	▁ BET s ▁tran scription al _ ▁pause ▁release ▁tran scription
D-1052	-0.5898265242576599	BETs transcriptional_ pause release transcription
P-1052	-0.3182 -0.0233 -1.5760 -0.7564 -0.1039 -0.0717 -1.3680 -0.3996 -0.7495 -0.5339 -0.1016 -1.5538 -0.1118
S-278	At 6 wk after the procedures, only ANS mice showed significant decreases in LV fractional shortening and increases in lung weight with a high incidence.<unk>
T-278	lv_fractional_shortening lung incidence
H-278	-0.41154101490974426	▁ ANS _ mi ce ▁LV ▁ fraction al _ short en ing ▁lung ▁weight
D-278	-0.41154101490974426	ANS_mice LV fractional_shortening lung weight
P-278	-0.9844 -0.0342 -1.0142 -0.7627 -0.1860 -0.5592 -0.5481 -0.0011 -0.0094 -0.1651 -0.3037 -0.0582 -0.1486 -0.0578 -1.9549 -0.1021 -0.1067
S-188	We sought to evaluate the relationship between sex, EF, and BNP in HF patients and determine prognostic significance of BNP as it relates to sex and EF.<unk>
T-188	ef bnp hf patients prognostic significance bnp ef
H-188	-1.7176958322525024	▁ec b NP
D-188	-1.7176958322525024	ecbNP
P-188	-4.2791 -0.7462 -0.7079 -2.7284 -0.1269
S-1942	However, with similar dose uptitration, the former versus the latter had a significantly larger HR reduction (17±22 versus 4±15 bpm; P value=0.027).<unk>
T-1942	uptitration hr_reduction bpm p_value
H-1942	-0.9040616154670715	▁dose ▁up tit ration ▁HR ▁re duction
D-1942	-0.9040616154670715	dose uptitration HR reduction
P-1942	-1.7494 -1.3647 -0.1441 -0.0779 -1.8994 -1.5060 -0.0891 -1.2262 -0.0797
S-1910	Screening with a 12-lead ECG in older athletes is of limited value given the overwhelming contribution of atherosclerotic CAD to sudden cardiac death.<unk>
T-1910	ecg atherosclerotic_cad cardiac_death
H-1910	-0.5034622550010681	▁e CG ▁a ther os cle ro tic _ ▁CAD
D-1910	-0.5034622550010681	eCG atherosclerotic_ CAD
P-1910	-2.0045 -0.1987 -0.3769 -0.0183 -0.1552 -0.0853 -0.0163 -0.3030 -0.2384 -0.9875 -1.4975 -0.1599
S-446	Within a diverse community-based cohort with incident systolic heart failure, use of spironolactone was not independently associated with risks of hospitalization or death.<unk>
T-446	systolic_heart_failure spironolactone hospitalization death
H-446	-0.47913849353790283	▁sy sto lic _ heart ▁failure ▁spi rono lac tone
D-446	-0.47913849353790283	systolic_heart failure spironolactone
P-446	-3.6531 -0.0240 -0.0436 -0.1409 -0.6144 -0.1231 -0.0222 -0.0027 -0.0059 -0.0333 -0.9764 -0.1101
S-1087	PERK inhibition prevented the loss of full-length SCN5A and Kv4.3 mRNA levels resulting from expressing Na+ channel mRNA splice variants.<unk>
T-1087	perk scn5a kv4.3 mrna mrna_splice
H-1087	-0.8093032836914062	▁per k ▁inhibi tion ▁full - leng th ▁s CN 5 a ▁Kv 4.3 ▁m RNA
D-1087	-0.8093032836914062	perk inhibition full-length sCN5a Kv4.3 mRNA
P-1087	-1.4214 -0.5499 -0.6416 -0.0319 -3.7489 -0.0046 -0.0003 -0.0262 -0.6339 -1.0698 -0.5493 -0.5530 -1.1059 -0.1455 -0.0051 -0.0088 -3.9592 -0.1124
S-1673	In this study, we have investigated the potential dysfunction of a naturally occurring Rad variant (Q66P) that has been associated with congestive heart failure in humans.<unk>
T-1673	dysfunction rad_variant q66p congestive_heart_failure
H-1673	-1.1232918500900269	▁Rad ▁variant ▁con ges tive _ heart ▁failure
D-1673	-1.1232918500900269	Rad variant congestive_heart failure
P-1673	-3.8588 -1.6839 -2.8212 -0.0632 -0.4702 -0.0978 -1.5784 -0.1849 -0.4176 -0.0570
S-1614	Two networks were established and then functional enrichment analysis revealed that "regulation of programmed cell death" was most significantly over-represented in common DEGs.<unk>
T-1614	functional_enrichment_analysis regulation cell_death degs
H-1614	-0.900131106376648	▁functional _ ▁en rich ment _ analyse ▁programme d _ ▁cell _ ▁death ▁DE G s
D-1614	-0.900131106376648	functional_ enrichment_analyse programmed_ cell_ death DEGs
P-1614	-3.4316 -1.7108 -1.0858 -0.0094 -0.0463 -2.5907 -0.0915 -1.2257 -0.0284 -0.0569 -1.7108 -1.3412 -0.2451 -1.7987 -0.5005 -0.1231 -0.0924 -0.1133
S-1812	Moreover, elevated Mena expression correlates with HF in human and animal models, yet the precise role of Mena in cardiac pathophysiology is unclear.<unk>
T-1812	elevated mena_expression correlates hf mena cardiac pathophysiology
H-1812	-0.9470570087432861	▁Men a ▁expression ▁ HF
D-1812	-0.9470570087432861	Mena expression HF
P-1812	-1.1476 -0.0402 -1.5769 -0.3134 -0.0357 -3.3516 -0.1641
S-1751	The benefits of controlled randomized trials can be replicated in the real world, emphasizing the importance of tailored follow-up and long-term continuity of care.<unk>
T-1751	randomized follow-up
H-1751	-0.5649794936180115	▁voordelen ▁control led _ ▁random ized _ ▁trial s
D-1751	-0.5649794936180115	voordelen controlled_ randomized_ trials
P-1751	-1.9257 -0.8557 -0.1227 -0.0572 -1.0432 -0.1271 -0.4807 -0.5441 -0.0261 -0.9672 -0.0650
S-1358	RECENT FINDINGS: Apart from these perturbations, increasing evidence points to alterations in intestinal morphology, permeability, and absorption function in patients with CHF.<unk>
T-1358	evidence intestinal patients chf
H-1358	-0.9376981854438782	▁REC ENT _ ▁FIN DING s ▁intestinal _ morph ology ▁ab sor p tion ▁function ▁CHF
D-1358	-0.9376981854438782	RECENT_ FINDINGs intestinal_morphology absorption function CHF
P-1358	-2.4587 -0.2070 -0.5679 -0.2667 -1.3439 -0.5621 -4.6266 -0.9282 -0.0052 -0.6321 -2.2635 -0.2594 -0.7060 -0.3189 -1.2071 -0.3207 -0.1105 -0.0940
S-1024	We have reviewed the current status of NP measurement together with the potential contribution of POC measurement of NPs to clinical care delivery in the emergency and other settings.<unk>
T-1024	poc nps clinical
H-1024	-0.9662569165229797	▁ NP ▁measure ment ▁ NP s
D-1024	-0.9662569165229797	NP measurement NPs
P-1024	-0.2440 -0.0174 -2.0759 -0.0173 -2.6838 -0.2176 -1.9027 -1.4388 -0.0987
S-679	Trastuzumab users were more likely to develop CHF than nontrastuzumab users (hazard ratio [HR], 1.95; 95% CI, 1.75 to 2.17).<unk>
T-679	trastuzumab chf nontrastuzumab_users hazard_ratio
H-679	-1.2566397190093994	▁Tras tuz um ab ▁CHF ▁non tras tuz um ab
D-679	-1.2566397190093994	Trastuzumab CHF nontrastuzumab
P-679	-3.5457 -0.0737 -0.0140 -0.3962 -1.0649 -2.2422 -0.0423 -0.0278 -0.0169 -1.3355 -6.1531 -0.1675
S-1353	Patients with atrial fibrillation (AF) and heart failure (HF) are at risk for stroke, and progress in anticoagulation has led to new options for these patients.<unk>
T-1353	patients atrial_fibrillation heart_failure hf stroke anticoagulation patients
H-1353	-0.8223281502723694	▁at rial _ fi bril lation AF ▁heart ▁failure HF
D-1353	-0.8223281502723694	atrial_fibrillationAF heart failureHF
P-1353	-1.9421 -0.0318 -1.0653 -0.5426 -0.0083 -0.0132 -1.4112 -1.8801 -0.1150 -0.6234 -2.1910 -0.0439
S-234	Our data suggest that Fontan failure is a distinct circulatory derangement with hemodynamic features similar to portal hypertension, albeit with limited ability to augment cardiac output.<unk>
T-234	fontan_failure circulatory hemodynamic portal_hypertension cardiac_output
H-234	-0.2768070101737976	▁Font an ▁failure ▁circula tory ▁de rang ement ▁hem o dynamic ▁portal ▁hyper tension ▁aug ment ▁cardiac ▁output
D-234	-0.2768070101737976	Fontan failure circulatory derangement hemodynamic portal hypertension augment cardiac output
P-234	-0.3240 -0.0527 -0.7134 -0.2956 -0.0275 -0.9798 -0.0010 -0.2949 -0.2101 -0.0514 -0.0001 -0.3133 -0.2501 -0.0240 -1.7757 -0.0285 -0.0564 -0.0190 -0.0865 -0.0320
S-433	Combination of these into an echocardiographic score allowed prediction of LV reverse remodeling with a sensitivity of 84% and a specificity of 79%.<unk>
T-433	combination echocardiographic lv_reverse_remodeling sensitivity specificity
H-433	-0.40683987736701965	▁e cho car dio graphic ▁score ▁LV ▁rever se ▁remodel ing
D-433	-0.40683987736701965	echocardiographic score LV reverse remodeling
P-433	-0.0773 -0.0083 -0.0119 -0.3703 -0.3023 -0.7778 -0.2176 -0.5478 -0.0303 -2.4736 -0.0323 -0.2842 -0.1552
S-112	We sought to evaluate the differential effect of LVEF on long-term mortality after hospitalization for acute decompensated HF in a real-world setting.<unk>
T-112	differential_effect lvef mortality hospitalization acute decompensated_hf
H-112	-0.6557793617248535	▁LV EF ▁long - term _ ▁mortal ity ▁a cute ▁de com pensa ted _ HF
D-112	-0.6557793617248535	LVEF long-term_ mortality acute decompensated_HF
P-112	-0.4144 -0.0782 -3.8093 -0.0415 -0.0356 -0.1805 -0.6636 -0.6504 -2.6872 -0.0361 -2.4817 -0.0573 -0.0100 -0.0912 -0.2997 -0.0946 -0.0749 -0.0976
S-508	The occlusion time of the bottleneck stent and the timing of myocardial infarction could be modulated by the duration of antiplatelet medication.<unk>
T-508	bottleneck_stent myocardial_infarction antiplatelet_medication
H-508	-0.4135425090789795	▁bottle ne ck ▁sten t ▁my o card ial _ in far ction ▁anti plate let ▁medication
D-508	-0.4135425090789795	bottleneck stent myocardial_infarction antiplatelet medication
P-508	-0.3042 -0.0231 -0.0087 -1.7129 -0.0250 -2.2742 -0.2203 -0.2410 -0.1506 -1.3220 -0.4378 -0.0115 -0.0115 -0.0124 -0.0407 -0.0528 -0.8339 -0.0788 -0.0960
S-282	After the addition of salt loading and uninephrectomy to the ANG II infusion mouse model, cardiac function was significantly impaired, and mice developed HF.<unk>
T-282	salt_loading uninephrectomy ang_ii_infusion cardiac_function hf
H-282	-0.4376327693462372	▁salt ▁load ing ▁un ine ph r ecto my ▁ANG ▁II ▁in fusion ▁mouse ▁model ▁cardiac ▁function ▁ HF
D-282	-0.4376327693462372	salt loading uninephrectomy ANG II infusion mouse model cardiac function HF
P-282	-0.1699 -0.1857 -0.0128 -0.0665 -0.4934 -0.4975 -0.0283 -0.0202 -0.6861 -0.2215 -1.4567 -0.1027 -0.0078 -0.6074 -1.0523 -0.0140 -1.2136 -2.1477 -0.1381 -0.0336 -0.0345
S-296	For patients requiring biventricular support, we have used a hybrid system consisting of a HeartMate II LVAD and CentriMag right ventricular assist device (RVAD).<unk>
T-296	patients biventricular_support heartmate_ii lvad centrimag right_ventricular_assist_device rvad
H-296	-0.805348813533783	▁bi ven tri cular _ support ▁Heart Mate _ ▁II ▁l VAD ▁Centri Mag ▁right _ ▁vent ri cular _ assist ▁device ▁r VAD
D-296	-0.805348813533783	biventricular_support HeartMate_ II lVAD CentriMag right_ ventricular_assist device rVAD
P-296	-5.2112 -0.0190 -0.0432 -0.6115 -1.8003 -0.6513 -2.3555 -0.0451 -1.5217 -1.4173 -1.3051 -0.0047 -0.0458 -0.0230 -1.1189 -0.4461 -0.4471 -0.1785 -0.0901 -0.4944 -0.3677 -0.7649 -1.7773 -0.0058 -0.0707 -0.1232
S-521	Blood pressure was measured by arm cuff; stroke volume (SV), ejection fraction, and end-diastolic volume were assessed by echocardiography.<unk>
T-521	blood_pressure arm_cuff stroke_volume ejection_fraction end-diastolic_volume echocardiography
H-521	-0.29295995831489563	▁Blood ▁pressure ▁arm ▁cu ff ▁stroke ▁volume ▁e je ction ▁ fraction ▁end - dia sto lic _ ▁volume ▁e cho card i ography
D-521	-0.29295995831489563	Blood pressure arm cuff stroke volume ejection fraction end-diastolic_ volume echocardiography
P-521	-0.3410 -0.4402 -1.3854 -0.0179 -0.0010 -0.0594 -0.1934 -0.9027 -0.0173 -0.0046 -0.7872 -0.0002 -2.1483 -0.0181 -0.0114 -0.0412 -0.0439 -0.7094 -0.0393 -0.0146 -0.0044 -0.0402 -0.1062 -0.1367 -0.0761 -0.0771
S-1060	The percentage of fibrosis of heart failure myocardial tissue was compared with similar left ventricular tissue from control animals using trichrome blue histologic analysis.<unk>
T-1060	fibrosis heart_failure myocardial_tissue left_ventricular trichrome_blue_histologic_analysis
H-1060	-0.7614667415618896	▁fibro sis _ van _ heart ▁failure _ my o card ial _ ▁tissu e ▁left _ ▁vent ri cular _ ▁tissu e ▁tri ch rom e _ blue _ ▁his t ologic
D-1060	-0.7614667415618896	fibrosis_van_heart failure_myocardial_ tissue left_ ventricular_ tissue trichrome_blue_ histologic
P-1060	-0.0021 -0.0619 -2.3119 -3.2305 -0.1119 -1.3192 -0.6988 -1.0304 -4.0170 -0.1599 -0.2310 -0.1883 -1.1189 -0.1152 -0.1047 -1.8575 -0.9246 -0.3273 -0.5773 -0.2810 -0.9994 -0.2709 -0.0471 -0.0474 -0.0110 -0.0008 -0.0315 -0.1969 -1.0069 -1.3015 -2.7906 -0.0683 -0.0491 -1.0434 -0.1169
S-781	We evaluated the Kansas City Cardiomyopathy Questionnaire (KCCQ), a validated measure of HF with reduced EF, in patients with HFpEF.<unk>
T-781	kansas_city_cardiomyopathy_questionnaire kccq hf_with_reduced_ef patients hfpef
H-781	-0.6873445510864258	▁Kansas ▁City ▁Card i om yo pathy ▁Question naire ▁k cc q ▁ HF ▁ HF p EF
D-781	-0.6873445510864258	Kansas City Cardiomyopathy Questionnaire kccq HF HFpEF
P-781	-0.0169 -0.4720 -3.0367 -0.0826 -0.0254 -2.2957 -0.1850 -0.9439 -0.0016 -1.0013 -0.2884 -0.4775 -0.1774 -0.1519 -2.6993 -1.0420 -0.6365 -0.0493 -0.0922 -0.0715
S-1642	Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial.<unk>
T-1642	outcomes patients atrial_fibrillation early_treatment_of_atrial_fibrillation_for_stroke_prevention_trial
H-1642	-1.2924867868423462	▁at rial _ fi bril lation
D-1642	-1.2924867868423462	atrial_fibrillation
P-1642	-4.1931 -0.0290 -0.9514 -0.9567 -0.0386 -0.0257 -4.0944 -0.0510
S-491	Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis.<unk>
T-491	tricuspid_annular_plane_systolic_excursion pulmonary_arterial_systolic_pressure heart_failure right_ventricular_contractile_function prognosis
H-491	-0.613579511642456	▁tri cus pid ▁ann ular _ ▁plane ▁sy sto lic _ excursion ▁pulmonar y ▁arterial ▁sy sto lic _ ▁pressure ▁heart ▁failure ▁index ▁vent ri cular ▁contract ile
D-491	-0.613579511642456	tricuspid annular_ plane systolic_excursion pulmonary arterial systolic_ pressure heart failure index ventricular contractile
P-491	-0.5277 -0.0335 -0.1010 -0.6701 -0.0131 -0.8884 -0.4512 -0.2192 -0.0920 -0.2314 -0.8840 -0.1901 -0.0021 -0.0123 -0.5403 -0.5337 -0.0087 -0.0285 -0.1660 -3.8433 -2.8638 -1.3087 -2.1503 -1.4816 -0.2641 -0.1529 -0.3446 -0.0129 -0.3001 -0.0918
S-1728	In contrast, patients cared for by high-volume physicians had higher readmission rates (25.8% versus 21.5%; P<0001); this relationship was similar across hospital volume groups.<unk>
T-1728	patients physicians readmission hospital
H-1728	-0.7240262031555176	▁high - volu me _ ▁physician s
D-1728	-0.7240262031555176	high-volume_ physicians
P-1728	-3.0124 -0.0266 -0.0300 -0.0482 -0.2570 -0.6647 -0.0320 -2.3565 -0.0889
S-564	CONCLUSIONS: Beyond divergent etiology and comorbidities, younger patients exhibited striking differences in presentation and outcomes compared with older counterparts.<unk>
T-564	etiology comorbidities patients outcomes
H-564	-0.6405632495880127	▁di ver gent ▁et i ology ▁como rbi di ties
D-564	-0.6405632495880127	divergent etiology comorbidities
P-564	-3.9892 -0.0040 -0.0048 -0.8303 -0.1147 -0.1685 -0.6523 -0.0069 -0.1325 -0.0092 -1.7309 -0.0436
S-1934	Given that exercise training improves outcomes in HF patients, assessment of perceived barriers may facilitate individualized approaches to implement exercise training therapy in clinical practice.<unk>
T-1934	exercise training outcomes hf patients exercise training therapy clinical
H-1934	-0.7880869507789612	▁exercise ▁training ▁ therapy
D-1934	-0.7880869507789612	exercise training therapy
P-1934	-1.3539 -0.9922 -1.6668 -0.0705 -0.5461 -0.0990
S-95	Of these proteins, 176 exhibited altered expression during cardiac hypertrophy and failure; we conducted extensive functional characterization of one of these proteins, Nucleolin.<unk>
T-95	proteins expression cardiac_hypertrophy proteins nucleolin
H-95	-0.5941803455352783	▁protein s ▁cardiac ▁hyper trop hy ▁nu cle olin
D-95	-0.5941803455352783	proteins cardiac hypertrophy nucleolin
P-95	-2.4049 -0.0705 -0.6571 -1.1851 -0.0078 -0.5213 -1.4790 -0.0014 -0.0227 -0.0938 -0.0924
S-768	The underlying myocardial DD was obvious from high muscle strip stiffness, which was largely (±80%) attributable to titin hypophosphorylation.<unk>
T-768	myocardial_dd muscle titin_hypophosphorylation
H-768	-0.5944415330886841	▁my o card ial ▁ DD ▁muscle ▁strip ▁sti ff ness ▁titi n ▁hypo phos phor y lation
D-768	-0.5944415330886841	myocardial DD muscle strip stiffness titin hypophosphorylation
P-768	-1.7680 -0.0658 -0.0236 -0.0397 -1.3572 -0.0183 -3.6840 -0.6124 -0.0587 -0.0135 -2.7806 -0.0277 -0.0428 -0.3680 -0.0194 -0.1913 -0.5916 -0.0563 -0.0830 -0.0869
S-1158	OBJECTIVES: This study sought to examine the relationships between right ventricular (RV) function, body composition, and prognosis in patients with advanced heart failure (HF).<unk>
T-1158	right_ventricular rv prognosis patients heart_failure hf
H-1158	-1.408921480178833	▁right _ ▁vent ri cular _ RV
D-1158	-1.408921480178833	right_ ventricular_RV
P-1158	-4.6076 -1.5140 -0.9034 -0.1632 -0.0469 -1.3317 -0.4474 -3.5993 -0.0669
S-1969	Beneficial effect of ARNI was consistent also for total and cardiovascular mortality, for hospitalization for heart failure and in other pre-specified subgroup analyses, including quality of life.<unk>
T-1969	arni cardiovascular_mortality hospitalization heart_failure quality_of_life
H-1969	-0.87937331199646	▁AR NI ▁cardiovascular ▁mortal ity ▁hospital ization _ voor _ heart ▁failure
D-1969	-0.87937331199646	ARNI cardiovascular mortality hospitalization_voor_heart failure
P-1969	-2.3924 -0.4902 -1.0203 -0.7443 -0.2960 -0.2006 -0.4191 -1.6996 -2.4226 -0.3866 -0.6234 -0.5048 -0.9474 -0.1638
S-340	However, functional MS could develop even in patients with a history of successful valve plasty and annular size reduction for degenerative MR if the LV were dilated by another disease.<unk>
T-340	functional_ms patients valve_plasty degenerative_mr dilated disease
H-340	-0.3055032193660736	▁functional ▁MS ▁val ve ▁plast y ▁ann ular _ ▁size ▁re duction ▁de genera tive _ ▁MR ▁LV
D-340	-0.3055032193660736	functional MS valve plasty annular_ size reduction degenerative_ MR LV
P-340	-0.0223 -0.0675 -1.7059 -0.0041 -0.0658 -0.0461 -0.0180 -0.0003 -0.7450 -0.4956 -0.2771 -0.0084 -0.0318 -0.0002 -0.0655 -0.4028 -0.8810 -0.3751 -0.8607 -0.0368
S-131	Higher EO-CFUs and lower CD34+VEGFR2+ cells were associated with improved functional capacity and reduced mortality in nondiabetic patients.<unk>
T-131	eo-cfus cells functional_capacity mortality nondiabetic patients
H-131	-0.834151029586792	▁ EO - c FU s ▁CD 34 + ve g FR 2 _ ▁cell s
D-131	-0.834151029586792	EO-cFUs CD34+vegFR2_ cells
P-131	-0.5617 -0.0081 -0.0132 -1.2413 -0.0769 -1.1954 -1.2139 -0.1130 -2.5705 -0.5592 -1.3588 -0.2405 -0.4226 -2.7766 -0.8770 -0.0985 -1.5988 -0.0888
S-842	In conclusion, in the HF-ACTION cohort, there was no correlation with baseline Hgb and baseline HRQoL as measured by the KCCQ.<unk>
T-842	hf-action correlation baseline hgb baseline hrqol kccq
H-842	-0.28790083527565	▁ HF - AC TION ▁co hor t ▁base line _ h gb ▁base line _ HR Qo L ▁k cc q
D-842	-0.28790083527565	HF-ACTION cohort baseline_hgb baseline_HRQoL kccq
P-842	-0.0839 -0.0483 -0.0107 -0.8582 -0.1762 -0.3306 -0.0064 -0.0107 -0.0824 -0.0034 -1.2121 -0.3011 -0.0004 -1.0192 -0.0027 -0.2713 -0.7291 -0.0069 -0.2935 -0.7216 -0.3281 -0.3602 -0.0130 -0.0396
S-1001	BACKGROUND: Frailty, an important prognostic indicator in heart failure (HF), may be defined as a biological phenotype or an accumulation of deficits.<unk>
T-1001	frailty prognostic heart_failure hf biological_phenotype
H-1001	-0.9896578788757324	▁fra il ty ▁heart ▁failure ▁ HF
D-1001	-0.9896578788757324	frailty heart failure HF
P-1001	-0.8564 -0.3599 -0.0266 -3.5464 -0.2006 -2.6571 -0.0209 -1.1761 -0.0630
S-375	This case report demonstrates that functional MS could develop even in a patient with a history of successful valve plasty for degenerative MR, if the LV is dilated by another disease.<unk>
T-375	report functional_ms patient valve_plasty degenerative_mr dilated disease
H-375	-0.38034653663635254	▁functional ▁MS ▁val ve ▁plast y ▁de genera tive _ ▁MR ▁LV
D-375	-0.38034653663635254	functional MS valve plasty degenerative_ MR LV
P-375	-0.0338 -0.1821 -2.4399 -0.0047 -0.3552 -0.0915 -0.0999 -0.0002 -0.0721 -0.6636 -0.4317 -0.5121 -0.4024 -0.0357
S-1750	CONCLUSIONS: Evidence-based treatment has led to dramatic improvement in the prognosis of idiopathic dilated cardiomyopathy during the past 3 decades.<unk>
T-1750	evidence-based prognosis idiopathic_dilated_cardiomyopathy
H-1750	-0.5699040293693542	▁ idio pathi c ▁dil ated _ ▁cardio my o pathy
D-1750	-0.5699040293693542	idiopathic dilated_ cardiomyopathy
P-1750	-0.9409 -1.8091 -0.0650 -0.0484 -2.3276 -0.3315 -0.1726 -0.4712 -0.8898 -0.2130 -0.0289 -0.0749 -0.0359
S-1035	It is a consequence of pathological remodelling of the heart, which involves cardiac hypertrophy (a robust predictor of subsequent HF and death), fibrosis and inflammation.<unk>
T-1035	pathological remodelling heart cardiac_hypertrophy hf death fibrosis inflammation
H-1035	-0.45665186643600464	▁cardiac ▁hyper trop hy ▁ HF ▁fibro sis ▁ inflammation
D-1035	-0.45665186643600464	cardiac hypertrophy HF fibrosis inflammation
P-1035	-3.7456 -0.8207 -0.0031 -0.2463 -0.2055 -0.0113 -0.0197 -0.0424 -0.2069 -0.0010 -0.1090 -0.0683
S-1917	The combined training resulted in an improvement in peak work rate (range: 6% to 36%) and peak quadriceps force (range: 3% to 80%) in all participants.<unk>
T-1917	combined_training peak_work_rate peak_quadriceps_force
H-1917	-0.8884757161140442	▁pe ak _ work ▁rate ▁pe ak ▁quadri cep s ▁force
D-1917	-0.8884757161140442	peak_work rate peak quadriceps force
P-1917	-4.1516 -0.0083 -0.3691 -1.1703 -1.0239 -0.3264 -0.0187 -2.3627 -0.0354 -0.0437 -1.7176 -0.1951 -0.1274
S-1756	We excluded 921 patients who did not perform a maximal exercise, based on lack of achievement of anaerobic metabolism (peak respiratory quotient ≤1.05).<unk>
T-1756	patients exercise anaerobic_metabolism peak_respiratory_quotient
H-1756	-1.4098831415176392	▁aan ero bic _ ▁metabolism pe ak ▁respirator y
D-1756	-1.4098831415176392	aanerobic_ metabolismpeak respiratory
P-1756	-7.1955 -2.8160 -0.1733 -1.1008 -0.4155 -0.3535 -0.0200 -2.2919 -0.0235 -0.9936 -0.1250
S-2014	Simulations consist of 10,000 pairs of virtual cohorts used to generate estimates of resource use, costs, survival, and incremental cost-effectiveness ratios from user inputs.<unk>
T-2014	costs
H-2014	-1.1195448637008667	▁virtual _ co hor ts ▁resource
D-2014	-1.1195448637008667	virtual_cohorts resource
P-2014	-1.6398 -1.2002 -0.3672 -0.0134 -0.0950 -0.6847 -4.8905 -0.0656
S-192	RESULTS: There were 47,025 patients with reduced (37% female), 13,950 with borderline (48% female), and 38,955 with preserved (65% female) EF.<unk>
T-192	patients ef
H-192	-1.999883770942688	
D-192	-1.999883770942688	
P-192	-3.8968 -0.1030
S-177	This study assesses the impact of RAS- and β-blocker uptitrations in patients with HFrEF versus HFpEF during and immediately after a hospital admission.<unk>
T-177	β-blocker uptitrations patients hfref hfpef hospital admission
H-177	-0.6042582988739014	▁ RAS - ▁β - block er _ up ti tra tions ▁H Fr EF ▁ HF p EF
D-177	-0.6042582988739014	RAS- β-blocker_uptitrations HFrEF HFpEF
P-177	-0.4152 -0.0068 -0.1029 -2.8469 -0.0121 -0.1034 -0.0469 -3.0089 -0.2347 -0.2605 -0.8603 -0.9840 -1.6194 -0.1253 -0.1682 -0.7289 -0.0364 -0.0579 -0.1878 -0.7609 -0.1222
S-1604	The American College of Cardiology/American Heart Association guidelines on evaluation and management of patients with RAS provide the framework for determining individualized assessment and treatment plans for patients with RAS.<unk>
T-1604	american_college_of_cardiology american_heart_association patients ras patients ras
H-1604	-0.735986590385437	▁American ▁College _ of _ ▁Card i ology _ American _ ▁Heart ▁Association ▁ RAS
D-1604	-0.735986590385437	American College_of_ Cardiology_American_ Heart Association RAS
P-1604	-2.6664 -1.6159 -0.1395 -0.7886 -0.1536 -2.8488 -0.0973 -0.0421 -0.5789 -0.0438 -0.1216 -0.5727 -0.3585 -1.7127 -0.1850 -0.5098 -0.0766
S-265	METHODS: NT-proBNP levels were measured in plasma obtained from 99 patients with dyspnea and left ventricular dysfunction upon admission to the ED.<unk>
T-265	nt-probnp plasma patients dyspnea left_ventricular_dysfunction admission
H-265	-0.6240571141242981	▁NT - pro b NP ▁plasma ▁dys pne a ▁left ▁vent ri cular ▁dys function ▁ED
D-265	-0.6240571141242981	NT-probNP plasma dyspnea left ventricular dysfunction ED
P-265	-1.2807 -0.0220 -0.0055 -0.7624 -0.0619 -1.4333 -1.9115 -0.0122 -0.1454 -0.1642 -1.0121 -0.7837 -0.5219 -1.1811 -0.0905 -1.7121 -0.0600 -0.0725
S-1857	BACKGROUND: There is a class I recommendation for implantable cardioverter-defibrillator deactivation discussions to occur between physicians and heart failure patients.<unk>
T-1857	implantable_cardioverter-defibrillator physicians heart_failure patients
H-1857	-0.5426613092422485	▁implant able _ ▁cardio ver ter - de fi br illa tor ▁de activa tion
D-1857	-0.5426613092422485	implantable_ cardioverter-defibrillator deactivation
P-1857	-2.5620 -0.0165 -0.3289 -1.4674 -0.0067 -0.1689 -0.3604 -0.0104 -0.2359 -0.2277 -0.1190 -0.0239 -0.2542 -0.0083 -0.3117 -3.0184 -0.1049
S-120	BACKGROUND: Circulating progenitor cells (CPCs) are involved in the process of endothelial repair and are a prognostic factor in cardiovascular diseases.<unk>
T-120	circulating_progenitor_cells cpcs endothelial prognostic cardiovascular_diseases
H-120	-0.3792572617530823	▁circula ting _ pro gen itor ▁cell s ▁c PC s ▁en dot heli al _ ▁repair ▁cardiovascular ▁disease s
D-120	-0.3792572617530823	circulating_progenitor cells cPCs endothelial_ repair cardiovascular diseases
P-120	-0.3237 -0.1695 -0.3741 -1.1016 -0.0282 -0.0221 -0.7000 -0.0454 -0.2465 -0.1153 -0.6861 -0.0727 -0.4712 -0.0339 -0.0087 -1.0893 -0.1657 -0.2934 -2.2292 -0.0622 -0.0566 -0.0482
S-476	However, the improvement in contractile function is not paralleled by any attenuation in LV dilatation, LV end-diastolic pressure/wall stress, and lung weight.<unk>
T-476	contractile_function lv_dilatation lv_end-diastolic_pressure wall_stress lung
H-476	-0.6138768196105957	▁contract ile ▁function ▁LV ▁di la tation ▁LV ▁end - dia sto lic _ ▁pressure _ wall ▁stress ▁lung ▁weight
D-476	-0.6138768196105957	contractile function LV dilatation LV end-diastolic_ pressure_wall stress lung weight
P-476	-0.0026 -0.0133 -0.7585 -0.6196 -1.4488 -0.0516 -0.0027 -1.7886 -2.9066 -0.0099 -0.0069 -0.0367 -0.0216 -0.1902 -1.4123 -1.5071 -0.0896 -0.5426 -0.0061 -1.9633 -0.0499 -0.0768
S-478	However, LV remodeling and diastolic properties are not improved, which may explain the failure of XO inhibition to improve symptoms and hospitalizations in patients with severe heart failure.<unk>
T-478	lv_remodeling diastolic xo_inhibition symptoms hospitalizations patients severe_heart_failure
H-478	-0.41741621494293213	▁LV ▁remodel ing ▁dia sto lic ▁properties ▁ XO ▁inhibi tion
D-478	-0.41741621494293213	LV remodeling diastolic properties XO inhibition
P-478	-0.0853 -0.4614 -0.0139 -0.0527 -0.0128 -0.0051 -1.8398 -0.2038 -0.0279 -0.9067 -0.0956 -1.6179 -0.1036
S-1802	A total of 569 individuals aged 55-85 and Caucasian were genotyped for SNP rs10927887 in the Ka renal chloride channel gene (CLCNKA).<unk>
T-1802	genotyped snp rs10927887 ka_renal_chloride_channel_gene clcnka
H-1802	-0.8230838179588318	▁Cau ca sian ▁s NP ▁rs 109 27 887 ▁ka ▁renal _ ▁chlor ide _ ▁channel ▁gene CL CN KA
D-1802	-0.8230838179588318	Caucasian sNP rs10927887 ka renal_ chloride_ channel geneCLCNKA
P-1802	-4.9038 -0.0014 -0.0240 -1.6988 -0.0128 -1.8958 -0.0681 -1.2901 -0.0715 -0.6761 -0.0199 -0.7078 -0.6959 -0.1482 -1.2040 -0.5316 -2.4041 -0.0960 -0.6005 -0.8336 -0.1036 -0.1200
S-1385	The objective of this study was to investigate the impact of ventricular assist device (VAD) and extracorporeal membrane oxygenation (ECMO) on renal function in children.<unk>
T-1385	ventricular_assist_device vad extracorporeal_membrane_oxygenation ecmo renal_function
H-1385	-0.4461965560913086	▁vent ri cular _ assist ▁device VAD ▁extra corp o real _ ▁membran e _ ▁oxygen ation ▁ec MO ▁renal ▁function
D-1385	-0.4461965560913086	ventricular_assist deviceVAD extracorporeal_ membrane_ oxygenation ecMO renal function
P-1385	-0.0336 -0.3269 -0.0918 -0.6413 -0.2265 -1.0544 -2.1040 -0.0302 -0.0121 -0.2765 -0.0117 -0.1113 -0.2074 -0.0313 -0.8118 -0.7751 -0.0524 -0.4123 -0.6271 -0.1640 -1.8881 -0.2344 -0.1382
S-999	However, after cardiac magnetic resonance, the typical amyloidotic pattern is found and the final diagnosis of multiple myeloma is made at osteomedullary biopsy.<unk>
T-999	cardiac_magnetic_resonance amyloidotic diagnosis multiple_myeloma osteomedullary_biopsy
H-999	-0.2751995325088501	▁cardiac ▁magnetic _ ▁res on ance ▁a my lo ido tic _ ▁pattern ▁multiple ▁mye loma ▁osteo me dulla ry ▁bio psy
D-999	-0.2751995325088501	cardiac magnetic_ resonance amyloidotic_ pattern multiple myeloma osteomedullary biopsy
P-999	-0.0267 -0.1206 -0.7933 -0.1502 -0.0694 -0.0798 -0.0302 -0.0700 -0.0119 -0.0103 -0.9861 -1.4897 -0.1585 -0.4487 -0.7834 -0.1429 -0.0179 -0.1119 -0.0303 -0.9001 -0.0680 -0.0088 -0.0658 -0.0303
S-1303	Diagnosis of HFpEF is frequently challenging and relies upon careful clinical evaluation, echo-Doppler cardiography, and invasive haemodynamic assessment.<unk>
T-1303	diagnosis hfpef clinical echo-doppler_cardiography invasive_haemodynamic_assessment
H-1303	-0.2722116708755493	▁ HF p EF ▁e cho - D opp ler ▁card i ography ▁invasi ve ▁ha emo dynamic ▁assessment
D-1303	-0.2722116708755493	HFpEF echo-Doppler cardiography invasive haemodynamic assessment
P-1303	-0.2033 -0.2269 -0.0291 -0.0558 -1.3411 -0.0070 -0.0092 -1.0029 -0.0448 -0.3356 -1.0896 -0.0610 -0.1111 -0.0061 -0.0285 -0.2864 -0.2006 -0.0008 -0.5764 -0.0632 -0.0372
S-1068	Implantable cardioverter-defibrillators (ICDs) decrease mortality, and cardiac resynchronization therapy (CRT) improves symptoms and mortality.<unk>
T-1068	implantable_cardioverter-defibrillators icds mortality cardiac_resynchronization_therapy crt symptoms mortality
H-1068	-0.42059800028800964	▁implant able ▁cardio ver ter - de fi br illa tors IC d s ▁cardiac ▁re syn chron ization ▁ therapy ▁c RT
D-1068	-0.42059800028800964	implantable cardioverter-defibrillatorsICds cardiac resynchronization therapy cRT
P-1068	-1.4090 -0.0070 -1.1944 -0.0138 -1.1206 -0.1316 -0.0212 -0.1603 -0.2601 -0.1437 -0.2050 -0.5310 -0.9061 -0.1153 -0.1008 -0.1896 -0.0052 -0.0069 -0.8913 -1.2304 -0.0117 -1.3244 -0.1052 -0.3678 -0.0626
S-448	Vascular endothelial growth factor blockade prevents the beneficial effects of beta-blocker therapy on cardiac function, angiogenesis, and remodeling in heart failure.<unk>
T-448	vascular_endothelial_growth_factor_blockade beta-blocker therapy cardiac_function angiogenesis remodeling heart_failure
H-448	-0.6145356297492981	▁Vas cular ▁en dot heli al _ ▁growth ▁factor ▁block ade ▁beta - block er ▁ therapy ▁cardiac ▁function ▁ang io gene sis ▁remodel ing ▁heart ▁failure
D-448	-0.6145356297492981	Vascular endothelial_ growth factor blockade beta-blocker therapy cardiac function angiogenesis remodeling heart failure
P-448	-1.0428 -0.0694 -1.3218 -1.7236 -0.0290 -0.0144 -0.7907 -1.7599 -0.7527 -1.9721 -0.1889 -0.8088 -0.0084 -0.0398 -0.0948 -0.7142 -0.0072 -0.0780 -2.9299 -0.5456 -0.6641 -0.0138 -0.2031 -0.3825 -0.0084 -0.4110 -1.0898 -0.0876 -0.0691
S-915	Low-sodium DASH diet improves diastolic function and ventricular-arterial coupling in hypertensive heart failure with preserved ejection fraction.<unk>
T-915	dash diastolic_function ventricular-arterial_coupling hypertensive_heart_failure_with_preserved_ejection_fraction
H-915	-0.4682856500148773	▁DAS h ▁die t ▁dia sto lic _ ▁function ▁vent ri cular - arte rial _ ▁coup ling ▁hyper tensi ve _ heart ▁failure ▁pres er ved ▁e je ction ▁ fraction
D-915	-0.4682856500148773	DASh diet diastolic_ function ventricular-arterial_ coupling hypertensive_heart failure preserved ejection fraction
P-915	-1.7918 -0.3924 -2.4750 -0.0425 -0.0785 -0.0064 -0.0379 -2.0869 -1.1294 -0.0039 -0.4994 -0.0786 -0.1751 -0.0697 -0.0233 -0.6905 -0.1358 -0.2269 -0.1461 -0.0520 -0.1562 -0.1130 -1.2003 -0.4865 -0.0617 -0.1085 -0.4910 -1.6698 -0.0367 -0.0140 -1.2260 -0.0008 -0.1319 -0.0832
S-314	Neither BTT nor DT currently meet traditional cost-effectiveness limits in models using historical data, although BTT is standard practice for a limited number of patients in many regions.<unk>
T-314	btt dt btt patients
H-314	-0.7251306176185608	▁b TT ▁ DT
D-314	-0.7251306176185608	bTT DT
P-314	-0.8859 -0.8411 -0.4840 -0.0193 -2.0632 -0.0574
S-1800	Overall, in the scenario of lower total expenditure on health per capita and lower gross national income per capita, new strategies are essential for prevention and treatment of HF in LA.<unk>
T-1800	expenditure health income hf
H-1800	-1.568407416343689	▁health ▁per ▁capita ▁gross _ national _ ▁income
D-1800	-1.568407416343689	health per capita gross_national_ income
P-1800	-7.1885 -0.8438 -0.0420 -2.1989 -0.0791 -0.3488 -0.3919 -0.5344 -3.9335 -0.1233
S-1600	Adequate blood pressure control, goal-directed lipid-lowering therapy, smoking cessation, and other preventive measures form the foundation of management of patients with RAS.<unk>
T-1600	blood_pressure therapy patients ras
H-1600	-0.43003517389297485	▁blood ▁pressure ▁control ▁goal - direct ed ▁lipid - lo wering ▁ therapy ▁smoking ▁ces s ation
D-1600	-0.43003517389297485	blood pressure control goal-directed lipid-lowering therapy smoking cessation
P-1600	-1.5894 -0.3433 -0.9989 -1.4409 -0.0041 -0.0006 -0.0204 -0.4307 -0.0354 -0.0453 -0.0147 -1.0384 -0.0219 -0.0042 -0.3960 -0.0165 -0.1081 -1.5693 -0.0925
S-196	After adjusting for over 20 clinical variables, the ability of BNP to predict inhospital mortality was similar among all subgroups (P for heterogeneity = .47).<unk>
T-196	clinical bnp inhospital mortality
H-196	-0.7802028059959412	▁b NP ▁in hospital _ ▁mortal ity
D-196	-0.7802028059959412	bNP inhospital_ mortality
P-196	-1.3932 -0.5685 -0.7112 -0.0724 -1.4377 -0.1242 -0.3670 -2.3104 -0.0371
S-1442	SDQT increased significantly in the HFVT(+) and HFVT(-) groups compared with the HNorm group during fixed-rate atrial pacing (P = 0.008).<unk>
T-1442	sdqt atrial_pacing
H-1442	-0.43822747468948364	▁SD QT ▁ HF VT ▁ HF VT ▁h Nor m _ groep ▁fixed - rate _ at rial ▁pa cing
D-1442	-0.43822747468948364	SDQT HFVT HFVT hNorm_groep fixed-rate_atrial pacing
P-1442	-0.0520 -0.1320 -0.0784 -0.0312 -0.1218 -0.7943 -0.1201 -0.2968 -2.9462 -1.3704 -0.0135 -1.8254 -0.4147 -0.2163 -0.0647 -0.0776 -0.0633 -0.4058 -0.0147 -0.4145 -0.2274 -0.2622 -0.1359
S-108	Time-dependent analysis showed that the development of IEs among CRT-D recipients was associated with more than twofold (p = 0.01) increased risk for subsequent heart failure or death.<unk>
T-108	ies crt-d heart_failure death
H-108	-0.9732810258865356	▁c RT - D
D-108	-0.9732810258865356	cRT-D
P-108	-2.1130 -0.1907 -0.0227 -0.6692 -2.7101 -0.1338
S-952	CONCLUSIONS: Our results suggest that AF can be effectively and safely treated with a composite of repeat procedures and pharmaceuticals in patients with HFPEF.<unk>
T-952	pharmaceuticals patients hfpef
H-952	-0.7673789858818054	▁AF ▁ pharma ce u tical s
D-952	-0.7673789858818054	AF pharmaceuticals
P-952	-0.8554 -2.6791 -0.4872 -0.1693 -0.0303 -0.0083 -0.1220 -2.4901 -0.0648
S-1007	RESULTS: Among 223 patients (mean age 71 ± 14, 61% male), 21% were frail and 48% intermediate frail according to the biological phenotype.<unk>
T-1007	patients frail frail biological_phenotype
H-1007	-0.48226505517959595	▁fra il
D-1007	-0.48226505517959595	frail
P-1007	-0.7029 -0.1283 -1.0392 -0.0586
S-738	Sixty-one patients with confirmed HFPEF entered a longitudinal outcome-monitoring phase (mean, 22.9±5.0 months), during which 16 had a cardiac event.<unk>
T-738	patients hfpef longitudinal cardiac_event
H-738	-1.0910905599594116	▁H FP EF ▁longitud in al _ monitor ing _ ▁phase ▁cardiac
D-738	-1.0910905599594116	HFPEF longitudinal_monitoring_ phase cardiac
P-738	-3.7594 -0.0962 -0.1647 -1.4884 -0.0299 -0.1123 -0.4488 -3.3278 -0.0104 -3.2348 -0.6612 -0.1164 -1.7485 -0.0763
S-1722	Physician volume is associated with better outcomes for patients undergoing procedures, but its association with outcomes for medically managed diseases, such as HF, is not well understood.<unk>
T-1722	physician outcomes patients outcomes medically diseases hf
H-1722	-0.5790648460388184	▁Physic ian ▁volume ▁ HF
D-1722	-0.5790648460388184	Physician volume HF
P-1722	-0.2013 -0.0784 -0.1218 -2.4586 -0.7655 -0.3398 -0.0881
S-1063	CONCLUSION: The proposed T1-mapping technique can quantify diffuse myocardial changes associated with heart failure without the use of a contrast agent and without breath-holding.<unk>
T-1063	t1-mapping myocardial heart_failure
H-1063	-0.989676833152771	▁diffuse _ my o card ial _ ▁changes ▁heart ▁failure ▁contrast ▁agent ▁breath - hold ing
D-1063	-0.989676833152771	diffuse_myocardial_ changes heart failure contrast agent breath-holding
P-1063	-5.4313 -0.3919 -3.8617 -0.1434 -0.3294 -0.2206 -1.3872 -2.3439 -2.1288 -0.6257 -0.3287 -0.1295 -0.0933 -0.0622 -0.0679 -0.0233 -0.1351 -0.1102
S-1224	BACKGROUND: Underuse of eplerenone in patients with HF-REF may be due to fear of inducing hyperkalemia or WRF in high-risk patients.<unk>
T-1224	eplerenone patients hf-ref hyperkalemia patients
H-1224	-0.4900888502597809	▁e pler en one ▁ HF - RE F ▁hyper kal emia ▁w RF
D-1224	-0.4900888502597809	eplerenone HF-REF hyperkalemia wRF
P-1224	-0.0769 -0.0074 -0.1209 -0.3602 -0.2706 -0.0922 -0.0150 -0.5664 -0.2335 -5.1980 -0.1734 -0.0389 -0.3757 -0.0837 -0.1135 -0.1152
S-827	Of 124 patients, 66 were below the median exercise-induced PASP increase of 30 mm Hg (low PASP), and 58 patients were above the median (high PASP).<unk>
T-827	patients exercise-induced_pasp pasp patients pasp
H-827	-1.2425709962844849	▁pas p
D-827	-1.2425709962844849	pasp
P-827	-3.4806 -0.4880 -0.9379 -0.0638
S-149	OBJECTIVE: To determine whether RM strategies improve outcomes for adults who have been recently discharged (<28 days) following an unplanned admission due to heart failure.<unk>
T-149	rm outcomes discharged admission heart_failure
H-149	-0.876484215259552	▁RM ▁strategie s
D-149	-0.876484215259552	RM strategies
P-149	-0.7429 -0.6257 -0.0121 -2.9388 -0.0629
S-887	In patients with LBBB receiving implantable cardioverter defibrillator-CRT, there was a reduction in the primary outcome and in each individual component of the primary outcome.<unk>
T-887	patients lbbb implantable primary_outcome primary_outcome
H-887	-0.2776939868927002	▁ LB bb ▁implant able _ ▁cardio ver ter _ de fi br illa tor - C RT
D-887	-0.2776939868927002	LBbb implantable_ cardioverter_defibrillator-CRT
P-887	-0.4636 -0.0069 -0.6978 -0.5988 -0.0167 -0.2325 -0.5232 -0.0095 -0.0686 -0.5986 -0.4247 -0.0157 -0.0553 -0.0835 -0.0112 -0.2450 -1.0347 -0.2177 -0.1916 -0.0582
S-880	BACKGROUND: The impact of QRS morphology and duration on the effectiveness of cardiac resynchronization therapy (CRT) has been usually assessed separately.<unk>
T-880	qrs_morphology cardiac_resynchronization_therapy crt
H-880	-0.415958046913147	▁QR s ▁ morph ology ▁cardiac ▁re syn chron ization ▁ therapy ▁c RT
D-880	-0.415958046913147	QRs morphology cardiac resynchronization therapy cRT
P-880	-0.1299 -0.6453 -0.1444 -0.0052 -0.3722 -0.2138 -0.7306 -0.0431 -0.0101 -1.0522 -2.1469 -0.0241 -0.9907 -0.0686 -0.0297 -0.0486
S-639	Although aberrant reactivation of embryonic gene programs is intricately linked to pathological heart disease, the transcription factors driving these gene programs remain ill-defined.<unk>
T-639	gene pathological heart_disease transcription_factors driving gene
H-639	-1.1459319591522217	▁em bry o nic _ ▁gene ▁programs ▁path ological _ heart ▁disease
D-639	-1.1459319591522217	embryonic_ gene programs pathological_heart disease
P-639	-5.3038 -0.2900 -0.1889 -0.7566 -0.6100 -3.1580 -0.5589 -0.1119 -0.2218 -0.2629 -1.4568 -1.6739 -1.2884 -0.1612
S-807	Values of standard error of measurement and MDC may be used in daily clinical practice with these populations to define what is expected and what represents true change in repeated measures.<unk>
T-807	standard_error_of_measurement mdc clinical change
H-807	-0.7572881579399109	▁standard ▁error _ of _ ▁measure ment ▁m DC
D-807	-0.7572881579399109	standard error_of_ measurement mDC
P-807	-2.5372 -1.3365 -0.6346 -1.3373 -0.1694 -1.3811 -0.0241 -0.3411 -0.0154 -0.4167 -0.1368
S-409	Patients with low sST2/low-dose BB or high sST2/high-dose BB had intermediate odds ratios for cardiovascular events (P=0.18 and 0.02).<unk>
T-409	patients sst2 sst2 odds_ratios cardiovascular_events
H-409	-0.6819126605987549	▁s ST 2/ low - dos e ▁BB ▁s ST 2/ high - dos e _ bb
D-409	-0.6819126605987549	sST2/low-dose BB sST2/high-dose_bb
P-409	-0.3474 -1.1492 -0.7377 -0.5806 -0.0177 -0.6257 -0.0957 -0.2463 -0.5750 -0.7769 -0.5443 -1.3678 -0.0228 -0.6288 -0.0576 -1.7487 -0.8498 -2.3974 -0.1869
S-1994	The centrifugal flow pump is designed for enhanced hemocompatibility by incorporating a magnetically levitated rotor with wide blood-flow paths and an artificial pulse.<unk>
T-1994	centrifugal_flow_pump hemocompatibility blood-flow pulse
H-1994	-0.5274324417114258	▁centri fu gal _ ▁flow _ pump ▁hem o com pati bility ▁magnet ically ▁le vita ted ▁ro tor ▁blood - flow ▁path s ▁artificial _ ▁puls e
D-1994	-0.5274324417114258	centrifugal_ flow_pump hemocompatibility magnetically levitated rotor blood-flow paths artificial_ pulse
P-1994	-0.0344 -0.0563 -0.0446 -0.1211 -1.3878 -2.1187 -0.5966 -2.7988 -0.0961 -0.0259 -0.0406 -0.1895 -0.0224 -0.1308 -0.1170 -0.0067 -0.0386 -0.4608 -0.0071 -4.1027 -0.0417 -0.0173 -1.3378 -0.0273 -0.0656 -1.3804 -0.2602 -0.1816 -0.0756 -0.0391
S-1264	CONCLUSIONS: This meta-analysis indicated that biomedical treatment plus CHM is more effective than biomedical treatment alone in treating patients with DCM and heart failure.<unk>
T-1264	meta-analysis biomedical biomedical patients dcm heart_failure
H-1264	-1.230216383934021	▁bio medic al _ ▁treatment ▁CH m ▁bio medic al _ ▁treatment ▁d CM
D-1264	-1.230216383934021	biomedical_ treatment CHm biomedical_ treatment dCM
P-1264	-0.0141 -0.1145 -0.0076 -3.6615 -1.7300 -4.3692 -0.8966 -0.2005 -0.0366 -0.0137 -2.2744 -1.2908 -1.6667 -0.0173 -3.2636 -0.1263
S-436	CONCLUSIONS: A multiparametric echocardiographic score is helpful in selecting patients likely to undergo reverse remodeling after CRT and predicts clinical outcomes.<unk>
T-436	echocardiographic patients reverse_remodeling crt clinical outcomes
H-436	-0.32646095752716064	▁multi para metric ▁e cho car dio graphic ▁score ▁rever se _ ▁remodel ing ▁c RT
D-436	-0.32646095752716064	multiparametric echocardiographic score reverse_ remodeling cRT
P-436	-0.4667 -0.0132 -0.0720 -0.2972 -0.0304 -0.0085 -0.4154 -0.3882 -0.4265 -1.4374 -0.0129 -0.6942 -0.0469 -0.0079 -1.0158 -0.0945 -0.3802 -0.0682
S-57	As the authors suggest, patient categorization in the emergency department is perhaps the single most important component that is not focused on in modern acute heart failure (AHF) clinical studies.<unk>
T-57	patient emergency_department acute_heart_failure ahf clinical
H-57	-1.2459903955459595	▁a cute _ heart ▁failure
D-57	-1.2459903955459595	acute_heart failure
P-57	-2.2201 -0.0840 -0.0396 -1.4149 -0.8890 -3.9943 -0.0800
S-1056	MATERIALS AND METHODS: Yorkshire swine were implanted with pacemakers and were ventricularly paced at 200 beats/min to induce heart failure.<unk>
T-1056	yorkshire implanted pacemakers ventricularly beats heart_failure
H-1056	-0.5334367156028748	▁York shire ▁s win e ▁pace makers ▁vent ri cular ly ▁pace d
D-1056	-0.5334367156028748	Yorkshire swine pacemakers ventricularly paced
P-1056	-1.8272 -0.0042 -0.1039 -0.0185 -0.2418 -0.1547 -0.0354 -0.0307 -0.1211 -0.0163 -0.0622 -1.4072 -0.0427 -3.7808 -0.1549
S-516	OBJECTIVES: The study aimed to determine whether isolated heart rate (HR) reduction with ivabradine reduces afterload of patients with systolic heart failure.<unk>
T-516	heart_rate ivabradine afterload patients systolic_heart_failure
H-516	-0.5470765233039856	▁i va bra dine ▁sy sto lic _ heart ▁failure
D-516	-0.5470765233039856	ivabradine systolic_heart failure
P-516	-4.1018 -0.0487 -0.0399 -0.0432 -0.5806 -0.0238 -0.0331 -0.2031 -0.8538 -0.4822 -0.0829 -0.0718
S-1786	Reduced mitochondrial complex V activity was evident at 3 weeks post-AAC, concomitant with a reduction in the ratio of phosphocreatine to ATP.<unk>
T-1786	mitochondrial_complex_v_activity phosphocreatine atp
H-1786	-0.7594579458236694	▁mito cho ndri al _ ▁complex _ v ▁activity
D-1786	-0.7594579458236694	mitochondrial_ complex_v activity
P-1786	-0.3770 -0.2016 -0.1701 -0.0201 -1.3299 -0.0944 -0.7046 -1.0835 -1.6328 -2.6386 -0.1015
S-1243	Perturbations in skeletal muscle sarcomere structure in patients with heart failure and type 2 diabetes: restorative effects of (-)-epicatechin-rich cocoa.<unk>
T-1243	skeletal_muscle sarcomere patients heart_failure type_2_diabetes
H-1243	-0.48389244079589844	▁skelet al _ ▁muscle ▁sar com ere ▁structure ▁heart ▁failure ▁type ▁2 ▁diabetes ▁e pica tech in - rich ▁coco a
D-1243	-0.48389244079589844	skeletal_ muscle sarcomere structure heart failure type 2 diabetes epicatechin-rich cocoa
P-1243	-0.3575 -0.0956 -0.7400 -1.1951 -0.6717 -0.0672 -0.4536 -1.2110 -2.7165 -0.1103 -0.4971 -0.8749 -0.0379 -0.7701 -0.0017 -0.0300 -0.0497 -0.0852 -0.0103 -0.9617 -0.0228 -0.0925 -0.0771
S-696	BACKGROUND: ST2 is involved in cardioprotective signaling in the myocardium and has been identified as a potentially promising biomarker in heart failure (HF).<unk>
T-696	st2 cardioprotective_signaling myocardium biomarker heart_failure hf
H-696	-0.4282016158103943	▁ST 2 ▁cardio protec tive _ signal ing ▁my o car dium ▁bio mark er ▁heart ▁failure
D-696	-0.4282016158103943	ST2 cardioprotective_signaling myocardium biomarker heart failure
P-696	-2.7154 -0.1260 -0.1620 -0.0798 -0.4149 -0.3020 -0.3929 -0.1172 -0.3862 -0.0204 -0.0008 -0.0300 -0.0245 -0.0101 -0.1273 -2.2789 -0.1219 -0.7786 -0.0468
S-1550	Treatment of MI animals with metoprolol partially reversed the elevated levels of plasma norepinephrine and dopamine without affecting the elevated levels of epinephrine.<unk>
T-1550	mi metoprolol elevated plasma_norepinephrine dopamine elevated epinephrine
H-1550	-0.3126184642314911	▁met o pro lol ▁plasma ▁no re pine ph rine ▁dop amine ▁e pine ph rine
D-1550	-0.3126184642314911	metoprolol plasma norepinephrine dopamine epinephrine
P-1550	-3.2928 -0.1230 -0.0100 -0.0754 -0.2919 -0.0486 -0.2655 -0.1180 -0.6475 -0.0896 -0.0006 -0.0078 -0.0975 -0.0050 -0.3627 -0.0269 -0.0789 -0.0855
S-1602	The current ongoing Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial may provide more concrete data regarding the role of stenting in RAS.<unk>
T-1602	cardiovascular_outcomes_in_renal_atherosclerotic_lesions coral stenting ras
H-1602	-0.44738706946372986	▁Card io vas cular ▁Out com es ▁Ren al _ ▁Ath eros cle ro tic _ Les ions co RAL ▁sten ting ▁ RAS
D-1602	-0.44738706946372986	Cardiovascular Outcomes Renal_ Atherosclerotic_LesionscoRAL stenting RAS
P-1602	-0.8541 -0.3560 -0.0288 -0.1146 -1.1745 -0.0063 -0.0757 -1.1050 -0.0779 -0.3581 -0.1087 -0.0698 -0.0593 -0.5010 -0.6531 -0.3343 -1.2145 -0.0431 -1.3638 -0.0091 -2.4869 -0.0715 -0.3967 -0.0014 -0.0881 -0.0799
S-60	BACKGROUND: Many current predictors of mortality in heart failure (HF) were evaluated before the use of implantable cardioverter defibrillators (ICDs).<unk>
T-60	mortality heart_failure hf implantable_cardioverter_defibrillators icds
H-60	-0.840808093547821	▁mortal ity ▁ HF ▁implant able _ ▁cardio ver ter _ de fi br illa tors IC d s
D-60	-0.840808093547821	mortality HF implantable_ cardioverter_defibrillatorsICds
P-60	-5.7883 -2.0923 -3.9822 -0.3754 -1.3886 -0.0239 -0.1197 -0.4573 -0.0059 -0.1318 -0.3634 -0.7435 -0.0286 -0.0977 -0.0878 -0.1620 -0.5647 -1.0355 -0.0748 -0.0874 -0.0462
S-686	We therefore evaluated associations of Mediterranean and Dietary Approaches to Stop Hypertension (DASH) diet scores with mortality among postmenopausal women with HF.<unk>
T-686	dietary_approaches_to_stop_hypertension dash mortality postmenopausal hf
H-686	-0.5656951069831848	▁Mediterrane an _ diet ary _ App ro ach es _ to ▁Stop _ ▁Hyper tension DAS h ▁die t ▁score s ▁mortal ity ▁post meno paus al _ ▁women ▁ HF
D-686	-0.5656951069831848	Mediterranean_dietary_Approaches_to Stop_ HypertensionDASh diet scores mortality postmenopausal_ women HF
P-686	-0.8100 -0.0136 -0.3656 -1.5718 -0.1905 -0.0996 -1.1932 -0.3192 -1.6509 -0.0315 -1.3577 -1.7148 -0.4349 -0.2023 -0.4106 -0.0488 -0.2534 -0.1934 -1.1438 -0.0214 -0.0383 -0.1423 -0.5753 -1.0069 -0.0963 -0.0538 -0.0017 -0.0140 -1.4437 -2.1599 -1.4928 -0.0060 -0.0549 -0.1208
S-1025	Several POC systems for measuring NP levels are now available: these produce test results within 15 minutes and appear sufficiently sensitive and robust to be used routinely in diagnostic evaluations.<unk>
T-1025	poc diagnostic
H-1025	-1.5080949068069458	▁PO c ▁ NP ▁levels
D-1025	-1.5080949068069458	POc NP levels
P-1025	-1.2866 -1.5898 -3.9417 -0.3783 -2.7258 -0.5587 -0.0758
S-1977	DESIGN, SETTING, AND PARTICIPANTS: Randomized, attention-controlled, 2 × 2 factorial trial conducted from February 2009 through November 2014 in an urban academic medical center.<unk>
T-1977	randomized medical
H-1977	-2.18359112739563	
D-1977	-2.18359112739563	
P-1977	-4.3305 -0.0366
S-151	DATA SOURCES: Fourteen electronic databases (including MEDLINE, EMBASE and PsycINFO) were searched to January 2012, and supplemented by hand-searching relevant articles.<unk>
T-151	medline embase psycinfo
H-151	-0.5127661228179932	▁electronic _ ▁database s ▁MED LINE ▁ EMBA se ▁Psy c INFO ▁hand - search ing
D-151	-0.5127661228179932	electronic_ databases MEDLINE EMBAse PsycINFO hand-searching
P-151	-3.0794 -1.1995 -0.3352 -0.1765 -0.8994 -0.7189 -0.2085 -0.0016 -0.8632 -0.1871 -0.0187 -0.0015 -0.8643 -0.0090 -0.0069 -0.0134 -0.5986 -0.0482
S-1725	We used patient-level regression to compare 30-day risk-adjusted mortality, readmissions, and costs across volume groups, controlling for patient, physician, and hospital characteristics.<unk>
T-1725	mortality readmissions costs patient physician hospital
H-1725	-0.4735378324985504	▁patient - level ▁re gression ▁risk - ad just ed _ ▁mortal ity ▁read missions ▁kosten
D-1725	-0.4735378324985504	patient-level regression risk-adjusted_ mortality readmissions kosten
P-1725	-1.2928 -0.0057 -0.0348 -0.4722 -0.0002 -1.9969 -0.0091 -0.0025 -0.0319 -0.0468 -0.1332 -0.6519 -0.2329 -0.2270 -0.1626 -1.6858 -1.4664 -0.0710
S-890	CONCLUSIONS: In patients with LBBB, there was a continuous relationship between broader QRS and greater benefit from implantable cardioverter defibrillator-CRT.<unk>
T-890	patients lbbb qrs implantable
H-890	-0.4133058488368988	▁ LB BB ▁QR s ▁implant able _ ▁cardio ver ter _ de fi br illa tor - C RT
D-890	-0.4133058488368988	LBBB QRs implantable_ cardioverter_defibrillator-CRT
P-890	-0.5441 -0.0083 -1.2788 -2.2280 -1.3320 -0.4522 -0.0134 -0.5344 -0.2707 -0.0054 -0.0613 -0.4078 -0.4598 -0.0108 -0.0410 -0.0743 -0.0103 -0.1768 -1.0239 -0.0681 -0.0571 -0.0343
S-453	At the end of a 10-week treatment period, echocardiography revealed reduced cardiac diameters and improved cardiac function in B-treated compared with vehicle-treated rats.<unk>
T-453	echocardiography cardiac cardiac_function
H-453	-0.8539268970489502	▁e cho card i ography ▁cardiac _ ▁diameter s
D-453	-0.8539268970489502	echocardiography cardiac_ diameters
P-453	-0.0710 -0.0117 -0.0819 -0.4255 -0.2336 -0.9279 -2.6831 -2.4317 -0.1745 -2.2944 -0.0579
S-618	RESULTS: Overall significant improvements were not found in quality of life or functional capacity; some participants demonstrated significant improvements with others showing minor improvement or no improvement in one or both domains.<unk>
T-618	quality_of_life functional_capacity
H-618	-1.279119849205017	▁quality _ of _ ▁life ▁functional ▁capacity
D-618	-1.279119849205017	quality_of_ life functional capacity
P-618	-3.9068 -1.0092 -1.5988 -0.0725 -2.7815 -0.1618 -1.6515 -0.2559 -0.0740
S-1950	We aimed to assess the safety and potential efficacy of therapeutic left-to-right interatrial shunting in patients with heart failure with reduced ejection fraction.<unk>
T-1950	therapeutic interatrial_shunting patients heart_failure_with_reduced_ejection_fraction
H-1950	-0.5073637962341309	▁ therapeut ic ▁left - to - right _ inter at rial _ ▁sh unting ▁heart ▁failure ▁e je ction
D-1950	-0.5073637962341309	therapeutic left-to-right_interatrial_ shunting heart failure ejection
P-1950	-1.6826 -0.1094 -0.0941 -1.2967 -0.0461 -0.0339 -0.1450 -0.0157 -0.2746 -0.1951 -0.0545 -0.0489 -0.3447 -1.5627 -0.3653 -1.5150 -0.2979 -1.4319 -0.0374 -0.0155 -1.5257 -0.0694
S-336	Four years later he developed heart failure, severe hypertension, mild mitral regurgitation, and significant mitral stenosis, which were reversed by aggressive medical treatment for heart failure.<unk>
T-336	heart_failure hypertension mitral_regurgitation mitral_stenosis medical_treatment heart_failure
H-336	-0.525650143623352	▁heart ▁failure ▁гипер tension ▁mit ral ▁re gur gi tation ▁mit ral ▁sten osis
D-336	-0.525650143623352	heart failure гиперtension mitral regurgitation mitral stenosis
P-336	-1.4990 -0.0795 -3.3786 -0.4199 -0.0460 -0.0070 -0.4588 -0.0371 -0.0201 -0.0095 -0.0419 -0.0120 -0.2424 -0.0037 -2.1013 -0.0533
S-636	The use of antagonists and inhibitors of the renin-angiotensin-aldosterone and sympathetic nervous systems has significantly improved clinical outcomes in CHF.<unk>
T-636	antagonists renin-angiotensin-aldosterone sympathetic_nervous_systems clinical outcomes chf
H-636	-0.3828599154949188	▁re nin - angi oten sin - al do ster one ▁sympa the tic _ ▁ner vous ▁systems ▁CHF
D-636	-0.3828599154949188	renin-angiotensin-aldosterone sympathetic_ nervous systems CHF
P-636	-1.7676 -0.3070 -0.0288 -0.0108 -0.0181 -0.6228 -0.1832 -0.0652 -0.5364 -0.0148 -0.1655 -0.0172 -0.1576 -0.3227 -0.1999 -1.8854 -0.5440 -0.5729 -0.5344 -0.0296 -0.0561
S-831	CONCLUSIONS: Exercise-induced PASP increase is of high clinical and prognostic relevance in pulmonary hypertension patients and may indicate right ventricular contractile reserve.<unk>
T-831	exercise-induced_pasp clinical prognostic pulmonary_hypertension patients right_ventricular_contractile_reserve
H-831	-0.6670992970466614	▁pulmonar y ▁hyper tension ▁vent ri cular ▁contract ile ▁reserve
D-831	-0.6670992970466614	pulmonary hypertension ventricular contractile reserve
P-831	-2.9261 -0.0681 -1.4155 -0.0557 -1.4061 -0.3582 -0.5024 -1.0122 -0.0834 -0.0438 -0.0835 -0.0502
S-1650	All patients will be followed up until the end of the trial for the composite primary outcome of cardiovascular death, stroke, worsening of heart failure, and myocardial infarction.<unk>
T-1650	patients followed_up composite_primary_outcome cardiovascular_death stroke heart_failure myocardial_infarction
H-1650	-2.1082937717437744	▁cardiovascular _ ▁death
D-1650	-2.1082937717437744	cardiovascular_ death
P-1650	-2.5933 -2.5626 -0.9737 -4.3178 -0.0942
S-1861	SETTING AND PARTICIPANTS: Patients with an implantable cardioverter-defibrillator, from the Heart Function Clinic at University Health Network (Toronto, Canada).<unk>
T-1861	patients implantable_cardioverter-defibrillator heart_function_clinic university_health_network toronto canada
H-1861	-0.6327828764915466	▁implant able _ ▁cardio ver ter - de fi br illa tor ▁Heart _ ▁Fun ction ▁Clinic Tor onto
D-1861	-0.6327828764915466	implantable_ cardioverter-defibrillator Heart_ Function ClinicToronto
P-1861	-1.1694 -0.0176 -0.4653 -0.8503 -0.0071 -0.1522 -0.2053 -0.0116 -0.0528 -0.1014 -0.0940 -0.0122 -0.9953 -1.0158 -0.6959 -0.0015 -0.4342 -5.1325 -0.0008 -1.8135 -0.0597
S-1086	PERK activation destabilized SCN5A and, surprisingly, Kv4.3 channel mRNAs but not transient receptor potential cation channel M7 (TRPM7) channel mRNA.<unk>
T-1086	perk scn5a kv4.3 mrnas transient_receptor_potential_cation_channel_m7 trpm7 mrna
H-1086	-0.7218539714813232	▁PER K ▁activa tion ▁destabiliz ed ▁s CN 5 a ▁kv 4.3 ▁channel ▁m RNA s ▁trans ient _ ▁receptor ▁potential ▁ cation ▁channel ▁m 7 TR PM 7 ▁channel ▁m RNA
D-1086	-0.7218539714813232	PERK activation destabilized sCN5a kv4.3 channel mRNAs transient_ receptor potential cation channel m7TRPM7 channel mRNA
P-1086	-1.7491 -1.0512 -0.2554 -0.0523 -3.4018 -0.0809 -0.9487 -0.5379 -0.3144 -0.6079 -1.0310 -0.0756 -0.4020 -0.0025 -0.0044 -1.7387 -0.0104 -0.0389 -1.0802 -0.3571 -3.1884 -0.8240 -0.0758 -0.4845 -0.8029 -0.3394 -1.3588 -0.0623 -1.9821 -1.3548 -0.0179 -0.0056 -0.1524 -0.1538
S-845	BACKGROUND: Cardiac-resynchronization therapy (CRT) reduces morbidity and mortality in chronic systolic heart failure with a wide QRS complex.<unk>
T-845	cardiac-resynchronization_therapy crt morbidity mortality chronic_systolic_heart_failure wide_qrs_complex
H-845	-0.6234689950942993	▁Card iac - re syn chron ization ▁ therapy ▁c RT ▁morbi d ity ▁sy sto lic _ heart ▁failure ▁QR S
D-845	-0.6234689950942993	Cardiac-resynchronization therapy cRT morbidity systolic_heart failure QRS
P-845	-0.7843 -0.0870 -0.0385 -0.0922 -0.0489 -0.0061 -1.1153 -1.5077 -0.0465 -0.8273 -0.2044 -1.9373 -0.0080 -0.9510 -2.7255 -0.0400 -0.1140 -0.1809 -1.4146 -1.0938 -0.0587 -1.4978 -0.1203 -0.0630
S-423	In patients with systolic HF, CXL-1020 reduced both left and right heart filling pressures and systemic vascular resistance, while increasing cardiac and stroke volume index.<unk>
T-423	patients systolic_hf cxl-1020 right_heart_filling_pressures systemic_vascular_resistance cardiac stroke_volume_index
H-423	-0.9294362664222717	▁sy sto lic _ HF ▁c XL -10 20 ▁left _ ▁right _ heart ▁fill ing _ ▁pressure s ▁system ic _ ▁vas cular ▁resist ance ▁cardiac ▁stroke ▁volume ▁index
D-423	-0.9294362664222717	systolic_HF cXL-1020 left_ right_heart filling_ pressures systemic_ vascular resistance cardiac stroke volume index
P-423	-0.0346 -0.0122 -0.0043 -0.4777 -0.2660 -1.9285 -0.0354 -0.8968 -0.0319 -3.2324 -1.1250 -3.9890 -0.2579 -3.5238 -1.4902 -0.0379 -2.0581 -0.5127 -0.3313 -0.0379 -0.0896 -0.3862 -0.7581 -0.0433 -1.8939 -0.0055 -0.0318 -4.6111 -1.2140 -0.2127 -0.1309 -0.0812
S-1799	LA is under the awful paradox of having the HF risk factors and HF epidemiology of developed countries with the added factors of SH, C'D, and rheumatic fever.<unk>
T-1799	hf hf epidemiology rheumatic_fever
H-1799	-0.6491374373435974	▁ HF ▁ HF ▁ HF ▁epidemi ology ▁SH ▁c ' d ▁rhe u matic ▁fe ver
D-1799	-0.6491374373435974	HF HF HF epidemiology SH c'd rheumatic fever
P-1799	-0.3838 -0.0411 -1.0496 -0.1089 -2.1503 -0.1616 -0.8813 -0.3375 -1.1580 -1.7833 -1.3817 -0.3740 -0.0144 -0.0072 -0.3056 -1.8846 -0.0031 -0.1891 -0.1186
S-1976	OBJECTIVE: To determine whether caloric restriction (diet) or aerobic exercise training (exercise) improves exercise capacity and QOL in obese older patients with HFPEF.<unk>
T-1976	exercise training exercise exercise_capacity qol obese patients hfpef
H-1976	-0.7590129971504211	▁calor ic ▁restriction _ diet ▁aero bic _ ▁exercise _ training _ exe rci se ▁Q OL
D-1976	-0.7590129971504211	caloric restriction_diet aerobic_ exercise_training_exercise QOL
P-1976	-0.4868 -0.0510 -0.6272 -3.8724 -0.0316 -0.1389 -0.0243 -0.3049 -1.2075 -1.6235 -0.1322 -1.3978 -0.0293 -0.0019 -0.0246 -2.8562 -0.0409 -1.4964 -0.0737
S-1813	In these studies, we evaluated mice with cardiac myocyte-specific Mena overexpression (TTA/TgTetMena) comparable to that observed in cardiac pathology.<unk>
T-1813	cardiac myocyte-specific_mena_overexpression cardiac pathology
H-1813	-0.43352946639060974	▁cardiac _ my o cy te - specific ▁Men a ▁over expression ▁t g t et Men a ▁cardiac _ path ology
D-1813	-0.43352946639060974	cardiac_myocyte-specific Mena overexpression tgtetMena cardiac_pathology
P-1813	-1.0457 -0.8403 -1.5607 -0.1384 -0.0099 -0.0459 -0.5507 -0.0633 -1.6563 -0.0445 -0.0497 -0.0146 -1.3833 -0.0312 -0.4625 -0.0595 -0.3792 -0.0247 -0.0178 -0.7576 -0.7629 -0.3719 -0.0702 -0.0641
S-722	Some data suggest that outpatient assessments of patients with heart failure within 7 days of hospital discharge may prevent readmissions, although little is known about patient needs at 7-day follow-up visits.<unk>
T-722	outpatient patients heart_failure hospital discharge readmissions patient follow-up
H-722	-1.5097219944000244	▁in patient ▁assessment s ▁patients ▁heart ▁failure
D-722	-1.5097219944000244	inpatient assessments patients heart failure
P-722	-4.6882 -0.0103 -1.9622 -0.1832 -1.6355 -2.4200 -0.3191 -2.2865 -0.0825
S-839	It was hypothesized that baseline Hgb would be correlated with baseline KCCQ scales and that Hgb would moderate the beneficial effect of exercise training on HRQoL.<unk>
T-839	baseline hgb correlated baseline kccq hgb exercise training hrqol
H-839	-0.7249923348426819	▁base line _ h gb ▁k cc q ▁scale s ▁h gb
D-839	-0.7249923348426819	baseline_hgb kccq scales hgb
P-839	-1.1827 -0.0144 -0.6442 -0.6084 -0.0007 -2.9045 -0.0878 -0.3594 -0.9393 -0.0085 -1.2395 -0.0008 -2.0528 -0.1070
S-1172	BACKGROUND: Because symptoms of HFpEF are typically exertional, optimization of diastolic filling time by controlling heart rate may delay the onset of symptoms.<unk>
T-1172	symptoms hfpef diastolic_filling_time heart_rate symptoms
H-1172	-0.4756622612476349	▁ HF p EF ▁dia sto lic _ ▁fill ing ▁time ▁control ling _ ▁heart ▁rate
D-1172	-0.4756622612476349	HFpEF diastolic_ filling time controlling_ heart rate
P-1172	-0.3316 -0.0892 -0.0988 -0.1829 -2.0712 -0.0240 -0.0268 -1.1727 -0.2791 -0.0165 -1.9751 -0.2490 -0.0307 -0.3164 -0.9050 -0.5955 -0.1246 -0.0728
S-1472	Understanding of chronic heart failure (HF) has progressed from the concept of a purely hemodynamic disorder to that of a syndrome that results from dysfunction in interconnected molecular pathways.<unk>
T-1472	chronic_heart_failure hf hemodynamic syndrome dysfunction molecular_pathways
H-1472	-0.8008133172988892	▁chronic _ heart ▁failure ▁ HF ▁hem o dynamic _ ▁disorder ▁syndrome
D-1472	-0.8008133172988892	chronic_heart failure HF hemodynamic_ disorder syndrome
P-1472	-0.7031 -0.1841 -1.2093 -0.5381 -2.8325 -0.0274 -1.5431 -0.0949 -0.0004 -1.0880 -0.5581 -0.3049 -2.0509 -0.0767
S-1458	In this guideline, the International Right Heart Foundation Working Group moves a step forward to develop a common language to describe the development and defects that exemplify the common syndrome of right heart failure.<unk>
T-1458	international_right_heart_foundation_working_group step syndrome right_heart_failure
H-1458	-1.1088027954101562	▁ international _ ▁Right _ ▁Heart _ ▁Foundation _ work ing _ groep
D-1458	-1.1088027954101562	international_ Right_ Heart_ Foundation_working_groep
P-1458	-2.4194 -2.9981 -0.1984 -1.5917 -0.7678 -0.8041 -0.6338 -1.3252 -0.8977 -0.4609 -0.1157 -1.6204 -1.0615 -1.6509 -0.0867
S-667	CONCLUSIONS: Variation in the use of guideline-recommended medications for patients with heart failure and reduced ejection fraction exists in the outpatient setting.<unk>
T-667	medications patients heart_failure_and_reduced_ejection_fraction outpatient
H-667	-0.6410327553749084	▁guide line - re com mend ed ▁medication s ▁heart ▁failure ▁reduce d _ e je ction ▁ fraction
D-667	-0.6410327553749084	guideline-recommended medications heart failure reduced_ejection fraction
P-667	-3.6307 -0.0048 -0.1882 -0.0057 -0.0069 -0.0109 -0.0500 -1.0682 -0.1391 -2.9282 -0.1583 -1.3088 -0.0368 -0.6087 -1.4278 -0.1322 -0.0169 -1.4071 -0.0035 -0.2256 -0.1032
S-1081	In this work, we tested whether truncated Na+ channels activate the unfolded protein response (UPR), contributing to SCN5A electric remodeling in HF.<unk>
T-1081	activate unfolded_protein_response upr scn5a remodeling hf
H-1081	-0.33986926078796387	▁tru nca ted _ na + ▁channel s ▁un fold ed _ ▁protein ▁response ▁u PR ▁s CN 5 a ▁electric ▁remodel ing ▁ HF
D-1081	-0.33986926078796387	truncated_na+ channels unfolded_ protein response uPR sCN5a electric remodeling HF
P-1081	-1.5184 -0.0118 -0.0090 -1.2379 -0.3718 -0.3323 -0.1563 -0.0453 -0.0728 -0.0002 -0.0063 -0.1303 -0.2811 -0.1985 -0.7407 -0.0170 -0.6531 -0.9351 -0.0908 -0.7408 -0.2489 -0.6797 -0.0062 -0.5517 -0.0187 -0.0647 -0.0571
S-1780	METHODS AND RESULTS: Mice were subjected to cardiac hypertrophy secondary to pressure-overload as a result of an abdominal aortic constriction (AAC).<unk>
T-1780	cardiac_hypertrophy pressure-overload abdominal_aortic_constriction aac
H-1780	-0.4735811948776245	▁cardiac ▁hyper trop hy ▁pressure - over load ▁abdominal ▁a or tic _ con stri ction ▁a ac
D-1780	-0.4735811948776245	cardiac hypertrophy pressure-overload abdominal aortic_constriction aac
P-1780	-1.7670 -0.7353 -0.0052 -0.3257 -0.3114 -0.0374 -0.0011 -0.0236 -0.1809 -0.3547 -0.5369 -0.8160 -0.6086 -0.7802 -0.1154 -0.0237 -1.9435 -0.7483 -0.0700 -0.0868
S-1355	Additional progress is needed, including better tools for risk stratification and clarity regarding the need for antiplatelet agents in combination with anticoagulants for those with other vascular diseases.<unk>
T-1355	risk_stratification antiplatelet_agents combination anticoagulants vascular_diseases
H-1355	-0.5683070421218872	▁anti plate let ▁agents ▁antico a gul ants
D-1355	-0.5683070421218872	antiplatelet agents anticoagulants
P-1355	-1.7964 -0.1410 -0.3501 -0.9874 -0.0900 -0.0638 -0.0977 -0.0347 -2.0353 -0.0865
S-477	In conclusion, allopurinol improves LV contractile function and efficiency possibly by diminishing the known XO-mediated ROS effects on myofilament Ca(2+) sensitivity.<unk>
T-477	allopurinol lv_contractile_function xo-mediated_ros myofilament sensitivity
H-477	-0.5215082168579102	▁allo puri nol ▁contract ile ▁function ▁ XO - media ted _ ROS ▁my o fila ment
D-477	-0.5215082168579102	allopurinol contractile function XO-mediated_ROS myofilament
P-477	-0.0267 -0.0055 -0.0097 -0.2464 -0.0211 -1.6666 -1.5166 -0.4226 -0.0048 -0.0717 -0.0132 -0.4644 -0.4349 -3.6377 -0.0160 -0.0023 -0.0863 -1.1523 -0.1101
S-1562	Similarly, crude and adjusted ankle-brachial index, pulse-wave velocity, and coronary artery calcium scores did not differ between the two groups.<unk>
T-1562	ankle-brachial_index pulse-wave coronary_artery_calcium_scores
H-1562	-0.2720663249492645	▁an kle - bra chi al ▁index ▁puls e - wa ve _ ▁veloci ty ▁corona ry ▁arter y ▁calci um ▁score s
D-1562	-0.2720663249492645	ankle-brachial index pulse-wave_ velocity coronary artery calcium scores
P-1562	-1.9192 -0.0513 -0.0501 -0.0778 -0.3996 -0.0952 -0.3113 -0.0167 -0.0997 -0.0357 -0.0096 -0.0392 -1.0510 -0.2987 -0.0361 -0.0052 -0.3806 -1.0228 -0.2256 -0.0703 -0.0075 -0.0730 -0.3309 -0.1574 -0.0372
S-1156	These changes in myofiber dynamics delay the onset of myofiber shortening, thus giving rise to prolonged EMD in dyssynchronous HF.<unk>
T-1156	myofiber_dynamics myofiber_shortening emd dyssynchronous_hf
H-1156	-0.41803693771362305	▁my o fi ber ▁dynamic s ▁my o fi ber ▁short en ing ▁prolong ed _ ▁EM d ▁dys syn chron ous _ HF
D-1156	-0.41803693771362305	myofiber dynamics myofiber shortening prolonged_ EMd dyssynchronous_HF
P-1156	-0.9427 -0.0964 -0.0077 -0.0364 -0.9513 -0.0283 -1.3494 -0.0245 -0.0065 -0.0244 -1.2397 -0.0224 -0.0696 -1.4781 -0.0760 -1.0162 -0.7439 -1.1604 -0.0294 -0.0007 -0.0009 -0.6989 -0.6234 -0.0666 -0.0805 -0.0946
S-225	We hypothesized that Fontan failure is hemodynamically distinct from traditional heart failure and characterized by low systemic vascular resistance (SVR) index and preserved cardiac index.<unk>
T-225	fontan_failure hemodynamically heart_failure systemic_vascular_resistance svr cardiac_index
H-225	-0.6113991737365723	▁Font an ▁failure ▁hem o dynamic ally ▁traditional _ ▁heart ▁failure ▁system ic _ ▁vas cular _ ▁resist ance ▁s VR ▁pres er ved _ ▁cardiac ▁index
D-225	-0.6113991737365723	Fontan failure hemodynamically traditional_ heart failure systemic_ vascular_ resistance sVR preserved_ cardiac index
P-225	-0.1280 -0.2330 -0.8069 -1.7112 -0.0304 -0.0002 -0.1734 -4.5238 -0.4670 -0.9803 -0.0897 -1.4928 -0.1115 -0.1076 -1.7507 -0.1886 -1.2574 -0.6884 -0.0095 -0.6240 -0.0326 -1.6113 -0.0419 -0.2172 -0.1812 -0.0734 -0.0612 -0.0722 -0.0652
S-16	During follow up body weight was unaltered in all groups even though FM increased by 1.35 kg (p<0.05) and FFM decreased by 0.5 kg (p<0.05) in CC patients.<unk>
T-16	follow_up ffm patients
H-16	-1.0226001739501953	▁figuur ▁f FM
D-16	-1.0226001739501953	figuur fFM
P-16	-1.7985 -1.5738 -0.6072 -1.0688 -0.0647
S-1776	Men should be counseled on physical activity with the goal of achieving at least a moderate level of CRF, thereby presumably decreasing their risk of HF mortality.<unk>
T-1776	physical activity crf hf mortality
H-1776	-1.2521306276321411	▁c RF ▁ HF
D-1776	-1.2521306276321411	cRF HF
P-1776	-4.7009 -0.1479 -1.1325 -0.4268 -1.0262 -0.0786
S-1610	Data processing and differential analysis were carried out with packages of R. Cluster analysis was also performed for all the samples to globally observe the difference among the three groups of samples.<unk>
T-1610	differential_analysis cluster_analysis
H-1610	-1.4784780740737915	▁r
D-1610	-1.4784780740737915	r
P-1610	-1.6067 -2.7784 -0.0503
S-1715	MEASUREMENTS: Thirty-day rehospitalization derived from Medicare hospital claims using the implementation of Medicare's post-acute care transfer policy as a quasi-experiment.<unk>
T-1715	rehospitalization medicare hospital medicare policy
H-1715	-0.8080065846443176	▁Medica re _ hospital _ ▁claims ▁Medica re ▁post - a cute _ care _ transfer _ policy
D-1715	-0.8080065846443176	Medicare_hospital_ claims Medicare post-acute_care_transfer_policy
P-1715	-1.0350 -0.0025 -1.0711 -0.6508 -2.0478 -0.7082 -0.2251 -0.0019 -1.9989 -0.0078 -0.0170 -0.0046 -0.0215 -3.1750 -1.1069 -1.1077 -1.8836 -0.6182 -0.3148 -0.1616
S-710	METHODS AND RESULTS: Between January 2000 and December 2009, adult patients undergoing isolated heart transplant were prospectively classified as ECCT based on prespecified criteria.<unk>
T-710	patients heart_transplant prospectively ecct
H-710	-1.0109201669692993	▁isola ted _ heart ▁transplant
D-710	-1.0109201669692993	isolated_heart transplant
P-710	-4.2708 -0.0928 -0.2557 -1.0963 -0.4601 -0.8131 -0.0876
S-663	A median rate ratio was calculated for each therapy, which describes the likelihood that the treatment of a patient with given comorbidities would differ at 2 randomly selected practices.<unk>
T-663	rate_ratio therapy patient comorbidities
H-663	-1.216475248336792	▁media n _ ▁rate _ ▁ratio
D-663	-1.216475248336792	median_ rate_ ratio
P-663	-3.3170 -0.0653 -0.3858 -1.4330 -1.4331 -0.1001 -2.8638 -0.1337
S-1242	CONCLUSION: In the study population, the therapeutic strategy used to manage AF in patients with severe heart failure appears to have little influence on the overall financial burden, which remains substantial.<unk>
T-1242	therapeutic patients severe_heart_failure financial
H-1242	-1.5022152662277222	▁ therapeut ic _ strategi e _ te _ ▁manage _ aan _ de _ heart ▁failure ▁financial
D-1242	-1.5022152662277222	therapeutic_strategie_te_ manage_aan_de_heart failure financial
P-1242	-0.8550 -0.0430 -0.0490 -1.8032 -0.2251 -2.7414 -2.8758 -3.7367 -1.3816 -1.6856 -0.5749 -4.0435 -0.3556 -2.6358 -0.9841 -2.6924 -0.7008 -1.2931 -1.3242 -0.0437
S-1823	While our country has physicians experienced in the management of patients with advanced heart failure, these professionals are not distributed evenly across the country, and equitable access to therapeutic options is not provided.<unk>
T-1823	physicians patients heart_failure equitable therapeutic
H-1823	-1.6077632904052734	▁physician s ▁advanced _ heart ▁failure
D-1823	-1.6077632904052734	physicians advanced_heart failure
P-1823	-3.4094 -0.0338 -5.5927 -0.2028 -1.5342 -0.5858 -1.3890 -0.1145
S-1543	The risk of heart failure increased significantly with increasing refill compliance for etidronate (P for trend < 0.01), whereas it decreased for alendronate (P for trend < 0.01).<unk>
T-1543	heart_failure compliance etidronate alendronate
H-1543	-0.6399009227752686	▁risk _ van _ heart ▁failure ▁et id rona te ▁ale ndr onate
D-1543	-0.6399009227752686	risk_van_heart failure etidronate alendronate
P-1543	-1.0039 -1.8359 -1.0530 -0.0719 -0.4457 -0.8761 -2.3603 -0.1075 -0.0110 -0.0127 -1.3465 -0.0058 -0.0479 -0.3655 -0.0548
S-1762	Nonidentification of AT remained associated to prognosis also when compared with metabolic exercise and cardiac and kidney index score (P<0.01; HR=1.459; CI=1.09-1.10).<unk>
T-1762	prognosis metabolic_exercise cardiac kidney
H-1762	-0.6392284035682678	▁metabol ic _ ▁exercise ▁cardiac _ ▁ki dne y ▁index ▁score
D-1762	-0.6392284035682678	metabolic_ exercise cardiac_ kidney index score
P-1762	-2.9811 -0.0055 -0.9119 -0.2105 -0.0234 -1.4606 -2.0382 -0.0457 -0.0227 -0.0900 -0.0302 -0.3794 -0.1108
S-249	OBJECTIVE: This study was performed to evaluate the impact of ET on HDL-mediated protective effects and the respective molecular pathways in patients with chronic heart failure (CHF).<unk>
T-249	molecular_pathways patients chronic_heart_failure chf
H-249	-1.1897863149642944	▁ec l - media ted _ protec ive _ effect s ▁molecular ▁path ways ▁chronic _ heart ▁failure
D-249	-1.1897863149642944	ecl-mediated_protecive_effects molecular pathways chronic_heart failure
P-249	-4.6241 -1.7445 -0.2114 -0.1274 -0.0378 -0.3215 -3.7489 -0.3230 -1.6016 -0.0862 -2.6912 -1.5038 -1.0581 -0.0218 -1.6964 -0.1868 -1.5869 -1.1937 -0.9758 -0.0547
S-451	Importantly, β-adrenergic receptor blocker therapy has been also shown to improve myocardial perfusion by enhancing neoangiogenesis in the failing heart.<unk>
T-451	β-adrenergic_receptor_blocker_therapy myocardial_perfusion neoangiogenesis heart
H-451	-0.4491058886051178	▁β - ad r energi c _ ▁receptor ▁block er ▁ therapy ▁my o card ial _ per fusion ▁neo angi ogen es is ▁fail ing _ heart
D-451	-0.4491058886051178	β-adrenergic_ receptor blocker therapy myocardial_perfusion neoangiogenesis failing_heart
P-451	-0.0561 -0.0427 -0.0168 -0.4031 -0.7679 -0.0210 -1.5013 -0.1430 -1.0249 -0.1082 -1.3941 -0.0090 -3.0806 -0.1664 -0.2915 -0.3371 -0.4480 -0.9206 -0.0066 -0.0161 -0.0076 -0.0399 -0.0390 -0.4708 -0.0258 -0.0338 -1.1743 -0.6625 -0.1262 -0.1381
S-1996	METHODS: The primary endpoint was 6-month survival compared with INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support)-derived performance goal.<unk>
T-1996	primary_endpoint intermacs interagency_registry_for_mechanically_assisted_circulatory_support
H-1996	-0.7972283363342285	▁inter age ncy _ ▁Registr y ▁Mechanic ally _ ▁Assist ed _ ▁Circula tory _ ▁Support
D-1996	-0.7972283363342285	interagency_ Registry Mechanically_ Assisted_ Circulatory_ Support
P-1996	-1.8866 -4.3320 -0.0103 -0.7661 -1.6760 -0.0326 -1.2852 -0.3133 -0.6250 -0.6109 -0.2472 -0.0617 -0.2748 -0.0960 -1.3917 -0.4075 -0.2174 -0.1157
S-1260	Meta-analysis was performed on the overall effects on effective rate, left ventricular ejection fraction, left ventricular diastolic end diameter, and other outcome measures.<unk>
T-1260	meta-analysis left_ventricular_ejection_fraction left_ventricular_diastolic_end_diameter outcome
H-1260	-0.5336896181106567	▁vent ri cular ▁e je ction ▁ fraction ▁left ▁vent ri cular ▁dia sto lic _ ▁end ▁diameter
D-1260	-0.5336896181106567	ventricular ejection fraction left ventricular diastolic_ end diameter
P-1260	-2.8361 -0.4177 -0.3257 -1.8961 -0.0659 -0.0196 -0.9766 -0.0014 -0.0636 -0.1219 -0.4781 -0.1876 -0.2161 -0.0086 -0.0160 -0.7193 -1.5927 -0.4335 -0.1576 -0.1397
S-1887	Half of these patients have normal, or near normal, left ventricular ejection fraction and are classified as heart failure with preserved ejection fraction (HFpEF).<unk>
T-1887	patients left_ventricular_ejection_fraction heart_failure_with_preserved_ejection_fraction hfpef
H-1887	-0.6456023454666138	▁left ▁vent ri cular _ e je ction ▁ fraction ▁heart ▁failure ▁pres er ved _ e je ction ▁ fraction HF p EF
D-1887	-0.6456023454666138	left ventricular_ejection fraction heart failure preserved_ejection fractionHFpEF
P-1887	-2.1146 -0.5602 -0.2994 -0.4419 -1.1720 -0.9917 -0.0866 -0.0497 -0.9312 -0.0013 -3.1896 -0.5511 -3.6579 -0.1070 -0.2476 -0.1148 -0.8070 -0.2099 -0.0264 -0.7245 -0.0104 -0.2729 -0.0347 -0.0230 -0.0658 -0.0943
S-1523	Prevalence, clinical characteristics, and outcomes associated with eccentric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction.<unk>
T-1523	prevalence clinical outcomes concentric_left_ventricular_hypertrophy heart_failure_with_preserved_ejection_fraction
H-1523	-0.8686439394950867	▁ecce n tric ▁concentr ic _ ▁left _ ▁vent ri cular _ ▁hyper trop hy ▁heart ▁failure ▁pres er ved _ e je ction ▁ fraction
D-1523	-0.8686439394950867	eccentric concentric_ left_ ventricular_ hypertrophy heart failure preserved_ejection fraction
P-1523	-3.4719 -0.0140 -0.0409 -2.9193 -0.0518 -0.1598 -2.6390 -0.2477 -3.0361 -1.2267 -0.8467 -0.7213 -1.3967 -0.0065 -0.5219 -2.2666 -0.5142 -0.0853 -0.1232 -0.4835 -0.5054 -1.3305 -0.0845 -0.0203 -1.4383 -0.0007 -0.1124 -0.0567
S-1085	Induction of SCN5A variants with AngII or hypoxia or the expression of exogenous variants induced the UPR with concomitant downregulation of Na+ current.<unk>
T-1085	scn5a angii hypoxia expression upr downregulation
H-1085	-0.8154904842376709	▁s cn 5 a ▁Ang II ▁hypo xia ▁ex ogen ous _ ▁variant s ▁u PR
D-1085	-0.8154904842376709	scn5a AngII hypoxia exogenous_ variants uPR
P-1085	-1.2345 -0.4874 -0.7970 -0.4438 -3.2479 -0.2140 -0.0235 -0.0055 -2.9934 -0.0022 -0.1959 -1.2703 -0.3171 -0.2967 -0.7346 -0.0193 -2.2951 -0.1006
S-1708	CONCLUSIONS: AAs with HF exhibited less hyperkalemia and more hypokalemia with spironolactone compared with non-AAs and seemed to derive less clinical benefit.<unk>
T-1708	aas hf hyperkalemia hypokalemia spironolactone clinical
H-1708	-0.371802419424057	▁ HF ▁hyper kal emia ▁hypo kal emia ▁spi rono lac tone
D-1708	-0.371802419424057	HF hyperkalemia hypokalemia spironolactone
P-1708	-0.7191 -0.0633 -2.2241 -0.0541 -0.0097 -0.6958 -0.4435 -0.0623 -0.0058 -0.0019 -0.0031 -0.0245 -0.8561 -0.0418
S-1888	Newer imaging techniques have confirmed that systolic function in HFpEF patients is not completely normal, with reduced long axis function and extensive but subtle changes on exercise.<unk>
T-1888	systolic_function hfpef patients long_axis_function exercise
H-1888	-0.8244175910949707	▁sy sto lic _ ▁function ▁ HF p EF
D-1888	-0.8244175910949707	systolic_ function HFpEF
P-1888	-2.0117 -0.0542 -0.1257 -1.5719 -0.6588 -0.1916 -0.0063 -0.0765 -0.0301 -4.2052 -0.1366
S-1407	Importantly, both of these receptors can be regulated by the actions of G-protein-coupled receptor kinase-2, which triggers desensitization and downregulation processes.<unk>
T-1407	receptors g-protein-coupled_receptor kinase-2 downregulation
H-1407	-0.42517033219337463	▁g - prote in - co up led _ ▁receptor ▁kina se -2
D-1407	-0.42517033219337463	g-protein-coupled_ receptor kinase-2
P-1407	-2.5333 -0.1502 -0.0584 -0.1768 -0.0315 -0.0028 -0.0095 -0.4008 -0.7963 -0.0668 -0.3006 -0.0120 -0.5257 -1.2188 -0.0941
S-1522	These findings support the development of a next generation NT-proBNP assay targeting nonterminal epitopes as well as avoiding the central glycosylated region of this molecule.<unk>
T-1522	nt-probnp nonterminal_epitopes central_glycosylated_region
H-1522	-0.6563760042190552	▁NT - pro b NP ▁as say
D-1522	-0.6563760042190552	NT-probNP assay
P-1522	-0.3902 -0.0308 -0.0050 -0.7437 -0.0761 -0.6695 -0.0593 -3.8402 -0.0925
S-82	Compared with placebo, there was no effect of low-dose dopamine or nesiritide on secondary end points reflective of decongestion, renal function, or clinical outcomes.<unk>
T-82	placebo dopamine nesiritide secondary_end_points renal_function clinical outcomes
H-82	-0.5418210029602051	▁dop amine ▁nesi riti de ▁de con gestion ▁renal
D-82	-0.5418210029602051	dopamine nesiritide decongestion renal
P-82	-3.5509 -0.1277 -0.1288 -0.0018 -0.0304 -0.0762 -0.0031 -0.0050 -0.0010 -1.9946 -0.0405
S-1571	Multivariate logistic regression analysis established that a high BNP was strongly and independently associated with the highest quartile of E/e', highlighting these patients' diastolic dysfunction.<unk>
T-1571	multivariate_logistic_regression_analysis bnp patients diastolic_dysfunction
H-1571	-0.712227463722229	▁b NP ▁dia sto lic ▁dys function
D-1571	-0.712227463722229	bNP diastolic dysfunction
P-1571	-1.6675 -0.2957 -2.4807 -0.0161 -0.1011 -1.6032 -0.1109 -0.0912 -0.0437
S-240	In HART, 208 patients had HFpEF and 692 had HF with reduced ejection fraction (HFrEF) and were followed for a median of 1,080 days.<unk>
T-240	hart patients hfpef hf_with_reduced_ejection_fraction hfref
H-240	-0.8153512477874756	▁H ART ▁ HF p EF ▁ HF _ met _ reducing _ e je ction _ fraction HF r EF
D-240	-0.8153512477874756	HART HFpEF HF_met_reducing_ejection_fractionHFrEF
P-240	-0.9488 -0.0023 -0.3273 -0.0171 -3.2486 -0.0956 -0.4045 -0.0174 -3.9583 -2.5560 -0.6684 -2.9533 -0.9549 -1.1964 -0.0810 -0.0463 -0.8092 -0.0807 -0.1226 -0.0686 -0.0298 -0.0984 -0.0676
S-1312	Concurrent HF was associated with a multivariate-adjusted odds ratio of 2.2 for 28-day mortality and a hazard ratio of 2.2 for 1-year mortality in 28-day survivors.<unk>
T-1312	hf multivariate-adjusted_odds_ratio mortality hazard_ratio mortality
H-1312	-1.282947063446045	▁ HF ▁ HF
D-1312	-1.282947063446045	HF HF
P-1312	-0.9396 -0.5744 -2.5620 -0.6678 -2.7421 -0.2117
S-741	Extracellular matrix of left ventricular biopsies (n=9), quantified by TissueFAXS technology correlated with T1 time (R=0.98; P<0.01).<unk>
T-741	extracellular_matrix left_ventricular biopsies tissuefaxs correlated t1_time
H-741	-0.4757401645183563	▁extra cel lular _ ▁matri x ▁left _ ▁vent ri cular ▁bio psi es ▁t issue FAX s ▁technologie
D-741	-0.4757401645183563	extracellular_ matrix left_ ventricular biopsies tissueFAXs technologie
P-741	-0.7447 -0.0125 -0.0463 -0.6860 -0.2071 -0.0402 -0.2699 -1.1615 -0.4466 -0.4815 -0.4404 -0.7158 -0.2817 -0.0682 -1.2172 -0.0040 -0.0488 -1.2233 -1.3490 -0.4473 -0.0985
S-773	As left ventricular assist devices (LVADs) have become more widely used for treating patients with advanced heart failure, the incidence of pump dysfunction requiring pump replacement has increased.<unk>
T-773	left_ventricular_assist_devices lvads patients heart_failure incidence pump_dysfunction pump
H-773	-0.6833363175392151	▁left ▁vent ri cular _ assist ▁devices ▁l VAD s
D-773	-0.6833363175392151	left ventricular_assist devices lVADs
P-773	-0.1766 -0.4219 -0.4571 -0.1270 -0.6727 -0.2992 -1.1745 -0.5396 -0.0086 -0.1389 -4.1070 -0.0770
S-98	The mechanisms underlying these defects involve perturbed bone morphogenetic protein 4 expression, decreased rRNA transcription, and a shift to more heterochromatic chromatin.<unk>
T-98	bone_morphogenetic_protein_4 expression rrna_transcription shift heterochromatic_chromatin
H-98	-0.6863834261894226	▁bone ▁mor pho gene tic _ ▁protein ▁r RNA ▁tran scription ▁hetero ch ro matic ▁chr omat in
D-98	-0.6863834261894226	bone morphogenetic_ protein rRNA transcription heterochromatic chromatin
P-98	-3.5012 -0.8332 -0.2709 -0.4672 -1.9320 -0.6505 -0.2450 -0.9579 -0.0044 -0.0350 -0.0174 -0.5595 -0.0851 -0.0549 -0.2266 -3.2237 -0.0154 -0.4436 -0.1224 -0.0817
S-939	These results suggest that elevated resistin is a biomarker of anthracycline-induced cardiotoxicity and may contribute in the development of heart failure via its direct effects on macrophages.<unk>
T-939	elevated resistin biomarker anthracycline-induced_cardiotoxicity heart_failure macrophages
H-939	-0.31443241238594055	▁eleva ted _ ▁resist in ▁an thra cycli ne - indu ced _ ▁cardio toxic ity ▁heart ▁failure ▁macro pha ges
D-939	-0.31443241238594055	elevated_ resistin anthracycline-induced_ cardiotoxicity heart failure macrophages
P-939	-0.2196 -0.0271 -1.0553 -0.4983 -0.0638 -0.3868 -0.0035 -0.0686 -0.5759 -0.3707 -0.0075 -0.2216 -0.3003 -0.1578 -0.1616 -1.1325 -0.9131 -0.8133 -0.1086 -0.0006 -0.0654 -0.0427 -0.0374
S-873	The top pathways were in the categories of actin cytoskeleton, mitochondrial function, intermediate metabolism, glycolysis/gluconeogenesis, and citrate cycle.<unk>
T-873	actin_cytoskeleton mitochondrial_function metabolism glycolysis gluconeogenesis citrate_cycle
H-873	-0.3582289516925812	▁act in ▁cy tos kelet on ▁mito cho ndri al ▁function ▁intermedi ate _ ▁metabolism ▁gly col ysis / glu cone ogen es is ▁cit rate ▁cycle
D-873	-0.3582289516925812	actin cytoskeleton mitochondrial function intermediate_ metabolism glycolysis/gluconeogenesis citrate cycle
P-873	-0.1701 -0.1991 -0.2184 -0.3193 -0.0297 -0.1759 -0.0024 -0.0850 -0.1470 -0.0298 -1.7417 -0.7054 -0.1904 -0.9473 -0.0682 -0.0010 -0.0094 -0.0363 -2.8752 -0.0036 -0.0119 -0.1669 -0.0402 -0.1365 -0.0151 -0.0054 -1.9785 -0.0355 -0.0436
S-421	In conscious dogs with tachypacing-induced HF, CXL-1020 increased contractility assessed by end-systolic elastance and provided venoarterial dilation.<unk>
T-421	tachypacing-induced_hf cxl-1020 contractility end-systolic_elastance venoarterial_dilation
H-421	-0.42011281847953796	▁ conscious ▁dog s ▁ta chy pac ing - indu ced ▁ HF ▁contract ility ▁end - sy sto lic ▁elastan ce ▁ve no arte rial
D-421	-0.42011281847953796	conscious dogs tachypacing-induced HF contractility end-systolic elastance venoarterial
P-421	-0.7708 -0.1287 -1.3161 -0.0471 -2.1221 -0.1717 -0.0034 -0.0640 -0.0419 -0.0038 -0.0278 -0.3678 -0.0095 -0.9224 -0.0188 -3.8352 -0.0079 -0.0313 -0.0154 -0.0146 -0.1157 -0.2174 -0.0360 -0.0383 -0.0107 -0.0097 -1.3073 -0.1078
S-704	In multivariable models, ST2 remained independently associated with outcomes after adjustment for clinical variables and amino-terminal pro-B-type natriuretic peptide.<unk>
T-704	multivariable_models st2 outcomes clinical amino-terminal_pro-b-type_natriuretic_peptide
H-704	-0.5131120085716248	▁ST 2 ▁amino - termin al _ pro - B - type ▁na tri ure tic ▁pe pti de
D-704	-0.5131120085716248	ST2 amino-terminal_pro-B-type natriuretic peptide
P-704	-1.1604 -0.3142 -1.5963 -0.0141 -0.0265 -0.0058 -0.5201 -0.5543 -0.0235 -0.6277 -0.0376 -0.0051 -0.2083 -0.0057 -0.6296 -1.6819 -3.1214 -0.0144 -0.0766 -0.0962 -0.0556
S-1304	In this review, the principal mechanisms, diagnostic approaches, and clinical trials are reviewed, along with a discussion of novel treatment strategies that are currently under investigation or hold promise for the future.<unk>
T-1304	principal diagnostic clinical
H-1304	-0.7996358275413513	▁mechanism s ▁diagnostic ▁approach es ▁clinic al ▁trial s
D-1304	-0.7996358275413513	mechanisms diagnostic approaches clinical trials
P-1304	-4.5428 -0.0587 -0.6630 -1.5182 -0.0115 -0.1601 -0.0169 -1.2853 -0.0307 -0.4722 -0.0365
S-1538	RESULTS: The mean follow-up times were 2.8, 5.5 and 4.9 years for alendronate-, etidronate- and raloxifene-treated patients, respectively.<unk>
T-1538	follow-up patients
H-1538	-0.5410186052322388	▁ale ndr onate ▁et id rona te ▁ra lo xi fen e
D-1538	-0.5410186052322388	alendronate etidronate raloxifene
P-1538	-4.4236 -0.0116 -0.0253 -0.2089 -0.0269 -0.0044 -0.0071 -1.7514 -0.0107 -0.0526 -0.0507 -0.0711 -0.8688 -0.0612
S-891	However, our data do not support the use of implantable cardioverter defibrillator-CRT in patients with non-LBBB, especially when the QRS duration is <160 ms.<unk>
T-891	implantable patients qrs_duration
H-891	-0.4199700951576233	▁implant able _ ▁cardio ver ter _ de fi br illa tor - C RT ▁non - LB bb ▁QR s
D-891	-0.4199700951576233	implantable_ cardioverter_defibrillator-CRT non-LBbb QRs
P-891	-0.6777 -0.0155 -0.2503 -0.5684 -0.0083 -0.0472 -0.4963 -0.3377 -0.0110 -0.0770 -0.0701 -0.0161 -0.3160 -1.9008 -0.2683 -1.5445 -0.0083 -0.0111 -0.8468 -0.0651 -1.1801 -0.9096 -0.0333
S-790	The KCCQ domains demonstrated high internal consistency among patients with HFpEF (Cronbach's α=0.96 for overall summary and ≥0.69 in all subdomains).<unk>
T-790	kccq patients hfpef
H-790	-0.6555735468864441	▁k cc q _ ▁domain s ▁ HF p EF ▁c ron bach
D-790	-0.6555735468864441	kccq_ domains HFpEF cronbach
P-790	-1.5405 -0.1064 -0.4110 -3.3462 -0.3279 -0.0403 -0.5937 -0.4201 -0.0565 -0.1264 -1.2951 -0.0036 -0.0016 -1.4893 -0.0749
S-138	Using each metric, we calculated the absolute change and correlation between performance; the percent of hospitals remaining in extreme deciles and level of agreement; and differences in longitudinal performance.<unk>
T-138	change correlation hospitals longitudinal
H-138	-1.3039835691452026	▁ metric
D-138	-1.3039835691452026	metric
P-138	-1.2721 -0.1558 -3.5966 -0.1914
S-1833	RESULTS: 78 553 saxagliptin users and 298 124 sitagliptin users contributed an average of 7 to 9 months of follow-up data to 1 or more pairwise comparisons.<unk>
T-1833	saxagliptin sitagliptin follow-up
H-1833	-1.7283958196640015	▁sax ag lip tin ▁si tag lip tin
D-1833	-1.7283958196640015	saxagliptin sitagliptin
P-1833	-0.0619 -0.0432 -0.7852 -4.4763 -5.9324 -0.2416 -0.1069 -2.9217 -2.6449 -0.0699
S-31	Methods: This guideline is based on published literature in the English language on anemia and iron deficiency from 1947 to July 2012 that was identified using MEDLINE and the Cochrane Library.<unk>
T-31	anemia medline cochrane_library
H-31	-0.6492682099342346	▁an emia ▁ir on ▁de fici en cy ▁MED LINE ▁co ch rane ▁Library
D-31	-0.6492682099342346	anemia iron deficiency MEDLINE cochrane Library
P-31	-5.8461 -0.0839 -1.3115 -0.1584 -0.1522 -0.0053 -0.1019 -0.0796 -1.0881 -0.7017 -0.2982 -0.0126 -0.0107 -0.3782 -0.0612 -0.0986
S-473	Sprague-Dawley rats were randomized to either sham or ACF ± allopurinol (100 mg·kg(-1)·day(-1), n ≥7 rats/group).<unk>
T-473	sprague-dawley randomized acf allopurinol
H-473	-0.41207247972488403	▁Spr a gue - Da w ley ▁rat s ▁sham ▁a CF ▁allo puri nol
D-473	-0.41207247972488403	Sprague-Dawley rats sham aCF allopurinol
P-473	-0.1815 -0.1732 -0.2236 -0.0557 -1.3689 -0.0027 -0.0453 -1.3656 -0.0404 -0.0673 -2.2719 -0.1331 -0.0798 -0.0113 -0.0613 -0.7707 -0.1529
S-408	Compared with low sST2/high-dose BB, those with high sST2 treated with low-dose BB had an odds ratio of 6.77 (P<0.001) for a cardiovascular event.<unk>
T-408	sst2 sst2 odds_ratio cardiovascular_event
H-408	-0.9048893451690674	▁s st 2/ high - dos e ▁BB
D-408	-0.9048893451690674	sst2/high-dose BB
P-408	-0.3844 -1.8477 -2.2444 -0.5150 -0.0225 -1.3579 -0.0569 -1.3541 -1.1769 -0.0891
S-1064	These T1 changes appear to be associated with increases in the percentage of myocardial collagen that in this study were not detected by traditional myocardial delayed enhancement imaging.<unk>
T-1064	t1 myocardial_collagen myocardial
H-1064	-1.9687778949737549	▁my o card ial
D-1064	-1.9687778949737549	myocardial
P-1064	-3.3340 -0.1216 -0.1577 -0.1619 -8.0037 -0.0338
S-1259	DESIGN: Studies on biomedical treatment plus CHM versus biomedical treatment alone in treating patients with DCM and heart failure were retrieved from PubMed and other major databases (1980-2011).<unk>
T-1259	biomedical biomedical patients dcm heart_failure pubmed
H-1259	-0.8752695918083191	▁bio medic al _ ▁treatment ▁CH m ▁bio medic al _ ▁treatment ▁d CM ▁heart ▁failure ▁Pub Med
D-1259	-0.8752695918083191	biomedical_ treatment CHm biomedical_ treatment dCM heart failure PubMed
P-1259	-0.0337 -0.0687 -0.0025 -3.7596 -1.5577 -2.8681 -0.9300 -0.0675 -0.0171 -0.0038 -1.7495 -0.8455 -1.1024 -0.0134 -2.2429 -0.8390 -1.1294 -0.0153 -0.2002 -0.0592
S-587	At the second evaluation, higher serum levels of creatinine and BNP, higher furosemide dose and oxygen flow, and dobutamine or norepinephrine requirement were associated with poor outcome.<unk>
T-587	creatinine bnp furosemide dobutamine norepinephrine outcome
H-587	-0.27694177627563477	▁creati nine ▁b NP ▁fur os em ide ▁dose ▁oxygen ▁flow ▁dobu tamine ▁no re pine ph rine
D-587	-0.27694177627563477	creatinine bNP furosemide dose oxygen flow dobutamine norepinephrine
P-587	-0.5754 -0.0275 -1.4339 -0.1935 -0.0708 -0.0543 -0.0059 -0.0151 -1.8701 -0.1639 -0.0123 -0.0244 -0.0259 -0.0136 -0.0605 -0.0081 -0.2953 -0.0148 -0.6348 -0.0388
S-319	BACKGROUND: Biventricular pacing (BiVP) improves cardiac output (CO) in selected cardiac surgery patients, but response remains variable, necessitating a better understanding of the mechanism.<unk>
T-319	biventricular_pacing bivp cardiac_output cardiac surgery patients
H-319	-0.8705587983131409	▁bi ven tri cular _ pa cing ▁bi VP ▁cardiac ▁output
D-319	-0.8705587983131409	biventricular_pacing biVP cardiac output
P-319	-1.3129 -0.0782 -0.3805 -1.2034 -0.7204 -0.4383 -0.4996 -1.8208 -0.1218 -0.0745 -1.0740 -3.4810 -0.1118
S-111	Contemporary heart failure (HF) therapies have not resulted in improved outcomes among patients with HF and preserved left ventricular ejection fraction (LVEF).<unk>
T-111	heart_failure hf therapies outcomes patients hf preserved_left_ventricular_ejection_fraction lvef
H-111	-0.6403698325157166	▁con tempor ary _ heart ▁failure HF ▁ therapie s ▁ therapie s ▁ HF ▁pres er ved _ ▁left _ ▁vent ri cular ▁e je ction ▁ fraction LV EF
D-111	-0.6403698325157166	contemporary_heart failureHF therapies therapies HF preserved_ left_ ventricular ejection fractionLVEF
P-111	-0.7366 -0.0001 -0.0256 -0.0906 -0.9953 -0.3489 -2.0312 -1.5144 -0.1560 -0.0472 -1.7913 -1.7835 -0.0608 -1.2626 -0.4120 -1.1192 -0.0518 -0.1455 -0.5663 -0.5900 -0.7321 -0.8325 -0.5933 -0.7012 -2.2320 -0.1958 -0.0730 -1.8702 -0.0289 -0.0301 -0.0036 -0.0399 -0.0708
S-389	METHODS AND RESULTS: Patients with systolic HF were identified in The Danish Heart Failure database and new-onset ESRD from the Danish Registry on Dialysis.<unk>
T-389	patients systolic_hf the_danish_heart_failure_database esrd danish_registry_on_dialysis
H-389	-0.6027494668960571	▁sy sto lic _ HF ▁Danish _ ▁Heart ▁Fail ure ▁database ▁ES RD ▁Danish _ ▁Registr y _ ▁on _ dia lys is
D-389	-0.6027494668960571	systolic_HF Danish_ Heart Failure database ESRD Danish_ Registry_ on_dialysis
P-389	-0.2404 -0.0138 -0.0112 -0.4812 -0.2975 -1.0055 -0.4268 -1.4838 -0.6217 -0.6646 -1.0301 -3.0831 -0.1322 -0.1903 -0.2305 -1.4281 -0.0649 -0.4515 -1.0050 -0.2495 -1.3570 -0.0793 -0.2233 -0.2109 -0.0865
S-674	Chemotherapy, trastuzumab use, comorbidities, and CHF were identified using International Classification of Diseases, version 9, and Healthcare Common Procedure Coding System codes.<unk>
T-674	chemotherapy trastuzumab comorbidities chf international_classification_of_diseases healthcare_common_procedure_coding_system_codes
H-674	-0.734217643737793	▁che mo therapy ▁tras tuz um ab ▁como rbi di ties ▁CHF
D-674	-0.734217643737793	chemotherapy trastuzumab comorbidities CHF
P-674	-1.2823 -0.0518 -0.0155 -0.0376 -0.0108 -0.0107 -0.1427 -4.6292 -0.0011 -0.1442 -0.0076 -0.0731 -3.8224 -0.0500
S-1283	The interval from transplantation to consultation was shorter for the MT group (50 vs 82 days; P = 0.015), whereas the interval from consultation to operation was longer (5 vs 1 day; P = 0.03).<unk>
T-1283	transplantation consultation consultation operation
H-1283	-1.356622576713562	▁interval ▁transplant ation _ to ▁consultation
D-1283	-1.356622576713562	interval transplantation_to consultation
P-1283	-2.5644 -2.2552 -0.0279 -2.4413 -0.8480 -0.5629 -2.0965 -0.0568
S-853	There were 45 deaths in the CRT group and 26 in the control group (11.1% vs. 6.4%; hazard ratio, 1.81; 95% CI, 1.11 to 2.93; P=0.02).<unk>
T-853	deaths crt hazard_ratio
H-853	-0.9113644361495972	▁c RT _ groep ▁hazard ▁ratio
D-853	-0.9113644361495972	cRT_groep hazard ratio
P-853	-0.3956 -0.4190 -2.5928 -0.7629 -1.8718 -0.0657 -1.1238 -0.0592
S-11	We tested the hypothesis that neurohormones and adipokines are associated with body composition in CC and that a progressive loss of fat free mass (FFM) and fat mass (FM) takes place.<unk>
T-11	neurohormones adipokines fat_free_mass ffm fat_mass
H-11	-0.7664915919303894	▁neuro hormon es ▁adi pok ines cc
D-11	-0.7664915919303894	neurohormones adipokinescc
P-11	-0.2634 -0.0104 -0.1124 -0.0738 -0.0097 -0.0167 -2.7280 -3.6133 -0.0707
S-1678	However, our results do not rule out the possibility that decreased expression, mistargeting or altered regulation of Rad Q66P may reduce the RGK protein's efficacy in vivo.<unk>
T-1678	rule expression regulation rad q66p rgk_protein in_vivo
H-1678	-1.1261574029922485	▁r GK _ ▁protein
D-1678	-1.1261574029922485	rGK_ protein
P-1678	-3.2002 -0.1331 -1.3958 -0.7707 -1.2000 -0.0573
S-1411	CONCLUSIONS: We demonstrate that restoration of cardiac plasma membrane levels of S1PR1 produces beneficial effects that counterbalance the deleterious β1AR overstimulation in heart failure.<unk>
T-1411	cardiac_plasma_membrane s1pr1 β1ar heart_failure
H-1411	-0.9437253475189209	▁cardiac ▁plasma ▁membran e ▁s 1 PR 1 ▁over stimul ation ▁heart ▁failure
D-1411	-0.9437253475189209	cardiac plasma membrane s1PR1 overstimulation heart failure
P-1411	-2.8950 -1.3027 -0.0585 -0.0304 -3.1665 -0.2652 -0.0748 -1.5008 -1.8325 -0.2015 -0.0990 -2.2836 -0.3198 -0.0754 -0.0500
S-1518	Consistent with this result, AlphaLISA immunoassays demonstrated that antibodies targeting the extreme N or C termini measured a low apparent concentration of circulating NT-proBNP.<unk>
T-1518	alphalisa immunoassays antibodies c_termini nt-probnp
H-1518	-0.5539827942848206	▁Alpha LIS a ▁immun o assa ys ▁anti bo dies ▁n ▁c ▁termini ▁circula ting ▁NT - pro b NP
D-1518	-0.5539827942848206	AlphaLISa immunoassays antibodies n c termini circulating NT-probNP
P-1518	-0.0300 -0.0605 -1.1543 -0.0402 -0.1014 -0.0248 -0.4712 -0.0489 -0.0053 -1.0963 -4.3272 -2.8965 -0.0303 -0.0171 -0.0649 -0.7359 -0.0359 -0.0078 -0.9398 -0.0140 -0.0382 -0.0471
S-2002	Support with the fully magnetically levitated LVAS significantly reduced mortality risk by 66% compared with the Seattle Heart Failure Model-predicted survival of 78% (p = 0.0093).<unk>
T-2002	fully_magnetically_levitated_lvas mortality seattle heart_failure
H-2002	-0.9297852516174316	▁fully _ magnet ically _ ▁le vita ted _ ▁l VAS ▁Seattle _ ▁Heart _ ▁Fail ure
D-2002	-0.9297852516174316	fully_magnetically_ levitated_ lVAS Seattle_ Heart_ Failure
P-2002	-3.9454 -0.8823 -1.9133 -0.0607 -0.2203 -0.7085 -0.0095 -0.0307 -0.1474 -3.0983 -0.0888 -1.5011 -0.2131 -1.0666 -1.2211 -0.2549 -0.6369 -1.5595 -0.1076
S-89	Myocyte hypertrophy antecedent to heart failure involves changes in global gene expression, although the preceding mechanisms to coordinate DNA accessibility on a genomic scale are unknown.<unk>
T-89	myocyte_hypertrophy heart_failure global_gene_expression dna genomic
H-89	-0.8004670143127441	▁My o cy te ▁hyper trop hy _ ▁antecede nt _ to _ ▁heart ▁failure ▁global _ ▁gene ▁expression
D-89	-0.8004670143127441	Myocyte hypertrophy_ antecedent_to_ heart failure global_ gene expression
P-89	-1.0928 -0.0358 -0.0414 -0.0803 -0.5563 -0.0087 -0.4639 -2.9794 -0.6652 -0.0160 -0.3528 -1.4923 -0.7244 -1.1858 -0.6066 -2.2917 -0.5756 -1.0018 -0.8648 -1.6672 -0.1069
S-944	METHODS: Catheter ablation for AF was performed in a consecutive 74 patients with compensated HFPEF (left ventricular [LV] ejection fraction >50%).<unk>
T-944	catheter_ablation patients compensated_hfpef left_ventricular ejection_fraction
H-944	-0.723472535610199	▁Cat heter ▁ab lation ▁AF ▁compensa ted _ h FP EF ▁le ft ▁vent ri cular LV ▁e je ction
D-944	-0.723472535610199	Catheter ablation AF compensated_hFPEF left ventricularLV ejection
P-944	-2.6862 -0.0250 -0.0679 -0.0694 -3.7698 -0.0815 -0.0224 -0.7609 -0.9027 -0.4810 -0.1654 -1.2561 -0.0040 -0.9129 -0.5283 -0.0703 -0.2849 -1.7924 -0.0215 -0.0060 -1.9523 -0.0557
S-1952	Patients (aged ≥18 years) with New York Heart Association (NYHA) class III chronic heart failure with reduced ejection fraction were enrolled under the Canadian special access programme.<unk>
T-1952	patients new_york_heart_association nyha chronic_heart_failure reduced_ejection_fraction
H-1952	-0.9442421793937683	▁New ▁York _ ▁Heart ▁Association NY HA ▁chronic _ heart ▁failure ▁reduce d _ e je ction _ fraction
D-1952	-0.9442421793937683	New York_ Heart AssociationNYHA chronic_heart failure reduced_ejection_fraction
P-1952	-1.6113 -0.4216 -0.3415 -2.4154 -0.4058 -1.2008 -0.1616 -3.1381 -0.0690 -1.0435 -1.2399 -3.7424 -0.0336 -0.1614 -1.0919 -0.0523 -0.0218 -0.9451 -0.0151 -1.6025 -0.1145
S-972	The Swedish National Inpatient Registry was used to obtain the primary end point, which was rehospitalization for stroke, myocardial infarction, or heart failure ≤90 days after CABG.<unk>
T-972	inpatient primary_end_point rehospitalization stroke myocardial_infarction heart_failure cabg
H-972	-0.43383780121803284	▁Swedish _ national _ in patient ▁Registr y ▁re hospital ization ▁stroke ▁my o card ial _ in far ction ▁heart ▁failure ▁ca BG
D-972	-0.43383780121803284	Swedish_national_inpatient Registry rehospitalization stroke myocardial_infarction heart failure caBG
P-972	-0.1407 -0.6055 -0.4213 -0.1167 -0.1385 -0.0294 -1.0426 -0.0218 -0.1186 -0.0064 -0.3848 -2.9512 -0.6385 -0.2866 -0.0655 -0.1260 -0.6363 -0.6153 -0.0181 -0.0665 -0.2988 -0.6268 -1.6996 -0.0898 -0.0587 -0.0756
S-1826	Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study.<unk>
T-1826	hospitalized heart_failure saxagliptin sitagliptin antihyperglycemic_drugs retrospective_cohort_study
H-1826	-0.7420705556869507	▁Hospital ized _ ▁Heart ▁Fail ure ▁Sax ag lip tin ▁Si tag lip tin ▁anti hy per gly ce mic _ drug s
D-1826	-0.7420705556869507	Hospitalized_ Heart Failure Saxagliptin Sitagliptin antihyperglycemic_drugs
P-1826	-6.1342 -0.0778 -0.1531 -0.6154 -0.1813 -0.2957 -0.1145 -0.0126 -0.3776 -2.8143 -1.2961 -0.0401 -0.0530 -1.7918 -0.3094 -0.2650 -0.0810 -0.4682 -0.3206 -0.5238 -1.4288 -0.8444 -0.0494 -0.2256 -0.0779
S-431	Cox proportional hazards models were used to identify the association of the score with death, transplantation or LV assist device implantation, and heart failure hospitalization during 57±22 months of follow-up.<unk>
T-431	cox_proportional_hazards_models death transplantation lv_assist_device_implantation heart_failure hospitalization follow-up
H-431	-0.7222422361373901	▁co x ▁proportion al _ ▁hazard s ▁models ▁score ▁death ▁transplant ation ▁LV ▁assist _ ▁device ▁implant ation ▁heart ▁failure
D-431	-0.7222422361373901	cox proportional_ hazards models score death transplantation LV assist_ device implantation heart failure
P-431	-0.3091 -0.0015 -0.4210 -0.0033 -0.2983 -0.2945 -0.1080 -3.4484 -1.6256 -3.0654 -1.5791 -0.0308 -0.1261 -0.6506 -1.0423 -0.7749 -0.8493 -0.0741 -0.1899 -0.6053 -0.3108 -0.0810
S-964	Nicorandil also preserved phosphocreatine and adenine nucleotides contents by restoring mitochondrial oxidative phosphorylation capacity and creatine kinase activity.<unk>
T-964	nicorandil phosphocreatine adenine_nucleotides mitochondrial_oxidative_phosphorylation_capacity creatine kinase activity
H-964	-0.35157227516174316	▁Nico rand il ▁ phos pho creati ne ▁a den ine ▁nucleo ti des ▁mito cho ndri al ▁oxid ative _ phos phor y lation ▁capacity ▁creati ne ▁kina se
D-964	-0.35157227516174316	Nicorandil phosphocreatine adenine nucleotides mitochondrial oxidative_phosphorylation capacity creatine kinase
P-964	-0.0044 -0.0077 -0.1029 -0.1118 -0.0040 -0.0784 -0.1499 -0.7171 -0.0468 -0.0010 -0.5312 -0.0701 -0.0273 -0.0409 -0.3829 -0.1062 -0.0611 -0.0629 -0.6238 -0.1109 -0.6386 -0.0286 -0.6732 -1.3871 -0.0959 -4.2596 -0.0037 -0.3659 -0.0305 -0.0179 -0.4213 -0.0867
S-801	The intraclass correlation coefficient (ICC), kappa coefficient, standard error of measurement, and absolute and relative minimal detectable change (MDC) values were calculated.<unk>
T-801	intraclass_correlation_coefficient icc kappa_coefficient standard_error_of_measurement minimal_detectable_change mdc
H-801	-0.48287469148635864	▁intra class ▁corre lation ▁co e ffi cient IC c ▁ka ppa ▁co e ffi cient
D-801	-0.48287469148635864	intraclass correlation coefficientICc kappa coefficient
P-801	-1.7524 -0.0942 -0.4532 -0.3483 -0.1751 -0.3163 -0.0686 -0.0136 -1.0645 -0.3548 -0.0055 -0.0115 -0.0574 -0.0948 -0.0156 -0.0051 -3.7880 -0.0729
S-1629	Race, exercise training, and outcomes in chronic heart failure: findings from Heart Failure - a Controlled Trial Investigating Outcomes in Exercise TraiNing (HF-ACTION).<unk>
T-1629	exercise training outcomes chronic_heart_failure heart_failure_-_a_controlled_trial_investigating_outcomes_in_exercise_training hf-action
H-1629	-0.8195187449455261	▁race _ training ▁chronic _ heart ▁failure ▁Heart _ ▁Fail ure ▁control led _ tri al _ ▁Investiga ting _ out com es ▁Exerci se _ ▁Tra i N ing HF - AC TION
D-1629	-0.8195187449455261	race_training chronic_heart failure Heart_ Failure controlled_trial_ Investigating_outcomes Exercise_ TraiNingHF-ACTION
P-1629	-1.8613 -3.9487 -0.6640 -1.9451 -0.3711 -0.7067 -0.2116 -3.4157 -1.4006 -0.4905 -0.4496 -2.8342 -0.1199 -0.0588 -0.5012 -0.0211 -0.3308 -0.2666 -0.0294 -0.2156 -0.5796 -0.0362 -0.0216 -2.9498 -0.0371 -0.3343 -1.6877 -0.6256 -1.8414 -0.4500 -0.4066 -0.0502 -0.4068 -0.0829 -0.0791 -0.0714
S-990	The ability of cardiomyocytes to detect mechanical and humoral stimuli is critical for adaptation of the myocardium in response to new conditions and for sustaining the increased workload during stress.<unk>
T-990	cardiomyocytes myocardium conditions
H-990	-0.46011385321617126	▁cardio my o cy tes ▁mechanic al ▁humor al ▁stimul i ▁my o car dium
D-990	-0.46011385321617126	cardiomyocytes mechanical humoral stimuli myocardium
P-990	-0.0804 -0.0750 -0.1512 -0.0374 -0.0466 -1.8955 -0.0053 -0.6882 -0.0391 -2.4605 -0.1298 -0.5968 -0.0322 -0.0018 -0.1501 -1.3465 -0.0857
S-301	The mean duration of biventricular support was 17 ± 11.9 days (range, 6 to 56 days) with 91.8% (n = 31) of RVADs successfully explanted.<unk>
T-301	biventricular_support rvads explanted
H-301	-1.4822109937667847	▁r VAD s
D-301	-1.4822109937667847	rVADs
P-301	-5.9307 -0.5886 -0.4853 -0.2370 -0.1694
S-411	CONCLUSIONS: Although BB therapy exerted dose-related benefits across all study participants, sST2 measurement identifies patients with chronic heart failure who may particularly benefit from higher BB doses.<unk>
T-411	therapy sst2 patients chronic_heart_failure
H-411	-1.0071722269058228	▁BB ▁ therapy ▁s st 2 ▁measure ment ▁chronic _ heart ▁failure
D-411	-1.0071722269058228	BB therapy sst2 measurement chronic_heart failure
P-411	-0.4050 -1.3465 -0.0626 -2.0843 -1.4643 -0.0261 -4.3611 -0.0206 -1.1140 -0.3120 -1.1616 -0.5725 -1.0611 -0.1089
S-1337	Therefore, the objective of this study was to determine the effect of CHF on the number and phenotype of cardiac explant c-Kit+ progenitors and elucidate mechanisms of their regulation.<unk>
T-1337	chf phenotype cardiac explant progenitors regulation
H-1337	-0.5903873443603516	▁CHF ▁cardiac ▁ex plant ▁c - K it _ pro geni tors
D-1337	-0.5903873443603516	CHF cardiac explant c-Kit_progenitors
P-1337	-0.5052 -2.2035 -1.1303 -0.0019 -0.0234 -0.0392 -0.2401 -0.0131 -0.6201 -2.0922 -0.0997 -0.1029 -1.1507 -0.0430
S-396	CONCLUSIONS: ESRD is rare in outpatients with systolic HF and is mainly observed in patients with an eGFR <30 mL/min per 1.73 m(2).<unk>
T-396	esrd outpatients systolic_hf patients egfr
H-396	-0.3685184121131897	▁ES RD ▁sy sto lic _ HF ▁e G FR
D-396	-0.3685184121131897	ESRD systolic_HF eGFR
P-396	-2.4662 -0.1329 -0.2219 -0.0160 -0.0162 -0.4185 -0.0556 -0.0419 -0.5394 -0.1089 -0.3117 -0.0932
S-1579	INTERVENTION: An intensive transitions of care program was implemented to ensure adequate self-management training of patients and appropriate out-patient follow-up and monitoring of the patient by the health care system.<unk>
T-1579	transitions training patients out-patient follow-up patient health_care
H-1579	-1.6937028169631958	▁transition s _ van _ care
D-1579	-1.6937028169631958	transitions_van_care
P-1579	-5.6864 -0.2004 -0.8691 -1.4826 -0.0647 -1.3507 -3.7421 -0.1537
S-425	CONCLUSIONS: These data show the functional efficacy of a novel pure HNO donor to enhance myocardial function and present first-in-man evidence for its potential usefulness in HF.<unk>
T-425	hno_donor myocardial_function evidence hf
H-425	-1.070608377456665	▁functional _ ef fica cy ▁pure _ h no ▁donor ▁ HF
D-425	-1.070608377456665	functional_efficacy pure_hno donor HF
P-425	-3.3907 -0.5234 -0.2848 -0.1671 -0.1232 -2.2027 -0.2972 -0.6565 -0.4324 -0.6237 -3.9402 -1.9858 -0.3040 -0.0570
S-172	In the TUNEL assay there was no significant difference between numbers of apoptotic cells in any of the groups, although a few TUNEL-positive cells were detected in the paced groups.<unk>
T-172	tunel apoptotic_cells tunel-positive_cells
H-172	-0.5573936700820923	▁tu nel ▁as say ▁apo pto tic ▁cell s ▁tu nel - posi tive _ ▁cell s ▁pace d
D-172	-0.5573936700820923	tunel assay apoptotic cells tunel-positive_ cells paced
P-172	-1.1137 -0.1447 -1.3227 -0.0642 -2.2661 -0.0517 -0.1892 -1.6931 -0.0420 -0.9338 -0.1718 -0.0472 -0.0023 -0.1070 -1.0191 -0.9511 -0.0261 -0.7426 -0.0090 -0.7259 -0.0820
S-501	The TAPSE vs. PASP relationship as a possible index of the length-force relationship may be a step forward for a more efficient RV function evaluation and is not affected by the quality of LV dysfunction.<unk>
T-501	tapse pasp step rv_function lv_dysfunction
H-501	-1.1184614896774292	▁t AP se _ pas p ▁length - force _ ▁relationship ▁ RV
D-501	-1.1184614896774292	tAPse_pasp length-force_ relationship RV
P-501	-4.5753 -0.1838 -1.0947 -1.3000 -1.2804 -0.5788 -2.5592 -0.0693 -0.0190 -0.9038 -0.9060 -0.4317 -0.1040 -2.6784 -0.0925
S-1013	As the biological phenotype is not routinely assessed clinically, the deficit index, which can be ascertained from medical records, is a feasible alternative to ascertain frailty.<unk>
T-1013	biological_phenotype clinically deficit_index medical frailty
H-1013	-0.6877105236053467	▁bi ological _ ▁ph eno type
D-1013	-0.6877105236053467	biological_ phenotype
P-1013	-0.6584 -0.1866 -0.8866 -0.3249 -0.0159 -0.0006 -3.3581 -0.0705
S-1380	Conversely, the tachycardia in response to intravenous atropine (indicative of cardiac vagal tone) was not improved in CHF-DNx vs. CHF-INV animals.<unk>
T-1380	tachycardia intravenous atropine cardiac vagal_tone
H-1380	-0.3112141191959381	▁ta chy car dia ▁intra ven ous ▁a tropi ne ▁cardiac ▁va gal ▁tone ▁CHF - DN x ▁CHF - IN v
D-1380	-0.3112141191959381	tachycardia intravenous atropine cardiac vagal tone CHF-DNx CHF-INv
P-1380	-0.5399 -0.2175 -0.0041 -0.0043 -0.0674 -0.0034 -1.9057 -1.0051 -0.0198 -1.1314 -0.0198 -0.2805 -0.0434 -0.1560 -0.0165 -0.0229 -0.3600 -0.0401 -0.0694 -0.0110 -0.4186 -0.7048 -0.3818 -0.0455
S-1583	CONCLUSIONS: An intensive transitions of care program decreases the 30-day readmission rate for patients with congestive heart failure in a non-urbanized Midwestern state like South Dakota.<unk>
T-1583	transitions readmission patients congestive_heart_failure south_dakota
H-1583	-1.1078933477401733	▁con ges tive _ heart ▁failure ▁non - urban ized _ mid we stern
D-1583	-1.1078933477401733	congestive_heart failure non-urbanized_midwestern
P-1583	-3.6560 -0.8190 -0.4961 -0.1408 -1.7910 -0.7665 -3.2540 -0.0221 -0.0014 -0.0519 -1.0867 -0.3400 -0.1668 -0.0618 -4.8774 -0.1947
S-162	CONCLUSIONS: STS HH and TM with medical support provided during office hours showed beneficial trends, particularly in reducing all-cause mortality for recently discharged patients with heart failure.<unk>
T-162	sts hh medical all-cause_mortality discharged patients heart_failure
H-162	-1.8471688032150269	▁s ts ▁ HH ▁ HH
D-162	-1.8471688032150269	sts HH HH
P-162	-1.6601 -3.1921 -0.3443 -0.0078 -4.3756 -0.0726 -4.9894 -0.1354
S-452	METHODS AND RESULTS: Eight weeks from surgically induced myocardial infarction, heart failure rats were randomized to receive bisoprolol (B) or vehicle.<unk>
T-452	surgically myocardial_infarction heart_failure randomized bisoprolol
H-452	-0.8762173056602478	▁sur g ically _ ▁induc ed ▁my o card ial _ in far ction ▁heart ▁failure
D-452	-0.8762173056602478	surgically_ induced myocardial_infarction heart failure
P-452	-5.7374 -0.1250 -0.2268 -1.8280 -0.4246 -0.2220 -1.0325 -0.1060 -0.2921 -0.2862 -0.6852 -0.8619 -0.0270 -0.0657 -0.3926 -0.0717 -3.3336 -0.0537
S-1444	SDQT remained elevated in the HFVT(+) group relative to the HNorm group despite acute β-adrenoceptor blockade with esmolol (P = 0.02).<unk>
T-1444	sdqt elevated acute β-adrenoceptor_blockade esmolol
H-1444	-0.4581345021724701	▁SD QT ▁ HF VT ▁h Nor m ▁β - ad re no cept or ▁block ade ▁es mol ol
D-1444	-0.4581345021724701	SDQT HFVT hNorm β-adrenoceptor blockade esmolol
P-1444	-0.1408 -0.1075 -0.2114 -0.0170 -0.3442 -2.0429 -0.9673 -0.0061 -3.0014 -0.0100 -0.0045 -0.2360 -0.0777 -0.1144 -0.1941 -1.2251 -0.1000 -1.0702 -0.0004 -0.0449 -0.0996 -0.0634
S-137	STUDY DESIGN: We calculated 30-day readmission rates using three metrics, for three disease groups: heart failure (HF), acute myocardial infarction (AMI), and pneumonia.<unk>
T-137	readmission disease heart_failure hf acute_myocardial_infarction ami pneumonia
H-137	-1.6844512224197388	▁ STU DY
D-137	-1.6844512224197388	STUDY
P-137	-3.1344 -0.3661 -0.0386 -4.8153 -0.0680
S-894	BACKGROUND: Peritoneal dialysis (PD) for long-term management of diuretic resistant volume overload in heart failure (HF) may provide potential benefit with few adverse consequences.<unk>
T-894	peritoneal_dialysis pd diuretic volume_overload heart_failure hf
H-894	-0.4096594750881195	▁Peri tone al _ ▁di al ysis PD ▁di ure tic _ ▁resist ant _ ▁volume ▁over load ▁heart ▁failure
D-894	-0.4096594750881195	Peritoneal_ dialysisPD diuretic_ resistant_ volume overload heart failure
P-894	-0.3945 -0.0635 -0.0416 -0.6246 -1.8032 -0.0285 -0.0564 -0.3202 -0.3321 -0.1439 -0.6886 -0.2365 -2.4060 -0.0101 -0.1738 -0.1024 -0.0602 -0.0534 -0.8619 -0.1861 -0.3665 -0.0586
S-415	Here, we report on effects of a novel, stable, pure HNO donor (CXL-1020) in isolated myoctyes and intact hearts in experimental models and in patients with heart failure (HF).<unk>
T-415	report stable hno_donor cxl-1020 myoctyes hearts patients heart_failure hf
H-415	-1.033596396446228	▁h no ▁donor ▁c XL _ -10 20 ▁isola ted _ my oc ty es ▁intact _ heart s ▁ HF
D-415	-1.033596396446228	hno donor cXL_-1020 isolated_myoctyes intact_hearts HF
P-415	-4.4153 -0.6416 -0.3491 -2.2539 -0.0783 -2.9797 -1.8714 -0.6012 -2.7618 -0.0222 -0.5414 -1.2276 -0.0291 -0.0121 -0.1930 -0.0151 -0.7693 -0.8782 -0.0195 -3.2676 -0.5995 -0.1663 -0.0795
S-1567	Peripheral artery disease (PAD) and heart failure (HF) share many risk factors; however, the prevalence and characteristics of HF in patients with PAD have not been fully examined.<unk>
T-1567	peripheral_artery_disease pad heart_failure hf prevalence hf patients pad
H-1567	-0.6680892109870911	▁Peri pher al ▁arter y ▁disease PAD ▁heart ▁failure ▁ HF
D-1567	-0.6680892109870911	Peripheral artery diseasePAD heart failure HF
P-1567	-1.1885 -0.0106 -0.0760 -1.2766 -0.1750 -0.8916 -0.7466 -2.0470 -0.1282 -1.0642 -0.0039 -0.9968 -0.0800
S-1974	IMPORTANCE: More than 80% of patients with heart failure with preserved ejection fraction (HFPEF), the most common form of heart failure among older persons, are overweight or obese.<unk>
T-1974	patients heart_failure_with_preserved_ejection_fraction hfpef heart_failure obese
H-1974	-0.7467055916786194	▁heart ▁failure ▁pres er ved _ e je ction _ fraction h FP EF
D-1974	-0.7467055916786194	heart failure preserved_ejection_fractionhFPEF
P-1974	-2.9034 -0.3637 -1.7980 -0.0753 -0.3752 -0.0724 -1.1344 -0.2600 -0.0664 -0.4579 -0.0272 -0.9826 -0.3486 -0.4282 -2.5845 -0.0695
S-387	BACKGROUND: Renal dysfunction is an important prognostic factor in heart failure (HF), but whether this dysfunction progresses to end-stage renal disease (ESRD) is unknown.<unk>
T-387	renal_dysfunction prognostic heart_failure hf dysfunction end-stage_renal_disease esrd
H-387	-1.1206929683685303	▁Ren al ▁dys function ▁heart ▁failure ▁ HF ▁renal ▁disease ES RD
D-387	-1.1206929683685303	Renal dysfunction heart failure HF renal diseaseESRD
P-387	-3.5934 -0.1631 -0.8948 -0.0521 -1.9738 -0.1225 -2.9654 -0.0063 -3.0837 -1.4678 -1.1881 -0.0591 -0.0664 -0.0532
S-963	Nicorandil was effective in alleviating the decrement of heart rate and aortic blood flow and the state of mitochondrial oxidative stress induced by doxorubicin cardiotoxicity.<unk>
T-963	nicorandil heart_rate aortic blood_flow mitochondrial oxidative_stress doxorubicin cardiotoxicity
H-963	-0.3215109705924988	▁Nico rand il ▁a or tic _ ▁blood ▁flow ▁mito cho ndri al ▁oxid ative _ stress ▁do xor ubi cin ▁cardio toxic ity
D-963	-0.3215109705924988	Nicorandil aortic_ blood flow mitochondrial oxidative_stress doxorubicin cardiotoxicity
P-963	-0.0023 -0.0027 -0.0246 -3.8025 -0.0443 -0.2509 -0.1505 -0.2288 -0.1298 -0.0008 -0.0560 -0.0639 -0.0153 -0.2298 -0.0148 -0.9879 -1.2079 -0.0065 -0.0002 -0.0031 -0.1624 -0.1940 -0.0869 -0.5487 -0.0737 -0.0710
S-1492	OBJECTIVES: The peripheral muscle pump is key in promoting cardiac filling during exercise, especially in subjects who lack a subpulmonary ventricle (the Fontan circulation).<unk>
T-1492	peripheral_muscle_pump cardiac_filling exercise subpulmonary_ventricle fontan_circulation
H-1492	-0.3003271818161011	▁per i pher al _ ▁muscle ▁pump ▁cardiac ▁fill ing ▁sub pul mon ary _ ▁vent ric le ▁Font an ▁circulation
D-1492	-0.3003271818161011	peripheral_ muscle pump cardiac filling subpulmonary_ ventricle Fontan circulation
P-1492	-0.0500 -0.0633 -0.0029 -0.0318 -0.3755 -0.3813 -0.5764 -1.5359 -0.7058 -0.0158 -0.1078 -0.0608 -0.4134 -0.0517 -0.3768 -0.1257 -0.5012 -0.2316 -0.0347 -0.0500 -1.0118 -0.1316 -0.0713
S-430	Regression analysis was performed to create an echocardiographic score for prediction of LV reverse remodeling (defined as ≥15% reduction in the LV end-systolic volume).<unk>
T-430	regression_analysis echocardiographic lv_reverse_remodeling lv_end-systolic_volume
H-430	-0.33429932594299316	▁e cho car dio graphic ▁score ▁LV ▁rever se _ ▁remodel ing ▁LV ▁end - sy sto lic ▁volume
D-430	-0.33429932594299316	echocardiographic score LV reverse_ remodeling LV end-systolic volume
P-430	-0.1252 -0.0139 -0.0048 -0.2321 -0.1719 -0.7557 -0.3516 -0.5340 -0.0168 -0.2469 -0.1574 -0.0289 -0.4888 -2.8896 -0.0203 -0.0250 -0.0360 -0.0027 -0.7791 -0.0754 -0.0640
S-660	METHODS AND RESULTS: Cardiology practices participating in the National Cardiovascular Disease Registry Practice Innovation and Clinical Excellence registry from July 2008 to December 2010 were evaluated.<unk>
T-660	cardiology national_cardiovascular_disease_registry_practice_innovation_and_clinical_excellence_registry
H-660	-0.7817707061767578	▁Card i ology ▁practice s ▁National ▁Card io vas cular _ ▁Disease ▁Registr y ▁Practic e ▁Innovation ▁Clinic al ▁Excellence ▁registr y
D-660	-0.7817707061767578	Cardiology practices National Cardiovascular_ Disease Registry Practice Innovation Clinical Excellence registry
P-660	-1.4882 -0.6154 -0.1853 -2.1820 -0.0285 -3.8259 -1.9080 -0.8412 -0.2011 -0.4190 -0.7267 -0.4360 -0.5534 -0.0198 -2.8133 -0.0121 -0.2642 -0.8412 -0.0029 -0.3276 -0.9281 -0.0300 -0.0510 -0.0616
S-440	We identified all adults with newly diagnosed heart failure, left ventricular ejection fraction of <40%, and no previous spironolactone use from 2006 to 2008 in Kaiser Permanente Northern California.<unk>
T-440	diagnosed heart_failure left_ventricular_ejection_fraction spironolactone kaiser_permanente northern_california
H-440	-0.7540096044540405	▁heart ▁failure ▁left _ ▁vent ri cular ▁e je ction ▁spi rono lac tone
D-440	-0.7540096044540405	heart failure left_ ventricular ejection spironolactone
P-440	-4.7705 -0.5469 -1.4144 -0.9860 -0.3513 -0.3463 -0.3956 -1.0775 -0.0341 -0.0213 -0.2231 -0.0024 -0.0041 -0.0219 -1.8160 -0.0527
S-1894	Physical examination should include the patient's BMI and weight, heart rate and rhythm, lying and standing blood pressure and auscultation to rule out valvular disease and pulmonary congestion.<unk>
T-1894	physical_examination patient bmi heart_rate rhythm blood_pressure auscultation rule valvular_disease pulmonary_congestion
H-1894	-0.6599284410476685	▁b MI ▁heart ▁rate ▁ rhythm ▁ly ing ▁standing _ ▁blood ▁pressure ▁uit cul tation ▁val vu lar _ ▁disease ▁pulmonar y ▁con gestion
D-1894	-0.6599284410476685	bMI heart rate rhythm lying standing_ blood pressure uitcultation valvular_ disease pulmonary congestion
P-1894	-1.4222 -0.9249 -4.4305 -0.1088 -0.6454 -0.0139 -0.0090 -0.0212 -1.3337 -0.4390 -0.7192 -0.3330 -2.1095 -0.0427 -0.0090 -0.0291 -0.0754 -0.1361 -1.6760 -1.2355 -0.0011 -0.0465 -1.0730 -0.0165 -0.1942 -0.1128
S-735	Our aims were to estimate myocardial extracellular matrix using cardiac magnetic resonance T1 mapping and to assess the relationship between pathobiology/pathophysiology and prognosis.<unk>
T-735	myocardial_extracellular_matrix cardiac_magnetic_resonance t1_mapping pathobiology pathophysiology prognosis
H-735	-0.367198646068573	▁my o card ial _ ▁extra cel lular ▁matri x ▁cardiac ▁magnetic _ ▁res on ance _ t 1 ▁ma pping ▁path obi ology pat ho phy si ology ▁prognos is
D-735	-0.367198646068573	myocardial_ extracellular matrix cardiac magnetic_ resonance_t1 mapping pathobiologypathophysiology prognosis
P-735	-1.2077 -0.2072 -0.1281 -0.0633 -0.9575 -0.6014 -0.0281 -0.0088 -0.7456 -0.0812 -0.0007 -0.3029 -0.2196 -0.3587 -0.0529 -0.0429 -1.1843 -1.4027 -0.2291 -1.5701 -0.0155 -0.3534 -0.0398 -0.4278 -0.2387 -0.3340 -0.0751 -0.8455 -0.1124 -0.1315 -0.0539 -0.0455 -0.0517
S-1948	Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction: a safety and proof-of-principle cohort study.<unk>
T-1948	interatrial_shunting patients heart_failure_with_reduced_ejection_fraction proof-of-principle_cohort_study
H-1948	-0.9187976121902466	▁rechts - to - right _ inter at rial _ ▁sh unting ▁patients ▁heart ▁failure ▁e je ction ▁ fraction
D-1948	-0.9187976121902466	rechts-to-right_interatrial_ shunting patients heart failure ejection fraction
P-1948	-5.5269 -0.1417 -0.1080 -0.1277 -0.0300 -0.8722 -0.1405 -0.0462 -0.0604 -0.5306 -3.6445 -0.4386 -2.4882 -2.5868 -0.3152 -1.2217 -0.0364 -0.0390 -1.0456 -0.0023 -0.7376 -0.0736
S-1738	These trial results provide the background for aldosterone antagonist therapy in chronic advanced heart failure patients as well as post-myocardial infarction heart failure patients with reduced ejection.<unk>
T-1738	aldosterone_antagonist therapy chronic_advanced_heart_failure patients post-myocardial_infarction heart_failure patients
H-1738	-0.7169076204299927	▁al do ster one ▁anta gon ist _ therapy ▁post - my o card ial _ in far ction _ heart ▁failure
D-1738	-0.7169076204299927	aldosterone antagonist_therapy post-myocardial_infarction_heart failure
P-1738	-0.4235 -0.1048 -0.0170 -0.2341 -1.2011 -0.0327 -0.2612 -1.8602 -0.0287 -5.3324 -0.0180 -0.4092 -0.2964 -0.4967 -0.2587 -0.6194 -0.5382 -0.0449 -0.0771 -1.0017 -1.8366 -0.1919 -1.7962 -0.1250
S-968	Relation between preoperative renal dysfunction and cardiovascular events (stroke, myocardial infarction, or heart failure or death) within three months of isolated coronary artery bypass grafting.<unk>
T-968	preoperative renal_dysfunction cardiovascular_events stroke myocardial_infarction heart_failure death isolated_coronary_artery_bypass_grafting
H-968	-0.35356712341308594	▁pre operativ e ▁renal ▁dys function ▁cardiovascular ▁events stro ke ▁my o card ial ▁in far ction ▁heart ▁failure
D-968	-0.35356712341308594	preoperative renal dysfunction cardiovascular eventsstroke myocardial infarction heart failure
P-968	-1.9649 -0.0207 -0.0199 -0.0169 -0.1161 -0.0169 -0.1553 -0.6764 -0.1789 -0.0086 -0.5239 -0.1275 -0.0515 -0.0378 -0.8611 -0.0197 -0.0447 -0.0871 -0.0287 -2.4049 -0.0634
S-554	Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity).<unk>
T-554	clinical outcomes heart_failure charm candesartan_in_heart_failure_assessment_of_reduction_in_mortality_and_morbidity
H-554	-1.0499839782714844	▁clinic al _ be langen _ van _ heart ▁failure ▁CHA RM _ programm Can des ar tan _ in _ ▁Heart ▁Fail ure
D-554	-1.0499839782714844	clinical_belangen_van_heart failure CHARM_programmCandesartan_in_ Heart Failure
P-554	-5.8291 -0.0100 -1.6129 -4.2067 -1.1019 -2.0135 -1.1941 -0.1469 -1.3047 -0.4292 -1.0490 -0.2358 -1.7392 -0.7372 -0.4686 -0.0278 -0.0078 -0.0022 -0.3152 -0.6969 -0.1120 -0.5452 -0.2338 -0.6457 -2.5773 -0.0569
S-947	RESULTS: During a 34 ± 16-month follow-up period, single- and multiple-procedure drug-free success rates were 27% (n = 20) and 45% (n = 33), respectively.<unk>
T-947	follow-up
H-947	-1.4604603052139282	
D-947	-1.4604603052139282	
P-947	-2.8599 -0.0610
S-1027	Furthermore, the use of protocol-driven POC testing of NP within the time frame of a patient consultation in the ED may facilitate and accelerate the throughput and disposition of at-risk patients.<unk>
T-1027	poc frame patient consultation patients
H-1027	-0.8622132539749146	▁protocol - driv en _ po c ▁ NP
D-1027	-0.8622132539749146	protocol-driven_poc NP
P-1027	-0.4591 -0.0195 -0.0013 -0.0123 -0.7740 -0.8237 -1.8149 -2.8611 -0.0514 -2.5148 -0.1522
S-1730	The relationship between physician volume and mortality was strongest for internists (9.2% versus 10.6%; P<0.001) and weakest for cardiologists (6.4% versus 6.7%; P=0.485).<unk>
T-1730	physician mortality internists cardiologists
H-1730	-0.5317855477333069	▁physician ▁volume _ ▁mortal ity ▁intern ists ▁cardio logist s
D-1730	-0.5317855477333069	physician volume_ mortality internists cardiologists
P-1730	-0.2721 -0.3839 -1.9804 -0.5264 -0.5827 -0.0507 -1.5970 -0.2870 -0.0524 -0.1026 -0.4980 -0.0481
S-1322	Similar improvements in shuttle walk test (18% vs 19%), body mass (-1.3 kg vs -1.0 kg), and hand grip strength (2.1 kg vs 2.5 kg) from baseline were observed in both groups.<unk>
T-1322	shuttle_walk_test hand baseline
H-1322	-0.7006531357765198	▁shu ttle _ ▁walk ▁test ▁body ▁mass ▁hand _ ▁grip ▁strength
D-1322	-0.7006531357765198	shuttle_ walk test body mass hand_ grip strength
P-1322	-0.6902 -0.0003 -0.4049 -1.3100 -0.6138 -1.2421 -0.3326 -0.1429 -0.6347 -0.5374 -2.0962 -0.9405 -0.1630
S-457	After 10 weeks, histological analysis revealed reduced capillary and coronary perfusion in B-treated plus Ad-Flk rats compared with B-treated plus Ad-C rats.<unk>
T-457	histological capillary coronary_perfusion
H-457	-0.8082224726676941	▁cap illa ry ▁corona ry _ per fusion ▁ad - F lk ▁rat s
D-457	-0.8082224726676941	capillary coronary_perfusion ad-Flk rats
P-457	-5.0686 -0.0238 -0.1391 -2.0079 -0.1903 -1.0135 -0.5900 -0.0089 -0.9657 -0.0237 -0.5141 -0.0191 -0.3365 -0.0861 -1.8252 -0.1191
S-1901	Recent evidence suggests that exercise prevents cell senescence, and active individuals are at lower risk of developing certain malignancies including cancer of the prostate and the colon, osteoporosis, depression and dementia.<unk>
T-1901	evidence exercise cell_senescence active osteoporosis
H-1901	-1.4075586795806885	▁exercise ▁prevent s ▁cell ▁se nesc ence
D-1901	-1.4075586795806885	exercise prevents cell senescence
P-1901	-3.9018 -4.6250 -0.2950 -0.2743 -0.1202 -0.0067 -0.0522 -3.3233 -0.0697
S-374	In addition to the leaflet configurations, the serial evaluation strongly suggested that the MS in this patient was subvalvular and therefore dynamic, as opposed to annular MS with a fixed ring size.<unk>
T-374	leaflet patient subvalvular annular_ms
H-374	-1.1443253755569458	▁le a flet
D-374	-1.1443253755569458	leaflet
P-374	-0.9737 -0.0228 -0.0001 -4.6722 -0.0529
S-1630	BACKGROUND: The strength of race as an independent predictor of long-term outcomes in a contemporary chronic heart failure (HF) population and its association with exercise training response have not been well established.<unk>
T-1630	outcomes chronic_heart_failure hf exercise training
H-1630	-1.192719578742981	▁strength _ van _ ▁race _ aan _ dependent _ de _ LONG - term _ ▁outcome s ▁con tempor ary _ ▁chronic _ heart ▁failure ▁ HF
D-1630	-1.192719578742981	strength_van_ race_aan_dependent_de_LONG-term_ outcomes contemporary_ chronic_heart failure HF
P-1630	-3.6266 -1.1834 -2.2378 -0.0121 -1.2563 -3.8535 -3.3208 -0.3462 -2.9664 -0.0744 -2.0542 -0.1778 -3.6880 -0.1671 -0.0465 -0.3165 -2.6397 -0.0850 -0.9677 -0.0066 -0.0270 -0.1701 -0.4554 -0.0487 -1.3326 -0.4663 -2.3051 -0.0042 -1.8879 -0.0579
S-227	Fifty-four predominantly asymptomatic pediatric Fontan (PF) patients who underwent catheterization during the same period were randomly selected to perform a control:case cohort analysis.<unk>
T-227	asymptomatic pediatric_fontan patients catheterization
H-227	-0.7308517098426819	▁as ym pto matic ▁pediatr ic ▁Font an _ PF
D-227	-0.7308517098426819	asymptomatic pediatric Fontan_PF
P-227	-1.8853 -0.0470 -0.0043 -0.0833 -0.4876 -0.0587 -1.0284 -0.1614 -2.4032 -0.3468 -2.1732 -0.0911
S-1152	We used MRI-based models of dyssynchronous nonfailing and HF canine electromechanics and constructed additional models in which varying combinations of the four remodeling aspects were represented.<unk>
T-1152	dyssynchronous_nonfailing hf combinations remodeling
H-1152	-0.4219571352005005	▁m RI - based _ model ▁dys syn chron ous _ ▁non fail ing ▁ HF ▁can ine _ ▁electro me chan ics
D-1152	-0.4219571352005005	mRI-based_model dyssynchronous_ nonfailing HF canine_ electromechanics
P-1152	-1.1430 -0.5190 -0.0737 -0.0096 -1.8949 -0.4560 -0.1270 -0.0010 -0.0020 -0.2929 -0.1125 -1.1643 -0.0550 -0.0209 -0.0834 -0.0076 -1.5822 -0.6046 -0.3641 -1.0400 -0.0238 -0.0048 -0.2286 -0.6757 -0.0621
S-835	Anemia in HF remains poorly understood, with significant gaps in its impact on health-related quality of life (HRQoL), with most studies in HF being retrospective or from registries.<unk>
T-835	anemia hf health-related_quality_of_life hrqol hf
H-835	-0.9308822154998779	▁an emia ▁ HF
D-835	-0.9308822154998779	anemia HF
P-835	-0.4722 -0.0027 -1.0334 -0.0243 -3.9971 -0.0554
S-1990	CONCLUSIONS AND RELEVANCE: Among obese older patients with clinically stable HFPEF, caloric restriction or aerobic exercise training increased peak VO2, and the effects may be additive.<unk>
T-1990	obese patients clinically stable hfpef exercise training peak_vo2
H-1990	-0.7205830216407776	▁H FP EF ▁calor ic _ ▁restriction ▁aero bic _ training ▁pe ak _ vo 2
D-1990	-0.7205830216407776	HFPEF caloric_ restriction aerobic_training peak_vo2
P-1990	-4.8135 -0.3370 -0.2725 -0.1493 -0.0589 -2.0953 -0.1163 -0.0080 -0.0165 -0.5211 -2.0070 -1.4969 -0.0105 -0.3564 -0.3737 -0.0643 -0.1724 -0.1007
S-1336	For instance, the majority of potential candidates for cell therapy suffer from chronic heart failure (CHF), and it is unclear how this disease affects the explant-derived progenitor cells.<unk>
T-1336	cell_therapy chronic_heart_failure chf disease progenitor_cells
H-1336	-0.6418922543525696	▁cell ▁ therapy ▁chronic _ heart ▁failure CH F ▁ex plant - der i ved _ pro gen itor
D-1336	-0.6418922543525696	cell therapy chronic_heart failureCHF explant-derived_progenitor
P-1336	-3.2379 -0.1919 -0.0119 -0.3608 -0.3671 -0.8865 -0.6471 -3.0182 -0.6316 -0.2078 -0.0016 -0.0362 -0.0608 -0.0610 -0.4650 -0.1435 -0.9507 -0.0066 -0.0223 -2.1162 -0.0551
S-1807	In The Lancet, Anoop Shah and colleagues provide a new systematic review of the effects of air pollution on heart failure, a common disorder associated with high morbidity and mortality, especially in elderly people.<unk>
T-1807	the_lancet anoop_shah air heart_failure morbidity mortality
H-1807	-1.0846736431121826	▁Lance t ▁air ▁pollution _ on _ heart ▁failure ▁morbi d ity
D-1807	-1.0846736431121826	Lancet air pollution_on_heart failure morbidity
P-1807	-0.1622 -0.0104 -1.6728 -1.4751 -2.7798 -2.6354 -0.2899 -0.7121 -0.4022 -2.3627 -0.0109 -0.4857 -2.0189 -0.1675
S-1586	The majority of studies have shown that patients with reduced or abnormal HR variability have an increased risk of mortality within a few years after an AMI or after a diagnosis of CHF/LV dysfunction.<unk>
T-1586	patients hr_variability mortality ami diagnosis chf lv_dysfunction
H-1586	-1.1879934072494507	▁HR ▁variabil ity ▁ AMI ▁CHF / LV
D-1586	-1.1879934072494507	HR variability AMI CHF/LV
P-1586	-4.2129 -0.9344 -0.4465 -1.3295 -0.3350 -1.5980 -1.3975 -0.1615 -1.3983 -0.0662
S-284	Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk--the atherosclerosis risk in communities study.<unk>
T-284	troponin_t n-terminal_pro-b-type_natriuretic_peptide biomarker heart_failure atherosclerosis_risk_in_communities
H-284	-0.7200923562049866	▁Tro ponin _ t ▁n - termin al _ pro - B - type ▁na tri ure tic _ pe pti de ▁bio mark er _ ▁approach ▁heart ▁failure ▁risk ▁at hero sc ler osis
D-284	-0.7200923562049866	Troponin_t n-terminal_pro-B-type natriuretic_peptide biomarker_ approach heart failure risk atherosclerosis
P-284	-0.7031 -0.0008 -2.5541 -0.9186 -1.8825 -0.0121 -0.0300 -0.0055 -0.7859 -1.5737 -0.0201 -1.3126 -0.0572 -0.0203 -0.2229 -0.0070 -0.3376 -1.2168 -0.4346 -0.4496 -0.0390 -0.0827 -0.1919 -0.0064 -0.0567 -1.2008 -2.5084 -2.8967 -0.3704 -1.9021 -1.9891 -0.1655 -0.0328 -1.9955 -0.0346 -0.5562 -0.0696
S-1660	Interestingly, because patients with ventricular assist devices are housed on units accustomed to managing the device, cardiac nurses are often asked about the management of gastrointestinal bleeding.<unk>
T-1660	patients ventricular_assist_devices cardiac nurses gastrointestinal_bleeding
H-1660	-0.4109218418598175	▁vent ri cular _ assist ▁devices ▁cardiac ▁nurse s ▁management ▁gastro inte stin al _ ▁ble ed ing
D-1660	-0.4109218418598175	ventricular_assist devices cardiac nurses management gastrointestinal_ bleeding
P-1660	-0.0167 -0.5573 -0.1285 -0.6739 -0.3030 -1.1353 -0.5338 -0.4348 -0.0766 -1.0166 -1.1380 -0.1150 -0.1914 -0.1063 -0.6874 -0.2130 -0.5460 -0.1723 -0.1088 -0.0635
S-708	BACKGROUND: Extended criteria cardiac transplant (ECCT) programs expand the transplant pool by matching donors and recipients typically excluded from the transplant process because of age or comorbidity.<unk>
T-708	extended_criteria_cardiac_transplant ecct transplant donors transplant comorbidity
H-708	-1.2207802534103394	▁cardiac ▁transplant ▁ec CT ▁transplant ▁pool
D-708	-1.2207802534103394	cardiac transplant ecCT transplant pool
P-708	-1.5102 -1.2216 -1.6442 -0.5028 -1.0315 -2.0887 -1.7152 -0.0521
S-782	METHODS AND RESULTS: Using a prospective HF registry, we dichotomized patients into HF with reduced EF (EF≤ 40) and HFpEF (EF≥50).<unk>
T-782	prospective hf patients hf_with_reduced_ef ef hfpef ef
H-782	-1.2426838874816895	▁ HF ▁ HF ▁ HF
D-782	-1.2426838874816895	HF HF HF
P-782	-0.2658 -0.6601 -1.4800 -0.5668 -1.9914 -0.6820 -4.2064 -0.0890
S-1633	We examined characteristics and outcomes (mortality/hospitalization, mortality, and cardiovascular mortality/HF hospitalization) by race using adjusted Cox models and explored an interaction with exercise training.<unk>
T-1633	outcomes mortality hospitalization mortality cardiovascular_mortality hf hospitalization cox_models exercise training
H-1633	-1.088094711303711	▁mortal ity _ hospital ization ▁cardiovascular _ ▁mortal ity HF _ hospital ization
D-1633	-1.088094711303711	mortality_hospitalization cardiovascular_ mortalityHF_hospitalization
P-1633	-6.0148 -0.3388 -3.1102 -0.0257 -0.2280 -0.3913 -0.9207 -0.1228 -0.3076 -1.4870 -1.8754 -0.2040 -0.2315 -0.9078 -0.1557
S-30	Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the treatment of anemia and iron deficiency in adult patients with heart disease.<unk>
T-30	american_college_of_physicians acp evidence clinical anemia patients heart_disease
H-30	-0.8482577204704285	▁ Американ _ ▁College _ of _ ▁Physic ians ▁a CP ▁an emia ▁ir on ▁de fici en cy
D-30	-0.8482577204704285	Американ_ College_of_ Physicians aCP anemia iron deficiency
P-30	-2.2670 -2.1219 -0.4209 -1.7865 -0.1114 -0.5702 -0.1106 -0.1170 -0.0061 -1.3686 -0.0158 -4.7950 -0.0745 -0.2288 -0.1276 -0.1154 -0.0053 -0.1442 -0.0617 -3.2722 -0.0927
S-1877	BAT significantly reduced N-terminal pro-brain natriuretic peptide (p = 0.02) and was associated with a trend toward fewer days hospitalized for HF (p = 0.08).<unk>
T-1877	bat n-terminal_pro-brain_natriuretic_peptide hospitalized hf
H-1877	-0.5852375030517578	▁BAT ▁n - termin al _ pro - bra in ▁na tri ure tic _ pe pti de
D-1877	-0.5852375030517578	BAT n-terminal_pro-brain natriuretic_peptide
P-1877	-0.1619 -4.6903 -0.0129 -0.1262 -0.0093 -0.1891 -1.8743 -0.0746 -0.1865 -0.0525 -0.1048 -0.0042 -0.4560 -0.7580 -0.8143 -0.2425 -0.0243 -0.0315 -1.8345 -0.0569
S-1549	MI-induced decreases in septum (systolic) thickness as well as increase in LV posterior wall thickness and LV internal diameter were partially or fully reversible by metoprolol.<unk>
T-1549	septum systolic lv_posterior_wall lv_internal_diameter metoprolol
H-1549	-0.7853075265884399	▁sept um sy sto lic _ ▁thi ck ness ▁LV ▁posterior _ ▁wall _ ▁thi ck ness ▁LV ▁internal ▁diameter ▁met o pro lol
D-1549	-0.7853075265884399	septumsystolic_ thickness LV posterior_ wall_ thickness LV internal diameter metoprolol
P-1549	-2.9419 -0.0135 -1.6834 -0.1148 -0.0177 -1.6216 -1.9047 -0.0091 -1.0289 -0.5336 -2.6695 -0.2419 -2.9827 -1.3515 -1.0397 -0.0051 -0.3944 -0.2904 -0.9087 -0.2902 -0.0899 -0.0802 -0.0031 -0.0199 -0.0781 -0.1032
S-1139	The tachycardic response caused by methylatropine was considered to be the vagal tone, whereas the bradycardic response caused by propranolol was considered to be the sympathetic tone.<unk>
T-1139	tachycardic methylatropine vagal_tone bradycardic propranolol sympathetic_tone
H-1139	-0.5451973676681519	▁met hy la tropi ne ▁va gal _ ▁tone ▁bra dy car dic ▁propra no lol ▁sympa the tic _ ▁tone
D-1139	-0.5451973676681519	methylatropine vagal_ tone bradycardic propranolol sympathetic_ tone
P-1139	-3.3083 -0.1761 -0.3003 -0.0084 -0.7753 -0.2782 -0.0160 -1.7541 -0.1514 -0.1613 -0.4187 -0.0086 -0.3165 -2.4560 -0.0062 -0.0140 -0.0322 -0.1661 -0.2485 -1.8040 -0.0401 -0.0598 -0.0396
S-442	We used Cox regression with time-varying covariates to evaluate the independent association between spironolactone use and death, hospitalization, severe hyperkalemia, and acute kidney injury.<unk>
T-442	cox_regression covariates spironolactone death hospitalization hyperkalemia acute_kidney_injury
H-442	-0.5690855383872986	▁co x ▁re gression ▁spi rono lac tone
D-442	-0.5690855383872986	cox regression spironolactone
P-442	-0.6104 -0.0048 -0.0777 -0.0028 -0.2646 -0.0108 -0.0197 -0.0483 -4.5266 -0.1251
S-1095	We will then focus on two distinct populations of patients who are at risk for acute RV failure: those with chronic pulmonary arterial hypertension (PAH) and those with acute pulmonary embolism.<unk>
T-1095	patients acute_rv_failure chronic_pulmonary_arterial_hypertension pah acute pulmonary_embolism
H-1095	-0.6415141820907593	▁a cute _ RV _ ▁failure ▁chronic ▁pulmonar y ▁arterial _ ▁hyper tension PA h ▁a cute _ ▁pulmonar y ▁e mbol ism
D-1095	-0.6415141820907593	acute_RV_ failure chronic pulmonary arterial_ hypertensionPAh acute_ pulmonary embolism
P-1095	-2.3220 -0.0106 -0.2195 -1.3464 -2.2487 -0.0957 -0.6177 -0.0717 -0.0153 -0.3451 -0.8701 -1.2003 -0.0234 -1.7745 -0.3135 -0.3356 -0.0118 -1.0544 -0.0813 -0.0306 -2.5494 -0.0009 -0.3521 -0.0989 -0.0484
S-962	Moreover, mitochondrial oxidative phosphorylation capacity, creatine kinase activity and oxidative stress markers were measured together with the examination of DNA fragmentation and ultrastructural changes.<unk>
T-962	mitochondrial_oxidative_phosphorylation_capacity creatine kinase activity oxidative_stress dna_fragmentation
H-962	-0.47373273968696594	▁mito cho ndri al ▁oxid ative _ phos phor y lation ▁capacity ▁creati ne ▁kina se ▁activity ▁oxid ative _ stress ▁marker s ▁DNA
D-962	-0.47373273968696594	mitochondrial oxidative_phosphorylation capacity creatine kinase activity oxidative_stress markers DNA
P-962	-0.0005 -0.1097 -0.0741 -0.0320 -0.8052 -0.0866 -0.5626 -0.0521 -0.4519 -1.2197 -0.0724 -1.4244 -0.0023 -0.1169 -0.0054 -0.0423 -3.1960 -0.0019 -0.0215 -0.3905 -1.1321 -0.0806 -0.1317 -0.7962 -1.4647 -0.0436
S-751	BACKGROUND: Current guidelines recommend cardiac resynchronization therapy (CRT) in mild heart failure (HF) patients with QRS prolongation and ejection fraction (EF) ≤30%.<unk>
T-751	cardiac_resynchronization_therapy crt mild_heart_failure hf patients qrs_prolongation ejection_fraction ef
H-751	-0.5048536062240601	▁cardiac ▁re syn chron ization ▁ therapy ▁c RT ▁mild _ heart ▁failure HF ▁QR s ▁e je ction ▁ fraction EF
D-751	-0.5048536062240601	cardiac resynchronization therapy cRT mild_heart failureHF QRs ejection fractionEF
P-751	-0.5520 -0.2017 -0.0158 -0.0073 -0.6899 -1.1119 -0.0281 -1.5008 -0.1774 -1.0237 -0.2238 -0.5016 -0.3868 -2.2498 -0.1360 -1.0098 -0.8300 -0.0630 -0.0162 -1.1008 -0.0018 -0.1308 -0.0840 -0.0735
S-509	Fractional flow reserve measurements and positron emission tomography imaging showed severe ischemia after bottleneck stenting covering over 50% of the left ventricle in the proximal LAD model.<unk>
T-509	fractional_flow_reserve positron_emission_tomography ischemia bottleneck_stenting left_ventricle lad
H-509	-0.6177046298980713	▁fra ction al _ ▁flow ▁reserve ▁measure ments ▁posi tron ▁e mission _ tom ography ▁imagin g ▁bottle ne ck ▁sten ting ▁left _ ▁vent ric le ▁proxima l ▁ LAD
D-509	-0.6177046298980713	fractional_ flow reserve measurements positron emission_tomography imaging bottleneck stenting left_ ventricle proximal LAD
P-509	-1.6189 -0.0005 -0.1385 -0.6311 -0.7656 -0.0479 -3.4712 -0.2665 -0.0098 -0.0120 -0.7977 -0.5839 -0.9295 -0.3403 -0.2235 -2.6202 -0.0391 -1.7934 -0.0424 -0.0143 -1.4393 -0.0791 -0.2294 -1.3131 -0.3433 -0.7809 -0.3576 -0.1179 -0.0007 -1.2037 -0.0039 -0.1317 -0.0375
S-2007	Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure.<unk>
T-2007	tools_for_economic_analysis_of_patient_management_interventions_in_heart_failure_cost-effectiveness_model disease heart_failure
H-2007	-1.166297197341919	▁Economic _ analys is _ van _ ▁Patient ▁Management ▁Interven tions ▁Heart _ ▁Fail ure
D-2007	-1.166297197341919	Economic_analysis_van_ Patient Management Interventions Heart_ Failure
P-2007	-3.4099 -1.2832 -1.1701 -0.0825 -1.4169 -2.8040 -0.0817 -2.3735 -0.6146 -0.7765 -0.1522 -0.4587 -1.8067 -0.1739 -0.6289 -2.4837 -0.1100
S-1462	Neprilysin inhibitors augment the natriuretic peptide system by preventing the breakdown of atrial natriuretic peptide and B-type natriuretic peptide.<unk>
T-1462	neprilysin_inhibitors natriuretic_peptide atrial_natriuretic_peptide b-type_natriuretic_peptide
H-1462	-0.688572347164154	▁Ne pri ly sin ▁inhibi tors ▁na tri ure tic _ pe pti de
D-1462	-0.688572347164154	Neprilysin inhibitors natriuretic_peptide
P-1462	-1.6305 -0.0221 -1.3121 -0.7219 -0.1926 -0.2152 -0.0616 -0.0157 -0.9522 -1.9461 -0.5016 -0.2334 -0.0532 -0.1631 -2.8976 -0.0983
S-1326	Functional electrical stimulation of peripheral muscles improves endothelial function and clinical and emotional status in heart failure patients with preserved left ventricular ejection fraction.<unk>
T-1326	functional_electrical_stimulation peripheral_muscles endothelial_function clinical heart_failure patients preserved_left_ventricular_ejection_fraction
H-1326	-0.7176861763000488	▁Fun ction al _ stimul ation ▁per i pher al _ ▁muscle s ▁en dot heli al _ function ▁heart ▁failure ▁patients ▁pres er ved ▁left _ ▁vent ri cular ▁e je ction
D-1326	-0.7176861763000488	Functional_stimulation peripheral_ muscles endothelial_function heart failure patients preserved left_ ventricular ejection
P-1326	-2.2970 -0.0066 -0.0990 -1.5599 -1.1217 -0.0725 -0.1768 -0.2014 -0.0272 -0.1907 -1.0716 -0.3808 -0.0234 -0.3707 -0.5667 -0.0044 -0.0067 -2.0486 -1.3972 -3.1672 -0.1588 -3.6334 -0.3664 -0.0435 -0.1860 -0.7706 -0.7880 -0.9075 -0.4555 -0.7829 -0.8387 -0.1047 -0.0582 -1.1372 -0.0975
S-1441	There was a trend toward a higher baseline SDQT-to-SDRR ratio in the HFVT(+) group compared with the HFVT(-) and HNorm groups (P = 0.09).<unk>
T-1441	baseline
H-1441	-0.6704113483428955	▁SD QT - to - SD RR ▁ HF VT
D-1441	-0.6704113483428955	SDQT-to-SDRR HFVT
P-1441	-1.3948 -0.1484 -0.1033 -0.0428 -0.0099 -0.0305 -0.1847 -0.9458 -0.0695 -0.2902 -4.7558 -0.0692
S-1148	Among the most important are altered ventricular structure (both geometry and fiber/sheet orientation), abnormal Ca(2+) handling, slowed conduction, and reduced wall stiffness.<unk>
T-1148	ventricular wall_stiffness
H-1148	-0.6915194988250732	▁vent ri cular ▁structure ▁fiber / she et ▁ orientation
D-1148	-0.6915194988250732	ventricular structure fiber/sheet orientation
P-1148	-0.2786 -0.7022 -0.1424 -0.9854 -0.1825 -1.8497 -0.0302 -0.0258 -0.6197 -0.0058 -3.3797 -0.0962
S-1677	Thus, we conclude that if Rad Q66P contributes to cardiomyopathy, it does so via a mechanism that is not related to its ability to inhibit L-type channel-dependent processes per se.<unk>
T-1677	rad q66p cardiomyopathy
H-1677	-0.6692243814468384	▁Rad ▁Q 66 p ▁cardio my o pathy
D-1677	-0.6692243814468384	Rad Q66p cardiomyopathy
P-1677	-0.5404 -1.7148 -0.1523 -0.5865 -0.1779 -0.6953 -0.1496 -0.0359 -2.5570 -0.0825
S-937	Intriguingly, serum resistin levels in women undergoing anthracycline-containing chemotherapy increased significantly at 3 months and remained elevated at 6 months in those with subsequent cardiotoxicity.<unk>
T-937	resistin chemotherapy elevated cardiotoxicity
H-937	-0.5182244777679443	▁se rum ▁resist in ▁levels ▁an thra cycli ne - conta ining _ ▁che mo therapy ▁cardio toxic ity
D-937	-0.5182244777679443	serum resistin levels anthracycline-containing_ chemotherapy cardiotoxicity
P-937	-0.4608 -0.0285 -0.0947 -0.1531 -2.4022 -0.3416 -0.0404 -0.2476 -1.2040 -0.2259 -0.0011 -0.6010 -0.1953 -2.2915 -0.2049 -0.0438 -0.1275 -0.1917 -1.9055 -0.0737 -0.0477
S-405	Patients with low sST2 titrated to high-dose BB had the lowest cardiovascular event rate at 0.53 events (P=0.001), and lowest cumulative hazard (P=0.003).<unk>
T-405	patients sst2 titrated cardiovascular_event
H-405	-1.1196110248565674	▁s ST 2 ▁ti tra ted _ to ▁high - dos e ▁BB ▁cardiovascular _ event _ ▁rate
D-405	-1.1196110248565674	sST2 titrated_to high-dose BB cardiovascular_event_ rate
P-405	-0.4105 -1.4752 -0.4994 -4.1741 -0.1612 -0.0224 -3.0829 -1.7958 -1.7272 -0.0057 -1.1744 -0.0822 -1.3649 -0.7034 -1.0397 -1.1401 -2.3271 -0.2241 -0.8897 -0.0922
S-533	Postoperative survival of patients with preoperative hypoalbuminemia (<3.5 g/dl, n = 125) and those with normal albumin concentration (≥3.5 g/dl, n = 147) was compared.<unk>
T-533	postoperative patients preoperative hypoalbuminemia albumin
H-533	-0.7994301319122314	▁post operativ e ▁hypo album in emia
D-533	-0.7994301319122314	postoperative hypoalbuminemia
P-533	-1.5548 -0.0339 -0.0307 -2.6994 -0.0962 -0.0896 -0.0701 -2.5517 -0.0685
S-174	Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.<unk>
T-174	uptitration renin-angiotensin_system_blocker beta-blocker therapy patients hospitalized heart_failure preserved_left_ventricular_ejection_fractions
H-174	-0.46757233142852783	▁re nin - angi oten sin ▁system ▁block er ▁beta - block er ▁ therapy ▁heart ▁failure ▁pres er ved ▁left _ ▁vent ri cular ▁e je ction
D-174	-0.46757233142852783	renin-angiotensin system blocker beta-blocker therapy heart failure preserved left_ ventricular ejection
P-174	-0.0143 -0.3502 -0.0281 -0.0796 -0.0690 -0.2736 -0.4385 -0.3927 -0.1007 -0.2802 -0.0118 -0.0218 -0.0577 -1.4408 -0.0084 -1.9786 -0.3851 -0.6503 -0.0404 -0.2147 -1.6721 -0.8175 -1.3031 -0.5792 -0.7153 -1.0710 -0.1052 -0.0355 -0.7614 -0.1306
S-1180	(Use of Exercise and Medical Therapies to Improve Cardiac Function Among Patients With Exertional Shortness of Breath Due to Lung Congestion; ACTRN12610001087044).<unk>
T-1180	use_of_exercise_and_medical_therapies_to_improve_cardiac_function_among_patients_with_exertional_shortness_of_breath_due_to_lung_congestion
H-1180	-1.1853529214859009	▁Exerci se _ ▁Medical ▁Therapie s ▁Card iac _ ▁Fun ction ▁pulmonar _ con gestion
D-1180	-1.1853529214859009	Exercise_ Medical Therapies Cardiac_ Function pulmonar_congestion
P-1180	-3.0259 -0.0139 -2.2235 -3.0488 -0.5093 -0.0640 -2.3428 -0.0579 -0.6224 -0.5982 -0.0028 -4.8985 -1.8557 -0.2519 -0.0549 -0.5364 -0.0437
S-206	The authors evaluated how often the nurse assessment of cognitive impairment at hospitalization was documented by the physician at the time of discharge in a cohort of elderly patients hospitalized for heart failure.<unk>
T-206	nurse hospitalization physician discharge patients hospitalized heart_failure
H-206	-1.156527042388916	▁nurse ▁assessment ▁cognitive _ ▁im pair ment
D-206	-1.156527042388916	nurse assessment cognitive_ impairment
P-206	-0.5393 -2.6330 -0.2261 -0.9585 -1.6838 -0.0445 -0.1661 -4.0297 -0.1279
S-1822	Still, patients with advanced heart failure should be managed by a "heart team," as indicated by guidelines; communication and collaboration among cardiologists, cardiovascular surgeons, and other medical staff responsible for patient care is necessary.<unk>
T-1822	patients heart_failure heart cardiologists cardiovascular surgeons medical patient
H-1822	-0.9473376870155334	▁heart _ team ▁cardio logist s ▁cardiovascular ▁surge ons
D-1822	-0.9473376870155334	heart_team cardiologists cardiovascular surgeons
P-1822	-4.3734 -2.3953 -0.3761 -0.9347 -0.0165 -0.1146 -0.0628 -0.6196 -0.1388 -1.3299 -0.0590
S-1632	METHODS: We performed an analysis of HF-ACTION, which randomized 2331 patients with HF having an ejection fraction ≤35% to usual care with or without exercise training.<unk>
T-1632	hf-action randomized patients hf ejection_fraction exercise training
H-1632	-0.9275926351547241	▁ HF - AC TION ▁ HF ▁ HF
D-1632	-0.9275926351547241	HF-ACTION HF HF
P-1632	-0.1245 -0.5947 -0.1221 -1.1026 -0.3573 -0.6272 -0.4317 -2.4565 -0.3908 -3.8976 -0.0985
S-1542	When the two most commonly used bisphosphonates, alendronate and etidronate, were analysed separately, significant trends in the risk of heart failure were observed across refill compliance strata.<unk>
T-1542	bisphosphonates alendronate etidronate heart_failure compliance
H-1542	-0.2651577591896057	▁bis phos phon ates ▁ale ndr onate ▁et id rona te
D-1542	-0.2651577591896057	bisphosphonates alendronate etidronate
P-1542	-0.2526 -0.0047 -0.0701 -0.0601 -0.0752 -0.0026 -0.0097 -0.0031 -0.0445 -0.0029 -0.0051 -2.8644 -0.0520
S-1097	Individuals with acute RV failure in the setting of pulmonary embolism represent a group with particularly high mortality, and the specific diagnostic and management strategies that are important for improved survival will be discussed.<unk>
T-1097	acute_rv_failure pulmonary_embolism mortality diagnostic
H-1097	-0.6037845015525818	▁a cute _ RV ▁failure ▁pulmonar y ▁e mbol ism
D-1097	-0.6037845015525818	acute_RV failure pulmonary embolism
P-1097	-1.4796 -0.0075 -0.2703 -0.8539 -1.2229 -0.0294 -0.0111 -1.2289 -0.0030 -0.3182 -1.7507 -0.0701
S-500	This study shows that the TAPSE vs. PASP relationship is shifted downward in nonsurvivors with a similar distribution in HFrEF and HFpEF, and their ratio improves prognostic resolution.<unk>
T-500	tapse pasp downward hfref hfpef prognostic resolution
H-500	-0.7203598022460938	▁T AP se ▁pas p ▁non sur viv ors ▁h Fr EF ▁ HF p EF
D-500	-0.7203598022460938	TAPse pasp nonsurvivors hFrEF HFpEF
P-500	-1.9494 -0.0816 -0.9775 -3.0020 -0.4755 -3.3672 -0.0275 -0.0034 -0.1022 -1.3262 -0.1831 -0.2497 -0.3347 -0.0192 -0.0240 -0.1913 -0.6062 -0.0459
S-1258	OBJECTIVES: To evaluate the effectiveness and safety of Chinese herbal medicine (CHM) as an adjunctive treatment for patients with dilated cardiomyopathy (DCM) and heart failure.<unk>
T-1258	medicine patients dilated_cardiomyopathy dcm heart_failure
H-1258	-0.6064246892929077	▁Chinese ▁herbal ▁medicine CH m ▁ad ju nc tive _ ▁treatment ▁dil ated _ ▁cardio my o pathy DC m ▁heart ▁failure
D-1258	-0.6064246892929077	Chinese herbal medicineCHm adjunctive_ treatment dilated_ cardiomyopathyDCm heart failure
P-1258	-1.8714 -1.2983 -0.3500 -2.6687 -0.7026 -2.2408 -0.0035 -0.0003 -0.0641 -0.5504 -1.0569 -0.2392 -0.1318 -0.1671 -0.1914 -1.1709 -0.3438 -0.0139 -0.1026 -0.7443 -0.2627 -0.2397 -0.0581 -0.0815
S-1376	Baroreflex sensitivity and time domain heart rate variability (HRV) were both decreased in the CHF-INV group compared with sham-INV and were restored to sham levels by renal DNx.<unk>
T-1376	baroreflex_sensitivity heart_rate_variability hrv renal_dnx
H-1376	-0.41966772079467773	▁Baro re flex ▁ sensitiv ity ▁time ▁domain ▁heart ▁rate ▁variabil ity HR v ▁CHF - in v ▁sham - IN v ▁renal ▁DN x
D-1376	-0.41966772079467773	Baroreflex sensitivity time domain heart rate variabilityHRv CHF-inv sham-INv renal DNx
P-1376	-0.0569 -0.0117 -0.0340 -1.7396 -0.0008 -0.2942 -1.2462 -0.0473 -1.2890 -0.5023 -0.0690 -0.4403 -0.7761 -1.1415 -0.0724 -0.0306 -0.9128 -0.3551 -0.1259 -0.0565 -0.7076 -0.2000 -0.8217 -0.2117 -0.0241 -0.0878 -0.0757
S-347	This time, he had severe hypertension of 191/104 mm Hg, diabetes mellitus, and grade 2 to 3/6 systolic as well as diastolic murmurs were audible at the apex.<unk>
T-347	hypertension diabetes_mellitus grade systolic diastolic_murmurs apex
H-347	-0.29846543073654175	▁hyper tension ▁diabetes ▁mell itus ▁sy sto lic ▁dia sto lic
D-347	-0.29846543073654175	hypertension diabetes mellitus systolic diastolic
P-347	-0.8528 -0.0136 -0.5323 -0.0031 -0.0122 -0.0337 -0.0040 -0.0077 -1.2472 -0.0124 -0.0410 -1.0721 -0.0479
S-956	In the present study, the cardioprotective effect of nicorandil was investigated on hemodynamic alterations and mitochondrial dysfunction induced by cumulative administration of doxorubicin in rats.<unk>
T-956	cardioprotective nicorandil hemodynamic mitochondrial_dysfunction administration doxorubicin
H-956	-0.29988959431648254	▁cardio protec tive _ effect ▁nic oran dil ▁hem o dynamic ▁altera tions ▁mito cho ndri al ▁dys function ▁do xor ubi cin ▁rat s
D-956	-0.29988959431648254	cardioprotective_effect nicorandil hemodynamic alterations mitochondrial dysfunction doxorubicin rats
P-956	-0.2309 -0.2689 -0.2244 -0.8611 -0.1414 -0.4220 -0.0215 -0.0531 -1.5120 -0.0665 -0.0003 -2.4766 -0.1454 -0.0003 -0.0439 -0.0082 -0.0135 -0.1858 -0.0084 -0.5970 -0.0028 -0.0043 -0.1303 -0.4786 -0.0669 -0.0909 -0.0419
S-1147	In addition to the left bundle branch block type of electrical activation, there are further remodeling aspects associated with dyssynchronous heart failure (HF) that affect the electromechanical behavior of the heart.<unk>
T-1147	left_bundle_branch_block remodeling dyssynchronous_heart_failure hf heart
H-1147	-0.7381036281585693	▁elektri al ▁activa tion ▁dys syn chron ous _ heart ▁failure ▁ HF ▁electro me chan ical _ ▁behavior
D-1147	-0.7381036281585693	elektrial activation dyssynchronous_heart failure HF electromechanical_ behavior
P-1147	-4.2700 -0.3052 -1.1073 -0.0541 -0.1242 -0.0011 -0.0028 -0.7133 -0.2005 -1.6967 -0.5084 -2.3181 -0.0063 -0.0368 -0.0162 -0.0008 -0.1024 -0.7975 -1.5651 -1.6010 -0.0724
S-643	Furthermore, in vivo inhibition of miR-25 by a specific antagomir evoked spontaneous cardiac dysfunction and sensitized the murine myocardium to heart failure in a Hand2-dependent manner.<unk>
T-643	in_vivo mir-25 antagomir cardiac_dysfunction murine myocardium heart_failure
H-643	-0.47762560844421387	▁in ▁vivo ▁inhibi tion ▁mi R -25 ▁anta go mir ▁spontane ous ▁cardiac ▁dys function ▁mur ine _ my o car dium ▁to ▁heart ▁failure ▁Hand 2- dependent
D-643	-0.47762560844421387	in vivo inhibition miR-25 antagomir spontaneous cardiac dysfunction murine_myocardium to heart failure Hand2-dependent
P-643	-0.9803 -0.0049 -0.2102 -0.0625 -0.1246 -1.0267 -0.0295 -2.1989 -0.0045 -0.1187 -0.8435 -0.1613 -0.3098 -0.2219 -0.0168 -0.0123 -0.3437 -0.2382 -1.0957 -0.0464 -0.0048 -0.1179 -2.8917 -0.9487 -0.8335 -0.8774 -0.0490 -0.0264 -0.4481 -0.0812
S-270	CONCLUSION: Elevated NT-proBNP levels at the time of admission are a strong and independent predictor of all-cause mortality in patients with acute HF 4 years after admission.<unk>
T-270	elevated nt-probnp admission all-cause_mortality patients acute_hf admission
H-270	-0.5800904631614685	▁NT - pro b NP
D-270	-0.5800904631614685	NT-probNP
P-270	-0.2157 -0.0124 -0.0040 -0.4478 -0.0319 -3.2706 -0.0782
S-1041	Both epigenetic 'writer' proteins (histone acetyltransferases) and epigenetic 'erasers' (histone deacetylases) have been implicated in cardiac development and disease.<unk>
T-1041	epigenetic proteins histone_acetyltransferases epigenetic histone_deacetylases cardiac disease
H-1041	-0.19464224576950073	▁epi gene tic _ writer _ ▁protein s hi stone ▁a ce tyl transfer as es ▁epi gene tic _ eras ers hi stone ▁de ace ty las es ▁cardiac
D-1041	-0.19464224576950073	epigenetic_writer_ proteinshistone acetyltransferases epigenetic_erasershistone deacetylases cardiac
P-1041	-0.2317 -0.0086 -0.4800 -0.4711 -0.1270 -1.3037 -0.1779 -0.0231 -0.0187 -0.0150 -0.0667 -0.1967 -0.0816 -0.0069 -0.0303 -0.0533 -0.0478 -0.0078 -0.4182 -0.3105 -0.3277 -0.0256 -0.0293 -0.0811 -0.0516 -0.0640 -0.0636 -0.0085 -0.0088 -0.0178 -1.4023 -0.0715
S-1449	Haematopoietic cell transplantation (HCT) survivors are at increased risk for developing congestive heart failure (CHF), primarily due to pre-HCT exposure to anthracyclines.<unk>
T-1449	haematopoietic_cell_transplantation hct congestive_heart_failure chf anthracyclines
H-1449	-0.885840117931366	▁ha e mato po ie tic _ ▁cell ▁transplant ation ▁h CT ▁con ges tive _ heart ▁failure CH F ▁pre - H CT ▁an thra cycli nes
D-1449	-0.885840117931366	haematopoietic_ cell transplantation hCT congestive_heart failureCHF pre-HCT anthracyclines
P-1449	-0.1758 -0.8595 -0.0524 -0.4120 -0.2258 -1.4941 -1.0892 -3.7412 -0.1061 -0.0520 -1.3706 -0.3485 -3.4649 -1.5944 -0.7836 -0.1198 -2.2180 -0.3929 -2.1607 -0.6736 -1.0551 -0.0041 -1.1209 -0.1418 -0.3296 -0.0054 -0.0489 -2.3144 -0.1485 -0.0713
S-1111	Carvedilol, a nonselective β-blocker, may be more effective than the selective β-blocker metoprolol in reducing the risk of thromboembolic events in heart failure.<unk>
T-1111	carvedilol nonselective_β-blocker selective_β-blocker metoprolol thromboembolic_events heart_failure
H-1111	-0.6889486312866211	▁car vedi lol ▁β - block er ▁met o pro lol ▁ thro mbo e mbol ic _ ▁events ▁heart ▁failure
D-1111	-0.6889486312866211	carvedilol β-blocker metoprolol thromboembolic_ events heart failure
P-1111	-0.3017 -0.0017 -0.0087 -2.2378 -0.0282 -0.0892 -0.1941 -3.6038 -0.1557 -0.0077 -0.0379 -0.8788 -0.8691 -0.4733 -0.4227 -0.0113 -0.4977 -1.7665 -1.3587 -2.0021 -0.6331 -0.1275 -0.1386
S-1700	CONCLUSIONS: Composite measures of quality for HF, AMI, and PNA performed better than existing measures at explaining variation in future mortality and predicting future high and low performers.<unk>
T-1700	hf ami pna mortality
H-1700	-0.7377426028251648	▁ HF ▁ AMI ▁p na
D-1700	-0.7377426028251648	HF AMI pna
P-1700	-0.9747 -0.8388 -0.5543 -0.1601 -0.7753 -0.8543 -1.6855 -0.0589
S-716	After adjustment for baseline characteristics, standard criteria cardiac transplant survival was higher than ECCT at 1 (89% versus 86%; P=0.18) and 5 (77% versus 66%; P=0.035) years.<unk>
T-716	baseline cardiac_transplant ecct
H-716	-1.3485543727874756	▁cardiac ▁transplant ▁survival
D-716	-1.3485543727874756	cardiac transplant survival
P-716	-2.5230 -1.6006 -2.0022 -0.5568 -0.0602
S-685	BACKGROUND: Current dietary recommendations for patients with heart failure (HF) are largely based on data from non-HF populations; evidence on associations of dietary patterns with outcomes in HF is limited.<unk>
T-685	patients heart_failure hf evidence outcomes hf
H-685	-1.7139183282852173	▁ HF ▁ HF
D-685	-1.7139183282852173	HF HF
P-685	-2.6057 -2.2520 -3.2244 -0.9964 -1.1480 -0.0570
S-1590	Because of remodeling of the arrhythmia substrate after AMI, early measurement of HR variability to identify those at high risk should likely be repeated later in order to assess the risk of fatal arrhythmia events.<unk>
T-1590	remodeling arrhythmia ami hr_variability arrhythmia
H-1590	-0.43971458077430725	▁ar rhythm ia ▁substrat e ▁ AMI ▁HR ▁variabil ity
D-1590	-0.43971458077430725	arrhythmia substrate AMI HR variability
P-1590	-1.0240 -0.0188 -0.3745 -0.1062 -0.0305 -0.4962 -0.0100 -0.1636 -1.6244 -0.2804 -1.0795 -0.0684
S-919	METHODS AND RESULTS: Thirteen patients with treated hypertension and compensated HFPEF consumed the DASH/SRD (target sodium, 50 mmol/2100 kcal) for 21 days.<unk>
T-919	patients hypertension compensated_hfpef dash sodium
H-919	-0.8175286054611206	▁hyper tension ▁compensa ted _ h FP EF ▁DAS h / S RD ▁so dium
D-919	-0.8175286054611206	hypertension compensated_hFPEF DASh/SRD sodium
P-919	-5.2291 -0.2691 -0.0223 -0.0645 -1.2446 -0.3965 -0.2250 -0.3535 -0.1820 -0.1376 -1.8392 -1.3919 -0.3413 -0.5748 -0.3768 -1.1967 -0.0531
S-1154	The simulation results revealed that deranged Ca(2+) handling is the primary culprit in extending EMD in dyssynchronous HF, with the other aspects of remodeling contributing insignificantly.<unk>
T-1154	emd dyssynchronous_hf remodeling insignificantly
H-1154	-0.4672330915927887	▁de rang ed _ ca (2 +) ▁handling ▁EM d ▁dys syn chron ous _ HF ▁remodel ing
D-1154	-0.4672330915927887	deranged_ca(2+) handling EMd dyssynchronous_HF remodeling
P-1154	-0.7594 -0.0004 -0.0073 -1.2751 -0.0854 -0.2582 -0.0028 -0.8360 -3.1611 -1.1377 -0.0210 -0.0007 -0.0015 -0.4727 -0.4362 -0.2244 -0.5261 -0.0054 -0.0933 -0.0397
S-1997	Patients were adults with ejection fraction ≤ 25%, cardiac index ≤ 2.2 l/min/m(2) without inotropes or were inotrope-dependent on optimal medical management, or listed for transplant.<unk>
T-1997	patients ejection_fraction cardiac_index inotropes medical transplant
H-1997	-0.28069889545440674	▁e je ction ▁ fraction ▁cardiac ▁index ▁in o trop es ▁in ot rope - dependent
D-1997	-0.28069889545440674	ejection fraction cardiac index inotropes inotrope-dependent
P-1997	-0.2676 -0.0153 -0.0199 -0.4335 -0.0011 -0.0246 -0.0168 -0.0160 -0.3209 -0.0113 -0.9468 -0.0188 -0.1741 -0.0118 -0.4641 -0.0353 -2.1742 -0.1005
S-933	Moreover, doxorubicin-induced cardiotoxicity was greater in the Hum-Retn mice than in littermate controls not expressing human resistin (Retn(-/-)).<unk>
T-933	doxorubicin-induced_cardiotoxicity resistin retn
H-933	-0.49288877844810486	▁do xor ubi cin - indu ced _ ▁cardio toxic ity ▁Hum - Re t n ▁litt er mate
D-933	-0.49288877844810486	doxorubicin-induced_ cardiotoxicity Hum-Retn littermate
P-933	-0.0016 -0.0012 -0.0060 -0.2562 -0.0581 -0.0043 -0.1847 -1.2820 -0.1204 -0.1418 -1.3304 -0.0793 -0.0193 -0.4030 -0.0993 -0.0382 -0.9531 -0.0306 -0.0461 -5.2426 -0.0528
S-1302	While early research focused on the importance of diastolic dysfunction in the pathophysiology of HFpEF, recent studies have revealed that multiple non-diastolic abnormalities in cardiovascular function also contribute.<unk>
T-1302	diastolic_dysfunction pathophysiology hfpef cardiovascular_function
H-1302	-0.4740692675113678	▁dia sto lic _ ▁dys function ▁pat ho phy si ology ▁ HF p EF
D-1302	-0.4740692675113678	diastolic_ dysfunction pathophysiology HFpEF
P-1302	-0.3361 -0.0456 -0.3715 -1.1623 -0.4167 -0.0347 -0.9081 -0.0739 -0.1603 -1.3702 -0.5814 -0.1348 -0.0085 -0.0270 -0.0208 -2.3633 -0.0439
S-1432	8-fluo-cAMP binding by wild type and phosphomimic Ser77 and Ser83 mutant RIα proteins demonstrated reduced Kd for the double mutant as compared to WT RIα.<unk>
T-1432	8-fluo-camp phosphomimic ser77 ser83 riα proteins riα
H-1432	-0.5068503618240356	▁8- flu o - c AMP ▁ binding ▁wild ▁type ▁ phos pho mi mic ▁Ser 77 ▁Ser 83 ▁mu tant ▁RI α ▁protein s ▁double _ mu tant ▁ WT ▁RI α
D-1432	-0.5068503618240356	8-fluo-cAMP binding wild type phosphomimic Ser77 Ser83 mutant RIα proteins double_mutant WT RIα
P-1432	-1.7271 -0.0241 -0.1742 -0.0371 -0.1055 -0.0073 -0.1352 -0.0270 -1.7765 -0.0880 -0.0376 -0.0029 -0.0137 -0.1357 -0.3684 -0.1912 -0.6633 -1.1977 -0.8993 -2.9516 -0.1297 -0.2403 -0.0400 -1.3297 -0.0286 -1.2973 -0.1213 -0.5644 -0.0461 -0.7383 -0.1474 -2.2866 -0.0577 -0.0603 -0.0885
S-246	RATIONALE: High-density lipoprotein (HDL) exerts endothelial-protective effects via stimulation of endothelial cell (EC) nitric oxide (NO) production.<unk>
T-246	high-density_lipoprotein hdl endothelial_cell nitric_oxide
H-246	-0.6455674767494202	▁High - dens ity _ ▁lipo prote in HD L ▁en dot heli al - protec tive ▁en dot heli al _ ▁cell ▁ni tric ▁oxid e
D-246	-0.6455674767494202	High-density_ lipoproteinHDL endothelial-protective endothelial_ cell nitric oxide
P-246	-1.5986 -0.1083 -0.1815 -0.9301 -1.2306 -0.2541 -0.3215 -0.7609 -0.2699 -1.6128 -0.4364 -0.5331 -0.0322 -0.0134 -0.1435 -0.0974 -0.2506 -3.7877 -0.6043 -0.0776 -0.0171 -1.2198 -0.9838 -1.7167 -0.0454 -0.0356 -0.0634 -1.2950 -0.1003
S-910	Dialysis patients demonstrated the following 3-year event rates: HF hospitalization, 31%; all-cause hospitalization, 100%; mortality, 73%; and HF hospitalization or death, 82%.<unk>
T-910	dialysis patients hf hospitalization all-cause_hospitalization mortality hf hospitalization death
H-910	-0.8055194020271301	▁Dia lys is ▁ HF ▁hospital ization
D-910	-0.8055194020271301	Dialysis HF hospitalization
P-910	-0.9423 -0.0118 -0.0785 -2.3281 -0.0478 -1.5431 -0.5767 -1.6527 -0.0687
S-1398	The purpose of this study was to determine whether a significant difference in outcome ratings exists from admission to discharge for hospitalized older adults with heart failure (HF) using Nursing Outcomes Classification (NOC).<unk>
T-1398	outcome admission discharge hospitalized heart_failure hf nursing_outcomes_classification noc
H-1398	-1.2814130783081055	▁ad mission ▁to ▁dis charge _ van _ hospital ized _ ▁older _ ▁adults ▁heart ▁failure no c
D-1398	-1.2814130783081055	admission to discharge_van_hospitalized_ older_ adults heart failurenoc
P-1398	-2.8729 -0.2187 -0.6783 -0.5922 -0.0192 -4.5243 -1.1099 -0.5067 -0.4110 -0.0761 -0.3825 -3.0153 -0.8950 -1.8217 -3.1723 -0.5846 -3.9904 -0.4400 -0.2359 -0.0812
S-1840	CONCLUSION: In this large cohort study, a higher risk for hHF was not observed in users of saxagliptin or sitagliptin compared with other selected antihyperglycemic agents.<unk>
T-1840	cohort_study saxagliptin sitagliptin antihyperglycemic_agents
H-1840	-0.5328409075737	▁h HF ▁sax ag lip tin ▁si tag lip tin ▁anti hy per gly ce mic ▁agents
D-1840	-0.5328409075737	hHF saxagliptin sitagliptin antihyperglycemic agents
P-1840	-0.4427 -1.4920 -0.1904 -0.0065 -0.2068 -2.1215 -0.5065 -0.0733 -0.0347 -1.2586 -0.0782 -0.2930 -0.0736 -0.2172 -0.1618 -0.5022 -2.1964 -0.2216 -0.0470
S-535	Multivariate analysis revealed that preoperative albumin was independently associated with mortality after LVAD implantation (hazard ratio 0.521, 95% confidence interval 0.290 to 0.934; p = 0.029.)<unk>
T-535	multivariate_analysis preoperative albumin mortality lvad implantation hazard_ratio confidence_interval
H-535	-0.5604146122932434	▁pre operativ e ▁album in ▁mortal ity ▁l VAD
D-535	-0.5604146122932434	preoperative albumin mortality lVAD
P-535	-0.6945 -0.0562 -0.0144 -0.5398 -0.0656 -0.5774 -0.5565 -1.2240 -0.0149 -2.3290 -0.0923
S-854	CONCLUSIONS: In patients with systolic heart failure and a QRS duration of less than 130 msec, CRT does not reduce the rate of death or hospitalization for heart failure and may increase mortality.<unk>
T-854	patients systolic_heart_failure qrs_duration crt death hospitalization heart_failure mortality
H-854	-0.7574397325515747	▁sy sto lic _ heart ▁failure ▁QR s ▁c RT
D-854	-0.7574397325515747	systolic_heart failure QRs cRT
P-854	-0.2081 -0.0232 -0.0616 -0.1980 -1.2071 -0.2044 -0.0928 -1.3396 -2.4750 -0.7509 -2.4611 -0.0675
S-1608	This study aims to discover differentially expressed genes (DEGs) between non-ischemic or ischemic heart failure samples and healthy control, which may be used for diagnosis and treatment of heart failure.<unk>
T-1608	differentially_expressed_genes degs ischemic_heart_failure healthy diagnosis heart_failure
H-1608	-1.3772138357162476	▁de G s ▁non - ische mic ▁ ische mic _ heart ▁failure ▁healthy _ control
D-1608	-1.3772138357162476	deGs non-ischemic ischemic_heart failure healthy_control
P-1608	-4.5582 -2.5850 -0.5727 -2.4574 -0.0224 -0.0247 -0.0991 -3.5412 -0.0489 -0.0829 -0.8991 -4.4553 -0.3942 -1.1999 -1.2428 -0.0241 -2.4907 -0.0913
S-2003	Key adverse events included reoperation for bleeding (14%), driveline infection (10%), gastrointestinal bleeding (8%), and debilitating stroke (modified Rankin Score > 3) (8%).<unk>
T-2003	adverse_events reoperation bleeding driveline infection gastrointestinal_bleeding stroke rankin_score
H-2003	-0.3577688932418823	▁re opera tion ▁ble ed ing ▁drive line ▁infection ▁gastro inte stin al ▁ble ed ing ▁de bilitat ing ▁stroke
D-2003	-0.3577688932418823	reoperation bleeding driveline infection gastrointestinal bleeding debilitating stroke
P-2003	-2.0324 -0.0905 -0.0987 -0.8646 -0.4814 -0.1552 -0.0423 -0.0210 -0.6752 -0.0082 -0.0543 -0.2416 -0.0832 -0.3582 -0.4938 -0.0942 -0.0080 -0.0020 -0.0147 -1.8133 -0.1889 -0.0492
S-605	These groups were compared in Cox regression models stratified by propensity score decile and adjusted for oral glucocorticoid dosage, prior HF hospitalisations, and the use of loop diuretics.<unk>
T-605	cox_regression_models propensity_score oral glucocorticoid hf hospitalisations loop_diuretics
H-605	-0.338342547416687	▁co x ▁re gression ▁models ▁pro pens ity ▁score ▁de cile ▁oral ▁gluco cor tico id _ ▁dos age ▁ HF ▁loop ▁di ure tics
D-605	-0.338342547416687	cox regression models propensity score decile oral glucocorticoid_ dosage HF loop diuretics
P-605	-0.1016 -0.0019 -0.0649 -0.0029 -1.3601 -0.0114 -0.0024 -0.1319 -0.0145 -0.0201 -0.0003 -0.0152 -0.0279 -0.0405 -0.1874 -0.1310 -2.8710 -0.9982 -0.0048 -0.8293 -0.0024 -0.1683 -0.6099 -1.3226 -0.0505 -0.1275 -0.0367
S-653	Insulin resistance is a hallmark of type 2 diabetes, and insulin receptor substrates 1 and 2 (IRS1 and IRS2) are the major insulin-signaling components regulating cellular metabolism and survival.<unk>
T-653	insulin_resistance type_2_diabetes insulin_receptor_substrates_1 irs1 irs2 cellular_metabolism
H-653	-0.555019199848175	▁in s ulin ▁resist ance ▁type ▁2 ▁diabetes ▁insulin ▁receptor ▁substrat es ▁I RS ▁insulin - signal ing
D-653	-0.555019199848175	insulin resistance type 2 diabetes insulin receptor substrates IRS insulin-signaling
P-653	-1.2147 -0.4924 -0.0092 -0.5564 -0.0114 -0.3635 -0.5685 -0.0337 -0.0099 -0.0752 -0.0776 -0.0935 -2.7942 -0.2416 -2.2056 -0.0480 -0.0081 -0.0235 -2.1792 -0.0940
S-1149	In dyssynchronous HF, the electromechanical delay (EMD), the time interval between local myocyte depolarization and myofiber shortening onset, is prolonged.<unk>
T-1149	dyssynchronous_hf electromechanical_delay emd myocyte_depolarization myofiber_shortening
H-1149	-0.30078694224357605	▁dys syn chron ous ▁ HF ▁electro me chan ical _ ▁de lay EM d ▁my o cy te ▁de po lar ization ▁my o fi ber
D-1149	-0.30078694224357605	dyssynchronous HF electromechanical_ delayEMd myocyte depolarization myofiber
P-1149	-0.2901 -0.0017 -0.0004 -0.3823 -0.7689 -0.0041 -0.0041 -0.0202 -0.0024 -0.0717 -0.7250 -0.7709 -0.0271 -1.1807 -0.7102 -2.0551 -0.0322 -0.3546 -0.0739 -0.0279 -0.0240 -0.0273 -0.2399 -0.3958 -0.0240 -0.0068 -0.0267 -0.4018 -0.0729
S-1936	OBJECTIVE: Beta blockers reduce all-cause mortality and readmissions in heart failure with reduced ejection fraction (HFrEF), which may be explained by their effect on heart rate (HR).<unk>
T-1936	beta_blockers all-cause_mortality readmissions heart_failure_with_reduced_ejection_fraction hfref heart_rate
H-1936	-0.850527286529541	▁Beta ▁block ers ▁read missions ▁heart ▁failure ▁e je ction ▁ fraction HF r EF
D-1936	-0.850527286529541	Beta blockers readmissions heart failure ejection fractionHFrEF
P-1936	-1.2843 -0.5250 -0.0621 -3.7380 -0.1196 -0.6068 -0.1353 -3.2333 -0.1212 -0.0207 -0.5412 -0.0050 -0.8187 -0.0276 -0.0802 -3.0839 -0.0561
S-1327	BACKGROUND: Functional electrical stimulation (FES) improves exercise capacity, quality of life, emotional stress, and endothelial function in chronic heart failure with impaired systolic function.<unk>
T-1327	functional_electrical_stimulation fes exercise_capacity quality_of_life endothelial_function chronic_heart_failure systolic_function
H-1327	-0.6975595355033875	▁Fun ction al _ elektr al _ stimul ation ▁f es ▁exercise ▁capacity ▁emotional ▁stress ▁en dot heli al _ ▁function ▁chronic _ heart ▁failure ▁sy sto lic _ ▁function
D-1327	-0.6975595355033875	Functional_elektral_stimulation fes exercise capacity emotional stress endothelial_ function chronic_heart failure systolic_ function
P-1327	-0.3855 -0.0015 -0.0305 -0.8655 -1.5355 -0.0792 -1.7525 -0.1004 -0.0361 -0.8936 -0.8184 -3.4427 -0.8323 -0.1289 -1.2351 -0.0934 -0.3658 -0.0124 -0.0033 -1.6230 -0.4924 -1.6627 -0.5362 -1.5214 -0.5814 -0.2043 -0.0190 -0.0613 -2.2444 -0.6140 -0.1132 -0.0359
S-595	Here, we present a case report of a patient with right atrial myxoma and massive embolism to the pulmonary arteries treated surgically with right atrial mass removal and pulmonary embolectomy.<unk>
T-595	report patient right_atrial_myxoma massive_embolism pulmonary_arteries surgically right_atrial pulmonary_embolectomy
H-595	-0.5194604992866516	▁right _ at rial _ my xo ma ▁pulmonar y ▁arteri es ▁right _ at rial _ ▁mass ▁remo val ▁pulmonar y ▁e mbol ecto my
D-595	-0.5194604992866516	right_atrial_myxoma pulmonary arteries right_atrial_ mass removal pulmonary embolectomy
P-595	-3.7156 -0.5973 -0.6736 -0.0235 -0.2407 -1.8485 -0.0186 -0.1667 -0.1465 -0.0137 -0.2598 -0.0325 -2.6998 -0.2038 -0.2785 -0.0126 -0.2542 -1.2530 -0.2197 -0.0563 -0.0004 -0.0169 -0.8079 -0.0022 -0.1173 -0.7798 -0.0714 -0.0341
S-896	METHODS: A consecutive case series of 10 transplant ineligible patients receiving PD solely for HF volume management between 2007 and 2011 was evaluated with clinical data reviewed pre- and post-PD initiation.<unk>
T-896	transplant patients pd hf clinical
H-896	-0.5159478187561035	▁transplant ▁in elig ible ▁patients ▁ HF ▁volume ▁management
D-896	-0.5159478187561035	transplant ineligible patients HF volume management
P-896	-1.7880 -0.2659 -0.0002 -0.0312 -0.6551 -1.0035 -0.1810 -0.2732 -0.3205 -1.1213 -0.0355
S-1478	We discuss the need for strict statistical standards in biomarker studies, provide an overview of biomarker-guided clinical trial design, and discuss the therapeutic potential of a multimarker-based strategy.<unk>
T-1478	biomarker clinical therapeutic
H-1478	-0.5161228775978088	▁statistic al _ standard s ▁bio mark er - guide d _ ▁clinic al _ ▁trial
D-1478	-0.5161228775978088	statistical_standards biomarker-guided_ clinical_ trial
P-1478	-0.7391 -0.0091 -1.1364 -0.3991 -0.0151 -0.0038 -0.0250 -0.0489 -1.3049 -0.0051 -0.0143 -0.7995 -0.2761 -0.0101 -0.5835 -0.7730 -3.0860 -0.0614
S-231	By imaging, the SAF cohort demonstrated a greater incidence of abnormal liver texture changes (96% vs 75%, p = 0.04) and nodularity (77% vs 42%, p = 0.02).<unk>
T-231	saf incidence liver nodularity
H-231	-0.7052217125892639	▁ SAF _ co hor t ▁ab normal _ liver _ ▁texture
D-231	-0.7052217125892639	SAF_cohort abnormal_liver_ texture
P-231	-0.7645 -0.0342 -2.5770 -0.3729 -0.0254 -0.0195 -0.2476 -0.0113 -0.2408 -1.3908 -1.1287 -0.4650 -2.4710 -0.1245
S-1004	Frailty according to the biological phenotype was defined as 3 or more of: weak grip strength, physical exhaustion, slowness, low activity and unintentional weight loss >10 lb in 1 year.<unk>
T-1004	frailty biological_phenotype physical activity
H-1004	-0.8042382597923279	▁fra il ty ▁we ak _ ▁grip _ ▁strength ▁physical _ ▁exhaust ion ▁slow ness ▁low _ ▁activity ▁un inten tional _ gewicht
D-1004	-0.8042382597923279	frailty weak_ grip_ strength physical_ exhaustion slowness low_ activity unintentional_gewicht
P-1004	-0.7922 -0.1923 -0.0611 -1.3132 -0.0118 -1.5316 -0.5761 -1.3227 -0.8293 -0.5826 -1.5750 -0.6432 -0.0396 -0.3620 -1.3412 -2.6426 -0.7009 -3.0504 -0.0774 -0.0060 -0.0274 -0.1727 -1.3378 -0.7879 -0.1288
S-109	In conclusion, our data suggest that treatment with CRT-D does not reduce the risk of IE in patients with IC and that the benefit of CRT-D is attenuated after the development of IEs in this population.<unk>
T-109	crt-d patients ic crt-d ies
H-109	-1.1314139366149902	▁c RT - D
D-109	-1.1314139366149902	cRT-D
P-109	-1.5894 -0.1566 -0.0369 -0.6834 -4.2546 -0.0676
S-467	Conclusions—Low-volume EDs were more likely to discharge patients with heart failure home, but low-volume ED cases exhibited worse outcomes (driven largely by readmissions or repeat ED visits).<unk>
T-467	eds discharge patients heart_failure outcomes driven readmissions
H-467	-0.9962520003318787	▁hoog - volu me _ ▁ED s ▁dis charge ▁patients ▁heart ▁failure _ home
D-467	-0.9962520003318787	hoog-volume_ EDs discharge patients heart failure_home
P-467	-5.2568 -0.0104 -0.0108 -0.0388 -0.5574 -2.4727 -0.9439 -1.5204 -0.0140 -0.4462 -1.1303 -0.0598 -1.3981 -0.8387 -1.1887 -0.0529
S-879	Impact of QRS morphology and duration on outcomes after cardiac resynchronization therapy: Results from the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT).<unk>
T-879	qrs_morphology outcomes cardiac_resynchronization_therapy resynchronization-defibrillation_for_ambulatory_heart_failure_trial raft
H-879	-0.39848199486732483	▁QR s ▁ morph ology ▁cardiac ▁re syn chron ization _ therapy ▁re syn chron ization - Def i bril lation ▁Amb ulator y _ ▁Heart ▁Fail ure ▁Tri al RAF t
D-879	-0.39848199486732483	QRs morphology cardiac resynchronization_therapy resynchronization-Defibrillation Ambulatory_ Heart Failure TrialRAFt
P-879	-0.0297 -0.7052 -0.1160 -0.0039 -0.2318 -0.4917 -0.0792 -0.0048 -0.0035 -0.4142 -1.1250 -0.2441 -0.7261 -0.0051 -0.0093 -0.4622 -0.4906 -0.8499 -0.4917 -0.1222 -0.0483 -0.8806 -0.0103 -0.0497 -0.0798 -0.2830 -0.5555 -1.6167 -1.9639 -0.0140 -0.2112 -1.0982 -0.0640 -0.0670
S-1295	Based on the acute right heart failure with therapy refractory cardiogenic shock we decided within our heart team for an extra corporeal membrane oxygenation (ECMO) applied during CPR in the ICU.<unk>
T-1295	acute_right_heart_failure therapy refractory_cardiogenic_shock heart extra_corporeal_membrane_oxygenation ecmo cpr icu
H-1295	-0.6003124713897705	▁a cute _ ▁right _ heart ▁failure ▁ therapy ▁re frac tory _ ▁cardio ge nic _ ▁shock ▁heart ▁team ▁extra ▁corpore al _ ▁membran e ▁oxygen ation ▁ec mo ▁c PR ICU
D-1295	-0.6003124713897705	acute_ right_heart failure therapy refractory_ cardiogenic_ shock heart team extra corporeal_ membrane oxygenation ecmo cPRICU
P-1295	-0.7610 -0.0026 -0.1803 -2.6650 -0.2227 -1.4638 -0.1961 -1.0599 -0.0038 -0.1478 -0.0088 -0.4010 -0.0541 -0.6175 -0.0794 -0.1273 -0.5526 -0.0667 -3.4490 -1.3734 -0.4660 -0.5877 -0.0157 -0.2472 -0.2557 -0.0173 -2.7246 -0.0663 -0.9749 -0.9717 -0.4097 -0.0390 -0.6977 -0.0558 -0.0492
S-201	The guidelines are intended to assist practitioners in office-based or emergency room practice, who encounter children with undiagnosed heart disease and symptoms of possible HF, rather than those who have already received surgical palliation.<unk>
T-201	emergency_room undiagnosed heart_disease symptoms hf surgical_palliation
H-201	-1.0820107460021973	▁un diagnos ed _ heart ▁disease ▁ HF
D-201	-1.0820107460021973	undiagnosed_heart disease HF
P-201	-7.1058 -0.0079 -0.0125 -0.3459 -0.8894 -0.4866 -1.5069 -0.0335 -0.3572 -0.0744
S-168	Gene expression of Bax remained unchanged during the pacing period; Bcl-2 mRNA expression transiently decreased in moderate heart failure and their ratio (Bcl-2/Bax) was not significantly altered.<unk>
T-168	gene_expression bax pacing bcl-2 mrna expression heart_failure bcl-2 bax
H-168	-0.9315121173858643	▁Bax ▁b cl -2 ▁m RNA
D-168	-0.9315121173858643	Bax bcl-2 mRNA
P-168	-1.5548 -1.4586 -0.0748 -0.2853 -0.0177 -0.0080 -3.9831 -0.0698
S-745	This study aimed to verify the impact of heart magnetic resonance imaging on chelation choices and patient compliance in a single-institution cohort as well as its predictive value for heart failure and arrhythmias.<unk>
T-745	heart_magnetic_resonance_imaging chelation patient compliance heart_failure arrhythmias
H-745	-0.7474203109741211	▁heart ▁magnetic _ ▁res on ance _ ▁imagin g ▁che lation ▁choice s
D-745	-0.7474203109741211	heart magnetic_ resonance_ imaging chelation choices
P-745	-1.5327 -0.2177 -0.2955 -1.1018 -0.1947 -0.4243 -0.4978 -1.8302 -0.0657 -0.0079 -0.0150 -0.8694 -0.0542 -4.0369 -0.0677
S-413	BACKGROUND: The nitroxyl (HNO) donor, Angeli's salt, exerts positive inotropic, lusitropic, and vasodilator effects in vivo that are cAMP independent.<unk>
T-413	nitroxyl hno inotropic lusitropic vasodilator in_vivo camp
H-413	-0.44785648584365845	▁ni tro x yl h no ▁donor ▁Angeli ' s ▁salt ▁in o tropi c ▁ lusi tropi c ▁vaso dila tor ▁c AMP
D-413	-0.44785648584365845	nitroxylhno donor Angeli's salt inotropic lusitropic vasodilator cAMP
P-413	-0.0026 -0.0056 -0.0871 -0.1297 -2.0195 -0.5900 -2.9245 -0.0132 -2.1934 -0.1027 -0.0077 -0.5679 -0.7235 -0.0041 -0.0376 -0.3190 -0.0045 -0.0131 -0.0439 -0.0036 -0.0008 -0.0188 -1.5514 -0.0024 -0.1587 -0.1189
S-897	RESULTS: The mean ejection fraction (EF) pre-PD was 24.5 ± 6.0% with the majority of patients having NYHA class IIIB symptoms and moderate-severe right ventricular dysfunction.<unk>
T-897	ejection_fraction ef patients nyha_class_iiib symptoms right_ventricular_dysfunction
H-897	-0.9620105624198914	▁e je ction ▁ fraction EF
D-897	-0.9620105624198914	ejection fractionEF
P-897	-0.5339 -0.0474 -0.0168 -0.5141 -0.0056 -2.1507 -4.3560 -0.0715
S-124	CPCs were measured as early-outgrowth colony-forming units (EO-CFUs) and circulating CD34+, VEGFR2+ and/or CD133+ cells.<unk>
T-124	cpcs early-outgrowth_colony-forming_units eo-cfus cells
H-124	-0.46766090393066406	▁c PC s ▁early - out g row th ▁colon y - form ing ▁unit s ▁o - c FU ▁circula ting ▁CD 34 ▁v EG FR 2 ▁CD 133 +
D-124	-0.46766090393066406	cPCs early-outgrowth colony-forming units o-cFU circulating CD34 vEGFR2 CD133+
P-124	-0.6405 -0.1190 -0.7317 -1.0890 -0.0187 -0.0189 -0.7248 -0.0110 -0.0226 -0.5371 -0.0175 -0.0165 -0.0075 -0.0170 -0.2522 -0.2868 -2.2744 -0.1348 -0.3225 -0.2225 -0.9456 -0.0670 -0.2461 -0.8304 -1.7329 -0.2511 -0.0461 -0.3485 -1.0055 -0.0780 -1.7108 -0.6204 -0.0857
S-309	We reviewed the evidence on clinical effects and cost-effectiveness of 2 types of continuous-flow LVADs (HeartMate II [HM II] and HeartWare), for BTT and DT patients.<unk>
T-309	evidence clinical continuous-flow_lvads heartmate_ii hm_ii heartware btt dt patients
H-309	-1.1132581233978271	▁clinic al _ effect ive ness ▁continuo us - flow _ L VAD s ▁he art Mate _ ▁II ▁Heart War e ▁ DT
D-309	-1.1132581233978271	clinical_effectiveness continuous-flow_LVADs heartMate_ II HeartWare DT
P-309	-6.2045 -0.0180 -1.3668 -0.0330 -0.1109 -2.0991 -0.7709 -0.0499 -0.2889 -0.0500 -0.3906 -6.0250 -0.0569 -1.3268 -0.2898 -0.6954 -0.0712 -1.6325 -0.8548 -2.4901 -0.0809 -0.0127 -3.5368 -0.2368 -0.1938 -0.0585
S-1643	BACKGROUND: Even on optimal therapy including anticoagulation and rate control, major cardiovascular complications (stroke, cardiovascular death, and acute heart failure) are common in patients with atrial fibrillation (AF).<unk>
T-1643	therapy anticoagulation rate_control cardiovascular complications stroke cardiovascular_death acute_heart_failure patients atrial_fibrillation
H-1643	-0.5725013613700867	▁antico ag ulation ▁rate ▁control ▁cardiovascular ▁complica tions stro ke ▁cardiovascular ▁death ▁a cute _ heart ▁failure ▁at rial _ fi bril lation AF
D-1643	-0.5725013613700867	anticoagulation rate control cardiovascular complicationsstroke cardiovascular death acute_heart failure atrial_fibrillationAF
P-1643	-2.0631 -0.0199 -0.0397 -1.4925 -0.3311 -1.3947 -0.4672 -0.7385 -0.8971 -0.0063 -0.4692 -1.7028 -0.0238 -0.0053 -0.0618 -1.1352 -0.4014 -1.6458 -0.0267 -0.5151 -1.0318 -0.0103 -0.0709 -0.1923 -0.1041 -0.0383
S-753	METHODS AND RESULTS: The results of patients with baseline EF >30% (n=177) and those with EF ≤30% (n=431), as determined by a blinded core laboratory, were compared.<unk>
T-753	patients baseline ef ef core
H-753	-1.4360862970352173	▁patients ▁base line ▁EF
D-753	-1.4360862970352173	patients baseline EF
P-753	-5.0663 -0.4882 -0.0055 -0.6276 -2.3515 -0.0774
S-197	CONCLUSIONS: In a large registry, we found that despite sex/EF differences in BNP values, there was no significant difference in the ability of BNP to predict inhospital mortality among these subgroups.<unk>
T-197	ef bnp bnp inhospital mortality
H-197	-1.1961798667907715	▁b NP ▁in hospital ▁mortal ity
D-197	-1.1961798667907715	bNP inhospital mortality
P-197	-2.8211 -0.6781 -4.3709 -0.0919 -1.2324 -0.2186 -0.1099 -0.0466
S-693	CONCLUSIONS: Higher DASH diet scores were associated with modestly lower mortality in women with HF, and there was a nonsignificant trend toward an inverse association with Mediterranean diet scores.<unk>
T-693	dash mortality hf nonsignificant
H-693	-0.4555804431438446	▁DAS h ▁die t ▁score s ▁ HF
D-693	-0.4555804431438446	DASh diet scores HF
P-693	-0.4140 -0.2850 -1.2187 -0.0306 -0.0180 -0.0319 -1.4365 -0.0457 -1.0159 -0.0594
S-1499	Skeletal muscle mass assessed by relative appendicular lean mass index was significantly reduced compared with age-matched and sex-matched reference values (Z-score -1.46±0.22, p<0.0001).<unk>
T-1499	skeletal_muscle lean_mass z-score
H-1499	-1.143385410308838	▁s kelet al _ ▁muscle ▁mass ▁index ▁z - s core
D-1499	-1.143385410308838	skeletal_ muscle mass index z-score
P-1499	-3.0984 -0.0043 -0.0295 -1.0334 -1.6144 -0.9429 -5.5223 -2.1675 -0.0514 -0.0333 -0.0164 -0.2151 -0.1350
S-706	CONCLUSIONS: ST2 was modestly associated with functional capacity and was significantly associated with outcomes in a well-treated cohort of ambulatory patients with HF although it did not significantly affect reclassification of risk.<unk>
T-706	st2 functional_capacity outcomes ambulatory patients hf
H-706	-1.1565229892730713	▁ST 2 ▁functional ▁capacity
D-706	-1.1565229892730713	ST2 functional capacity
P-706	-3.3694 -0.2054 -0.1375 -0.5936 -2.5734 -0.0599
S-561	Quality of life was worse, but all-cause mortality was lowest in the youngest age group (3-year mortality rates across the respective age categories: 12%, 13%, 13%, 19%, and 31%, respectively).<unk>
T-561	quality_of_life all-cause_mortality mortality
H-561	-1.2306288480758667	▁Quality _ of _ ▁life
D-561	-1.2306288480758667	Quality_of_ life
P-561	-1.5869 -1.0824 -1.2169 -0.1592 -0.9612 -3.5252 -0.0826
S-1046	Gene expression profiling of cultured cardiomyocytes in the presence or absence of JQ1 showed that the drug abrogated the induction of a substantial subset of phenylephrine-induced genes.<unk>
T-1046	gene_expression cardiomyocytes jq1 drug genes
H-1046	-0.6626690030097961	▁culture d _ ▁cardio my o cy tes ▁j q 1 ▁drug ▁ phen yle ph rine - indu ced _ ▁gene s
D-1046	-0.6626690030097961	cultured_ cardiomyocytes jq1 drug phenylephrine-induced_ genes
P-1046	-6.0556 -0.1748 -0.6117 -2.1303 -0.9450 -0.3010 -0.0974 -0.0575 -1.2340 -0.3515 -1.3197 -0.2913 -0.4207 -0.0188 -0.0673 -0.2233 -0.0409 -0.2298 -0.0024 -0.0919 -1.1274 -0.5983 -0.0215 -0.1070 -0.0476
S-1801	A CLCNKA polymorphism (rs10927887; p.Arg83Gly) previously linked to heart failure is associated with the estimated glomerular filtration rate in the RENASTUR cohort.<unk>
T-1801	clcnka polymorphism rs10927887 p.arg83gly heart_failure estimated_glomerular_filtration_rate renastur
H-1801	-0.5844886898994446	▁CL CN ka ▁poly morph ism ▁p . Ar g 83 G ly ▁heart ▁failure ▁glo mer ular _ ▁filtr ation ▁rate ▁RE NAS tur
D-1801	-0.5844886898994446	CLCNka polymorphism p.Arg83Gly heart failure glomerular_ filtration rate RENAStur
P-1801	-0.0345 -1.1783 -0.6937 -0.2220 -0.0032 -0.3116 -2.8453 -0.0827 -0.4328 -0.0041 -0.3299 -0.8070 -0.0682 -1.8074 -0.7524 -0.1804 -0.0934 -0.0582 -0.3903 -1.4257 -0.0577 -2.2270 -0.8731 -0.0037 -0.2917 -0.4946 -0.1123
S-285	BACKGROUND: Among the various cardiovascular diseases, heart failure (HF) is projected to have the largest increases in incidence over the coming decades; therefore, improving HF prediction is of significant value.<unk>
T-285	cardiovascular_diseases heart_failure hf incidence hf
H-285	-0.6092758178710938	▁cardiovascular ▁disease s ▁heart ▁failure ▁ HF
D-285	-0.6092758178710938	cardiovascular diseases heart failure HF
P-285	-0.5774 -2.1855 -0.0627 -0.9198 -0.1560 -1.2556 -0.0171 -0.2615 -0.0479
S-455	Importantly, 2 weeks after B treatment was started, increased cardiac VEGF expression and Akt and endothelial NO synthase activation were observed by comparing B-treated with drug-untreated failing hearts.<unk>
T-455	cardiac_vegf_expression endothelial_no_synthase_activation hearts
H-455	-0.5261504650115967	▁cardiac _ ve GF ▁expression ▁Akt ▁en dot heli al _ no ▁synth ase ▁activa tion ▁drug - un tre ated ▁fail ing _ heart s
D-455	-0.5261504650115967	cardiac_veGF expression Akt endothelial_no synthase activation drug-untreated failing_hearts
P-455	-1.6955 -1.8033 -0.4603 -0.0622 -1.2136 -0.0175 -0.0350 -0.7010 -0.0019 -0.0049 -0.1684 -0.8794 -0.1369 -0.9972 -0.3232 -0.0769 -2.6229 -0.0271 -0.0692 -0.0009 -0.0696 -0.6468 -0.0353 -1.5385 -0.6529 -0.2134 -0.1994 -0.0792
S-1924	Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients: Insights From Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION).<unk>
T-1924	psychosocial exercise outcomes heart_failure patients heart_failure outcomes exercise training hf-action
H-1924	-0.8119841814041138	▁psycho social _ factor s ▁Exerci se ▁Ad her ence ▁Heart ▁Fail ure ▁Patient s ▁Insight s _ van _ ▁Heart ▁Fail ure ▁ HF - AC TION
D-1924	-0.8119841814041138	psychosocial_factors Exercise Adherence Heart Failure Patients Insights_van_ Heart Failure HF-ACTION
P-1924	-1.3615 -0.0484 -1.8431 -0.3354 -0.0890 -1.4662 -0.0095 -0.5331 -0.1044 -0.1366 -0.9577 -0.3518 -1.3934 -2.5577 -0.0722 -1.5529 -0.0073 -1.5566 -1.6882 -0.2992 -0.2994 -0.7897 -0.5924 -2.5789 -2.4831 -0.0450 -0.6815 -0.1972 -0.2387 -0.0894
S-402	METHODS AND RESULTS: A total of 151 subjects with heart failure attributable to left ventricular systolic dysfunction were examined in this post hoc analysis; >96% were taking BB at enrollment.<unk>
T-402	heart_failure left_ventricular_systolic_dysfunction post_hoc_analysis
H-402	-0.8757628798484802	▁heart ▁failure ▁left ▁vent ri cular _ ▁sy sto lic _ ▁dys function
D-402	-0.8757628798484802	heart failure left ventricular_ systolic_ dysfunction
P-402	-3.8993 -0.6275 -1.6733 -1.5940 -1.2262 -0.3842 -0.6949 -0.7959 -0.0343 -0.1475 -0.6954 -0.3390 -0.1031 -0.8738 -0.0480
S-1186	A derivation cohort was formed of consecutive patients who had undergone coronary angiography with a primary diagnosis of systolic HF of unclear etiology (ejection fraction <50%).<unk>
T-1186	patients coronary_angiography diagnosis systolic_hf etiology ejection_fraction
H-1186	-0.32760298252105713	▁deriva tion ▁co hor t ▁corona ry _ ▁ang i ography ▁sy sto lic _ HF ▁un clear ▁et i ology
D-1186	-0.32760298252105713	derivation cohort coronary_ angiography systolic_HF unclear etiology
P-1186	-1.3645 -0.0223 -0.2763 -0.0035 -0.0116 -0.5301 -0.2070 -0.3536 -2.1722 -0.4624 -0.1359 -0.0096 -0.0040 -0.0065 -0.3378 -0.1699 -0.5768 -0.0037 -0.2394 -0.2115 -0.1880 -0.2029 -0.0452
S-1784	Marked cardiac insulin-resistance by 2 weeks post-AAC was evidenced by a significant decrease in insulin-stimulated rates of glycolysis and glucose oxidation, and plasma membrane translocation of glucose transporter 4.<unk>
T-1784	cardiac insulin-resistance glycolysis glucose_oxidation plasma_membrane_translocation glucose
H-1784	-0.20501849055290222	▁cardiac _ ▁insulin - re si stance ▁insulin - stimul ated _ ▁rates ▁gly col ysis ▁gluco se ▁oxid ation ▁plasma ▁membran e ▁trans location ▁gluco se ▁transporter
D-1784	-0.20501849055290222	cardiac_ insulin-resistance insulin-stimulated_ rates glycolysis glucose oxidation plasma membrane translocation glucose transporter
P-1784	-0.2970 -1.1932 -0.3930 -0.0289 -0.0502 -0.1701 -0.0014 -0.5779 -0.0317 -0.0092 -0.0705 -1.2914 -0.0408 -0.0308 -0.0108 -0.0297 -0.0443 -0.1722 -0.0410 -0.0188 -0.0044 -0.0577 -0.0255 -0.4661 -0.2856 -0.0829 -0.0572 -0.5235 -0.0863 -0.0585
S-1083	Cells were exposed to angiotensin II (AngII) and hypoxia, known activators of abnormal SCN5A mRNA splicing, or were induced to overexpress SCN5A variants.<unk>
T-1083	cells angiotensin_ii angii hypoxia scn5a mrna_splicing scn5a
H-1083	-0.3287130892276764	▁ang io ten sin ▁II ▁ang II ▁hypo xia ▁activa tors ▁s cn 5 a ▁m RNA ▁s plic ing ▁over express ▁S CN 5 A
D-1083	-0.3287130892276764	angiotensin II angII hypoxia activators scn5a mRNA splicing overexpress SCN5A
P-1083	-0.0697 -0.4171 -0.0207 -0.3849 -0.6432 -0.9878 -0.2904 -0.0226 -0.0028 -0.1850 -0.0556 -1.0443 -0.6454 -0.2258 -0.7980 -0.0359 -0.0114 -0.0791 -0.0273 -0.0073 -0.1044 -0.0178 -1.2601 -0.3653 -0.1786 -0.5849 -0.6599 -0.0786
S-824	On the basis of the assumption that exercise-induced PASP is a measure of right ventricular contractile reserve, patients were classified into 2 groups according to an exercise-induced PASP increase above or below the median.<unk>
T-824	exercise-induced_pasp right_ventricular_contractile_reserve patients exercise-induced_pasp
H-824	-0.6735103130340576	▁exercise - indu ced _ pas p ▁vent ri cular _ contract ile ▁reserve
D-824	-0.6735103130340576	exercise-induced_pasp ventricular_contractile reserve
P-824	-2.8974 -0.0460 -0.0195 -0.0618 -0.4955 -0.4503 -0.8745 -2.3873 -0.4527 -0.5114 -0.4308 -0.9491 -0.1240 -0.0633 -0.9489 -0.0637
S-922	Effective arterial elastance (Ea) end-systolic elastance (Ees) and ventricular-arterial coupling (defined as the ratio Ees:Ea) were determined using previously published techniques.<unk>
T-922	arterial_elastance ea end-systolic_elastance ees ventricular-arterial_coupling ees ea
H-922	-0.5336984395980835	▁arterial ▁elastan ce ▁e a ▁end - sy sto lic ▁elastan ce ▁e es ▁vent ri cular - arte rial _ ▁coup ling ▁ratio ▁e es
D-922	-0.5336984395980835	arterial elastance ea end-systolic elastance ees ventricular-arterial_ coupling ratio ees
P-922	-0.4738 -2.1011 -0.1826 -2.0466 -0.9068 -2.9417 -0.0247 -0.0194 -0.0073 -0.0119 -1.2999 -0.1477 -0.5567 -0.0179 -0.0325 -0.2258 -0.0984 -0.0750 -0.0222 -0.0071 -0.4351 -0.2380 -0.0910 -1.0662 -0.6920 -0.0252 -1.0924 -0.1047
S-920	We measured baseline and post-DASH/SRD brachial and central blood pressure (via radial arterial tonometry) and cardiovascular function with echocardiographic measures (all previously invasively validated).<unk>
T-920	baseline central_blood_pressure radial_arterial_tonometry cardiovascular_function echocardiographic invasively
H-920	-0.5694000124931335	▁post - DAS h / s RD ▁bra chi al _ central _ ▁blood ▁pressure ▁radi al _ ▁arterial _ ▁ton ometr y ▁e cho car dio graphic
D-920	-0.5694000124931335	post-DASh/sRD brachial_central_ blood pressure radial_ arterial_ tonometry echocardiographic
P-920	-0.5204 -0.0293 -0.0386 -0.1384 -1.8739 -0.8824 -0.8240 -2.1602 -0.1286 -0.0155 -1.6428 -0.9232 -0.4023 -1.5717 -1.0137 -0.0730 -0.0171 -0.8447 -0.5855 -0.2665 -0.8189 -0.0669 -0.0841 -0.7886 -0.0047 -0.0024 -0.1576 -0.4251 -0.7257 -0.0562
S-1609	MATERIALS AND METHODS: Gene expression profile GSE9128 was downloaded from Gene Expression Omnibus, including 3 normal samples, 4 non-ischemic heart failure samples and 4 ischemic samples.<unk>
T-1609	gene_expression_profile gse9128 gene_expression_omnibus non-ischemic_heart_failure ischemic
H-1609	-0.5868229269981384	▁Gene _ expression _ ▁profile ▁g se 91 28 ▁Gene ▁Express ion ▁Omni bus ▁non - ische mic _ heart ▁failure
D-1609	-0.5868229269981384	Gene_expression_ profile gse9128 Gene Expression Omnibus non-ischemic_heart failure
P-1609	-0.7355 -1.7045 -0.3386 -1.3395 -0.8697 -0.6245 -0.2064 -0.1501 -0.0676 -0.7292 -0.2844 -0.0172 -0.2556 -0.2490 -1.2336 -0.0121 -0.0191 -0.1479 -0.2659 -2.1531 -0.4933 -1.5100 -0.0900
S-1653	Early rhythm control therapy will consist of usual care plus rhythm control therapy by antiarrhythmic drugs, catheter ablation, and a patient-operated electrocardiographic device to monitor the ongoing rhythm.<unk>
T-1653	rhythm_control_therapy rhythm_control_therapy antiarrhythmic_drugs catheter_ablation electrocardiographic rhythm
H-1653	-0.27428388595581055	▁ rhythm ▁control ▁ therapy ▁anti ar rhythm ic ▁drugs ▁cat heter ▁ab lation ▁electro car dio graphic
D-1653	-0.27428388595581055	rhythm control therapy antiarrhythmic drugs catheter ablation electrocardiographic
P-1653	-0.5285 -0.1976 -1.7747 -0.3455 -0.0066 -0.0328 -0.0275 -0.0321 -0.0544 -0.2140 -0.0864 -0.0005 -0.0028 -0.0104 -0.0133 -0.0020 -0.0880 -0.2058 -1.7548 -0.1079
S-1240	However, these differences were offset by higher expenditures due to hospitalizations for noncardiovascular diagnoses, implantable cardiac arrhythmia devices, and noncardiovascular drugs in the rate-control group.<unk>
T-1240	expenditures hospitalizations noncardiovascular diagnoses implantable_cardiac_arrhythmia_devices noncardiovascular drugs rate-control
H-1240	-0.35652956366539	▁ex pendi tures ▁non car dio vas cular ▁diagnose s ▁implant able ▁cardiac ▁ar rhythm ia ▁devices ▁non car dio vas cular ▁drugs
D-1240	-0.35652956366539	expenditures noncardiovascular diagnoses implantable cardiac arrhythmia devices noncardiovascular drugs
P-1240	-2.9452 -0.0050 -0.0386 -0.5010 -0.0019 -0.1163 -0.1492 -0.2742 -1.2878 -0.0151 -0.0379 -0.0151 -0.0345 -0.2014 -0.0095 -0.2306 -0.1453 -0.0408 -0.0024 -0.0374 -0.0503 -0.5050 -1.0380 -1.1792 -0.0516
S-1488	Although there is good evidence for the treatment of HF with reduced ejection fraction (HFrEF), the treatment for HF with preserved ejection fraction (HFpEF) is not well defined.<unk>
T-1488	evidence hf_with_reduced_ejection_fraction hfref hf_with_preserved_ejection_fraction hfpef
H-1488	-0.8441668748855591	▁ HF ▁reduc er ved _ e je ction _ fraction HF r EF
D-1488	-0.8441668748855591	HF reducerved_ejection_fractionHFrEF
P-1488	-0.5227 -0.0152 -6.2315 -0.7582 -1.1472 -0.0847 -0.9635 -0.1457 -0.0571 -0.8653 -0.0283 -0.4786 -0.8753 -0.0283 -1.2589 -0.0461
S-1298	CONCLUSION: Extracorporeal life support is feasible und effective for bridging therapy in patients with acute ischemic right heart failure with refractory cardiogenic shock and successful reperfusion therapy.<unk>
T-1298	extracorporeal_life_support therapy patients acute_ischemic_right_heart_failure refractory_cardiogenic_shock reperfusion therapy
H-1298	-0.42308205366134644	▁extra corp o real _ ▁life ▁support ▁ brid ging _ therapy ▁a cute _ ische mic _ ▁right _ heart ▁failure ▁re frac tory _ ▁cardio ge nic _ ▁shock ▁reper fusion ▁ therapy
D-1298	-0.42308205366134644	extracorporeal_ life support bridging_therapy acute_ischemic_ right_heart failure refractory_ cardiogenic_ shock reperfusion therapy
P-1298	-0.3810 -0.0034 -0.0881 -0.0018 -0.1608 -0.8932 -1.5738 -0.8095 -0.1083 -0.0055 -1.1855 -0.0080 -1.0524 -0.0202 -0.1726 -0.3527 -0.2405 -0.0613 -3.0632 -0.1930 -2.5949 -0.0988 -0.0096 -0.0056 -0.2194 -0.2275 -0.3268 -0.1813 -0.3456 -0.3674 -0.1507 -0.0108 -0.0044 -0.5912 -0.0031 -0.0856 -0.0563
S-1332	CONCLUSION: As in heart failure and reduced left ventricular ejection fraction, FES also improves exercise capacity, quality of life, emotional status, and endothelial function in HFpEF.<unk>
T-1332	heart_failure reduced_left_ventricular_ejection_fraction fes exercise_capacity quality_of_life endothelial_function hfpef
H-1332	-0.6891874074935913	▁heart ▁failure ▁left _ ▁vent ri cular _ ▁e je ction ▁ fraction ▁f es ▁exercise ▁capacity ▁en dot heli al _ ▁function ▁ HF p EF
D-1332	-0.6891874074935913	heart failure left_ ventricular_ ejection fraction fes exercise capacity endothelial_ function HFpEF
P-1332	-0.7284 -0.2653 -2.3268 -1.2987 -0.7347 -0.4052 -0.8968 -1.0826 -1.1161 -0.0542 -0.0541 -0.9127 -0.0014 -0.9037 -0.8995 -1.4705 -0.8528 -2.2373 -0.7251 -0.0332 -0.0042 -1.0744 -1.1307 -0.5831 -0.0342 -0.0362 -0.0481 -0.0336 -0.0425
S-220	Intubation rates declined from 3.6% in 1996 to 1.7% in 2008, a 53% (95% CI: 31%-68%, P < .001, R(2) = 0.83, P < .001) relative decrease.<unk>
T-220	intubation
H-220	-0.6485706567764282	▁in tub ation ▁rates
D-220	-0.6485706567764282	intubation rates
P-220	-0.1490 -0.0086 -0.0778 -1.6897 -1.8797 -0.0867
S-1814	We found that the hearts of TTA/TgTetMena mice were functionally and morphologically comparable to wild-type littermates, except for mildly increased heart mass in the transgenic mice.<unk>
T-1814	hearts heart_mass transgenic
H-1814	-0.5458806753158569	▁heart s ▁ TTA ▁t g t et Men a _ mi ce ▁wild - type ▁litt er mates ▁trans ge nic _ mi ce
D-1814	-0.5458806753158569	hearts TTA tgtetMena_mice wild-type littermates transgenic_mice
P-1814	-1.0336 -0.2523 -2.0842 -0.0134 -3.4541 -0.0532 -0.3823 -0.1555 -0.2101 -0.0477 -1.9611 -0.5814 -0.2317 -0.6776 -0.0170 -0.0037 -0.0766 -0.0254 -0.0910 -1.2179 -0.2820 -0.6302 -0.4953 -0.5479 -0.0897 -0.0863 -0.0375
S-1541	By comparison, raloxifene, which is used for the same indication but has a different mechanism of action, was not associated with an increased risk of heart failure: adjusted HR 1.07 (95% CI 0.76-1.50).<unk>
T-1541	raloxifene heart_failure
H-1541	-0.8084865808486938	▁ra lo xi fen e
D-1541	-0.8084865808486938	raloxifene
P-1541	-0.3853 -0.0065 -0.0264 -0.0291 -0.6560 -4.4736 -0.0825
S-1938	METHODS AND RESULTS: Fifty consecutive patients with recent onset HFrEF (<30 days) performed a standardized exercise protocol with respiratory gas analysis at baseline as well as after 6 and 12 months.<unk>
T-1938	patients hfref exercise respiratory_gas_analysis baseline
H-1938	-1.6924382448196411	▁H Fr EF
D-1938	-1.6924382448196411	HFrEF
P-1938	-4.9878 -0.5042 -0.5133 -2.3926 -0.0643
S-1126	RESULTS: Among 295 patients not receiving guideline-recommended drugs for heart failure, chart review identified biomedical reasons for nonprescribing in 42%-58% of patients and contextual reasons in 11%-17%.<unk>
T-1126	patients drugs heart_failure biomedical nonprescribing patients
H-1126	-0.6732367873191833	▁guide line - re com mend ed _ ▁drugs ▁heart ▁failure ▁chart ▁review ▁bio medic al ▁reasons
D-1126	-0.6732367873191833	guideline-recommended_ drugs heart failure chart review biomedical reasons
P-1126	-3.9689 -0.0046 -0.2432 -0.0055 -0.0050 -0.0042 -0.0809 -1.1190 -0.2512 -2.9388 -0.1306 -0.7231 -0.5771 -0.0045 -0.0062 -0.0029 -1.5095 -1.1064 -0.1098
S-1641	CONCLUSIONS: Black race in patients with chronic HF was associated with increased prevalence of modifiable risk factors, lower exercise performance, and increased HF hospitalization, but not increased mortality or a differential response to exercise training.<unk>
T-1641	patients chronic_hf prevalence exercise hf hospitalization mortality exercise training
H-1641	-1.1774625778198242	▁black ▁race ▁ HF ▁ HF
D-1641	-1.1774625778198242	black race HF HF
P-1641	-0.3869 -0.7287 -1.7979 -0.3543 -2.9478 -0.6322 -2.4880 -0.0839
S-1169	Wasting of fat but not of lean mass was predictive of adverse outcome, suggesting that fat loss is either a surrogate of enhanced catabolism or adipose tissue is cardioprotective in the context of HF.<unk>
T-1169	lean_mass adverse_outcome adipose_tissue cardioprotective hf
H-1169	-0.63264399766922	▁lean ▁mass ▁fat ▁loss ▁enhance d _ ▁cata bol ism ▁adi pose ▁tissu e ▁cardio protec tive ▁ HF
D-1169	-0.63264399766922	lean mass fat loss enhanced_ catabolism adipose tissue cardioprotective HF
P-1169	-3.5126 -1.0885 -2.0605 -3.2778 -0.3732 -0.0196 -0.7330 -0.0615 -0.0347 -0.0904 -0.0015 -0.0078 -0.3523 -0.0483 -0.0101 -0.0240 -0.2110 -1.2798 -0.0063 -0.0359 -0.0569
S-546	Of these LVADs, 225 were CF devices (203 HeartMate II devices, Thoratec Corp, Pleasanton, Calif; and 22 HVAD devices, HeartWare Intl, Inc, Framingham, Mass).<unk>
T-546	lvads heartmate_ii thoratec_corp pleasanton calif hvad heartware framingham
H-546	-0.5218701958656311	▁l VAD s ▁CF _ ▁devices ▁Thor a tec ▁Corp ▁Ple asan ton ▁Cali f ▁h VAD ▁devices ▁Heart War e ▁in t l ▁Fram ing ham ▁Mass
D-546	-0.5218701958656311	lVADs CF_ devices Thoratec Corp Pleasanton Calif hVAD devices HeartWare intl Framingham Mass
P-546	-1.8688 -0.0118 -0.4389 -1.5069 -2.2648 -0.9240 -0.7492 -0.0312 -0.0006 -0.9419 -0.0957 -0.0005 -0.0065 -0.1869 -0.0022 -1.0102 -0.1396 -2.3451 -0.6017 -0.1290 -0.0268 -0.7971 -0.0133 -0.0015 -0.5642 -0.0228 -0.0025 -0.6861 -0.2301 -0.0563
S-97	However, hearts of fish lacking Nucleolin displayed severe developmental impairment, abnormal chamber patterning and functional deficits, ostensibly due to defects in cardiac looping and myocyte differentiation.<unk>
T-97	hearts nucleolin chamber_patterning cardiac_looping myocyte_differentiation
H-97	-0.5806244015693665	▁heart s ▁la cking ▁nu cle olin ▁cha mber ▁pattern ing ▁functional ▁deficit s ▁cardiac ▁loop ing ▁my o cy te
D-97	-0.5806244015693665	hearts lacking nucleolin chamber patterning functional deficits cardiac looping myocyte
P-97	-0.8598 -0.1661 -4.2902 -0.0213 -1.0285 -0.0012 -0.0053 -3.7892 -0.0010 -0.1796 -0.0565 -0.4457 -1.2884 -0.0636 -0.0193 -0.0718 -0.0204 -0.3511 -0.0282 -0.0215 -0.0546 -0.5548 -0.0361
S-1520	CONCLUSIONS: In plasma collected from HF patients, immunoreactive NT-proBNP was present as multiple N- and C-terminally truncated fragments of the full length NT-proBNP molecule.<unk>
T-1520	plasma collected hf patients immunoreactive nt-probnp c-terminally nt-probnp
H-1520	-0.6965817809104919	▁ HF ▁immun ore active ▁NT - pro b NP
D-1520	-0.6965817809104919	HF immunoreactive NT-probNP
P-1520	-1.7505 -0.0246 -0.4217 -1.1453 -0.2050 -1.9524 -0.0446 -0.0303 -0.9958 -0.0786 -1.6505 -0.0596
S-19	CONCLUSIONS: FM was associated with plasma NPs and total adiponectin at baseline; whereas changes in FM and FFM did not correlate to changes in NPs or adiponectin during follow up.<unk>
T-19	plasma_nps adiponectin baseline ffm correlate nps adiponectin follow_up
H-19	-0.7416912317276001	▁FM ▁plasma ▁ NP s ▁totale _ ▁adi pon ect in ▁f FM
D-19	-0.7416912317276001	FM plasma NPs totale_ adiponectin fFM
P-19	-1.5316 -1.2177 -0.3093 -0.0017 -0.0175 -2.9532 -0.2101 -0.1268 -0.0009 -0.1095 -0.4548 -1.8066 -0.5055 -1.8278 -0.0522
S-935	Macrophages, but not cardiomyocytes, from Hum-Retn mice treated with doxorubicin in vitro showed dramatic induction of hRetn (human resistin) mRNA and protein expression.<unk>
T-935	macrophages cardiomyocytes doxorubicin in_vitro resistin mrna protein_expression
H-935	-0.5139399170875549	▁cardio my o cy tes ▁Hum - Re t n ▁mi ce ▁do xor ubi cin ▁h Re t n _ human _ ▁resist in ▁m RNA ▁protein ▁expression
D-935	-0.5139399170875549	cardiomyocytes Hum-Retn mice doxorubicin hRetn_human_ resistin mRNA protein expression
P-935	-1.2482 -0.2677 -0.1289 -0.0206 -0.0120 -0.1849 -0.0399 -1.5163 -0.2785 -0.0379 -4.0179 -0.1621 -0.1015 -0.0039 -0.0129 -0.0803 -0.5219 -1.2049 -0.0301 -0.0146 -2.6157 -0.0970 -0.8238 -0.5626 -0.0571 -0.7072 -0.0007 -0.6187 -0.3299 -0.1723 -0.0622
S-1438	The beat-to-beat QT interval was measured on 3-min records of surface ECGs at baseline and during interventions (atrial pacing and esmolol, isoprenaline, and atropine infusion).<unk>
T-1438	qt_interval ecgs baseline atrial_pacing esmolol isoprenaline atropine infusion
H-1438	-0.47262755036354065	▁beat - to - beat ▁ QT ▁interval ▁surface _ e CG s at rial ▁pa cing ▁es mol ol ▁iso pren a line ▁a tropi ne ▁in fusion
D-1438	-0.47262755036354065	beat-to-beat QT interval surface_eCGsatrial pacing esmolol isoprenaline atropine infusion
P-1438	-0.0737 -0.0176 -0.0188 -0.0203 -0.0695 -1.2562 -0.0254 -1.1991 -3.6385 -0.6956 -1.9127 -0.0871 -0.7025 -1.8502 -0.3005 -0.1970 -0.1212 -1.3012 -0.0013 -0.1100 -0.0010 -0.0032 -0.0250 -0.0144 -0.0138 -0.0135 -0.4281 -0.2285 -0.0105 -0.2491 -0.0661
S-1378	To assess whether this was due to a withdrawal of sympathetic tone or an increase in parasympathetic tone, the heart rate response was measured after an intravenous bolus of metoprolol or atropine.<unk>
T-1378	sympathetic_tone parasympathetic_tone heart_rate intravenous_bolus metoprolol atropine
H-1378	-0.36600372195243835	▁sympa the tic ▁tone ▁para sy mpa the tic _ ▁tone ▁heart ▁rate ▁response ▁met o pro lol ▁a tropi ne
D-1378	-0.36600372195243835	sympathetic tone parasympathetic_ tone heart rate response metoprolol atropine
P-1378	-0.8570 -0.1668 -0.2929 -1.3495 -0.0085 -0.0073 -0.0368 -0.3461 -0.2961 -0.5646 -0.0596 -0.5181 -0.1695 -2.2560 -0.9779 -0.2113 -0.0133 -0.0391 -0.0300 -0.0040 -0.1149 -0.0598 -0.0389
S-1533	In conclusion, the presence of EH denotes a distinct subset of HFpEF that is pathophysiologically similar to HF with reduced EF (HFrEF) and may benefit from HFrEF therapy.<unk>
T-1533	hfpef pathophysiologically hf_with_reduced_ef hfref hfref therapy
H-1533	-0.6843225955963135	▁EH ▁ HF p EF ▁ HF _ met ▁reduce d _ ▁EF HF r EF ▁h Fr EF
D-1533	-0.6843225955963135	EH HFpEF HF_met reduced_ EFHFrEF hFrEF
P-1533	-0.0033 -0.5620 -0.0613 -0.2899 -0.0597 -0.5270 -0.1139 -4.3254 -1.8878 -1.1850 -0.0039 -0.0808 -1.6602 -1.3294 -0.0913 -0.0312 -1.1790 -0.1712 -0.1989 -0.5632 -0.0464
S-4	The results show a significant decline in adverse event rates for acute myocardial infarction and congestive heart failure, translating to an estimated 81,000 in-hospital adverse events averted in 2010–2011.<unk>
T-4	adverse_event acute_myocardial_infarction congestive_heart_failure adverse_events
H-4	-0.6059105396270752	▁advers e _ ▁event ▁rates ▁a cute _ in far ction ▁con ges tive _ heart ▁failure ▁in - hospital
D-4	-0.6059105396270752	adverse_ event rates acute_infarction congestive_heart failure in-hospital
P-4	-1.4959 -0.0081 -0.3469 -1.8499 -0.2479 -0.1849 -0.0140 -0.0939 -3.4478 -0.1138 -0.1053 -0.4580 -0.1237 -0.2148 -0.0375 -0.9332 -0.2066 -0.8010 -0.0440 -0.0050 -2.5496 -0.0481
S-803	However, statistical improvement occurred in the total sample from the first to the second trial with large limits of agreement (mean difference, -.97s; 95% confidence interval, 3.00 to -4.94s; P<.01).<unk>
T-803	confidence_interval
H-803	-1.2669074535369873	▁statistic al
D-803	-1.2669074535369873	statistical
P-803	-2.2652 -0.0116 -2.7563 -0.0345
S-721	OBJECTIVES: The study objectives were to quantify the change in 7-day follow-up visits and 30-day readmissions as part of a hospital quality improvement initiative and to characterize events at 7-day follow-up visits.<unk>
T-721	change follow-up readmissions hospital follow-up
H-721	-1.5496184825897217	
D-721	-1.5496184825897217	
P-721	-3.0400 -0.0593
S-1049	Detailed transcriptional analysis of cardiac tissue from mice that were either TAC- or sham-operated and treated with either JQ1 or vehicle revealed that BET inhibition suppresses a pathological cardiac gene expression programme.<unk>
T-1049	cardiac jq1 bet pathological cardiac gene_expression
H-1049	-0.7107790112495422	▁cardiac _ ▁tissu e ▁ TAC - ▁sham - opera ted ▁j Q 1 ▁vehicle ▁ BET ▁inhibi tion ▁path ological _ ▁cardiac _ ▁gene ▁expression ▁programme
D-1049	-0.7107790112495422	cardiac_ tissue TAC- sham-operated jQ1 vehicle BET inhibition pathological_ cardiac_ gene expression programme
P-1049	-1.4383 -2.3749 -0.0996 -0.0662 -1.1678 -0.0693 -0.1104 -1.1968 -0.0117 -0.0008 -0.0132 -0.8493 -0.8886 -0.1423 -2.0484 -0.0795 -0.0301 -1.9557 -0.0917 -1.8508 -0.3302 -0.1893 -0.4804 -0.9558 -2.8740 -0.2073 -0.8608 -0.1517 -0.0777
S-1377	Power spectral analysis indicated an increase in low-frequency/high-frequency (LF/HF) ratio in the CHF-INV compared with the sham-INV, which was normalized to sham levels by DNx.<unk>
T-1377	power_spectral_analysis hf dnx
H-1377	-0.8371833562850952	▁power ▁spec tral _ analyse ▁low - fre quen ncy _ high - fre quen ncy LF _ HF ▁CHF - in v ▁sham - in v ▁sham ▁levels ▁DN x
D-1377	-0.8371833562850952	power spectral_analyse low-frequenncy_high-frequenncyLF_HF CHF-inv sham-inv sham levels DNx
P-1377	-0.3295 -3.5876 -0.0012 -4.2364 -0.0724 -2.5747 -0.0314 -0.0186 -0.4110 -0.1895 -1.4222 -0.3871 -0.1010 -0.0103 -0.3096 -0.1750 -1.3088 -2.1434 -0.0621 -3.6917 -0.0366 -0.5520 -0.5237 -0.0053 -0.2023 -0.8626 -0.3200 -1.1071 -2.3338 -0.0320 -0.0350 -0.4175 -0.1359
S-1511	BACKGROUND: The use of nonstandardized N-terminal pro-B-type natriuretic peptide (NT-proBNP) assays can contribute to the misdiagnosis of heart failure (HF).<unk>
T-1511	n-terminal_pro-b-type_natriuretic_peptide nt-probnp misdiagnosis heart_failure hf
H-1511	-0.6892632246017456	▁non - termin al _ pro - B - type ▁na tri ure tic _ pe pti de NT - pro b NP ▁mis diagnos is ▁heart ▁failure HF
D-1511	-0.6892632246017456	non-terminal_pro-B-type natriuretic_peptideNT-probNP misdiagnosis heart failureHF
P-1511	-3.7572 -0.8242 -0.2105 -0.0360 -1.0035 -3.0119 -0.0290 -0.9612 -0.0794 -0.0066 -0.3725 -0.0282 -0.8352 -1.7828 -0.5035 -0.4394 -0.0334 -0.0914 -0.5180 -0.0074 -0.0108 -0.7893 -0.0196 -0.3750 -0.0429 -0.0930 -3.6136 -0.5678 -1.1872 -0.0869 -0.0501
S-698	METHODS AND RESULTS: HF-ACTION randomized 2331 patients with left ventricular ejection fraction <0.35 and New York Heart Association class II to IV HF to either exercise training or usual care.<unk>
T-698	hf-action randomized patients left_ventricular_ejection_fraction new_york_heart_association_class_ii hf exercise training
H-698	-0.6682969331741333	▁ HF - AC TION ▁left _ ▁vent ri cular _ ▁e je ction ▁ fraction ▁New ▁York _ ▁Heart ▁Association ▁IV ▁ HF
D-698	-0.6682969331741333	HF-ACTION left_ ventricular_ ejection fraction New York_ Heart Association IV HF
P-698	-0.4214 -0.2657 -0.1020 -1.5871 -0.8506 -1.4425 -1.1671 -0.7802 -0.6018 -0.6559 -1.0738 -1.1445 -0.0770 -0.0652 -0.8494 -0.0027 -1.3018 -0.3214 -0.4242 -0.6129 -0.5126 -2.3055 -0.2799 -0.0143 -0.4365 -0.0796
S-762	The relative importance for myocardial DD of collagen deposition and titin modification was investigated in obese, diabetic ZSF1 rats after heart failure with preserved ejection fraction development at 20 weeks.<unk>
T-762	myocardial_dd collagen_deposition titin obese diabetic zsf1 heart_failure_with_preserved_ejection_fraction
H-762	-0.449504554271698	▁my o card ial ▁ DD ▁collage n ▁de position ▁titi n ▁modification ▁obes e ▁diabet ic ▁z SF 1 ▁rat s ▁heart ▁failure ▁pres er ved _ e je ction
D-762	-0.449504554271698	myocardial DD collagen deposition titin modification obese diabetic zSF1 rats heart failure preserved_ejection
P-762	-1.3154 -0.0396 -0.0563 -0.0225 -2.6142 -0.0041 -0.0067 -0.1025 -0.0293 -0.0630 -0.0472 -0.0150 -1.9740 -1.2565 -0.0266 -0.2024 -0.0134 -0.6209 -0.0061 -0.3824 -0.1961 -0.1257 -1.8783 -0.3925 -0.0588 -0.0504 -0.3294 -0.4512 -1.3160 -0.0262 -0.0190 -1.1080 -0.0842
S-743	CONCLUSIONS: In the present preliminary study, cardiac magnetic resonance postcontrast T1 time is associated with prognosis in HFPEF, suggesting postcontrast T1 as possible biomarker for HFPEF.<unk>
T-743	cardiac_magnetic_resonance_postcontrast_t1_time prognosis hfpef postcontrast_t1 biomarker hfpef
H-743	-0.44229331612586975	▁cardiac ▁magnetic _ ▁res on ance ▁post contra st _ t 1 ▁h FP EF ▁bio mark er ▁H FP EF
D-743	-0.44229331612586975	cardiac magnetic_ resonance postcontrast_t1 hFPEF biomarker HFPEF
P-743	-0.0875 -0.6742 -0.4143 -0.2378 -0.0742 -0.0837 -0.2622 -0.0067 -0.0102 -0.3117 -1.0793 -0.2482 -3.6288 -0.2467 -0.2045 -0.8164 -0.0181 -0.0431 -1.4787 -0.0858 -0.0530 -0.0421 -0.0657
S-524	Although contractility remained unchanged, ventricular-arterial coupling was markedly improved (p = 0.002), resulting in a higher SV (p < 0.0001) in the ivabradine-treated patients.<unk>
T-524	contractility ventricular-arterial_coupling patients
H-524	-0.2516421973705292	▁contract ility ▁vent ri cular - arte rial _ ▁coup ling ▁i va bra dine - tre ated
D-524	-0.2516421973705292	contractility ventricular-arterial_ coupling ivabradine-treated
P-524	-0.0996 -0.0472 -0.0129 -0.3689 -0.1146 -0.0825 -0.0368 -0.0093 -0.6463 -1.2801 -0.3303 -0.5721 -0.0249 -0.0494 -0.0385 -0.1861 -0.0291 -0.2013 -0.7746 -0.1283
S-642	Conversely, conditional gene-targeted Hand2 mice demonstrated a marked resistance to pressure-overload-induced hypertrophy, fibrosis, ventricular dysfunction and induction of a fetal gene program.<unk>
T-642	hand2 hypertrophy fibrosis ventricular_dysfunction gene
H-642	-0.49881771206855774	▁condition al _ ▁gene - tar get ed ▁Hand 2 ▁mi ce ▁pressure - over load - indu ced ▁hyper trop hy ▁fibro sis ▁vent ri cular ▁dys function ▁fet al _ ▁gene ▁program
D-642	-0.49881771206855774	conditional_ gene-targeted Hand2 mice pressure-overload-induced hypertrophy fibrosis ventricular dysfunction fetal_ gene program
P-642	-0.3810 -0.0276 -0.7067 -2.7493 -0.0672 -0.0141 -0.0141 -0.0527 -1.3967 -0.1731 -4.2473 -0.0811 -0.2300 -0.0354 -0.0030 -0.0407 -0.3010 -0.0301 -0.1090 -1.1159 -0.0021 -0.6278 -0.0016 -0.0351 -0.0006 -0.2167 -0.1766 -1.3259 -0.0128 -0.0088 -0.0083 -0.5066 -1.5096 -1.5864 -0.0879 -0.0746
S-264	To our best knowledge, our study is the first research done to identify a predictive cutoff value for admission NT-proBNP to the prescriptive 4-year survival of patients admitted to ED with acute HF diagnosis.<unk>
T-264	admission nt-probnp patients acute_hf diagnosis
H-264	-1.1458346843719482	▁ nc - pro b NP
D-264	-1.1458346843719482	nc-probNP
P-264	-3.2888 -3.3674 -0.0816 -0.0262 -0.3783 -0.1029 -1.8096 -0.1118
S-1193	In conclusion, a simple clinical prediction rule can accurately identify patients with CAD and eliminate the need for angiography in a substantial proportion of patients with systolic HF, with potentially significant cost savings and risk avoidance.<unk>
T-1193	clinical rule patients cad angiography patients systolic_hf cost
H-1193	-1.2178301811218262	▁clinic al _ ▁predict ion ▁rule ▁CAD
D-1193	-1.2178301811218262	clinical_ prediction rule CAD
P-1193	-3.4509 -0.0055 -0.6572 -1.2996 -0.0228 -0.2997 -0.9174 -4.2700 -0.0374
S-1053	This study implicates epigenetic readers in cardiac biology and suggests that the manipulation of cardiac gene control via the targeting of chromatin-dependent signal transduction could potentially abrogate pathological gene expression and HF progression.<unk>
T-1053	epigenetic cardiac cardiac gene signal_transduction pathological gene_expression hf
H-1053	-0.6050640940666199	▁epi gene tic _ ▁readers ▁cardiac _ ▁bi ology ▁cardiac _ ▁gene ▁control ▁chr omat in - dependent _ signal ▁trans duction ▁path ological _ ▁gene ▁expression ▁ HF
D-1053	-0.6050640940666199	epigenetic_ readers cardiac_ biology cardiac_ gene control chromatin-dependent_signal transduction pathological_ gene expression HF
P-1053	-0.5881 -0.0044 -0.3691 -2.0744 -0.0341 -0.0478 -1.3381 -1.2230 -0.1962 -1.8169 -0.6861 -1.7174 -0.7379 -0.0041 -0.0049 -0.1042 -0.0401 -0.0128 -0.0711 -1.0075 -0.0369 -0.3810 -1.0273 -0.2300 -0.1503 -1.8038 -1.8844 -0.1959 -0.0009 -0.8846 -0.0837
S-277	Systolic blood pressure was significantly elevated and left ventricular (LV) hypertrophy was found in AT, AN, AS, and ANS mice, and there were no significant differences in those parameters between the four groups.<unk>
T-277	systolic_blood_pressure elevated left_ventricular hypertrophy
H-277	-0.7313445806503296	▁sy sto lic _ ▁blood ▁pressure ▁left ▁vent ri cular _ LV _ ▁hyper trop hy ▁AT ▁AN ▁AS ▁ ANS
D-277	-0.7313445806503296	systolic_ blood pressure left ventricular_LV_ hypertrophy AT AN AS ANS
P-277	-1.4435 -0.0086 -0.0386 -0.4079 -0.6220 -0.3858 -1.2968 -1.0142 -0.5425 -0.3288 -1.1022 -1.7164 -2.8591 -0.2413 -0.0042 -0.1793 -2.1976 -0.8375 -0.4197 -0.5279 -0.0022 -0.5883 -0.0565
S-1747	During follow-up, 271 patients (45%) reached a combined end point including death (heart failure related, n=142; sudden death, n=71; and noncardiac, n=22) or cardiac transplant (n=36).<unk>
T-1747	follow-up patients combined_end_point death heart_failure death cardiac_transplant
H-1747	-2.0164906978607178	▁cardiac ▁transplant
D-1747	-2.0164906978607178	cardiac transplant
P-1747	-6.1500 -1.6356 -0.2179 -0.0624
S-1601	Catheter-based percutaneous revascularization with angioplasty and stenting showed modest clinical benefit for patients in small retrospective studies, but data from randomized clinical trials failed to confirm these beneficial results.<unk>
T-1601	percutaneous revascularization angioplasty stenting clinical patients randomized clinical
H-1601	-0.6533806324005127	▁Cat heter - based _ per cuta ne _ re vas cular ization ▁ang io plast y ▁sten ting
D-1601	-0.6533806324005127	Catheter-based_percutane_revascularization angioplasty stenting
P-1601	-2.8983 -0.0153 -0.1670 -0.0638 -0.8270 -0.6999 -0.0050 -0.1590 -2.3588 -1.4045 -0.1654 -0.3874 -0.5042 -0.8035 -1.5843 -0.0944 -0.1531 -0.0620 -0.1290 -1.1981 -0.0409
S-1176	Work load-corrected chronotropic response (the difference in heart rate at the same exercise time at the baseline and follow-up tests) showed a slower increase in heart rate during exercise than in the placebo-treated group.<unk>
T-1176	chronotropic_response heart_rate exercise baseline follow-up tests heart_rate exercise
H-1176	-1.1031436920166016	▁load - corre cted ▁chr ono tropi c _ ▁response ▁heart ▁rate
D-1176	-1.1031436920166016	load-corrected chronotropic_ response heart rate
P-1176	-4.4242 -0.0549 -0.0025 -0.3056 -1.2314 -0.0525 -0.0550 -0.0827 -2.6771 -0.7383 -3.4768 -0.9386 -1.3254 -0.0789
S-1943	Peak oxygen consumption (VO2max) was significantly higher when resting HR was <70 versus ≥70 bpm (17.5±5.5 versus 14.4±3.3 mL/min/kg, respectively; P value=0.038).<unk>
T-1943	peak_oxygen_consumption vo2max resting_hr bpm p_value
H-1943	-1.3876293897628784	▁oxygen _ ▁consum p tion VO 2 max
D-1943	-1.3876293897628784	oxygen_ consumptionVO2max
P-1943	-4.0749 -2.3499 -1.1423 -0.0245 -0.1693 -2.3374 -0.0279 -0.0101 -3.5827 -0.1573
S-1624	Cox-proportional hazard models and negative binomial regression models were used to assess the relationship between the intervention and survival and utilization, controlling for demographic and health characteristics that were statistically different between groups after matching.<unk>
T-1624	cox-proportional_hazard_models negative_binomial_regression_models health
H-1624	-0.6620066165924072	▁co x - propor tional _ ▁hazard ▁models ▁negative ▁bi nom ial _ ▁re gression ▁models ▁intervention
D-1624	-0.6620066165924072	cox-proportional_ hazard models negative binomial_ regression models intervention
P-1624	-0.2174 -0.0073 -0.0203 -0.0112 -0.0080 -0.1651 -3.5792 -0.4484 -0.0302 -2.8351 -0.0762 -0.0082 -0.7296 -0.2402 -0.0010 -0.3550 -1.0008 -2.7934 -0.0515
S-1251	In a pilot study, five patients with HF and T2D consumed ERC for 3 months; treadmill testing [VO2max (maximum oxygen consumption)] and SkM biopsies were performed.<unk>
T-1251	patients hf t2d erc vo2max maximum_oxygen_consumption skm biopsies
H-1251	-0.570489764213562	▁ HF ▁t 2 d ▁ ERC ▁tre ad m ill ▁testing VO 2 max ▁oxygen ▁consum p tion ▁Sk m ▁bio psi es
D-1251	-0.570489764213562	HF t2d ERC treadmill testingVO2max oxygen consumption Skm biopsies
P-1251	-0.2435 -0.0284 -3.0343 -0.0075 -0.6382 -0.6718 -0.0539 -0.0288 -0.0006 -0.1286 -0.0160 -3.8573 -1.6360 -0.0070 -0.0088 -3.2103 -0.1042 -0.0151 -0.0678 -0.1138 -0.6829 -0.0086 -0.1166 -0.0290 -0.0866 -0.0371
S-1961	One (10%) patient was admitted to hospital with gastrointestinal bleeding at month 1; one (10%) patient died after incessant ventricular tachycardia storm, which led to terminal heart failure 2 months post-procedure.<unk>
T-1961	patient hospital gastrointestinal_bleeding patient ventricular_tachycardia terminal_heart_failure
H-1961	-0.6377702355384827	▁hospital ▁gastro inte stin al _ ▁ble ed ing ▁ince ssant ▁vent ri cular _ ta chy car dia ▁storm ▁terminal _ heart
D-1961	-0.6377702355384827	hospital gastrointestinal_ bleeding incessant ventricular_tachycardia storm terminal_heart
P-1961	-2.9900 -1.0351 -0.0371 -0.6771 -0.0934 -1.3157 -0.0354 -0.1928 -0.0692 -1.1577 -0.0030 -0.8006 -0.3500 -0.2733 -0.4181 -2.0099 -0.1028 -0.0068 -0.0198 -0.0146 -0.2173 -0.1831 -2.5617 -1.3243 -0.0554
S-1214	Chronic β-AR stimulation via catecholamine infusions in rats enhanced PDE2 expression ~2-fold and cAMP hydrolytic activity ~4-fold, which correlated with blunted cardiac β-AR responsiveness.<unk>
T-1214	chronic β-ar catecholamine infusions pde2 expression camp activity correlated cardiac β-ar_responsiveness
H-1214	-0.6160756349563599	▁cate chol amine ▁in fusion s ▁p de 2 ▁c AMP ▁hydro ly tic _ activ iteit ▁blu n ted _ ▁cardiac ▁β - AR ▁responsive ness
D-1214	-0.6160756349563599	catecholamine infusions pde2 cAMP hydrolytic_activiteit blunted_ cardiac β-AR responsiveness
P-1214	-4.8962 -0.0241 -0.0253 -0.0406 -0.0017 -0.3377 -1.1395 -1.2104 -0.0329 -0.0364 -0.0026 -0.3111 -0.3530 -0.9677 -2.4012 -0.2913 -2.1263 -0.0428 -0.1190 -0.2742 -0.5376 -0.0397 -0.1923 -0.0083 -0.0614 -1.0354 -0.9359 -0.2908 -0.1308
S-758	CONCLUSIONS: Among subjects with mild HF, QRS prolongation, and LVEF >30%, CRT produced reverse remodeling and similar clinical benefit compared with subjects with more severe LV systolic dysfunction.<unk>
T-758	mild_hf qrs_prolongation lvef crt reverse_remodeling clinical systolic_dysfunction
H-758	-0.36899688839912415	▁ HF ▁QR s ▁prolong ation ▁LV EF ▁c RT ▁rever se _ ▁remodel ing
D-758	-0.36899688839912415	HF QRs prolongation LVEF cRT reverse_ remodeling
P-758	-0.4031 -0.0342 -0.0286 -0.8769 -0.0802 -0.0280 -0.0491 -0.0161 -0.5221 -0.1320 -0.1026 -0.0033 -0.5522 -0.0393 -0.0049 -3.3604 -0.0400
S-1096	In chronic PAH, we will examine clinical circumstances common to hospitalized patients that may provoke acute RV decompensation, as well as pharmacologic therapies that are unique to RV failure management in PAH.<unk>
T-1096	chronic_pah clinical hospitalized patients acute rv_decompensation pharmacologic therapies rv_failure pah
H-1096	-0.5265073180198669	▁chronic ▁p AH ▁ RV ▁de com pensa tion ▁ pharma c ologic ▁ therapie s ▁ RV ▁failure ▁management ▁p AH
D-1096	-0.5265073180198669	chronic pAH RV decompensation pharmacologic therapies RV failure management pAH
P-1096	-0.1328 -2.8433 -0.0083 -1.2368 -2.3521 -0.9710 -0.0548 -0.0157 -0.0685 -0.1736 -0.2270 -0.0073 -0.0699 -0.5934 -0.0775 -0.1752 -0.4128 -0.1502 -0.2638 -0.8490 -1.7410 -0.0029 -0.0797 -0.1294
S-268	During the 4-year follow-up period, 76 patients died; survivors were significantly younger than non-survivors (64.26 ± 11.42 years vs 72.83 ± 11.07 years, P = .002).<unk>
T-268	follow-up patients
H-268	-1.4417786598205566	
D-268	-1.4417786598205566	
P-268	-2.8029 -0.0806
S-1129	The most common contextual reasons were comanagement with other clinicians (32%-35% of patients), patient preferences and nonadherence (15%-24%), and clinician belief that the medication is not indicated in the patient (12%-20%).<unk>
T-1129	clinicians patients patient clinician medication patient
H-1129	-0.7690019011497498	▁co management ▁patient ▁preference s ▁non adh er ence ▁clinic ian
D-1129	-0.7690019011497498	comanagement patient preferences nonadherence clinician
P-1129	-0.6551 -0.0077 -4.8048 -0.6730 -0.0194 -0.4730 -0.0012 -0.0340 -0.8534 -0.2069 -0.1098 -2.0944 -0.0642
S-628	Compared to non-frail participants, moderate (HR 1.36, 95% CI 1.08-1.71) and severe frailty (HR 1.88, 95% CI 1.02-3.47) by Gill index was associated with a higher risk for HF.<unk>
T-628	frailty gill_index hf
H-628	-1.1909228563308716	▁non - fra il _ ▁participants ▁gre il ty ▁Gill ▁index ▁ HF
D-628	-1.1909228563308716	non-frail_ participants greilty Gill index HF
P-628	-2.9618 -0.0093 -0.0004 -0.0433 -4.2060 -1.1491 -5.9684 -0.3146 -0.9647 -0.2799 -0.1440 -1.6219 -0.0509 -0.0591 -0.0904
S-625	METHODS: We assessed the association between frailty, using the Health ABC Short Physical Performance Battery (HABC Battery) and the Gill index, and incident HF in 2825 participants aged 70 to 79 years.<unk>
T-625	frailty health_abc_short_physical_performance_battery habc_battery gill_index hf
H-625	-0.49855053424835205	▁fra il ty ▁Health ▁ABC _ short _ ▁Physic al _ ▁Performance _ ▁Bat tery h ABC _ bat tery ▁Gill ▁index ▁ HF
D-625	-0.49855053424835205	frailty Health ABC_short_ Physical_ Performance_ BatteryhABC_battery Gill index HF
P-625	-2.5944 -0.1508 -0.1742 -1.1670 -0.5320 -0.4836 -0.2023 -0.0079 -2.1455 -0.0148 -0.4626 -0.0202 -0.9529 -0.6706 -0.0021 -1.1998 -0.0716 -0.2081 -1.0079 -0.0035 -0.0263 -0.0632 -0.7182 -0.0102 -0.0343 -0.0384
S-295	Patients requiring temporary RV support after LVAD insertion are a heterogeneous group of patients consisting of those in cardiogenic shock after myocardial infarction, to those with chronic decompensated heart failure.<unk>
T-295	patients rv_support lvad patients cardiogenic_shock myocardial_infarction chronic_decompensated_heart_failure
H-295	-0.6381101608276367	▁ RV ▁l VAD ▁ insertion ▁cardio ge nic _ ▁shock ▁my o card ial _ in far ction ▁chronic ▁de com pensa ted _ heart ▁failure
D-295	-0.6381101608276367	RV lVAD insertion cardiogenic_ shock myocardial_infarction chronic decompensated_heart failure
P-295	-1.1201 -0.2738 -6.3289 -0.0336 -1.7725 -0.0188 -0.1544 -0.0783 -0.5067 -0.3721 -0.1668 -2.1794 -0.1213 -0.3724 -0.1986 -0.9038 -0.6439 -0.0402 -0.0356 -0.5686 -0.4234 -0.0480 -0.0114 -0.1019 -0.1594 -0.8828 -0.7603 -0.0947 -0.1332
S-1357	PURPOSE OF REVIEW: Chronic heart failure (CHF) is increasingly recognized as a multisystem disease with important comorbidities such as anemia, insulin resistance, autonomic dysbalance, or cardiac cachexia.<unk>
T-1357	chronic_heart_failure chf multisystem_disease comorbidities anemia insulin_resistance autonomic_dysbalance cardiac_cachexia
H-1357	-0.5344731211662292	▁Chro nic _ heart ▁failure CH F ▁multi system ▁disease ▁an emia ▁insulin ▁resist ance ▁autonomi c _ ▁dys balance ▁cardiac ▁cache xia
D-1357	-0.5344731211662292	Chronic_heart failureCHF multisystem disease anemia insulin resistance autonomic_ dysbalance cardiac cachexia
P-1357	-1.5268 -0.1980 -0.1469 -1.3099 -0.4389 -2.4749 -1.1964 -1.8187 -0.1228 -2.1777 -0.2040 -0.0101 -0.0200 -0.1196 -0.0126 -0.0075 -0.0494 -0.8164 -0.4958 -0.0466 -0.0005 -0.0287 -0.0090 -0.0803 -0.0505
S-470	Xanthine oxidase (XO) is increased in human and rat left ventricular (LV) myocytes with volume overload (VO) of mitral regurgitation and aortocaval fistula (ACF).<unk>
T-470	xanthine_oxidase xo left_ventricular myocytes volume_overload vo mitral_regurgitation aortocaval_fistula acf
H-470	-0.6732677221298218	▁Xan thi ne ▁oxid ase ▁ XO ▁rat ▁left ▁vent ri cular LV ▁volume ▁over load _ VO ▁mit ral ▁re gur gi tation ▁a orto ca val _ ▁fi stu la
D-470	-0.6732677221298218	Xanthine oxidase XO rat left ventricularLV volume overload_VO mitral regurgitation aortocaval_ fistula
P-470	-0.0050 -0.0183 -0.2195 -0.0491 -0.1624 -2.7234 -0.0004 -4.6895 -0.4588 -0.7722 -0.3092 -0.1526 -1.6714 -2.2593 -0.0169 -0.0180 -4.4331 -1.2019 -0.6310 -0.0361 -0.2902 -0.0156 -0.0146 -0.0061 -0.0341 -0.0065 -0.0013 -0.0766 -0.9966 -1.0548 -0.0018 -0.0725 -0.4363 -0.0560
S-767	Only the obese ZSF1 groups had developed heart failure with preserved ejection fraction, which was evident from increased lung weight, preserved left ventricular ejection fraction, and left ventricular DD.<unk>
T-767	obese zsf1 heart_failure_with_preserved_ejection_fraction lung preserved_left_ventricular_ejection_fraction left_ventricular_dd
H-767	-0.7798836827278137	▁obes e ▁z SF 1 ▁groups ▁heart ▁failure ▁pres er ved _ e je ction _ fraction ▁lung ▁weight ▁pres er ved ▁left _ ▁vent ri cular ▁e je ction ▁ fraction ▁left _ ▁vent ri cular ▁ DD
D-767	-0.7798836827278137	obese zSF1 groups heart failure preserved_ejection_fraction lung weight preserved left_ ventricular ejection fraction left_ ventricular DD
P-767	-1.0582 -0.0264 -0.8408 -0.0354 -1.4558 -4.2394 -4.5351 -0.4008 -2.8948 -0.0164 -0.1183 -0.3663 -1.2175 -0.0912 -0.0327 -0.9736 -0.0100 -0.4347 -1.0016 -0.8250 -0.0127 -0.0896 -2.1487 -1.3189 -0.3215 -0.3209 -0.2753 -1.7602 -0.0669 -0.0473 -1.3509 -0.0020 -0.0860 -0.5518 -1.1617 -0.3032 -0.0831 -1.2494 -0.0244 -0.1207 -0.1061
S-1727	Patients cared for by the high-volume physicians had lower mortality than those by the low-volume physicians (8.9% versus 9.7%; P<0.001); this relationship was strongest in low-volume hospitals.<unk>
T-1727	patients physicians mortality physicians hospitals
H-1727	-0.500000536441803	▁high - volu me _ ▁physician s ▁low - volu me _ ▁physician s
D-1727	-0.500000536441803	high-volume_ physicians low-volume_ physicians
P-1727	-2.4570 -0.0160 -0.0408 -0.0555 -0.7318 -0.2337 -0.0282 -2.1964 -0.0157 -0.0914 -0.0249 -0.3516 -1.0549 -0.0171 -0.5795 -0.1055
S-1307	METHODS AND RESULTS: Western Australian linked administrative health data were used to identify 20 812 consecutive patients, aged 40 to 84 years, without prior HF hospitalized with an index (first) AMI between 1996 and 2007.<unk>
T-1307	western administrative health patients hf hospitalized ami
H-1307	-1.2014892101287842	▁Western _ ▁Australian _ link ed _ administra _ ▁health ▁data ▁ HF ▁index ▁ AMI
D-1307	-1.2014892101287842	Western_ Australian_linked_administra_ health data HF index AMI
P-1307	-1.2153 -1.0137 -3.5453 -0.9957 -0.9603 -0.1376 -0.0452 -0.3423 -2.0158 -2.0784 -2.2698 -0.7294 -4.6894 -1.0914 -0.2921 -0.0186 -0.0946 -0.0919
S-1825	The aims of the present consensus report are to strengthen the connection between certified, experienced centers and those that care for patients irrespective of disease phase and healthcare staff, as well as to raise awareness and provide information regarding conditions in Turkey.<unk>
T-1825	report connection patients disease healthcare conditions turkey
H-1825	-2.2201077938079834	
D-1825	-2.2201077938079834	
P-1825	-4.3749 -0.0653
S-1403	Validating and incorporating nursing-sensitive outcome measures in future prospective experimental research can contribute to the advancement of science regarding effective treatment of older adults hospitalized with HF, while highlighting the contribution of nursing care to outcomes.<unk>
T-1403	outcome prospective hospitalized hf nursing outcomes
H-1403	-1.1916159391403198	▁nur sing - sensitiv e ▁outcome ▁measure s
D-1403	-1.1916159391403198	nursing-sensitive outcome measures
P-1403	-4.0281 -0.0028 -0.0257 -0.0005 -0.0207 -4.2622 -0.4415 -0.0166 -3.0717 -0.0465
S-1310	Between the periods 1996-1998 and 2005-2007, the prevalence of HF after AMI declined from 28.1% to 16.5%, with an adjusted odds ratio of 0.50 (95% CI, 0.44 to 0.55).<unk>
T-1310	prevalence hf ami adjusted_odds_ratio
H-1310	-0.5796718001365662	▁ HF ▁ AMI
D-1310	-0.5796718001365662	HF AMI
P-1310	-0.4724 -0.4254 -0.8015 -0.4812 -1.2412 -0.0563
S-1482	miRNAs are small noncoding RNAs that regulate expression of target genes by sequence-specific binding to the 3' untranslated region of messenger RNA, which results in degradation or translational repression.<unk>
T-1482	mirnas rnas expression genes messenger_rna repression
H-1482	-0.7946890592575073	▁mi RNA s ▁non co ding _ RNA s ▁ binding ▁messenger ▁ RNA ▁degrada tion ▁translation al ▁re pression
D-1482	-0.7946890592575073	miRNAs noncoding_RNAs binding messenger RNA degradation translational repression
P-1482	-0.8546 -0.0004 -0.2812 -3.5125 -0.0019 -0.0584 -0.8709 -0.0189 -0.1031 -2.4861 -2.1994 -0.8211 -0.5494 -0.0010 -2.8997 -0.1316 -0.3835 -0.0206 -2.0496 -0.0112 -0.1701 -0.0579
S-1055	OBJECTIVE: The purpose of this article is to evaluate a free-breathing pulse sequence to quantify myocardial T1 changes in a swine model of tachycardia-induced heart failure.<unk>
T-1055	pulse myocardial_t1 heart_failure
H-1055	-0.42625680565834045	▁free - bre a thing _ ▁puls e ▁se quen nce ▁my o card ial _ ▁T 1 ▁s win e _ model ▁ta chy car dia - indu ced _ heart ▁failure
D-1055	-0.42625680565834045	free-breathing_ pulse sequennce myocardial_ T1 swine_model tachycardia-induced_heart failure
P-1055	-2.1666 -0.0494 -0.0080 -0.0389 -0.3261 -1.1658 -0.1660 -0.0461 -0.7658 -0.2351 -2.4445 -0.8681 -0.0443 -0.0406 -0.0112 -0.4137 -1.4951 -0.1254 -0.0420 -0.0046 -0.0423 -1.5310 -0.4531 -0.4601 -0.0259 -0.0056 -0.0093 -0.1183 -0.0048 -0.1268 -0.1367 -1.0243 -0.3841 -0.0506 -0.0886
S-1173	METHODS: Sixty-one patients with HFpEF were randomly assigned to ivabradine 5 mg twice daily (n = 30) or placebo (n = 31) for 7 days in this double-blind trial.<unk>
T-1173	patients hfpef ivabradine placebo double-blind
H-1173	-0.3989317715167999	▁ HF p EF ▁i va bra dine
D-1173	-0.3989317715167999	HFpEF ivabradine
P-1173	-0.2982 -0.6218 -0.1095 -0.1268 -0.0299 -0.0257 -0.0752 -0.0198 -2.6290 -0.0534
S-229	The adults were more symptomatic than the PF cohort (New York Heart Association classes I and II or III and IV: 48% or 52% [SAF] vs 94% or 6% [PF], respectively, p <0.01).<unk>
T-229	symptomatic new_york_heart_association_classes saf
H-229	-1.0761414766311646	▁ PF _ co hor t ▁New ▁York _ ▁Heart ▁Association
D-229	-1.0761414766311646	PF_cohort New York_ Heart Association
P-229	-0.5420 -0.7239 -3.9762 -0.8121 -0.0131 -0.0279 -2.3421 -0.3776 -0.1802 -1.5524 -0.6232 -2.7718 -0.0472
S-463	Methods and Results—Retrospective cohort of all adults presenting to 93 EDs between 1999 and 2009 with a most responsible diagnosis of heart failure (n=44 925 ED visits; mean age, 76.4 years).<unk>
T-463	retrospective_cohort eds diagnosis heart_failure
H-463	-1.0828081369400024	▁ver tro spec tive _ co hor t ▁ diagnos is _ van _ heart ▁failure
D-463	-1.0828081369400024	vertrospective_cohort diagnosis_van_heart failure
P-463	-6.1160 -0.5468 -0.0346 -0.0948 -0.1766 -0.4817 -0.0164 -0.0935 -4.6270 -2.2535 -0.1700 -1.1490 -0.8857 -0.1044 -1.6489 -0.7873 -0.2345 -0.0699
S-1335	BACKGROUND: Cardiac c-Kit+ cells isolated from cardiac explant-derived cells modestly improve cardiac functions after myocardial infarction; however, their full potential has not yet been realized.<unk>
T-1335	cardiac cells cardiac cells cardiac_functions myocardial_infarction
H-1335	-0.5363094210624695	▁Card iac ▁c - K it _ ▁cell s ▁cardiac ▁ex plant - der i ved _ ▁cell s ▁cardiac ▁function s ▁my o card ial _ in far ction
D-1335	-0.5363094210624695	Cardiac c-Kit_ cells cardiac explant-derived_ cells cardiac functions myocardial_infarction
P-1335	-1.3757 -0.0101 -0.0721 -0.0170 -0.5631 -0.0076 -1.0383 -1.2818 -0.0472 -0.4104 -0.7368 -0.0006 -0.0475 -0.0547 -0.1107 -0.0929 -1.2644 -1.3918 -0.0240 -0.8980 -2.2465 -0.2872 -2.1562 -0.1427 -0.2699 -0.5560 -1.2133 -0.5667 -0.0522 -0.0600 -0.0808 -0.0854
S-2022	It is crucial for nurses to understand the pathophysiology of HF and the importance that nursing actions have on enhancing medical management to alleviate symptoms and to deter the advancement of the pathophysiologic state.<unk>
T-2022	nurses pathophysiology hf nursing medical symptoms pathophysiologic
H-2022	-0.7785214185714722	▁pat ho phy si ology ▁ HF
D-2022	-0.7785214185714722	pathophysiology HF
P-2022	-2.7131 -0.1683 -0.1916 -0.7647 -0.2532 -0.4829 -0.0148 -2.3638 -0.0543
S-1043	The group utilized the recently developed first-in-class inhibitor JQ1, which displaces BETs from chromatin, resulting in the suppression of downstream signalling to RNA polymerase II (Pol II).<unk>
T-1043	jq1 bets chromatin downstream_signalling rna polymerase_ii pol_ii
H-1043	-0.7821023464202881	▁inhibi tor ▁j q 1 ▁ BET s ▁chr omat in ▁down stream _ signal ling ▁ RNA ▁poly mera se Pol ▁II
D-1043	-0.7821023464202881	inhibitor jq1 BETs chromatin downstream_signalling RNA polymerasePol II
P-1043	-2.0411 -0.0034 -1.4231 -0.5263 -0.9115 -1.1902 -0.8252 -2.2000 -0.0334 -0.0091 -0.2527 -4.0113 -0.0023 -0.9523 -0.6432 -0.2700 -0.6112 -0.0049 -0.6875 -0.0145 -0.0189 -2.4741 -0.2351 -0.1501 -0.0611
S-1022	However, levels of NPs are likely to be used also to guide treatment and to assess risk of adverse outcomes in other patients at risk of developing heart failure, including those with pulmonary embolism or diabetes, or receiving chemotherapy.<unk>
T-1022	nps adverse_outcomes patients heart_failure pulmonary_embolism diabetes chemotherapy
H-1022	-0.3521697521209717	▁ NP s ▁pulmonar y ▁e mbol ism ▁diabetes ▁che mo therapy
D-1022	-0.3521697521209717	NPs pulmonary embolism diabetes chemotherapy
P-1022	-0.5745 -0.0069 -0.3279 -2.9034 -0.0166 -0.4171 -0.0007 -0.2277 -0.1422 -0.1553 -0.0241 -0.0093 -0.0580 -0.0667
S-1691	OBJECTIVE: To combine structure, process, and outcome measures into an empirically derived composite quality measure for heart failure (HF), acute myocardial infarction (AMI), and pneumonia (PNA).<unk>
T-1691	outcome heart_failure hf acute_myocardial_infarction ami pneumonia pna
H-1691	-0.7332554459571838	▁em pir ically _ ▁deri ved _ com posit e _ quality _ ▁measure ▁heart ▁failure ▁a cute _ my o card ial _ in far ction ▁pneu monia ▁p NA
D-1691	-0.7332554459571838	empirically_ derived_composite_quality_ measure heart failure acute_myocardial_infarction pneumonia pNA
P-1691	-6.1438 -0.0039 -0.1091 -0.2939 -3.0576 -0.1402 -0.3990 -1.0639 -0.0100 -0.0092 -0.0332 -2.4518 -0.3328 -1.3495 -0.7742 -0.0716 -0.8627 -0.0057 -0.0324 -3.4688 -0.3033 -0.1913 -0.0956 -0.4610 -0.5615 -0.0201 -0.0314 -0.4746 -0.3294 -0.2192 -0.7386 -0.0788 -0.0794
S-1360	This intestinal dysfunction and disturbed intestinal barrier may lead to both the chronic inflammatory state and catabolic/anabolic imbalance as seen in cardiac cachexia, as a terminal stage of CHF, which carries a particularly poor prognosis.<unk>
T-1360	intestinal_dysfunction intestinal lead chronic inflammatory catabolic anabolic cardiac_cachexia terminal chf prognosis
H-1360	-0.5328416228294373	▁intestinal ▁dys function ▁intestinal _ ▁barrier ▁chronic _ ▁infla mma tory _ ▁state ▁cata bo lic _ ana bo lic _ ▁im balance ▁cardiac ▁cache xia ▁CHF
D-1360	-0.5328416228294373	intestinal dysfunction intestinal_ barrier chronic_ inflammatory_ state catabolic_anabolic_ imbalance cardiac cachexia CHF
P-1360	-0.1598 -3.6693 -0.0443 -1.5572 -1.7915 -0.2382 -1.4733 -0.5862 -0.2514 -0.0739 -0.0249 -0.8322 -0.5201 -0.0352 -0.0012 -0.0134 -0.5253 -0.0103 -0.0086 -0.0075 -0.5726 -2.4452 -0.0027 -0.0004 -0.0066 -0.0006 -0.4423 -0.0953 -0.0629
S-780	BACKGROUND: Despite the growing epidemic of heart failure with preserved ejection fraction (HFpEF), no valid measure of patients' health status (symptoms, function, and quality of life) exists.<unk>
T-780	epidemic heart_failure_with_preserved_ejection_fraction hfpef patients health symptoms quality_of_life
H-780	-0.5982967019081116	▁heart ▁failure ▁pres er ved _ e je ction _ fraction HF p EF
D-780	-0.5982967019081116	heart failure preserved_ejection_fractionHFpEF
P-780	-3.9929 -0.5018 -1.2352 -0.0466 -0.3068 -0.0610 -0.8492 -0.1985 -0.0753 -0.4812 -0.0499 -0.6250 -0.0241 -0.0962 -0.9917 -0.0375
S-1209	BACKGROUND: Diminished cyclic adenosine monophosphate (cAMP) and augmented cyclic guanosine monophosphate (cGMP) signaling is characteristic for failing hearts.<unk>
T-1209	cyclic_adenosine_monophosphate camp cyclic_guanosine_monophosphate cgmp hearts
H-1209	-0.4316506087779999	▁ cycli c ▁ad enos ines ▁mono phos pha te ▁c AMP ▁aug mente d ▁ cycli c ▁gua no sine ▁mono phos pha te ▁c G MP
D-1209	-0.4316506087779999	cyclic adenosines monophosphate cAMP augmented cyclic guanosine monophosphate cGMP
P-1209	-1.0047 -0.0743 -0.0287 -0.4389 -0.1988 -2.5061 -0.1076 -0.0041 -0.0066 -0.0556 -0.4974 -0.0020 -1.2496 -0.0091 -0.0014 -1.0703 -0.0056 -0.0166 -1.6258 -0.0083 -0.5411 -0.0764 -0.0028 -0.0065 -0.0635 -0.5576 -1.5029 -0.1381 -1.0270 -0.1223
S-1618	OBJECTIVES: To evaluate mortality and healthcare utilization effects of an intervention that combined care management and telehealth, targeting individuals with congestive heart failure, chronic obstructive pulmonary disease, or diabetes mellitus.<unk>
T-1618	mortality healthcare telehealth congestive_heart_failure chronic_obstructive_pulmonary_disease diabetes_mellitus
H-1618	-1.0591297149658203	▁mortal ity ▁health care ▁utiliza tion
D-1618	-1.0591297149658203	mortality healthcare utilization
P-1618	-1.1421 -0.3808 -1.5889 -0.0292 -0.3101 -0.0286 -4.9508 -0.0426
S-942	OBJECTIVES: This study sought to investigate the efficacy and safety of catheter ablation for atrial fibrillation (AF) in patients with heart failure with preserved ejection fraction (HFPEF).<unk>
T-942	catheter_ablation atrial_fibrillation patients heart_failure_with_preserved_ejection_fraction hfpef
H-942	-0.7194439768791199	▁cat heter ▁ab lation _ voor _ at rial _ fi bril lation AF ▁heart ▁failure ▁pres er ved _ e je ction _ fraction h FP EF
D-942	-0.7194439768791199	catheter ablation_voor_atrial_fibrillationAF heart failure preserved_ejection_fractionhFPEF
P-942	-3.9185 -0.0959 -0.2281 -0.0846 -1.6819 -3.5602 -0.2038 -0.7016 -0.0149 -0.2868 -0.8650 -0.0090 -0.0065 -1.8058 -1.7594 -0.4987 -1.3656 -0.0746 -0.3854 -0.0514 -1.0409 -0.3866 -0.0614 -0.9687 -0.0919 -0.8718 -0.2122 -0.2295 -0.0558 -0.0669
S-998	The described report deals with the case of a patient with diagnosis of ischemic-hypertensive cardiomyiopathy based on the history of angina and inducible myocardial ischemia with normal coronary arteries.<unk>
T-998	report patient diagnosis ischemic-hypertensive_cardiomyiopathy angina myocardial_ischemia coronary_arteries
H-998	-0.3954165279865265	▁ ische mic - hy per tensi ve _ ▁cardio my io pathy ▁ang ina ▁induc ible _ my o card ial _ ische mia ▁corona ry ▁arteri es
D-998	-0.3954165279865265	ischemic-hypertensive_ cardiomyiopathy angina inducible_myocardial_ischemia coronary arteries
P-998	-0.4203 -0.1646 -0.3222 -0.1416 -0.1389 -0.0410 -0.1264 -0.0952 -0.2820 -0.3800 -0.8763 -1.9207 -0.1117 -1.9915 -0.4109 -0.1176 -0.0792 -0.0741 -2.6258 -0.0581 -0.2653 -0.1082 -0.5902 -0.1312 -0.1348 -0.1837 -0.1107 -0.2093 -0.0396 -0.0748 -0.0323
S-604	Subjects with RA receiving methotrexate were eligible to enter the study cohort if they added or switched to a TNF antagonist or another non-biological disease modifying antirheumatic drug (nbDMARD).<unk>
T-604	ra methotrexate tnf_antagonist non-biological_disease_modifying_antirheumatic_drug nbdmard
H-604	-0.6538729071617126	▁met ho tre xa te ▁t NF ▁anta gon ist ▁non - bi ological _ ▁disease ▁mod ifying _ ▁anti r heu matic ▁drug n b DM ARD
D-604	-0.6538729071617126	methotrexate tNF antagonist non-biological_ disease modifying_ antirheumatic drugnbDMARD
P-604	-1.5760 -0.1496 -0.0075 -0.1172 -0.0112 -2.1931 -0.0503 -1.3315 -0.0048 -0.0974 -0.4630 -0.0085 -1.6220 -0.1745 -0.8543 -0.5041 -2.3752 -0.0550 -0.9120 -1.2038 -1.4005 -1.6252 -0.0817 -1.6183 -0.9374 -0.0028 -0.0233 -0.0620 -0.0463 -0.1076
S-104	We used multivariate Cox proportional hazards regression modeling to identify risk factors for the development of IE (comprising hospitalization for acute coronary syndromes and/or coronary interventions during the trial) among study patients.<unk>
T-104	multivariate_cox_proportional_hazards_regression_modeling hospitalization acute_coronary_syndromes coronary_interventions patients
H-104	-0.669516384601593	▁co x ▁proportion al _ ▁hazard s ▁re gression ▁model ing ▁i
D-104	-0.669516384601593	cox proportional_ hazards regression modeling i
P-104	-0.2124 -0.0028 -0.4370 -0.0105 -0.1742 -0.6044 -0.1270 -0.2778 -0.0011 -1.0649 -0.0315 -3.3852 -2.8995 -0.1450
S-1405	BACKGROUND: The sphingosine-1-phosphate receptor 1 (S1PR1) and β1-adrenergic receptor (β1AR) are G-protein-coupled receptors expressed in the heart.<unk>
T-1405	sphingosine-1-phosphate_receptor_1 s1pr1 β1-adrenergic_receptor β1ar g-protein-coupled_receptors heart
H-1405	-0.66374272108078	▁sp hing os ine -1 - phos pha te ▁receptor ▁s 1 PR 1) ▁β 1- ad r energi c ▁receptor β 1 AR ▁g - prote in - co up led _ ▁receptor s ▁heart
D-1405	-0.66374272108078	sphingosine-1-phosphate receptor s1PR1) β1-adrenergic receptorβ1AR g-protein-coupled_ receptors heart
P-1405	-0.0006 -2.1157 -1.7531 -5.6158 -2.0157 -0.2245 -0.0041 -0.0130 -0.0957 -0.0881 -0.6451 -0.2097 -0.0547 -3.8094 -0.0394 -0.4055 -0.0386 -0.3608 -1.4754 -0.0596 -0.9979 -0.2960 -0.1718 -0.1728 -0.7397 -0.0687 -0.0185 -0.1572 -0.0503 -0.0032 -0.0027 -0.1095 -0.4749 -0.8268 -0.2706 -1.6223 -0.1208 -0.0941
S-484	E/e'septal correlated more strongly with PCWP (r = 0.53) compared with E/e'lateral (r = 0.41) and E/e'mean (r = 0.50; all p values <0.001).<unk>
T-484	septal correlated pcwp p_values
H-484	-0.7785255312919617	▁e _ sept al ▁PC WP ▁e / e _ lateral ▁e / e _ me an ▁p
D-484	-0.7785255312919617	e_septal PCWP e/e_lateral e/e_mean p
P-484	-0.8338 -4.6116 -0.1432 -0.0150 -1.0079 -0.1284 -0.2065 -0.7158 -0.0427 -2.8015 -0.0740 -0.2264 -0.5740 -0.0552 -2.4468 -0.0590 -0.1116 -0.6591 -0.6765 -0.1813
S-864	The risk of inappropriate therapy caused by atrial fibrillation was also reduced in patients receiving carvedilol compared with metoprolol (HR: 0.50 [95% CI: 0.32 to 0.81]; p = 0.004).<unk>
T-864	therapy atrial_fibrillation patients carvedilol metoprolol
H-864	-0.467637300491333	▁in appropria te _ therapy ▁at rial _ fi bril lation ▁car vedi lol ▁met o pro lol
D-864	-0.467637300491333	inappropriate_therapy atrial_fibrillation carvedilol metoprolol
P-864	-2.6875 -0.0167 -0.0493 -0.5279 -0.0532 -3.4548 -0.0683 -0.3919 -1.0673 -0.0317 -0.0510 -0.0375 -0.0058 -0.0129 -0.1744 -0.2153 -0.0066 -0.0466 -0.3687 -0.0854
S-820	CONCLUSIONS: GLS was a major parameter and stronger than LVEF and Sa in predicting adverse CV events and could offer an additional prognostic benefit over conventional clinical and echocardiographic systolic parameters in AF.<unk>
T-820	gls lvef prognostic clinical echocardiographic systolic
H-820	-0.7544177770614624	▁g LS ▁LV EF ▁sa
D-820	-0.7544177770614624	gLS LVEF sa
P-820	-0.6140 -0.1120 -0.1869 -0.0220 -0.6856 -3.6182 -0.0422
S-1379	Bradycardia induced by intravenous metoprolol (indicative of cardiac sympathetic tone) was exacerbated in CHF-INV rabbits compared with sham-INV but was normalized in CHF-DNx.<unk>
T-1379	bradycardia intravenous metoprolol cardiac sympathetic_tone
H-1379	-0.3164792060852051	▁Brad y car dia ▁intra ven ous ▁met o pro lol ▁cardiac ▁sympa the tic ▁tone ▁CHF - in v ▁rabbi ts ▁sham - IN v ▁CHF - DN x
D-1379	-0.3164792060852051	Bradycardia intravenous metoprolol cardiac sympathetic tone CHF-inv rabbits sham-INv CHF-DNx
P-1379	-0.2926 -0.0669 -0.0072 -0.0287 -1.1755 -0.0038 -2.6087 -1.0970 -0.1130 -0.0102 -0.0890 -0.0090 -0.7024 -0.0751 -0.3763 -0.5223 -0.0675 -0.0158 -0.8767 -0.4499 -0.1448 -0.0372 -0.0017 -0.0230 -0.5352 -0.2826 -0.0198 -0.0269 -0.1312 -0.0830 -0.1399 -0.1142
S-1849	Outcomes will include proportion of eligible patients who were: prescribed a CPG-recommended pharmacological treatment; referred for device consideration; provided self-care education at discharge; and provided left ventricular function assessment.<unk>
T-1849	outcomes patients prescribed pharmacological discharge left_ventricular_function
H-1849	-0.5129125714302063	▁c PG - re com mend ed _ pharma c ological ▁treatment
D-1849	-0.5129125714302063	cPG-recommended_pharmacological treatment
P-1849	-1.2082 -0.0394 -0.1457 -0.0095 -0.0069 -0.0023 -0.0371 -0.8890 -0.1779 -0.0102 -0.2108 -1.9585 -2.4269 -0.0585
S-569	The purpose of this study was to compare, through a single-centre, parallel-group, randomized controlled trial, the effects of Nordic walking and standard cardiac rehabilitation care on functional capacity and other outcomes in patients with moderate to severe heart failure.<unk>
T-569	randomized walking cardiac_rehabilitation functional_capacity outcomes patients severe_heart_failure
H-569	-1.6338984966278076	▁Nordic _ ▁walking _ standard _ ▁cardiac ▁rehabilita tion
D-569	-1.6338984966278076	Nordic_ walking_standard_ cardiac rehabilitation
P-569	-4.2470 -0.5676 -3.3836 -1.4812 -3.2842 -0.0615 -0.1660 -0.7291 -0.1077 -3.8764 -0.0687
S-1674	Specifically, we have tested whether Rad Q66P limits, or even eliminates, the inhibitory actions of Rad on CaV1.2 and CaV1.3, the two L-type channel isoforms known to be expressed in the heart.<unk>
T-1674	rad q66p rad cav1.2 cav1.3 l-type_channel isoforms heart
H-1674	-0.6876255869865417	▁Rad ▁Q 66 p ▁inhibi tory _ action ▁Rad ▁on ▁ca v 1.2 ▁ca v 1.3 ▁l - type _ ▁channel ▁iso form s ▁heart
D-1674	-0.6876255869865417	Rad Q66p inhibitory_action Rad on cav1.2 cav1.3 l-type_ channel isoforms heart
P-1674	-0.3284 -1.6369 -0.2159 -0.4923 -2.5753 -0.0543 -0.9790 -1.3943 -1.0684 -1.4215 -1.3061 -0.4457 -0.2657 -1.5383 -0.2700 -0.2383 -0.7339 -0.0243 -0.0016 -0.1868 -1.5645 -0.0156 -0.0469 -0.5479 -1.0946 -0.0344 -0.0850
S-512	EF declined from 64 to 41% in the LCX model and to 44% in the LAD model 4 wk after stenting with 12 and 21% infarcted left ventricle in the LCX and LAD models, respectively.<unk>
T-512	ef lcx lad stenting infarcted left_ventricle lcx lad
H-512	-1.021172046661377	▁EF ▁ LC x ▁ LAD
D-512	-1.021172046661377	EF LCx LAD
P-512	-1.2330 -0.4900 -0.0132 -0.8859 -1.4082 -0.3930 -3.6474 -0.0986
S-644	Our results reveal that signalling cascades integrate with microRNAs to induce the expression of the bHLH transcription factor Hand2 in the postnatal mammalian myocardium with impact on embryonic gene programs in heart failure.<unk>
T-644	micrornas expression bhlh transcription_factor hand2 myocardium gene heart_failure
H-644	-0.35519900918006897	▁signal ling ▁casca des ▁micro RNA s ▁b HL h ▁tran scription ▁factor ▁Hand 2 ▁post na tal ▁mamma lian _ my o car dium ▁em bry o nic _ ▁gene ▁programs ▁heart ▁failure
D-644	-0.35519900918006897	signalling cascades microRNAs bHLh transcription factor Hand2 postnatal mammalian_myocardium embryonic_ gene programs heart failure
P-644	-1.9048 -0.0952 -0.0191 -0.0044 -0.0072 -0.0003 -0.1083 -0.0363 -0.0251 -0.2019 -0.3604 -0.0755 -0.4965 -0.9534 -0.2269 -0.0139 -0.1838 -0.0048 -0.2171 -0.1206 -0.5926 -2.3119 -0.0611 -0.0022 -0.1548 -0.2147 -0.0055 -0.0600 -0.4401 -0.1491 -2.2074 -0.4915 -0.2844 -0.6014 -0.0790 -0.0760
S-1254	ERC induced recovery/enhancement of DAPC protein levels, sarcomeric microstructure and, in a co-ordinated fashion, alterations in markers of SkM growth/differentiation consistent with myofibre regeneration.<unk>
T-1254	erc dapc_protein sarcomeric_microstructure skm myofibre_regeneration
H-1254	-0.6610323190689087	▁ ERC ▁DAP c ▁protein ▁levels ▁sar come ric ▁micro structure ▁marker s ▁Sk m
D-1254	-0.6610323190689087	ERC DAPc protein levels sarcomeric microstructure markers Skm
P-1254	-0.3725 -0.0008 -2.4263 -0.4829 -1.0081 -1.0539 -0.0017 -0.0883 -0.1238 -0.1063 -0.0112 -1.2750 -0.0119 -0.5793 -1.1473 -2.5020 -0.0464
S-360	Possible reasons for the modest reduction in MVA could be annular size reduction by the surgical ring implantation and mild restriction of leaflet motion by the leaflet resection and edge-to-edge anastomosis.<unk>
T-360	mva surgical implantation leaflet leaflet edge-to-edge_anastomosis
H-360	-0.48894378542900085	▁m VA ▁sur g ical ▁ring ▁implant ation ▁le a flet _ ▁motion ▁le a flet _ ▁res ection ▁edge - to - ed ge ▁an asto mos is
D-360	-0.48894378542900085	mVA surgical ring implantation leaflet_ motion leaflet_ resection edge-to-edge anastomosis
P-360	-0.7050 -2.5128 -3.4426 -0.0354 -0.0578 -0.8126 -0.1026 -0.0432 -0.0260 -0.0347 -0.0009 -1.2567 -2.4063 -0.6496 -0.0212 -0.0092 -0.7422 -0.4975 -0.0043 -0.1099 -0.0242 -0.0121 -0.0914 -0.0992 -0.0927 -1.1746 -0.0002 -0.0308 -0.0771 -0.0389 -0.0455
S-239	HART enrolled 902 patients in the New York Heart Association (NYHA) class II or III who had been recently hospitalized for HF to study the impact of self-management counseling on the primary outcome of death or HF hospitalization.<unk>
T-239	hart patients new_york_heart_association nyha hospitalized hf primary_outcome death hf hospitalization
H-239	-1.2055745124816895	▁H ART ▁New ▁York _ ▁Heart ▁Association NY HA ▁ HF ▁ HF
D-239	-1.2055745124816895	HART New York_ Heart AssociationNYHA HF HF
P-239	-3.7737 -0.0162 -2.9157 -0.4755 -0.2522 -1.9219 -0.2699 -0.8111 -0.0518 -1.2856 -3.0151 -2.3824 -0.2487 -0.5650 -0.0989
S-1038	show that the BET family bromodomain proteins (BETs), a family of acetyl-lysine reader proteins, are central to HF pathogenesis and that they are promising targets for the prevention of HF.<unk>
T-1038	bet bromodomain_proteins bets acetyl-lysine_reader_proteins hf pathogenesis hf
H-1038	-0.43995821475982666	▁ BET ▁bro modo main _ ▁protein s BET s ▁a ce tyl - ly sine _ ▁reader _ ▁protein s ▁ HF
D-1038	-0.43995821475982666	BET bromodomain_ proteinsBETs acetyl-lysine_ reader_ proteins HF
P-1038	-0.1964 -0.0115 -2.5375 -0.0078 -0.0649 -0.9533 -0.5321 -0.0539 -1.2660 -1.2253 -0.0819 -0.0420 -0.0258 -0.0214 -1.3968 -0.3831 -0.4147 -0.0971 -1.1318 -0.2080 -0.0100 -0.0683 -0.0255 -0.1720 -0.0721
S-1783	In vivo assessment of cardiac function (via echocardiography) demonstrated diastolic dysfunction by 2 weeks (20% increase in E/E'), and systolic dysfunction by 3 weeks (16% decrease in % ejection fraction).<unk>
T-1783	in_vivo cardiac_function echocardiography diastolic_dysfunction systolic_dysfunction ejection_fraction
H-1783	-0.5831263661384583	▁cardiac _ ▁function ▁e cho card i ography ▁dia sto lic _ ▁dys function ▁e / E
D-1783	-0.5831263661384583	cardiac_ function echocardiography diastolic_ dysfunction e/E
P-1783	-0.6322 -1.6317 -0.8253 -0.0656 -0.0110 -0.0349 -0.1301 -0.2214 -0.0346 -0.0075 -0.0610 -0.8661 -0.1093 -0.0154 -0.4156 -3.0505 -0.7600 -2.1455 -0.0615
S-1733	Aldosterone antagonism in heart failure Aldosterone, a neurohormone known to affect electrolytes, has recently been implicated as playing a major role in the progression of heart failure, particularly in patients with systolic dysfunction.<unk>
T-1733	aldosterone_antagonism heart_failure aldosterone neurohormone electrolytes heart_failure patients systolic_dysfunction
H-1733	-0.8166635036468506	▁al do ster one _ ▁anta gon ism ▁heart ▁failure ▁al do ster one ▁neuro hormon e ▁electro ly tes
D-1733	-0.8166635036468506	aldosterone_ antagonism heart failure aldosterone neurohormone electrolytes
P-1733	-1.5824 -0.1560 -0.0316 -0.0863 -3.5644 -1.9332 -0.0117 -0.3946 -3.7565 -0.3499 -2.1317 -0.0204 -0.0075 -0.0787 -0.7651 -0.0093 -0.0431 -0.0091 -0.2160 -0.0230 -2.7274 -0.0688
S-1531	EH was also associated with increased LV compliance compared with CH (LV end-diastolic volume at an idealized LV end-diastolic pressure of 20 mm Hg β coefficient = 14.2; 95% CI 9.4 to 19.1 ml).<unk>
T-1531	lv_compliance lv_end-diastolic_volume lv_end-diastolic_pressure β_coefficient
H-1531	-1.3907655477523804	▁EH ▁LV _ op _ de sto lic _ ▁volume ▁ideal ized _ ▁LV _ en - dia sto lic _ ▁pressure ▁β ▁co e ffi cient
D-1531	-1.3907655477523804	EH LV_op_destolic_ volume idealized_ LV_en-diastolic_ pressure β coefficient
P-1531	-0.1637 -3.8956 -2.8174 -4.1620 -3.3979 -2.5318 -1.7968 -0.0253 -0.3805 -0.1845 -6.1796 -0.1493 -0.8595 -1.4463 -0.5006 -4.8359 -0.4342 -0.0084 -0.0634 -0.0103 -0.1883 -1.0936 -3.3577 -0.8375 -0.1900 -0.0117 -0.0031 -0.6961 -0.1112
S-202	The guidelines have been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, and are accompanied by practical Recommendations for their application in the clinical setting, supplemented by online material.<unk>
T-202	grade clinical
H-202	-0.7269108295440674	▁Grad ing _ re com mend ations ▁ GRAD e
D-202	-0.7269108295440674	Grading_recommendations GRADe
P-202	-1.1126 -0.0571 -0.4991 -1.4342 -0.0092 -0.0048 -0.0020 -3.4983 -0.8709 -0.3318 -0.8447 -0.0582
S-563	Three-year HF hospitalization rates were 24%, 15%, 15%, 22%, and 28% in ages 20 to 39, 40 to 49, 50 to 59, 60 to 69, and ≥70 years, respectively (p < 0.0001).<unk>
T-563	hf hospitalization
H-563	-0.8016504049301147	▁ HF
D-563	-0.8016504049301147	HF
P-563	-0.6337 -0.4164 -2.0326 -0.1239
S-1460	These definitions will form the foundation for describing a uniform nomenclature for right heart circulatory failure with a view to foster collaborative research initiatives and conjoint education in an effort to provide insight into mechanisms of disease unique to the right heart.<unk>
T-1460	right_heart_circulatory_failure disease right_heart
H-1460	-1.655713438987732	▁ richt _ heart ▁circula tory _ ▁failure
D-1460	-1.655713438987732	richt_heart circulatory_ failure
P-1460	-4.3331 -4.7985 -0.7562 -3.9750 -0.6418 -0.1127 -0.5141 -0.0945 -1.2361 -0.0951
S-1671	Ca(2+) influx via L-type voltage-gated Ca(2+) channels supports the plateau phase of ventricular action potentials and is the trigger for excitation-contraction (EC) coupling in the myocardium.<unk>
T-1671	ventricular_action_potentials excitation-contraction myocardium
H-1671	-0.6757798194885254	▁l - type ▁volta ge - ga ted _ ca (2 +) ▁channel s ▁vent ri cular ▁action ▁potential s ▁excita tion - con traction ▁eu car dium
D-1671	-0.6757798194885254	l-type voltage-gated_ca(2+) channels ventricular action potentials excitation-contraction eucardium
P-1671	-4.8747 -0.0145 -0.0007 -0.0983 -0.0276 -0.0206 -0.0058 -0.0075 -2.6017 -0.1801 -0.7988 -0.0113 -2.0805 -0.2420 -0.3199 -0.4659 -0.6526 -0.6705 -2.5899 -0.1184 -0.2874 -0.0843 -0.0391 -0.0150 -0.0520 -2.4213 -1.0073 -0.3222 -0.0976 -0.1659
S-1967	Dual inhibition of AT1 receptors and neprilysin blocks renin-angiotensin-aldosteron (RAS) axis and concurrently supports natural vasodilatory and diuretic effect of natriuretic peptides.<unk>
T-1967	at1_receptors neprilysin renin-angiotensin-aldosteron ras vasodilatory diuretic natriuretic_peptides
H-1967	-0.44640156626701355	▁AT 1 ▁receptor s ▁nepri ly sin ▁block s ▁re nin - angi oten sin - al do ster on ▁ RAS ▁vaso dila tory ▁di ure tic _ pe pti des
D-1967	-0.44640156626701355	AT1 receptors neprilysin blocks renin-angiotensin-aldosteron RAS vasodilatory diuretic_peptides
P-1967	-0.9115 -0.5829 -0.7572 -0.2378 -0.0150 -0.0694 -0.6405 -0.1465 -0.1116 -0.0833 -0.0555 -0.0145 -0.0093 -0.0078 -0.7298 -0.1544 -0.0407 -1.1047 -0.0142 -0.2888 -1.6654 -0.0013 -3.0864 -0.0033 -0.0767 -1.0620 -0.2771 -0.5476 -1.7347 -0.3342 -0.0120 -0.1132 -0.2086 -0.0802
S-1171	OBJECTIVES: The aim of this study was to test the effects of treatment with ivabradine on exercise capacity and left ventricular filling in patients with heart failure with preserved ejection fraction (HFpEF).<unk>
T-1171	ivabradine exercise_capacity left_ventricular_filling patients heart_failure_with_preserved_ejection_fraction hfpef
H-1171	-0.5311763286590576	▁i va bra dine ▁exercise ▁capacity ▁left ▁vent ri cular _ ▁fill ing ▁heart ▁failure ▁pres er ved _ e je ction _ fraction HF p EF
D-1171	-0.5311763286590576	ivabradine exercise capacity left ventricular_ filling heart failure preserved_ejection_fractionHFpEF
P-1171	-0.0427 -0.0308 -0.0464 -0.0283 -4.0148 -0.6858 -0.0600 -0.2786 -0.2605 -0.1948 -1.2731 -0.2056 -0.0100 -1.5066 -0.3950 -0.6455 -0.0569 -0.2299 -0.0847 -1.2520 -0.2583 -0.0555 -1.3492 -0.0954 -2.1212 -0.0886 -0.0329 -0.0314 -0.0696
S-42	Study Selection: English-language trials of blood transfusions, iron, or erythropoiesis-stimulating agents in adults with anemia and congestive heart failure or coronary heart disease and observational studies of transfusion.<unk>
T-42	blood_transfusions erythropoiesis-stimulating_agents anemia congestive_heart_failure coronary_heart_disease transfusion
H-42	-0.5081075429916382	▁blood ▁trans fusion s ▁ir on ▁er y thro po ies is - stimul ating ▁agents ▁an emia ▁con ges tive _ ▁heart ▁failure ▁corona ry _ heart ▁disease ▁trans fusion
D-42	-0.5081075429916382	blood transfusions iron erythropoiesis-stimulating agents anemia congestive_ heart failure coronary_heart disease transfusion
P-42	-6.1480 -0.0218 -0.0052 -0.1861 -0.0563 -0.0321 -0.0734 -0.3497 -0.3354 -0.3646 -0.9197 -0.1650 -0.2651 -0.0190 -0.0899 -1.5711 -0.4873 -0.0025 -0.0155 -0.0504 -0.4783 -0.1898 -1.4524 -0.0138 -0.0033 -0.1498 -0.1945 -0.9596 -1.8338 -0.0901 -0.0152 -0.1775 -0.0515
S-1570	Univariate analysis showed that high BNP was associated with age, estimated glomerular filtration rate, hypertension, and transmitral E-wave/early diastolic mitral annular velocity (E/e') ratio.<unk>
T-1570	univariate_analysis bnp estimated_glomerular_filtration_rate hypertension transmitral e-wave diastolic_mitral_annular_velocity
H-1570	-0.4374532997608185	▁b NP ▁glo mer ular ▁filtr ation ▁rate ▁hyper tension ▁transmit ral _ e - wa ve _ ear ly _ dia sto lic _ met ral _ ▁ann ular _ ▁veloci ty
D-1570	-0.4374532997608185	bNP glomerular filtration rate hypertension transmitral_e-wave_early_diastolic_metral_ annular_ velocity
P-1570	-2.0180 -0.7167 -0.2944 -0.0265 -0.0110 -0.5887 -0.0336 -1.2947 -0.0487 -0.0038 -0.0166 -0.0132 -1.3625 -1.3976 -0.0328 -0.0058 -0.0052 -1.3091 -0.0599 -0.0154 -1.0010 -0.3071 -0.0190 -0.0052 -0.2270 -0.7763 -0.2081 -0.1819 -1.9165 -0.0004 -0.8263 -0.2231 -0.0098 -0.2928 -0.0624
S-1425	Nonetheless, β-blockade does not halt disease progression, suggesting that cAMP-dependent protein kinase (PKA) signaling downstream of β-adrenergic receptor activation may persist through unique post-translational states.<unk>
T-1425	β-blockade halt disease protein_kinase pka β-adrenergic_receptor
H-1425	-0.3588205873966217	▁β - block ade ▁c AMP - dependent _ ▁protein ▁kina se ▁p ka ▁β - ad r energi c _ ▁receptor ▁activa tion
D-1425	-0.3588205873966217	β-blockade cAMP-dependent_ protein kinase pka β-adrenergic_ receptor activation
P-1425	-0.4101 -0.0324 -0.2053 -0.1581 -0.5816 -0.0064 -0.0570 -0.0187 -1.0227 -0.5073 -0.0223 -0.0499 -0.5379 -0.9029 -0.9669 -0.0089 -0.0147 -0.3364 -0.8273 -0.0465 -1.2095 -0.0757 -0.3747 -0.1749 -0.6541 -0.1271
S-47	Moderate- to high-strength evidence from 17 trials of erythropoiesis-stimulating agent therapy found they offered no consistent benefits, but their use may be associated with harms, such as venous thromboembolism.<unk>
T-47	evidence erythropoiesis-stimulating_agent therapy venous_thromboembolism
H-47	-0.46646565198898315	▁er y thro po ies is - stimul ating ▁agent ▁ therapy
D-47	-0.46646565198898315	erythropoiesis-stimulating agent therapy
P-47	-0.6035 -0.1085 -0.2900 -0.4582 -1.0925 -0.1854 -0.0911 -0.0225 -0.1457 -1.1922 -0.6863 -0.0090 -1.5983 -0.0474
S-1456	A combined (clinical and genetic) CHF predictive model performed better [area under the curve (AUC), 0·79] than the genetic (AUC = 0·67) or the clinical (AUC = 0·69) models alone.<unk>
T-1456	clinical genetic chf area_under_the_curve auc genetic auc clinical auc
H-1456	-1.2413063049316406	▁ clin ical _ ▁genetic _ ▁CHF _ ▁predict ive _ model
D-1456	-1.2413063049316406	clinical_ genetic_ CHF_ predictive_model
P-1456	-3.2580 -0.0749 -0.0303 -1.2474 -1.6293 -2.0436 -2.5727 -1.5040 -1.2296 -0.0078 -0.7011 -0.7939 -2.2467 -0.0390
S-1638	After multivariable adjustment, black race was associated with increased mortality/hospitalization (hazard ratio [HR] 1.16, 95% CI 1.01-1.33) and cardiovascular mortality/HF hospitalization (HR 1.46, 95% CI 1.20-1.77).<unk>
T-1638	multivariable_adjustment mortality hospitalization hazard_ratio cardiovascular_mortality hf hospitalization
H-1638	-0.9236747622489929	▁black ▁race ▁mortal ity / hospital ization haz ard ▁ratio ▁cardiovascular _ ▁mortal ity HF
D-1638	-0.9236747622489929	black race mortality/hospitalizationhazard ratio cardiovascular_ mortalityHF
P-1638	-0.0116 -1.1132 -3.6545 -0.4428 -3.3696 -0.0255 -0.3988 -0.0477 -0.0020 -0.5980 -1.8200 -1.3502 -0.1911 -0.4985 -1.5617 -0.5050 -0.1121
S-504	In this study we developed a novel percutaneous one- and two-vessel model for chronic myocardial ischemia using a stent coated with a polytetrafluoroethylene tube formed in a bottleneck shape.<unk>
T-504	percutaneous chronic_myocardial_ischemia stent polytetrafluoroethylene
H-504	-0.588035523891449	▁per cuta ne ous _ ▁one - ve sel _ model ▁chronic _ my o card ial _ ische mia ▁sten t ▁poly te tra flu oro e thy lene _ ▁tube ▁bottle ne ck
D-504	-0.588035523891449	percutaneous_ one-vesel_model chronic_myocardial_ischemia stent polytetrafluoroethylene_ tube bottleneck
P-504	-2.4432 -0.0017 -0.0363 -0.3810 -0.7100 -3.1109 -0.0511 -1.9935 -0.0669 -0.4690 -0.7484 -1.1599 -0.1277 -4.5207 -0.1533 -0.5340 -0.1925 -0.5189 -0.1919 -0.7133 -0.0255 -0.0162 -0.3267 -0.0198 -0.5446 -0.0142 -0.0483 -0.4700 -0.0280 -0.2118 -1.0391 -0.3956 -0.0811 -0.0369 -0.0120 -0.2883 -0.0751
S-1031	The Centers for Medicare and Medicaid Services (CMS) has operationalized hospital quality of care outcomes through publicly reported 30-day risk-standardized mortality and readmission rates and associated penalties for higher-than-expected rates.<unk>
T-1031	centers_for_medicare_and_medicaid_services cms hospital outcomes reported mortality readmission penalties
H-1031	-0.74681556224823	▁Center s _ for ▁Medica re _ ▁Medica id ▁Services ▁c MS
D-1031	-0.74681556224823	Centers_for Medicare_ Medicaid Services cMS
P-1031	-0.5624 -0.0276 -0.6174 -2.7088 -0.8006 -0.0042 -1.3351 -0.7906 -0.1264 -0.2129 -0.2887 -0.2494 -2.6169 -0.1144
S-601	BACKGROUND: While heart failure (HF) is associated with elevations in tumor necrosis factor (TNF)α, several trials of TNF antagonists showed no benefit and possibly worsening of disease in those with known severe HF.<unk>
T-601	heart_failure hf tumor_necrosis_factor tnf tnf_antagonists disease severe_hf
H-601	-0.5651243925094604	▁heart ▁failure ▁ HF ▁tumor ▁nec rosi s ▁factor TN F _ α ▁T NF ▁anta gon ists
D-601	-0.5651243925094604	heart failure HF tumor necrosis factorTNF_α TNF antagonists
P-601	-0.5808 -0.1318 -3.0536 -0.0052 -0.2086 -0.2488 -0.0059 -0.0273 -0.2659 -0.3439 -0.1422 -2.9855 -0.0267 -1.3251 -0.0042 -0.3700 -0.0066 -0.1410 -1.3977 -0.0318
S-1040	These activate a signal transduction cascade that converges on a defined set of transcription factors, and pathological changes in cardiomyocytes occur through an interplay between these transcription factors and epigenetic changes in chromatin structure.<unk>
T-1040	activate signal_transduction transcription_factors pathological cardiomyocytes transcription_factors epigenetic chromatin_structure
H-1040	-0.3910006582736969	▁signal ▁trans duction ▁casca de ▁tran scription ▁factors ▁cardio my o cy tes ▁tran scription ▁factors ▁epi gene tic ▁chr omat in ▁structure
D-1040	-0.3910006582736969	signal transduction cascade transcription factors cardiomyocytes transcription factors epigenetic chromatin structure
P-1040	-0.6119 -0.0277 -0.8201 -0.0742 -0.0050 -0.9464 -0.1096 -0.6742 -0.2816 -0.4691 -0.4614 -0.0593 -0.0780 -0.8964 -0.1528 -0.4777 -0.1585 -0.0204 -0.7681 -1.7522 -0.0154 -0.3588 -0.3319 -0.1383 -0.0859
S-1416	We used Cox proportional hazard models with time-dependent covariates to analyze the effect of follow-up with a familiar physician within the first month after discharge on the primary outcome of death or urgent all-cause readmission over 6 months.<unk>
T-1416	cox_proportional_hazard_models covariates follow-up physician discharge primary_outcome death all-cause_readmission
H-1416	-0.7022157907485962	▁co x ▁proportion al _ ▁hazard ▁models
D-1416	-0.7022157907485962	cox proportional_ hazard models
P-1416	-0.1501 -0.0016 -0.0850 -0.0048 -0.1268 -0.3640 -1.1479 -4.3499 -0.0900
S-1760	At multivariable logistic analysis, failure in detecting AT resulted significantly in reduced peak oxygen uptake and higher metabolic exercise and cardiac and kidney index score value, a powerful prognostic composite HF index (P<0.001).<unk>
T-1760	multivariable_logistic_analysis peak_oxygen_uptake metabolic_exercise cardiac kidney prognostic hf_index
H-1760	-2.8123810291290283	▁ nc _ monitor ing _ analyse
D-1760	-2.8123810291290283	nc_monitoring_analyse
P-1760	-3.7570 -5.8971 -2.7961 -4.1117 -0.3281 -2.9124 -0.4187 -5.0360 -0.0544
S-334	The mechanism is a combination of annular size reduction by surgery and diastolic mitral valve tethering, restricting the anterior leaflet opening due to posteriorly displaced papillary muscles with left ventricular dilatation.<unk>
T-334	combination surgery diastolic_mitral_valve_tethering anterior_leaflet papillary_muscles left_ventricular_dilatation
H-334	-0.4398088753223419	▁ann ular _ ▁size ▁re duction ▁dia sto lic _ ▁mit ral _ ▁val ve ▁te ther ing ▁anterior ▁le a flet ▁opening ▁posterior ly ▁dis place d _ ▁papil lar y ▁muscle s ▁left ▁vent ri cular ▁di la tation
D-334	-0.4398088753223419	annular_ size reduction diastolic_ mitral_ valve tethering anterior leaflet opening posteriorly displaced_ papillary muscles left ventricular dilatation
P-334	-0.3986 -0.0002 -1.6616 -0.5678 -0.2424 -0.0031 -0.5417 -0.0051 -0.0123 -0.2532 -1.5275 -0.0158 -0.4039 -1.0451 -0.0513 -0.1298 -0.0370 -0.0153 -0.5897 -1.2709 -0.0363 -0.0004 -0.0671 -1.0272 -0.8373 -0.9157 -0.0582 -0.0256 -1.2532 -0.3191 -0.0915 -0.2364 -1.0178 -0.1829 -0.1045 -0.9054 -0.2295 -0.1239 -2.4196 -0.1161 -0.0012 -0.1055 -0.0654
S-926	CONCLUSIONS: In patients with hypertensive HFPEF, the sodium-restricted DASH diet was associated with favorable changes in ventricular diastolic function, arterial elastance, and ventricular-arterial coupling.<unk>
T-926	patients hypertensive_hfpef dash ventricular_diastolic_function arterial_elastance ventricular-arterial_coupling
H-926	-0.367939293384552	▁hyper tensi ve ▁H FP EF ▁so dium - re strict ed ▁DAS h ▁vent ri cular ▁dia sto lic ▁function ▁arterial ▁elastan ce ▁vent ri cular - arte rial ▁coup ling
D-926	-0.367939293384552	hypertensive HFPEF sodium-restricted DASh ventricular diastolic function arterial elastance ventricular-arterial coupling
P-926	-1.1462 -0.1570 -0.0335 -0.6723 -0.0658 -0.0792 -0.0053 -0.0270 -0.0025 -0.0047 -0.0047 -0.0137 -0.8995 -0.3835 -1.8250 -0.3759 -0.0846 -1.1947 -0.0139 -0.0171 -2.5515 -0.0064 -0.2511 -0.1002 -0.0027 -0.5174 -0.1048 -0.1437 -0.0451 -0.0094 -1.3284 -0.2767 -0.1188 -0.0476
S-1450	We examined the association between the development of CHF after HCT and polymorphisms in 16 candidate genes involved in anthracycline metabolism, iron homeostasis, anti-oxidant defence, and myocardial remodelling.<unk>
T-1450	chf hct polymorphisms genes anthracycline metabolism iron_homeostasis anti-oxidant_defence myocardial_remodelling
H-1450	-0.5081362128257751	▁CHF ▁CHF ▁h CT ▁an thra cycli ne ▁metabolism ▁ir on _ ▁home osta sis ▁anti - oxid ant _ ▁de fen ce ▁my o card ial ▁remodel ling
D-1450	-0.5081362128257751	CHF CHF hCT anthracycline metabolism iron_ homeostasis anti-oxidant_ defence myocardial remodelling
P-1450	-0.3066 -1.7020 -5.2742 -0.6406 -1.3658 -0.0030 -0.0282 -0.4566 -0.8089 -0.0510 -0.0181 -1.3229 -0.7974 -0.0418 -0.0270 -0.0007 -0.0133 -0.0010 -0.0129 -0.7183 -0.8686 -0.0124 -0.2874 -0.3007 -0.0348 -0.2081 -0.0858 -0.1599 -0.0426 -0.1200 -0.0417
S-1187	Using multivariate logistic regression analysis, we derived a prediction rule for severe CAD (≥50% diameter stenosis in the left main, 3-vessel CAD, and 2-vessel CAD involving the proximal left anterior descending artery).<unk>
T-1187	multivariate_logistic_regression_analysis rule cad stenosis 3-vessel_cad 2-vessel_cad left_anterior_descending_artery
H-1187	-1.3565574884414673	▁ europe se _ ▁logistic ▁re gression _ analyse ▁severe _ ▁CAD ▁diameter _ ▁sten osis ▁3- ves sel _ ▁CAD ▁proxima l _ ▁left _ ▁anterior _ ▁descend ing ▁arter y
D-1187	-1.3565574884414673	europese_ logistic regression_analyse severe_ CAD diameter_ stenosis 3-vessel_ CAD proximal_ left_ anterior_ descending artery
P-1187	-3.6995 -6.4303 -0.0615 -0.4200 -3.8644 -0.1624 -0.0018 -4.5945 -0.0703 -3.8848 -0.5296 -1.0485 -2.7991 -0.6774 -0.3495 -0.0091 -5.6366 -0.0985 -0.0015 -0.9419 -0.4203 -0.5075 -0.0024 -0.0856 -4.1403 -0.1975 -4.2414 -0.6120 -0.1158 -0.0135 -0.2611 -0.0421 -0.1476 -0.0545
S-1305	Trends from 1996 to 2007 in incidence and mortality outcomes of heart failure after acute myocardial infarction: a population-based study of 20,812 patients with first acute myocardial infarction in Western Australia.<unk>
T-1305	incidence mortality outcomes heart_failure acute_myocardial_infarction patients acute_myocardial_infarction western_australia
H-1305	-1.03634512424469	▁heart ▁failure ▁a cute _ my o card ial _ in far ction
D-1305	-1.03634512424469	heart failure acute_myocardial_infarction
P-1305	-4.2490 -0.4219 -1.5350 -0.0113 -0.0453 -4.7840 -0.3335 -0.6472 -0.3133 -0.4746 -0.3672 -0.0637 -0.1507 -2.0394 -0.1091
S-1735	The first was the Randomized Aldactone Evaluation Study, which was done in symptomatic chronic advanced heart failure patients and showed that an aldosterone antagonist, spironolactone, reduced mortality significantly compared with placebo.<unk>
T-1735	randomized_aldactone_evaluation_study symptomatic_chronic_advanced_heart_failure patients aldosterone_antagonist spironolactone mortality placebo
H-1735	-0.6552091836929321	▁Rand om ized _ al da cto ne ▁Evalua tion ▁Study ▁symptom a tic ▁chronic _ ▁advanced _ heart ▁failure ▁patients ▁al do ster one ▁anta gon ist ▁spi rono lac tone
D-1735	-0.6552091836929321	Randomized_aldactone Evaluation Study symptomatic chronic_ advanced_heart failure patients aldosterone antagonist spironolactone
P-1735	-4.6246 -0.0850 -0.0624 -0.9650 -1.0574 -0.1158 -0.0187 -0.3940 -0.3678 -0.0810 -1.0495 -2.4614 -0.0491 -0.1715 -2.6701 -0.2239 -1.4962 -0.0763 -1.3861 -0.4125 -1.9489 -0.2684 -0.1433 -0.0171 -0.1937 -0.6858 -0.0041 -0.2139 -0.0003 -0.0022 -0.0075 -0.0399 -0.8978 -0.0858
S-559	They were less likely to adhere to medication (nonadherence in youngest vs. oldest: 24% vs. 7%, p = 0.001), salt intake, and other dietary measures (21% vs. 9%, p = 0.002).<unk>
T-559	medication
H-559	-1.8974661827087402	▁medication no nadh er ence
D-559	-1.8974661827087402	medicationnonadherence
P-559	-2.3325 -2.1781 -3.1778 -0.0228 -2.7382 -2.6562 -0.1766
S-1278	Given the different pathophysiological origin, a multivariate assessment with the inclusion of all the aforementioned parameters should be encouraged, not only for diagnostic and prognostic purposes but also for evaluating the effect of interventions.<unk>
T-1278	pathophysiological diagnostic prognostic
H-1278	-0.9104530215263367	▁pat ho phy si ological
D-1278	-0.9104530215263367	pathophysiological
P-1278	-0.9576 -0.4153 -0.3064 -0.9197 -0.2664 -3.4586 -0.0491
S-534	Survival after LVAD surgery was better in patients with normal albumin levels compared with those with hypoalbuminemia before surgery (3 and 12 months: 93.2% vs 82.4% and 88.4% vs 75.2%, respectively, p <0.001).<unk>
T-534	lvad surgery patients albumin hypoalbuminemia surgery
H-534	-1.1138696670532227	▁l VAD ▁album in ▁levels ▁hypo album in emia
D-534	-1.1138696670532227	lVAD albumin levels hypoalbuminemia
P-534	-1.3026 -0.0373 -4.8740 -0.0926 -5.1343 -0.0457 -0.0654 -0.0327 -0.0205 -0.5458 -0.1017
S-310	We systematically searched the scientific literature (January 2008-June 2012) and identified 14 clinical studies (approximately 2900 HM II and approximately 200 HeartWare patients), and 3 economic evaluations (HM II) using simulation models.<unk>
T-310	clinical hm_ii heartware patients economic hm_ii
H-310	-1.4247976541519165	▁scientific _ ▁literature ▁ HM _ ▁II ▁Heart War e
D-310	-1.4247976541519165	scientific_ literature HM_ II HeartWare
P-310	-1.0660 -2.8252 -0.7601 -0.4921 -0.1291 -2.6315 -1.8631 -3.3744 -0.0293 -0.0673 -3.7999 -0.0595
S-717	In a multivariate model that included listing criteria, creatinine (hazard ratio, 1.05 per 0.1 mg/dL; 95% confidence interval, 1.02-1.09; P=0.001) was a significant predictor of post-transplant mortality.<unk>
T-717	multivariate_model creatinine hazard_ratio confidence_interval mortality
H-717	-0.7161949872970581	▁creati nine haz ard _ ▁ratio
D-717	-0.7161949872970581	creatininehazard_ ratio
P-717	-0.2751 -0.0850 -0.1886 -0.0023 -1.9601 -0.0177 -3.0883 -0.1125
S-313	Although complications after implantation are frequent, LVAD therapy is often highly effective across transplantation eligibility status and device, with 1-year survival reaching 86% for BTT and 78% for DT (compared with 25% for medical therapy).<unk>
T-313	complications implantation lvad_therapy transplantation btt dt medical_therapy
H-313	-0.6997032165527344	▁l VAD ▁ therapy ▁transplant ation ▁e ligi bility ▁status ▁b TT ▁medical ▁ therapy
D-313	-0.6997032165527344	lVAD therapy transplantation eligibility status bTT medical therapy
P-313	-1.4453 -0.0112 -0.7551 -0.0092 -2.3246 -0.0317 -0.4015 -0.0037 -0.0990 -0.5171 -3.1715 -0.5059 -2.0270 -0.4648 -0.0067 -0.0795 -0.0412
S-580	METHODS: Clinical, biologic, and radial artery tonometry variables were prospectively obtained at admission and at day 3 to 5 in 53 consecutive patients with PH admitted to our ICU for clinical deterioration.<unk>
T-580	clinical artery_tonometry prospectively admission patients icu clinical
H-580	-0.9388852715492249	▁bio c ▁radi al ▁arter y _ ▁ton ometr y
D-580	-0.9388852715492249	bioc radial artery_ tonometry
P-580	-3.9124 -0.5191 -0.4814 -0.0298 -1.7042 -0.1398 -1.3481 -0.3402 -0.0410 -0.0532 -2.6385 -0.0589
S-1591	Future randomized trials using HR variability/turbulence as one of the pre-defined inclusion criteria will show whether routine measurement of HR variability/turbulence will become a routine clinical tool for risk stratification of cardiac patients.<unk>
T-1591	randomized hr_variability hr_variability clinical risk_stratification cardiac patients
H-1591	-1.0020095109939575	▁HR ▁variabil ity _ tur bul ence
D-1591	-1.0020095109939575	HR variability_turbulence
P-1591	-2.4257 -0.2722 -0.7351 -1.3018 -0.0236 -0.0587 -1.8165 -2.1273 -0.2571
S-72	IMPORTANCE: Small studies suggest that low-dose dopamine or low-dose nesiritide may enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction; however, neither strategy has been rigorously tested.<unk>
T-72	dopamine nesiritide renal_function patients acute_heart_failure renal_dysfunction
H-72	-1.0096904039382935	▁low - dos e ▁dop amine ▁nesi riti de ▁renal _ function
D-72	-1.0096904039382935	low-dose dopamine nesiritide renal_function
P-72	-3.4562 -0.0124 -1.2636 -0.1663 -0.4249 -0.0229 -4.2053 -0.0043 -0.0557 -0.4629 -2.8115 -0.7890 -0.4161 -0.0445
S-977	The risk of death was significantly increased in patients with estimated glomerular filtration rate of 15 to 45 ml/min/1.73 m(2) (odds ratio 1.76, 95% confidence interval 1.38 to 2.25) even after adjustment for all confounders.<unk>
T-977	death patients estimated_glomerular_filtration_rate odds_ratio confidence_interval
H-977	-1.0045567750930786	▁risk _ of _ ▁death ▁glo mer ular _ ▁filtr ation _ ▁rate
D-977	-1.0045567750930786	risk_of_ death glomerular_ filtration_ rate
P-977	-1.0567 -1.9837 -1.7533 -0.6148 -0.2965 -1.6445 -0.0850 -0.0416 -0.1643 -2.1792 -0.1631 -2.4318 -0.2771 -2.1786 -0.1981
S-672	Breast cancer patients at least 66 years old with full Medicare coverage, diagnosed with stage I-III breast cancer between 2005 and 2009, and treated with chemotherapy were identified in the SEER-Medicare and in the Texas Cancer Registry–Medicare databases.<unk>
T-672	breast_cancer patients medicare diagnosed breast_cancer chemotherapy seer-medicare texas medicare
H-672	-0.629876971244812	▁breast ▁cancer ▁patients ▁full ▁Medica re ▁coverage ▁stage ▁I - III ▁breast ▁cancer ▁che mo therapy ▁s EER - Medic are ▁Texas _ cancer ▁Registr y _ Medic are
D-672	-0.629876971244812	breast cancer patients full Medicare coverage stage I-III breast cancer chemotherapy sEER-Medicare Texas_cancer Registry_Medicare
P-672	-3.1648 -0.8437 -0.9779 -0.7896 -0.1190 -0.0028 -0.3729 -3.6410 -1.4418 -0.0244 -0.0272 -0.4448 -0.2622 -0.5527 -0.0579 -0.0336 -0.7228 -0.0039 -0.0319 -0.0399 -0.1524 -0.1124 -0.7953 -2.0218 -0.7352 -0.0062 -0.7942 -0.1285 -0.1146 -1.0161 -0.0947
S-995	ERK1/2 signalling requires a signalosome complex where a scaffold protein drives the assembly of these three kinases into a linear pathway to facilitate their sequential phosphorylation, ultimately targeting specific effector molecules.<unk>
T-995	signalosome_complex scaffold_protein drives kinases phosphorylation effector_molecules
H-995	-0.622595489025116	▁e RK 1/2 ▁signal ling ▁sc af fold ▁protein ▁kina ses ▁sequenti al _ phos phor y lation ▁effect or ▁mole cules
D-995	-0.622595489025116	eRK1/2 signalling scaffold protein kinases sequential_phosphorylation effector molecules
P-995	-1.6760 -0.0072 -0.5847 -0.4764 -1.0734 -4.6303 -0.2152 -0.1284 -0.9107 -0.4155 -0.4163 -0.1021 -0.0201 -0.8427 -0.0351 -0.3217 -1.3630 -0.0722 -1.1365 -0.0299 -0.2984 -0.0036 -0.0946 -0.0885
S-2006	CONCLUSIONS: The results show that the fully magnetically levitated centrifugal-flow chronic LVAS is safe, with high 30-day and 6-month survival rates, a favorable adverse event profile, and improved quality of life and functional status.<unk>
T-2006	fully_magnetically_levitated_centrifugal-flow_chronic_lvas adverse_event quality_of_life functional_status
H-2006	-0.7335222363471985	▁magnet ically ▁le vita ted ▁centri fu gal - flow ▁chronic _ L VAS
D-2006	-0.7335222363471985	magnetically levitated centrifugal-flow chronic_LVAS
P-2006	-2.5234 -0.0931 -0.7690 -0.0205 -0.0648 -1.3865 -0.1421 -0.0626 -0.1210 -0.0270 -2.9961 -0.8390 -2.1659 -0.0392 -0.4353 -0.0508
S-1215	In diseased cardiomyocytes, higher PDE2 activity could be further enhanced by stimulation of cGMP synthesis via nitric oxide donors, whereas specific PDE2 inhibition partially restored β-AR responsiveness.<unk>
T-1215	diseased cardiomyocytes pde2 activity cgmp_synthesis nitric_oxide donors pde2_inhibition β-ar_responsiveness
H-1215	-0.4840528070926666	▁disease d ▁cardio my o cy tes ▁p de 2 ▁activity ▁c G MP ▁ni tric ▁oxid e ▁donor s ▁p de 2 ▁inhibi tion ▁β - AR
D-1215	-0.4840528070926666	diseased cardiomyocytes pde2 activity cGMP nitric oxide donors pde2 inhibition β-AR
P-1215	-1.8124 -0.0920 -0.4946 -0.9492 -0.8797 -0.0939 -0.0705 -0.6843 -0.9268 -0.0345 -3.5354 -0.0246 -0.8818 -0.1844 -0.1851 -0.0241 -0.0297 -0.0569 -0.0699 -0.1063 -0.7175 -1.1332 -0.0639 -0.4040 -0.0901 -0.0497 -0.0057 -0.1046 -0.7202 -0.0966
S-186	Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with inhospital outcomes: findings from the Get With The Guideline-Heart Failure Registry.<unk>
T-186	ejection_fraction b-type_natriuretic_peptide patients hospitalized heart_failure inhospital outcomes get_with_the_guideline-heart_failure_registry
H-186	-0.6080707311630249	▁e je ction ▁ fraction ▁na tri ure tic _ pe pti de ▁patients ▁hospital ized ▁heart ▁failure ▁in hospital ▁outcome s ▁Guide line - He art _ ▁Fail ure ▁Registr y
D-186	-0.6080707311630249	ejection fraction natriuretic_peptide patients hospitalized heart failure inhospital outcomes Guideline-Heart_ Failure Registry
P-186	-1.0571 -0.0346 -0.0049 -0.3033 -0.0011 -0.5959 -0.0254 -0.4790 -0.7345 -0.6215 -0.3011 -0.0065 -0.0783 -2.6152 -1.4445 -0.1287 -2.8223 -0.2501 -0.3921 -0.1362 -1.8865 -0.0288 -2.0450 -0.0058 -0.7182 -0.9205 -0.4355 -1.2776 -0.2891 -0.4880 -0.3493 -0.0317 -0.0482 -0.1178
S-1404	beta1-adrenergic receptor and sphingosine-1-phosphate receptor 1 (S1PR1) reciprocal downregulation influences cardiac hypertrophic response and progression to heart failure: protective role of S1PR1 cardiac gene therapy.<unk>
T-1404	beta1-adrenergic_receptor sphingosine-1-phosphate_receptor_1 s1pr1 downregulation cardiac hypertrophic heart_failure s1pr1 cardiac gene therapy
H-1404	-0.8030782341957092	▁beta 1- ad r energi c ▁receptor ▁sp hing os ine -1 - phos pha te ▁receptor ▁s 1 PR _ ▁reciproc al _ ▁down regul ation ▁cardiac ▁hyper trop hic ▁response ▁heart ▁failure ▁s 1 PR 1 ▁cardiac ▁gene ▁ therapy
D-1404	-0.8030782341957092	beta1-adrenergic receptor sphingosine-1-phosphate receptor s1PR_ reciprocal_ downregulation cardiac hypertrophic response heart failure s1PR1 cardiac gene therapy
P-1404	-4.9877 -1.1715 -0.0824 -0.2338 -0.2521 -0.0439 -0.3502 -0.0011 -0.7305 -0.6579 -3.9190 -1.6798 -0.2413 -0.0007 -0.0058 -0.0936 -0.0441 -0.4004 -0.2186 -0.3935 -5.0242 -1.4248 -0.0034 -0.2551 -0.9813 -0.0457 -0.0388 -0.0111 -0.4206 -0.0011 -0.1499 -3.5672 -2.7384 -0.6226 -1.4954 -0.0988 -0.0808 -1.7809 -0.0663 -0.6737 -0.2089 -0.0047 -0.0801 -0.0540
S-251	ECs were incubated with HDL, and phosphorylation of eNOS-Ser(1177), eNOS-Thr(495), PKC-βII-Ser(660), and p70S6K-Ser(411) was evaluated.<unk>
T-251	ecs hdl phosphorylation
H-251	-0.38330671191215515	▁EC s ▁HD L ▁ phos phor y lation ▁e NOS - Ser ▁e NOS - Th r ▁PK c - β II - Ser ▁p 70 s 6 k - Ser
D-251	-0.38330671191215515	ECs HDL phosphorylation eNOS-Ser eNOS-Thr PKc-βII-Ser p70s6k-Ser
P-251	-1.4584 -2.1389 -0.8800 -1.0290 -0.0206 -0.0020 -0.0350 -0.4177 -0.1145 -0.0098 -0.0223 -0.0475 -0.2704 -0.0150 -0.0185 -0.0436 -0.3333 -0.0017 -0.0267 -0.5648 -0.1348 -0.7363 -0.6808 -0.0515 -0.0499 -0.0561 -0.4293 -0.5968 -0.1855 -2.0233 -0.0427 -0.2639 -0.1968 -0.1350
S-155	RESULTS: Twenty-one RCTs that enrolled 6317 patients were identified (11 studies evaluated STS (10 of which were HH, while 1 was HM), 9 studies assessed TM, and 1 study assessed both STS and TM).<unk>
T-155	rcts patients sts hh sts
H-155	-1.352588176727295	▁s ts ▁ HH ▁ HM
D-155	-1.352588176727295	sts HH HM
P-155	-4.2142 -0.8110 -0.8350 -0.3428 -2.8675 -0.1520 -1.5471 -0.0511
S-417	In adult mouse ventricular myocytes, it dose dependently increased sarcomere shortening by 75% to 210% (50-500 μmol/L), with a ≈30% rise in the peak Ca(2+) transient only at higher doses.<unk>
T-417	ventricular_myocytes sarcomere shortening
H-417	-0.5503632426261902	▁mouse ▁vent ri cular _ my o cy tes ▁sar com ere
D-417	-0.5503632426261902	mouse ventricular_myocytes sarcomere
P-417	-0.6140 -0.0506 -0.2814 -0.2905 -0.5094 -2.1483 -0.0693 -0.0567 -0.0633 -0.3097 -0.0209 -0.0380 -3.1919 -0.0610
S-1415	METHODS: We used data from linked administrative databases for all adults aged 20 years or more in the province of Alberta who were discharged alive from hospital between January 1999 and June 2009 with a first-time diagnosis of heart failure.<unk>
T-1415	administrative alberta discharged hospital diagnosis heart_failure
H-1415	-1.7040653228759766	▁administratie ▁database s ▁provincial _ ▁Albert a
D-1415	-1.7040653228759766	administratie databases provincial_ Alberta
P-1415	-5.3581 -1.4095 -0.1343 -3.5547 -1.3260 -0.8058 -0.0515 -2.6614 -0.0353
S-829	Low PASP was associated with a significantly lower 6-minute walking distance, peak o2 per kilogram, and 1-, 3-, and 4-year survival rates (92%, 69%, and 48%, respectively, versus 96%, 92%, and 89%).<unk>
T-829	pasp 6-minute_walking_distance peak_o2
H-829	-1.349597454071045	▁pas p
D-829	-1.349597454071045	pasp
P-829	-2.0676 -0.8358 -2.4131 -0.0818
S-757	After adjusting for important covariates, the CRT ON assignment remained independently associated with improved time to death or first HF hospitalization (hazard ratio, 0.54; P=0.035), whereas there was no significant interaction with LVEF.<unk>
T-757	covariates crt death hf hospitalization hazard_ratio lvef
H-757	-0.9376890659332275	▁c RT _ on _ ▁assign ment
D-757	-0.9376890659332275	cRT_on_ assignment
P-757	-0.3771 -0.2044 -2.6986 -0.2391 -0.7892 -0.2307 -0.0082 -3.8531 -0.0388
S-1062	The animals with heart failure also had a difference histologically in the percentage of myocardial collagen compared with tissue from healthy control animals (control, 5.4% ± 1.0%; heart failure, 9.4% ± 1.6%; p < 0.001).<unk>
T-1062	heart_failure histologically myocardial_collagen healthy heart_failure
H-1062	-1.749192237854004	▁animals ▁my o card ial ▁collage n
D-1062	-1.749192237854004	animals myocardial collagen
P-1062	-4.2042 -6.1601 -0.2412 -0.1034 -0.0899 -0.5492 -0.0626 -4.2121 -0.1199
S-656	L-DKO mice had decreased cardiac IRS1 and IRS2 proteins and exhibited features of heart failure, with impaired cardiac energy metabolism gene expression and activation of p38α mitogen-activated protein kinase (p38).<unk>
T-656	l-dko cardiac irs1 irs2 proteins heart_failure cardiac_energy_metabolism_gene_expression p38α mitogen-activated_protein_kinase p38
H-656	-0.583107054233551	▁l - d ko _ mi ce ▁cardiac ▁I RS 1 ▁I RS 2 ▁protein s ▁heart ▁failure ▁cardiac _ energie ▁metabolism ▁p 38 α ▁mit ogen - activa ted _ ▁protein ▁kina se
D-656	-0.583107054233551	l-dko_mice cardiac IRS1 IRS2 proteins heart failure cardiac_energie metabolism p38α mitogen-activated_ protein kinase
P-656	-2.1328 -0.0755 -1.4368 -0.4130 -2.4514 -0.5787 -0.1594 -0.1340 -0.7248 -0.0107 -1.5588 -1.4688 -0.0307 -0.0829 -1.6172 -0.0399 -1.4558 -0.4480 -1.5707 -0.8962 -1.2049 -0.4350 -0.0498 -0.2101 -0.1039 -0.6134 -0.0214 -0.0882 -0.0015 -0.1132 -0.3433 -0.3387 -0.0066 -0.0102 -0.0928 -0.0724
S-967	In conclusion, nicorandil was effective against the development of doxorubicin-induced heart failure in rats as indicated by improvement of hemodynamic perturbations, mitochondrial dysfunction and ultrastructural changes without affecting its antitumor activity.<unk>
T-967	nicorandil heart_failure hemodynamic mitochondrial_dysfunction antitumor activity
H-967	-0.17484836280345917	▁nic oran dil ▁do xor ubi cin - indu ced _ heart ▁failure ▁rat s ▁hem o dynamic ▁perturba tions ▁mito cho ndri al ▁dys function ▁ultra struct ural ▁anti tum or
D-967	-0.17484836280345917	nicorandil doxorubicin-induced_heart failure rats hemodynamic perturbations mitochondrial dysfunction ultrastructural antitumor
P-967	-0.1884 -0.0020 -0.0205 -0.0266 -0.0011 -0.0044 -0.1631 -0.0564 -0.0046 -0.1756 -0.1334 -0.9647 -0.2939 -2.0261 -0.0314 -0.0767 -0.0182 -0.0002 -0.1872 -0.0944 -0.0003 -0.0345 -0.0086 -0.0166 -0.4753 -0.0080 -0.0095 -0.0053 -0.0044 -0.0395 -0.0985 -0.0116 -0.7168 -0.0471
S-1646	RATIONALE: Rhythm control therapy applied early after the first diagnosis of AF could preserve atrial structure and function and maintain sinus rhythm more effectively than the current practice of delayed rhythm control (when symptoms persist after otherwise effective rate control).<unk>
T-1646	rhythm_control_therapy diagnosis atrial sinus_rhythm rhythm_control symptoms rate_control
H-1646	-1.0333856344223022	▁ Rhythm ▁control ▁ therapy
D-1646	-1.0333856344223022	Rhythm control therapy
P-1646	-0.2810 -0.6603 -1.3866 -0.3312 -0.0093 -4.5010 -0.0643
S-1540	The relative risk (RR) of heart failure was significantly increased in users of bisphophonates: crude RR 1.71 [95% confidence interval (CI) 1.63-1.79]; adjusted hazard ratio (HR) 1.41 (95% CI 1.34-1.48).<unk>
T-1540	relative_risk rr heart_failure bisphophonates rr confidence_interval hazard_ratio
H-1540	-1.0603116750717163	▁ RR _ van _ heart ▁failure ▁bis pho phon ates ▁cru de _ RR
D-1540	-1.0603116750717163	RR_van_heart failure bisphophonates crude_RR
P-1540	-2.7035 -0.1934 -3.3635 -1.6551 -0.2423 -1.2520 -1.0412 -2.9736 -0.0175 -0.3168 -0.5994 -0.1017 -0.0077 -0.3099 -0.3007 -2.8122 -0.1348
S-1841	Effectiveness of implementation strategies in improving physician adherence to guideline recommendations in heart failure: a systematic review protocol Introduction The uptake of Clinical Practice Guideline (CPG) recommendations that improve outcomes in heart failure (HF) remains suboptimal.<unk>
T-1841	physician heart_failure clinical_practice_guideline cpg outcomes heart_failure hf
H-1841	-0.8383403420448303	▁physician ▁ad her ence ▁guide line _ ▁recommendations ▁heart ▁failure
D-1841	-0.8383403420448303	physician adherence guideline_ recommendations heart failure
P-1841	-2.8590 -0.0388 -0.0496 -0.2374 -0.3381 -0.0051 -0.7500 -1.4747 -1.8385 -0.1373 -2.2543 -0.0772
S-83	CONCLUSION AND RELEVANCE: In participants with acute heart failure and renal dysfunction, neither low-dose dopamine nor low-dose nesiritide enhanced decongestion or improved renal function when added to diuretic therapy.<unk>
T-83	acute_heart_failure renal_dysfunction dopamine nesiritide renal_function diuretic therapy
H-83	-0.5691608190536499	▁a cute _ heart ▁failure ▁renal ▁dys function ▁low - dos e ▁dop amine ▁nesi riti de ▁renal ▁function ▁di ure tic ▁ therapy
D-83	-0.5691608190536499	acute_heart failure renal dysfunction low-dose dopamine nesiritide renal function diuretic therapy
P-83	-1.4388 -0.0055 -0.3387 -1.0232 -0.1028 -0.0649 -0.3834 -0.0173 -0.3067 -0.0128 -0.4608 -0.0822 -0.4718 -0.0146 -3.0327 -0.0045 -0.0466 -1.9308 -2.0570 -0.0613 -0.5412 -0.6485 -1.6044 -0.0145 -0.0835 -0.0498
S-1161	METHODS: Subjects with advanced HF (n = 408) underwent prospective assessment of body composition (skinfold thickness, dual-energy X-ray absorptiometry), comprehensive echocardiography, and blood testing.<unk>
T-1161	hf prospective dual-energy_x-ray_absorptiometry echocardiography blood
H-1161	-1.5420160293579102	▁ HF ▁ HF
D-1161	-1.5420160293579102	HF HF
P-1161	-0.3621 -0.2403 -2.4099 -0.8370 -5.3419 -0.0610
S-1621	PARTICIPANTS: High-cost Medicare fee-for-service beneficiaries (N = 1,767) enrolled in two Centers for Medicare and Medicaid Services demonstration participating clinics and a propensity-score matched control group.<unk>
T-1621	medicare centers_for_medicare_and_medicaid_services clinics propensity-score
H-1621	-0.7360444664955139	▁hoog - co st ▁Medica re ▁fee - for - service ▁beneficiar ies ▁Center s ▁Medica re ▁Medica id ▁Services
D-1621	-0.7360444664955139	hoog-cost Medicare fee-for-service beneficiaries Centers Medicare Medicaid Services
P-1621	-3.7508 -0.0265 -0.0267 -0.0282 -0.5847 -0.0204 -1.1538 -0.0128 -0.0124 -0.0308 -0.0387 -2.3319 -0.0717 -0.4262 -0.3886 -1.2170 -0.0051 -2.4560 -1.2804 -0.6540 -1.5610 -0.1155
S-1032	The objective of the measure is to motivate hospitals to improve the quality of care they provide patients hospitalized for heart failure (HF) and other conditions such as acute myocardial infarction, pneumonia, with expected future expansion to other conditions.<unk>
T-1032	hospitals patients hospitalized heart_failure hf conditions acute_myocardial_infarction pneumonia conditions
H-1032	-1.004128098487854	▁hospital s ▁heart ▁failure ▁ HF ▁a cute _ my o card ial ▁in far ction ▁pneu monia
D-1032	-1.004128098487854	hospitals heart failure HF acute_myocardial infarction pneumonia
P-1032	-5.2775 -0.3266 -5.2092 -0.2508 -3.5844 -0.0180 -0.4091 -0.0019 -0.1253 -2.2314 -0.1159 -0.2301 -0.1031 -1.7985 -0.0113 -0.0643 -0.0007 -0.0613 -0.1633 -0.0997
S-1744	Patients were subdivided in 4 enrollment periods on the basis of heart failure treatment eras: (1) 1977-1984 (n=66); (2) 1985-1990 (n=102); (3) 1991-2000 (n=197); (4) 2001-2011 (n=238).<unk>
T-1744	patients heart_failure
H-1744	-1.804437279701233	▁en roll ment
D-1744	-1.804437279701233	enrollment
P-1744	-4.0462 -0.1449 -0.1233 -4.6026 -0.1052
S-788	KCCQ summary scores were strongly associated with New York Heart Association class in both patients with HFpEF (r=-0.62; P<0.001) and HF with reduced EF (r=-0.55; P=0.27 for interaction).<unk>
T-788	kccq new_york_heart_association_class patients hfpef hf_with_reduced_ef
H-788	-0.7538301348686218	▁k cc q ▁summary ▁score s ▁New ▁York _ ▁Heart ▁Association ▁ HF p EF ▁ HF
D-788	-0.7538301348686218	kccq summary scores New York_ Heart Association HFpEF HF
P-788	-1.5934 -0.2510 -0.5850 -3.3323 -0.0927 -0.0738 -0.7817 -0.3104 -0.2895 -1.7814 -0.9209 -0.7565 -0.1034 -0.3334 -0.0354 -0.1195 -0.1085 -2.7788 -0.0751
S-36	Recommendation 1: ACP recommends using a restrictive red blood cell transfusion strategy (trigger hemoglobin threshold of 7 to 8 g/dL compared with higher hemoglobin levels) in hospitalized patients with coronary heart disease.<unk>
T-36	acp red_blood_cell_transfusion hemoglobin hemoglobin hospitalized patients coronary_heart_disease
H-36	-1.1384117603302002	▁a CP ▁restrict ive _ ▁red _ ▁blood ▁cell ▁trans fusion _ strategi e tri gger _ ▁hem o glob in ▁thre s hold
D-36	-1.1384117603302002	aCP restrictive_ red_ blood cell transfusion_strategietrigger_ hemoglobin threshold
P-36	-1.5165 -0.1489 -0.0481 -0.0101 -0.3496 -0.7790 -0.6493 -3.7845 -1.9596 -0.9084 -0.0342 -4.0065 -0.8923 -2.5803 -0.5970 -0.0003 -0.1287 -2.3807 -0.4491 -0.2944 -0.6457 -1.9448 -0.0451 -0.1219 -5.2003 -0.1235
S-1962	INTERPRETATION: This first-in-man experience with an implanted left-to-right interatrial shunt demonstrates initial safety and early beneficial clinical and haemodynamic outcomes in patients with heart failure with reduced ejection fraction.<unk>
T-1962	implanted interatrial_shunt clinical haemodynamic outcomes patients heart_failure_with_reduced_ejection_fraction
H-1962	-0.9456254243850708	▁implant ed ▁left - to - right _ inter at rial _ ▁shu nt
D-1962	-0.9456254243850708	implanted left-to-right_interatrial_ shunt
P-1962	-6.4132 -0.0480 -1.1667 -0.0244 -0.0243 -0.1110 -0.0135 -0.7301 -0.1008 -0.0782 -0.0672 -0.3995 -0.4663 -0.0494 -5.3533 -0.0842
S-1973	Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.<unk>
T-1973	exercise training peak_oxygen_consumption quality_of_life obese patients heart_failure_with_preserved_ejection_fraction randomized clinical
H-1973	-0.5596524477005005	▁Cal o ric _ re stri ction ▁aero bic _ ▁Exerci se ▁Training ▁Peak ▁o xy gen ▁Consum p tion
D-1973	-0.5596524477005005	Caloric_restriction aerobic_ Exercise Training Peak oxygen Consumption
P-1973	-0.0971 -0.2404 -1.1201 -0.6992 -0.2691 -0.0635 -0.0126 -0.3562 -0.1074 -0.3209 -1.6591 -0.0789 -1.0198 -0.0111 -1.3550 -0.0110 -0.0051 -0.1593 -0.0185 -0.0339 -4.6052 -0.0690
S-308	Left ventricular assist devices (LVADs) are used in chronic end-stage heart failure as "bridge to transplantation" (BTT) and, more recently, for transplant-ineligible patients as "destination therapy" (DT).<unk>
T-308	left_ventricular_assist_devices lvads chronic_end-stage_heart_failure bridge_to_transplantation btt patients destination_therapy dt
H-308	-0.6229200959205627	▁le ft ▁vent ri cular _ assist ▁devices ▁l VAD s ▁chronic _ ▁end - s tage _ heart ▁failure bridge ▁to _ ▁transplant ation ▁b TT ▁transplant - ine ligi ble ▁patients ▁de stin ation ▁ therapy
D-308	-0.6229200959205627	left ventricular_assist devices lVADs chronic_ end-stage_heart failurebridge to_ transplantation bTT transplant-ineligible patients destination therapy
P-308	-1.1456 -0.0018 -0.4945 -0.6534 -0.5186 -0.7200 -0.3151 -1.1747 -0.2390 -0.0139 -0.1462 -1.7812 -0.2720 -2.6190 -0.0563 -0.2362 -0.0040 -0.0630 -1.7615 -0.6626 -1.9233 -0.2991 -0.9389 -0.4147 -0.0247 -2.2903 -0.2391 -0.3121 -0.0924 -0.8490 -0.0107 -0.0571 -2.0065 -0.9527 -0.0581 -0.0510 -0.8805 -0.0190 -0.5657 -0.0536
S-742	T1 time also correlated with right ventricular-pulmonary arterial coupling (pulmonary vascular resistance: R=-0.36; P<0.01; right ventricular ejection fraction: R=0.28; P=0.01).<unk>
T-742	t1_time correlated right_ventricular-pulmonary_arterial_coupling pulmonary_vascular_resistance right_ventricular_ejection_fraction
H-742	-0.7766364216804504	▁vent ri cular - pul mon ary _ ▁arterial _ ▁coup ling pul mon ary _ vas cular ▁resist ance ▁right _ ▁vent ri cular _ e je ction
D-742	-0.7766364216804504	ventricular-pulmonary_ arterial_ couplingpulmonary_vascular resistance right_ ventricular_ejection
P-742	-1.5821 -0.3859 -0.1343 -0.5656 -0.5083 -1.4751 -0.1842 -0.6884 -3.0471 -0.9479 -1.1859 -0.3357 -1.1000 -0.1961 -0.0266 -0.2850 -1.2766 -0.0752 -1.4105 -0.0230 -1.8884 -1.2591 -0.1563 -0.1508 -0.2162 -0.2556 -2.6124 -0.1048 -0.0400 -1.8647 -0.0938
S-855	Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy).<unk>
T-855	carvedilol metoprolol implantable_cardioverter-defibrillator therapy madit-crt multicenter_automatic_defibrillator_implantation_with_cardiac_resynchronization_therapy
H-855	-0.42563825845718384	▁car vedi lol ▁met o pro lol ▁implant able ▁cardio ver ter - de fi br illa tor ▁ therapy ▁MAD IT - C RT ▁multi center _ automat ic _ de ib rilla tor ▁Implant ation ▁Card iac _ re syn chron ization ▁Therapy
D-855	-0.42563825845718384	carvedilol metoprolol implantable cardioverter-defibrillator therapy MADIT-CRT multicenter_automatic_deibrillator Implantation Cardiac_resynchronization Therapy
P-855	-0.0084 -0.0015 -0.0083 -0.0876 -0.0556 -0.0035 -0.0299 -0.4701 -0.0116 -0.9316 -0.0139 -0.3809 -0.2071 -0.0225 -0.3287 -0.3071 -0.0753 -0.0453 -1.1171 -0.0069 -0.0234 -1.3694 -0.0176 -1.3616 -0.3693 -3.9734 -0.0242 -0.9920 -0.6521 -0.0752 -0.0663 -1.5475 -0.0925 -0.2501 -0.0180 -0.3911 -0.1418 -0.8433 -0.0481 -0.6753 -1.6245 -0.0068 -0.0011 -0.5918 -0.4459 -0.2435 -0.0467
S-610	Oral glucocorticoids were associated with a dose-related gradient of HF risk: compared with no use, 1≤5 mg HR 1.30 (95% CI 0.91 to 1.85), ≥5 mg HR 1.54 (95% CI 1.09 to 2.19).<unk>
T-610	oral glucocorticoids hf
H-610	-0.9321187734603882	▁gluco cor tico ids ▁ HF
D-610	-0.9321187734603882	glucocorticoids HF
P-610	-2.5428 -0.0922 -0.6790 -0.0805 -0.5625 -0.1173 -3.2893 -0.0933
S-523	After 8 months of treatment, HR was significantly reduced in the ivabradine group (p < 0.0001) and was accompanied by marked reduction in Ea (p < 0.0001) and improved TAC (p = 0.004) compared with placebo.<unk>
T-523	ivabradine ea tac placebo
H-523	-0.6626421809196472	▁i va bra dine _ groep ▁Ea ▁ TAC
D-523	-0.6626421809196472	ivabradine_groep Ea TAC
P-523	-1.8561 -0.0216 -0.0264 -0.0029 -1.8408 -0.5219 -1.8581 -0.8634 -0.0356 -0.1939 -0.0684
S-385	CONCLUSIONS: The HFPSI uses readily available data to predict the 6-month risk of death and/or all-cause medical hospitalization in HF clinic outpatients and could potentially help allocate specialized HF resources within health systems.<unk>
T-385	hfpsi death medical hospitalization hf clinic outpatients hf health
H-385	-0.9807961583137512	▁ HF PSI ▁ HF PSI
D-385	-0.9807961583137512	HFPSI HFPSI
P-385	-0.0341 -0.0556 -0.2141 -0.9124 -0.1497 -0.9392 -5.4667 -0.0744
S-1265	However, further studies with long-term follow-up, systemic adverse events evaluation, and other ethnic groups are still required to verify the efficacy and safety of CHM as an adjunctive treatment in all patients with DCM and heart failure.<unk>
T-1265	follow-up systemic adverse_events patients dcm heart_failure
H-1265	-1.3097596168518066	▁CH m ▁d CM ▁heart ▁failure
D-1265	-1.3097596168518066	CHm dCM heart failure
P-1265	-3.5617 -0.8828 -3.8468 -0.0352 -1.8559 -0.2032 -0.0551 -0.0373
S-862	Treatment with carvedilol was associated with a significantly decreased risk of inappropriate therapy compared with metoprolol (hazard ratio [HR]: 0.64 [95% confidence interval (CI): 0.48 to 0.85]; p = 0.002).<unk>
T-862	carvedilol therapy metoprolol hazard_ratio confidence_interval
H-862	-0.7459632158279419	▁car vedi lol ▁met o pro lol haz ard ▁ratio
D-862	-0.7459632158279419	carvedilol metoprololhazard ratio
P-862	-0.0778 -0.0038 -0.0165 -4.3955 -0.2972 -0.0106 -0.0259 -0.4135 -0.0023 -0.8581 -2.7302 -0.1201
S-1325	CONCLUSIONS: This study shows for the first time that testosterone supplementation during a program of exercise rehabilitation is feasible and can positively impact on a range of key health outcomes in elderly male patients with CHF who have a low testosterone status.<unk>
T-1325	testosterone_supplementation exercise_rehabilitation health outcomes patients chf testosterone
H-1325	-1.2978488206863403	▁testosteron e ▁supplement ation
D-1325	-1.2978488206863403	testosterone supplementation
P-1325	-0.4975 -0.0157 -2.4799 -0.0928 -4.6557 -0.0454
S-1987	The change in peak VO2 was positively correlated with the change in percent lean body mass (r = 0.32; P = .003) and the change in thigh muscle:intermuscular fat ratio (r = 0.27; P = .02).<unk>
T-1987	change peak_vo2 correlated change lean_body_mass change thigh muscle
H-1987	-1.2375746965408325	▁pe ak _ vo 2 ▁percentage ▁lean _ ▁body ▁mass
D-1987	-1.2375746965408325	peak_vo2 percentage lean_ body mass
P-1987	-4.3675 -0.0173 -1.1022 -0.3737 -0.0271 -4.2004 -0.5220 -0.0942 -0.5337 -0.7599 -2.6970 -0.1558
S-189	METHODS: We included hospitals in Get With The Guidelines-Heart Failure that admitted 99,930 HF patients with reduced (EF <40%), borderline (EF 40%-49%), or preserved (EF ≥50%) EF.<unk>
T-189	hospitals get_with_the_guidelines-heart_failure hf patients ef ef ef ef
H-189	-0.9625171422958374	▁hospital s ▁Guide lines - He art ▁Fail ure ▁ HF
D-189	-0.9625171422958374	hospitals Guidelines-Heart Failure HF
P-189	-5.2908 -0.2090 -0.4843 -0.1236 -0.1758 -1.1673 -0.1670 -1.0462 -0.2351 -0.4305 -0.1226 -2.9999 -0.0608
S-830	In the multivariate Cox model analysis adjusted for age and sex, PASP increase during exercise and peak o2 per kilogram remained independent prognostic markers (hazard ratio, 2.56 for peak o2 per kilogram and 2.84 for PASP increase).<unk>
T-830	multivariate_cox_model pasp exercise peak_o2 prognostic hazard_ratio peak_o2 pasp
H-830	-1.2645220756530762	▁co x ▁model
D-830	-1.2645220756530762	cox model
P-830	-0.1984 -0.0030 -0.5543 -5.4811 -0.0857
S-1787	CONCLUSIONS: The development of cardiac insulin-resistance and decreased mitochondrial oxidative metabolism are early metabolic changes in the development of cardiac hypertrophy, which create an energy deficit that may contribute to the progression from hypertrophy to heart failure.<unk>
T-1787	cardiac insulin-resistance mitochondrial_oxidative_metabolism metabolic cardiac_hypertrophy hypertrophy heart_failure
H-1787	-0.3345410227775574	▁cardiac ▁insulin - re si stance ▁mito cho ndri al ▁oxid ative ▁metabolism ▁cardiac ▁hyper trop hy ▁energy
D-1787	-0.3345410227775574	cardiac insulin-resistance mitochondrial oxidative metabolism cardiac hypertrophy energy
P-1787	-0.0748 -0.3802 -0.0137 -0.0125 -0.5201 -0.0004 -0.1598 -0.0475 -0.0287 -0.0238 -0.2410 -0.0213 -0.1610 -0.2492 -0.5486 -0.0027 -0.3394 -1.8044 -1.9907 -0.0709
S-1672	Rad, a member of the RGK (Rem, Rem2, Rad, Gem/Kir) family of monomeric G proteins, regulates ventricular action potential duration and EC coupling gain through its ability to inhibit cardiac L-type channel activity.<unk>
T-1672	rad rgk rem rem2 rad monomeric_g_proteins ventricular_action_potential gain cardiac l-type_channel activity
H-1672	-0.6136159300804138	▁r GK ▁re m ▁rem 2 ▁Rad ▁Gem / Kir ▁mono me ric _ g _ ▁protein s ▁vent ri cular ▁action ▁ec ▁coup ling ▁cardiac _ type _ ▁channel ▁activity
D-1672	-0.6136159300804138	rGK rem rem2 Rad Gem/Kir monomeric_g_ proteins ventricular action ec coupling cardiac_type_ channel activity
P-1672	-0.3703 -0.4794 -1.5347 -0.0314 -0.3384 -0.0367 -2.2713 -0.8364 -1.1778 -0.0148 -0.0613 -0.0454 -0.1057 -0.3401 -1.7780 -1.7969 -0.4376 -0.0200 -0.1233 -0.2558 -0.2487 -0.7929 -2.1973 -0.2984 -0.0186 -0.4623 -1.2662 -0.6407 -1.0532 -0.4497 -0.4993 -0.1458 -0.1212
S-338	The mechanism is a combination of annular size reduction by surgery and diastolic mitral valve tethering, restricting the anterior leaflet opening due to posteriorly displaced papillary muscles with left ventricular (LV) dilatation.<unk>
T-338	combination surgery diastolic_mitral_valve_tethering anterior_leaflet papillary_muscles left_ventricular dilatation
H-338	-0.431124210357666	▁ann ular ▁size ▁re duction ▁dia sto lic _ ▁mit ral _ ▁val ve ▁te ther ing ▁anterior ▁le a flet ▁opening ▁posterior ly ▁dis place d ▁papil lar y ▁muscle s ▁left ▁vent ri cular LV
D-338	-0.431124210357666	annular size reduction diastolic_ mitral_ valve tethering anterior leaflet opening posteriorly displaced papillary muscles left ventricularLV
P-338	-0.4719 -0.0002 -1.3692 -0.3436 -0.0035 -0.3617 -0.0051 -0.0186 -0.5048 -1.5485 -0.0166 -0.4746 -1.2500 -0.0479 -0.1583 -0.0375 -0.0160 -0.3644 -1.3043 -0.0327 -0.0004 -0.0786 -0.9861 -0.7087 -1.0075 -0.0497 -0.0192 -1.0442 -0.0897 -0.1737 -1.1954 -0.1599 -0.1056 -1.2025 -0.1884 -0.0561 -0.9563 -0.3691 -0.0935
S-734	BACKGROUND: The underlying pathophysiology of heart failure with preserved ejection fraction (HFPEF) is incompletely understood, but myocardial extracellular matrix accumulation is thought to play a major role.<unk>
T-734	pathophysiology heart_failure_with_preserved_ejection_fraction hfpef myocardial_extracellular_matrix
H-734	-0.534898579120636	▁pat ho phy si ology ▁heart ▁failure ▁pres er ved _ e je ction _ fraction ▁h FP EF ▁my o card ial ▁extra cel lular ▁matri x ▁accumula tion
D-734	-0.534898579120636	pathophysiology heart failure preserved_ejection_fraction hFPEF myocardial extracellular matrix accumulation
P-734	-3.9335 -0.1798 -0.1729 -1.1530 -0.2543 -1.6000 -0.2510 -0.4512 -0.0456 -0.3119 -0.1003 -1.0683 -0.1611 -0.0587 -0.8490 -0.0167 -2.1571 -0.3396 -0.1722 -0.5702 -0.0348 -0.1974 -0.0917 -1.2087 -0.0291 -0.0141 -0.4257 -0.1081 -0.6261 -0.2652 -0.2029 -0.0665
S-1346	A protocol was originally designed to study breathing control during and following cardiac arrest in humans, taking advantage of the period of pulseless ventricular fibrillation (PVF) produced while testing a newly implanted cardioverter-defibrillator device.<unk>
T-1346	breathing cardiac_arrest advantage pulseless_ventricular_fibrillation pvf implanted cardioverter-defibrillator_device
H-1346	-0.3806326985359192	▁breath ing ▁control ▁cardiac ▁arrest ▁puls e less _ ▁vent ri cular _ fi bril lation PV F ▁cardio ver ter - de fi br illa tor ▁device
D-1346	-0.3806326985359192	breathing control cardiac arrest pulseless_ ventricular_fibrillationPVF cardioverter-defibrillator device
P-1346	-1.6485 -0.0352 -1.0664 -0.7033 -0.1005 -0.0243 -0.0699 -0.4988 -0.2407 -0.3548 -0.4439 -0.3534 -0.2242 -1.3337 -0.0870 -0.0544 -0.4293 -0.4769 -0.8038 -0.0067 -0.1436 -0.1904 -0.0206 -0.0428 -0.0550 -0.0620 -0.0170 -1.7737 -0.1069 -0.0513
S-14	RESULTS: N-terminal proBNP (NT-proBNP), midregional proANP (MR-proANP), and total adiponectin were elevated in CHF (p<0.001) and correlated inversely to BMI and FM.<unk>
T-14	n-terminal_probnp nt-probnp midregional_proanp mr-proanp adiponectin elevated chf correlated bmi
H-14	-0.6168313026428223	▁N - termin al ▁pro B NP NT - pro B NP ▁mid region al ▁pro AN P MR - pro AN P
D-14	-0.6168313026428223	N-terminal proBNPNT-proBNP midregional proANPMR-proANP
P-14	-3.3118 -0.0217 -0.1128 -0.0055 -1.0559 -0.6525 -0.0142 -1.5845 -0.0041 -0.0350 -1.2779 -0.0108 -0.2177 -0.0293 -0.0108 -1.2362 -0.5504 -1.4254 -0.0347 -0.0204 -0.0053 -0.3415 -1.0804 -2.3380 -0.0440
S-1136	We investigated the long-term (4 wk) effects of the acetylcholinesterase inhibitor pyridostigmine on sympathovagal balance, cardiac remodeling, and cardiac function in the onset of HF following myocardial infarction.<unk>
T-1136	acetylcholinesterase_inhibitor pyridostigmine sympathovagal_balance cardiac_remodeling cardiac_function hf myocardial_infarction
H-1136	-0.5140003561973572	▁a ce tyl cho line ster ase ▁inhibi tor ▁py rido stig mine ▁sympa t hova gal _ ▁balance ▁cardiac _ ▁remodel ing ▁ HF
D-1136	-0.5140003561973572	acetylcholinesterase inhibitor pyridostigmine sympathovagal_ balance cardiac_ remodeling HF
P-1136	-0.1308 -2.3813 -0.1781 -0.1363 -0.4343 -0.3470 -1.6575 -0.3667 -0.0054 -0.0929 -0.0040 -0.0002 -0.0998 -0.0294 -0.0986 -0.1769 -0.1019 -1.1981 -0.2339 -0.0007 -2.7148 -0.8590 -0.0056 -0.6411 -0.0197 -1.9070 -0.0571
S-1112	The aim of this study was, first, to assess whether there is a differential response in cardiac sympathetic activity by (123)I-meta-iodobenzylguanidine ((123)I-MIBG) imaging when either β-blocker is used.<unk>
T-1112	cardiac_sympathetic_activity β-blocker
H-1112	-0.5426530838012695	▁i - meta - i odob enz yl guan i dine ▁i - MI BG ▁β - block er
D-1112	-0.5426530838012695	i-meta-iodobenzylguanidine i-MIBG β-blocker
P-1112	-5.8578 -0.7279 -0.3705 -0.0216 -0.1871 -0.0223 -0.4112 -1.1491 -0.0259 -0.1648 -0.0246 -1.3249 -0.1978 -0.3536 -0.1325 -0.1195 -0.0092 -0.0286 -0.0639 -0.0514 -0.1514
S-971	From the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies registry, we included all 36,284 patients who underwent primary isolated CABG from 2000 to 2008 in Sweden.<unk>
T-971	evidence-based heart_disease therapies patients cabg sweden
H-971	-0.8401678204536438	▁Swedish _ web - system _ voor _ en han ce ment _ de _ de _ e viden ce - based _ care _ in _ heart ▁disease ▁Reco mmende d _ ▁Therapie s ▁registr y
D-971	-0.8401678204536438	Swedish_web-system_voor_enhancement_de_de_evidence-based_care_in_heart disease Recommended_ Therapies registry
P-971	-0.3580 -0.9610 -1.7339 -0.1002 -0.1275 -0.8347 -2.7285 -0.2011 -0.5611 -0.0215 -1.5445 -0.0748 -0.2806 -1.6459 -0.2993 -2.7583 -0.6543 -4.4124 -0.1445 -0.1141 -0.0478 -0.0045 -0.0359 -2.1207 -1.7727 -0.5769 -0.6683 -1.3814 -1.4185 -0.3035 -0.0003 -0.0094 -0.3163 -0.8205 -0.0111 -1.1486 -0.0109 -2.4477 -0.1154
S-756	In the LVEF <30% subgroup, significant improvements in clinical composite response (P=0.02), reverse remodeling parameters, and time to death or first HF hospitalization (hazard ratio, 0.58; P=0.047) were observed.<unk>
T-756	lvef clinical reverse_remodeling death hf hospitalization hazard_ratio
H-756	-0.5568700432777405	▁LV EF ▁clinic al ▁com posit e _ ▁response ▁rever se _ ▁remodel ing ▁parameter s ▁ HF
D-756	-0.5568700432777405	LVEF clinical composite_ response reverse_ remodeling parameters HF
P-756	-0.0823 -0.0343 -3.6435 -0.0050 -0.6138 -0.0021 -0.0066 -0.8980 -0.2673 -0.0094 -0.0023 -0.7593 -0.0251 -0.0067 -0.4400 -0.0256 -2.4742 -1.0236 -0.7686 -0.0497
S-1569	In all, 36 (30%) patients had brain natriuretic peptide (BNP) levels ≥ 100 pg/mL (high BNP group), and 84 (70%) patients had BNP levels < 100 pg/mL (low BNP group).<unk>
T-1569	patients brain_natriuretic_peptide bnp bnp patients bnp bnp
H-1569	-0.6520611047744751	▁brain ▁na tri ure tic _ pe pti de ▁b NP
D-1569	-0.6520611047744751	brain natriuretic_peptide bNP
P-1569	-0.6401 -0.0449 -0.0088 -0.3095 -2.8524 -0.5218 -0.4162 -0.0615 -0.3014 -0.9136 -0.0559 -2.2899 -0.0608
S-1210	Among the PDE superfamily, PDE2 has the unique property of being able to be stimulated by cGMP, thus leading to a remarkable increase in cAMP hydrolysis mediating a negative cross talk between cGMP and cAMP signaling.<unk>
T-1210	pde pde2 cgmp leading camp_hydrolysis cross_talk cgmp camp_signaling
H-1210	-0.5787838101387024	▁p de _ super family ▁p de 2 ▁c g MP ▁c AMP ▁hydro lys is ▁c g MP ▁c AMP ▁signal ing
D-1210	-0.5787838101387024	pde_superfamily pde2 cgMP cAMP hydrolysis cgMP cAMP signaling
P-1210	-0.1670 -0.1447 -2.0893 -0.4633 -0.0184 -1.6972 -0.1586 -0.0369 -0.0041 -2.5505 -0.2671 -0.0131 -0.3474 -0.1552 -0.0194 -0.0459 -0.1878 -3.5643 -0.3661 -0.0965 -0.1577 -1.7392 -0.0221 -0.0974 -0.0605
S-493	We hypothesized that the relationship between TAPSE (longitudinal RV fiber shortening) and PASP (force generated by the RV) provides an index of in vivo RV length-force relationship, with their ratio better disclosing prognosis.<unk>
T-493	tapse longitudinal_rv_fiber_shortening pasp rv in_vivo rv prognosis
H-493	-1.1804840564727783	▁t AP se long itud in al _ RV _ ▁fiber ▁short en ing ▁PAS p ▁ RV
D-493	-1.1804840564727783	tAPselongitudinal_RV_ fiber shortening PASp RV
P-493	-3.5718 -0.5966 -1.3647 -2.7239 -0.0979 -0.2798 -0.1869 -0.3677 -2.5392 -1.9766 -0.4788 -1.1874 -0.0725 -0.1515 -0.9365 -1.0282 -1.4496 -1.3052 -3.1574 -0.1376
S-870	BACKGROUND: We investigated the protective effects of mitochondrial-targeted antioxidant and protective peptides, Szeto-Schiller (SS) 31 and SS20, on cardiac function, proteomic remodeling, and signaling pathways.<unk>
T-870	peptides szeto-schiller ss ss20 cardiac_function proteomic_remodeling signaling_pathways
H-870	-0.43506574630737305	▁mito cho ndri al - tar get ed ▁antioxidant ▁Sze to - Sch iller ▁SS 20 ▁cardiac ▁function ▁prote om ic ▁remodel ing ▁signal ing ▁path ways
D-870	-0.43506574630737305	mitochondrial-targeted antioxidant Szeto-Schiller SS20 cardiac function proteomic remodeling signaling pathways
P-870	-0.3343 -0.0666 -0.1673 -0.0145 -0.0469 -0.0069 -0.0158 -0.0053 -0.7192 -1.8176 -0.0064 -0.0038 -0.2256 -0.0148 -1.0236 -0.7185 -0.8639 -3.8055 -0.1033 -0.0117 -0.8205 -0.3981 -0.0087 -0.7794 -0.0519 -0.4458 -0.0141 -0.0822 -0.0446
S-2017	CONCLUSION: The Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model provides researchers and providers with a tool for conducting long-term cost-effectiveness analyses of disease management programs in heart failure.<unk>
T-2017	tools_for_economic_analysis_of_patient_management_interventions_in_heart_failure_cost-effectiveness_model disease heart_failure
H-2017	-1.0861074924468994	▁Tools _ economic _ analys is _ van _ ▁Patient ▁Management _ ▁Interven tions ▁Heart ▁Fail ure _ ▁Cost - E ff ective ness
D-2017	-1.0861074924468994	Tools_economic_analysis_van_ Patient Management_ Interventions Heart Failure_ Cost-Effectiveness
P-2017	-4.1012 -1.6094 -1.9941 -0.5535 -1.2954 -0.0795 -0.8785 -2.3182 -0.0637 -1.3567 -0.7145 -1.2375 -0.3926 -0.1526 -0.6366 -1.1810 -0.7848 -1.6787 -2.5372 -0.0593 -1.1331 -0.1177 -0.0024 -0.6600 -2.6023 -0.0981
2021-01-17 14:23:49 | INFO | fairseq.logging.progress_bar | :    101 / 145 wps=150
S-900	There was a significant decrease in re-hospitalization from an average of 3.2 ± 2.5 to 0.1 ± 0.3 admissions per patient (p = 0.007) and reduced average length of stay from 37 ± 36.7 to 0.78 ± 2.3 days (p = 0.019).<unk>
T-900	re-hospitalization admissions patient
H-900	-0.528096079826355	▁re - hospital ization ▁ad missions
D-900	-0.528096079826355	re-hospitalization admissions
P-900	-0.2384 -0.0749 -0.0416 -0.4422 -0.7901 -0.1206 -2.4201 -0.0969
S-79	MAIN OUTCOMES AND MEASURES: Coprimary end points included 72-hour cumulative urine volume (decongestion end point) and the change in serum cystatin C from enrollment to 72 hours (renal function end point).<unk>
T-79	outcomes coprimary_end_points end_point change serum_cystatin_c renal_function end_point
H-79	-0.8070247173309326	▁co prima ry _ end ▁points ▁cum ul ative _ ▁urin e ▁volume ▁de con gestion ▁se rum ▁cyst atin ▁c ren al _ function
D-79	-0.8070247173309326	coprimary_end points cumulative_ urine volume decongestion serum cystatin crenal_function
P-79	-3.9436 -0.0167 -0.2138 -1.5259 -4.7905 -1.9416 -0.9641 -0.0237 -0.0236 -0.1112 -1.2091 -0.0830 -0.0848 -0.2857 -0.0042 -0.0241 -1.3079 -0.0731 -0.0130 -0.0574 -1.5557 -0.5768 -0.0428 -0.5015 -1.2807 -1.0484 -0.0869
S-1291	HISTORY AND CLINICAL FINDINGS: We present a 41-year-old man with cardiac arrest in need of cardiopulmonary resuscitation (CPR) with the diagnosis of a posterior wall infarction, who was hospitalized in our cardiac centre.<unk>
T-1291	clinical cardiac_arrest cardiopulmonary_resuscitation cpr diagnosis posterior_wall_infarction hospitalized cardiac
H-1291	-0.5990028381347656	▁cardiac ▁arrest ▁cardio pul mon ary _ ▁res uscita tion ▁posterior _ ▁wall ▁in far ction ▁cardiac ▁centre
D-1291	-0.5990028381347656	cardiac arrest cardiopulmonary_ resuscitation posterior_ wall infarction cardiac centre
P-1291	-1.8735 -1.3833 -0.1336 -0.0587 -1.8250 -0.3190 -0.1615 -0.8504 -0.0077 -0.2651 -1.3214 -0.1434 -1.4598 -0.3358 -0.0870 -0.0664 -0.0343 -1.4876 -0.0728 -0.0939
S-1831	PATIENTS: Patients aged 18 years or older with type 2 diabetes who initiated therapy with saxagliptin, sitagliptin, pioglitazone, second-generation sulfonylureas, or long-acting insulin products from 2006 to 2013.<unk>
T-1831	patients patients type_2_diabetes therapy saxagliptin sitagliptin pioglitazone second-generation_sulfonylureas insulin
H-1831	-0.45338451862335205	▁diabetes ▁sax ag lip tin ▁si tag lip tin ▁pi og lita zone ▁sul fon yl ure as ▁long - ac ting ▁insulin ▁products
D-1831	-0.45338451862335205	diabetes saxagliptin sitagliptin pioglitazone sulfonylureas long-acting insulin products
P-1831	-3.7831 -0.6030 -0.0051 -0.1640 -1.6070 -0.2753 -0.0266 -0.0214 -1.3747 -0.0246 -0.0038 -0.0673 -0.0081 -0.5831 -0.0153 -0.1488 -0.2317 -0.0083 -0.5171 -0.0088 -0.0095 -0.0090 -0.7524 -1.3328 -0.1536 -0.0538
S-1702	BACKGROUND: The incidence of hyperkalemia caused by mineralocorticoid receptor antagonists may vary by race, but whether race influences efficacy of mineralocorticoid receptor antagonists in heart failure (HF) is unknown.<unk>
T-1702	incidence hyperkalemia mineralocorticoid_receptor_antagonists mineralocorticoid_receptor_antagonists heart_failure hf
H-1702	-0.5749385952949524	▁hyper kal emia ▁mineral o cor tico id ▁receptor ▁anta gon ists
D-1702	-0.5749385952949524	hyperkalemia mineralocorticoid receptor antagonists
P-1702	-1.4451 -0.1141 -0.0460 -0.3204 -0.0832 -0.1684 -0.3841 -0.1154 -0.7558 -0.1513 -0.0098 -0.3644 -4.0362 -0.0551
S-37	(Grade: weak recommendation; low-quality evidence) Recommendation 2: ACP recommends against the use of erythropoiesis-stimulating agents in patients with mild to moderate anemia and congestive heart failure or coronary heart disease.<unk>
T-37	grade evidence acp erythropoiesis-stimulating_agents patients anemia congestive_heart_failure coronary_heart_disease
H-37	-0.7647344470024109	▁er y thro po ies is - stimul ating _ agent ▁an emia ▁con ges tive _ heart ▁failure ▁corona ry _ heart
D-37	-0.7647344470024109	erythropoiesis-stimulating_agent anemia congestive_heart failure coronary_heart
P-37	-3.8166 -0.2727 -0.7562 -0.5439 -0.9904 -0.1675 -0.1380 -0.0217 -0.3024 -2.0000 -0.4567 -3.5350 -0.0175 -0.0443 -0.0469 -0.7280 -0.2287 -1.1052 -0.2814 -0.1141 -0.2079 -0.7706 -1.1337 -1.3440 -0.0952
S-175	In ambulatory patients with heart failure (HF) and reduced ejection fraction (rEF), renin-angiotensin system (RAS) and β-blockers at guideline-recommended target dose reduce all-cause mortality and readmissions.<unk>
T-175	ambulatory patients heart_failure hf reduced_ejection_fraction renin-angiotensin_system ras β-blockers all-cause_mortality readmissions
H-175	-0.596152126789093	▁ambula tory ▁patients ▁heart ▁failure ▁ HF ▁reduce d ▁e je ction ▁ fraction ▁r EF ▁re nin - angi oten sin ▁system ▁ RAS ▁β - block ers
D-175	-0.596152126789093	ambulatory patients heart failure HF reduced ejection fraction rEF renin-angiotensin system RAS β-blockers
P-175	-2.4147 -0.0501 -1.2808 -1.0500 -0.0538 -4.2312 -0.0097 -2.3377 -0.1227 -0.1912 -0.0309 -0.0235 -0.6620 -0.0091 -0.9295 -0.0067 -0.0014 -0.5075 -0.0334 -0.0373 -0.0531 -0.4236 -0.4910 -1.9380 -0.0012 -0.0479 -0.0028 -0.0134 -0.0341 -1.3539 -0.1387
S-1082	METHODS AND RESULTS: UPR and SCN5A were analyzed in human ventricular systolic HF tissue samples and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).<unk>
T-1082	upr scn5a ventricular_systolic_hf human_induced_pluripotent_stem_cell-derived_cardiomyocytes hipsc-cms
H-1082	-0.4881773591041565	▁u PR ▁s cn 5 a ▁vent ri cular ▁sy sto lic ▁ HF ▁tissu e ▁sample s ▁human ▁induc ed ▁pluri potent ▁stem ▁cell - der i ved _ ▁cardio my o cy tes hi PS c - CM s
D-1082	-0.4881773591041565	uPR scn5a ventricular systolic HF tissue samples human induced pluripotent stem cell-derived_ cardiomyocyteshiPSc-CMs
P-1082	-1.3723 -0.0852 -3.3641 -0.5238 -0.4154 -0.2216 -1.2815 -1.0158 -0.3653 -0.4416 -0.0068 -0.0149 -0.8609 -0.0140 -1.6249 -0.0606 -1.0388 -0.0505 -1.4975 -0.1243 -0.0322 -0.2480 -0.0001 -0.3895 -1.2388 -0.0715 -0.1027 -0.0977 -0.1801 -0.8303 -0.6022 -1.1894 -0.3249 -0.0276 -0.0861 -0.4320 -0.1528 -0.4297 -0.0361 -0.0055 -0.0237 -0.0586 -0.0524
S-802	RESULTS: Good agreement was observed, in general, for both the total sample and subgroups (COPD, CHF, CRF), with ICC values ranging from .85 to .98, and kappa coefficients from .49 to 1.00.<unk>
T-802	copd chf crf icc kappa_coefficients
H-802	-0.5594674944877625	▁co PD ▁CHF ▁c RF ▁ka ppa ▁co ef fici ents
D-802	-0.5594674944877625	coPD CHF cRF kappa coefficients
P-802	-4.2309 -0.1297 -0.1324 -0.8019 -0.0712 -0.6804 -0.0296 -0.4098 -0.0012 -0.0033 -0.5122 -0.2124 -0.0580
S-1865	CONCLUSION: The patient preferences identified in this study support the need to include information on implantable cardioverter-defibrillator deactivation at implant, with change in clinical status and within broader discussions about end-of-life treatment preferences.<unk>
T-1865	patient implantable_cardioverter-defibrillator implant change clinical
H-1865	-0.551243007183075	▁implant able _ ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁implant
D-1865	-0.551243007183075	implantable_ cardioverter-defibrillator deactivation implant
P-1865	-2.9397 -0.0208 -0.5424 -2.0921 -0.0074 -0.2463 -0.4817 -0.0214 -0.2720 -0.2522 -0.0989 -0.0199 -0.1506 -0.0050 -0.2147 -0.5580 -1.9503 -0.0490
S-1913	METHODS: Patients (n = 5) with stable heart failure and a left ventricular ejection fraction of less than 45% completed a four-week aerobic training period with three trainings per week and an integrated dynamic resistance training of the lower limbs.<unk>
T-1913	patients stable_heart_failure left_ventricular_ejection_fraction training training
H-1913	-1.2543816566467285	▁heart ▁failure ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁aero bic _ training
D-1913	-1.2543816566467285	heart failure left ventricular ejection fraction aerobic_training
P-1913	-5.8069 -0.4761 -0.2552 -0.5074 -0.5605 -0.8559 -0.7873 -0.0524 -0.0223 -3.3142 -0.0467 -3.4816 -0.0386 -1.6789 -0.0606 -3.3049 -0.0751
S-987	The remaining patients, which will be focused on below, have heart failure that is principally related to poor myocardial function and largely comprise those children with dilated poorly contracting ventricles, which can be related to specific aetiologies in some cases.<unk>
T-987	patients heart_failure myocardial_function dilated contracting ventricles aetiologies
H-987	-0.9624396562576294	▁heart ▁failure ▁my o card ial ▁function ▁dil ated _ contract ing ▁vent ric les
D-987	-0.9624396562576294	heart failure myocardial function dilated_contracting ventricles
P-987	-2.6438 -0.3277 -4.9993 -0.0864 -0.1620 -0.3969 -1.1676 -1.0045 -0.0330 -0.5418 -3.7502 -0.0236 -0.1736 -0.5253 -0.2715 -0.1858 -0.0685
S-1847	We will classify interventions according to their level of application (ie, provider, organisation, systems level) and common underlying characteristics (eg, education, decision-support, financial incentives) using the Cochrane Effective Practice and Organisation of Care Taxonomy.<unk>
T-1847	financial cochrane_effective_practice_and_organisation_of_care_taxonomy
H-1847	-0.5616158246994019	▁co ch rane _ effect _ ▁Practic e _ ▁Organisation _ of _ care _ ▁Tax ono my
D-1847	-0.5616158246994019	cochrane_effect_ Practice_ Organisation_of_care_ Taxonomy
P-1847	-0.6775 -0.0245 -0.0151 -1.4212 -0.4056 -1.2947 -0.6710 -0.0027 -1.5665 -1.5389 -0.1352 -0.4136 -0.1183 -1.0224 -0.7505 -0.9761 -0.0042 -0.0869 -0.0707 -0.0369
S-1675	We have found that mouse Rad Q65P (the murine equivalent of human Rad Q66P) inhibits L-type currents conducted by CaV1.2 or CaV1.3 channels as potently as wild-type Rad (>95% inhibition of both channels).<unk>
T-1675	rad q65p murine rad q66p l-type_currents cav1.2 cav1.3 wild-type_rad
H-1675	-0.8637491464614868	▁mouse _ rad _ q 65 p ▁mur ine _ ▁equivalent _ ▁human _ Rad ▁Q 66 p ▁l - type _ current s ▁ca v 1.2 _ ca v 1.3 _ ▁channel s ▁wild - type _ Rad
D-1675	-0.8637491464614868	mouse_rad_q65p murine_ equivalent_ human_Rad Q66p l-type_currents cav1.2_cav1.3_ channels wild-type_Rad
P-1675	-0.2080 -1.7587 -4.7091 -2.0212 -1.0784 -0.3249 -0.5548 -0.2725 -0.2188 -1.8274 -0.8311 -1.0123 -2.1367 -0.1994 -1.5910 -0.2387 -0.1383 -0.4254 -3.9095 -0.0217 -0.0010 -0.2332 -1.0295 -0.1189 -0.6268 -0.3789 -0.3968 -2.7378 -0.5431 -0.1374 -0.2134 -1.3453 -2.0774 -0.1098 -0.0859 -0.0296 -0.0029 -0.0797 -1.4759 -0.2148 -0.0979
S-1866	Using this process to help patients determine and communicate their implantable cardioverter-defibrillator deactivation preferences may reduce the number of patients experiencing distressing implantable cardioverter-defibrillator shocks at end of life.<unk>
T-1866	patients implantable_cardioverter-defibrillator patients implantable_cardioverter-defibrillator
H-1866	-0.3966679573059082	▁implant able _ ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁preference s ▁di stress ing ▁implant able _ ▁cardio ver ter - de fi br illa tor _ ▁shock s
D-1866	-0.3966679573059082	implantable_ cardioverter-defibrillator deactivation preferences distressing implantable_ cardioverter-defibrillator_ shocks
P-1866	-1.1178 -0.0176 -0.3555 -2.0020 -0.0065 -0.2463 -0.2991 -0.0123 -0.3817 -0.2177 -0.0896 -0.0275 -0.2820 -0.0072 -0.2509 -2.0124 -0.0447 -1.2328 -0.0094 -0.0896 -0.4166 -0.0313 -0.1080 -1.5257 -0.0102 -0.2521 -0.2716 -0.0134 -0.2168 -0.1090 -0.0940 -0.0208 -1.7332 -0.8477 -0.1025 -0.1488 -0.0725
S-274	Although the mouse heart failure (HF) model of hypertensive heart disease (HHD) is useful to investigate the pathophysiology and new therapeutic targets for HHD, the model using simple experimental procedures and stable phenotypes has not been established.<unk>
T-274	heart_failure hf hypertensive_heart_disease hhd pathophysiology therapeutic hhd stable phenotypes
H-274	-0.6618117690086365	▁mouse _ heart ▁failure _ HF ▁model ▁hyper tensi ve _ heart ▁disease h HD ▁pat ho phy si ology ▁h HD
D-274	-0.6618117690086365	mouse_heart failure_HF model hypertensive_heart diseasehHD pathophysiology hHD
P-274	-0.0169 -0.7250 -1.1289 -0.1258 -1.9482 -0.0501 -1.2698 -0.3317 -0.0673 -0.0692 -0.0310 -1.6534 -1.1254 -0.9091 -0.4499 -1.9263 -0.0454 -0.0751 -0.9709 -0.1177 -1.7498 -0.2008 -0.8561 -0.0394
S-1108	Further adjustment for patient and MI characteristics yielded hazard ratios of 0.86 (95% CI: 0.66, 1.11) and 0.63 (95% CI: 0.45, 0.88) for early- and late-onset HF, respectively.<unk>
T-1108	patient mi hazard_ratios hf
H-1108	-1.405742883682251	▁MI _ karakter istic s
D-1108	-1.405742883682251	MI_karakteristics
P-1108	-3.5142 -2.7523 -0.9094 -0.0908 -0.0600 -2.2568 -0.2567
S-1693	RESEARCH DESIGN: Using national Medicare data, we created a cohort of older patients treated at an acute care hospital for HF (n=1,203,595), AMI (n=625,595), or PNA (n=1,234,299).<unk>
T-1693	medicare patients acute hospital hf ami pna
H-1693	-1.8100411891937256	▁ europe se _ ▁Medica re
D-1693	-1.8100411891937256	europese_ Medicare
P-1693	-3.3215 -4.2300 -0.0241 -0.3402 -3.5802 -0.0064 -2.9159 -0.0622
S-289	Adding cTnT and NT-proBNP to the ARIC HF model significantly improved all statistical parameters (AUCs increased by 0.040 and 0.057; the continuous NRIs were 50.7% and 54.7% in women and men, respectively).<unk>
T-289	ctnt nt-probnp aric hf aucs nris
H-289	-0.49276748299598694	▁c t n t ▁NT - pro b NP ▁a RIC ▁ HF
D-289	-0.49276748299598694	ctnt NT-probNP aRIC HF
P-289	-0.0182 -0.6143 -0.0320 -0.5962 -0.3124 -0.0109 -0.0060 -0.4986 -0.0383 -0.2783 -0.3004 -1.6502 -0.1285 -2.8618 -0.0455
S-404	Cardiovascular events were examined as a function of baseline sST2 status (low ≤35 versus high >35 ng/mL) and final achieved BB dose (high ≥50 versus low <50 mg daily equivalent dose of metoprolol succinate).<unk>
T-404	cardiovascular_events baseline sst2 metoprolol_succinate
H-404	-2.4248619079589844	▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s b _ s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s ▁s t _ s nc
D-404	-2.4248619079589844	s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s sb_s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s st_snc
P-404	-1.2899 -2.5930 -1.4826 -1.0932 -0.8790 -0.7509 -0.6876 -0.6521 -0.6212 -0.6274 -0.6164 -0.6350 -0.6610 -0.6643 -0.6982 -0.6999 -0.7578 -0.7896 -0.8048 -0.8406 -0.8979 -0.9307 -0.9832 -1.0182 -1.0714 -1.1201 -1.1605 -1.2044 -1.2511 -1.3054 -1.3419 -1.4194 -1.4615 -1.5383 -1.5981 -1.6408 -1.6901 -1.7316 -1.8064 -1.8820 -1.9248 -2.0154 -2.0365 -2.0977 -2.1628 -2.1967 -2.2868 -2.3036 -2.3853 -2.4152 -2.5258 -2.5222 -2.6083 -2.6645 -2.6928 -2.7294 -2.8049 -2.8674 -2.8882 -2.9478 -2.9699 -3.0442 -4.9403 -3.3813 -2.7403 -3.2813 -2.8278 -2.6776 -2.6199 -2.6140 -2.6671 -2.7915 -2.9518 -3.0065 -3.0218 -3.0984 -3.1731 -3.1766 -3.2059 -3.2007 -3.1970 -3.1916 -3.2169 -3.2354 -3.2098 -3.2245 -3.2478 -3.2489 -3.2794 -3.2594 -3.2653 -3.2648 -3.2589 -3.2869 -3.3109 -3.2751 -3.2954 -3.3523 -3.3683 -3.3578 -3.3973 -3.3974 -3.4329 -3.4388 -3.4379 -3.4513 -3.4751 -3.4823 -3.5171 -3.5117 -3.5250 -3.5272 -3.5869 -3.5523 -3.5954 -3.5946 -4.8471 -3.3486 -2.9891 -4.0848 -3.8022 -0.1284
S-255	Incubation of EC with HDL(NYHA-IIIb) triggered a lower stimulation of phosphorylation at eNOS-Ser(1177) and a higher phosphorylation at eNOS-Thr(495) when compared with HDL(healthy).<unk>
T-255	hdl nyha-iiib phosphorylation phosphorylation hdl healthy
H-255	-0.6407461762428284	▁in cuba tion ▁EC ▁HD L NY HA - III b ▁ phos phor y lation ▁e NOS - Ser ▁ phos phor y lation ▁e NOS - Th r
D-255	-0.6407461762428284	incubation EC HDLNYHA-IIIb phosphorylation eNOS-Ser phosphorylation eNOS-Thr
P-255	-3.0526 -0.0002 -0.0107 -1.5787 -3.0841 -0.8397 -2.0081 -0.2406 -0.1568 -0.0433 -0.0047 -0.4429 -0.1076 -0.2071 -0.8793 -0.0872 -0.0329 -0.0050 -0.0310 -0.0327 -2.0522 -0.0830 -0.1874 -0.5196 -0.1267 -0.1596 -0.0089 -0.0810 -0.1089 -0.0019 -4.1273 -0.2023
S-117	In conclusion, patients hospitalized for HF who have preserved LVEF experience similar long-term mortality as patients with mild or moderate reductions in LVEF, whereas severely reduced LVEF remains an independent predictor of long-term mortality in this population.<unk>
T-117	patients hospitalized hf preserved_lvef mortality patients lvef lvef mortality
H-117	-1.0835086107254028	▁ HF ▁ HF ▁LV EF
D-117	-1.0835086107254028	HF HF LVEF
P-117	-0.9208 -0.0299 -2.8949 -0.0685 -2.7507 -0.0458 -1.8911 -0.0664
S-1551	Although sarcoplasmic reticular (SR) Ca(2+)-uptake, as well as protein content for SR Ca(2+)-pump and phospholamban, were reduced in the infarcted hearts; these changes were partially reversible with metoprolol.<unk>
T-1551	sarcoplasmic_reticular protein phospholamban infarcted hearts metoprolol
H-1551	-0.4618796408176422	▁sar co plas mic ▁reti cular SR ▁ca (2 +) - up take ▁protein ▁content ▁SR ▁ca (2 +) - pump ▁ phos pho lam ban ▁in far cted _ heart s ▁met o pro lol
D-1551	-0.4618796408176422	sarcoplasmic reticularSR ca(2+)-uptake protein content SR ca(2+)-pump phospholamban infarcted_hearts metoprolol
P-1551	-0.0126 -0.0316 -0.3872 -1.6613 -0.5913 -0.0918 -0.7756 -2.4127 -0.3615 -0.0022 -0.0215 -0.0929 -0.3636 -2.5503 -2.6549 -0.2868 -1.3102 -0.2730 -0.0012 -0.0078 -0.0181 -0.1547 -0.0016 -0.0145 -0.6301 -0.1370 -0.1184 -0.0076 -0.9242 -0.4107 -0.7937 -0.0900 -0.2179 -0.0421 -0.0072 -0.0180 -0.0367 -0.0388
S-809	OBJECTIVE: Although global left ventricular longitudinal systolic strain (GLS) is a sensitive measure of left ventricular mechanics, its relationship with adverse cardiovascular (CV) events in atrial fibrillation (AF) has not been evaluated.<unk>
T-809	global_left_ventricular_longitudinal_systolic_strain gls left_ventricular cardiovascular atrial_fibrillation
H-809	-0.5235483050346375	▁global ▁left _ ▁vent ri cular _ ▁longitud in al _ ▁sy sto lic _ ▁strain ▁g LS ▁left _ ▁vent ri cular _ ▁mechanic s ▁advers e ▁cardiovascular _ CV ▁at rial _ ▁fi bril lation AF
D-809	-0.5235483050346375	global left_ ventricular_ longitudinal_ systolic_ strain gLS left_ ventricular_ mechanics adverse cardiovascular_CV atrial_ fibrillationAF
P-809	-0.0899 -1.7970 -0.4599 -1.6355 -0.3831 -0.3686 -1.5531 -0.0897 -0.0449 -0.0963 -0.1497 -1.3665 -0.0305 -0.0121 -0.6970 -0.0940 -0.2330 -0.0857 -0.4823 -0.8211 -0.2526 -0.3242 -0.2678 -0.4711 -0.3788 -0.0048 -0.7512 -0.0038 -0.9542 -1.3919 -0.2347 -2.7008 -0.0091 -0.6061 -1.0201 -0.0055 -0.0149 -0.9599 -0.0424 -0.0582
S-1109	Declines in early-onset and late-onset HF were observed for HF with reduced EF (<50%) but not for HF with preserved EF, indicating a change in the case mix of HF after MI that requires new prevention strategies.<unk>
T-1109	hf hf_with_reduced_ef hf_with_preserved_ef change hf mi
H-1109	-1.1951345205307007	▁ HF ▁ HF
D-1109	-1.1951345205307007	HF HF
P-1109	-0.4208 -0.2564 -1.1156 -0.0813 -5.2361 -0.0605
S-1118	In addition, treatment with carvedilol resulted in a lower von Willebrand factor than did metoprolol (149% ± 13% vs. 157% ± 13%, respectively, P = 0.01), irrespective of β2-adrenergic receptor haplotype.<unk>
T-1118	carvedilol von_willebrand_factor metoprolol β2-adrenergic_receptor_haplotype
H-1118	-0.5472284555435181	▁car vedi lol ▁met o pro lol ▁β 2- ad r energi c _ ▁receptor ▁ha plo type
D-1118	-0.5472284555435181	carvedilol metoprolol β2-adrenergic_ receptor haplotype
P-1118	-0.6073 -0.0172 -0.0628 -5.5283 -0.1898 -0.0154 -0.0441 -1.0347 -0.2903 -0.0239 -0.1562 -0.8892 -0.0275 -1.5166 -0.0950 -0.1954 -0.0025 -0.0089 -0.1762 -0.0634
S-1317	BACKGROUND: This study assessed the feasibility of a 12-week program of exercise, with and without intramuscular testosterone supplementation, in male patients with chronic heart failure (CHF) and low testosterone status and collected preliminary data for key health outcomes.<unk>
T-1317	exercise intramuscular_testosterone_supplementation patients chronic_heart_failure chf testosterone collected health outcomes
H-1317	-1.5514847040176392	▁in mus cular _ ▁testosteron e _ ▁supplement ation
D-1317	-1.5514847040176392	inmuscular_ testosterone_ supplementation
P-1317	-6.7825 -0.7295 -0.1154 -0.4699 -0.7615 -0.0138 -3.2454 -0.3660 -0.0450 -4.4962 -0.0411
S-187	BACKGROUND: In heart failure (HF), there are known differences in plasma B-type natriuretic peptide (BNP) levels between reduced and preserved ejection fraction (EF), but few HF studies have explored sex differences.<unk>
T-187	heart_failure hf plasma_b-type_natriuretic_peptide bnp preserved_ejection_fraction ef hf
H-187	-0.790045440196991	▁heart ▁failure ▁ HF ▁plasma ▁B - type ▁na tri ure tic _ pe pti de ▁b NP ▁reduce d _ ▁pres er ved _ e je ction ▁ fraction ▁ HF
D-187	-0.790045440196991	heart failure HF plasma B-type natriuretic_peptide bNP reduced_ preserved_ejection fraction HF
P-187	-1.0635 -0.1259 -2.4443 -0.0177 -1.5633 -1.7758 -0.0905 -0.0062 -0.2570 -0.0136 -1.0412 -2.5291 -0.5842 -0.4104 -0.0291 -0.2307 -1.4146 -0.1263 -3.9827 -0.0052 -0.4560 -2.8756 -0.0501 -0.2185 -0.1452 -1.2122 -0.1591 -0.0291 -1.4866 -0.0056 -0.7337 -0.4934 -1.2067 -0.0786
S-818	In direct comparison, GLS outperformed left ventricular ejection fraction (LVEF) and systolic mitral annulus velocity (Sa) in predicting adverse CV events both in univariate and multivariate models (p ≤ 0.043).<unk>
T-818	gls left_ventricular_ejection_fraction lvef systolic_mitral_annulus_velocity multivariate_models
H-818	-0.6731384992599487	▁g LS ▁out per form ed ▁left _ ▁vent ri cular _ e je ction ▁ fraction LV EF ▁sy sto lic _ met ral _ ▁ann ulus _ ▁veloci ty ▁sa
D-818	-0.6731384992599487	gLS outperformed left_ ventricular_ejection fractionLVEF systolic_metral_ annulus_ velocity sa
P-818	-0.3092 -0.3927 -4.5835 -0.0137 -0.0185 -0.1158 -0.1653 -0.6606 -2.1612 -0.8089 -0.9397 -0.8811 -1.2518 -0.1768 -0.3566 -1.3935 -0.0199 -0.2751 -0.0256 -0.0017 -0.0087 -0.0165 -0.1432 -1.4972 -0.1443 -0.1420 -2.6572 -0.1772 -0.7543 -0.3294 -0.0095 -0.1474 -2.1967 -0.1123
S-153	RM interventions included home telemonitoring (TM) (including implanted monitoring devices) with medical support provided during office hours or 24/7 and structured telephone support (STS) programmes delivered via human-to-human contact (HH) or human-to-machine interface (HM).<unk>
T-153	rm telemonitoring implanted medical structured_telephone_support sts human-to-human_contact hh human-to-machine_interface
H-153	-1.1618616580963135	▁home _ monitor ing TM ▁implant ed ▁monitoring ▁devices ▁medical ▁support ▁structure d _ ▁telephone _ support ▁( ST s ▁human - to - human ▁contact HH
D-153	-1.1618616580963135	home_monitoringTM implanted monitoring devices medical support structured_ telephone_support (STs human-to-human contactHH
P-153	-4.6471 -1.2360 -0.0195 -0.0122 -4.2084 -0.5655 -0.0582 -1.3913 -0.2072 -2.2928 -1.2552 -3.1657 -0.0032 -0.6456 -0.6724 -1.8627 -0.4616 -4.1749 -0.3122 -0.7018 -1.9563 -0.0165 -0.0067 -0.0308 -0.0213 -0.4561 -1.7287 -1.5307 -0.0532
S-794	OBJECTIVE: To investigate the within-day test-retest reliability of the Timed Up & Go (TUG) test in patients with advanced chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF), and chronic renal failure (CRF).<unk>
T-794	tug patients chronic_obstructive_pulmonary_disease copd chronic_heart_failure chf chronic_renal_failure crf
H-794	-1.1551647186279297	▁test - re test ▁Time d _ up _ go ▁tu g ▁patients ▁advanced ▁chronic _ ob struct ive _ ▁pulmonar y ▁disease co PD ▁chronic _ heart ▁failure CH F ▁chronic _ ▁renal ▁failure CR F
D-794	-1.1551647186279297	test-retest Timed_up_go tug patients advanced chronic_obstructive_ pulmonary diseasecoPD chronic_heart failureCHF chronic_ renal failureCRF
P-794	-5.6991 -0.1271 -0.0208 -0.0627 -4.2864 -0.0125 -0.3996 -0.4680 -0.5817 -2.4181 -0.4136 -1.7046 -5.1291 -3.3885 -1.1183 -0.2316 -0.9983 -0.1631 -0.1066 -0.3258 -0.1317 -0.0574 -1.2331 -3.3425 -0.0667 -0.0879 -0.0590 -3.1764 -0.1358 -2.6977 -0.7667 -0.7483 -0.7799 -0.3553 -0.8864 -2.2400 -0.4978 -0.0401 -0.0934
S-859	Using time-dependent Cox regression analysis, we compared patients treated with different types of beta-blockers or no beta-blockers on the primary endpoint of inappropriate therapy, delivered as antitachycardia pacing (ATP) or shock therapy.<unk>
T-859	cox_regression_analysis patients beta-blockers beta-blockers primary_endpoint therapy antitachycardia_pacing atp shock_therapy
H-859	-0.4024466574192047	▁co x ▁re gression analyse ▁beta - block ers ▁beta - block ers ▁in appropria te _ therapy ▁anti ta chy car dia ▁pa cing ▁a TP ▁shock ▁ therapy
D-859	-0.4024466574192047	cox regressionanalyse beta-blockers beta-blockers inappropriate_therapy antitachycardia pacing aTP shock therapy
P-859	-0.4752 -0.0046 -0.3429 -0.0094 -4.0945 -1.5226 -0.0378 -0.0443 -0.0288 -0.7668 -0.0285 -0.0707 -0.0467 -1.2408 -0.0208 -0.0315 -0.8806 -0.0475 -0.0055 -0.4281 -0.2796 -0.0064 -0.0170 -0.3208 -0.1922 -1.3086 -0.0498 -0.0452 -0.4129 -0.0057 -0.0438 -0.0687
S-1680	Two of the most ethically complex situations in pediatrics are those involving families whose religious beliefs preclude the provision of life-sustaining treatment and those involving young adults who have reached the age of legal majority and who face decisions about life-sustaining treatment.<unk>
T-1680	ethically legal decisions
H-1680	-1.152538537979126	▁et h ically _ ▁complex ▁pediatr ics ▁religious _ ▁belief s
D-1680	-1.152538537979126	ethically_ complex pediatrics religious_ beliefs
P-1680	-0.6159 -0.0498 -0.5415 -2.1197 -2.7966 -1.6781 -0.1659 -2.1835 -0.7578 -0.6096 -0.0562 -3.3598 -0.0485
S-1122	BACKGROUND: Little is known about how often contextual factors such as patient preferences and competing priorities impact prescribing of guideline-recommended medications, or about the extent to which these factors are documented in medical records and available to performance measurement systems.<unk>
T-1122	patient prescribing medications medical
H-1122	-1.073556661605835	▁patient ▁preference s ▁guide line - re com mend ed _ ▁medication s
D-1122	-1.073556661605835	patient preferences guideline-recommended_ medications
P-1122	-6.9198 -0.1518 -0.0261 -5.4393 -0.0116 -0.0813 -0.0076 -0.0143 -0.0210 -0.0822 -1.9210 -0.1877 -0.0571 -1.1149 -0.0676
S-1241	The total cost per patient was not significantly different between rhythm-control ($72,764 [95% CI, $61,575-$85,145]) and rate-control ($78,767 [95% CI, $67,101-$92,139]) strategies.<unk>
T-1241	cost patient rhythm-control rate-control
H-1241	-1.3262089490890503	▁ rhythm - control
D-1241	-1.3262089490890503	rhythm-control
P-1241	-0.4751 -3.7419 -0.1499 -0.0040 -3.2369 -0.3493
S-393	Median age was 70 years (Q, 61-77), 28% were women, median left ventricular ejection fraction was 30% (Q, 24-40), and median eGFR was 68 (Q, 51-85) mL/min per 1.73 m(2).<unk>
T-393	left_ventricular_ejection_fraction egfr
H-393	-1.0474210977554321	▁media n _ ▁age ▁women ▁media n _ ▁left _ ▁vent ri cular ▁e je ction ▁ fraction ▁media n ▁e G FR
D-393	-1.0474210977554321	median_ age women median_ left_ ventricular ejection fraction median eGFR
P-393	-1.3569 -0.0274 -1.5234 -2.7341 -4.8012 -1.2641 -0.0534 -0.5599 -2.5954 -0.4608 -0.9147 -0.6231 -0.8834 -1.1358 -0.2704 -0.1730 -1.3210 -0.0101 -1.2666 -0.0294 -0.9539 -1.4673 -0.1897 -1.3601 -0.2104
S-127	A decrease in CD34+VEGFR2+ cells was independently associated with increased functional capacity; a 10-cell decrease in CD34+VEGFR2+ cells was associated with an increase of 0.2 mL/kg/min in peak VO2 (P < 0.05).<unk>
T-127	cells functional_capacity cells peak_vo2
H-127	-1.0066584348678589	▁CD 34 _ ve g FR 2 + ▁cell s ▁functional ▁capacity ▁CD 34 _ ve g FR 2 + ▁cell s
D-127	-1.0066584348678589	CD34_vegFR2+ cells functional capacity CD34_vegFR2+ cells
P-127	-0.8103 -0.2649 -2.9050 -0.2221 -1.8696 -0.4243 -0.1915 -1.0510 -0.2472 -0.0362 -1.1157 -1.0241 -2.4208 -0.1682 -2.5388 -0.9783 -1.5142 -1.6230 -0.1328 -1.0035 -1.5303 -0.0410 -1.9679 -0.0791
S-1773	When grouped into categories of fit and unfit (upper 80% and lower 20% of CRF distribution, respectively), hazard ratios were significantly lower in fit compared with unfit men in normal and overweight body mass index strata (P<0.002) but not in obese men.<unk>
T-1773	crf hazard_ratios body_mass_index obese
H-1773	-1.3117531538009644	▁fit ▁un fit ▁c RF
D-1773	-1.3117531538009644	fit unfit cRF
P-1773	-0.5755 -1.4929 -0.0147 -3.5118 -0.0765 -3.4449 -0.0660
S-2	This study used the Medicare Patient Safety Monitoring System (MPSMS) database to assess national trends in adverse event rates between 2005 through 2011 for patients hospitalized with acute myocardial infarction, congestive heart failure, pneumonia, or conditions requiring surgery.<unk>
T-2	medicare_patient_safety_monitoring_system mpsms adverse_event patients hospitalized acute_myocardial_infarction congestive_heart_failure pneumonia conditions surgery
H-2	-0.6525029540061951	▁Medica re _ ▁Patient _ ▁Safety ▁Monitor ing ▁System MP SMS _ ▁database ▁advers e _ ▁event ▁rates ▁a cute _ my o card ial _ in far ction ▁con ges tive _ heart ▁failure ▁pneu monia ▁surgery
D-2	-0.6525029540061951	Medicare_ Patient_ Safety Monitoring SystemMPSMS_ database adverse_ event rates acute_myocardial_infarction congestive_heart failure pneumonia surgery
P-2	-0.0561 -0.0013 -1.2443 -0.6694 -1.2468 -0.2989 -1.0016 -0.0157 -1.5862 -1.1499 -0.1170 -3.2323 -2.1084 -0.6693 -0.0072 -0.1739 -1.6206 -0.6597 -1.7498 -0.0043 -0.0433 -3.8832 -0.2220 -0.3175 -0.1005 -0.4884 -0.6663 -0.0201 -0.0287 -0.0393 -0.0295 -0.1800 -0.0372 -1.3563 -0.0991 -0.0097 -0.0915 -0.7686 -0.0466 -0.0597
S-382	The HFPSI model included blood urea nitrogen, B-type natriuretic peptide, New York Heart Association class, diabetes status, history of atrial fibrillation/flutter, and all-cause hospitalization within the prior 1 and 2 to 6 months.<unk>
T-382	hfpsi blood_urea_nitrogen b-type_natriuretic_peptide new_york_heart_association_class diabetes atrial_fibrillation all-cause_hospitalization
H-382	-0.6119081377983093	▁ HF PSI ▁blood ▁u rea ▁nit rogen ▁na tri ure tic _ pe pti de ▁New ▁York _ ▁Heart ▁Association ▁diabetes ▁status ▁at rial ▁fi bril lation flu tter
D-382	-0.6119081377983093	HFPSI blood urea nitrogen natriuretic_peptide New York_ Heart Association diabetes status atrial fibrillationflutter
P-382	-0.2292 -0.3335 -3.3691 -4.5353 -0.0349 -0.1766 -0.0597 -0.0086 -1.3547 -0.0154 -0.2765 -1.2786 -0.4102 -0.3907 -0.0116 -0.0620 -0.1093 -0.1560 -0.6946 -0.5721 -0.4793 -0.4470 -1.3781 -0.8312 -0.0077 -0.7792 -0.0121 -0.0891 -0.7043 -0.0054 -0.7253 -0.0437
S-852	The primary outcome occurred in 116 of 404 patients in the CRT group, as compared with 102 of 405 in the control group (28.7% vs. 25.2%; hazard ratio, 1.20; 95% confidence interval [CI], 0.92 to 1.57; P=0.15).<unk>
T-852	primary_outcome patients crt hazard_ratio confidence_interval
H-852	-1.1711291074752808	▁c RT _ groep ▁hazard ▁ratio
D-852	-1.1711291074752808	cRT_groep hazard ratio
P-852	-0.5878 -0.3466 -3.2232 -0.2640 -2.5710 -0.1713 -2.1546 -0.0504
S-1311	The crude 28-day case-fatality rate for patients with concurrent HF declined marginally from 20.5% to 15.9% (P < 0.05) compared with those without concurrent HF, in whom the case-fatality rate declined from 11.0% to 4.8% (P < 0.001).<unk>
T-1311	case-fatality_rate patients hf hf case-fatality_rate
H-1311	-1.277542233467102	▁cru de _ in day _ case - fat ality ▁ HF
D-1311	-1.277542233467102	crude_inday_case-fatality HF
P-1311	-2.4640 -0.0133 -0.4323 -5.0856 -2.1814 -0.1533 -1.5319 -0.0574 -0.0198 -0.0023 -3.1003 -0.3416 -2.4475 -0.0550
S-659	BACKGROUND: The objective of this study is to examine practice-level variation in rates of guideline-recommended treatment for outpatients with heart failure and reduced ejection fraction, and to examine the association between treatment variation and practice site, independent of patient factors.<unk>
T-659	outpatients heart_failure_and_reduced_ejection_fraction patient
H-659	-0.7710054516792297	▁guide line - re com mend ed _ ▁treatment _ out patient s ▁heart ▁failure ▁reduce d _ e je ction _ fraction
D-659	-0.7710054516792297	guideline-recommended_ treatment_outpatients heart failure reduced_ejection_fraction
P-659	-6.9820 -0.0046 -0.2380 -0.0049 -0.0133 -0.0166 -0.0700 -0.8549 -1.5247 -2.8437 -1.3120 -0.0029 -0.0345 -1.1589 -0.0634 -0.2842 -0.0146 -0.3723 -1.3847 -0.1176 -0.0090 -1.0927 -0.0088 -0.7768 -0.0900
S-1453	This cohort formed the sampling frame for selecting controls (without CHF) matched on: age, race/ethnicity, cumulative anthracycline exposure, stem cell source (allogeneic, autologous), and length of follow-up.<unk>
T-1453	frame chf anthracycline stem_cell allogeneic autologous follow-up
H-1453	-1.2908400297164917	▁co hor t ▁sa mp ling _ frame _ control s ▁CHF
D-1453	-1.2908400297164917	cohort sampling_frame_controls CHF
P-1453	-3.3518 -0.0237 -0.0169 -2.1428 -0.1509 -0.0475 -1.2958 -0.2435 -4.5997 -0.7940 -0.0876 -0.7950 -4.4903 -0.0322
S-765	Resting tension (Fpassive)-sarcomere length relations were obtained in small muscle strips before and after KCl-KI treatment, which unanchors titin and allows contributions of titin and extracellular matrix to Fpassive to be discerned.<unk>
T-765	resting_tension fpassive muscle kcl-ki titin titin extracellular_matrix fpassive
H-765	-1.2584165334701538	▁wind ing ▁tension _ F pass ive _ - sar com ere _ leng ▁relations ▁muscle ▁strip s ▁k c l - KI
D-765	-1.2584165334701538	winding tension_Fpassive_-sarcomere_leng relations muscle strips kcl-KI
P-765	-5.2241 -0.5661 -2.1838 -3.5900 -1.6371 -0.1764 -0.0248 -0.7779 -2.3219 -0.2949 -0.0072 -0.0663 -1.3840 -1.1169 -1.2404 -5.3468 -0.1604 -0.0071 -1.1624 -0.2545 -0.0190 -0.0192 -0.0450 -3.7925 -0.0418
S-1922	The combined aerobic and resistance training intervention with augmented feedback resulted in benefits in exercise capacity, muscle strength and quality of life, as well as an improvement of cardiac (NT-ProBNP) and inflammatory (IL6, hsCRP) biomarkers.<unk>
T-1922	training exercise_capacity muscle quality_of_life cardiac nt-probnp inflammatory il6 hscrp biomarkers
H-1922	-1.1643937826156616	▁aero bic _ ▁resist ance _ training
D-1922	-1.1643937826156616	aerobic_ resistance_training
P-1922	-0.0503 -0.0743 -1.6076 -1.6323 -0.0316 -2.1783 -0.1839 -4.6644 -0.0568
S-135	OBJECTIVE: To quantify the differential impact on hospital performance of three readmission metrics: all-cause readmission (ACR), 3M Potential Preventable Readmission (PPR), and Centers for Medicare and Medicaid 30-day readmission (CMS).<unk>
T-135	hospital readmission all-cause_readmission acr potential_preventable_readmission ppr medicare medicaid readmission cms
H-135	-0.7685550451278687	▁read mission ▁a CR ▁Potential _ preven en table _ ▁Read mission ▁p PR ▁Center s ▁Medica re ▁Medica id ▁c MS
D-135	-0.7685550451278687	readmission aCR Potential_prevenentable_ Readmission pPR Centers Medicare Medicaid cMS
P-135	-4.3442 -1.1215 -1.4962 -1.0912 -1.2900 -0.7832 -0.6218 -0.0681 -0.4371 -0.0441 -1.1990 -0.2009 -0.3315 -0.0799 -0.3523 -0.0606 -1.0176 -0.0089 -1.6681 -0.0450 -1.7285 -0.2743 -0.0953 -0.0857
S-1547	In order to examine the reversibility of heart failure due to myocardial infarction (MI) by β-adrenoceptor blockade, 12 weeks infarcted rats were treated with or without metoprolol (50 mg/kg/day) for 8 weeks.<unk>
T-1547	heart_failure myocardial_infarction mi β-adrenoceptor_blockade infarcted metoprolol
H-1547	-0.6012266874313354	▁heart ▁failure ▁my o card ial _ in far ction ▁m ▁β - ad re no cept or ▁block ade ▁in far cted _ ▁rat s ▁met o pro lol
D-1547	-0.6012266874313354	heart failure myocardial_infarction m β-adrenoceptor blockade infarcted_ rats metoprolol
P-1547	-5.5859 -0.3668 -1.7246 -0.2831 -0.2909 -0.1800 -0.9549 -0.4889 -0.0160 -0.0627 -2.8416 -0.9557 -0.0040 -0.0067 -0.2502 -0.1826 -0.2390 -0.1616 -0.7734 -0.0398 -1.1552 -0.0269 -0.5579 -1.3550 -0.0523 -0.1056 -0.1213 -0.1205 -0.0124 -0.0444 -0.2355 -0.0437
S-1882	The exercise duration was increased from 8 min to 23 min after rehabilitation (P < 0.001); distance 6 minutes walking was increased from 394 m to 470 m (P < 0.05); score of Minnesota quality of life was decreased from 25 to 3 in exercise group (P < 0.01).<unk>
T-1882	exercise rehabilitation walking minnesota_quality_of_life exercise
H-1882	-1.9708610773086548	
D-1882	-1.9708610773086548	
P-1882	-3.8883 -0.0534
S-218	Congestive heart failure visits declined from 1.6% of all ED visits in 1996 to 1.2% in 2008, a 26% relative decrease (95% CI: 21%-30%, P < .001, correlation coefficient R(2) = 0.94, P < .001).<unk>
T-218	congestive_heart_failure correlation_coefficient
H-218	-0.9246736764907837	▁con ges tive _ heart ▁failure ▁visit s
D-218	-0.9246736764907837	congestive_heart failure visits
P-218	-0.7596 -0.0086 -0.3583 -0.0860 -1.8686 -0.6945 -2.7646 -0.0386 -2.6005 -0.0675
S-637	Excessive secretion of arginine vasopressin (AVP) has the potential for deleterious effects on various physiologic processes in CHF Inhibition of AVP through vasopressin receptor antagonist therapy is a potentially beneficial new therapeutic approach to CHF.<unk>
T-637	arginine_vasopressin avp physiologic chf avp vasopressin_receptor_antagonist therapy therapeutic chf
H-637	-0.8122883439064026	▁argi nine ▁vaso press in ▁a VP ▁physio logic _ process es ▁CHF
D-637	-0.8122883439064026	arginine vasopressin aVP physiologic_processes CHF
P-637	-2.3174 -0.1890 -0.3904 -0.0610 -0.2632 -0.4781 -0.0249 -3.8930 -0.2622 -0.9565 -0.1536 -0.0330 -0.0628 -2.9961 -0.1032
S-1205	(1) With therapies ranging from medication and physical therapy to implantable defibrillators and circulatory support, and possibly transplantation, accurate risk stratification of patient with heart failure and delivery of therapies appropriate to the level of their disease severity is becoming increasingly important.<unk>
T-1205	therapies medication physical_therapy implantable_defibrillators circulatory_support transplantation risk_stratification patient heart_failure therapies disease
H-1205	-0.570221483707428	▁medication ▁physical ▁ therapy ▁implant able ▁de fi br illa tors ▁circula tory ▁support ▁transplant ation
D-1205	-0.570221483707428	medication physical therapy implantable defibrillators circulatory support transplantation
P-1205	-2.9026 -1.9709 -0.5558 -0.0033 -0.1067 -0.0109 -0.0659 -0.0208 -0.1182 -0.0702 -0.1671 -0.0006 -0.0155 -1.4042 -0.0818 -0.0224 -2.6761 -0.0709
S-961	Rats were then sacrificed and hearts were rapidly excised for estimation of caspase-3 activity, phosphocreatine and adenine nucleotides contents in addition to cytochrome c, Bcl2, Bax and caspase 3 expression.<unk>
T-961	hearts caspase-3 activity phosphocreatine adenine_nucleotides cytochrome_c bcl2 bax caspase_3 expression
H-961	-0.4022449851036072	▁rat s ▁ phos pho creati ne ▁a den ine ▁nucleo ti des ▁cy to ch rom e ▁b cl 2 ▁Bax ▁cas pas e ▁3
D-961	-0.4022449851036072	rats phosphocreatine adenine nucleotides cytochrome bcl2 Bax caspase 3
P-961	-0.4624 -0.2262 -4.0544 -0.5460 -0.2671 -0.4165 -0.2880 -0.0776 -0.0033 -0.4782 -0.8528 -0.0187 -0.0243 -0.4342 -0.0147 -0.0217 -0.0004 -0.0817 -0.2342 -0.0107 -0.0311 -0.0048 -0.0932 -0.0313 -0.1823 -1.5709 -0.7569 -0.0791
S-166	After 7 weeks rapid right ventricular pacing, gene expressions of Bax, Bcl-2 and Caspase-3 were measured by RTQ-PCR from interventricular septum biopsies that were taken weekly in 21 beagle dogs during the development of heart failure.<unk>
T-166	right_ventricular_pacing gene_expressions bax bcl-2 caspase-3 rtq-pcr interventricular_septum biopsies heart_failure
H-166	-0.4988301992416382	▁rapid _ ▁vent ri cular _ pa cing ▁Bax ▁b cl -2 ▁Cas pas e -3 ▁RT q - PC r ▁interven tri cular _ ▁sept um ▁bio psi es ▁beag le ▁dog s ▁heart ▁failure
D-166	-0.4988301992416382	rapid_ ventricular_pacing Bax bcl-2 Caspase-3 RTq-PCr interventricular_ septum biopsies beagle dogs heart failure
P-166	-3.8832 -0.1911 -3.1104 -0.2183 -0.1278 -0.3609 -0.8185 -0.0394 -0.3258 -0.8534 -0.0520 -0.7809 -0.0232 -0.0061 -0.0119 -0.5364 -0.7770 -0.8666 -0.0456 -0.1140 -0.2629 -0.0265 -0.0032 -0.1120 -0.2908 -0.4921 -0.0077 -0.0194 -0.0162 -0.0155 -0.0033 -0.0190 -1.6903 -0.0666 -1.5998 -1.1093 -0.0393 -0.0396
S-661	Practice rates of treatment with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and β-blockers and an optimal combined treatment measure were determined for patients with heart failure and reduced ejection fraction and no documented contraindications.<unk>
T-661	angiotensin-converting_enzyme_inhibitors angiotensin_receptor_blockers β-blockers patients heart_failure_and_reduced_ejection_fraction
H-661	-0.6625480651855469	▁ang io ten sin - con ver ting _ ▁enzym e ▁inhibi tors _ angi oten sin ▁receptor ▁block ers ▁β - block ers
D-661	-0.6625480651855469	angiotensin-converting_ enzyme inhibitors_angiotensin receptor blockers β-blockers
P-661	-4.9582 -0.7269 -0.0815 -1.2851 -0.3401 -0.0133 -0.0056 -0.2462 -1.1849 -0.3844 -0.0293 -0.0309 -0.4333 -2.5685 -0.1616 -0.0314 -0.4092 -1.3964 -0.8115 -0.0514 -0.0088 -0.0077 -0.0232 -0.0333 -1.9426 -0.0610
S-918	We hypothesized that the sodium-restricted dietary approaches to stop hypertension diet (DASH/SRD) would improve left ventricular diastolic function, arterial elastance, and ventricular-arterial coupling in hypertensive HFPEF.<unk>
T-918	dietary_approaches_to_stop_hypertension dash left_ventricular_diastolic_function arterial_elastance ventricular-arterial_coupling hypertensive_hfpef
H-918	-0.7031506896018982	▁so dium - re strict ed _ ▁dieta ry _ ▁approach es ▁stop ▁hyper tension ▁die t DAS h / S RD ▁vent ri cular - arte rial _ ▁coup ling ▁hyper tensi ve
D-918	-0.7031506896018982	sodium-restricted_ dietary_ approaches stop hypertension dietDASh/SRD ventricular-arterial_ coupling hypertensive
P-918	-0.0263 -0.0274 -0.0031 -0.0035 -0.0056 -0.0100 -0.8661 -2.9810 -0.2740 -1.7944 -2.8073 -0.0432 -3.4881 -1.4460 -0.0350 -1.3619 -0.0273 -0.1248 -0.1295 -1.4874 -1.0731 -0.3037 -1.2880 -0.4025 -0.1079 -0.6131 -0.2605 -0.0089 -0.5071 -0.8432 -0.1243 -0.6822 -0.1604 -0.0247 -1.9177 -0.0542
S-1017	Despite neutral results in many acute HF trials, recent studies including RELAX-AHF, ASTRONAUT, and PRONTO have highlighted the role of appropriate timing of patient enrollment, targeting the "right" patients, and selecting appropriate end points and sites.<unk>
T-1017	acute_hf relax-ahf astronaut pronto patient patients end_points
H-1017	-0.5443154573440552	▁a cute _ HF _ ▁trial s ▁RELA X - a HF ▁ AST RON AUT ▁PR ONTO
D-1017	-0.5443154573440552	acute_HF_ trials RELAX-aHF ASTRONAUT PRONTO
P-1017	-0.6577 -0.0030 -0.2841 -0.2946 -2.8570 -2.9744 -0.0285 -0.2437 -0.3443 -0.0121 -0.8406 -0.1978 -0.2312 -0.0138 -0.2617 -0.0032 -0.1101 -0.0011 -1.4788 -0.0486
S-1119	CONCLUSION: Compared with metoprolol, carvedilol resulted in greater reduction of sympathetic activity after 6 wk of treatment and lower von Willebrand factor concentrations in both Arg16/Gln27 and Gly16/Glu27 individuals.<unk>
T-1119	metoprolol carvedilol sympathetic_activity von_willebrand_factor
H-1119	-0.5579150915145874	▁met o pro lol ▁car vedi lol ▁sympa the tic
D-1119	-0.5579150915145874	metoprolol carvedilol sympathetic
P-1119	-0.2065 -0.1681 -0.0084 -0.0248 -0.0166 -0.0130 -0.0229 -0.3603 -0.0840 -0.1962 -5.5583 -0.0359
S-1832	MEASUREMENTS: Hospitalized HF, identified by International Classification of Diseases, Ninth Revision, Clinical Modification codes 402.x1, 404.x1, 404.x3, and 428.xx recorded as the principal discharge diagnosis.<unk>
T-1832	hospitalized hf international_classification_of_diseases clinical principal discharge diagnosis
H-1832	-0.6736170053482056	▁Hospital ized _ HF ▁Nin th _ ▁Re vision ▁Clinic al _ ▁Modifica tion ▁code s
D-1832	-0.6736170053482056	Hospitalized_HF Ninth_ Revision Clinical_ Modification codes
P-1832	-2.4255 -0.0311 -1.1211 -0.1958 -4.2741 -0.0129 -0.2043 -1.0617 -0.0093 -0.4168 -0.0013 -0.8350 -0.0273 -0.0339 -0.0694 -0.0471 -1.3050 -0.0534
S-1676	In addition, Rad Q65P attenuates the gating movement of both channels as effectively as wild-type Rad, indicating that the Q65P substitution does not differentially impair any of the three described modes of L-type channel inhibition by RGK proteins.<unk>
T-1676	rad q65p movement wild-type_rad q65p l-type_channel rgk_proteins
H-1676	-1.0368919372558594	▁Rad ▁Q 65 p ▁ga ting _ ▁movement ▁wild - type _ Rad ▁Q 65 p
D-1676	-1.0368919372558594	Rad Q65p gating_ movement wild-type_Rad Q65p
P-1676	-0.5676 -1.0216 -0.2797 -0.8734 -5.2457 -0.0162 -0.9791 -0.1677 -1.5699 -0.0093 -0.0022 -0.3502 -0.9941 -1.2991 -0.0892 -0.9217 -4.1744 -0.1031
S-876	SS20 had only modest effects on heart failure and this tracked with only partial attenuation of global proteomics changes; furthermore, actin cytoskeleton pathways were significantly protected in SS20, whereas mitochondrial and metabolic pathways essentially were not.<unk>
T-876	ss20 heart_failure proteomics actin_cytoskeleton ss20 mitochondrial metabolic_pathways
H-876	-1.4280390739440918	▁heart ▁failure ▁global _ prote o mics
D-876	-1.4280390739440918	heart failure global_proteomics
P-876	-4.5978 -0.6348 -1.5736 -0.8884 -1.0237 -0.4514 -0.0018 -3.5971 -0.0839
S-324	Echocardiograms were taken of the left ventricular base, midpapillary, and apex during baseline, IVC occlusion, and each BiVP setting for STE analysis of twist, apical and basal rotations, CS, RS, and synchrony.<unk>
T-324	echocardiograms left_ventricular_base midpapillary apex baseline ivc_occlusion bivp ste rs
H-324	-0.45144134759902954	▁e cho card i ogram s ▁left ▁vent ri cular ▁base ▁mid pap illa ry ▁ap ex ▁IV c
D-324	-0.45144134759902954	echocardiograms left ventricular base midpapillary apex IVc
P-324	-0.5767 -0.0025 -0.0201 -0.1147 -0.0011 -0.1999 -0.1615 -0.0587 -0.3138 -0.0355 -1.5006 -0.2804 -0.0740 -0.0397 -0.0646 -0.9349 -0.0218 -0.2906 -0.2958 -4.4308 -0.0627
S-1145	It was demonstrated that the long-term administration of pyridostigmine started right after coronary artery ligation augmented cardiac vagal and reduced sympathetic tone, attenuating cardiac remodeling and left ventricular dysfunction during the progression of HF in rats.<unk>
T-1145	administration pyridostigmine coronary_artery_ligation cardiac sympathetic_tone cardiac_remodeling left_ventricular_dysfunction hf
H-1145	-0.23367144167423248	▁py rido stig mine ▁corona ry ▁arter y ▁liga tion ▁cardiac ▁va gal ▁sympa the tic _ ▁tone ▁cardiac ▁remodel ing ▁left ▁vent ri cular ▁dys function ▁ HF
D-1145	-0.23367144167423248	pyridostigmine coronary artery ligation cardiac vagal sympathetic_ tone cardiac remodeling left ventricular dysfunction HF
P-1145	-0.6362 -0.0064 -0.0003 -0.0456 -0.4476 -0.1508 -0.2577 -0.0915 -0.0499 -0.2758 -0.3169 -0.0118 -0.0051 -0.0985 -0.0372 -0.1757 -1.1332 -0.0833 -0.0507 -0.0683 -0.0147 -0.2598 -0.7854 -0.3876 -0.1633 -1.1255 -0.0487 -0.2867 -0.0404 -0.1553 -0.0339
S-1229	(A Comparison Of Outcomes In Patients In New York Heart Association [NYHA] Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines [EMPHASIS-HF Study]; NCT00232180).<unk>
T-1229	outcomes patients new_york_heart_association nyha heart_failure eplerenone placebo heart_failure medicines emphasis-hf
H-1229	-1.252610445022583	▁ europe se _ heart _ association ▁ny HA ▁Class ▁II _ ▁Heart ▁Fail ure ▁e pler en one ▁Place bo ▁standard _ heart _ ▁Fail ure _ ▁Medicine s EMP HA SIS - HF
D-1229	-1.252610445022583	europese_heart_association nyHA Class II_ Heart Failure eplerenone Placebo standard_heart_ Failure_ MedicinesEMPHASIS-HF
P-1229	-2.8407 -6.1802 -0.1612 -0.0772 -3.6696 -1.2347 -0.7585 -3.5213 -0.9796 -4.0096 -1.1719 -0.2817 -1.6837 -0.9950 -0.7525 -0.4185 -0.0039 -0.1497 -0.3378 -0.6392 -0.0022 -4.3016 -0.1154 -1.6329 -0.6693 -1.5782 -1.3174 -1.9453 -0.1907 -0.0219 -2.3041 -1.1156 -0.5893 -0.1567 -0.0366 -0.3846 -0.1186
S-1418	RESULTS: In the first month after discharge, 5336 (21.9%) of the 24 373 identified patients had no follow-up visits, 16 855 (69.2%) saw a familiar physician, and 2182 (9.0%) saw unfamiliar physician(s) exclusively.<unk>
T-1418	discharge patients follow-up physician physician
H-1418	-1.4926005601882935	
D-1418	-1.4926005601882935	
P-1418	-2.9363 -0.0489
S-1665	As a consequence of the worldwide increase in life expectancy, and due to improvements in the treatment of heart failure in recent years, the proportion of patients that reach an advanced phase of the disease, so-called end stage, refractory or terminal heart failure, is steadily growing.<unk>
T-1665	life_expectancy heart_failure patients disease terminal_heart_failure
H-1665	-1.7620720863342285	▁heart ▁failure
D-1665	-1.7620720863342285	heart failure
P-1665	-5.7644 -0.5723 -0.6393 -0.0723
S-723	METHODS: We performed a single-center, retrospective chart review of all heart failure discharges at the University of Connecticut Health Center (398 patients) the year before (2008) and the year after (2011) a quality improvement initiative that included mandatory 7-day follow-up visits.<unk>
T-723	heart_failure discharges university_of_connecticut_health_center patients follow-up
H-723	-1.2234293222427368	▁heart ▁failure _ ▁dis charge s ▁University ▁of _ ▁Connect i cut _ health ▁Center
D-723	-1.2234293222427368	heart failure_ discharges University of_ Connecticut_health Center
P-723	-6.4344 -1.2021 -2.6689 -2.1359 -0.0490 -0.0806 -2.1081 -0.9941 -0.6746 -1.2788 -0.0185 -0.0474 -0.2367 -1.6663 -0.5460 -0.6095 -0.0473
S-1959	Pulmonary capillary wedge pressure was reduced from a mean of 23 mm Hg (SD 5) at baseline to 17 mm Hg (8) at 3 months (p=0·035), with no changes in right atrial pressure, pulmonary arterial pressure, or pulmonary resistance.<unk>
T-1959	pulmonary_capillary_wedge_pressure baseline right_atrial_pressure pulmonary_arterial_pressure pulmonary_resistance
H-1959	-0.9522526860237122	▁Pul mon ary _ cap illa ry _ ▁we dge _ ▁pressure ▁h g ▁pulmonar y _ ▁arterial _ ▁pressure ▁pulmonar y ▁resist ance
D-1959	-0.9522526860237122	Pulmonary_capillary_ wedge_ pressure hg pulmonary_ arterial_ pressure pulmonary resistance
P-1959	-1.2827 -1.4927 -0.2688 -0.3588 -1.9761 -0.3658 -0.0613 -0.6236 -0.8391 -0.0718 -1.2244 -0.2239 -6.2612 -0.1437 -3.5004 -0.0087 -0.5244 -0.5471 -1.4841 -2.1893 -0.0010 -0.0240 -1.1304 -0.0235 -0.0849 -0.0471
S-1015	The last decade of acute heart failure (HF) research is characterized by disappointments in large phase 2 and 3 pharmacologic studies of therapeutics including calcium-sensitizing agents and antagonists of endothelin, vasopressin, and adenosine.<unk>
T-1015	acute_heart_failure hf pharmacologic therapeutics calcium-sensitizing_agents antagonists endothelin vasopressin adenosine
H-1015	-0.4510831832885742	▁a cute _ heart ▁failure ▁ HF ▁ pharma c ologic ▁studies ▁calci um - sensi t izing ▁agents ▁en do the lin ▁vaso press in ▁ad enos ine
D-1015	-0.4510831832885742	acute_heart failure HF pharmacologic studies calcium-sensitizing agents endothelin vasopressin adenosine
P-1015	-0.3128 -0.0083 -0.0655 -0.7211 -0.4652 -2.3451 -0.4392 -1.0603 -0.3087 -0.0229 -0.0614 -2.9481 -0.0626 -0.0174 -0.0286 -0.0091 -0.9273 -0.0073 -1.5946 -0.1409 -0.0419 -0.0922 -1.8280 -0.0050 -0.0060 -0.0719 -0.0035 -0.0029 -0.2507 -0.0741 -0.0610
S-542	OBJECTIVES: New-onset aortic insufficiency (AI) can be encountered after instituting mechanical circulatory support and seems more common and severe with continuous flow (CF) left ventricular assist devices (LVADs) compared with pulsatile devices.<unk>
T-542	aortic_insufficiency mechanical_circulatory_support continuous_flow left_ventricular_assist_devices lvads pulsatile_devices
H-542	-0.5154452323913574	▁a or tic _ insu ffi cie ncy ▁mechanic al ▁circula tory ▁support ▁continuo us _ ▁flow ▁left _ ▁vent ri cular _ assist ▁devices ▁l VAD s ▁pulsa tile ▁devices
D-542	-0.5154452323913574	aortic_insufficiency mechanical circulatory support continuous_ flow left_ ventricular_assist devices lVADs pulsatile devices
P-542	-0.3191 -0.0880 -0.9153 -0.6432 -0.6390 -0.4473 -0.6319 -0.0149 -1.2596 -0.0056 -0.4676 -0.0868 -1.7999 -0.0812 -0.0338 -0.3451 -0.1405 -2.8375 -0.7854 -0.5499 -0.1960 -0.1683 -0.4558 -0.3554 -0.5343 -0.6183 -0.0051 -0.9848 -0.0027 -0.0023 -1.4779 -0.0534 -0.0635
S-1047	In vivo experiments of HF induced in mice via phenylephrine or haemodynamic stress (using the surgical method of transverse aortic constriction (TAC)) showed that JQ1 protected against several pathological changes, including cardiac hypertrophy.<unk>
T-1047	in_vivo hf phenylephrine haemodynamic surgical transverse_aortic_constriction tac jq1 pathological cardiac_hypertrophy
H-1047	-0.5373018383979797	▁ HF ▁ HF ▁ phen yle ph rine ▁ha emo dynamic _ ▁stress ▁sur g ical _ methode ▁trans verse _ a or tic _ con stri ction ▁ TAC ▁cardiac ▁hyper trop hy
D-1047	-0.5373018383979797	HF HF phenylephrine haemodynamic_ stress surgical_methode transverse_aortic_constriction TAC cardiac hypertrophy
P-1047	-0.2025 -0.0375 -0.8812 -0.8607 -0.8078 -1.0219 -0.0126 -0.0885 -0.0141 -0.0112 -0.0246 -0.0006 -1.2513 -0.5980 -2.3818 -0.0834 -0.0514 -0.5657 -0.5380 -0.0077 -0.0520 -0.1534 -0.9623 -0.0799 -0.6347 -0.0953 -0.9568 -0.1102 -0.0109 -3.1909 -0.0058 -2.4481 -1.2372 -0.0021 -0.3889 -0.0855 -0.0256
S-1490	This review aims to look first at the evidence for these drugs, and second at the newer drugs that act on the RAAS, namely, direct renin inhibitors, neutral endopeptidase inhibitors, vasopeptidase inhibitors, and angiotensin receptor blockers.<unk>
T-1490	evidence drugs drugs raas renin_inhibitors endopeptidase_inhibitors vasopeptidase_inhibitors angiotensin_receptor_blockers
H-1490	-0.3891999125480652	▁drugs ▁RA as ▁direct ▁re nin ▁inhibi tors ▁neutral ▁en dop ep tida se ▁inhibi tors ▁vaso pe pti das e ▁inhibi tors ▁ang io ten sin ▁receptor ▁block ers
D-1490	-0.3891999125480652	drugs RAas direct renin inhibitors neutral endopeptidase inhibitors vasopeptidase inhibitors angiotensin receptor blockers
P-1490	-3.7233 -2.4169 -0.1280 -0.0207 -0.3815 -0.5368 -0.0634 -0.0451 -0.1086 -0.4781 -0.0558 -0.4535 -0.0142 -0.0296 -0.9592 -0.0668 -0.0068 -0.0401 -0.0779 -1.4744 -0.0416 -0.0753 -0.0834 -0.1193 -0.1063 -0.0224 -0.1963 -0.2381 -0.3036 -0.0163 -0.1127 -0.0586
S-1216	Accordingly, PDE2 overexpression in healthy cardiomyocytes reduced the rise in cAMP levels and L-type Ca2(+) current amplitude, and abolished the inotropic effect following acute β-AR stimulation, without affecting basal contractility.<unk>
T-1216	pde2 healthy cardiomyocytes camp inotropic_effect acute β-ar contractility
H-1216	-0.45307081937789917	▁p de 2 ▁over expression ▁healthy ▁cardio my o cy tes ▁c AMP ▁l - type ▁ca 2 ▁in o tropi c ▁β - AR _ stimul ation ▁bas al ▁contract ility
D-1216	-0.45307081937789917	pde2 overexpression healthy cardiomyocytes cAMP l-type ca2 inotropic β-AR_stimulation basal contractility
P-1216	-0.4455 -0.2430 -0.0323 -0.1474 -0.0182 -0.9122 -0.7668 -0.2376 -0.2205 -0.0832 -0.0338 -0.0007 -0.0006 -2.9687 -0.0073 -0.0008 -1.2022 -0.0308 -2.2974 -0.3141 -0.0132 -0.0156 -1.5269 -0.0024 -0.1869 -2.6342 -0.1199 -0.0641 -0.0252 -0.0103 -0.6663 -0.0466 -0.0651 -0.0647
S-505	The bottleneck stent was implanted in the proximal left anterior descending (LAD) or proximal circumflex artery (LCX), or in both proximal LCX and mid LAD 1 wk later (2-vessel model), and pigs were followed for 4-5 wk.<unk>
T-505	bottleneck_stent implanted lad circumflex_artery lcx lcx lad
H-505	-0.7673579454421997	▁bottle ne ck ▁sten t ▁lager ▁proxima l _ ▁circum flex ▁arter y LC X ▁mid ▁ LAD
D-505	-0.7673579454421997	bottleneck stent lager proximal_ circumflex arteryLCX mid LAD
P-505	-0.0399 -0.0125 -0.0075 -2.0551 -0.0201 -4.7060 -0.9106 -0.0036 -0.5827 -0.5005 -0.0045 -0.2982 -0.0830 -1.0246 -0.6014 -2.1406 -0.8453 -0.0341 -1.3740 -0.1030
S-1306	BACKGROUND: Advances in treatment for acute myocardial infarction (AMI) are likely to have had a beneficial impact on the incidence of and deaths attributable to heart failure (HF) complicating AMI, although limited data are available to support this contention.<unk>
T-1306	acute_myocardial_infarction ami incidence deaths heart_failure hf ami
H-1306	-0.9404763579368591	▁a cute _ my o card ial _ in far ction ▁ AMI
D-1306	-0.9404763579368591	acute_myocardial_infarction AMI
P-1306	-1.9032 -0.0541 -0.1078 -4.5493 -0.1929 -0.4395 -0.1728 -0.3510 -0.2867 -0.0305 -0.0339 -2.6872 -0.1140 -3.1526 -0.0317
S-1117	RESULTS: (123)I-MIBG cardiac washout was lower during carvedilol than metoprolol treatment (12.9% ± 3.9% vs. 22.1% ± 2.8%, respectively, P = 0.003), irrespective of β2-adrenergic receptor haplotype.<unk>
T-1117	cardiac_washout carvedilol metoprolol β2-adrenergic_receptor_haplotype
H-1117	-0.761664092540741	▁i - MI BG ▁cardiac ▁was hout ▁car vedi lol ▁met o pro lol
D-1117	-0.761664092540741	i-MIBG cardiac washout carvedilol metoprolol
P-1117	-0.7023 -0.4630 -0.8543 -1.1572 -1.7135 -3.7553 -0.0539 -0.0705 -0.0096 -0.0140 -0.1510 -0.1651 -0.0072 -0.0709 -2.9048 -0.0942
S-1502	Muscle aerobic capacity, measured by the rate constant (k) of postexercise phosphocreatine resynthesis, was significantly impaired in Fontan adults versus controls (1.48±0.13 vs 2.40±0.33 min(-1), p=0.02).<unk>
T-1502	muscle_aerobic_capacity postexercise_phosphocreatine_resynthesis fontan
H-1502	-0.47701185941696167	▁mus cle ▁aero bic ▁capacity ▁poste xer ci se _ phos pho creati ne ▁re syn the sis ▁Font an
D-1502	-0.47701185941696167	muscle aerobic capacity postexercise_phosphocreatine resynthesis Fontan
P-1502	-0.6348 -0.0784 -0.0956 -0.0469 -2.0620 -0.3575 -0.0051 -0.0107 -0.2183 -0.2431 -0.0368 -0.2893 -0.6372 -1.4860 -1.2591 -0.0076 -0.2357 -0.4048 -0.0335 -0.0288 -2.2633 -0.0595
S-904	Cardiac resynchronization therapy (CRT) is often deferred in dialysis-dependent patients with heart failure (HF) because of a perceived lack of benefit and potentially higher risks, although the outcomes associated with CRT in dialysis have not been reported.<unk>
T-904	cardiac_resynchronization_therapy crt patients heart_failure hf outcomes crt dialysis reported
H-904	-0.6382039189338684	▁Card iac ▁re syn chron ization ▁ therapy ▁c RT ▁di al ysis - dependent ▁patients ▁heart ▁failure HF
D-904	-0.6382039189338684	Cardiac resynchronization therapy cRT dialysis-dependent patients heart failureHF
P-904	-0.5169 -0.0388 -1.2024 -0.0205 -0.0037 -0.8799 -1.0926 -0.0328 -1.0062 -0.1164 -1.0342 -0.0644 -0.0347 -0.1867 -0.0646 -2.2736 -1.5882 -0.0967 -2.3941 -0.7181 -0.0368
S-1221	Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).<unk>
T-1221	eplerenone patients hyperkalemia renal_function emphasis-hf eplerenone patients hospitalization heart_failure
H-1221	-0.5609782934188843	▁e pler en one ▁hyper kal emia ▁renal ▁function ▁EM PHA SIS - HF ▁e pler en one
D-1221	-0.5609782934188843	eplerenone hyperkalemia renal function EMPHASIS-HF eplerenone
P-1221	-0.0860 -0.0607 -0.1488 -0.6677 -2.3622 -0.2303 -0.0229 -0.2400 -1.2964 -0.0730 -0.0168 -0.1569 -0.0383 -0.0092 -0.3860 -0.1002 -0.2047 -1.1809 -3.8509 -0.0879
S-655	H-DKO mice had reduced ventricular mass; developed cardiac apoptosis, fibrosis, and failure; and showed diminished Akt→forkhead box class O-1 signaling that was accompanied by impaired cardiac metabolic gene expression and reduced ATP content.<unk>
T-655	h-dko ventricular_mass cardiac_apoptosis fibrosis cardiac_metabolic_gene_expression atp
H-655	-0.717930018901825	▁h - d ko ▁vent ri cular ▁mass ▁cardiac ▁apo pto sis ▁fibro sis
D-655	-0.717930018901825	h-dko ventricular mass cardiac apoptosis fibrosis
P-655	-2.4749 -0.1428 -1.3067 -0.5026 -1.3369 -0.4129 -0.1896 -0.9724 -0.0265 -0.3022 -0.0172 -0.1077 -0.0022 -0.0122 -3.6070 -0.0732
S-863	The reduction in risk was consistent for inappropriate ATP (HR: 0.66 [95% CI: 0.48 to 0.90]; p = 0.009) and inappropriate shock therapy (HR: 0.54 [95% CI: 0.36 to 0.80]; p = 0.002).<unk>
T-863	atp shock_therapy
H-863	-0.6645544767379761	▁in appropria te _ ▁ATP ▁in appropria te _ ▁shock ▁ therapy
D-863	-0.6645544767379761	inappropriate_ ATP inappropriate_ shock therapy
P-863	-0.7245 -0.0119 -0.0270 -0.2711 -2.8023 -1.4713 -0.0703 -0.0334 -0.0359 -2.4388 -0.6332 -0.0105 -0.6788 -0.0948
S-1766	BACKGROUND: We evaluated the individual and joint associations among cardiorespiratory fitness (CRF), body mass index, and heart failure (HF) mortality, as well as the additive effect of an increasing number of cardiovascular risk factors on HF mortality in fit versus unfit men.<unk>
T-1766	joint cardiorespiratory_fitness crf body_mass_index heart_failure hf mortality cardiovascular hf mortality
H-1766	-0.6713741421699524	▁cardio re spira tory _ ▁fitness CR F ▁body ▁mass ▁index ▁heart ▁failure ▁ HF
D-1766	-0.6713741421699524	cardiorespiratory_ fitnessCRF body mass index heart failure HF
P-1766	-1.1742 -0.0175 -0.0994 -0.0710 -1.0611 -0.4761 -2.1142 -0.8120 -0.1012 -0.1173 -0.0050 -0.6725 -0.1209 -1.5812 -0.0531 -2.8695 -0.0672
S-1827	BACKGROUND: Recent postmarketing trials produced conflicting results about the risk for hospitalized heart failure (hHF) associated with dipeptidyl peptidase-4 (DPP-4) inhibitors, creating uncertainty about the safety of these antihyperglycemic agents.<unk>
T-1827	hospitalized heart_failure dipeptidyl_peptidase-4 dpp-4 antihyperglycemic_agents
H-1827	-0.7983430027961731	▁post marketing _ studie s ▁risk ▁hospital ized _ heart ▁failure h HF ▁di pe pti dy l ▁pep tida se -4 ▁d PP -4 ▁anti hy per gly ce mic
D-1827	-0.7983430027961731	postmarketing_studies risk hospitalized_heart failurehHF dipeptidyl peptidase-4 dPP-4 antihyperglycemic
P-1827	-1.1657 -0.0192 -3.6038 -2.1094 -0.0146 -1.1583 -1.5964 -0.0755 -0.4143 -1.5035 -0.6139 -1.2711 -0.0966 -0.0366 -0.0157 -0.0093 -4.8533 -2.1374 -0.4175 -0.0479 -0.2239 -0.2631 -0.5543 -0.0657 -0.9026 -0.1056 -0.5127 -0.0167 -0.2246 -0.1171 -0.5818 -1.5498 -0.0673
S-380	METHODS AND RESULTS: Using a quality improvement database and multivariable Cox modeling, we derived the Heart Failure Patient Severity Index (HFPSI) in the University of Michigan HF clinic (UM cohort, n = 1,536; 314 reached primary outcome).<unk>
T-380	cox_modeling heart_failure_patient_severity_index hfpsi university_of_michigan hf clinic primary_outcome
H-380	-0.7937644124031067	▁quality ▁improvement ▁database ▁multi vari able _ co x ▁model ing ▁Heart _ ▁Fail ure _ ▁Patient _ ▁Sever ity _ index ▁ HF PSI ▁University _ ▁Michigan ▁ HF ▁co hor t
D-380	-0.7937644124031067	quality improvement database multivariable_cox modeling Heart_ Failure_ Patient_ Severity_index HFPSI University_ Michigan HF cohort
P-380	-1.8370 -0.4879 -0.3688 -1.1999 -0.0369 -0.0070 -0.9479 -0.1010 -0.0070 -0.7793 -0.0212 -1.0902 -0.7227 -0.8393 -0.8605 -0.5481 -0.3957 -1.5984 -0.3026 -0.2098 -1.7922 -0.2855 -1.7922 -0.1084 -2.3676 -3.0775 -0.6850 -0.3552 -0.7451 -0.5644 -3.1870 -0.0082 -0.0071 -0.3973 -0.0478
S-1585	Heart rate (HR) variability has been extensively studied in cardiac patients, especially in patients surviving an acute myocardial infarction (AMI) and also in patients with congestive heart failure (CHF) or left ventricular (LV) dysfunction.<unk>
T-1585	heart_rate cardiac patients patients acute_myocardial_infarction ami patients congestive_heart_failure chf left_ventricular dysfunction
H-1585	-0.7962706089019775	▁cardiac ▁patients ▁a cute _ my o card ial _ in far ction ▁ AMI ▁con ges tive _ ▁heart ▁failure CH F ▁left ▁vent ri cular LV
D-1585	-0.7962706089019775	cardiac patients acute_myocardial_infarction AMI congestive_ heart failureCHF left ventricularLV
P-1585	-2.6549 -1.6290 -1.0803 -0.0060 -0.1852 -3.5253 -0.1555 -0.1511 -0.2954 -1.0079 -0.5584 -0.0197 -0.0570 -4.2891 -0.0082 -0.3314 -0.0355 -0.4319 -0.1680 -1.6219 -0.1294 -2.2502 -0.8528 -0.0576 -1.2433 -0.4265 -0.0666 -0.4025 -0.1577 -0.0900
S-657	Using neonatal rat ventricular cardiomyocytes, we further found that chronic insulin exposure reduced IRS1 and IRS2 proteins and prevented insulin action through activation of p38, revealing a fundamental mechanism of cardiac dysfunction during insulin resistance and type 2 diabetes.<unk>
T-657	ventricular_cardiomyocytes chronic insulin irs1 irs2 proteins insulin p38 cardiac_dysfunction insulin_resistance type_2_diabetes
H-657	-0.47673070430755615	▁ne ona tal _ ▁rat ▁vent ri cular _ ▁cardio my o cy tes ▁chronic _ ▁insulin ▁exposure ▁I RS 2 ▁protein s ▁prevent ed ▁insulin ▁action ▁p 38 ▁cardiac ▁dys function ▁insulin ▁resist ance ▁type ▁2 ▁diabetes
D-657	-0.47673070430755615	neonatal_ rat ventricular_ cardiomyocytes chronic_ insulin exposure IRS2 proteins prevented insulin action p38 cardiac dysfunction insulin resistance type 2 diabetes
P-657	-0.1712 -0.0019 -0.0023 -0.9382 -0.8726 -0.0692 -0.4716 -0.6620 -0.4889 -0.1770 -0.3884 -0.1188 -0.0557 -0.0605 -0.1666 -0.9140 -0.4059 -0.1557 -0.7234 -0.0032 -1.3120 -0.9029 -0.0286 -1.9482 -0.0303 -0.8425 -2.4794 -0.2389 -0.3845 -1.0880 -1.7784 -0.0376 -0.0309 -0.1665 -0.0123 -0.1967 -0.4853 -0.1411 -0.0608 -0.0571
S-323	Echocardiograms of the left ventricular midpapillary level were taken at varying atrioventricular delay (AVD) and interventricular delay (VVD) for STE analysis of regional circumferential strain (CS) and radial strain (RS).<unk>
T-323	echocardiograms left_ventricular midpapillary atrioventricular_delay avd interventricular_delay vvd ste circumferential_strain radial_strain rs
H-323	-0.49751797318458557	▁e cho card i ogram s ▁left ▁vent ri cular _ mid pap illa ry ▁level ▁at rio ven tri cular ▁de lay ▁v d ▁interven tri cular ▁de lay ▁ STE
D-323	-0.49751797318458557	echocardiograms left ventricular_midpapillary level atrioventricular delay vd interventricular delay STE
P-323	-1.9643 -0.0042 -0.0325 -0.1346 -0.0140 -0.5565 -0.1093 -0.1353 -0.4938 -0.2159 -0.5553 -0.1404 -0.4550 -0.1798 -0.2359 -1.1931 -2.2590 -0.1229 -0.0075 -0.0709 -0.1226 -0.6455 -0.0082 -0.9215 -0.2779 -0.1955 -0.0106 -0.0332 -0.7036 -0.0342 -1.0665 -0.4244 -3.5379 -0.0536
S-1870	METHODS: Patients with New York Heart Association (NYHA) functional class III HF and ejection fractions < 35% on chronic stable guideline-directed medical therapy (GDMT) were enrolled at 45 centers in the United States, Canada, and Europe.<unk>
T-1870	patients new_york_heart_association nyha functional_class hf ejection_fractions chronic stable guideline-directed_medical_therapy gdmt united_states canada europe
H-1870	-0.7179965972900391	▁New ▁York _ ▁Heart ▁Association _ NY HA ▁functional ▁class ▁III ▁ HF ▁e je ction ▁ fraction s ▁chronic _ stabil _ ▁guide line - direct ed _ ▁medical ▁ therapy GD MT
D-1870	-0.7179965972900391	New York_ Heart Association_NYHA functional class III HF ejection fractions chronic_stabil_ guideline-directed_ medical therapyGDMT
P-1870	-1.3177 -0.4785 -0.3581 -2.9636 -0.3666 -4.3405 -0.0778 -0.0601 -1.6691 -0.9698 -0.4268 -0.3369 -0.0053 -0.1039 -0.0187 -0.0079 -0.2693 -0.0001 -0.0370 -0.3629 -0.3297 -4.9356 -1.0469 -1.6829 -0.0020 -0.1751 -0.0007 -0.1482 -0.0734 -1.9225 -0.6140 -0.0236 -0.4990 -0.0430 -0.1422 -0.0386
S-889	In patients with non-LBBB and QRS ≥160 ms, the hazard ratio for the primary outcome was 0.52 (0.29-0.96; P=0.033); in patients with QRS <160 ms, the hazard ratio was 1.38 (0.88-2.14; P=0.155).<unk>
T-889	patients qrs hazard_ratio primary_outcome patients qrs hazard_ratio
H-889	-0.734474778175354	▁non - LB bb ▁QR s
D-889	-0.734474778175354	non-LBbb QRs
P-889	-1.5088 -0.0063 -0.0249 -0.9624 -0.1475 -1.1399 -1.9828 -0.1032
S-1428	Examination of PKA subunits demonstrated no change in type II regulatory (RIIα) or catalytic (Cα) subunit expression, although site specific RIIα (Ser96) and Cα (Thr197) phosphorylation were increased in HF.<unk>
T-1428	pka change riiα cα expression riiα ser96 cα thr197 phosphorylation hf
H-1428	-0.6914099454879761	▁p ka ▁sub un its ▁type ▁II ▁regulator y ▁r II α ▁cata ly tic ▁c α ▁ phos phor y lation ▁ HF
D-1428	-0.6914099454879761	pka subunits type II regulatory rIIα catalytic cα phosphorylation HF
P-1428	-0.3356 -0.3101 -4.5051 -0.3078 -0.0069 -0.6093 -1.1427 -0.8446 -0.0670 -1.6499 -1.7539 -0.0713 -2.4470 -0.1080 -0.1516 -0.7783 -0.0385 -1.0638 -0.1975 -0.2944 -0.3501 -0.0495 -0.7838 -0.0048 -0.0364 -0.0688
S-1155	Mechanistically, we found that abnormal Ca(2+) handling in dyssynchronous HF slows myofiber shortening velocity at the early-activated septum and depresses both myofiber shortening and stretch rate at the late-activated lateral wall.<unk>
T-1155	dyssynchronous_hf myofiber_shortening septum myofiber_shortening stretch wall
H-1155	-0.8618351221084595	▁ab normal ▁Ca (2 +) ▁handling ▁dys syn chron ous _ ▁ HF ▁my o fi ber ▁short en ing _ ▁veloci ty ▁sept um ▁my o fi ber ▁short en ing _ ▁stretch
D-1155	-0.8618351221084595	abnormal Ca(2+) handling dyssynchronous_ HF myofiber shortening_ velocity septum myofiber shortening_ stretch
P-1155	-2.5408 -0.0017 -1.4653 -0.0493 -0.0048 -2.0516 -0.0598 -0.0007 -0.0011 -0.4086 -0.6194 -2.2354 -0.0137 -4.0992 -0.0332 -0.0042 -0.0228 -1.0709 -0.0466 -0.1734 -1.3354 -1.0732 -0.0410 -1.9725 -0.0041 -2.5254 -0.0096 -0.0029 -0.0209 -1.6848 -0.0435 -0.1443 -1.5435 -2.4669 -3.1891 -0.0665
S-1342	CHF-derived c-Kit+ cells exhibited upregulated transforming growth factor-β (TGF-β) signaling, increased level of epithelial to mesenchymal transition markers, and diminished expression of pluripotency markers compared with shams.<unk>
T-1342	cells transforming_growth_factor-β tgf-β epithelial mesenchymal transition expression pluripotency_markers
H-1342	-0.6648905277252197	▁c - K it + ▁cell s ▁transform ing _ ▁growth ▁factor - β ▁t GF - β ▁epi the li al ▁mes en chy mal _ ▁transition ▁marker s ▁pluri pote ncy
D-1342	-0.6648905277252197	c-Kit+ cells transforming_ growth factor-β tGF-β epithelial mesenchymal_ transition markers pluripotency
P-1342	-1.2602 -0.0315 -3.2438 -0.0099 -1.2888 -0.3758 -0.1662 -1.3838 -0.0259 -1.7322 -2.2115 -0.8423 -0.1763 -0.0209 -1.1039 -0.0149 -0.0467 -0.0124 -2.4856 -0.0151 -0.0543 -0.0211 -0.0494 -0.0791 -0.1328 -1.1480 -0.3651 -1.9232 -0.2302 -0.0230 -0.1819 -0.0275 -0.0099 -2.4869 -0.0907
S-871	METHODS AND RESULTS: We applied an improved label-free shotgun proteomics approach to evaluate the global proteomics changes in transverse aortic constriction (TAC)-induced heart failure and the associated signaling pathway changes using ingenuity pathway analysis.<unk>
T-871	proteomics proteomics transverse_aortic_constriction tac heart_failure signaling_pathway ingenuity_pathway_analysis
H-871	-0.691536545753479	▁label - free _ shot gun _ prote o mics ▁global _ prote o mics ▁trans verse _ a or tic _ con stri ction ▁ TAC _ indu ced _ heart ▁failure
D-871	-0.691536545753479	label-free_shotgun_proteomics global_proteomics transverse_aortic_constriction TAC_induced_heart failure
P-871	-1.2597 -0.0120 -0.0253 -0.6259 -0.7282 -0.0170 -1.5873 -1.2113 -0.3246 -0.0011 -1.3872 -0.5249 -1.2710 -0.3581 -0.0012 -0.0553 -0.0872 -0.1775 -1.2108 -0.1116 -1.0695 -0.0746 -1.2703 -1.4745 -0.0196 -2.4434 -0.0355 -1.8758 -0.5664 -0.0461 -0.1250 -0.9071 -1.7798 -1.4803 -0.0583
S-178	In consecutive patients (209 HFrEF with left ventricular ejection fraction <40% and 108 HFpEF with left ventricular ejection fraction ≥40%), RAS- and β-blocker dose changes were followed during 6 months after an index HF hospitalization.<unk>
T-178	patients hfref left_ventricular_ejection_fraction hfpef left_ventricular_ejection_fraction β-blocker hf hospitalization
H-178	-0.49978670477867126	▁h Fr EF ▁left _ ▁vent ri cular _ ▁e je ction ▁ fraction ▁ HF p EF ▁left _ ▁vent ri cular _ ▁e je ction ▁ fraction ▁ RAS - ▁β - block er ▁index ▁ HF
D-178	-0.49978670477867126	hFrEF left_ ventricular_ ejection fraction HFpEF left_ ventricular_ ejection fraction RAS- β-blocker index HF
P-178	-1.1555 -0.7783 -0.2214 -0.4767 -1.3028 -0.9174 -0.7508 -2.3114 -0.8142 -1.4533 -0.1026 -0.3041 -0.6114 -0.0110 -0.4836 -0.2662 -0.2658 -0.0213 -0.4818 -0.4009 -0.4143 -0.9819 -1.3727 -0.5610 -1.0067 -0.0944 -0.1292 -0.4035 -0.0195 -0.2209 -0.4997 -0.5402 -0.1782 -0.0135 -0.0099 -0.0326 -0.2557 -0.2627 -0.0041 -0.2235 -0.1367
S-257	In addition, an elevated activation of p70S6K, PKC-βII by HDL(NYHA-IIIb), and a higher amount of malondialdehyde bound to HDL(NYHA-IIIb) compared with HDL(healthy) was measured.<unk>
T-257	elevated p70s6k pkc-βii hdl nyha-iiib malondialdehyde bound hdl nyha-iiib hdl healthy
H-257	-0.6090565323829651	▁p 70 s 6 k ▁PK c - β II ▁HD L NY HA - III b ▁malo ndi alde hy de
D-257	-0.6090565323829651	p70s6k PKc-βII HDLNYHA-IIIb malondialdehyde
P-257	-0.6880 -0.4342 -0.6764 -0.0894 -1.6967 -0.0228 -0.3622 -0.0434 -0.0934 -0.4239 -2.0913 -1.3975 -0.7770 -0.2638 -0.2573 -0.3811 -0.0191 -0.0152 -0.0036 -0.0058 -0.4525 -0.0499 -4.2567 -0.1162
S-1410	This cross talk between these 2 distinct G-protein-coupled receptors appears to have physiological significance, because they interact and show reciprocal regulation in mouse hearts undergoing chronic β-adrenergic receptor stimulation and in a rat model of postischemic heart failure.<unk>
T-1410	cross_talk g-protein-coupled_receptors physiological significance regulation hearts chronic β-adrenergic_receptor postischemic_heart_failure
H-1410	-0.5631991624832153	▁g - prote in - co up led _ ▁receptor s
D-1410	-0.5631991624832153	g-protein-coupled_ receptors
P-1410	-0.5790 -0.1091 -0.0615 -0.2322 -0.0293 -0.0023 -0.0161 -0.1968 -1.0745 -0.1039 -0.3535 -4.4771 -0.0863
S-1989	Body weight decreased by 7% (7 kg [SD, 1]) in the diet group, 3% (4 kg [SD, 1]) in the exercise group, 10% (11 kg [SD, 1] in the exercise + diet group, and 1% (1 kg [SD, 1]) in the control group.<unk>
T-1989	exercise exercise
H-1989	-2.1983962059020996	▁figuur
D-1989	-2.1983962059020996	figuur
P-1989	-3.2093 -3.1763 -0.2096
S-1920	NT-ProBNP (+233 to –733 ng/ml) and the inflammatory biomarkers (hsCRP and IL6) decreased in four of five patients (IL 6: +0.5 to –2 mg/l, hsCRP: +0.2 to –6.5 mg/l).<unk>
T-1920	nt-probnp inflammatory biomarkers hscrp il6 patients hscrp
H-1920	-0.5342276692390442	▁NT - pro b NP ▁infla mma tory ▁bio mark ers ▁h s CR p ▁IL 6
D-1920	-0.5342276692390442	NT-probNP inflammatory biomarkers hsCRp IL6
P-1920	-0.0614 -0.0514 -0.8054 -0.9079 -0.0370 -1.0927 -0.2088 -0.1257 -0.7893 -0.0059 -0.0834 -0.3824 -0.0121 -0.8833 -1.1258 -1.1138 -1.4338 -0.9431 -0.0871
S-1010	After adjustment for age, sex and ejection fraction, patients categorized as frail by the biological phenotype had a 2-fold increased risk of death compared to those with no frailty, whereas a 0.1 unit increase in the deficit index was associated with a 44% increased risk of death.<unk>
T-1010	ejection_fraction patients frail biological_phenotype death frailty deficit_index death
H-1010	-0.7257556915283203	▁e je ction ▁ fraction ▁fra il ▁bi ological _ ▁ph eno type
D-1010	-0.7257556915283203	ejection fraction frail biological_ phenotype
P-1010	-3.9685 -0.0174 -0.0044 -0.6458 -0.0019 -0.1166 -0.0322 -1.7296 -0.2025 -0.4082 -0.2001 -0.0044 -0.0007 -3.4710 -0.0833
S-1945	Patients in whom resting HR decreased at follow-up compared to baseline had a 2.0±3.2 mL/min/kg increase in VO2max compared to a 1.2±7.7 mL/min/kg increase in patients who did not demonstrate a lower resting HR (P value=0.033).<unk>
T-1945	patients resting_hr follow-up baseline vo2max patients resting_hr p_value
H-1945	-1.3206589221954346	▁rest ing _ HR
D-1945	-1.3206589221954346	resting_HR
P-1945	-2.8647 -0.2453 -1.4093 -0.4200 -2.7678 -0.2168
S-1344	CONCLUSIONS: Taken together, our findings suggest that TGF-β inhibition positively modulates c-Kit+ cell phenotype and function in vitro, and this strategy may be considered in optimizing cardiac progenitor function and cell expansion protocols for clinical application.<unk>
T-1344	tgf-β cell phenotype in_vitro cardiac_progenitor_function cell clinical
H-1344	-0.6279863715171814	▁T GF - β ▁inhibi tion ▁c - K it + ▁cell _ ▁ph eno type
D-1344	-0.6279863715171814	TGF-β inhibition c-Kit+ cell_ phenotype
P-1344	-1.5599 -0.0417 -0.0497 -0.0283 -1.0541 -0.1451 -0.0137 -0.0426 -1.0029 -0.0096 -1.5287 -0.2845 -2.0811 -0.5411 -0.0056 -0.0005 -2.8753 -0.0394
S-1044	Investigating the role of BETs in an in vitro model of neurohormonally induced heart disease, the authors showed that nanomolar doses of JQ1 significantly blocked phenylephrine-mediated hypertrophy of cardiomyocytes and pathological gene induction.<unk>
T-1044	bets in_vitro neurohormonally heart_disease nanomolar jq1 phenylephrine-mediated_hypertrophy cardiomyocytes pathological gene_induction
H-1044	-0.3091122508049011	▁ BET s ▁neuro hormon ally _ ▁induc ed _ heart ▁disease ▁na nomo lar _ ▁dos es ▁j q 1 ▁ phen yle ph rine - media ted _ ▁hyper trop hy ▁cardio my o cy tes ▁path ological ▁gene ▁in duction
D-1044	-0.3091122508049011	BETs neurohormonally_ induced_heart disease nanomolar_ doses jq1 phenylephrine-mediated_ hypertrophy cardiomyocytes pathological gene induction
P-1044	-0.2949 -0.0195 -0.7770 -0.3011 -0.0178 -0.1755 -1.3241 -0.3251 -0.0502 -0.1934 -1.3084 -0.5827 -0.2758 -0.0027 -0.0588 -1.1525 -0.2513 -0.0026 -0.6722 -0.8093 -1.5538 -0.4734 -0.0027 -0.0098 -0.1271 -0.0200 -0.2051 -0.0534 -0.0189 -0.3596 -0.6718 -0.0014 -0.5252 -0.0225 -0.1506 -0.2609 -0.0164 -0.0120 -0.0067 -0.0757 -0.5314 -0.0514 -0.0054 -0.1177 -0.0424
S-1524	Although concentric remodeling (CR) and concentric hypertrophy (CH) are common forms of left ventricular (LV) remodeling in heart failure with preserved ejection fraction (HFpEF), eccentric hypertrophy (EH) can also occur in these patients.<unk>
T-1524	concentric_remodeling concentric_hypertrophy left_ventricular remodeling heart_failure_with_preserved_ejection_fraction hfpef eccentric_hypertrophy patients
H-1524	-0.637619137763977	▁concentr ic _ ▁remodel ing CR ▁concentr ic _ ▁hyper trop hy CH ▁left ▁vent ri cular LV _ ▁remodel ing ▁heart ▁failure ▁pres er ved _ e je ction ▁ fraction ▁ HF p EF ▁ecce n tric _ ▁hyper trop hy EH
D-1524	-0.637619137763977	concentric_ remodelingCR concentric_ hypertrophyCH left ventricularLV_ remodeling heart failure preserved_ejection fraction HFpEF eccentric_ hypertrophyEH
P-1524	-0.0717 -0.0086 -1.1049 -0.6746 -0.0196 -3.3302 -0.4035 -0.0049 -0.1972 -0.6435 -0.0033 -0.2054 -3.3835 -1.1197 -0.7139 -0.3538 -0.1132 -0.1398 -4.7150 -1.4455 -0.0069 -3.1915 -0.0622 -0.3899 -0.0511 -0.1867 -0.1244 -1.0802 -0.1638 -0.0596 -1.0919 -0.0119 -2.3836 -0.0017 -0.0965 -0.0860 -0.0182 -0.0117 -0.0284 -0.6377 -0.5478 -0.0018 -0.1209 -0.1398 -0.0996 -0.0848
S-1878	CONCLUSIONS: BAT is safe and improves functional status, quality of life, exercise capacity, N-terminal pro-brain natriuretic peptide, and possibly the burden of heart failure hospitalizations in patients with GDMT-treated NYHA functional class III HF.<unk>
T-1878	bat functional_status quality_of_life exercise_capacity n-terminal_pro-brain_natriuretic_peptide heart_failure hospitalizations patients nyha_functional_class_iii hf
H-1878	-0.8854337334632874	▁BAT ▁functional ▁status ▁exercise ▁capacity ▁n - termin al _ ▁pro - bra in ▁na tri ure tic _ pe pti de
D-1878	-0.8854337334632874	BAT functional status exercise capacity n-terminal_ pro-brain natriuretic_peptide
P-1878	-0.3409 -6.1386 -0.3828 -2.5646 -0.4264 -1.7101 -0.0093 -0.0165 -0.0051 -0.7190 -1.2817 -0.0245 -0.0615 -0.0270 -0.0300 -0.0034 -0.3490 -0.8864 -0.8580 -0.3861 -0.0102 -0.0218 -4.9562 -0.0411
S-1986	There was no statistically significant change in MLHF total score with exercise and with diet (main effect: exercise, -1 unit [95% CI, -8 to 5], P = .70; diet, -6 units [95% CI, -12 to 1], P = .08).<unk>
T-1986	change exercise exercise
H-1986	-0.7361785173416138	▁ ML HF ▁ ML HF ▁ ML HF
D-1986	-0.7361785173416138	MLHF MLHF MLHF
P-1986	-0.0650 -0.0176 -0.1175 -1.4030 -0.1053 -0.0780 -1.8573 -0.3285 -0.0809 -3.9272 -0.1178
S-1374	Four treatment groups were used: nonpace, non-DNx [Sham-Innervated (Sham-INV)], nonpace DNx (sham-DNx), pace non-DNx (CHF-INV) or pace DNx (CHF-DNx).<unk>
T-1374	dnx dnx
H-1374	-1.062300682067871	▁non pa ce ▁non - DN x ▁s ham - I nner vat ed ▁s ham - in v ▁non pa ce ▁DN x ▁s ham - DN x ▁pace _ nc x
D-1374	-1.062300682067871	nonpace non-DNx sham-Innervated sham-inv nonpace DNx sham-DNx pace_ncx
P-1374	-1.0055 -1.2688 -0.0882 -0.9202 -0.0992 -1.4081 -0.3557 -2.5011 -0.2858 -0.0362 -1.7881 -0.0000 -0.0522 -0.0567 -2.0699 -0.2454 -0.0197 -0.3709 -0.3043 -0.8385 -0.2332 -0.1071 -1.1772 -0.0153 -2.2724 -0.0713 -0.0251 -6.2472 -0.0481 -2.1799 -3.5537 -3.5486 -0.5284 -3.3578 -0.1006
S-1929	Exercise time at 3 and 12 months correlated with PSSS (r= 0.09 and r= 0.13, respectively) and BTES (r=-0.11 and r=-0.12, respectively), with higher exercise time associated with higher PSSS and lower BTES (All P<0.005).<unk>
T-1929	exercise correlated psss btes exercise psss btes
H-1929	-0.6786049604415894	▁PS SS ▁b tes
D-1929	-0.6786049604415894	PSSS btes
P-1929	-1.6629 -0.2032 -1.1988 -0.4396 -0.5147 -0.0525
S-836	The purpose of this study was to explore the relation of hemoglobin (Hgb) with HRQoL and training-induced changes in HRQoL in a cohort of patients in Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION).<unk>
T-836	hemoglobin hgb hrqol hrqol patients heart_failure outcomes exercise training hf-action
H-836	-0.6100731492042542	▁hem o glob in ▁h gb ▁HR Qo L ▁HR Qo L ▁ HF - AC TION
D-836	-0.6100731492042542	hemoglobin hgb HRQoL HRQoL HF-ACTION
P-836	-0.5800 -0.1431 -0.0184 -0.1830 -1.5591 -0.0011 -0.0936 -0.0170 -0.5042 -0.8962 -0.0265 -0.4939 -3.6537 -2.5090 -0.0488 -0.5171 -0.1455 -0.1330 -0.0682
S-1166	Risk of event was greater in subjects with RV dysfunction (hazard ratio: 3.09 [95% confidence interval (CI): 2.18 to 4.45]) and cachexia (hazard ratio: 2.90 [95% CI: 2.00 to 4.12]) in univariate and multivariate analyses.<unk>
T-1166	rv_dysfunction hazard_ratio confidence_interval cachexia hazard_ratio multivariate_analyses
H-1166	-1.2989230155944824	▁ RV _ ▁dys function haz ard _ ▁ratio ▁ci
D-1166	-1.2989230155944824	RV_ dysfunctionhazard_ ratio ci
P-1166	-1.1328 -0.5183 -2.7374 -2.4159 -0.0699 -2.2956 -0.0016 -0.9520 -0.5304 -2.1478 -2.6306 -0.1548
S-1234	METHODS: In a substudy of the Atrial Fibrillation and Congestive Heart Failure trial, health care expenditures of patients from Québec randomized to rhythm and rate-control treatment strategies were compared from a single-payer perspective using a cost-minimization approach.<unk>
T-1234	atrial_fibrillation congestive_heart_failure health_care expenditures patients québec randomized rhythm rate-control
H-1234	-1.1728745698928833	▁At rial _ fi bril lation _ con ges tive _ ▁Heart _ ▁Fail ure
D-1234	-1.1728745698928833	Atrial_fibrillation_congestive_ Heart_ Failure
P-1234	-2.6525 -0.0125 -0.7416 -0.4750 -0.0418 -0.0162 -2.0847 -1.4798 -0.4918 -1.5202 -0.0427 -0.6257 -2.3891 -0.1062 -1.3825 -5.8160 -0.0607
S-640	Here we report that increased calcineurin/Nfat signalling and decreased miR-25 expression integrate to re-express the basic helix-loop-helix (bHLH) transcription factor dHAND (also known as Hand2) in the diseased human and mouse myocardium.<unk>
T-640	report calcineurin nfat mir-25 expression basic_helix-loop-helix bhlh transcription_factor dhand hand2 diseased myocardium
H-640	-0.7127455472946167	▁calci ne uri n _ N fat ▁signal ling ▁mi R -25 ▁expression ▁heli x - loop - heli x ▁b HL h ▁tran scription ▁factor ▁hand
D-640	-0.7127455472946167	calcineurin_Nfat signalling miR-25 expression helix-loop-helix bHLh transcription factor hand
P-640	-0.0132 -0.5321 -0.0270 -0.0781 -4.3085 -1.4303 -0.0437 -3.0125 -0.1025 -0.0833 -0.3926 -0.0294 -1.6696 -0.4862 -0.1028 -0.0347 -0.0027 -0.0917 -0.0060 -0.0307 -2.2317 -0.1021 -0.2425 -1.1465 -0.0175 -0.0351 -0.8631 -3.4145 -0.1389
S-1668	Every attempt should be made to identify and correct reversible causes for a worsening of heart failure, such as poor patient compliance, myocardial ischaemia, tachy- or bradyarrhythmias, valvular regurgitation, pulmonary embolism, infection, or renal dysfunction.<unk>
T-1668	heart_failure patient compliance myocardial_ischaemia bradyarrhythmias valvular_regurgitation pulmonary_embolism infection renal_dysfunction
H-1668	-0.41021934151649475	▁heart ▁failure ▁my o card ial ▁is cha emia ▁ta chy - ▁bra dy ar rhythm ias ▁val vu lar ▁re gur gi tation ▁pulmonar y ▁e mbol ism ▁renal ▁dys function
D-1668	-0.41021934151649475	heart failure myocardial ischaemia tachy- bradyarrhythmias valvular regurgitation pulmonary embolism renal dysfunction
P-1668	-6.3442 -0.2331 -2.0642 -0.0444 -0.2732 -0.0799 -1.5781 -0.0010 -0.0189 -0.1436 -0.0248 -0.0218 -0.6796 -1.1126 -0.0178 -0.0322 -0.1205 -0.0154 -0.0254 -0.0552 -0.1205 -0.0593 -0.0175 -0.0179 -0.0002 -0.0130 -0.1437 -0.0001 -0.1545 -0.0087 -0.3831 -0.0133 -0.0745 -0.0554
S-629	HABC Battery score was linearly associated with HF risk after adjusting for the Health ABC HF Model (HR 1.24, 95% CI 1.13-1.36 per SD decrease in score) and remained significant when controlled for death as a competing risk (HR 1.30; 95% CI 1.00-1.55).<unk>
T-629	habc_battery hf health_abc_hf_model death
H-629	-1.3916313648223877	▁h ABC ▁ HF ▁ HF _ model ▁SD
D-629	-1.3916313648223877	hABC HF HF_model SD
P-629	-3.1947 -0.4779 -1.7265 -0.2194 -2.4439 -0.3759 -2.0272 -0.7906 -1.2607 -2.6878 -0.1034
S-269	The optimal NT-proBNP cutoff point for predicting 4-year survival at the time of admission was 2300 pg/mL, which had 85.9% sensitivity and 39.1% specificity (95% confidence interval, area under the curve: 0.639, P = .044).<unk>
T-269	nt-probnp admission sensitivity specificity confidence_interval area_under_the_curve
H-269	-0.7325991988182068	▁NT - pro b NP ▁cut off ▁point
D-269	-0.7325991988182068	NT-probNP cutoff point
P-269	-0.5067 -0.0208 -0.0275 -0.4850 -0.0984 -0.7060 -0.0122 -1.4696 -3.9154 -0.0842
S-1588	The prognostic power of various measures, except of those reflecting rapid R-R interval oscillations, has been almost identical, albeit some non-linear HR variability measures, such as short-term fractal scaling exponent have provided somewhat better prognostic information than the others.<unk>
T-1588	prognostic r-r_interval hr_variability short-term_fractal_scaling_exponent prognostic
H-1588	-0.9119645357131958	▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r ▁r
D-1588	-0.9119645357131958	r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r
P-1588	-2.1387 -2.1726 -0.8407 -0.5622 -0.4497 -0.3918 -0.3595 -0.3413 -0.3328 -0.3179 -0.3231 -0.3194 -0.3122 -0.3283 -0.3374 -0.3436 -0.3475 -0.3564 -0.3632 -0.3766 -0.3890 -0.3965 -0.4168 -0.4222 -0.4352 -0.4476 -0.4643 -0.4741 -0.4771 -0.4966 -0.5349 -0.5355 -0.5504 -0.5662 -0.5741 -0.5918 -0.6268 -0.6338 -0.6566 -0.6655 -0.7018 -0.7086 -0.7226 -0.7501 -0.7703 -0.7855 -0.7802 -0.8255 -0.8028 -0.8437 -0.8463 -0.8428 -0.8808 -0.8862 -0.8948 -0.9117 -0.9223 -0.9380 -0.9490 -0.9681 -0.9921 -0.9957 -0.9756 -1.0047 -1.0027 -1.0035 -0.9993 -1.0186 -1.0230 -1.0496 -1.0339 -1.0372 -1.0772 -1.0412 -1.0810 -1.0834 -1.0744 -1.0841 -1.0904 -1.0967 -1.0873 -1.1113 -1.0792 -1.1393 -1.0838 -1.0897 -1.1110 -1.1399 -1.1163 -1.0991 -1.1096 -1.0873 -1.1072 -1.0989 -1.0989 -1.0952 -1.1257 -1.0662 -1.1119 -1.0848 -1.1419 -1.1051 -1.0792 -1.1253 -1.0849 -1.0993 -1.0995 -1.1040 -1.0721 -1.0947 -1.0690 -1.0854 -1.0828 -1.0668 -1.0431 -1.0646 -1.0684 -1.0366 -1.0371 -1.0334 -1.0314 -1.0542 -1.0452 -1.0195 -1.0223 -1.0392 -1.0366 -1.0068 -0.9920 -1.0015 -0.9874 -1.0047 -0.9670 -0.9929 -0.9776 -0.9519 -0.9525 -0.9662 -0.9394 -0.9298 -0.9603 -0.9451 -0.9362 -0.9194 -0.9250 -0.8969 -0.8860 -0.9052 -0.8998 -0.8926 -0.8618 -0.8632 -0.8627 -0.8654 -0.8490 -0.8339 -0.8554 -0.8273 -0.8390 -0.8291 -0.8292 -0.8054 -0.8056 -0.8077 -0.7834 -0.8051 -0.8104 -0.7742 -0.7833 -0.7634 -0.7866 -0.7940 -0.7555 -0.7562 -0.7494 -0.7651 -0.7419 -0.7556 -0.7557 -0.7445 -0.7456 -0.7567 -0.7351 -0.7276 -0.7164 -0.7402 -0.7352 -0.7222 -0.7277 -0.7383 -0.7100 -0.7334 -0.7381 -0.7079 -0.7283 -0.7370 -0.7147 -0.7403 -0.7011 -0.7331 -12.7713
S-1437	This study was performed in 29 subjects: 10 heart failure (HF) patients with spontaneous ventricular tachycardia [HFVT(+)], 10 HF patients without spontaneous VT [HFVT(-)], and 9 subjects with structurally normal hearts (HNorm).<unk>
T-1437	heart_failure hf patients spontaneous_ventricular_tachycardia hf patients spontaneous_vt hearts
H-1437	-0.8901933431625366	▁heart ▁failure ▁ HF ▁patients ▁spontane ous _ ▁vent ri cular _ ta chy car dia ▁ HF VT
D-1437	-0.8901933431625366	heart failure HF patients spontaneous_ ventricular_tachycardia HFVT
P-1437	-1.6291 -0.2744 -2.4307 -0.0233 -4.7775 -0.1676 -0.2612 -0.9084 -0.2478 -0.5145 -0.5072 -0.2944 -2.0713 -0.1539 -0.0082 -0.0089 -0.8527 -0.0074 -0.7660 -2.7372 -0.0523
S-819	Besides, the addition of GLS to a Cox model containing chronic heart failure, hypertension, age ≥ 75 years, diabetes, prior stroke score, estimated glomerular filtration rate, LVEF and Sa provided an additional benefit in the prediction of adverse CV events (p=0.022).<unk>
T-819	gls cox_model chronic_heart_failure hypertension diabetes stroke estimated_glomerular_filtration_rate lvef
H-819	-0.4010406732559204	▁g LS ▁co x ▁model ▁chronic _ heart ▁failure ▁hyper tension ▁diabetes ▁prior _ stro ▁score ▁glo mer ular _ ▁filtr ation ▁rate ▁LV EF
D-819	-0.4010406732559204	gLS cox model chronic_heart failure hypertension diabetes prior_stro score glomerular_ filtration rate LVEF
P-819	-0.5595 -0.2685 -0.6073 -0.0029 -0.2671 -0.8820 -0.4086 -1.3528 -0.2592 -0.1433 -0.0206 -0.0599 -0.4587 -0.2374 -0.9942 -0.0241 -0.0250 -0.0188 -0.0238 -0.2311 -1.2741 -0.0518 -0.9216 -0.0276 -0.0104 -1.6422 -0.0557
S-921	Diastolic function was quantified via the parametrized diastolic filling formalism that yields relaxation/viscoelastic (c) and passive/stiffness (k) constants through the analysis of Doppler mitral inflow velocity (E-wave) contours.<unk>
T-921	diastolic_function diastolic_filling_formalism relaxation doppler_mitral_inflow_velocity e-wave
H-921	-0.4638265371322632	▁dia sto lic _ ▁fill ing ▁formal ism ▁relax ation vis co ela stic ▁passiv e _ sti ff ness ▁do pp ler ▁mit ral _ in flow ▁veloci ty ▁e - wa ve
D-921	-0.4638265371322632	diastolic_ filling formalism relaxationviscoelastic passive_stiffness doppler mitral_inflow velocity e-wave
P-921	-0.0576 -0.0013 -0.0077 -2.0391 -4.2876 -0.0375 -1.4390 -0.0817 -0.3856 -0.0171 -0.7625 -0.0033 -0.0010 -0.0066 -0.0266 -0.0126 -1.2226 -1.0398 -0.0105 -0.3790 -0.6063 -0.0027 -0.8536 -0.8911 -0.0637 -0.5724 -0.3797 -0.0189 -0.5446 -0.0334 -0.6160 -0.0147 -0.0056 -0.0209 -0.1738 -0.0821
S-1387	The patient population was divided into three groups: the VAD group included patients receiving ventricular assist device support; the ECMO group included patients receiving extracorporeal membrane oxygenation membrane support for more than 14 days; and the ECMO+VAD group included patients receiving ECMO followed by VAD support.<unk>
T-1387	patient vad patients ventricular_assist_device ecmo patients extracorporeal_membrane_oxygenation ecmo vad patients ecmo vad
H-1387	-0.6704965233802795	▁ VAD ▁vent ri cular _ assist _ ▁device ▁support ▁EC mo ▁extra corp o real _ ▁membran e _ ▁oxygen ation _ ▁membran e
D-1387	-0.6704965233802795	VAD ventricular_assist_ device support ECmo extracorporeal_ membrane_ oxygenation_ membrane
P-1387	-0.7635 -0.0452 -0.2585 -0.5286 -0.1155 -0.5299 -0.2521 -1.2282 -0.8367 -1.7112 -0.6421 -1.0508 -1.9248 -0.0387 -0.2960 -0.0710 -0.0780 -0.7543 -0.0267 -0.4477 -1.3157 -0.1517 -1.8812 -0.0924 -0.0150 -2.8524 -0.1955
S-244	In conclusion, indicators of functional status (6-MWT and NYHA class) were common to both patients with HFpEF and those with HFrEF, whereas gender and adherence to prescribed therapy were unique to patients having HFpEF in predicting death or HF hospitalization.<unk>
T-244	functional_status 6-mwt nyha_class patients hfpef hfref prescribed therapy patients hfpef death hf hospitalization
H-244	-0.5504878759384155	▁functional ▁status ▁w t ▁NY HA ▁ HF p EF ▁h Fr EF ▁ HF p EF
D-244	-0.5504878759384155	functional status wt NYHA HFpEF hFrEF HFpEF
P-244	-0.4027 -0.1169 -1.9452 -0.1119 -0.5353 -0.4309 -0.7156 -0.2792 -0.0586 -0.0711 -1.3132 -0.1723 -0.2084 -1.5691 -0.3418 -0.1909 -0.0716 -1.8811 -0.0433
S-2016	Simulations to evaluate the cost-effectiveness of heart failure disease management programs across 3 scenarios demonstrate how the model can be used to design a program in which short-term improvements in functioning and use of evidence-based treatments are sufficient to demonstrate good long-term value to the health care system.<unk>
T-2016	heart_failure disease evidence-based health_care
H-2016	-1.200907588005066	▁kosten - effect ive ness ▁heart ▁failure _ management ▁programs
D-2016	-1.200907588005066	kosten-effectiveness heart failure_management programs
P-2016	-1.4915 -0.1183 -0.0074 -0.1253 -2.8651 -2.2087 -0.4451 -0.7960 -1.5082 -3.1026 -1.6817 -0.0609
S-930	To further our understanding of the role of human resistin in heart failure, we studied a humanized mouse model lacking murine resistin but transgenic for the human Retn gene (Hum-Retn mice), which exhibits basal and inflammation-stimulated resistin levels similar to humans.<unk>
T-930	resistin heart_failure murine resistin transgenic retn gene resistin
H-930	-0.8388745188713074	▁human ized _ ▁mouse _ model ▁mur ine _ ▁resist in ▁human _ ▁Ret n _ ▁gene ▁h um - Re t n _ mi ce ▁ inflammation - stimul ated _ ▁resist in
D-930	-0.8388745188713074	humanized_ mouse_model murine_ resistin human_ Retn_ gene hum-Retn_mice inflammation-stimulated_ resistin
P-930	-1.9762 -1.0572 -0.9530 -3.8460 -2.5189 -1.6401 -0.2369 -0.5863 -1.2930 -0.0937 -0.1552 -3.4944 -0.9201 -0.5659 -0.0105 -0.8554 -0.2711 -1.1956 -0.0426 -0.0124 -1.3446 -0.0206 -0.0041 -1.1267 -0.7146 -0.0981 -1.3238 -0.0182 -0.0272 -0.0035 -0.2024 -0.7469 -1.7231 -0.0562 -0.9465 -0.1186
S-1745	Rates of patients receiving angiotensin-converting enzyme inhibitors/angiotensin receptors blockers, β-blockers, and devices at final evaluation increased from 56%, 12%, 8% (period 1) to 97%, 86%, 17% (period 4), respectively (P<0.05).<unk>
T-1745	patients angiotensin-converting_enzyme_inhibitors angiotensin_receptors_blockers β-blockers
H-1745	-0.5549437403678894	▁ang io ten sin - con ver ting _ ▁enzym e ▁inhibi tors _ angi oten sin _ ▁receptor s ▁block ers ▁β - block ers
D-1745	-0.5549437403678894	angiotensin-converting_ enzyme inhibitors_angiotensin_ receptors blockers β-blockers
P-1745	-2.3628 -0.6589 -0.1563 -1.5883 -0.3913 -0.0172 -0.0103 -0.5570 -0.8690 -0.5574 -0.0363 -0.0905 -0.4277 -2.3595 -0.1836 -0.0448 -0.6608 -1.3802 -0.5639 -0.2029 -1.0256 -0.1357 -0.0165 -0.0064 -0.0185 -0.0526 -1.0777 -0.0867
S-1815	Interestingly, TTA/TgTetMena mice were particularly susceptible to cardiac injury, as these animals experienced pronounced decreases in ejection fraction and fractional shortening as well as heart dilatation and hypertrophy after transverse aortic constriction (TAC).<unk>
T-1815	cardiac_injury ejection_fraction fractional_shortening heart_dilatation hypertrophy transverse_aortic_constriction tac
H-1815	-0.44203507900238037	▁ TTA ▁t g t et Men a ▁mi ce ▁cardiac ▁injury ▁e je ction ▁ fraction ▁ fraction al _ short en ing ▁heart ▁di la tation ▁hyper trop hy ▁trans verse _ a or tic _ con stri ction
D-1815	-0.44203507900238037	TTA tgtetMena mice cardiac injury ejection fraction fractional_shortening heart dilatation hypertrophy transverse_aortic_constriction
P-1815	-1.1489 -0.0219 -2.2583 -0.0863 -0.3541 -0.1263 -0.4233 -0.0522 -1.5144 -0.1691 -0.0724 -0.4055 -0.3834 -0.0141 -0.0056 -0.3281 -0.0007 -1.5457 -0.0007 -1.2565 -0.5869 -0.7796 -0.0479 -0.1276 -0.1874 -1.4076 -0.2389 -0.0046 -0.2386 -0.0063 -0.1957 -0.0023 -0.1232 -0.3046 -1.0749 -0.2027 -0.7109 -0.0912 -0.9451 -0.1605 -0.0208 -1.3060 -0.0768
S-1505	In a sample of 659 heart failure patients from Italy, we performed confirmatory factor analysis (CFA) to test the original construct of the SCHFI v.6.2 scales (Self-Care Maintenance, Self-Care Management, and Self-Care Confidence), with limited success.<unk>
T-1505	heart_failure patients italy confirmatory_factor_analysis cfa schfi_v.6.2 self-care_maintenance self-care_management self-care_confidence
H-1505	-0.8022535443305969	▁heart ▁failure ▁patients ▁c fa ▁ SCH fi ▁Self - Car e _ management ▁Self - Car e ▁Confi den ce
D-1505	-0.8022535443305969	heart failure patients cfa SCHfi Self-Care_management Self-Care Confidence
P-1505	-3.7658 -0.1658 -1.3981 -4.1541 -0.7868 -0.8437 -0.4363 -1.4016 -1.9622 -0.0585 -0.5909 -0.0568 -0.9740 -0.4738 -0.1468 -0.0160 -0.3364 -0.0535 -0.5785 -0.0147 -0.1009 -0.0785 -0.0583
S-882	METHODS AND RESULTS: The Resynchronization-Defibrillation for Ambulatory Heart Failure Trial showed that implantable cardioverter defibrillator-CRT was associated with a significant reduction in the primary end point of all-cause mortality or heart failure hospitalization.<unk>
T-882	resynchronization-defibrillation_for_ambulatory_heart_failure_trial implantable primary_end_point all-cause_mortality heart_failure hospitalization
H-882	-0.38735464215278625	▁re syn chron ization - Def i bril lation ▁Amb ulator y _ ▁Heart ▁Fail ure ▁tri al ▁implant able ▁cardio ver ter ▁de fi br illa tor - C RT
D-882	-0.38735464215278625	resynchronization-Defibrillation Ambulatory_ Heart Failure trial implantable cardioverter defibrillator-CRT
P-882	-0.7129 -0.0038 -0.0064 -0.5593 -0.2742 -1.0510 -0.3867 -0.4600 -0.0303 -1.0369 -0.0138 -0.0321 -0.1631 -0.3197 -0.1822 -1.1539 -0.6883 -0.0498 -0.0300 -0.0145 -0.7369 -0.0085 -0.0713 -0.5096 -0.0188 -0.0426 -0.0489 -0.0130 -0.2760 -1.7665 -0.3477 -1.7344 -0.0396
S-102	There are limited data regarding risk factors for the development of ischemic events (IEs) among patients with ischemic cardiomyopathy (IC) who receive cardiac resynchronization therapy with a defibrillator (CRT-D) and their effect on the efficacy of the device.<unk>
T-102	ischemic_events ies patients ischemic_cardiomyopathy ic cardiac_resynchronization_therapy defibrillator crt-d
H-102	-0.6165952682495117	▁risk ▁factors ▁ ische mic _ ▁events ▁i ie s ▁ ische mic _ ▁cardio my o pathy ▁cardiac ▁re syn chron ization ▁ therapy ▁de fi br illa tor ▁c RT - D
D-102	-0.6165952682495117	risk factors ischemic_ events iies ischemic_ cardiomyopathy cardiac resynchronization therapy defibrillator cRT-D
P-102	-2.5338 -0.6759 -0.8039 -0.0217 -0.0853 -0.9563 -1.9531 -1.7480 -2.2842 -0.7375 -0.5096 -0.0266 -0.0585 -0.3955 -1.4525 -1.8753 -0.5439 -0.0222 -1.3426 -0.4183 -0.0036 -0.0044 -0.5144 -0.6057 -0.0078 -0.0975 -0.0106 -0.0216 -0.0422 -0.0092 -0.9853 -0.1732 -0.1576 -0.5189 -0.5460 -0.0549
S-69	Age, renal dysfunction, chronic obstructive pulmonary disease, diabetes, peripheral vascular disease, decreased left ventricular ejection fraction, and ICD shocks during follow-up were strong predictors of mortality; ischemic cardiomyopathy and male sex were not.<unk>
T-69	renal_dysfunction chronic_obstructive_pulmonary_disease diabetes peripheral_vascular_disease left_ventricular_ejection_fraction icd_shocks follow-up mortality ischemic_cardiomyopathy
H-69	-0.3074827790260315	▁renal ▁dys function ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁diabetes ▁per i pher al _ ▁vas cular ▁disease ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁I CD ▁shock s ▁ ische mic _ ▁cardio my o pathy ▁male ▁sex
D-69	-0.3074827790260315	renal dysfunction chronic obstructive pulmonary disease diabetes peripheral_ vascular disease left ventricular ejection fraction ICD shocks ischemic_ cardiomyopathy male sex
P-69	-0.0244 -0.1100 -0.0183 -0.0320 -1.5252 -0.0371 -0.0753 -0.3740 -0.0276 -0.4144 -0.0989 -0.0308 -0.0508 -0.0033 -0.0730 -0.2324 -0.6672 -0.0276 -0.6448 -0.3504 -0.5989 -0.3451 -0.4921 -0.5403 -0.0416 -0.0298 -1.0679 -0.0026 -0.7428 -0.0064 -0.5673 -0.0671 -1.0389 -0.0182 -0.0592 -0.4304 -0.5082 -0.3322 -0.0805 -0.0775 -0.2150 -1.3502 -0.0445 -0.0549
S-1318	METHODS: Male patients with CHF (n = 41, age 67.2 years, range 51-84 years) with mean ± SD testosterone levels of 10.7 ± 2.6 nmol/L (309 ± 76 ng/dL) were randomly allocated to exercise with testosterone or placebo groups.<unk>
T-1318	patients chf testosterone exercise testosterone placebo
H-1318	-1.2671300172805786	▁CHF ▁CHF ▁SD ▁testosteron e
D-1318	-1.2671300172805786	CHF CHF SD testosterone
P-1318	-0.4115 -2.0874 -3.5703 -0.5300 -0.0151 -2.2017 -0.0539
S-996	Interestingly, a number of different Raf-MEK1/2-ERK1/2 scaffold proteins have been identified, and their role in determining the adaptive or maladaptive cardiac remodelling is a promising field of investigation for the development of therapeutic strategies capable of selectively potentiating the adaptive response.<unk>
T-996	scaffold_proteins cardiac_remodelling field therapeutic
H-996	-0.48608505725860596	▁Raf - MEK 1/2 - ER k 1/2 ▁sc af fold ▁protein s ▁adapt ive _ ▁mal adapt ive _ ▁cardiac ▁remodel ling
D-996	-0.48608505725860596	Raf-MEK1/2-ERk1/2 scaffold proteins adaptive_ maladaptive_ cardiac remodelling
P-996	-0.0878 -0.0655 -0.0069 -0.4196 -0.0568 -1.1340 -0.1599 -0.4555 -2.7251 -0.2196 -0.0103 -0.4144 -0.0348 -1.3598 -0.0130 -0.4776 -2.4856 -0.0051 -0.0049 -0.3733 -0.0304 -0.1956 -0.0405 -1.3413 -0.0351
S-341	In addition, because functional MS is dynamic and proportional to LV dilatation, treatment for heart failure (HF), acting to reduce the LV size, can potentially improve such functional MS. A 52-year-old man had HF with severe MR due to prolapse of a degenerative mitral valve in 2008.<unk>
T-341	functional_ms lv_dilatation heart_failure hf functional_ms hf prolapse degenerative_mitral_valve
H-341	-0.8263546228408813	▁functional ▁MS ▁LV ▁di la tation ▁ HF ▁ HF ▁ HF ▁de genera tive _ ▁mit ral ▁val ve
D-341	-0.8263546228408813	functional MS LV dilatation HF HF HF degenerative_ mitral valve
P-341	-0.0632 -0.6043 -2.9280 -0.5855 -0.0252 -0.0009 -2.2710 -1.2011 -2.3015 -0.4588 -2.6841 -1.0433 -1.4634 -0.0005 -0.0882 -0.0948 -1.3479 -0.0227 -0.6015 -0.0108 -0.3470 -0.0362
S-1130	CONCLUSIONS: Contextual reasons for not prescribing angiotensin converting enzyme inhibitor / angiotensin-receptor blockers and β-blockers are present in two thirds of patients with heart failure who did not receive these medications, yet are poorly documented in medical records.<unk>
T-1130	prescribing angiotensin_converting_enzyme_inhibitor angiotensin-receptor_blockers β-blockers patients heart_failure medications medical
H-1130	-0.6232483386993408	▁ang io ten sin ▁convert ing _ ▁enzym e ▁inhibi tor ▁ang io ten sin - recept or ▁block ers ▁β - block ers
D-1130	-0.6232483386993408	angiotensin converting_ enzyme inhibitor angiotensin-receptor blockers β-blockers
P-1130	-4.1143 -1.1926 -0.0845 -0.4436 -0.4345 -0.1523 -1.1126 -0.6054 -0.0258 -0.1281 -0.0238 -0.5449 -0.4730 -0.1057 -0.4208 -0.5147 -0.1188 -0.1410 -1.8535 -0.2420 -0.0408 -0.0176 -0.0265 -0.1085 -3.1775 -0.1016
S-783	The associations between New York Heart Association class, a commonly used criterion standard, and KCCQ Overall Summary and Total Symptom domains were evaluated using Spearman correlations and 2-way ANOVA with differences between patients with HF with reduced EF and HFpEF tested with interaction terms.<unk>
T-783	new_york_heart_association_class kccq symptom spearman_correlations 2-way_anova patients hf_with_reduced_ef hfpef
H-783	-0.7716455459594727	▁New ▁York _ heart _ association ▁k cc q ▁over all _ ▁Summa ry ▁symptom ▁domain s ▁Spe ar man ▁corre lation s ▁ HF
D-783	-0.7716455459594727	New York_heart_association kccq overall_ Summary symptom domains Spearman correlations HF
P-783	-2.7862 -0.3723 -0.1836 -2.4514 -1.0897 -0.7234 -1.7869 -0.0595 -0.3315 -0.6744 -0.0439 -0.6833 -0.8339 -0.0164 -2.9495 -0.1018 -0.0142 -0.0905 -0.0010 -0.0305 -0.2415 -0.0010 -0.0345 -1.1459 -0.7510 -3.3899 -0.0468
S-951	LV systolic indices (LV ejection fraction, LV strain/strain rate at systole) and diastolic indices (E/E', ratio of LV strain rate at diastole with early transmitral flow) were improved only in patients maintaining sinus rhythm at follow-up.<unk>
T-951	systolic lv_ejection_fraction lv_strain strain systole diastolic lv_strain_rate diastole transmitral_flow patients sinus_rhythm follow-up
H-951	-0.6491028666496277	▁LV ▁e je ction ▁ fraction ▁LV ▁strain _ stra in _ ▁rate ▁sy stol e ▁dia sto lic _ ▁indice s ▁e / E
D-951	-0.6491028666496277	LV ejection fraction LV strain_strain_ rate systole diastolic_ indices e/E
P-951	-0.1766 -1.0556 -0.0550 -0.0186 -0.4750 -0.0041 -0.0781 -1.3448 -0.5823 -0.7937 -0.0210 -0.8151 -0.1546 -0.1933 -0.0070 -0.1313 -0.2546 -0.0711 -0.0036 -1.2253 -0.0852 -0.0020 -2.0366 -0.8997 -1.0980 -5.7301 -0.2137
S-276	Eight-week-old C57BL/6 male mice were treated with ANG II infusion (AT), ANG II infusion and uninephrectomy (AN), ANG II infusion and salt loading (AS), or ANG II infusion, uninephrectomy, and salt loading (ANS).<unk>
T-276	ang_ii_infusion ang_ii_infusion uninephrectomy ang_ii_infusion salt_loading ang_ii_infusion uninephrectomy salt_loading
H-276	-1.2325860261917114	▁c 57 BL ▁in fusion ▁ANG ▁II ▁in fusion ▁un ine ph r ecto my ▁ANG ▁II ▁in fusion ▁salt ▁load ing
D-276	-1.2325860261917114	c57BL infusion ANG II infusion uninephrectomy ANG II infusion salt loading
P-276	-2.3273 -0.9743 -1.3651 -5.7488 -0.0993 -2.7881 -3.0007 -0.3334 -0.0192 -0.4073 -1.1428 -1.1184 -0.0581 -0.0374 -0.4022 -1.9610 -2.5181 -0.2610 -0.0221 -0.5236 -0.0344 -0.0072 -4.3505 -0.0817
S-480	The ratio of early transmitral blood flow velocity over tissue Doppler early diastolic mitral annulus velocity (E/e') was found unreliable for estimating pulmonary capillary wedge pressure (PCWP) in patients with decompensated systolic heart failure (HF).<unk>
T-480	transmitral_blood_flow_velocity tissue_doppler diastolic_mitral_annulus_velocity pulmonary_capillary_wedge_pressure pcwp patients decompensated_systolic_heart_failure hf
H-480	-0.6352059841156006	▁early _ trans ral _ ▁blood _ ▁flow _ ▁veloci ty ▁do pp ler ▁early _ dia sto lic _ met ral _ ▁ann ulus _ ▁veloci ty ▁pulmonar y _ cap illa ry _ ▁we dge _ ▁pressure ▁de com pensa ted _ ▁sy sto lic _ heart ▁failure HF
D-480	-0.6352059841156006	early_transral_ blood_ flow_ velocity doppler early_diastolic_metral_ annulus_ velocity pulmonary_capillary_ wedge_ pressure decompensated_ systolic_heart failureHF
P-480	-3.3436 -0.4893 -3.2589 -0.2966 -0.1497 -2.3781 -1.8138 -0.1688 -0.8717 -0.7531 -0.0235 -2.2080 -0.0010 -0.3725 -3.0659 -0.1628 -0.5466 -0.0901 -0.0369 -0.0772 -1.4268 -0.1745 -0.0861 -2.4290 -0.1379 -1.3645 -0.2009 -0.0038 -0.2040 -0.0055 -0.5959 -0.8359 -0.0277 -0.0600 -0.2509 -0.5086 -0.0286 -1.0234 -0.3611 -0.5654 -0.0041 -0.0060 -0.0371 -0.5923 -0.1631 -0.0257 -0.0247 -0.0409 -1.0879 -0.2175 -0.9372 -0.0951 -0.0356
S-1984	By main effects analysis, peak VO2 was increased significantly by both interventions: exercise, 1.2 mL/kg body mass/min (95% CI, 0.7 to 1.7), P < .001; diet, 1.3 mL/kg body mass/min (95% CI, 0.8 to 1.8), P < .001.<unk>
T-1984	peak_vo2 exercise
H-1984	-0.9594780206680298	▁pe ak _ vo 2
D-1984	-0.9594780206680298	peak_vo2
P-1984	-1.4002 -0.0105 -0.3752 -0.4706 -0.0551 -4.1984 -0.2064
S-1698	In 2009, if an AMI patient had chosen a hospital in the worst versus best quintile of performance using 2005-2008 composite (vs. Hospital Compare) rankings, he or she would have had 1.61 (vs. 1.39) times the odds of dying in 30 days (P-value for difference <0.001).<unk>
T-1698	ami patient hospital hospital_compare p-value
H-1698	-1.1156015396118164	▁ AMI ▁ AMI ▁hospital ▁best _ ▁quin tile _ ▁performance ▁hospital _ com posit e
D-1698	-1.1156015396118164	AMI AMI hospital best_ quintile_ performance hospital_composite
P-1698	-0.0801 -0.0148 -3.0822 -0.1263 -2.3952 -3.0162 -0.6098 -0.6837 -0.0019 -0.7233 -0.8661 -2.1001 -1.8460 -0.7018 -0.0076 -0.0042 -3.7021 -0.1195
S-789	One-year event-free rates by KCCQ category among patients with HFpEF were 0 to 25=13.8%, 26 to 50=59.1%, 51 to 75=73.8%, and 76 to 100=77.8% (log rank P<0.001), with no significant interaction by EF (P=0.37).<unk>
T-789	kccq patients hfpef log_rank ef
H-789	-0.8965985178947449	▁K cc q ▁ HF p EF
D-789	-0.8965985178947449	Kccq HFpEF
P-789	-2.2896 -0.3350 -0.7112 -1.7328 -0.8534 -0.0529 -0.1839 -1.8242 -0.0864
S-292	A simple sex-specific model that includes age, race, cTnT, and NT-proBNP (which can be incorporated in a laboratory report) provides a good model, whereas adding cTnT and NT-proBNP to clinical characteristics results in an excellent HF prediction model.<unk>
T-292	ctnt nt-probnp report ctnt nt-probnp clinical hf
H-292	-0.5408790111541748	▁c t n t ▁c t n t ▁NT - pro b NP
D-292	-0.5408790111541748	ctnt ctnt NT-probNP
P-292	-0.5053 -0.5277 -0.0257 -0.8910 -0.5949 -0.4203 -0.0316 -0.6062 -1.2914 -0.0189 -0.0133 -0.4076 -0.0765 -2.6327 -0.0699
S-1517	RESULTS: Mass spectrometry identified the presence of several N- and C-terminally processed forms of circulating NT-proBNP, with physiological proteolysis between Pro2-Leu3, Leu3-Gly4, Pro6-Gly7, and Pro75-Arg76.<unk>
T-1517	mass_spectrometry c-terminally nt-probnp physiological proteolysis
H-1517	-0.5381690859794617	▁Mass ▁spec tro met ry ▁circula ting ▁NT - pro B NP ▁physio logic al _ ▁prote ol ysis ▁le u 3- G ly
D-1517	-0.5381690859794617	Mass spectrometry circulating NT-proBNP physiological_ proteolysis leu3-Gly
P-1517	-1.2704 -0.9120 -0.0275 -0.0077 -0.9085 -0.4924 -0.0740 -1.2051 -0.0297 -0.0539 -1.3918 -0.0494 -0.0288 -0.1977 -0.0260 -1.1097 -0.8974 -0.3350 -0.1726 -0.5126 -0.0021 -0.1491 -1.7172 -0.0372 -2.3393 -0.0451
S-1329	METHODS: Thirty HFpEF patients, 18 female and 12 male, aged 69 ± 8 years, in New York Heart Association class II or III and with mean ejection fraction 63% ± 6%, were randomly (1:1) assigned to a 6-week FES program or placebo.<unk>
T-1329	hfpef patients new_york_heart_association_class_ii ejection_fraction fes placebo
H-1329	-1.2199158668518066	▁ HF p EF
D-1329	-1.2199158668518066	HFpEF
P-1329	-0.1377 -0.8124 -0.1189 -0.0895 -6.1120 -0.0491
S-1548	The depressed left ventricular (LV) systolic pressure, positive and negative rates of changes in pressure development, ejection fraction, fractional shortening and cardiac output, as well as increased LV end-diastolic pressure in 20 weeks MI animals were partially reversed by metoprolol.<unk>
T-1548	left_ventricular systolic_pressure ejection_fraction fractional_shortening cardiac_output lv_end-diastolic_pressure mi metoprolol
H-1548	-0.6071845889091492	▁de press ed ▁left _ ▁vent ri cular LV ▁sy sto lic _ ▁pressure ▁pressure ▁e je ction ▁ fraction ▁ fraction al _ short en ing ▁cardiac ▁output ▁LV _ met o pro lol
D-1548	-0.6071845889091492	depressed left_ ventricularLV systolic_ pressure pressure ejection fraction fractional_shortening cardiac output LV_metoprolol
P-1548	-0.0261 -0.0029 -0.1459 -0.7091 -0.6441 -1.0522 -0.3430 -0.0905 -1.5019 -1.7956 -0.0284 -0.0578 -0.8787 -0.3057 -0.8682 -1.9295 -0.0228 -0.0032 -0.2398 -0.0002 -2.0127 -0.0005 -0.1566 -0.5556 -0.7546 -0.0533 -0.1514 -0.5421 -0.3410 -0.6019 -1.3381 -4.8617 -0.2082 -0.0083 -0.0416 -0.1061 -0.0865
S-1867	Comment on "Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction" OBJECTIVES: The objective of this clinical trial was to assess the safety and efficacy of carotid baroreflex activation therapy (BAT) in advanced heart failure (HF).<unk>
T-1867	baroreflex_activation_therapy_for_the_treatment_of_heart_failure_with_a_reduced_ejection_fraction clinical carotid baroreflex_activation_therapy bat heart_failure hf
H-1867	-0.8157204985618591	▁bar ore flex _ activ ation ▁Therapy ▁Heart _ ▁Fail ure ▁Red u ced _ e je ction _ fra ction
D-1867	-0.8157204985618591	baroreflex_activation Therapy Heart_ Failure Reduced_ejection_fraction
P-1867	-2.6332 -1.2353 -0.2074 -0.3450 -0.4864 -0.1005 -0.3426 -2.5917 -2.0250 -0.1993 -0.4059 -2.0169 -0.0177 -0.5001 -0.0466 -1.3507 -0.0894 -0.0177 -0.8323 -1.0366 -0.0039 -2.2388 -0.0386
S-1748	A more recent enrollment period represented the most powerful independent predictor of favorable outcome {period 2 versus 1 (hazard ratio [HR], 0.64; P=0.04), period 3 versus 1 (HR, 0.35; P<0.001), period 4 versus 1 (HR, 0.14; P<001)}.<unk>
T-1748	outcome hazard_ratio
H-1748	-1.8826231956481934	▁en roll ment
D-1748	-1.8826231956481934	enrollment
P-1748	-3.7078 -0.0071 -0.0776 -5.4916 -0.1291
S-1793	LA is a heterogeneous region with HF risk factors of developed and nondeveloped countries, including lower risk of raised blood glucose levels, obesity, tobacco, and aging, whereas systemic hypertension (SH), rheumatic fever, and Chagas' disease (C'D) are higher in LA.<unk>
T-1793	hf blood_glucose obesity systemic_hypertension rheumatic_fever disease
H-1793	-0.5164931416511536	▁ HF ▁ HF ▁raised _ ▁blood ▁gluco se ▁levels ▁obes ity ▁to ba cco ▁system ic _ ▁hyper tension ▁s ▁rhe u matic _ ▁fe ver ▁Cha gas _ ▁disease
D-1793	-0.5164931416511536	HF HF raised_ blood glucose levels obesity tobacco systemic_ hypertension s rheumatic_ fever Chagas_ disease
P-1793	-0.2693 -0.0134 -1.6057 -0.0749 -3.7904 -0.2524 -0.8695 -0.0128 -0.0164 -0.5358 -0.4544 -0.4248 -0.0024 -0.0060 -0.0021 -0.1499 -0.0352 -0.8779 -0.2540 -0.0065 -2.7973 -0.0253 -0.0053 -0.0701 -0.3007 -0.5274 -0.0058 -0.5757 -0.0022 -1.3710 -0.3562 -1.2629 -0.0906
S-1107	The age- and sex-adjusted risk declined from 1990-1996 to 2004-2010, with hazard ratios of 0.67 (95% confidence interval (CI): 0.54, 0.85) for early-onset HF and 0.63 (95% CI: 0.45, 0.86) for late-onset HF.<unk>
T-1107	hazard_ratios confidence_interval hf hf
H-1107	-1.1515848636627197	▁age - ad just ed _ risk ▁ HF
D-1107	-1.1515848636627197	age-adjusted_risk HF
P-1107	-1.2808 -0.0827 -4.1194 -0.0145 -0.0277 -0.6134 -0.8222 -3.0944 -2.0666 -0.4729 -0.0729
S-1772	Adjusted hazard ratios across high, moderate, and low CRF categories were 1.0, 1.63, and 3.97, respectively, whereas those of normal, overweight, and obese body mass index categories were 1.0, 1.56, and 3.71, respectively (P for trend <0.0001 for each).<unk>
T-1772	hazard_ratios crf obese body_mass_index
H-1772	-1.389084815979004	▁ad just ed _ ▁hazard ▁ratio s ▁c RF
D-1772	-1.389084815979004	adjusted_ hazard ratios cRF
P-1772	-4.8466 -0.0024 -0.0337 -0.5285 -2.5434 -0.0944 -0.1556 -2.2266 -0.4423 -4.3333 -0.0732
S-395	Baseline eGFR group II (P<0.001), eGFR group III (P<0.001), eGFR group IV (P<0.001), uncontrolled hypertension (P=0.049), need of diuretics, and age <60 years (P=0.016) were associated with time to ESRD.<unk>
T-395	baseline egfr egfr egfr hypertension diuretics esrd
H-395	-0.8448920845985413	▁e G FR ▁e G FR ▁e G FR ▁group ▁un control led _ ▁hyper tension ▁di ure tics
D-395	-0.8448920845985413	eGFR eGFR eGFR group uncontrolled_ hypertension diuretics
P-395	-0.0653 -0.7224 -0.0597 -2.3177 -0.7388 -0.0852 -3.5031 -0.6574 -0.0855 -2.5613 -3.0741 -0.0046 -0.1930 -0.4581 -0.3270 -0.0548 -0.3805 -0.4097 -0.0430 -1.9243 -0.0771
S-1208	OBJECTIVES: This study investigated whether myocardial phosphodiesterase-2 (PDE2) is altered in heart failure (HF) and determined PDE2-mediated effects on beta-adrenergic receptor (β-AR) signaling in healthy and diseased cardiomyocytes.<unk>
T-1208	myocardial phosphodiesterase-2 pde2 heart_failure hf beta-adrenergic_receptor β-ar healthy diseased cardiomyocytes
H-1208	-0.7075938582420349	▁my o card ial _ phos pho dies tera se -2 ▁p de 2 ▁heart ▁failure ▁ HF ▁p de 2- media ted ▁beta - ad r energi c _ ▁receptor β - AR ▁cardio my o cy tes
D-1208	-0.7075938582420349	myocardial_phosphodiesterase-2 pde2 heart failure HF pde2-mediated beta-adrenergic_ receptorβ-AR cardiomyocytes
P-1208	-0.9227 -0.1017 -0.1904 -0.4184 -1.3982 -0.0510 -0.8687 -3.9543 -0.0136 -0.6659 -0.9161 -0.2104 -0.7657 -1.0151 -1.2710 -0.0236 -2.8753 -0.0017 -0.4123 -0.7450 -0.0299 -2.4307 -0.0194 -0.9236 -0.0185 -0.0172 -0.2974 -1.8769 -0.0732 -1.6644 -0.0225 -0.2223 -0.0057 -0.3297 -3.0768 -0.7175 -0.1097 -0.0968 -0.0715 -0.0949 -0.0916
S-866	CONCLUSIONS: In heart failure patients undergoing either cardiac resynchronization therapy with a defibrillator or with an implantable cardioverter-defibrillator device, carvedilol was associated with a 36% lower rate of inappropriate ATP and shock therapy compared with metoprolol.<unk>
T-866	heart_failure patients cardiac_resynchronization_therapy defibrillator implantable_cardioverter-defibrillator carvedilol atp shock_therapy metoprolol
H-866	-0.33671995997428894	▁cardiac ▁re syn chron ization ▁ therapy ▁de fi br illa tor ▁implant able ▁cardio ver ter - de fi br illa tor ▁device ▁car vedi lol ▁in appropria te _ ▁ATP ▁shock ▁ therapy ▁met o pro lol
D-866	-0.33671995997428894	cardiac resynchronization therapy defibrillator implantable cardioverter-defibrillator device carvedilol inappropriate_ ATP shock therapy metoprolol
P-866	-0.8689 -0.9462 -0.0258 -0.0118 -0.7215 -2.3254 -0.0117 -0.0065 -0.0293 -0.0905 -0.0700 -0.0147 -0.1389 -0.0100 -0.6327 -0.0120 -0.1644 -0.1564 -0.0171 -0.0435 -0.0988 -0.1417 -0.0259 -1.4247 -0.0055 -0.0013 -0.0042 -1.0674 -0.0025 -0.0222 -0.3557 -0.3241 -2.6548 -1.0785 -0.0118 -0.0587 -0.0956 -0.0051 -0.0124 -0.0722 -0.0454
S-1245	We have demonstrated recently that (-)-ERC (epicatechin-rich cocoa) improves SkM mitochondrial structure [Taub, Ramirez-Sanchez, Ciaraldi, Perkins, Murphy, Naviaux, Hogan, Ceballos, Maisel, Henry et al.<unk>
T-1245	epicatechin-rich_cocoa skm mitochondrial_structure taub ramirez-sanchez ciaraldi perkins murphy naviaux hogan ceballos maisel henry
H-1245	-0.5573469996452332	▁ ERC ▁e pica tech in - rich ▁coco a ▁Sk m ▁mito cho ndri al ▁structure ▁ci ar aldi ▁per kin s ▁Murphy ▁na vi aux ▁Hoga n ▁ce ball os ▁Mais el ▁Henry
D-1245	-0.5573469996452332	ERC epicatechin-rich cocoa Skm mitochondrial structure ciaraldi perkins Murphy naviaux Hogan ceballos Maisel Henry
P-1245	-2.8053 -0.1161 -0.4163 -0.0012 -0.0656 -0.1401 -0.0415 -0.0163 -0.1628 -0.0057 -2.7103 -1.3188 -0.0910 -0.1455 -0.1053 -0.0100 -0.5551 -4.3178 -0.0209 -0.0016 -0.9706 -0.2396 -0.0043 -0.3764 -1.7644 -0.0317 -0.0172 -2.3877 -0.0061 -0.8386 -0.0253 -0.0124 -0.5682 -0.0008 -0.1590 -0.0987 -0.0734
S-1420	Taking into account all follow-up visits over the 6-month period, we found that the risk of death or urgent readmission was lower among patients who had all of their visits with a familiar physician than among those followed by unfamiliar physicians (adjusted HR 0.91, 95% CI 0.85-0.98).<unk>
T-1420	follow-up death readmission patients physician physicians
H-1420	-1.4929100275039673	▁follow - up ▁visit s
D-1420	-1.4929100275039673	follow-up visits
P-1420	-3.8385 -0.0177 -0.0046 -2.3789 -0.0353 -4.0970 -0.0783
S-1816	By "turning off" Mena overexpression in TTA/TgTetMena mice either immediately prior to or immediately after TAC surgery, we discovered that normalizing Mena levels eliminated cardiac hypertrophy in TTA/TgTetMena animals but did not preclude post-TAC cardiac functional deterioration.<unk>
T-1816	mena_overexpression tac surgery mena cardiac_hypertrophy cardiac
H-1816	-0.5616501569747925	▁men a ▁over expression ▁ TTA / t g t et Men a ▁mi ce ▁ TAC
D-1816	-0.5616501569747925	mena overexpression TTA/tgtetMena mice TAC
P-1816	-0.7091 -0.2562 -0.2549 -0.0086 -0.5888 -0.0102 -1.0974 -0.5229 -0.0791 -0.4383 -0.1815 -0.2845 -0.0348 -2.4923 -0.0773 -0.2903 -0.1090 -3.1418 -0.0944
S-901	SUMMARY: Objective criteriabased institution of PD for the treatment of diuretic refractory severe-end-stage HF was well tolerated and demonstrated favorable outcomes; these included improved clinical status, reduced hospitalizations and length of stay, with very few and easily treatable PDrelated complications.<unk>
T-901	pd diuretic hf outcomes clinical hospitalizations pdrelated complications
H-901	-0.6542320847511292	▁PD ▁di ure tic _ re frac tory _ ▁severe - end - s tage ▁ HF
D-901	-0.6542320847511292	PD diuretic_refractory_ severe-end-stage HF
P-901	-3.3802 -0.3955 -0.1375 -0.7631 -0.1215 -0.6943 -0.0214 -0.1468 -0.6471 -2.8188 -0.3138 -0.8375 -0.0502 -0.1646 -0.0014 -1.1762 -0.0018 -0.7316 -0.0272
S-1785	Overall ATP production rates were decreased at 2 and 3 weeks post-AAC (by 37% and 47%, respectively) because of a reduction in mitochondrial oxidation of glucose, lactate, and fatty acids that was not accompanied by an increase in myocardial glycolysis rates.<unk>
T-1785	atp mitochondrial_oxidation glucose lactate fatty_acids myocardial glycolysis
H-1785	-0.34484803676605225	▁ATP ▁mito cho ndri al ▁oxid ation ▁gluco se ▁lac tate ▁fa tty ▁acid s ▁my o card ial _ ▁gly col ysis
D-1785	-0.34484803676605225	ATP mitochondrial oxidation glucose lactate fatty acids myocardial_ glycolysis
P-1785	-0.5916 -3.8147 -0.0596 -0.0412 -0.0048 -0.3857 -0.0351 -0.0751 -0.0389 -0.0027 -0.0068 -0.0051 -0.1479 -0.6240 -0.0728 -0.7304 -0.0761 -0.2127 -0.4425 -0.7692 -0.0892 -0.0099 -0.0141 -0.3039 -0.0673
S-456	To test whether the proangiogenic effects of B act via activation of VEGF pathway, rats were intravenously injected with adenoviral vector encoding a decoy VEGF receptor (Ad-Flk) or a control adenovirus (Ad-C), at the start of the treatment with B.<unk>
T-456	proangiogenic vegf_pathway intravenously injected adenoviral vegf_receptor adenovirus
H-456	-0.5605179667472839	▁pro angi ogen ic ▁effects ▁B ▁activa tion ▁VE GF ▁path way ▁a den ovi ral _ ve ctor ▁de co y _ ve GF ▁receptor ▁ad - F lk ▁control ▁ade no virus ▁ad - c
D-456	-0.5605179667472839	proangiogenic effects B activation VEGF pathway adenoviral_vector decoy_veGF receptor ad-Flk control adenovirus ad-c
P-456	-0.2632 -0.0063 -0.0073 -0.1098 -2.8786 -2.0218 -1.4597 -0.0718 -1.5715 -0.0051 -0.8157 -0.0306 -0.1726 -0.0128 -0.0901 -0.0259 -0.9958 -0.8397 -0.0029 -0.0062 -0.0004 -0.0379 -0.9587 -1.1088 -0.6115 -1.4521 -0.6265 -0.0329 -0.8028 -0.0225 -0.3636 -2.3721 -0.0307 -0.0038 -0.7039 -0.0041 -0.8173 -0.4845 -0.0387
S-1226	RESULTS: In all high-risk subgroups, patients treated with eplerenone had an increased risk of potassium >5.5 mmol/l but not of potassium >6.0 mmol/l, and of hospitalization for hyperkalemia or discontinuation of study medication due to adverse events.<unk>
T-1226	patients eplerenone potassium potassium hospitalization hyperkalemia medication adverse_events
H-1226	-0.5168423652648926	▁e pler en one ▁po tas s ium
D-1226	-0.5168423652648926	eplerenone potassium
P-1226	-0.2423 -0.0079 -0.0631 -0.6242 -1.1133 -0.1385 -0.1528 -0.1044 -2.6327 -0.0890
S-514	The implantation of a novel bottleneck stent in the proximal LAD or LCX is a novel porcine model of reversible myocardial ischemia (open stent) and ischemic heart failure (occluded stent) and is feasible for the development of new therapeutic approaches.<unk>
T-514	implantation bottleneck_stent lad lcx myocardial_ischemia stent ischemic_heart_failure stent therapeutic
H-514	-0.58428955078125	▁bottle ne ck _ ▁sten t ▁proxima l ▁ LAD ▁ LC X ▁rever sible _ my o card ial _ ische mia open _ ▁sten t ▁ ische mic _ heart ▁failure
D-514	-0.58428955078125	bottleneck_ stent proximal LAD LCX reversible_myocardial_ischemiaopen_ stent ischemic_heart failure
P-514	-2.5311 -0.0146 -0.0061 -1.1211 -1.3728 -0.0163 -0.0786 -0.0007 -0.4376 -0.0023 -1.5634 -0.0047 -1.0899 -2.2349 -0.0016 -0.2000 -2.8365 -0.0829 -0.1636 -0.0706 -0.4747 -0.1804 -0.2357 -0.2051 -0.4134 -0.7557 -0.0164 -0.8423 -0.0229 -0.0350 -0.0803 -1.1925 -0.8057 -1.2992 -0.0615
S-1347	A patient aged in his 60s with New York Heart Association class III heart failure (HF) (left ventricular ejection fraction of 25%) who was originally part of this study displayed permanent periodic breathing (PB) and was then excluded from the final data analysis; his response is presented in this report.<unk>
T-1347	patient new_york_heart_association_class_iii heart_failure hf left_ventricular_ejection_fraction periodic_breathing pb report
H-1347	-0.9023491144180298	▁New ▁York _ heart _ association _ class _ ▁III _ heart ▁failure ▁ HF ▁le ft _ ▁vent ri cular ▁e je ction ▁p b
D-1347	-0.9023491144180298	New York_heart_association_class_ III_heart failure HF left_ ventricular ejection pb
P-1347	-3.8322 -0.6137 -0.2854 -1.4763 -0.9691 -1.0400 -0.8071 -1.3581 -1.3091 -1.1177 -0.0964 -1.7165 -0.8940 -2.8075 -0.1808 -0.9290 -0.0210 -0.5200 -1.3974 -0.4287 -0.3751 -1.4087 -0.0263 -0.0047 -0.7253 -0.7041 -0.1709 -0.0506
S-1705	Potassium increased with spironolactone in non-AAs (4.29±0.5-4.55±0.49 mmol/L) but not in AAs (4.32±0.54-4.31±0.49 mmol/L; race by treatment interaction, P=0.03) during the first month and remained higher throughout the trial.<unk>
T-1705	potassium spironolactone aas
H-1705	-0.8723242282867432	▁spi rono lac tone ▁AA s
D-1705	-0.8723242282867432	spironolactone AAs
P-1705	-1.1203 -0.0150 -0.0217 -0.0224 -2.4657 -1.0785 -2.1679 -0.0872
S-1880	METHODS: We performed symptom limited maximal CPET in 10 patients with CHF, randomly divided into two groups: 5 patients as control without exercise and 5 exercise patients used Δ50%W intensity to exercise 30 min/d, 5 d/w, x12 w. Before and after 12 w rehabilitation, we evaluated functions.<unk>
T-1880	symptom cpet patients chf patients exercise exercise patients exercise rehabilitation
H-1880	-1.1558502912521362	▁symptom ▁limited _ c PET ▁CHF
D-1880	-1.1558502912521362	symptom limited_cPET CHF
P-1880	-1.4488 -0.8434 -0.3467 -2.3775 -0.0389 -0.3958 -3.7570 -0.0386
S-357	Repeated echocardiography 4 months later demonstrated a reduction in LV end-diastolic volume of 66 mL/m2, disappearance of MR, improvement of the mitral valve opening to an MVA of 1.7 cm2, and a mean pressure gradient of 4.6 mm Hg (Fig 1C).<unk>
T-357	echocardiography lv_end-diastolic_volume mitral_valve_opening mva
H-357	-0.6459029912948608	▁e cho card i ography ▁LV ▁end - dia sto lic ▁volume ▁disappear ance ▁MR ▁mit ral ▁val ve ▁opening ▁m VA ▁pressure ▁gradi ent
D-357	-0.6459029912948608	echocardiography LV end-diastolic volume disappearance MR mitral valve opening mVA pressure gradient
P-357	-0.1928 -0.0333 -0.1001 -0.2234 -0.1429 -2.3547 -4.7035 -0.0140 -0.0068 -0.0371 -0.0059 -0.9119 -3.1373 -0.0114 -0.2680 -0.0166 -0.0066 -0.2778 -0.0147 -2.1845 -0.8979 -0.3925 -0.7110 -0.0664 -0.0076 -0.6817 -0.0389
S-552	CONCLUSIONS: Surgical treatment of post-LVAD AI with aortic valve oversewing or leaflet repair or by bioprosthetic aortic valve replacement is effective at restoring functional capacity for CF LVAD patients who develop symptomatic, severe AI and can be performed safely with good results.<unk>
T-552	surgical post-lvad_ai aortic_valve leaflet bioprosthetic_aortic_valve_replacement functional_capacity lvad patients symptomatic
H-552	-0.3859978914260864	▁post - L VAD ▁a or tic _ ▁val ve ▁over se wing ▁le a flet ▁repair ▁bio pro sthetic ▁a or tic _ ▁val ve ▁replace ment ▁CF ▁l VAD
D-552	-0.3859978914260864	post-LVAD aortic_ valve oversewing leaflet repair bioprosthetic aortic_ valve replacement CF lVAD
P-552	-0.7680 -0.0095 -1.5490 -0.0047 -1.4959 -0.1580 -0.7348 -0.2435 -1.1548 -0.0205 -0.0805 -0.1064 -0.1077 -0.0050 -0.0092 -0.0004 -0.1673 -0.0008 -0.0025 -0.0005 -0.5710 -0.0599 -0.3363 -0.0548 -0.5800 -0.0189 -0.4384 -0.0304 -0.5078 -1.7943 -0.0122 -1.6779 -0.0372
S-1123	METHODS: Mixed-methods study of 295 veterans aged 50 years and older in 4 VA health care systems who had systolic heart failure and were not prescribed a β-blocker and/or an angiotensin converting enzyme inhibitor or angiotensin-receptor blocker.<unk>
T-1123	mixed-methods_study health_care systolic_heart_failure prescribed β-blocker angiotensin_converting_enzyme_inhibitor angiotensin-receptor_blocker
H-1123	-0.5857443809509277	▁sy sto lic _ heart ▁failure ▁β - block er ▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tor ▁ang io ten sin - recept or ▁block er
D-1123	-0.5857443809509277	systolic_heart failure β-blocker angiotensin converting enzyme inhibitor angiotensin-receptor blocker
P-1123	-7.0565 -0.0402 -0.0506 -0.1731 -1.1708 -0.5278 -1.0587 -0.0129 -0.0306 -0.1232 -0.5372 -0.3126 -0.2349 -0.5476 -1.5814 -0.0733 -0.5762 -0.0242 -0.0275 -0.0063 -1.1867 -0.4264 -0.1666 -0.5455 -0.1238 -0.0976 -0.0326 -1.1067 -0.0558 -0.1689 -0.0818
S-822	BACKGROUND: This study sought to analyze a new approach to assess exercise-induced pulmonary artery systolic pressure (PASP) increase by means of stress Doppler echocardiography as a possible measure of right ventricular contractile reserve in patients with severe pulmonary hypertension and right heart failure.<unk>
T-822	exercise-induced_pulmonary_artery_systolic_pressure pasp stress_doppler_echocardiography right_ventricular_contractile_reserve patients pulmonary_hypertension right_heart_failure
H-822	-0.6154310703277588	▁exercise - indu ced ▁pulmonar y _ ▁arter y _ ▁sy sto lic _ ▁pressure ▁stress ▁do pp ler ▁e cho card i ography ▁right _ ▁vent ri cular _ ▁contract ile ▁reserve ▁pulmonar y ▁hyper tension ▁right _ heart ▁failure
D-822	-0.6154310703277588	exercise-induced pulmonary_ artery_ systolic_ pressure stress doppler echocardiography right_ ventricular_ contractile reserve pulmonary hypertension right_heart failure
P-822	-4.8511 -0.1076 -0.0222 -0.1672 -0.4014 -0.0806 -0.9170 -1.7425 -0.1284 -1.3180 -1.3397 -0.0243 -0.0610 -0.5029 -0.3094 -1.8013 -1.1880 -0.0030 -0.3888 -0.5749 -0.0624 -0.1792 -0.0941 -0.1896 -0.1299 -0.9459 -0.9134 -0.5121 -0.4976 -0.3432 -1.0873 -0.0555 -0.0833 -0.3347 -0.0157 -1.3400 -0.0166 -1.0077 -0.3303 -1.3031 -0.9353 -0.0981 -0.0593
S-1844	Methods and analysis We will conduct a literature search in the databases of MEDLINE, EMBASE, HEALTHSTAR, CINAHL, Cochrane Library, Campbell Collaboration, Joanna Briggs Institute Evidence Based Practice, Centre for Reviews and Dissemination and Evidence Based Practice Centres.<unk>
T-1844	medline embase healthstar cinahl cochrane_library campbell_collaboration joanna_briggs_institute_evidence_based_practice centre_for_reviews_and_dissemination evidence_based_practice_centres
H-1844	-0.6686486601829529	▁literature ▁search ▁MED LINE ▁ EMBA se ▁HE al th STAR ▁c INA HL ▁co ch rane ▁Library ▁Campbell _ ▁Col labora tion ▁Joan na ▁Brig gs ▁Institute _ review s
D-1844	-0.6686486601829529	literature search MEDLINE EMBAse HEalthSTAR cINAHL cochrane Library Campbell_ Collaboration Joanna Briggs Institute_reviews
P-1844	-3.3589 -1.1282 -0.7108 -0.7317 -0.6694 -0.0036 -0.9853 -1.7152 -1.1432 -1.4091 -0.8458 -0.3530 -0.2064 -0.1601 -0.3623 -0.0098 -0.0034 -0.1239 -0.0176 -1.8006 -0.7752 -0.0459 -0.0055 -0.0049 -0.0083 -0.0131 -0.0090 -0.3539 -0.9398 -1.2715 -0.0294 -2.7974 -0.0732
S-647	The base of treatment of heart failure is the blockade of the neuro-hormonal system, which includes the use of angiotensin converting enzyme inhibitors (angiotensin receptor blockers in case of angiotensin converting enzyme inhibitors intolerance), beta receptor blockers and mineralocorticoid receptor antagonists.<unk>
T-647	heart_failure neuro-hormonal_system angiotensin_converting_enzyme_inhibitors angiotensin_receptor_blockers angiotensin_converting_enzyme_inhibitors beta_receptor_blockers mineralocorticoid_receptor_antagonists
H-647	-0.6453390717506409	▁heart ▁failure ▁neuro - hormon al ▁system ▁ang io ten sin ▁convert ing _ ▁enzym e ▁inhibi tors angi oten sin ▁receptor ▁block ers ▁ang io ten sin _ ▁convert ing _ ▁enzym e ▁inhibi tors ▁in tolerance ▁mineral o cor tico id ▁receptor ▁anta gon ists
D-647	-0.6453390717506409	heart failure neuro-hormonal system angiotensin converting_ enzyme inhibitorsangiotensin receptor blockers angiotensin_ converting_ enzyme inhibitors intolerance mineralocorticoid receptor antagonists
P-647	-4.5836 -0.9699 -0.7206 -0.0333 -0.0044 -0.0148 -0.8513 -0.0824 -0.2368 -0.1796 -1.1928 -0.9194 -0.2422 -1.9233 -0.4181 -0.0487 -0.0441 -0.2198 -0.4931 -0.0216 -0.4057 -0.9560 -0.4414 -0.0538 -1.4445 -0.2255 -0.0944 -0.5123 -2.3616 -0.6906 -0.1596 -0.5023 -1.1491 -0.0502 -0.1068 -0.3934 -3.0364 -0.0028 -2.8858 -0.0897 -0.4512 -0.7189 -0.0784 -0.2673 -0.1572 -0.0032 -0.8857 -0.2412 -0.0569
S-330	CONCLUSIONS: In an open chest model, twist, RS, RS synchrony, and CS analyzed by STE may be noninvasive surrogates for changes in CO. During RVPO, changes in RS synchrony and CS with varying regional strain contributions may be the primary mechanism in which BiVP improves CO.<unk>
T-330	chest rs rs_synchrony ste noninvasive rvpo rs_synchrony strain bivp
H-330	-0.5840694308280945	▁open _ ▁che st ▁model ▁twist ▁RS ▁synchron y ▁CS
D-330	-0.5840694308280945	open_ chest model twist RS synchrony CS
P-330	-0.0336 -0.9001 -0.8248 -0.0019 -0.1749 -0.0003 -0.2221 -0.0546 -0.0368 -1.0102 -3.6629 -0.0866
S-498	Given the TAPSE, PASP, and TAPSE-to-PASP ratio (TAPSE/PASP) collinearity, separate Cox regression and Kaplan-Meier analyses were performed: one with TAPSE and PASP as individual measures, and the other combining them in ratio form.<unk>
T-498	tapse pasp tapse pasp cox_regression kaplan-meier_analyses tapse pasp
H-498	-0.8698864579200745	▁T AP se ▁PAS p ▁T AP se - to - PAS p _ ▁ratio TA PS e _ pas p ▁co x ▁re gression ▁ka plan - me ier
D-498	-0.8698864579200745	TAPse PASp TAPse-to-PASp_ ratioTAPSe_pasp cox regression kaplan-meier
P-498	-1.1921 -0.0856 -1.1378 -2.1217 -1.2454 -2.7446 -0.1116 -0.8639 -0.0765 -0.0284 -0.0222 -0.8408 -1.2374 -2.8159 -0.2886 -4.7189 -0.3512 -0.5669 -1.1304 -0.8062 -0.9174 -1.4285 -0.0101 -0.1355 -0.0013 -0.8513 -0.0207 -0.0147 -0.7315 -0.0217 -1.2336 -0.0839
S-1978	Of 577 initially screened participants, 100 older obese participants (mean [SD]: age, 67 years [5]; body mass index, 39.3 [5.6]) with chronic, stable HFPEF were enrolled (366 excluded by inclusion and exclusion criteria, 31 for other reasons, and 80 declined participation).<unk>
T-1978	obese body_mass_index chronic stable hfpef
H-1978	-1.1552351713180542	▁obes e _ ▁participants ▁me an _ SD ▁body ▁mass ▁index ▁chronic _ ▁stable _ h FP EF
D-1978	-1.1552351713180542	obese_ participants mean_SD body mass index chronic_ stable_hFPEF
P-1978	-5.3777 -0.0471 -3.6792 -1.5252 -3.3024 -0.0257 -2.3883 -0.0584 -0.8520 -0.2090 -0.0092 -0.7203 -0.5306 -2.0887 -0.4338 -0.7978 -0.2839 -0.2282 -0.4507 -0.0967
S-1080	BACKGROUND: Human heart failure (HF) increases alternative mRNA splicing of the type V, voltage-gated cardiac Na+ channel α-subunit (SCN5A), generating variants encoding truncated, nonfunctional channels that are trapped in the endoplasmic reticulum.<unk>
T-1080	heart_failure hf mrna_splicing cardiac scn5a endoplasmic_reticulum
H-1080	-0.49377328157424927	▁m RNA ▁volta ge - ga ted _ ▁cardiac _ na + ▁channel ▁α - sub un it ▁s cn 5 a
D-1080	-0.49377328157424927	mRNA voltage-gated_ cardiac_na+ channel α-subunit scn5a
P-1080	-2.7528 -0.0112 -0.8787 -0.0092 -0.0403 -0.0097 -0.0153 -0.4030 -0.3219 -0.7271 -0.5412 -0.4287 -0.4369 -0.7088 -0.0040 -0.0015 -0.0259 -0.0186 -0.6011 -0.9997 -0.5681 -0.2486 -2.0485 -0.0498
S-988	Particular topics of debate in paediatric heart failure concern: the diagnosis and management of myocarditis versus dilated cardiomyopathy the most appropriate investigations for new onset heart failure cellular responses to heart failure the increasing population of anthracycline treated survivors of childhood malignant disease treatment strategies.<unk>
T-988	heart_failure diagnosis myocarditis dilated_cardiomyopathy heart_failure heart_failure anthracycline disease
H-988	-0.6882039904594421	▁pa e dia tric _ heart ▁failure ▁my o card itis ▁dil ated _ ▁cardio my o pathy ▁heart ▁failure ▁an thra cycli ne
D-988	-0.6882039904594421	paediatric_heart failure myocarditis dilated_ cardiomyopathy heart failure anthracycline
P-988	-0.3849 -0.0651 -0.0421 -0.5003 -0.5280 -1.4272 -0.1442 -4.0659 -0.1167 -0.5339 -0.1821 -0.2199 -0.0357 -0.2055 -0.1059 -0.4209 -0.0971 -0.0346 -4.1591 -0.1392 -0.2796 -0.0018 -0.0422 -0.5502 -3.5436 -0.0675
S-2010	METHODS: We developed the Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model, a Web-based simulation tool designed to integrate data on demographic, clinical, and laboratory characteristics; use of evidence-based medications; and costs to generate predicted outcomes.<unk>
T-2010	tools_for_economic_analysis_of_patient_management_interventions_in_heart_failure_cost-effectiveness_model clinical evidence-based medications costs outcomes
H-2010	-0.9891608953475952	▁Tools _ economic _ analys is _ van _ ▁Patient ▁Management ▁Interven tions ▁Heart _ ▁Fail ure _ ▁Cost - E ff ective ness ▁model
D-2010	-0.9891608953475952	Tools_economic_analysis_van_ Patient Management Interventions Heart_ Failure_ Cost-Effectiveness model
P-2010	-3.1746 -1.7519 -1.7765 -0.5583 -0.8439 -0.0893 -0.9289 -3.2988 -0.0797 -0.8230 -0.5996 -1.0389 -0.1397 -0.8012 -0.9067 -0.3695 -0.7095 -1.1806 -3.1274 -0.0439 -0.8291 -0.1594 -0.0070 -0.5792 -1.6184 -1.2393 -0.0329
S-1020	The measurement of natriuretic peptides (NPs), B-type NP or N-terminal pro-B-type NP, can be an important tool in the diagnosis of acute heart failure in patients presenting to an Emergency Department (ED) with acute dyspnea, according to international guidelines.<unk>
T-1020	natriuretic_peptides nps b-type_np n-terminal_pro-b-type_np diagnosis acute_heart_failure patients emergency_department acute_dyspnea
H-1020	-0.7657769322395325	▁na tri ure tic _ pe pti des ▁na tri ure tic _ pe pti des ▁ NP ▁n - termin al _ pro - B - type _ NP ▁a cute _ heart ▁failure
D-1020	-0.7657769322395325	natriuretic_peptides natriuretic_peptides NP n-terminal_pro-B-type_NP acute_heart failure
P-1020	-0.0031 -0.0173 -0.6716 -2.6546 -1.1912 -0.4364 -0.0386 -0.3519 -1.1173 -0.0765 -0.5143 -2.3976 -0.7335 -1.0376 -0.0464 -0.2705 -3.1207 -0.0318 -1.7573 -0.0172 -0.0102 -0.0036 -1.2456 -1.4190 -0.0152 -0.6200 -0.0277 -0.0033 -0.8550 -1.0191 -0.3487 -0.0178 -0.0570 -3.3664 -0.8265 -1.8854 -0.1278
S-1275	Besides the widely accepted peak oxygen consumption (peak VO2) and VEN/VCO2 slope, other exercise variables - exercise oscillatory ventilation (EOV) and partial pressure of end-tidal CO2, (PETCO2) - should gain attention in the interpretation of cardiopulmonary exercise testing.<unk>
T-1275	peak_oxygen_consumption peak_vo2 exercise exercise_oscillatory_ventilation eov partial_pressure_of_end-tidal_co2 petco2 gain cardiopulmonary_exercise_testing
H-1275	-0.6024039387702942	▁pe ak _ ▁oxygen ▁consum p tion ▁ ven / v co 2 ▁s lope ▁exercise ▁os cilla tory _ ▁ventilation ▁e OV ▁parti al _ ▁pressure ▁p co 2 ▁cardio pul mon ary
D-1275	-0.6024039387702942	peak_ oxygen consumption ven/vco2 slope exercise oscillatory_ ventilation eOV partial_ pressure pco2 cardiopulmonary
P-1275	-0.1424 -0.0016 -0.3052 -2.8866 -0.1828 -0.0264 -0.1280 -2.3086 -0.4560 -1.0036 -0.3332 -0.7283 -0.0539 -0.2207 -0.0281 -0.2788 -0.1981 -0.0024 -0.0258 -0.6819 -0.0146 -0.3566 -0.0117 -1.7393 -0.0053 -0.1051 -0.7016 -4.4078 -0.3837 -0.5245 -0.5887 -0.0165 -0.1856 -0.2045 -2.3733 -0.0751
S-1536	DESIGN: In this nationwide retrospective cohort study from Denmark, all users of bisphosphonates and raloxifene between 1996 and 2006 (n = 102 342) were included in the 'exposed' group and three age- and gender-matched subjects (n = 307.026) from the general population comprised the control group.<unk>
T-1536	retrospective_cohort_study denmark bisphosphonates raloxifene
H-1536	-1.0977287292480469	▁nation wide _ ▁retro spec tive _ co hor t _ studie ▁Denmark ▁bis phos phon ates ▁ra lo xi fen e
D-1536	-1.0977287292480469	nationwide_ retrospective_cohort_studie Denmark bisphosphonates raloxifene
P-1536	-7.1735 -1.0134 -0.4506 -2.1483 -0.0110 -0.4313 -0.0715 -0.6820 -0.0802 -0.0871 -1.9296 -0.9340 -3.7073 -0.6810 -0.0104 -0.1370 -0.1236 -3.4834 -0.0325 -0.1250 -0.0924 -0.2540 -2.6112 -0.0755
S-429	METHODS AND RESULTS: Global longitudinal strain of left ventricle was added to standard echocardiographic measurements in 334 consecutive patients (224 men; mean, 65±12 years) who underwent baseline echocardiography before CRT and underwent follow-up echocardiograms at 1 year.<unk>
T-429	longitudinal strain left_ventricle echocardiographic patients baseline echocardiography crt follow-up echocardiograms
H-429	-0.8488136529922485	▁global ▁longitud in al _ ▁strain ▁left _ ▁vent ric le ▁e cho car dio graphic _ ▁measure ments ▁c RT ▁e cho card i ogram s
D-429	-0.8488136529922485	global longitudinal_ strain left_ ventricle echocardiographic_ measurements cRT echocardiograms
P-429	-4.1334 -0.5488 -0.0290 -0.0523 -0.1681 -2.0778 -1.2597 -0.3562 -0.7247 -1.1413 -0.5566 -0.1525 -0.0097 -0.0049 -0.3279 -0.2318 -2.0786 -0.9452 -0.0890 -5.8624 -0.6837 -1.8716 -0.0146 -0.0840 -0.5210 -0.0600 -0.4190 -0.1642 -0.0476
S-365	At this time, he had severe hypertension, moderate LV dilatation, LV dysfunction, mild MR, and significant MS. As the mitral valve demonstrated restricted closure and opening without any clear organic lesion, being consistent with systolic and diastolic tethering, a functional etiology of MR and MS was considered.<unk>
T-365	hypertension lv_dilatation lv_dysfunction mitral_valve organic lesion systolic diastolic_tethering etiology
H-365	-0.5721201300621033	▁hyper tension ▁LV ▁di la tation ▁LV ▁dys function ▁MR ▁MS
D-365	-0.5721201300621033	hypertension LV dilatation LV dysfunction MR MS
P-365	-2.2534 -0.0118 -0.1246 -0.2993 -0.0285 -0.0016 -0.3615 -0.1659 -0.0097 -1.7950 -1.9195 -0.4378 -0.0290
S-250	METHODS AND RESULTS: HDL was isolated from 16 healthy controls (HDL(healthy)) and 16 patients with CHF-NYHA-III (HDL(NYHA-IIIb)) before and after ET, as well as from 8 patients with CHF-NYHA-II (HDL(NYHA-II)).<unk>
T-250	hdl healthy hdl healthy patients chf-nyha-iii hdl nyha-iiib patients chf-nyha-ii hdl nyha-ii
H-250	-0.8607515692710876	▁HD L ▁CHF - NY HA - III HD L NY HA - III b ▁CHF - NY HA - II
D-250	-0.8607515692710876	HDL CHF-NYHA-IIIHDLNYHA-IIIb CHF-NYHA-II
P-250	-1.3610 -0.9461 -4.3189 -0.0689 -0.0140 -0.0925 -0.1031 -0.0845 -1.7429 -1.2460 -1.2724 -0.1499 -0.1377 -0.7889 -1.5357 -2.1787 -0.1641 -0.0534 -0.1729 -0.1726 -0.7692 -2.3622 -0.0619
S-1267	This study aimed at evaluating the changes in platelet-activating factor (PAF) and its metabolic enzymes over a 6-week follow-up period in patients with newly diagnosed heart failure ([HF] n = 12) compared with age-, sex-, and BMI-matched apparently healthy volunteers (n = 10).<unk>
T-1267	platelet-activating_factor paf metabolic enzymes follow-up patients diagnosed heart_failure hf healthy
H-1267	-0.719518780708313	▁plate let - activa ting ▁factor ▁p f ▁metabol ic ▁enzym es
D-1267	-0.719518780708313	platelet-activating factor pf metabolic enzymes
P-1267	-1.2218 -0.3398 -0.0805 -0.0032 -0.2645 -0.9819 -2.0819 -1.3516 -0.0197 -0.0192 -0.5034 -0.0302 -3.1149 -0.0606
S-1281	We reviewed our institutional experience between 2008 and 2012 with acute care surgery (ACS) consultations and procedures within 1 year of OHT in recipients bridged to transplantation with medical therapy (MT, n = 169), including intravenous inotropes, and ventricular assist devices (VADs, n = 74).<unk>
T-1281	acute_care_surgery acs consultations oht transplantation medical_therapy intravenous inotropes ventricular_assist_devices vads
H-1281	-0.5385005474090576	▁a cute _ care ▁surgery AC s ▁o HT ▁recipient s ▁ bridge d ▁to ▁transplant ation ▁medical ▁ therapy ▁intra ven ous ▁in o trop es ▁vent ri cular _ assist ▁devices VAD s
D-1281	-0.5385005474090576	acute_care surgeryACs oHT recipients bridged to transplantation medical therapy intravenous inotropes ventricular_assist devicesVADs
P-1281	-0.0229 -0.0111 -0.4133 -3.2938 -0.6693 -3.3229 -0.9964 -0.4710 -0.1299 -2.3005 -0.0300 -1.9131 -0.0006 -0.0315 -0.8984 -0.2121 -0.0408 -0.1311 -0.3652 -0.0046 -0.0426 -0.0023 -1.3654 -0.4460 -0.1575 -0.0093 -0.1944 -0.0071 -0.1916 -0.1036 -0.5161 -0.5541 -0.1961 -0.2367 -0.4796 -0.1135 -0.0501
S-1489	The renin-angiotensin-aldosterone system (RAAS) has been shown to be an effective target in the treatment of HFrEF using angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone blockade, although the evidence in HFpEF is less clear.<unk>
T-1489	renin-angiotensin-aldosterone_system raas hfref angiotensin-converting_enzyme_inhibitors angiotensin_receptor_blockers aldosterone_blockade evidence hfpef
H-1489	-0.5016996264457703	▁re nin - angi oten sin - al do ster one ▁system ▁re nin - angi oten sin - al do ster one ▁system ▁r as ▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁ang io ten sin _ con ver ting _ ▁enzym e ▁inhibi tors ▁al do ster one
D-1489	-0.5016996264457703	renin-angiotensin-aldosterone system renin-angiotensin-aldosterone system ras angiotensin-converting enzyme inhibitors angiotensin_converting_ enzyme inhibitors aldosterone
P-1489	-0.0094 -0.1738 -0.0435 -0.0241 -0.0072 -0.8982 -0.0828 -0.0396 -0.9700 -0.0169 -0.2993 -0.3345 -3.3256 -0.3691 -0.0151 -0.0496 -0.0127 -0.4949 -0.0547 -0.0674 -0.3475 -0.0088 -0.2097 -0.7311 -2.4459 -0.9128 -4.0637 -0.4138 -0.1067 -0.6887 -0.1163 -0.0054 -0.0034 -0.0713 -0.3844 -0.0196 -0.0092 -0.1903 -0.2970 -0.4881 -0.1071 -0.3562 -1.7085 -0.8516 -0.0102 -0.1011 -0.4778 -0.4963 -0.0417 -1.4447 -0.3452 -1.5790 -0.1332 -0.0075 -0.0741 -2.0216 -0.0390
S-1178	CONCLUSIONS: In patients with HFpEF, short-term treatment with ivabradine increased exercise capacity, with a contribution from improved left ventricular filling pressure response to exercise as reflected by the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity.<unk>
T-1178	patients hfpef ivabradine exercise_capacity left_ventricular_filling_pressure exercise peak_early_diastolic_mitral_flow_velocity peak_early_diastolic_mitral_annular_velocity
H-1178	-0.8100373148918152	▁ HF p EF ▁i va bra dine ▁i va bra dine ▁left ▁vent ri cular ▁fill ing _ ▁pressure ▁response ▁pe ak _ ▁early _ ▁dia sto lic _ met ral _ ▁flow ▁veloci ty
D-1178	-0.8100373148918152	HFpEF ivabradine ivabradine left ventricular filling_ pressure response peak_ early_ diastolic_metral_ flow velocity
P-1178	-0.7985 -0.0840 -0.2037 -0.0957 -0.0868 -0.0272 -0.0532 -0.0118 -4.7406 -0.0954 -0.1678 -0.0482 -4.1350 -0.1915 -0.4962 -0.2219 -1.4328 -0.0457 -1.0520 -0.7860 -3.5529 -1.5841 -0.0052 -0.8857 -0.4862 -0.7471 -1.0541 -0.0490 -0.0259 -0.0812 -2.0500 -0.1313 -0.1841 -3.0316 -0.8604 -0.0254 -1.1773 -0.0761
S-583	At admission, the LVET was shorter in patients with unfavorable outcome (median, 228 milliseconds [25th-75th percentiles, 212-278 milliseconds] vs 257 milliseconds [237-277 milliseconds], P = .032), whereas other tonometric indices were similar.<unk>
T-583	admission lvet patients outcome tonometric
H-583	-0.975925624370575	▁l VET ▁un favor able _ ▁outcome
D-583	-0.975925624370575	lVET unfavorable_ outcome
P-583	-1.0676 -0.6229 -3.3618 -0.0536 -0.0306 -1.2147 -0.6746 -1.6065 -0.1511
S-182	After correction for age, heart rate, blood pressure, renal function, and spironolactone use, this association remained significant for RAS blockers (HR 0.54, 95% CI 0.31 to 0.93, p = 0.027) but not for β-blockers (HR 0.65, 95% CI 0.39 to 1.09, p = 0.101).<unk>
T-182	heart_rate blood_pressure renal_function spironolactone ras_blockers β-blockers
H-182	-1.000982642173767	▁heart ▁rate ▁blood ▁pressure ▁renal ▁function ▁spi rono lac tone ▁ RAS _ block ers
D-182	-1.000982642173767	heart rate blood pressure renal function spironolactone RAS_blockers
P-182	-5.6843 -0.1291 -2.5707 -0.4011 -0.3121 -1.4838 -0.0023 -0.0023 -0.0053 -0.0194 -1.3205 -0.1580 -2.2778 -0.3376 -0.0426 -2.1815 -0.0885
S-1553	The results suggest that partial improvement of cardiac performance by β-adrenoceptor blockade at advanced stages of heart failure may be due to partial reversal of changes in SR Ca(2+)-pump function whereas partial to complete reverse cardiac remodeling may be due to partial reduction in the elevated levels of plasma catecholamines.<unk>
T-1553	cardiac β-adrenoceptor_blockade heart_failure reverse cardiac_remodeling elevated plasma_catecholamines
H-1553	-0.5191299915313721	▁cardiac ▁performance ▁β - ad re no cept or ▁block ade ▁heart ▁failure ▁SR _ ca (2 +) - pump _ function ▁rever se _ ▁cardiac ▁remodel ing ▁plasma ▁cate chol amine s
D-1553	-0.5191299915313721	cardiac performance β-adrenoceptor blockade heart failure SR_ca(2+)-pump_function reverse_ cardiac remodeling plasma catecholamines
P-1553	-2.6908 -0.4383 -0.1010 -0.0201 -0.0132 -0.2769 -0.3797 -0.2052 -0.1872 -1.0719 -0.1306 -2.6423 -0.5844 -0.1987 -1.5268 -0.0838 -0.8800 -0.0029 -0.0228 -0.0194 -2.4183 -0.9282 -2.3686 -0.0021 -0.2875 -0.0656 -0.1924 -0.0188 -0.0465 -0.0914 -0.0006 -0.0139 -0.0708 -0.1299 -0.0590
S-874	Concomitant treatment with SS31 ameliorated the congestive heart failure phenotypes and mitochondrial damage induced by TAC, in parallel with global attenuation of mitochondrial proteome changes, with an average of 84% protection of mitochondrial and 69% of nonmitochondrial protein changes.<unk>
T-874	ss31 congestive_heart_failure phenotypes mitochondrial tac mitochondrial_proteome mitochondrial nonmitochondrial_protein
H-874	-0.608862042427063	▁SS 31 ▁con ges tive _ ▁heart ▁failure _ ▁ph eno type s ▁mito cho ndri al _ ▁damage ▁ TAC ▁mito cho ndri al _ prote ome
D-874	-0.608862042427063	SS31 congestive_ heart failure_ phenotypes mitochondrial_ damage TAC mitochondrial_proteome
P-874	-1.5111 -1.5589 -0.1550 -0.0840 -0.5362 -0.1177 -2.6230 -0.3888 -2.6132 -0.6846 -0.0062 -0.0009 -0.0744 -0.0017 -0.0758 -0.0445 -0.0102 -1.9265 -0.8063 -0.3259 -0.0007 -0.3973 -0.0640 -0.1045 -0.0121 -0.9970 -0.9355 -0.0188 -2.1398 -0.0511
S-837	Using data from HF-ACTION, a randomized controlled trial of exercise training in patients with HF and low left ventricular ejection fractions, HRQoL was measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ) at baseline, 3 and 12 months, and annually up to 4 years.<unk>
T-837	hf-action randomized exercise training patients hf left_ventricular_ejection_fractions hrqol kansas_city_cardiomyopathy_questionnaire kccq baseline
H-837	-0.892937421798706	▁ HF - AC TION ▁ HF - ac TION ▁ HF ▁ HF ▁ HF ▁low _ ▁vent ri cular _ e je ction ▁ fraction s ▁HR Qo L ▁Kansas ▁City ▁Card i om yo pathy ▁Question naire ▁k cc q
D-837	-0.892937421798706	HF-ACTION HF-acTION HF HF HF low_ ventricular_ejection fractions HRQoL Kansas City Cardiomyopathy Questionnaire kccq
P-837	-0.0845 -0.0216 -0.0312 -0.7629 -0.4483 -1.2295 -0.3041 -2.2669 -0.7447 -0.8230 -1.7250 -0.7270 -3.1189 -0.4685 -3.5612 -0.8939 -3.9411 -0.1250 -2.2241 -0.4666 -0.6718 -0.6906 -1.2006 -0.1331 -0.0511 -1.7687 -0.0020 -0.3553 -0.3402 -0.0249 -1.2944 -0.0046 -1.1481 -2.0603 -0.0743 -0.0313 -2.7908 -0.2936 -1.3039 -0.0024 -0.7828 -0.7916 -0.3114 -0.0284 -0.0582
S-1196	Currently, tolvaptan is indicated for the treatment of severe hyponatremia in most countries, including the United States, but in Japan the indication is broader; it can be used in congestive heart failure patients in addition to standard or optimal diuretic therapy, regardless of their serum sodium levels or systolic function.<unk>
T-1196	tolvaptan hyponatremia united_states japan congestive_heart_failure patients diuretic therapy serum_sodium systolic_function
H-1196	-1.0126087665557861	▁to lv ap tan ▁to lv ap tan ▁severe _ ▁hypo na trem ia ▁Japan
D-1196	-1.0126087665557861	tolvaptan tolvaptan severe_ hyponatremia Japan
P-1196	-0.0831 -0.4362 -0.1049 -0.0139 -2.8772 -0.6977 -0.1623 -0.0324 -4.1023 -0.6531 -1.1325 -0.0844 -0.0358 -0.6448 -1.5026 -4.5860 -0.0652
S-1552	Depressed myofibrillar Ca(2+)-stimulated ATPase activity, as well as mRNA levels for SR Ca(2+)-pump, phospholamban and α-myosin heavy chain, were unaffected whereas increased mRNA level for β-myosin heavy chain was partially reversed by metoprolol.<unk>
T-1552	myofibrillar atpase activity mrna phospholamban α-myosin_heavy_chain mrna β-myosin_heavy_chain metoprolol
H-1552	-0.5072389841079712	▁my o fi bril lar ▁ca (2 +) - stimul ated _ ▁ATP ase ▁m RNA ▁levels ▁SR ▁ca (2 +) - pump ▁ phos pho lam ban ▁α - my os in _ ▁heavy ▁chain ▁met o pro lol
D-1552	-0.5072389841079712	myofibrillar ca(2+)-stimulated_ ATPase mRNA levels SR ca(2+)-pump phospholamban α-myosin_ heavy chain metoprolol
P-1552	-3.3077 -0.2329 -0.0151 -0.0235 -0.1464 -2.4760 -0.9085 -0.0170 -0.0149 -0.0590 -0.1757 -0.8675 -3.6672 -1.1443 -0.7807 -0.0037 -1.5925 -0.2547 -1.6067 -0.3197 -0.0030 -0.0156 -0.0291 -0.1101 -0.0008 -0.0183 -0.3438 -0.0535 -0.0845 -0.0065 -0.1377 -0.0254 -0.4161 -1.0116 -0.4402 -0.2287 -0.5076 -0.0939 -0.0081 -0.0160 -0.0791 -0.0609
S-420	In anesthetized dogs with coronary microembolization-induced HF, CXL-1020 reduced left ventricular end-diastolic pressure and myocardial oxygen consumption while increasing ejection fraction from 27% to 40% and maximal ventricular power index by 42% (both P<0.05).<unk>
T-420	anesthetized coronary_microembolization-induced_hf cxl-1020 left_ventricular_end-diastolic_pressure myocardial_oxygen_consumption ejection_fraction maximal_ventricular_power_index
H-420	-0.46104273200035095	▁an est ized ▁dog s ▁corona ry ▁micro e mbol ization - indu ced ▁ HF ▁c XL -10 20 ▁left ▁vent ri cular _ ▁end - dia sto lic _ ▁pressure ▁my o card ial _ ▁oxygen ▁consum p tion ▁e je ction _ fraction ▁vent ri cular _ power ▁index
D-420	-0.46104273200035095	anestized dogs coronary microembolization-induced HF cXL-1020 left ventricular_ end-diastolic_ pressure myocardial_ oxygen consumption ejection_fraction ventricular_power index
P-420	-2.3191 -0.0688 -0.2651 -0.9428 -0.0725 -0.0161 -0.1210 -0.4135 -0.1470 -0.0007 -0.3642 -0.1543 -0.0023 -0.0169 -0.1812 -0.0055 -1.1795 -0.0173 -2.5234 -0.0775 -1.0014 -0.2276 -0.5697 -0.1905 -0.7061 -3.9169 -0.0319 -0.0159 -0.0233 -0.0115 -0.4786 -0.4567 -0.5297 -0.0571 -0.1307 -0.1071 -0.1086 -1.4329 -0.6777 -0.0082 -0.1389 -0.2307 -0.0221 -0.0030 -1.8033 -0.0317 -1.0422 -0.3991 -0.0868 -0.3499 -0.8507 -0.0951 -0.2019 -0.0700
S-1061	RESULTS: In the study cohort, differences were found between the baseline and heart failure T1-mapping values before the administration of contrast agent (960 ± 96 and 726 ± 94 ms, respectively; p = 0.02) and after contrast agent administration (546 ± 180 and 300 ± 171 ms, respectively; p = 0.005).<unk>
T-1061	baseline heart_failure t1-mapping administration administration
H-1061	-1.5680654048919678	▁base line _ heart ▁failure _ t 1- ma pping _ waarde ▁contrast ▁agent
D-1061	-1.5680654048919678	baseline_heart failure_t1-mapping_waarde contrast agent
P-1061	-6.3067 -0.0821 -1.5249 -2.5460 -1.5151 -2.1745 -2.2198 -0.3902 -0.1757 -0.0058 -2.0255 -1.4605 -3.4802 -0.1025 -1.0243 -0.0553
S-805	For the total sample, a standard error of measurement value of approximately 1.6 seconds, an absolute value of MDC at the 95% confidence level (MDC95%) of approximately 4.5 seconds, and a relative value of MDC at the 95% confidence level (MDC95%%) of approximately 35% were found between the first 2 trials, with similar values found for the subgroups.<unk>
T-805	standard_error_of_measurement mdc mdc
H-805	-0.9006461501121521	▁m DC ▁m DC
D-805	-0.9006461501121521	mDC mDC
P-805	-0.9508 -0.0513 -1.8425 -0.0306 -2.3945 -0.1342
S-1794	Main etiologies of HF in LA are idiopathic dilated cardiomyopathy (from 1.3% to 37%), C'D (from 1.3% to 21%), ischemic (from 68% to 17%), SH (from 14% to 76%), valvular (from 3% to 22%), and alcohol related (from 1.1% to 8%).<unk>
T-1794	etiologies hf idiopathic_dilated_cardiomyopathy ischemic valvular
H-1794	-0.35364603996276855	▁ HF ▁ idio pathi c ▁dil ated _ ▁cardio my o pathy ▁c ' d ▁ ische mic ▁SH ▁val vu lar ▁alcohol
D-1794	-0.35364603996276855	HF idiopathic dilated_ cardiomyopathy c'd ischemic SH valvular alcohol
P-1794	-0.3074 -0.6809 -1.3570 -2.4980 -0.0105 -0.0385 -0.2779 -0.1421 -0.2077 -0.5203 -0.6945 -0.2771 -0.0100 -0.1766 -0.7154 -0.5501 -0.0319 -0.0145 -0.0184 -0.0624 -0.0233 -0.0012 -0.0244 -0.1166 -0.3905 -0.0478
S-697	We evaluated ST2 levels and their association with functional capacity and long-term clinical outcomes in a cohort of ambulatory patients with HF enrolled in the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study-a multicenter, randomized study of exercise training in HF.<unk>
T-697	st2 functional_capacity clinical outcomes ambulatory patients hf heart_failure outcomes exercise training hf-action randomized exercise training hf
H-697	-0.7028567790985107	▁ST 2 ▁functional ▁capacity ▁ambula tory ▁patients ▁ HF ▁Heart _ ▁Fail ure ▁control led _ tri al ▁Investiga ting _ out com es ▁Exerci se _ ▁Training ▁ HF - AC TION
D-697	-0.7028567790985107	ST2 functional capacity ambulatory patients HF Heart_ Failure controlled_trial Investigating_outcomes Exercise_ Training HF-ACTION
P-697	-1.1666 -0.3421 -0.5093 -0.9009 -1.9770 -0.0686 -0.3625 -0.4057 -0.0047 -1.5130 -2.0326 -0.1329 -0.1761 -3.7442 -0.1425 -0.2073 -1.0413 -0.0161 -0.6856 -0.0225 -0.1289 -0.7338 -0.0417 -0.0301 -2.8920 -0.0189 -0.4227 -1.0082 -0.9182 -0.0086 -0.1136 -0.3799 -0.1622 -2.2335 -0.0561
S-856	OBJECTIVES: The goal of this study was to evaluate the effects of carvedilol and metoprolol on the endpoint of inappropriate implantable cardioverter-defibrillator therapy in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy) study.<unk>
T-856	carvedilol metoprolol endpoint implantable_cardioverter-defibrillator therapy madit-crt multicenter_automatic_defibrillator_implantation_with_cardiac_resynchronization_therapy
H-856	-0.4001118838787079	▁car vedi lol ▁met o pro lol ▁in appropria te ▁implant able _ ▁cardio ver ter - de fi br illa tor ▁ therapy ▁MAD it - c RT Mul ti center ▁Automat ic _ ▁Def ib rilla tor ▁Implant ation ▁Card iac _ re syn chron ization ▁Therapy
D-856	-0.4001118838787079	carvedilol metoprolol inappropriate implantable_ cardioverter-defibrillator therapy MADit-cRTMulticenter Automatic_ Defibrillator Implantation Cardiac_resynchronization Therapy
P-856	-0.4594 -0.0079 -0.0095 -0.1591 -0.0500 -0.0047 -0.0223 -0.2007 -0.0031 -0.0344 -0.5959 -0.0078 -0.8992 -0.2978 -0.0133 -0.2576 -0.2370 -0.0234 -0.1355 -0.1925 -0.1109 -0.0339 -1.4744 -0.0087 -0.0298 -1.2625 -0.0211 -1.2937 -1.3425 -2.0159 -0.1026 -0.0453 -1.5029 -0.0255 -0.0396 -1.4764 -0.0151 -0.1550 -0.0135 -0.0974 -0.1008 -2.1216 -0.0355 -0.5830 -1.8001 -0.0081 -0.0014 -0.5865 -0.3352 -0.1125 -0.0436
S-666	The adjusted median rate ratio was 1.11 (95% confidence interval, 1.08-1.18) for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy, 1.08 (95% confidence interval, 1.05-1.15) for β-blockers therapy, and 1.17 (1.13-1.26) for optimal combined treatment.<unk>
T-666	rate_ratio confidence_interval angiotensin-converting_enzyme_inhibitors angiotensin_receptor_blockers therapy confidence_interval β-blockers therapy
H-666	-0.9830523133277893	▁ang io ten sin - con ver ting _ ▁enzym e ▁inhibi tors angi oten sin _ ▁receptor ▁block ers
D-666	-0.9830523133277893	angiotensin-converting_ enzyme inhibitorsangiotensin_ receptor blockers
P-666	-6.9249 -1.1121 -0.0705 -1.1365 -0.3131 -0.0077 -0.0096 -0.1426 -1.1891 -0.1176 -0.0242 -0.0307 -0.2122 -2.4011 -0.0321 -0.2068 -1.1646 -1.4435 -1.3171 -0.0463 -3.5969 -0.1278
S-1704	AA participants were significantly younger, less likely to have an ischemic HF pathogenesis, more likely to be NYHA functional class IV, and more likely to have a higher estimated glomerular filtration rate and heart rate, less hypertension, diabetes mellitus, or history of myocardial infarction compared with non-AA participants.<unk>
T-1704	aa ischemic_hf pathogenesis nyha_functional_class_iv estimated_glomerular_filtration_rate heart_rate hypertension diabetes_mellitus myocardial_infarction
H-1704	-0.5251380801200867	▁ ische mic ▁ HF _ path ogen es is ▁NY HA ▁functional _ ▁class ▁IV ▁glo mer ular _ ▁filtr ation ▁rate ▁hyper tension ▁diabetes ▁mell itus ▁my o card ial _ in far ction
D-1704	-0.5251380801200867	ischemic HF_pathogenesis NYHA functional_ class IV glomerular_ filtration rate hypertension diabetes mellitus myocardial_infarction
P-1704	-0.5141 -0.0233 -0.0300 -0.7067 -0.1296 -3.9190 -1.4173 -0.0710 -0.0153 -0.1588 -0.0288 -0.0264 -1.5642 -0.8059 -1.1477 -0.2150 -0.0227 -0.0173 -0.0108 -0.3512 -1.0494 -0.0483 -1.1955 -2.0873 -0.0316 -0.1116 -0.1951 -0.0077 -1.6080 -0.1577 -0.1315 -0.0993 -0.8993 -0.6057 -0.0121 -0.0393 -0.4301 -0.0707
S-752	To assess the effect of CRT in less severe systolic dysfunction, outcomes in the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study were evaluated in which patients with left ventricular (LV) ejection fraction (LVEF) >30% were included.<unk>
T-752	crt systolic_dysfunction outcomes resynchronization_reverses_remodeling_in_systolic_left_ventricular_dysfunction reverse patients left_ventricular ejection_fraction lvef
H-752	-0.6623960137367249	▁c RT ▁sy sto lic _ ▁sy sto lic _ ▁dys function ▁re syn chron ization ▁re VE rse s ▁re model ing ▁Sy sto lic _ ▁left _ ▁v _ en tri cular _ ▁dys function ▁re VERS e ▁left ▁vent ri cular LV ▁e je ction ▁ fraction LV EF
D-752	-0.6623960137367249	cRT systolic_ systolic_ dysfunction resynchronization reVErses remodeling Systolic_ left_ v_entricular_ dysfunction reVERSe left ventricularLV ejection fractionLVEF
P-752	-0.5693 -0.4175 -0.9202 -0.0171 -0.0491 -0.5942 -5.2499 -0.0224 -0.0297 -0.2298 -0.9008 -0.0423 -1.1015 -0.0197 -0.0046 -0.5520 -0.2256 -1.0981 -0.0312 -0.0071 -0.8995 -0.5059 -0.0358 -0.8232 -0.0025 -0.0054 -0.3780 -0.4115 -0.9221 -0.7619 -2.9752 -1.8295 -0.1469 -0.3509 -0.6283 -0.4872 -0.1466 -3.3941 -0.3147 -0.1024 -1.7577 -0.7776 -0.2500 -0.0953 -1.5447 -2.1336 -0.0461 -0.0100 -1.7604 -0.0342 -0.0303 -0.0253 -0.0385 -0.0620
S-1408	Although classic signaling paradigms suggest that simultaneous activation of β1ARs and S1PR1s in a myocyte would simply result in opposing action on cAMP production, in this report we have uncovered a direct interaction between these 2 receptors, with regulatory involvement of G-protein-coupled receptor kinase-2.<unk>
T-1408	β1ars s1pr1s myocyte camp report receptors g-protein-coupled_receptor kinase-2
H-1408	-0.6006069183349609	▁β 1 AR s ▁s 1 PR 1 s ▁my o cy te ▁c AMP ▁receptor s ▁g - prote in - co up led _ ▁receptor ▁kina se -2
D-1408	-0.6006069183349609	β1ARs s1PR1s myocyte cAMP receptors g-protein-coupled_ receptor kinase-2
P-1408	-5.3624 -1.4867 -0.3412 -1.6327 -1.4730 -0.5183 -0.0565 -1.2603 -0.4059 -0.5428 -0.0336 -0.0270 -0.0285 -0.0150 -0.0097 -2.0419 -0.7211 -0.9350 -0.0626 -0.0852 -0.0729 -0.0222 -0.0046 -0.0055 -0.2040 -0.1830 -0.3623 -0.0520 -0.0054 -1.0313 -0.1743 -0.0626
S-1270	At follow-up, PAF-CPT and PAF levels marginally increased (P = .1), lyso-PAF-AT (P < .001) remained downregulated, while PAF-AH (P = .004) and Lp-PLA2 (P < .001) remained elevated compared with the controls.<unk>
T-1270	follow-up paf-cpt paf lyso-paf-at downregulated paf-ah lp-pla2 elevated
H-1270	-0.7982414960861206	▁PA F - c PT ▁lys o - PA F - AT
D-1270	-0.7982414960861206	PAF-cPT lyso-PAF-AT
P-1270	-1.6218 -0.5888 -0.1543 -0.4791 -0.3880 -1.6159 -0.0325 -0.0192 -0.9693 -1.3254 -0.1781 -0.2445 -3.4758 -0.0829
S-488	E/e'lateral showed good diagnostic performance only in patients with s'lateral of >4.5 cm/s (n = 77, 59%; AUC = 0.82; 95% CI 0.71 to 0.92; s'lateral of ≤4.5 cm/s: AUC = 0.54; 95% CI 0.38 to 0.70; p = 0.005).<unk>
T-488	diagnostic patients auc auc
H-488	-1.3057090044021606	▁e _ lateral ▁s ' lateral ▁a UC
D-488	-1.3057090044021606	e_lateral s'lateral aUC
P-488	-1.0340 -5.3112 -0.0927 -2.0252 -1.2681 -0.0695 -1.9533 -0.1145 -0.9923 -0.1962
S-1239	Rate-control patients had fewer cardiac procedures (146 vs. 238, P < 0.001), driven by fewer cardioversions, and lower costs related to antiarrhythmic drugs (CAD $48 per patient [95% confidence interval {CI}, $21-$96] vs. $1319 per patient [95% CI, $1124-$1522]).<unk>
T-1239	rate-control patients cardiac driven cardioversions costs antiarrhythmic_drugs cad patient confidence_interval patient
H-1239	-0.9100680947303772	▁rate - control ▁patients ▁cardio version s ▁kosten ▁anti ar rhythm ic _ ▁drugs
D-1239	-0.9100680947303772	rate-control patients cardioversions kosten antiarrhythmic_ drugs
P-1239	-3.5716 -0.1326 -0.0009 -1.5109 -3.5146 -0.1780 -0.1267 -1.9362 -0.1597 -0.0783 -0.1378 -0.0620 -1.6743 -0.2737 -1.1283 -0.0756
S-443	Among 2,538 eligible patients with a median follow-up of 2.5 years, 521 patients (22%) initiated spironolactone, which was not associated with risk of hospitalization (adjusted hazard ratio 0.91, 95% confidence interval 0.77 to 1.08) or death (adjusted hazard ratio 0.93, confidence interval 0.60 to 1.44).<unk>
T-443	patients follow-up patients spironolactone hospitalization hazard_ratio confidence_interval death hazard_ratio confidence_interval
H-443	-0.7116609215736389	▁spi rono lac tone
D-443	-0.7116609215736389	spironolactone
P-443	-1.3991 -0.0072 -0.0133 -0.0231 -2.6912 -0.1361
S-906	We constructed a descriptive assessment of these patients (n = 15) and performed a case-control analysis matching for age, gender, bundle branch morphology, diabetes mellitus, cardiomyopathy origin, and β-blocker and angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use.<unk>
T-906	patients bundle_branch_morphology diabetes_mellitus cardiomyopathy β-blocker angiotensin-converting_enzyme_inhibitor angiotensin_ii_receptor_blocker
H-906	-0.38585275411605835	▁de script ive _ analyse ▁diabetes ▁mell itus ▁cardio my o pathy ▁β - block er ▁ang io ten sin - con ver ting _ ▁enzym e ▁inhibi tor ▁ang io ten sin ▁II ▁receptor ▁block er
D-906	-0.38585275411605835	descriptive_analyse diabetes mellitus cardiomyopathy β-blocker angiotensin-converting_ enzyme inhibitor angiotensin II receptor blocker
P-906	-1.5863 -0.0026 -0.0070 -1.4153 -1.1120 -2.9954 -0.0084 -0.0308 -0.0176 -0.3062 -0.3206 -0.0339 -1.1714 -0.0074 -0.0182 -0.0539 -0.2851 -0.1329 -0.1513 -0.3332 -0.1660 -0.0186 -0.0085 -0.0682 -0.7016 -0.1149 -0.0219 -0.0252 -0.0103 -0.5555 -0.1211 -0.0789 -0.1741 -2.0567 -0.2346 -0.3060 -0.0350 -0.3140 -0.0476
S-1737	Another study, the Eplerenone Post myocardial infarction Heart failure Efficacy and SUrvival Study (EPHESUS), done in post-myocardial infarction patients with heart failure, demonstrated a significant reduction in mortality and hospitalizations for patients randomized to the aldosterone antagonist eplerenone.<unk>
T-1737	eplerenone_post_myocardial_infarction_heart_failure_efficacy_and_survival_study ephesus post-myocardial_infarction patients heart_failure mortality hospitalizations patients randomized aldosterone_antagonist eplerenone
H-1737	-0.741360604763031	▁e pler en one ▁post _ my o card ial _ in far ction _ ▁Heart ▁failure ▁SU rvi val ▁e pler en one
D-1737	-0.741360604763031	eplerenone post_myocardial_infarction_ Heart failure SUrvival eplerenone
P-1737	-0.2865 -0.0013 -0.0941 -0.3755 -0.4919 -0.9353 -1.0899 -0.3736 -0.7452 -0.3738 -0.3771 -0.3049 -0.0788 -0.1396 -1.0377 -2.8060 -0.1483 -3.5413 -0.0208 -0.0228 -2.4788 -1.1056 -0.0546 -1.4551 -0.7379 -0.1992
S-1879	Preliminary report of using cardiopulmonary exercise testing guide exercise rehabilitation in patients with chronic heart failure OBJECTIVE: The exercise rehabilitation in patient with chronic heart failure (CHF) is standard clinical practice, but it is rare using CardioPulmonary Exercise Testing (CPET) guide to prescribe exercise rehabilitation in China.<unk>
T-1879	report cardiopulmonary_exercise_testing exercise_rehabilitation patients chronic_heart_failure exercise_rehabilitation patient chronic_heart_failure chf clinical cardiopulmonary_exercise_testing cpet exercise_rehabilitation china
H-1879	-1.260473370552063	▁cardio pul mon ary _ ▁exercise _ ▁testing _ guide _ ▁exercise ▁rehabilita tion ▁patients ▁chronic _ heart ▁failure ▁c PET
D-1879	-1.260473370552063	cardiopulmonary_ exercise_ testing_guide_ exercise rehabilitation patients chronic_heart failure cPET
P-1879	-0.0855 -0.0497 -1.2200 -0.2965 -0.6872 -2.3051 -2.3331 -1.9479 -2.4681 -2.0023 -1.7184 -0.6283 -0.3184 -0.1646 -2.4579 -1.2211 -0.1423 -1.3772 -0.6978 -3.9994 -1.1853 -1.5889 -0.0958
S-1749	Each period was associated with a 42% risk reduction versus the previous one (HR, 0.58; 95% confidence interval, 0.50-0.67; P<0.001), reflecting marked decreases in heart failure-related mortality and sudden death (period 4 versus 1: HR, 0.10; P<001 and HR, 0.13; P<0.0001, respectively).<unk>
T-1749	confidence_interval heart mortality death
H-1749	-1.2281659841537476	▁risk ▁re duction HR
D-1749	-1.2281659841537476	risk reductionHR
P-1749	-2.1039 -0.0863 -0.0113 -0.9985 -4.1096 -0.0595
S-924	The DASH/SRD reduced clinic and 24-hour brachial systolic pressure (155 ± 35 to 138 ± 30 and 130 ± 16 to 123 ± 18 mm Hg; both P=0.02), and central end-systolic pressure trended lower (116 ± 18 to 111 ± 16 mm Hg; P=0.12).<unk>
T-924	dash clinic brachial_systolic_pressure central_end-systolic_pressure
H-924	-0.8317251205444336	▁DAS h / s RD ▁bra chi al _ ▁sy sto lic _ ▁pressure
D-924	-0.8317251205444336	DASh/sRD brachial_ systolic_ pressure
P-924	-0.0177 -0.1905 -2.1687 -0.8619 -0.4103 -2.8205 -0.0797 -0.1039 -1.2110 -0.3477 -0.0255 -0.0397 -1.5472 -0.1099 -3.2787 -0.0948
S-113	All-cause mortality at 4 years after hospitalization for HF was assessed by LVEF (categorized as preserved [≥50%], mildly [40% to 49%], moderately [30% to 39%], and severely [<30%] reduced) among 1,620 patients enrolled in the Heart Failure Survey in ISrael.<unk>
T-113	all-cause_mortality hospitalization hf lvef patients heart_failure_survey israel
H-113	-1.372576355934143	▁mortal ity ▁ HF ▁LV EF
D-113	-1.372576355934143	mortality HF LVEF
P-113	-6.2817 -0.9056 -0.9560 -0.1635 -0.6945 -0.0281 -1.8954 -0.0558
S-558	RESULTS: The youngest patients with HF were more likely to be obese (youngest vs. oldest: body mass index ≥35 kg/m(2): 23% vs. 6%), of black ethnicity (18% vs. 2%), and have idiopathic-dilated cardiomyopathy (62% vs. 9%) (all p < 0.0001).<unk>
T-558	patients hf obese body_mass_index idiopathic-dilated_cardiomyopathy
H-558	-1.132491946220398	▁ HF ▁ HF
D-558	-1.132491946220398	HF HF
P-558	-0.3141 -0.0774 -2.0292 -0.4125 -3.8983 -0.0634
S-1743	METHODS AND RESULTS: From 1977 to 2011, 603 consecutive patients (age, 53±12 years; 73% men; left ventricular ejection fraction, 32±10%) fulfilling World Health Organization criteria for idiopathic dilated cardiomyopathy, including negative coronary angiography, were followed up for 8.8±6.3 years.<unk>
T-1743	patients left_ventricular_ejection_fraction world_health_organization idiopathic_dilated_cardiomyopathy coronary_angiography followed_up
H-1743	-1.0009021759033203	▁ met HOD s ▁ europe se _ international _ ▁criteri a ▁ idio pathi c _ ▁dil ated _ ▁cardio my o pathy ▁negative _ ang i ography
D-1743	-1.0009021759033203	metHODs europese_international_ criteria idiopathic_ dilated_ cardiomyopathy negative_angiography
P-1743	-1.1158 -2.2859 -1.4405 -0.6678 -2.9018 -2.5649 -0.0542 -0.2730 -5.7238 -1.8732 -1.6664 -0.0991 -0.5782 -0.0035 -0.0168 -0.0779 -0.2083 -1.6658 -0.1298 -0.1313 -0.2490 -1.0624 -0.2722 -0.0528 -0.0409 -0.0996 -4.2994 -1.0723 -0.1855 -0.1706 -0.0455
S-27	The European Society of Cardiology guidelines based definition of HFPEF requires a presence of signs and symptoms of heart failure, preserved LV ejection fraction of a non-dilated left ventricle, and evidence of diastolic dysfunction (impaired LV relaxation or increased LV diastolic stiffness) with elevated LV filling pressures.<unk>
T-27	european_society_of_cardiology hfpef symptoms heart_failure preserved_lv_ejection_fraction non-dilated_left_ventricle evidence diastolic_dysfunction lv_relaxation lv_diastolic_stiffness elevated lv_filling_pressures
H-27	-0.7602433562278748	▁ europe se _ soci e _ of _ card i ology ▁guidelines ▁h FP EF ▁heart ▁failure ▁pres er ved ▁LV ▁e je ction ▁ fraction ▁non - dila ted _ ▁left _ ▁vent ric le ▁dia sto lic _ ▁dys function ▁LV ▁dia sto lic _ ▁sti ff ness ▁eleva ted ▁LV ▁fill ing ▁pressure s
D-27	-0.7602433562278748	europese_socie_of_cardiology guidelines hFPEF heart failure preserved LV ejection fraction non-dilated_ left_ ventricle diastolic_ dysfunction LV diastolic_ stiffness elevated LV filling pressures
P-27	-2.0320 -0.0708 -0.0719 -0.0672 -0.9560 -2.1800 -0.0598 -3.4778 -0.0821 -1.3596 -0.1073 -0.2144 -2.3819 -1.8678 -0.4993 -0.2046 -3.8882 -0.2557 -2.7361 -0.0195 -0.0571 -0.5023 -1.1108 -0.0129 -0.0036 -3.2423 -0.0039 -0.8390 -0.0083 -0.0001 -0.0021 -0.9881 -0.2211 -0.7311 -0.2185 -0.4137 -0.1475 -0.0386 -0.0076 -0.0127 -0.6159 -2.1592 -0.0045 -2.6800 -2.6809 -0.0370 -0.0168 -1.3350 -0.0141 -0.0136 -0.4846 -1.4540 -0.0073 -0.9059 -0.7970 -0.0145 -0.9852 -0.0583 -0.2096 -0.0482
S-1803	The following variables were significantly associated with an estimated glomerular filtration rate of (eGFR) <60 ml/min./1.73 m(2): age, type 2 diabetes, total cholesterol, LDL-cholesterol, and the CLCNKA GG genotype (p=0.03; OR=1.65, 95% CI=1.04-2.62).<unk>
T-1803	estimated_glomerular_filtration_rate egfr type_2_diabetes cholesterol ldl-cholesterol clcnka genotype
H-1803	-0.7452495694160461	▁glo mer ular _ filtr ation ▁rate ▁e G FR ▁type ▁2 ▁diabetes ▁cholesterol ▁l DL - ch olesterol ▁CL CN KA ▁ GG ▁geno type
D-1803	-0.7452495694160461	glomerular_filtration rate eGFR type 2 diabetes cholesterol lDL-cholesterol CLCNKA GG genotype
P-1803	-0.3618 -0.1970 -0.0351 -0.7148 -1.5541 -0.1126 -1.9232 -0.4589 -0.9393 -0.0611 -4.0202 -0.4921 -0.1154 -2.8922 -1.3317 -0.5977 -0.5059 -0.7107 -0.0020 -0.0367 -0.2634 -0.9835 -0.7561 -0.2855 -1.3573 -0.0018 -0.1091 -0.0479
S-474	Echocardiography at 8 wk demonstrated a similar 37% increase in LV end-diastolic dimension (P < 0.001), a twofold increase in LV end-diastolic pressure/wall stress (P < 0.05), and a twofold increase in lung weight (P < 0.05) in treated and untreated ACF groups versus the sham group.<unk>
T-474	echocardiography lv_end-diastolic_dimension lv_end-diastolic_pressure wall_stress lung acf
H-474	-0.7696635127067566	▁e cho card i ography ▁LV ▁end - dia sto lic _ dimension ▁LV ▁end - dia sto lic _ ▁pressure _ wall ▁stress ▁lung _ ▁weight
D-474	-0.7696635127067566	echocardiography LV end-diastolic_dimension LV end-diastolic_ pressure_wall stress lung_ weight
P-474	-0.1489 -0.0096 -0.0897 -0.3282 -0.1064 -1.9477 -1.6354 -0.0295 -0.0146 -0.0722 -0.0551 -0.4164 -0.0968 -2.0803 -3.1006 -0.0225 -0.0215 -0.0578 -0.0495 -0.1776 -3.4828 -1.4662 -0.1605 -0.7153 -0.8959 -2.0254 -1.0656 -1.9588 -0.0895
S-570	METHODS: Between 2008 and 2009, 54 patients (aged 62.4 ± 11.4 years) with heart failure (mean ejection fraction = 26.9% ± 5.0%) were randomly assigned to standard cardiac rehabilitation care (n = 27) or Nordic walking (n = 27); both groups performed 200 to 400 minutes of exercise per week for 12 weeks.<unk>
T-570	patients heart_failure ejection_fraction cardiac_rehabilitation walking exercise
H-570	-0.7738745212554932	▁heart ▁failure ▁me an ▁e je ction ▁ fraction ▁standard _ ▁cardiac ▁rehabilita tion _ care ▁Nordic _ ▁walking
D-570	-0.7738745212554932	heart failure mean ejection fraction standard_ cardiac rehabilitation_care Nordic_ walking
P-570	-3.3836 -0.4146 -2.2047 -0.1280 -0.2130 -0.0258 -0.0101 -0.7028 -0.0004 -3.4179 -0.5187 -0.0464 -0.5356 -0.1894 -1.3274 -1.2694 -0.1051 -0.4813 -1.0300 -0.1782 -0.0689
S-1836	The DRS-stratified hazard ratios were 0.74 (CI, 0.64 to 0.85) for sitagliptin versus pioglitazone, 0.86 (CI, 0.77 to 0.95) for sitagliptin versus sulfonylureas, and 0.71 (CI, 0.64 to 0.78) for sitagliptin versus insulin.<unk>
T-1836	hazard_ratios sitagliptin pioglitazone sitagliptin sulfonylureas sitagliptin insulin
H-1836	-0.7528499364852905	▁d RS - stra t ified _ ▁hazard ▁ratio s ▁si tag lip tin ▁pi og lita zone ▁si tag lip tin ▁sul fon yl ure as ▁insulin
D-1836	-0.7528499364852905	dRS-stratified_ hazard ratios sitagliptin pioglitazone sitagliptin sulfonylureas insulin
P-1836	-0.5598 -0.1538 -0.1810 -0.0348 -0.0310 -0.0334 -0.6961 -0.5998 -0.4204 -0.1070 -3.2552 -0.2659 -0.4516 -3.3148 -2.2385 -0.0328 -0.1299 -0.0168 -2.3731 -0.2993 -0.1709 -3.0330 -0.7170 -0.0297 -0.1138 -0.2249 -0.0107 -2.8712 -0.1248 -0.0942
S-1501	Overall, skeletal muscle mass T-score (derived from comparison with young normal reference mean) was -1.47±0.21; 4/16 Fontan subjects had sarcopenic range muscle wasting (T-score <-2.0) and 9/16 had less marked, but clinically significant wasting (T-score <-1.0 but ≥-2.0).<unk>
T-1501	skeletal_muscle t-score fontan sarcopenic_range_muscle_wasting t-score clinically t-score
H-1501	-0.7376947999000549	▁skelet al _ ▁muscle ▁mass ▁T - s core
D-1501	-0.7376947999000549	skeletal_ muscle mass T-score
P-1501	-0.4411 -0.0142 -0.5065 -1.1161 -1.2536 -1.3960 -0.0311 -0.0647 -0.0208 -3.2361 -0.0345
S-181	Both RAS- and β-blocker uptitrations were associated with significant reductions in the composite end-point of all-cause mortality or HF readmissions in HFrEF (hazard ratio [HR] 0.36, 95% confidence interval [CI] 0.22 to 0.60 and HR 0.51, 95% CI 0.32 to 0.81, respectively).<unk>
T-181	β-blocker uptitrations composite_end-point all-cause_mortality hf readmissions hfref hazard_ratio confidence_interval
H-181	-0.8416889309883118	▁ RAS - ▁β - block er _ up ti tra tions ▁
D-181	-0.8416889309883118	RAS- β-blocker_uptitrations
P-181	-0.2250 -0.0028 -0.3191 -1.4306 -0.0085 -0.0265 -0.0212 -2.3448 -0.3976 -0.2401 -0.4204 -0.3715 -1.7862 -4.1893
S-1323	The exercise with testosterone group showed improvements from baseline in peak oxygen uptake (P < .01), Beck Depression Inventory (P < .05), leg strength (P < .05), and several Medical Outcomes Study Short-Form quality of life domains (P < .05), which were generally not apparent in the exercise with placebo group.<unk>
T-1323	exercise testosterone baseline peak_oxygen_uptake beck_depression_inventory leg medical_outcomes_study_short-form quality_of_life exercise placebo
H-1323	-0.7315199971199036	▁testosteron e ▁group ▁pe ak _ ▁oxygen ▁up take ▁Beck ▁de pression ▁in ven tory ▁leg _ ▁strength ▁Medical ▁Out com es ▁Short - Form _ ▁quality _ of _ ▁life ▁domain s
D-1323	-0.7315199971199036	testosterone group peak_ oxygen uptake Beck depression inventory leg_ strength Medical Outcomes Short-Form_ quality_of_ life domains
P-1323	-0.4507 -0.0096 -3.3320 -1.6836 -0.0033 -1.1392 -0.0739 -1.3293 -0.0325 -0.0465 -0.7664 -0.0635 -1.1595 -0.0350 -0.0079 -0.0207 -1.9153 -0.4324 -2.7306 -1.8076 -0.0120 -0.0211 -1.1630 -0.0548 -0.0888 -0.2549 -1.9959 -0.3732 -1.4199 -0.0437 -0.7265 -1.5970 -0.0956 -0.6077 -0.1097
S-1927	METHODS AND RESULTS: Of patients enrolled in Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION), 2279 (97.8%) completed surveys to assess social support and barriers to exercise, resulting in the perceived social support score (PSSS) and barriers to exercise score (BTES).<unk>
T-1927	patients heart_failure outcomes exercise training hf-action exercise perceived_social_support_score psss barriers_to_exercise_score btes
H-1927	-1.4324887990951538	▁patients ▁en roll ed ▁Heart ▁Fail ure ▁ HF - ac TION ▁social _ support _ te _ ▁exercise ▁score b tes
D-1927	-1.4324887990951538	patients enrolled Heart Failure HF-acTION social_support_te_ exercise scorebtes
P-1927	-5.5770 -1.7209 -0.0201 -0.1832 -1.1201 -0.3966 -0.1700 -1.7006 -2.0739 -0.0854 -0.9364 -1.0368 -2.3717 -0.6060 -2.1160 -2.7679 -4.1957 -0.7923 -2.2600 -1.3369 -2.2602 -0.3809 -0.2311 -0.0398
S-703	In univariable analysis, ST2 was significantly associated with death or hospitalization (hazard ratio, 1.48; P<0.0001), cardiovascular death or HF hospitalization (hazard ratio, 2.14; P<0.0001), and all-cause mortality (hazard ratio, 2.33; P<0.0001; all hazard ratios for log2 ng/mL).<unk>
T-703	univariable_analysis st2 death hospitalization hazard_ratio cardiovascular_death hf hospitalization hazard_ratio all-cause_mortality hazard_ratio hazard_ratios
H-703	-0.9694872498512268	▁ST 2 ▁cardiovascular _ ▁death ▁ HF _ hospital ization haz ard _ ▁ratio ▁log 2
D-703	-0.9694872498512268	ST2 cardiovascular_ death HF_hospitalizationhazard_ ratio log2
P-703	-1.7101 -0.9054 -3.5147 -1.7870 -0.5703 -1.1562 -0.0127 -2.0920 -0.4934 -0.9815 -0.0917 -0.0031 -0.8726 -0.0087 -0.9683 -0.5450 -1.6464 -0.0919
S-1495	DESIGN AND PATIENTS: Sixteen New York Heart Association Class I/II Fontan adults (30±2 years) underwent cardiopulmonary exercise testing and lean mass quantification with dual x-ray absorptiometry (DXA); eight had calf muscle (31)P magnetic resonance spectroscopy as did eight healthy age-matched and sex-matched controls.<unk>
T-1495	patients new_york_heart_association_class_i fontan cardiopulmonary_exercise_testing lean_mass_quantification dual_x-ray_absorptiometry dxa calf muscle magnetic_resonance_spectroscopy healthy
H-1495	-0.8047507405281067	▁ europe se _ heart _ association ▁cardio pul mon ary _ ▁exercise ▁testing ▁lean _ ▁mass ▁quant ification ▁dual _ ▁x - ray _ ▁ab sor pti ometr y ▁d XA ▁cal f ▁muscle ▁magnetic _ ▁res on ance ▁spec tros copy
D-1495	-0.8047507405281067	europese_heart_association cardiopulmonary_ exercise testing lean_ mass quantification dual_ x-ray_ absorptiometry dXA calf muscle magnetic_ resonance spectroscopy
P-1495	-2.8145 -4.9821 -0.3162 -0.0438 -2.3172 -0.8580 -0.7170 -4.7742 -0.0881 -1.3269 -0.3818 -0.5142 -0.6855 -0.9842 -0.0248 -0.2404 -0.6783 -1.8798 -0.1003 -0.0730 -0.4065 -0.6365 -0.0485 -0.4046 -0.3387 -0.5050 -1.0890 -0.1539 -0.0967 -0.1494 -2.8548 -0.4786 -0.0325 -0.0061 -0.5258 -0.6960 -0.4613 -0.6157 -0.2270 -0.2212 -1.4001 -0.0253 -0.4451 -0.5390 -0.0561
S-73	OBJECTIVE: To test the 2 independent hypotheses that, compared with placebo, addition of low-dose dopamine (2 μg/kg/min) or low-dose nesiritide (0.005 μg/kg/min without bolus) to diuretic therapy will enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction.<unk>
T-73	placebo dopamine nesiritide bolus diuretic therapy renal_function patients acute_heart_failure renal_dysfunction
H-73	-0.9101629853248596	▁dop amine ▁low - dos e ▁nesi riti de ▁di ure tic _ therapy ▁renal _ function
D-73	-0.9101629853248596	dopamine low-dose nesiritide diuretic_therapy renal_function
P-73	-6.0353 -0.0458 -1.7610 -0.0060 -0.3642 -0.0621 -0.5441 -0.0010 -0.0352 -2.5250 -0.7003 -0.4093 -1.4060 -0.0331 -0.1424 -2.3457 -0.6852 -0.1407 -0.0508
S-847	METHODS: We conducted a randomized trial involving 115 centers to evaluate the effect of CRT in patients with New York Heart Association class III or IV heart failure, a left ventricular ejection fraction of 35% or less, a QRS duration of less than 130 msec, and echocardiographic evidence of left ventricular dyssynchrony.<unk>
T-847	randomized crt patients new_york_heart_association_class_iii heart_failure left_ventricular_ejection_fraction qrs_duration echocardiographic evidence left_ventricular_dyssynchrony
H-847	-0.9786304831504822	▁ nc _ heart _ association _ class ▁III _ ▁IV _ heart ▁failure ▁left _ ▁vent ri cular _ e je ction ▁QR s ▁e cho car dio graphic ▁left _ ▁vent ri cular _ syn chron y
D-847	-0.9786304831504822	nc_heart_association_class III_ IV_heart failure left_ ventricular_ejection QRs echocardiographic left_ ventricular_synchrony
P-847	-2.5967 -3.0506 -2.9225 -1.2029 -0.9771 -0.5488 -2.0425 -2.5945 -0.7868 -0.5006 -4.4158 -0.2340 -2.7063 -0.8671 -0.1643 -1.2609 -0.4039 -0.3781 -0.3782 -1.2125 -1.3683 -0.1129 -0.0138 -0.0099 -1.1326 -0.4393 -0.0117 -0.0154 -0.1479 -0.2445 -2.5521 -0.3004 -0.8354 -1.4345 -0.6585 -0.6076 -0.6149 -0.0010 -0.2050 -0.1297 -0.0441
S-482	Therefore, 130 consecutive patients with a left ventricular (LV) ejection fraction of <35% and stable HF underwent right-sided cardiac catheterization and transthoracic echocardiography with measurement of transmitral flow velocities (E, A) and mitral annulus velocities during systole (s') and diastole (e').<unk>
T-482	patients left_ventricular ejection_fraction stable_hf right-sided_cardiac_catheterization transthoracic_echocardiography transmitral_flow mitral_annulus_velocities systole diastole
H-482	-0.4422680735588074	▁left ▁vent ri cular ▁v l ▁e je ction ▁ fraction ▁ HF ▁right - side d _ ▁cardiac ▁cat heter ization ▁trans t hora cic _ ▁e cho card i ography ▁transmit ral _ ▁flow ▁veloci ties ▁mit ral _ ▁ann ulus ▁dia stol e
D-482	-0.4422680735588074	left ventricular vl ejection fraction HF right-sided_ cardiac catheterization transthoracic_ echocardiography transmitral_ flow velocities mitral_ annulus diastole
P-482	-0.6278 -0.6545 -0.3091 -0.1023 -3.1100 -1.9135 -2.4387 -0.0117 -0.0082 -0.2138 -0.0797 -0.3590 -0.2645 -4.2009 -0.0075 -0.0990 -0.0770 -0.6458 -0.0441 -0.6500 -0.0055 -0.2245 -0.0021 -0.2221 -0.0036 -0.0066 -0.5347 -0.7845 -0.0246 -0.0453 -0.0886 -0.1229 -0.0106 -0.0735 -0.2561 -0.1323 -0.6791 -0.0031 -0.0626 -0.0070 -0.3017 -0.2922 -0.0240 -1.1488 -0.0001 -0.0315 -0.2872 -0.0369
S-1367	For patients with acute coronary syndromes, data have been derived from a great number of studies, whereas in patients with stable CAD, only a limited amount of recent data is available; although limited, these data show that elevations in BNP and NT-proBNP levels are associated with the extent of CAD, thus providing prognostic information for an unfavourable clinical outcome.<unk>
T-1367	patients acute_coronary_syndromes patients stable cad bnp nt-probnp cad prognostic clinical outcome
H-1367	-0.6290382146835327	▁a cute _ ▁corona ry ▁syndrome s ▁CAD
D-1367	-0.6290382146835327	acute_ coronary syndromes CAD
P-1367	-0.3982 -0.0016 -0.7385 -0.8875 -0.1318 -0.0627 -0.0246 -3.2012 -0.8022 -0.0421
S-1269	At baseline, patients with HF had lower median activities of lyso-PAF-AT (P < .001) and PAF-CPT (P = .07) in parallel with PAF levels (P = .05) and higher activities of PAF-AH (P = .02) and Lp-PLA2 (P < .001) than controls.<unk>
T-1269	baseline patients hf lyso-paf-at paf-cpt paf paf-ah lp-pla2
H-1269	-0.5147600769996643	▁ HF ▁lys o - PA F - AT ▁PA F - c PT ▁PA F - AH ▁l p - PLA 2
D-1269	-0.5147600769996643	HF lyso-PAF-AT PAF-cPT PAF-AH lp-PLA2
P-1269	-0.3409 -0.0099 -0.6252 -0.0248 -0.0209 -0.8360 -0.9935 -0.1164 -0.1222 -0.4442 -0.4805 -0.0569 -0.7361 -0.4397 -0.3362 -0.5391 -0.4690 -5.2403 -0.4111 -0.0144 -0.0465 -0.0003 -0.0588 -0.4213 -0.0850
S-549	After medical therapy had failed, 4 patients underwent redo sternotomy for aortic valve procedures (1 bioprosthetic valve replacement, 1 Dacron patch closure, and 2 aortic valve repairs), and 2 patients underwent transcatheter aortic valve procedure, with 1 requiring revision by open surgery for aortic valve replacement.<unk>
T-549	medical_therapy patients redo_sternotomy aortic_valve bioprosthetic_valve_replacement dacron_patch_closure aortic_valve patients transcatheter_aortic_valve_procedure surgery aortic_valve
H-549	-0.4297940135002136	▁medical ▁ therapy ▁redo ▁ster no to my ▁a or tic _ ▁val ve ▁procedure s ▁bio pro sthetic _ ▁val ve ▁replace ment ▁da cro n ▁patch ▁ closure ▁a or tic _ ▁val ve ▁repair s ▁trans cat heter ▁a or tic _ ▁val ve ▁procedure ▁open _ ▁surgery ▁a or tic _ ▁val ve ▁replace ment
D-549	-0.4297940135002136	medical therapy redo sternotomy aortic_ valve procedures bioprosthetic_ valve replacement dacron patch closure aortic_ valve repairs transcatheter aortic_ valve procedure open_ surgery aortic_ valve replacement
P-549	-3.1051 -0.6620 -0.0065 -0.3027 -0.5797 -0.0235 -0.1038 -1.1881 -0.4764 -0.0168 -0.7379 -0.2509 -0.6333 -0.0290 -0.7835 -0.6932 -0.0086 -0.0227 -0.0029 -0.7691 -0.6326 -0.0183 -2.4960 -0.0162 -0.2428 -0.0030 -0.0165 -0.0869 -0.8186 -0.0010 -0.0425 -0.0149 -0.2138 -0.1224 -0.2515 -0.0265 -2.5803 -0.3767 -0.0058 -0.0280 -0.0009 -0.2466 -0.0344 -0.3793 -0.1177 -0.4084 -0.0140 -0.9466 -0.8273 -0.4741 -0.6823 -1.0786 -0.0220 -0.7137 -0.0444 -0.6956 -0.0285 -0.8104 -0.0252 -0.2219 -0.0556
S-263	OBJECTIVE: The main objective of this study was to determine a predictive cutoff value for plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) that could successfully predict the long-term (4-year) survival of patients with acute heart failure (HF) at the time of admission to the emergency department (ED).<unk>
T-263	plasma_n-terminal_pro-b-type_natriuretic_peptide nt-probnp patients acute_heart_failure hf admission emergency_department
H-263	-0.6034538149833679	▁plasma ▁N - termin al _ pro - B - type ▁na tri ure tic _ pe pti de NT - pro b NP
D-263	-0.6034538149833679	plasma N-terminal_pro-B-type natriuretic_peptideNT-probNP
P-263	-2.6991 -2.4796 -0.0191 -0.0614 -0.0119 -0.7549 -1.0654 -0.0175 -0.8407 -0.0470 -0.0075 -0.4981 -0.0258 -1.2162 -1.3834 -0.6163 -0.6266 -0.0232 -0.0649 -0.8405 -0.0121 -0.0150 -0.6524 -0.0419 -1.6033 -0.0661
S-286	We evaluated whether cardiac troponin T (cTnT) measured with a high-sensitivity assay and N-terminal pro-B-type natriuretic peptide (NT-proBNP), biomarkers strongly associated with incident HF, improve HF risk prediction in the Atherosclerosis Risk in Communities (ARIC) study.<unk>
T-286	cardiac_troponin_t ctnt n-terminal_pro-b-type_natriuretic_peptide nt-probnp biomarkers hf hf atherosclerosis_risk_in_communities aric
H-286	-0.5955677032470703	▁cardiac ▁trop onin ▁t ▁c t n T ▁bio mark ers ▁incident ▁ HF ▁ HF ▁Ath eros cle rosi s ▁Risk ▁in ▁Communi ties ARI c
D-286	-0.5955677032470703	cardiac troponin t ctnT biomarkers incident HF HF Atherosclerosis Risk in CommunitiesARIc
P-286	-0.0060 -0.1641 -0.0125 -1.1796 -0.8112 -0.3110 -0.0109 -1.0174 -1.8139 -0.0299 -0.0879 -0.5675 -0.3274 -0.0097 -2.5215 -0.9962 -1.9376 -0.0194 -0.3721 -0.0728 -0.0090 -0.7378 -1.5315 -0.6486 -0.0025 -1.2668 -0.6734 -0.0801 -0.0530
S-1167	Increased body mass index was associated with a lower event rate (HR per kg/m(2): 0.92 [95% CI: 0.88 to 0.96]), and this protection was mediated by a higher fat mass (0.91 [95% CI: 0.87 to 0.96]) but not a fat-free mass index (0.97 [95% CI: 0.92 to 1.03]).<unk>
T-1167	body_mass_index fat_mass fat-free_mass
H-1167	-1.8413958549499512	▁in rea sed _ ▁body ▁mass ▁index
D-1167	-1.8413958549499512	inreased_ body mass index
P-1167	-5.9390 -1.3137 -0.2245 -0.1550 -1.8237 -1.9468 -0.0716 -4.9804 -0.1178
S-797	PARTICIPANTS: Subjects (N=235, 64% men; median age, 70y [interquartile range, 61-77y]; median body mass index, 25.6kg/m(2) [interquartile range, 22.8-29.4kg/m(2)]) with advanced COPD (n=95), CHF (n=68), or CRF (n=72).<unk>
T-797	interquartile_range body_mass_index interquartile_range copd chf crf
H-797	-2.611886978149414	
D-797	-2.611886978149414	
P-797	-5.0406 -0.1832
S-911	In the case-control analysis, controls demonstrated superior reverse remodeling (+9.2 ± 9.5% increase in ejection fraction), decreased mortality (73% vs 44%, p = 0.038), and all-cause hospitalizations (76% vs 100%, p = 0.047), with no difference in HF hospitalizations (p = 0.39), compared with dialysis patients.<unk>
T-911	reverse_remodeling ejection_fraction mortality all-cause_hospitalizations hf hospitalizations dialysis patients
H-911	-0.5019853115081787	▁rever se _ ▁remodel ing ▁e je ction ▁ fraction ▁mortal ity ▁ HF
D-911	-0.5019853115081787	reverse_ remodeling ejection fraction mortality HF
P-911	-0.5728 -0.0118 -0.3480 -0.3555 -0.0164 -0.0073 -0.0173 -0.0114 -1.0254 -0.0007 -1.0198 -0.6948 -1.4867 -0.3108 -2.0989 -0.0541
S-1530	After adjustment for covariates, EH was associated with reduced LV contractility compared with CH: lower LVEF (β coefficient = -3.2; 95% confidence interval [CI] -5.4 to -1.1%) and ratio of systolic blood pressure to end-systolic volume (β coefficient = -1.0; 95% CI -1.5 to -0.5 mm Hg/ml).<unk>
T-1530	covariates lv_contractility lvef β_coefficient confidence_interval systolic_blood_pressure end-systolic_volume β_coefficient
H-1530	-1.7990480661392212	▁EH ▁eu ▁contract ility ▁lower _ ▁LV EF _ in _ sy sto lic _ ▁volume
D-1530	-1.7990480661392212	EH eu contractility lower_ LVEF_in_systolic_ volume
P-1530	-0.2190 -5.4943 -2.6156 -0.0148 -4.0811 -0.7294 -1.5478 -0.2061 -4.7400 -5.1572 -2.2639 -2.3138 -0.0464 -0.0155 -0.0727 -0.3761 -2.4089 -0.0804
S-348	Echocardiography demonstrated moderately dilated LV with an end-diastolic volume index of 84 mL/m2, reduced LV ejection fraction of 0.40, mild MR, and limited mitral valve opening, resulting in a significant MS with an MVA of 1.2 cm2 and a mean pressure gradient of 8.4 mm Hg (Fig 1B).<unk>
T-348	echocardiography dilated_lv end-diastolic_volume_index lv_ejection_fraction mitral_valve_opening mva
H-348	-0.7008579969406128	▁e cho card i ography ▁ver - dia sto lic _ ▁volume ▁index ▁LV ▁e je ction ▁ fraction ▁mild _ ▁MR ▁mit ral _ ▁val ve ▁opening ▁m VA ▁pressure ▁gradi ent
D-348	-0.7008579969406128	echocardiography ver-diastolic_ volume index LV ejection fraction mild_ MR mitral_ valve opening mVA pressure gradient
P-348	-0.5017 -0.0052 -0.1543 -0.2018 -0.0780 -5.8505 -4.4003 -0.1421 -0.1014 -0.0062 -1.2834 -0.0225 -0.1269 -3.0790 -0.3727 -0.0237 -0.0081 -1.0042 -0.0031 -1.0141 -0.4299 -0.8738 -0.1055 -0.0054 -0.5342 -0.2791 -0.0116 -1.0432 -1.0045 -0.1216 -0.8332 -0.0792 -0.0041 -0.7890 -0.0365
S-74	DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, placebo-controlled clinical trial (Renal Optimization Strategies Evaluation [ROSE]) of 360 hospitalized patients with acute heart failure and renal dysfunction (estimated glomerular filtration rate of 15-60 mL/min/1.73 m2), randomized within 24 hours of admission.<unk>
T-74	double-blind clinical renal_optimization_strategies_evaluation rose hospitalized patients acute_heart_failure renal_dysfunction estimated_glomerular_filtration_rate randomized admission
H-74	-0.80073082447052	▁multi center ▁double - blind _ ▁place bo - control led _ ▁clinic al _ ▁trial ▁re nal _ optim ization _ strategi s ▁Evalua tion ROS e ▁a cute _ heart ▁failure ▁renal ▁dys function ▁glo mer ular _ ▁filtr ation ▁rate
D-74	-0.80073082447052	multicenter double-blind_ placebo-controlled_ clinical_ trial renal_optimization_strategis EvaluationROSe acute_heart failure renal dysfunction glomerular_ filtration rate
P-74	-6.0824 -0.0222 -3.6894 -0.0163 -0.0399 -1.5736 -1.2108 -0.0032 -0.0220 -0.0009 -0.8692 -0.6669 -0.5731 -0.0120 -0.6911 -0.4625 -0.9012 -0.1331 -0.6052 -0.1398 -0.4444 -2.4830 -0.1550 -0.9537 -2.0269 -0.1636 -0.7832 -0.1627 -1.7770 -0.0068 -0.0798 -1.3866 -0.5593 -0.0735 -1.9055 -0.0784 -0.0264 -0.0532 -0.0111 -0.5749 -0.9221 -0.0832 -2.4732 -1.0398 -0.0948
S-1051	Further molecular analysis revealed that BETs play a crucial role in chromatin-mediated signal transduction to Pol II, co-activating transcription factor networks that are known to be causal in HF pathogenesis, including nuclear factor of activated T cells (NFAT), nuclear factor-κB (NF-κB) and the transcription factor GATA4.<unk>
T-1051	bets signal_transduction pol_ii transcription_factor hf pathogenesis nuclear_factor_of_activated_t_cells nfat nuclear_factor-κb nf-κb transcription_factor gata4
H-1051	-0.5071324110031128	▁ BET s ▁chr omat in - media ted _ signal ▁trans duction ▁pol ▁II ▁co - activa ting ▁tran scription ▁factor ▁network s ▁ HF ▁nuclear _ factor ▁activa ted _ t ▁cell s ▁n FAT ▁nuclear _ factor - κ b NF - κ b ▁tran scription ▁factor ▁g ATA 4
D-1051	-0.5071324110031128	BETs chromatin-mediated_signal transduction pol II co-activating transcription factor networks HF nuclear_factor activated_t cells nFAT nuclear_factor-κbNF-κb transcription factor gATA4
P-1051	-0.4000 -0.0331 -1.4723 -0.1304 -0.0063 -0.1732 -0.0161 -0.0283 -0.0247 -0.4754 -0.5130 -0.0059 -0.1414 -0.8764 -0.1483 -1.0825 -0.0114 -0.0008 -0.0449 -0.2751 -0.0315 -0.0811 -1.0959 -0.1376 -0.2677 -0.6025 -1.1000 -0.7746 -0.2764 -0.6782 -0.0091 -0.1251 -1.3928 -2.2786 -0.0392 -2.6895 -0.0804 -0.2072 -0.5965 -0.4378 -0.4388 -3.0111 -0.1869 -1.9704 -0.0824 -1.1134 -0.1667 -0.6321 -0.1139 -0.0322 -1.0149 -0.0144 -0.1042 -0.1629 -0.0868
S-33	Outcomes evaluated for this guideline included mortality; hospitalization; exercise tolerance; quality of life; and cardiovascular events (defined as myocardial infarction, congestive heart failure exacerbation, arrhythmia, or cardiac death) and harms, including hypertension, venous thromboembolic events, and ischemic cerebrovascular events.<unk>
T-33	outcomes mortality hospitalization exercise_tolerance quality_of_life cardiovascular_events myocardial_infarction congestive_heart_failure arrhythmia cardiac_death hypertension venous_thromboembolic_events ischemic_cerebrovascular_events
H-33	-0.7735199332237244	▁mortal ity ▁hospital ization ▁exercise ▁ tolerance ▁cardiovascular ▁events ▁my o card ial _ in far ction ▁con ges tive _ heart ▁failure ▁ar rhythm ia ▁cardiac ▁death ▁hyper tension ▁ve nous _ thro mbol ic ▁cerebro vas cular
D-33	-0.7735199332237244	mortality hospitalization exercise tolerance cardiovascular events myocardial_infarction congestive_heart failure arrhythmia cardiac death hypertension venous_thrombolic cerebrovascular
P-33	-5.7806 -0.5418 -1.3921 -0.2397 -0.0758 -0.0334 -0.0002 -0.7408 -2.4983 -1.1603 -0.1005 -0.0995 -0.0935 -1.0631 -1.0926 -0.0317 -0.0622 -0.0470 -0.0893 -0.2876 -0.3098 -2.1468 -0.0427 -0.2265 -0.0764 -0.7975 -0.4701 -2.8580 -0.7601 -0.1370 -0.3102 -0.2447 -0.6923 -0.1554 -0.3468 -0.7790 -3.8255 -0.0388 -0.6825 -1.3251 -0.0592
S-128	We found an interaction effect (P = 0.02) between EO-CFUs and diabetes: in patients without diabetes, a 10-EO-CFU increase was independently associated with increased peak VO2 of 0.28 mL/kg/min (P = 0.01), and in patients with diabetes, a decrease in EO-CFUs was associated with an increased peak VO2 (P < 0.05).<unk>
T-128	eo-cfus diabetes patients diabetes peak_vo2 patients diabetes eo-cfus peak_vo2
H-128	-0.8725175261497498	▁ EO - c FU ▁ EO - c FU ▁diabetes
D-128	-0.8725175261497498	EO-cFU EO-cFU diabetes
P-128	-0.4449 -0.0521 -0.0100 -0.9495 -0.3460 -3.7471 -0.0992 -0.0110 -1.0385 -0.3504 -0.9875 -3.1378 -0.1687
S-562	Compared with the referent age group of 60 to 69 years, both all-cause and cardiovascular mortality were lower in the youngest group even after multivariable adjustment (hazard ratio: 0.60, 95% confidence interval: 0.36 to 1.00; p = 0.049, and hazard ratio: 0.71, 95% confidence interval: 0.42 to 1.18, p = 0.186, respectively).<unk>
T-562	cardiovascular_mortality multivariable_adjustment hazard_ratio confidence_interval hazard_ratio confidence_interval
H-562	-1.4980818033218384	▁cardiovascular ▁mortal ity
D-562	-1.4980818033218384	cardiovascular mortality
P-562	-3.7099 -1.1939 -0.8738 -1.6500 -0.0629
S-1212	METHODS: Immunoblotting, radioenzymatic- and fluorescence resonance energy transfer-based assays, video edge detection, epifluorescence microscopy, and L-type Ca2(+) current measurements were performed in myocardial tissues and/or isolated cardiomyocytes from human and/or experimental HF, respectively.<unk>
T-1212	immunoblotting video_edge_detection epifluorescence_microscopy myocardial_tissues cardiomyocytes hf
H-1212	-0.5455445051193237	▁immun o blo tting ▁radio en zy matic - ▁fluor esc ence _ ▁res on ance _ energie ▁transfer - based _ as say s ▁video ▁edge ▁det ection ▁epi flu o resc ence ▁micro s copy ▁l - type _ ca 2 ▁cardio my o cy tes ▁experimental ▁ HF
D-1212	-0.5455445051193237	immunoblotting radioenzymatic- fluorescence_ resonance_energie transfer-based_assays video edge detection epifluorescence microscopy l-type_ca2 cardiomyocytes experimental HF
P-1212	-0.3503 -0.1058 -0.0104 -0.1218 -0.0896 -0.1002 -0.1355 -0.1668 -0.4364 -0.6998 -3.1015 -1.8179 -0.7039 -1.0435 -0.1788 -0.8020 -1.4661 -1.5594 -0.3782 -0.2285 -0.0121 -1.5339 -0.2443 -0.0108 -0.0754 -0.2211 -0.1179 -0.5052 -0.0257 -0.0121 -0.0032 -0.6759 -0.0896 -0.4529 -0.1508 -0.0520 -0.0614 -1.0611 -0.0249 -0.0022 -1.3804 -0.0376 -0.0769 -5.3260 -0.4022 -0.4039 -0.1163 -0.0113 -1.2395 -0.9580 -0.0530 -0.0585 -0.0216
S-1980	MAIN OUTCOMES AND MEASURES: Exercise capacity measured as peak oxygen consumption (VO2, mL/kg/min; co-primary outcome) and QOL measured by the Minnesota Living with Heart Failure (MLHF) Questionnaire (score range: 0-105, higher scores indicate worse heart failure-related QOL; co-primary outcome).<unk>
T-1980	outcomes exercise_capacity peak_oxygen_consumption vo2 co-primary_outcome qol minnesota heart_failure heart qol co-primary_outcome
H-1980	-0.8861856460571289	▁ OUT COM es ▁Exerci se ▁capacity ▁pe ak _ ▁oxygen ▁consum p tion ▁m L / kg / min ▁Q OL ▁Minnesota _ ▁Living _ with _ ▁Heart ▁Fail ure ▁m HF
D-1980	-0.8861856460571289	OUTCOMes Exercise capacity peak_ oxygen consumption mL/kg/min QOL Minnesota_ Living_with_ Heart Failure mHF
P-1980	-1.8023 -1.2175 -0.4479 -0.2222 -4.4622 -0.0442 -1.0428 -1.2106 -0.0159 -0.2184 -0.7287 -0.2096 -0.0241 -0.1764 -2.4931 -1.4761 -0.4749 -0.3852 -0.2085 -0.0226 -1.9136 -0.0676 -0.6777 -1.5003 -1.1187 -0.0795 -2.3405 -0.0368 -0.7616 -0.8357 -1.7851 -1.3738 -0.2570 -1.2923 -0.0930
S-1649	DESIGN: The EAST (Early treatment of Atrial fibrillation for Stroke prevention Trial) will randomize approximately 3,000 patients with recent onset AF at risk for stroke (CHA2DS2VASc score ≥2) to either guideline-mandated usual care or to usual care plus early rhythm control therapy in a prospective, randomized, open, blinded outcome assessment trial.<unk>
T-1649	east early_treatment_of_atrial_fibrillation_for_stroke_prevention_trial randomize patients stroke rhythm_control_therapy prospective randomized outcome
H-1649	-1.0076135396957397	▁e ast ▁e ast _ at rial _ fi bril lation _ for _ ▁Stro ke ▁pre vention ▁tri al
D-1649	-1.0076135396957397	east east_atrial_fibrillation_for_ Stroke prevention trial
P-1649	-0.8429 -0.9237 -3.8550 -0.6240 -3.5323 -2.3658 -0.0712 -0.2358 -1.1122 -0.0174 -0.0049 -0.5521 -1.9636 -0.1552 -1.0228 -0.0206 -0.6717 -0.0074 -1.2307 -0.0126 -2.9019 -0.0437
S-55	Both patients with low left ventricular ejection fraction and patients with HF with preserved left ventricular ejection fraction are admitted to the hospital frequently and serially and keep physicians busy, in the acute and outpatient settings, for their management, also prompting them to search for better ways to deal with this worldwide epidemic and its impact on medical resources and financial costs.<unk>
T-55	patients left_ventricular_ejection_fraction patients hf preserved_left_ventricular_ejection_fraction hospital physicians acute outpatient epidemic medical financial_costs
H-55	-0.8802961707115173	▁patients ▁low _ ▁left _ ▁vent ri cular _ e je ction ▁ fraction ▁ HF ▁pres er ved _ ▁left _ ▁vent ri cular _ e je ction ▁ fraction ▁hospital ▁a cute _ out patient
D-55	-0.8802961707115173	patients low_ left_ ventricular_ejection fraction HF preserved_ left_ ventricular_ejection fraction hospital acute_outpatient
P-55	-2.4438 -4.1976 -0.2489 -2.7669 -0.1364 -1.8514 -0.6267 -1.1680 -0.2596 -0.9663 -0.2085 -0.0884 -1.4819 -0.0042 -1.0107 -0.0294 -3.0782 -0.0263 -0.3660 -0.1399 -0.8397 -0.1188 -1.2692 -0.5345 -0.4969 -0.3711 -0.9064 -0.3190 -0.0213 -0.9033 -0.0032 -1.4694 -1.5787 -0.0022 -0.2436 -0.4349 -0.0039 -3.6229 -0.0936
S-878	The global attenuation of TAC-induced proteomic alterations by the mitochondrial-targeted peptide SS31 suggests that perturbed mitochondrial function may be an upstream signal to many of the pathway alterations in TAC and supports the potential clinical application of mitochondrial-targeted peptide drugs for the treatment heart failure.<unk>
T-878	proteomic mitochondrial-targeted_peptide ss31 mitochondrial_function tac clinical mitochondrial-targeted_peptide drugs heart_failure
H-878	-0.4697365462779999	▁ TAC - indu ced _ ▁prote om ic _ ▁altera tions ▁mito cho ndri al - tar get ed _ pe pti de _ ▁SS 31 ▁per tur bed _ ▁mito cho ndri al _ ▁function ▁ TAC ▁mito cho ndri al - tar get ed _ pe pti de ▁drugs
D-878	-0.4697365462779999	TAC-induced_ proteomic_ alterations mitochondrial-targeted_peptide_ SS31 perturbed_ mitochondrial_ function TAC mitochondrial-targeted_peptide drugs
P-878	-0.2368 -0.0181 -0.1988 -0.0446 -0.1573 -0.4855 -2.0553 -0.0097 -0.1746 -2.3519 -0.8217 -0.2285 -0.0661 -0.1561 -0.4811 -0.0265 -0.1609 -0.0272 -0.0328 -0.0119 -0.0766 -0.6917 -0.0222 -0.0335 -2.9243 -0.9026 -0.2783 -0.3197 -0.0060 -0.2921 -0.4833 -0.3251 -0.1018 -0.0744 -0.0117 -0.4085 -1.1312 -1.7890 -0.2239 -2.2003 -0.1444 -1.3615 -0.0271 -0.1009 -0.0630 -0.0253 -0.0091 -0.0606 -1.1974 -0.0194 -0.0696 -0.7957 -1.3539 -0.0961
S-494	Two hundred ninety-three HF patients with reduced (HFrEF, n = 247) or with preserved left ventricular (LV) ejection fraction (HFpEF, n = 46) underwent echo-Doppler studies and N-terminal pro-brain-type natriuretic peptide assessment and were tracked for adverse events.<unk>
T-494	hf patients hfref left_ventricular ejection_fraction hfpef echo-doppler n-terminal_pro-brain-type_natriuretic_peptide adverse_events
H-494	-0.5767346620559692	▁ HF ▁patients ▁ HF r EF ▁pres er ved _ ▁left _ ▁vent ri cular LV ▁e je ction ▁ fraction HF p EF ▁e cho - D opp ler ▁studies ▁n - termin al _ ▁pro - bra in - type ▁na tri ure tic _ pe pti de
D-494	-0.5767346620559692	HF patients HFrEF preserved_ left_ ventricularLV ejection fractionHFpEF echo-Doppler studies n-terminal_ pro-brain-type natriuretic_peptide
P-494	-0.1955 -0.0079 -4.5458 -2.0702 -0.0176 -2.6992 -0.0336 -2.4621 -0.0260 -0.2181 -1.8722 -0.5307 -0.8368 -0.6710 -0.4914 -0.1775 -0.7382 -2.1480 -0.0516 -0.0168 -0.1605 -0.0061 -0.3634 -0.5309 -0.0720 -0.0629 -0.0098 -0.0102 -0.5369 -0.0113 -0.1659 -0.6045 -1.4634 -0.0099 -0.1075 -0.0052 -0.5391 -1.3786 -0.0139 -0.1830 -0.0250 -0.0199 -0.0018 -0.1928 -0.0023 -0.4098 -1.6538 -1.1833 -0.2715 -0.0135 -0.0650 -0.6181 -0.0648
S-464	Cases seen in low-volume EDs had less comorbidities and were less likely to be hospitalized (54.5%) than those seen in medium (61.8%; adjusted odds ratio [aOR] 1.16, [95% confidence interval {CI} 1.10–1.23]) or high-volume EDs (73.6%; aOR, 1.95 [95% CI, 1.83–2.07]).<unk>
T-464	eds comorbidities hospitalized adjusted_odds_ratio aor confidence_interval eds aor
H-464	-1.0081236362457275	▁low - volu me _ ▁ED s
D-464	-1.0081236362457275	low-volume_ EDs
P-464	-1.5512 -0.0187 -0.0261 -0.0319 -0.4384 -3.1183 -0.1168 -3.6742 -0.0975
S-631	Addition of HABC Battery scores to the Health ABC HF Risk Model improved discrimination (change in C-index, 0.014; 95% CI 0.018-0.010) and appropriately reclassified 13.4% (net-reclassification-improvement 0.073, 95% CI 0.021-0.125; P = .006) of participants (8.3% who developed HF and 5.1% who did not).<unk>
T-631	habc_battery health_abc_hf_risk_model change c-index net-reclassification-improvement hf
H-631	-0.7911654114723206	▁H ABC _ bat tery _ ▁score s ▁Health ▁ABC ▁ HF _ HF _ risk _ model ▁c - index net - re class ification - improv ement
D-631	-0.7911654114723206	HABC_battery_ scores Health ABC HF_HF_risk_model c-indexnet-reclassification-improvement
P-631	-1.3497 -0.1155 -1.1925 -4.0929 -0.0027 -1.2951 -0.2062 -0.0132 -1.2541 -0.1933 -1.0444 -0.0136 -0.4330 -3.0945 -0.4650 -2.7447 -1.4625 -0.1889 -1.4814 -0.0191 -0.0023 -1.8117 -0.0242 -0.0176 -0.0239 -0.1855 -0.1076 -0.0538 -0.0593 -1.5215 -0.0567
S-715	Compared with the patients who underwent standard criteria cardiac transplant, ECCT patients were older (median, 66.6 years versus 53.2 years; P<0.001), with higher frequency of diabetes mellitus (46.4% versus 24.6%; P<0.001) and chronic kidney disease (median estimated glomerular filtration rate, 55 versus 61.6 mL/min; P=0.001).<unk>
T-715	patients cardiac_transplant ecct patients diabetes_mellitus chronic_kidney_disease estimated_glomerular_filtration_rate
H-715	-0.5918688178062439	▁cardiac ▁transplant ▁EC CT ▁diabetes ▁mell itus ▁chronic ▁ki dne y ▁disease ▁glo mer ular _ ▁filtr ation ▁rate
D-715	-0.5918688178062439	cardiac transplant ECCT diabetes mellitus chronic kidney disease glomerular_ filtration rate
P-715	-1.0928 -0.3115 -1.1615 -0.1261 -1.6006 -0.0131 -0.0216 -0.1602 -0.1827 -0.0549 -0.0792 -2.7582 -0.0474 -0.0485 -0.0096 -0.3584 -1.5673 -0.1266 -2.1325 -0.4734 -0.1032
S-1507	Construct validity of individual scales showed excellent fit indices: CFI = .92, RMSEA = .05 for the Self-Care Maintenance Scale; CFI = .95, RMSEA = .07 for the Self-Care Management Scale; CFI = .99, RMSEA = .02 for the Self-Care Confidence scale.<unk>
T-1507	cfi rmsea self-care_maintenance cfi rmsea self-care_management cfi rmsea self-care_confidence
H-1507	-0.9961867332458496	▁c fi ▁RM se a ▁Self - Car e _ management ▁Scal e ▁c fi ▁RM se a
D-1507	-0.9961867332458496	cfi RMsea Self-Care_management Scale cfi RMsea
P-1507	-2.1135 -0.6868 -3.4123 -0.4124 -0.4831 -1.1700 -0.0402 -0.7560 -0.1452 -0.7501 -0.9160 -1.5175 -0.0105 -1.0798 -1.2649 -2.1432 -0.3219 -0.4761 -2.0784 -0.1457
S-1876	Patients assigned to BAT, compared with control group patients, experienced improvements in the distance walked in 6 min (59.6 ± 14 m vs. 1.5 ± 13.2 m; p = 0.004), quality-of-life score (–17.4 ± 2.8 points vs. 2.1 ± 3.1 points; p < 0.001), and NYHA functional class ranking (p = 0.002 for change in distribution).<unk>
T-1876	patients bat patients quality-of-life nyha_functional_class change
H-1876	-1.696740746498108	▁BAT
D-1876	-1.696740746498108	BAT
P-1876	-0.2513 -4.7173 -0.1216
S-537	Subgroup analysis of patients with preoperative hypoalbuminemia and postoperative normalization of albumin levels (n = 81) showed improved survival compared with those who remained hypoalbuminemia (n = 44) or those who had decreasing albumin levels during LVAD support (n = 40; 3-month survival: 92.6% vs 63.6% and 65.0%; p <0.01).<unk>
T-537	patients preoperative hypoalbuminemia postoperative albumin hypoalbuminemia albumin lvad
H-537	-0.4399087131023407	▁pre operativ e ▁hypo album in emia ▁post operativ e _ normal ization ▁album in ▁levels ▁l VAD
D-537	-0.4399087131023407	preoperative hypoalbuminemia postoperative_normalization albumin levels lVAD
P-537	-1.5139 -0.1682 -0.0198 -0.3066 -0.0889 -0.1366 -0.0213 -0.2225 -0.0821 -0.0412 -0.8302 -0.7158 -1.0644 -0.4270 -0.1224 -0.4035 -1.9347 -0.0153 -0.6348 -0.0487
S-1717	A 1-day decrease in length of stay was associated with an absolute increase in 30-day rehospitalization of 1.56 percentage points (95% confidence interval (CI) = 0.30-2.82) for acute myocardial infarction (AMI) with major complications and 0.81 percentage points (95% CI = 0.03-1.60) for kidney infection or urinary tract infection (UTI) without major complications.<unk>
T-1717	rehospitalization confidence_interval acute_myocardial_infarction ami complications kidney_infection urinary_tract_infection uti complications
H-1717	-0.9151772856712341	▁a cute _ my o card ial _ in far ction ▁ AMI ▁ki dne y ▁infection ▁urin ary _ ▁tract ▁infection
D-1717	-0.9151772856712341	acute_myocardial_infarction AMI kidney infection urinary_ tract infection
P-1717	-4.7310 -0.7584 -0.0758 -3.8286 -0.1617 -0.3011 -0.1177 -0.3462 -0.3567 -0.0206 -0.1428 -2.8561 -0.2210 -3.1348 -0.2093 -0.0269 -0.4291 -0.0340 -0.0372 -0.2654 -1.0823 -0.2126 -2.5024 -0.1128
S-54	Management of patients with heart failure (HF), stemming from ischemic and nonischemic cardiomyopathies, continues to be problematic, despite the inroads made in the pharmacological armamentarium, by implantable cardioverter defibrillators, cardiac resynchronization therapy, and the eventual resort to cardiac transplantation, and left and/or right ventricular assist devices.<unk>
T-54	patients heart_failure hf ischemic nonischemic_cardiomyopathies pharmacological implantable_cardioverter_defibrillators cardiac_resynchronization_therapy cardiac_transplantation right_ventricular_assist_devices
H-54	-0.47489500045776367	▁ ische mic _ ▁non ische mic _ ▁cardio my o pathi es ▁ pharma c ological _ arma ment arium ▁implant able ▁cardio ver ter ▁de fi br illa tors ▁cardiac ▁re syn chron ization ▁ therapy ▁cardiac ▁transplant ation ▁left ▁vent ri cular _ assist ▁devices
D-54	-0.47489500045776367	ischemic_ nonischemic_ cardiomyopathies pharmacological_armamentarium implantable cardioverter defibrillators cardiac resynchronization therapy cardiac transplantation left ventricular_assist devices
P-54	-1.4164 -0.2812 -0.3749 -0.6587 -3.8152 -0.0237 -0.1320 -0.1164 -1.0619 -1.0190 -0.2086 -0.0178 -0.1396 -1.8024 -0.9994 -0.0169 -0.2230 -1.3951 -0.4105 -0.0156 -0.0007 -0.0982 -0.0150 -1.0022 -0.0051 -0.1010 -0.5308 -0.0437 -0.0847 -0.0375 -0.1675 -0.0037 -0.0499 -0.0008 -0.0009 -0.4216 -0.9912 -0.0071 -0.0380 -0.2530 -0.0440 -0.3128 -3.5431 -0.1190 -0.0532 -0.7153 -0.2740 -0.5597 -0.1096 -0.0330
S-230	SAF versus PF mean catheterization findings were central venous pressure 18 ± 6 versus 14 ± 3 mm Hg (p <0.01), SVR index 1,680 ± 368 versus 1,960 ± 550 dyn s/cm(5)/m(2) (p = 0.02), and cardiac index 2.7 ± 0.8 versus 2.8 ± 0.7 L/min/m(2) (p = 0.25).<unk>
T-230	saf catheterization central_venous_pressure svr cardiac_index
H-230	-2.227976083755493	▁ SAF ▁ PF _ van _ PF _ de _ central _ ve nous _ ▁pressure ▁s VR _ ▁index
D-230	-2.227976083755493	SAF PF_van_PF_de_central_venous_ pressure sVR_ index
P-230	-0.6712 -0.1386 -3.1284 -0.6761 -4.3685 -5.5067 -0.5186 -5.0542 -3.0473 -5.5998 -2.4393 -4.0685 -0.3738 -1.7749 -0.3951 -0.3295 -1.2751 -3.1810 -0.1728 -2.5412 -0.8492 -4.7046 -0.4292
S-193	Women compared with men had higher admission median BNP levels with the greatest difference among reduced EF and smallest difference among preserved EF (median BNP in women vs men: EF reduced 1,259 vs 1,113 pg/mL, borderline 821 vs 732 pg/mL, and preserved 559 vs 540 pg/mL; P < .001 all comparisons).<unk>
T-193	admission bnp reduced_ef preserved_ef bnp ef
H-193	-1.4068586826324463	▁ad mission ▁media n _ b NP _ ▁levels ▁reduce d _ ▁EF
D-193	-1.4068586826324463	admission median_bNP_ levels reduced_ EF
P-193	-3.2405 -0.4858 -0.2055 -0.0148 -0.6407 -0.7503 -0.1656 -5.8568 -1.5510 -2.6704 -0.0131 -0.9632 -0.8496 -3.5216 -0.1741
S-435	The score was associated with heart failure admission, heart transplantation/LV assist device, or death (hazard ratio, 0.97; 95% confidence interval, 0.95-0.98; P<0.001) and all-cause death (hazard ratio, 0.97; 95% confidence interval, 0.96-0.98; P<0.001), independent of age, sex, ischemic cause, and initial functional class.<unk>
T-435	heart_failure admission heart_transplantation lv_assist_device death hazard_ratio confidence_interval death hazard_ratio confidence_interval ischemic functional_class
H-435	-1.1185953617095947	▁heart ▁failure ▁ad mission ▁heart ▁transplant ation LV _ assist ▁device ▁death haz ard
D-435	-1.1185953617095947	heart failure admission heart transplantationLV_assist device deathhazard
P-435	-2.2279 -0.8633 -0.7635 -0.1652 -2.7551 -1.5127 -0.0400 -2.1864 -0.7393 -0.4193 -1.2682 -1.6479 -0.3759 -0.0034 -2.8353 -0.0943
S-475	LV ejection fraction, velocity of circumferential shortening, maximal systolic elastance, and contractile efficiency were significantly depressed in ACF and significantly improved in ACF + allopurinol rats, all of which occurred in the absence of changes in the maximum O2 consumption rate measured in isolated cardiomyocytes using the extracellular flux analyzer.<unk>
T-475	lv_ejection_fraction shortening systolic_elastance contractile_efficiency acf acf allopurinol cardiomyocytes extracellular_flux_analyzer
H-475	-0.29756224155426025	▁LV ▁e je ction ▁ fraction ▁circum fer ential _ short en ing ▁sy sto lic ▁elastan ce ▁contract ile ▁efficiency ▁a CF ▁allo puri nol ▁rat s ▁maximum ▁o 2 ▁consum p tion ▁rate ▁isola ted ▁cardio my o cy tes ▁extra cel lular _ ▁flux ▁anal y zer
D-475	-0.29756224155426025	LV ejection fraction circumferential_shortening systolic elastance contractile efficiency aCF allopurinol rats maximum o2 consumption rate isolated cardiomyocytes extracellular_ flux analyzer
P-475	-1.7450 -0.0631 -0.0174 -0.0064 -0.8805 -0.0015 -0.2422 -0.0486 -0.1183 -0.5276 -0.4692 -0.0570 -0.0663 -1.2102 -0.0043 -0.0052 -0.6995 -0.0800 -0.0008 -0.0182 -0.6287 -0.9402 -0.2206 -0.3433 -0.0024 -0.0081 -0.1157 -0.0215 -0.3444 -1.9516 -0.0190 -0.9661 -0.0517 -0.0991 -1.5154 -0.2231 -0.0012 -0.7836 -0.1292 -0.1410 -0.0344 -0.0165 -0.0051 -0.0111 -0.0012 -0.2160 -0.0685 -0.1397 -0.0410 -0.0163 -0.1098 -0.0465
S-1526	We prospectively studied 402 patients with HFpEF, divided into 4 groups based on LV structure: normal geometry (no LV hypertrophy [LVH] and relative wall thickness [RWT] ≤0.42); CR (no LVH and RWT >0.42); CH (LVH and RWT >0.42); and EH (LVH and RWT ≤0.42).<unk>
T-1526	prospectively patients hfpef lv_hypertrophy lvh relative_wall_thickness rwt lvh rwt lvh rwt lvh rwt
H-1526	-0.9544110298156738	▁ HF p EF ▁LV ▁structure ▁normal _ ge ometr y ▁LV ▁hyper trop hy ▁v h ▁relative _ ▁wall ▁thi ck ness ▁r w t ▁CR ▁v h ▁r w
D-1526	-0.9544110298156738	HFpEF LV structure normal_geometry LV hypertrophy vh relative_ wall thickness rwt CR vh rw
P-1526	-0.1909 -0.0779 -0.0392 -0.0422 -2.1293 -4.3770 -3.4944 -1.0088 -0.6757 -0.3249 -0.1292 -0.5958 -2.0302 -0.0035 -0.1707 -3.5823 -0.6484 -0.7045 -0.0201 -2.0690 -0.5877 -0.0070 -0.5266 -0.7866 -0.1489 -1.0500 -2.3790 -1.4446 -0.1987 -0.6397 -0.3013 -1.0398 -0.0718
S-1463	LCZ696, an angiotensin receptor neprilysin inhibitor composed of a neprilysin inhibitor prodrug and the angiotensin receptor antagonist valsartan, has proven effective in hypertension, has shown promise in a pilot trial of heart failure with preserved ejection fraction, and is being tested in a large outcomes trial of heart failure with reduced ejection fraction.<unk>
T-1463	lcz696 angiotensin_receptor_neprilysin_inhibitor neprilysin_inhibitor prodrug angiotensin_receptor_antagonist valsartan hypertension heart_failure_with_preserved_ejection_fraction outcomes heart_failure_with_reduced_ejection_fraction
H-1463	-0.5004372596740723	▁ang io ten sin ▁receptor ▁nepri ly sin ▁inhibi tor ▁nepri ly sin ▁inhibi tor ▁pro drug ▁ang io ten sin ▁receptor ▁anta gon ist ▁val sar tan ▁hyper tension
D-1463	-0.5004372596740723	angiotensin receptor neprilysin inhibitor neprilysin inhibitor prodrug angiotensin receptor antagonist valsartan hypertension
P-1463	-1.2258 -0.9597 -0.1391 -1.1136 -0.3943 -0.0665 -0.2066 -0.7736 -0.1927 -0.0084 -0.3706 -0.1131 -0.8640 -0.5013 -0.0139 -2.2098 -0.0051 -0.1179 -0.2210 -0.0915 -0.5099 -0.3652 -0.2644 -0.0058 -0.2165 -0.5676 -0.0529 -0.0069 -1.6992 -0.0841 -2.5806 -0.0723
S-343	His blood pressure was 120/70 mm Hg, he underwent mitral valve plasty for degenerative MR, he had P3 prolapse with 2 chordal ruptures and he underwent triangular resection, edge-to-edge anastomosis, and ring annuloplasty with a Physio Ring 30 (Edwards Lifesciences, Irvine, CA) of just size.<unk>
T-343	blood_pressure mitral_valve_plasty degenerative_mr p3_prolapse chordal_ruptures triangular_resection edge-to-edge_anastomosis ring_annuloplasty physio_ring_30 edwards_lifesciences irvine
H-343	-0.32159319519996643	▁blood ▁pressure ▁mit ral ▁val ve ▁plast y ▁de genera tive _ ▁MR ▁p 3 ▁chor dal ▁rup tures ▁tri ang ular _ ▁res ection ▁edge - to - ed ge _ ▁an asto mos is ▁ring _ ▁ann ulo plast y ▁Ph y sio ▁ring
D-343	-0.32159319519996643	blood pressure mitral valve plasty degenerative_ MR p3 chordal ruptures triangular_ resection edge-to-edge_ anastomosis ring_ annuloplasty Physio ring
P-343	-0.8792 -0.1463 -0.2467 -0.0035 -0.7968 -0.0148 -0.0661 -0.0754 -0.0122 -0.0002 -0.0832 -1.0601 -0.1851 -0.8624 -0.0315 -0.0574 -0.0182 -0.2842 -0.0727 -0.0286 -0.0017 -0.0004 -0.3584 -1.6153 -0.0023 -0.1246 -0.0175 -0.0079 -0.0831 -0.0476 -0.0694 -0.5475 -0.9649 -0.0003 -0.0951 -0.0286 -0.0064 -0.3220 -1.9891 -0.0455 -0.0289 -0.0142 -0.8120 -0.0061 -0.0049 -1.0578 -2.2199 -0.0408
S-1320	Outcomes included an incremental shuttle walk test, peak oxygen uptake, muscular strength, echocardiographic measures, N-terminal pro-brain natriuretic peptide, inflammatory markers, depression (Beck Depression Inventory), and health-related quality of life (Minnesota Living with Heart Failure Questionnaire and Medical Outcomes Study Short-Form).<unk>
T-1320	outcomes incremental_shuttle_walk_test peak_oxygen_uptake muscular echocardiographic n-terminal_pro-brain_natriuretic_peptide inflammatory beck_depression_inventory health-related_quality_of_life minnesota_living_with_heart_failure_questionnaire medical_outcomes_study_short-form
H-1320	-0.570741593837738	▁shu ttle _ walk ▁test ▁pe ak ▁oxygen _ up take ▁muscular ▁strength ▁e cho car dio graphic ▁N - termin al _ ▁pro - bra in ▁na tri ure tic _ pe pti de ▁infla mma tory ▁marker s ▁depression ▁be ck ▁de pression ▁in ven tory
D-1320	-0.570741593837738	shuttle_walk test peak oxygen_uptake muscular strength echocardiographic N-terminal_ pro-brain natriuretic_peptide inflammatory markers depression beck depression inventory
P-1320	-1.6516 -0.0001 -0.6042 -1.3265 -0.2585 -1.4690 -0.0018 -0.1707 -1.3759 -0.4612 -0.0341 -0.0464 -2.2453 -0.0238 -0.0020 -0.0035 -0.1113 -0.3068 -3.1989 -0.0084 -0.0942 -0.0048 -0.6239 -1.1449 -0.0154 -0.1793 -0.0370 -0.0981 -0.0031 -0.3825 -1.1093 -0.6604 -1.0062 -0.0551 -0.0950 -0.7414 -0.1452 -0.0222 -1.0314 -0.0324 -1.2208 -1.9464 -0.0214 -0.8173 -0.2093 -1.7134 -0.1532 -0.0256 -1.5201 -0.1275
S-116	Interaction term analysis showed that the risk associated with severely reduced LVEF was evident only among patients ≤75 years (HR 1.49, p = 0.003), whereas among older patients, there was no difference in the risk of long-term mortality between those with preserved versus severely reduced LVEF (HR 1.02 [p = 0.86]; p value for age-by-LVEF interaction = 0.03).<unk>
T-116	interaction_term_analysis lvef patients patients mortality lvef p_value
H-116	-1.3541957139968872	▁inter action ▁term _ analyse ▁severe ly _ reducing d _ ▁LV EF
D-116	-1.3541957139968872	interaction term_analyse severely_reducingd_ LVEF
P-116	-5.2516 -0.0470 -0.0754 -2.3473 -0.0947 -4.4599 -0.1266 -0.9464 -1.2495 -0.5648 -0.7378 -0.9432 -0.0219 -3.3347 -0.1123
S-763	METHODS AND RESULTS: Four groups of rats (Wistar-Kyoto, n=11; lean ZSF1, n=11; obese ZSF1, n=11, and obese ZSF1 with high-fat diet, n=11) were followed up for 20 weeks with repeat metabolic, renal, and echocardiographic evaluations and hemodynamically assessed at euthanization.<unk>
T-763	wistar-kyoto zsf1 obese zsf1 obese zsf1 followed_up metabolic renal echocardiographic hemodynamically euthanization
H-763	-1.0154838562011719	▁w star - K yo to ▁lean _ z SF ▁obes e _ z SF ▁obes e _ z SF ▁high - fat ▁die t ▁eu than ization
D-763	-1.0154838562011719	wstar-Kyoto lean_zSF obese_zSF obese_zSF high-fat diet euthanization
P-763	-2.0746 -0.4069 -0.0252 -3.9388 -0.0315 -0.0071 -0.0533 -1.0845 -2.2573 -0.1744 -1.9113 -0.0140 -1.3660 -1.3476 -0.5412 -3.6586 -0.0121 -0.8430 -1.1937 -0.4142 -4.4263 -0.0091 -0.0583 -1.4243 -0.0232 -2.3730 -0.0772 -0.5967 -0.0774 -0.0436
S-384	Kaplan-Meier curves and log-rank testing demonstrated excellent risk stratification, particularly between a large, low-risk group (40% of patients, 6-month event rates in the UM/VA/VA-RT cohorts 8%/12%/12%) and a small, high-risk group (10% of patients, 6-month event rates in the UM/VA/VA-RT cohorts 57%/58%/79%).<unk>
T-384	kaplan-meier_curves log-rank_testing risk_stratification patients patients
H-384	-0.8578726649284363	▁ka plan - me ier _ ▁cur ves ▁log - rank ▁testing
D-384	-0.8578726649284363	kaplan-meier_ curves log-rank testing
P-384	-0.6753 -0.0061 -0.0180 -0.8261 -0.0676 -1.2384 -1.5908 -0.7256 -0.0616 -0.0137 -0.0049 -2.8817 -3.7848 -0.1158
S-950	Multivariate Cox regression analyses revealed that AF type (other than long-standing persistent AF) and lack of hypertension were independently associated with maintenance of sinus rhythm (hazard ratio [HR]: 1.81, 95% confidence interval [CI]: 1.03 to 3.17, p = 0.04; HR: 0.49, 95% CI: 0.24 to 0.96, p = 0.04, respectively).<unk>
T-950	multivariate_cox_regression_analyses hypertension sinus_rhythm hazard_ratio confidence_interval
H-950	-1.3994531631469727	▁multi varia te _ co x ▁re gression ▁analyse s ▁AF ▁type ▁hyper tension ▁sinus ▁ rhythm haz ard ▁ratio ▁ci
D-950	-1.3994531631469727	multivariate_cox regression analyses AF type hypertension sinus rhythmhazard ratio ci
P-950	-5.0878 -0.0120 -0.0675 -2.2689 -0.2487 -0.0139 -0.9055 -0.0083 -3.0690 -0.2923 -1.3776 -1.6613 -5.3083 -0.0391 -5.6394 -0.5977 -0.0567 -0.3692 -0.0014 -0.2777 -3.2818 -1.5061 -0.0974
S-1228	CONCLUSIONS: In patients with chronic HF-REF, in NYHA functional class II, and meeting specific inclusion and exclusion criteria, including an eGFR >30 ml/min/1.73 m(2) and potassium <5.0 mmol/l, eplerenone was both efficacious and safe when carefully monitored, even in subgroups at high risk of developing hyperkalemia or WRF.<unk>
T-1228	patients chronic hf-ref nyha_functional_class_ii egfr potassium eplerenone hyperkalemia
H-1228	-0.5255936980247498	▁chronic ▁ HF - RE F ▁NY HA ▁functional _ ▁class ▁II ▁e G FR ▁po tas s ium ▁e pler en one ▁w RF
D-1228	-0.5255936980247498	chronic HF-REF NYHA functional_ class II eGFR potassium eplerenone wRF
P-1228	-0.7673 -0.4273 -0.0788 -0.0375 -1.0640 -0.3816 -0.1667 -0.0361 -0.9552 -1.4087 -1.1106 -1.2237 -0.0761 -2.4018 -0.1283 -0.9026 -0.2797 -0.1166 -0.0305 -0.0348 -0.0206 -0.0371 -0.3689 -1.3966 -0.6494 -0.0354 -0.0551
S-12	METHODS: Body composition with regard to FFM, FM, and body fat distribution was assessed by dual energy X-ray absorptiometry (DXA) in 19 non-diabetic patients with chronic heart failure (CHF) and CC and 38 controls (non-cachectic CHF and individuals with prior myocardial infarction-both n = 19) who were followed for 12 months.<unk>
T-12	ffm dual_energy_x-ray_absorptiometry dxa patients chronic_heart_failure chf non-cachectic_chf myocardial
H-12	-0.7680848240852356	▁figuur ▁f FM ▁f FM ▁figuur ▁figuur ▁dual _ ▁energy _ x - ray _ ▁ab sor pti ometr y ▁d XA ▁non - dia be tic _ ▁patients ▁chronic _ ▁heart ▁failure ▁CC ▁non - ca che ctic ▁CHF ▁my o card ial _ in far ction - bo th
D-12	-0.7680848240852356	figuur fFM fFM figuur figuur dual_ energy_x-ray_ absorptiometry dXA non-diabetic_ patients chronic_ heart failure CC non-cachectic CHF myocardial_infarction-both
P-12	-1.3467 -1.1992 -0.1355 -1.5970 -0.4964 -1.7792 -3.4011 -1.4120 -1.1724 -1.7717 -1.1951 -3.1016 -0.1500 -0.6327 -0.6243 -0.5582 -1.5409 -0.1246 -0.2223 -0.2294 -0.6421 -0.0133 -1.8404 -0.0078 -0.0046 -0.0446 -0.2083 -3.6167 -0.6109 -1.1082 -0.1865 -3.0139 -0.1763 -1.7324 -1.0455 -0.0035 -0.0006 -0.0330 -0.0356 -0.6352 -1.2164 -0.0459 -0.1347 -0.2993 -0.3350 -0.4449 -0.0116 -0.0898 -0.2342 -0.0022 -0.0050 -0.2077 -0.0320
S-1707	After adjustment for differences in baseline characteristics and achieved study drug dose, spironolactone reduced the combined end point of death or hospitalization for HF in non-AAs (hazard ratio, 0.63; 95% confidence interval, 0.55-0.73) but not in AAs (hazard ratio, 1.07; 95% confidence interval, 0.67-1.71; P value for interaction=0.032).<unk>
T-1707	baseline drug spironolactone combined_end_point death hospitalization hf hazard_ratio confidence_interval aas hazard_ratio confidence_interval p_value
H-1707	-1.027843952178955	▁spi rono lac tone ▁ HF
D-1707	-1.027843952178955	spironolactone HF
P-1707	-1.4006 -0.0049 -0.0074 -0.0380 -3.1051 -0.4351 -3.1806 -0.0511
S-823	METHODS AND RESULTS: In this prospective study, patients with invasively diagnosed pulmonary arterial hypertension or inoperable chronic thromboembolic pulmonary hypertension and impaired right ventricular pump function despite a stable targeted pulmonary arterial hypertension medication underwent a broad panel of noninvasive assessments, including stress echocardiography and cardiopulmonary exercise testing.<unk>
T-823	prospective_study patients invasively diagnosed pulmonary_arterial_hypertension inoperable chronic_thromboembolic_pulmonary_hypertension right_ventricular pump stable pulmonary_arterial_hypertension medication noninvasive stress_echocardiography cardiopulmonary_exercise_testing
H-823	-0.7316108345985413	▁pulmonar y ▁arterial ▁hyper tension ▁in opera ble ▁chronic _ thro mbo e mbol ic _ ▁pulmonar y _ ▁hyper tension ▁im pair ed _ ▁right _ ▁vent ri cular _ pump
D-823	-0.7316108345985413	pulmonary arterial hypertension inoperable chronic_thromboembolic_ pulmonary_ hypertension impaired_ right_ ventricular_pump
P-823	-0.9838 -0.0144 -0.0979 -1.2579 -0.0353 -1.6886 -0.0187 -0.0960 -0.3464 -0.7881 -0.4353 -1.5576 -0.0805 -0.0044 -0.2914 -1.4296 -0.1730 -0.0459 -1.0877 -2.0844 -0.0449 -2.0599 -0.0043 -0.0193 -0.8882 -1.5438 -0.5088 -1.6726 -0.3613 -0.0524 -0.5100 -0.9069 -3.7390 -0.0467
S-1930	For cardiovascular death or HF hospitalization, there was a significant interaction between the randomization group and BTES (P=0.035), which corresponded to a borderline association between increasing BTES and cardiovascular death or HF hospitalization in the exercise group (hazard ratio 1.25, 95% confidence interval 0.99, 1.59), but no association in the usual care group (hazard ratio 0.83, 95% confidence interval 0.66, 1.06).<unk>
T-1930	cardiovascular_death hf hospitalization randomization btes btes cardiovascular_death hf hospitalization exercise hazard_ratio confidence_interval hazard_ratio confidence_interval
H-1930	-1.1428953409194946	▁b tes ▁cardiovascular _ ▁death ▁ HF _ hospital ization
D-1930	-1.1428953409194946	btes cardiovascular_ death HF_hospitalization
P-1930	-3.4067 -0.2147 -0.7005 -1.9674 -0.6676 -0.7821 -0.0118 -3.1602 -0.1914 -0.6657 -1.8810 -0.0656
S-466	Of patients hospitalized at the time of their index ED visit, low-volume ED cases exhibited a higher risk of 30-day death/all-cause readmission (24.3%) than those seen in medium (21.9%; aOR, 0.83 [95% CI, 0.76–0.91]) or high-volume EDs (18.1%; aOR, 0.77 [95% CI, 0.70–0.85]).<unk>
T-466	patients hospitalized death all-cause_readmission aor eds aor
H-466	-2.120504856109619	▁index - volu me _ index _ e _ visit ▁low - - volu me _ e _ car iten _ de _ de _ de _ de _ de _ de _ de _ de _ de _ de _ de _ de _ de _ corrupt ie
D-466	-2.120504856109619	index-volume_index_e_visit low--volume_e_cariten_de_de_de_de_de_de_de_de_de_de_de_de_de_corruptie
P-466	-0.1649 -2.5502 -1.6009 -0.0209 -0.4250 -5.0917 -0.3978 -4.6605 -1.2564 -3.7641 -4.4554 -0.0324 -3.8593 -0.2512 -0.0190 -0.2956 -4.3889 -1.7275 -5.0132 -4.6757 -2.5056 -1.4156 -0.9075 -3.1853 -1.0729 -3.3424 -0.9787 -3.2640 -0.8510 -3.3412 -0.8368 -3.3319 -0.8260 -3.3024 -0.7783 -3.3633 -0.7873 -3.3136 -0.7950 -3.4007 -0.7681 -3.3931 -0.7928 -3.4567 -0.7851 -3.4507 -0.7416 -4.2725 -0.8163 -3.3134 -0.1058
S-1863	Patients identified three stages where they felt implantable cardioverter-defibrillator deactivation should be discussed: (1) prior to implantation, (2) with any significant deterioration but while they were of sound mind to engage in and communicate their preferences and (3) at end of life, where patients wished further review of their previously established preferences and decisions about implantable cardioverter-defibrillator deactivation.<unk>
T-1863	patients implantable_cardioverter-defibrillator implantation engage patients decisions implantable_cardioverter-defibrillator
H-1863	-0.308956503868103	▁implant able _ ▁cardio ver ter - de fi br illa tor ▁de activa tion
D-1863	-0.308956503868103	implantable_ cardioverter-defibrillator deactivation
P-1863	-0.3640 -0.0136 -0.2365 -1.6215 -0.0072 -0.2489 -0.3403 -0.0193 -0.5734 -0.2631 -0.1099 -0.0202 -0.1503 -0.0108 -0.1801 -1.0545 -0.0388
S-739	Cardiac magnetic resonance T1 time (hazard ratio, 0.99; 95% confidence interval, 0.98-0.99; P=0.046), left atrial area (hazard ratio, 1.08; 95% confidence interval, 1.03-1.13; P<0.01), and pulmonary vascular resistance (hazard ratio, 1.01; 95% confidence interval, 1.00-1.01; P=0.03) were significantly associated with cardiac events.<unk>
T-739	cardiac_magnetic_resonance t1_time hazard_ratio confidence_interval left_atrial_area hazard_ratio confidence_interval pulmonary_vascular_resistance hazard_ratio confidence_interval cardiac_events
H-739	-1.1711785793304443	▁Card iac _ ▁magnetic _ ▁res on ance ▁left _ at rial ▁area ▁pulmonar y _ ▁vas cular ▁resist ance haz ard _ ▁ratio
D-739	-1.1711785793304443	Cardiac_ magnetic_ resonance left_atrial area pulmonary_ vascular resistancehazard_ ratio
P-739	-1.2242 -0.0256 -0.9640 -1.6227 -0.4993 -2.5803 -0.4640 -1.1151 -6.8486 -0.3432 -0.5574 -0.0266 -3.4890 -1.8035 -0.0409 -0.3784 -0.8531 -0.1423 -3.1058 -0.0444 -1.7701 -0.0038 -0.8667 -0.1217 -1.4770 -0.0831
S-1755	METHODS AND RESULTS: We recruited and prospectively followed up, in 14 dedicated HF units, 3058 patients with systolic (left ventricular ejection fraction <40%) HF in stable clinical conditions, New York Heart Association class I to III, who underwent clinical, laboratory, echocardiographic, and cardiopulmonary exercise test investigations at study enrollment.<unk>
T-1755	prospectively followed_up hf patients systolic left_ventricular_ejection_fraction hf stable clinical conditions new_york_heart_association_class_i clinical echocardiographic cardiopulmonary_exercise_test
H-1755	-0.6094020009040833	▁ HF ▁sy sto lic _ le ft _ ▁vent ri cular _ e je ction ▁ fraction ▁ HF ▁New ▁York _ ▁Heart ▁Association ▁e cho car dio graphic ▁cardio pul mon ary _ ▁exercise
D-1755	-0.6094020009040833	HF systolic_left_ ventricular_ejection fraction HF New York_ Heart Association echocardiographic cardiopulmonary_ exercise
P-1755	-0.3686 -1.5486 -3.5958 -0.0061 -0.0048 -2.3747 -0.8759 -0.0061 -0.2763 -0.9173 -0.2456 -0.4342 -0.2391 -0.9715 -0.1748 -0.1251 -0.5082 -0.0142 -0.7891 -0.1832 -1.0657 -0.2804 -0.7652 -0.4834 -1.0577 -1.5265 -0.0055 -0.0022 -0.0554 -0.0592 -0.0623 -0.0259 -0.4632 -0.1587 -0.9059 -1.4995 -1.0490 -0.0325
S-1666	Patients with end stage heart failure fall into stage D of the ABCD classification of the American College of Cardiology (ACC)/American Heart Association (AHA), and class III–IV of the New York Heart Association (NYHA) functional classification; they are characterised by advanced structural heart disease and pronounced symptoms of heart failure at rest or upon minimal physical exertion, despite maximal medical treatment according to current guidelines.<unk>
T-1666	patients end_stage_heart_failure abcd_classification american_college_of_cardiology acc american_heart_association aha new_york_heart_association nyha heart_disease symptoms heart_failure physical medical_treatment
H-1666	-1.1992710828781128	▁ab d _ ▁classifica tion ▁American _ ▁College _ of _ ▁Card i ology ▁a cc _ American _ ▁Heart ▁Association ▁ AHA ▁New ▁York _ ▁Heart ▁Association NY HA
D-1666	-1.1992710828781128	abd_ classification American_ College_of_ Cardiology acc_American_ Heart Association AHA New York_ Heart AssociationNYHA
P-1666	-6.8996 -0.2409 -3.1650 -0.0986 -0.0103 -2.4244 -0.8531 -1.1151 -0.1843 -1.0245 -0.1617 -1.5165 -0.1015 -0.0414 -0.9216 -0.0590 -2.4227 -0.1359 -0.0585 -1.4692 -0.1029 -3.1875 -0.0748 -3.2228 -0.4174 -0.2760 -3.8691 -1.3095 -0.2624 -0.0848 -2.5941 -0.0717
S-345	The MVA was obtained by a continuity equation (LV end-diastolic volume - LV end-systolic volume = mitral filling flow volume = MVA × velocity time integral of mitral filling flow by continuous wave Doppler echocardiography), which can be utilized even in the presence of MR. His mitral valve plasty was successfully performed without major concerns.<unk>
T-345	mva continuity_equation lv_end-diastolic_volume lv_end-systolic_volume mitral_filling_flow mva mitral_filling_flow continuous_wave_doppler_echocardiography mitral_valve_plasty
H-345	-1.1470308303833008	▁m v ▁v v ▁v ▁v ▁v ▁v ▁v ▁v ▁v ▁v ▁v ▁v ▁v ▁v ▁v ▁v ▁v ▁v ▁v ▁v ▁v ▁v ▁v v ▁mit ral _ ▁fill ing _ ▁flow ▁volume ▁m VA ▁veloci ty _ ▁time ▁integral ▁mit ral _ ▁fill ing _ ▁flow ▁continuo us _ ▁wa ve ▁do pp ler ▁e cho card i ography ▁MR ▁mit ral _ ▁val ve ▁plast y
D-345	-1.1470308303833008	mv vv v v v v v v v v v v v v v v v v v v v v vv mitral_ filling_ flow volume mVA velocity_ time integral mitral_ filling_ flow continuous_ wave doppler echocardiography MR mitral_ valve plasty
P-345	-1.4544 -2.9066 -3.1035 -1.7000 -2.6997 -2.6683 -2.4853 -2.2896 -2.3032 -2.2524 -2.1923 -2.1447 -2.2065 -2.1599 -2.0758 -2.1367 -2.1336 -2.1510 -2.0946 -2.1503 -2.0971 -2.1093 -2.0923 -2.0722 -2.0780 -2.1248 -3.4248 -0.0235 -1.7883 -0.9644 -0.0327 -0.5005 -1.1174 -0.3361 -0.3547 -0.8957 -0.7944 -0.0018 -0.7515 -0.3607 -2.2588 -0.1429 -0.0080 -0.9839 -0.2740 -0.0120 -0.3575 -0.3356 -3.3051 -0.0184 -0.2560 -0.1242 -0.0202 -1.3676 -0.0079 -0.1559 -0.4762 -0.0063 -0.0402 -0.0421 -0.1033 -0.0433 -0.4756 -0.0069 -0.5065 -0.5256 -0.0051 -0.1344 -0.0531 -0.0708 -0.0937
S-157	Compared with usual care, although not reaching statitistical significance, RM trended to reduce all-cause mortality for STS HH (HR: 0.77, 95% credible interval (CrI): 0.55, 1.08), TM during office hours (HR: 0.76, 95% CrI: 0.49, 1.18) and TM24/7 (HR: 0.49, 95% CrI: 0.20, 1.18).<unk>
T-157	significance rm all-cause_mortality sts hh cri cri cri
H-157	-1.7749227285385132	▁stati tis tical _ ▁significa nce ▁RM ▁s ts ▁ HH
D-157	-1.7749227285385132	statitistical_ significance RM sts HH
P-157	-4.1102 -0.0554 -0.1038 -1.9622 -2.9550 -1.3213 -2.2627 -3.7950 -1.2932 -1.3081 -0.0303 -3.7935 -0.0834
S-381	We externally validated the HFPSI in the Ann Arbor Veterans' Affairs HF clinic (VA cohort, n = 445; 106 outcomes) and explored "real-time" HFPSI use (VA-RT cohort, n = 486; 141 outcomes) by tracking VA patients for 6 months from their most recently calculated HFPSI, rather than using an arbitrary start date for the cohort.<unk>
T-381	hfpsi hf clinic outcomes hfpsi outcomes tracking patients hfpsi
H-381	-0.7803844213485718	▁ HF PSI ▁Ann ▁Ar bor ▁Veteran s _ ▁Affairs ▁ HF _ ▁clinic VA - RT _ co hor t ▁
D-381	-0.7803844213485718	HFPSI Ann Arbor Veterans_ Affairs HF_ clinicVA-RT_cohort
P-381	-0.1142 -0.3741 -0.7938 -1.1267 -0.9367 -0.0039 -0.6913 -0.0063 -0.4603 -0.2169 -0.3894 -0.2952 -1.8583 -0.7175 -1.2797 -0.2133 -0.1397 -2.0107 -0.4032 -0.0071 -0.0067 -0.4920 -5.4119
S-1706	Compared with AAs, non-AAs were more likely to attain maximal spironolactone dose (13.9% versus 5.8%; P=0.04) and had higher rates of hyperkalemia (potassium>5.5 mmol/L; 9.7% versus 4.2%; P<0.046), as well as lower rates of hypokalemia (potassium<3.5 mmol/L; 5.6% versus 17.9%; P<0.001).<unk>
T-1706	aas spironolactone hyperkalemia potassium hypokalemia potassium
H-1706	-0.6769370436668396	▁AA s ▁spi rono lac tone ▁dose ▁hyper kal emia po tas s ium
D-1706	-0.6769370436668396	AAs spironolactone dose hyperkalemiapotassium
P-1706	-1.8491 -1.5752 -0.3777 -0.0049 -0.0224 -0.0254 -0.4313 -2.1874 -0.2313 -0.0198 -1.3219 -0.1407 -0.0576 -0.0928 -2.4065 -0.0871
S-115	Multivariate analysis showed that patients with preserved LVEF had a similar risk of long-term mortality as patients with mild or moderate reduction in LVEF (hazard ratio [HR] 0.92 [p = 0.40] and 1.01 [p = 0.90], respectively) while severely reduced LVEF conferred increased increase rate compared with preserved LVEF (HR 1.20, p = 0.04).<unk>
T-115	multivariate_analysis patients preserved_lvef mortality patients lvef hazard_ratio lvef preserved_lvef
H-115	-1.4522786140441895	▁pres er ved _ ▁LV EF
D-115	-1.4522786140441895	preserved_ LVEF
P-115	-4.4321 -0.0459 -0.0855 -0.4971 -2.3926 -0.0591 -3.9873 -0.1186
S-242	In patients having HFpEF, predictors of primary outcome were male gender (odds ratio [OR] 3.45, p = 0.004), NYHA class III (OR 3.05, p = 0.008), distance covered on a 6-minute walk test (6-MWT) of <620 feet (OR 2.81, p = 0.013), and <80% adherence to prescribed medications (OR 2.61, p = 0.018).<unk>
T-242	patients hfpef primary_outcome odds_ratio nyha_class_iii 6-minute_walk_test 6-mwt feet prescribed medications
H-242	-1.1630914211273193	▁ HF p EF
D-242	-1.1630914211273193	HFpEF
P-242	-0.1709 -0.0319 -0.0580 -0.1260 -6.4383 -0.1535
S-492	Abstract Echo-derived pulmonary arterial systolic pressure (PASP) and right ventricular (RV) tricuspid annular plane systolic excursion (TAPSE; from the end of diastole to end-systole) are of basic relevance in the clinical follow-up of heart failure (HF) patients, carrying two- to threefold increase in cardiac risk when increased and reduced, respectively.<unk>
T-492	echo-derived_pulmonary_arterial_systolic_pressure pasp right_ventricular rv tricuspid_annular_plane_systolic_excursion tapse diastole end-systole clinical follow-up heart_failure hf patients cardiac
H-492	-0.5876298546791077	▁e cho - der i ved ▁pulmonar y _ ▁arterial _ ▁sy sto lic _ ▁pressure PAS p ▁right ▁vent ri cular ▁tri cus pid _ ▁ann ular _ ▁plane ▁sy sto lic _ excursion TA PS e ▁dia stol e ▁end - sy stol e
D-492	-0.5876298546791077	echo-derived pulmonary_ arterial_ systolic_ pressurePASp right ventricular tricuspid_ annular_ plane systolic_excursionTAPSe diastole end-systole
P-492	-2.3511 -0.0023 -0.0268 -0.1051 -0.0675 -0.1570 -0.0210 -0.0330 -2.2009 -0.3626 -0.6863 -1.2821 -0.0209 -0.0855 -0.6753 -0.1846 -2.0461 -1.4258 -1.7690 -0.7128 -0.2467 -0.0684 -1.7157 -0.0108 -0.0300 -0.5365 -0.4246 -0.0036 -0.0577 -1.1024 -0.1413 -0.0188 -0.0177 -1.1183 -0.0129 -3.5572 -0.3140 -0.6565 -0.4749 -0.0004 -0.0532 -2.2154 -0.0299 -0.0350 -0.0005 -0.0293 -1.0747 -0.0440
S-1190	The independent predictors of severe CAD included diabetes (odds ratio 5.1, p = 0.005), electrocardiographic Q waves or left bundle branch block (odds ratio 3.8, p = 0.02), and ≥2 nondiabetes risk factors: age (men ≥55 or women ≥65 years), dyslipidemia, hypertension, and tobacco use (odds ratio 4.8, p = 0.02).<unk>
T-1190	cad diabetes odds_ratio electrocardiographic_q_waves left_bundle_branch_block odds_ratio nondiabetes dyslipidemia hypertension odds_ratio
H-1190	-0.4653271734714508	▁severe ▁CAD ▁electro car dio graphic _ q ▁wa ves ▁left ▁bund le _ ▁bran ch ▁block ▁non dia bete s ▁dys li pide mia ▁hyper tension ▁to ba cco
D-1190	-0.4653271734714508	severe CAD electrocardiographic_q waves left bundle_ branch block nondiabetes dyslipidemia hypertension tobacco
P-1190	-2.5082 -1.4746 -0.7807 -0.0017 -0.0784 -0.0763 -0.5505 -1.3271 -0.5397 -0.2294 -0.2315 -0.5244 -0.1439 -0.2137 -0.2653 -0.0328 -0.2629 -1.6138 -0.0359 -0.0146 -0.0031 -2.0627 -0.0155 -0.0035 -0.1331 -0.0412 -0.0180 -0.0138 -0.0192 -0.0765 -1.5155 -0.0828
S-485	The area under the receiver operating characteristic curve (AUC) of E/e' ratios for PCWP estimation was 0.79 (95% confidence interval [CI] 0.70 to 0.87) for E/e'septal, 0.72 (95% CI 0.63 to 0.82) for E/elateral, and 0.79 (95% CI 0.70 to 0.87) for E/emean (all p values <0.0001).<unk>
T-485	area_under_the_receiver_operating_characteristic_curve auc pcwp confidence_interval septal p_values
H-485	-0.9684346318244934	▁receive r _ ▁operating ▁character istic _ cur ve ▁e / e _ ▁ratio s ▁pc WP
D-485	-0.9684346318244934	receiver_ operating characteristic_curve e/e_ ratios pcWP
P-485	-3.6959 -0.0086 -1.0302 -2.3282 -1.5466 -0.0264 -0.4059 -0.3812 -0.0205 -2.3633 -0.4755 -0.0387 -1.4213 -0.6852 -0.0248 -0.2710 -0.8686 -2.6477 -0.1608
S-680	Among trastuzumab-treated patients, older age (age > 80 years; HR, 1.53; 95% CI, 1.16 to 2.10), coronary artery disease (HR, 1.82; 95% CI, 1.34 to 2.48), hypertension (HR, 1.24; 95% CI, 1.02 to 1.50), and weekly trastuzumab administration (HR, 1.33; 95% CI, 1.05 to 1.68) increased the risk of CHF.<unk>
T-680	patients coronary_artery_disease hypertension trastuzumab administration chf
H-680	-0.998749852180481	▁tras tuz um ab - tre ated ▁patients ▁corona ry ▁arter y ▁disease ▁HR
D-680	-0.998749852180481	trastuzumab-treated patients coronary artery disease HR
P-680	-0.4931 -0.0220 -0.0207 -1.1172 -0.3814 -0.0319 -0.1749 -2.4044 -2.2161 -0.1870 -0.1470 -0.1327 -0.8306 -3.9260 -3.7965 -0.0984
S-754	In the LVEF >30% subgroup, there was a trend for improvement in the clinical composite response with CRT ON versus CRT OFF (P=0.06) and significant reductions in LV end systolic volume index (-6.7 ± 21.1 versus 2.1 ± 17.6 mL/m(2); P=0.01) and LV mass (-20.6 ± 50.5 versus 5.0 ± 42.4 g; P=0.04) after 12 months.<unk>
T-754	lvef clinical crt crt systolic_volume_index lv_mass
H-754	-0.8150248527526855	▁LV EF ▁clinic al _ com posit e _ ▁response ▁c RT _ on ▁c RT _ ▁OFF ▁LV
D-754	-0.8150248527526855	LVEF clinical_composite_ response cRT_on cRT_ OFF LV
P-754	-0.9576 -0.0705 -3.2340 -0.0055 -0.7066 -0.3562 -0.0034 -0.0042 -0.8641 -0.6213 -0.3262 -0.0358 -1.9767 -1.0649 -0.5475 -0.1386 -0.9393 -0.7242 -0.6835 -3.7952 -0.0602
S-1343	We show that intervention with TGF-β signaling by inhibiting TGF-β receptor type I or Smad 2/3 using small-molecule inhibitors improved c-Kit+ cell yield, attenuated epithelial to mesenchymal transition markers, stimulated the pluripotency marker Nanog, and improved efficiency of c-Kit+ cell differentiation toward cardiomyocyte-like cells in vitro.<unk>
T-1343	tgf-β_signaling tgf-β_receptor_type_i cell yield epithelial mesenchymal transition pluripotency_marker nanog cell cells in_vitro
H-1343	-0.3882710337638855	▁T GF - β ▁signal ing ▁T GF - β ▁receptor ▁type ▁s mad ▁small - mo le cule ▁inhibi tors ▁c - K it + ▁cell ▁yi eld ▁epi the li al ▁mes en chy mal _ ▁transition ▁marker s ▁pluri pote ncy ▁marker ▁na nog ▁c - K it + ▁cell ▁differenti ation ▁cardio my o cy te - like ▁cell s
D-1343	-0.3882710337638855	TGF-β signaling TGF-β receptor type smad small-molecule inhibitors c-Kit+ cell yield epithelial mesenchymal_ transition markers pluripotency marker nanog c-Kit+ cell differentiation cardiomyocyte-like cells
P-1343	-1.0206 -0.0050 -0.0660 -0.1064 -2.0460 -0.0481 -1.5452 -0.0285 -0.1122 -0.6224 -2.1618 -0.9354 -0.8342 -0.0093 -0.2021 -0.0084 -0.0659 -0.3816 -0.0256 -0.9119 -0.0780 -0.0052 -0.0441 -0.7270 -0.0079 -1.4767 -0.3672 -0.2287 -0.0001 -0.2304 -0.0110 -0.0506 -0.0164 -0.0194 -0.0649 -0.0690 -0.6969 -0.9395 -0.2316 -0.0315 -0.5571 -0.0198 -0.0317 -0.0048 -0.7968 -1.2894 -0.0027 -0.0571 -0.0111 -0.5693 -0.0139 -1.7581 -1.0078 -0.1231 -0.0448 -0.0182 -0.2194 -0.2244 -0.0620 -0.1056 -0.3334 -0.5847 -0.5556 -0.0090 -0.7614 -0.0320
S-243	In patients having HFrEF, the predictors were being on diuretics (OR 3.06, p = 0.001), having ≥3 co-morbidities (OR 2.11, p = 0.0001), distance covered on a 6-MWT of <620 feet (OR 1.94, p = 0.001), NYHA class III (OR 1.90, p = 0.001), and age >65 years (OR 1.63, p = 0.01).<unk>
T-243	patients hfref diuretics co-morbidities 6-mwt feet nyha_class_iii
H-243	-1.0353888273239136	▁H Fr EF ▁di ure tics ▁co - mor bid ities ▁NY HA
D-243	-1.0353888273239136	HFrEF diuretics co-morbidities NYHA
P-243	-1.6951 -0.2242 -0.2685 -2.1568 -3.0808 -0.3112 -1.9675 -0.0105 -0.0135 -0.0127 -0.2673 -2.7587 -0.1504 -2.5564 -0.0572
S-344	After the surgery, HF disappeared and postoperative echocardiography confirmed a normal sized LV with an end-diastolic volume index of 71 mL/m2, normal LV ejection fraction of 0.70, no MR and preserved mitral valve opening with a mitral valve area (MVA) of 1.8 cm2, and a mean pressure gradient of 4.4 mm Hg (Fig 1A).<unk>
T-344	surgery hf postoperative echocardiography end-diastolic_volume_index lv_ejection_fraction mitral_valve_opening mitral_valve_area mva
H-344	-0.6967757344245911	▁ HF ▁ HF ▁post operativ e ▁e cho card i ography ▁end - dia sto lic ▁volume ▁index ▁LV ▁e je ction ▁ fraction ▁MR ▁pres er ved ▁mit ral _ ▁val ve _ open ▁mit ral _ ▁val ve ▁m VA ▁pressure ▁gradi ent
D-344	-0.6967757344245911	HF HF postoperative echocardiography end-diastolic volume index LV ejection fraction MR preserved mitral_ valve_open mitral_ valve mVA pressure gradient
P-344	-0.4439 -0.0126 -2.8171 -0.1793 -3.8439 -0.3739 -0.0047 -0.8933 -0.0181 -0.0759 -0.1349 -0.0701 -5.5493 -0.0137 -0.0224 -0.0142 -0.0068 -0.5140 -0.0446 -1.6706 -0.4770 -0.0275 -0.0068 -1.5056 -0.0043 -0.0295 -0.7223 -0.0340 -0.0749 -0.1153 -0.0207 -0.8963 -0.4797 -0.0143 -2.9545 -1.1823 -0.1029 -0.0234 -0.5812 -0.4243 -0.0169 -4.5389 -0.5377 -0.8136 -0.1297 -0.0027 -0.9913 -0.0344
S-519	METHODS: Among the patients with systolic heart failure (ejection fraction ≤35%) randomized to either placebo or ivabradine in the SHIFT (Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial), 275 patients (n = 132, placebo; n = 143, ivabradine 7.5 mg twice a day) were included in the echocardiographic substudy.<unk>
T-519	patients systolic_heart_failure ejection_fraction randomized placebo ivabradine shift systolic_heart_failure_treatment_with_the_if_inhibitor_ivabradine_trial patients placebo ivabradine echocardiographic
H-519	-0.6306137442588806	▁sy sto lic _ heart ▁failure ▁i va bra dine ▁SHI ft ▁in hib itor ▁i va bra dine ▁tri al ▁i va bra dine
D-519	-0.6306137442588806	systolic_heart failure ivabradine SHIft inhibitor ivabradine trial ivabradine
P-519	-0.7242 -0.0135 -0.0282 -0.2202 -1.0395 -0.1623 -3.0598 -0.2020 -0.0726 -0.0343 -0.1475 -0.5563 -4.7384 -0.1268 -0.0078 -1.5087 -0.0452 -0.0445 -0.0236 -1.0541 -0.0322 -1.3159 -0.0464 -0.0697 -0.0159 -1.6931 -0.0439
S-499	Hazard ratios for variables retained in the multivariate regression were as follows: TAPSE/PASP </≥ 0.36 mm/mmHg [hazard ratio (HR): 10.4, P < 0.001]; TAPSE </≥ 16 mm (HR: 5.1, P < 0.01); New York Heart Association functional class </≥ 3 (HR: 4.4, P < 0.001); E/e' (HR: 4.1, P < 0.001).<unk>
T-499	hazard_ratios multivariate_regression tapse pasp hazard_ratio tapse new_york_heart_association_functional_class
H-499	-2.2159900665283203	▁t AP se _ pas p
D-499	-2.2159900665283203	tAPse_pasp
P-499	-4.8329 -1.2696 -1.4572 -2.7843 -0.3212 -0.4550 -6.4640 -0.1437
S-390	Renal function was estimated by The Chronic Kidney Disease Epidemiology Collaboration equation and patients grouped by estimated glomerular filtration rate (eGFR)-group I: ≥60 mL/min per 1.73 m(2), group II: 30 to 59 mL/min per 1.73 m(2), group III: 15 to 29 mL/min per 1.73 m(2), group IV: <15 mL/min per 1.73 m(2).<unk>
T-390	renal_function the_chronic_kidney_disease_epidemiology_collaboration patients estimated_glomerular_filtration_rate egfr
H-390	-0.7779493927955627	▁Chro nic _ ▁Kid ney ▁Disease ▁Epidemi ology ▁Col labora tion ▁e qu ation ▁glo mer ular _ ▁filtr ation ▁rate ▁e G FR
D-390	-0.7779493927955627	Chronic_ Kidney Disease Epidemiology Collaboration equation glomerular_ filtration rate eGFR
P-390	-2.0702 -0.5133 -0.5978 -0.4052 -0.0783 -0.2259 -0.0993 -0.3526 -4.4958 -0.0087 -0.0226 -2.2577 -0.0217 -0.0703 -0.5089 -0.2147 -0.0807 -0.4660 -2.1890 -0.0971 -2.0246 -0.4714 -0.5907 -0.4766 -1.6625 -0.2253
S-1968	Large-scale prospective randomized multicenter trial PARADIGM-HF with more than 8000 individuals with stabilized chronic heart failure with systolic dysfunction (LV EF 40%, later 35%), mostly in functional class NYHA II-III with elevated BNP/NT-pro BNP has shown 20% decrease in primary endpoint (cardiovascular death or hospitalization for heart failure) in a group treated by ARNI (LCZ696; sacubiltril - valsartan).<unk>
T-1968	prospective randomized paradigm-hf chronic_heart_failure systolic_dysfunction lv_ef functional_class nyha elevated bnp nt-pro_bnp primary_endpoint cardiovascular_death hospitalization heart_failure arni lcz696 sacubiltril valsartan
H-1968	-0.8411786556243896	▁para dig m - HF ▁stabil ized _ ▁chronic _ heart ▁failure ▁sy sto lic _ ▁dys function ▁functional ▁class ▁NY HA _ ▁II - III ▁b NP car dio vas cular _ ▁death ▁ar ni ▁sa cubi lt ril ▁val sar tan
D-1968	-0.8411786556243896	paradigm-HF stabilized_ chronic_heart failure systolic_ dysfunction functional class NYHA_ II-III bNPcardiovascular_ death arni sacubiltril valsartan
P-1968	-2.2358 -1.4190 -0.7401 -0.0454 -0.0974 -3.9027 -0.0452 -1.5512 -1.5208 -0.1746 -1.8825 -0.4522 -0.4363 -0.0077 -0.0798 -1.5730 -0.1430 -0.0062 -2.8155 -0.5442 -0.0380 -0.0351 -2.1153 -1.4913 -0.0325 -0.0056 -1.3714 -0.2060 -3.6830 -0.0227 -0.2185 -0.2097 -0.5956 -1.3899 -4.5446 -0.9859 -0.4275 -0.0057 -0.0064 -0.0209 -0.4792 -0.0201 -0.0137 -0.2185 -0.0431
S-1703	METHODS AND RESULTS: We assessed hyperkalemia and outcomes in African Americans (AAs; n=120) and non-AAs (n=1543; white 93%) with New York Heart Association (NYHA) class III or IV HF and left ventricular dysfunction who were randomized to spironolactone, titrated to 25 or 50 mg daily or placebo, in the Randomized Aldactone Evaluation Study (RALES).<unk>
T-1703	hyperkalemia outcomes african_americans aas new_york_heart_association nyha hf left_ventricular_dysfunction randomized spironolactone titrated placebo randomized_aldactone_evaluation_study rales
H-1703	-0.7745255827903748	▁hyper kal emia ▁African ▁American s ▁non - AA s ▁New ▁York _ ▁Heart ▁Association ▁IV _ HF ▁left _ ▁vent ri cular _ ▁dys function ▁spi rono lac tone
D-1703	-0.7745255827903748	hyperkalemia African Americans non-AAs New York_ Heart Association IV_HF left_ ventricular_ dysfunction spironolactone
P-1703	-1.9420 -0.0894 -0.0217 -2.3292 -1.5705 -0.2637 -0.3320 -0.0029 -0.0105 -0.0224 -2.8036 -0.1674 -1.2996 -1.0811 -0.1998 -2.5891 -0.4835 -1.5280 -0.7117 -0.4732 -0.5621 -0.8985 -0.5899 -1.7185 -0.3534 -0.0896 -0.0143 -0.0010 -0.0013 -0.0062 -2.5689 -0.0601
S-432	LV reverse remodeling (n=161; 48%) was associated with pre-CRT LV end-diastolic dimension index <3.1 cm/m(2), global longitudinal strain of left ventricle <-7%, left atrial area <26 cm(2), right ventricular end-diastolic area index <10.0 cm(2)/m(2), right atrial area <20 cm(2), and right ventricular fractional area change ≥35%.<unk>
T-432	lv_reverse_remodeling lv_end-diastolic_dimension longitudinal strain left_ventricle left_atrial_area right_ventricular_end-diastolic_area_index right_atrial right_ventricular_fractional_area change
H-432	-1.056349515914917	▁rever se _ ▁remodel ing ▁pre - C RT _ van _ de - c RT _ in _ dia sto lic _ dimension _ index ▁global _ ▁longitud in al _ ▁strain ▁left _ ▁vent ric le ▁left _ at rial _ ▁area ▁right _ ▁vent ri cular ▁ fraction al _ ▁area
D-432	-1.056349515914917	reverse_ remodeling pre-CRT_van_de-cRT_in_diastolic_dimension_index global_ longitudinal_ strain left_ ventricle left_atrial_ area right_ ventricular fractional_ area
P-432	-0.4715 -0.0046 -1.2036 -0.0743 -0.0071 -1.7055 -0.0032 -1.0463 -0.1225 -1.9003 -5.4807 -0.3499 -3.8886 -0.9815 -2.1804 -0.4492 -1.4370 -5.6835 -1.7592 -0.2031 -0.0735 -0.0079 -0.8863 -0.0653 -2.9638 -0.3913 -1.6479 -0.7995 -0.0911 -0.0107 -0.0289 -0.1101 -0.7773 -0.1450 -0.3136 -1.4874 -0.8079 -0.4221 -0.2943 -0.3328 -1.6281 -0.0083 -1.7073 -2.5744 -1.8983 -0.3622 -0.8083 -0.1468 -0.1886 -6.7631 -0.1285 -0.0063 -0.2000 -1.1648 -0.8631 -0.0986
S-1364	B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide – Diagnostic role in stable coronary artery disease B-type natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP) are released from ventricular cardiomyocytes in response to an increase in ventricular wall stress and to myocardial ischemia.<unk>
T-1364	b-type_natriuretic_peptide n-terminal_pro-b-type_natriuretic_peptide diagnostic stable coronary_artery_disease b-type_natriuretic_peptide bnp nt-probnp ventricular_cardiomyocytes ventricular wall_stress myocardial_ischemia
H-1364	-0.8331153392791748	▁b - type ▁na tri ure tic _ pe pti de ▁n - termin al _ pro - B - type ▁na tri ure tic _ pe pti de ▁stable ▁corona ry _ ▁arter y ▁disease ▁b - type ▁na tri ure tic _ pe pti de ▁b NP ▁n - termin al _ pro b NP ▁vent ri cular _ ▁cardio my o cy tes ▁vent ri cular _ ▁wall ▁stress ▁my o card ial _ ische mia
D-1364	-0.8331153392791748	b-type natriuretic_peptide n-terminal_pro-B-type natriuretic_peptide stable coronary_ artery disease b-type natriuretic_peptide bNP n-terminal_probNP ventricular_ cardiomyocytes ventricular_ wall stress myocardial_ischemia
P-1364	-2.9531 -0.3285 -0.0566 -0.2913 -0.0394 -0.4885 -2.1157 -1.4285 -0.6225 -0.0346 -0.0796 -3.5339 -0.0089 -0.0348 -0.0039 -1.6744 -1.5488 -0.0189 -1.0206 -0.0845 -0.0124 -0.4199 -0.0386 -0.5205 -2.2147 -0.6865 -1.0255 -0.0563 -0.0450 -4.9742 -1.1821 -0.3206 -2.0739 -0.3336 -0.2709 -1.0758 -1.5851 -0.7671 -0.0054 -0.1266 -0.0406 -0.3732 -2.5116 -0.7768 -1.9006 -0.0921 -0.1555 -1.8834 -0.3669 -2.1936 -0.0031 -0.0481 -0.0021 -0.7161 -1.8990 -1.6896 -0.9345 -0.0638 -0.5902 -1.7715 -0.2881 -4.6111 -0.1467 -0.1486 -0.0408 -0.0150 -0.0428 -0.9392 -0.8976 -0.2341 -3.4417 -0.6524 -0.9229 -0.0871 -0.2027 -0.4422 -1.3479 -0.4055 -0.2270 -0.1386 -0.1364
S-654	To determine the role of IRS1 and IRS2 in the heart and examine whether hyperinsulinemia causes myocardial insulin resistance and cellular dysfunction via IRS1 and IRS2, we generated heart-specific IRS1 and IRS2 gene double-knockout (H-DKO) mice and liver-specific IRS1 and IRS2 double-knockout (L-DKO) mice.<unk>
T-654	irs1 irs2 heart hyperinsulinemia myocardial_insulin_resistance cellular_dysfunction irs1 irs2 heart-specific_irs1_and_irs2_gene_double-knockout h-dko liver-specific_irs1_and_irs2_double-knockout l-dko
H-654	-0.9145665168762207	▁i RS 1 ▁i RS 2 ▁hyper insu line mia ▁my o card ial _ ▁insulin ▁resist ance ▁i RS 1 ▁i RS 2 ▁double - k no ckou t ▁l - d ko
D-654	-0.9145665168762207	iRS1 iRS2 hyperinsulinemia myocardial_ insulin resistance iRS1 iRS2 double-knockout l-dko
P-654	-0.9283 -0.0422 -2.8706 -1.4390 -0.1102 -0.3415 -3.0748 -0.0183 -0.0678 -2.2383 -1.9600 -0.1560 -0.2203 -0.0852 -1.2662 -0.0927 -0.6661 -0.0305 -0.8131 -0.0317 -2.3333 -1.0218 -0.1944 -0.3179 -4.7641 -0.0268 -0.5143 -0.0727 -0.0134 -0.0016 -3.4599 -0.0479 -1.5180 -0.6335 -1.4080 -0.1439
S-665	The unadjusted practice-level prescription rates ranged from 44% to 100% for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (median, 85%; interquartile range, 75%-89%), from 49% to 100% for β-blockers (median, 92%; interquartile range, 83%-95%), and from 37% to 100% for optimal combined treatment (median, 79%; interquartile range, 66%-85%).<unk>
T-665	prescription angiotensin-converting_enzyme_inhibitors angiotensin_receptor_blockers interquartile_range β-blockers interquartile_range interquartile_range
H-665	-0.6439955830574036	▁ang io ten sin - con ver ting _ ▁enzym e ▁inhibi tors _ angi oten sin ▁receptor ▁block ers ▁inter quart ile _ ▁range ▁β - block ers
D-665	-0.6439955830574036	angiotensin-converting_ enzyme inhibitors_angiotensin receptor blockers interquartile_ range β-blockers
P-665	-6.1587 -1.0740 -0.0796 -1.5556 -0.1946 -0.0127 -0.0107 -0.1558 -1.2028 -0.1220 -0.0255 -0.0342 -0.1493 -2.3418 -0.1628 -0.0141 -0.2025 -2.2013 -0.6413 -0.0332 -0.1778 -0.0026 -0.0029 -1.1267 -0.5182 -1.1752 -0.0116 -0.0174 -0.0481 -0.4159 -0.0951
S-1177	Therapy with ivabradine (β = 0.34, p = 0.04) and change with treatment in exertional increase in the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity (β = -0.30, p = 0.02) were independent correlates of increase in exercise capacity, and therapy with ivabradine (β = 0.32, p = 0.007) was independently correlated with increase in peak oxygen uptake.<unk>
T-1177	therapy ivabradine change peak_early_diastolic_mitral_flow_velocity peak_early_diastolic_mitral_annular_velocity correlates exercise_capacity therapy ivabradine correlated peak_oxygen_uptake
H-1177	-0.9368538856506348	▁i va bra dine ▁i va bra dine
D-1177	-0.9368538856506348	ivabradine ivabradine
P-1177	-0.0990 -0.0172 -0.0254 -0.0121 -4.4208 -0.1976 -0.0661 -0.0497 -4.2870 -0.1938
S-45	Data Synthesis: Low-strength evidence from 6 trials and 26 observational studies suggests that liberal transfusion protocols do not improve short-term mortality rates compared with less aggressive protocols (combined relative risk among trials, 0.94 [95% CI, 0.61 to 1.42]; I2 = 16.8%), although decreased mortality rates occurred in a small trial of patients with the acute coronary syndrome (1.8% vs. 13.0%; P = 0.032).<unk>
T-45	evidence transfusion mortality relative_risk mortality patients acute_coronary_syndrome
H-45	-1.0049611330032349	▁liberal _ trans fusion ▁protocol s
D-45	-1.0049611330032349	liberal_transfusion protocols
P-45	-1.3260 -0.8009 -0.4156 -0.1173 -1.1395 -0.0315 -4.1096 -0.0995
S-1419	The risk of death or unplanned readmission during the 6-month observation period was lower among patients who saw a familiar physician (43.6%; adjusted hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.83-0.91) or an unfamiliar physician (43.6%; adjusted HR 0.90, 95% CI 0.83-0.97) for early follow-up visits, as compared with patients who had no follow-up visits (62.9%).<unk>
T-1419	death readmission patients physician hazard_ratio confidence_interval physician follow-up patients follow-up
H-1419	-1.2922626733779907	▁risk _ of _ ▁death ▁un plan ned _ ▁read mission
D-1419	-1.2922626733779907	risk_of_ death unplanned_ readmission
P-1419	-1.6013 -2.6511 -3.5649 -0.3044 -2.1404 -1.1768 -0.0106 -0.0421 -0.0181 -1.4349 -0.4299 -3.3489 -0.0759
S-1409	METHODS AND RESULTS: In HEK (human embryonic kidney) 293 cells overexpressing both β1AR and S1PR1, we demonstrated that β1AR downregulation can occur after stimulation with sphingosine-1-phosphate (an S1PR1 agonist), whereas S1PR1 downregulation can be triggered by isoproterenol (a β-adrenergic receptor agonist) treatment.<unk>
T-1409	hek human_embryonic_kidney cells β1ar s1pr1 β1ar downregulation sphingosine-1-phosphate s1pr1_agonist s1pr1 downregulation isoproterenol β-adrenergic_receptor_agonist
H-1409	-1.433375358581543	▁h ek ▁ europe se _ em bry o nic _ ▁ki dne y ▁β 1 AR ▁s 1 PR 1 _ ▁down regul ation ▁sp hing os ine -1 - phos pha te ▁s 1 PR 1
D-1409	-1.433375358581543	hek europese_embryonic_ kidney β1AR s1PR1_ downregulation sphingosine-1-phosphate s1PR1
P-1409	-2.0959 -0.9573 -4.5888 -3.8917 -0.4645 -0.3074 -4.5788 -0.0259 -0.1085 -0.1588 -0.3978 -0.1435 -0.0769 -0.0391 -1.8360 -0.7357 -1.0147 -4.4611 -0.6605 -0.4688 -2.9184 -6.7439 -2.6052 -0.5298 -0.0369 -0.4814 -0.7458 -0.2608 -3.0854 -2.3336 -0.0885 -0.0028 -0.0038 -0.0274 -1.7754 -0.2865 -0.7532 -1.8896 -5.6727 -0.0824
S-1330	Assessment was performed at baseline and after completion of training protocol and included 6-minute walked distance, quality of life (Kansas City Cardiomyopathy Questionnaire and Minnesota Living with Heart Failure Questionnaire), depressive symptoms (Beck Depression Inventory and Zung self-rated depression scores), B-type natriuretic peptide, endothelial function (flow-mediated dilatation), and left ventricular diastolic function.<unk>
T-1330	baseline training 6-minute_walked_distance quality_of_life kansas_city_cardiomyopathy_questionnaire minnesota_living_with_heart_failure_questionnaire symptoms beck_depression_inventory zung_self-rated_depression_scores b-type_natriuretic_peptide endothelial_function flow-mediated_dilatation left_ventricular_diastolic_function
H-1330	-0.7625799179077148	▁kan sas ▁City ▁Card i om yo pathy ▁Question naire ▁Minnesota ▁ depressiv e _ ▁symptoms ▁be ck ▁de pression ▁in ven tory ▁z ung ▁na tri ure tic _ pe pti de ▁vent ri cular _ dia sto lic ▁function
D-1330	-0.7625799179077148	kansas City Cardiomyopathy Questionnaire Minnesota depressive_ symptoms beck depression inventory zung natriuretic_peptide ventricular_diastolic function
P-1330	-1.8649 -0.0006 -1.2512 -1.3163 -0.0485 -0.0159 -2.1680 -0.2289 -4.4922 -0.0049 -0.0046 -3.6799 -0.3702 -0.0069 -1.8677 -0.5262 -0.3011 -0.0109 -0.5674 -0.1283 -0.9417 -0.0428 -0.0020 -0.7553 -0.0670 -2.3950 -0.0039 -0.2498 -0.5026 -0.2624 -0.8628 -0.0072 -0.0471 -2.9872 -0.4193 -0.6455 -0.4496 -0.6950 -0.0230 -0.0137 -2.3280 -0.1740 -0.0613
S-976	Odds ratios with 95% confidence intervals for cardiovascular events after adjustment for age, gender, atrial fibrillation, left ventricular ejection fraction, diabetes mellitus, peripheral vascular disease, and history of myocardial infarction, heart failure, or stroke was 1.24 (1.06 to 1.45) in patients with an estimated glomerular filtration rate of 15 to 45 ml/min/1.73 m(2) but became nonsignificant after acute kidney injury was introduced into the statistical model.<unk>
T-976	odds_ratios confidence_intervals cardiovascular_events atrial_fibrillation left_ventricular_ejection_fraction diabetes_mellitus peripheral_vascular_disease myocardial_infarction heart_failure stroke patients estimated_glomerular_filtration_rate nonsignificant acute_kidney_injury
H-976	-0.46027547121047974	▁cardiovascular ▁events ▁at rial ▁fi bril lation ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁diabetes ▁mell itus ▁per i pher al _ ▁vas cular ▁disease ▁my o card ial ▁in far ction ▁heart ▁failure
D-976	-0.46027547121047974	cardiovascular events atrial fibrillation left ventricular ejection fraction diabetes mellitus peripheral_ vascular disease myocardial infarction heart failure
P-976	-5.1239 -2.2576 -1.6008 -0.0038 -0.4014 -0.0025 -0.0062 -0.0690 -0.3279 -0.3074 -0.5167 -0.4653 -0.0336 -0.0310 -0.7592 -0.0010 -0.0498 -0.0051 -0.0178 -0.2249 -0.0611 -0.0162 -0.0200 -0.1256 -0.8578 -0.0176 -0.8191 -0.2264 -0.0806 -0.1084 -0.0559 -0.8001 -0.0180 -0.0329 -0.3221 -0.0193 -1.6617 -0.0426
S-925	In conjunction, diastolic function improved (c=24.3 ± 5.3 to 22.7 ± 8.1 g/s; P=0.03; k=252 ± 115 to 170 ± 37 g/s(2); P=0.03), Ea decreased (2.0 ± 0.4 to 1.7 ± 0.4 mm Hg/mL; P=0.007), and ventricular-arterial coupling improved (Ees:Ea=1.5 ± 0.3 to 1.7 ± 0.4; P=0.04).<unk>
T-925	diastolic_function ea ventricular-arterial_coupling ees ea
H-925	-1.3663442134857178	▁dia sto lic _ ▁function ▁p =0 . 03
D-925	-1.3663442134857178	diastolic_ function p=0.03
P-925	-0.3584 -0.0784 -0.0815 -2.8229 -1.1873 -3.2329 -0.6105 -0.9549 -1.4798 -4.0762 -0.1470
S-1835	The hazard ratios from the disease risk score (DRS)-stratified analyses were 0.83 (95% CI, 0.70 to 0.99) for saxagliptin versus sitagliptin, 0.63 (CI, 0.47 to 0.85) for saxagliptin versus pioglitazone, 0.69 (CI, 0.54 to 0.87) for saxagliptin versus sulfonylureas, and 0.61 (CI, 0.50 to 0.73) for saxagliptin versus insulin.<unk>
T-1835	hazard_ratios disease_risk_score drs saxagliptin sitagliptin saxagliptin pioglitazone saxagliptin sulfonylureas saxagliptin insulin
H-1835	-1.541062355041504	▁disease ▁risk ▁score ▁d RS - stra t ified _ analyse s ▁sax ag lip tin ▁si tag lip tin ▁sax ag lip tin ▁pi og lita zone
D-1835	-1.541062355041504	disease risk score dRS-stratified_analyses saxagliptin sitagliptin saxagliptin pioglitazone
P-1835	-3.5204 -1.1262 -0.0606 -2.5734 -0.1114 -5.8938 -0.5004 -0.0171 -0.0226 -2.2794 -0.0269 -0.0327 -1.6096 -0.0199 -1.0097 -2.8724 -4.3764 -0.5132 -0.6228 -2.1850 -3.4082 -0.0226 -0.8824 -3.0204 -4.6424 -0.0355 -0.1229 -0.0156 -4.5739 -0.1342
S-106	Independent predictors for the development of IE among study patients included previous revascularization (coronary artery bypass surgery: hazard ratio [HR] 1.88, p = 0.003; percutaneous coronary intervention: HR 3.21, p <0.001) and increased systolic blood pressure (HR 1.67, p = 0.02), whereas a left bundle branch block pattern on the baseline electrocardiogram was associated with reduced risk for IE (HR 0.62, p = 0.02).<unk>
T-106	patients revascularization coronary_artery_bypass_surgery hazard_ratio percutaneous_coronary_intervention systolic_blood_pressure left_bundle_branch_block_pattern baseline electrocardiogram
H-106	-0.5234313607215881	▁re vas cular ization ▁co ron ary _ ▁arter y _ ▁by pass ▁surgery ▁hazard ▁ratio ▁per cuta ne ous _ ▁corona ry ▁intervention ▁sy sto lic _ ▁blood ▁pressure
D-106	-0.5234313607215881	revascularization coronary_ artery_ bypass surgery hazard ratio percutaneous_ coronary intervention systolic_ blood pressure
P-106	-4.8152 -0.0291 -0.1002 -0.3716 -1.3269 -0.0222 -0.0822 -0.7380 -0.5730 -0.0465 -0.9589 -1.0633 -0.0435 -0.1822 -0.2895 -0.0034 -0.2820 -0.0004 -0.0205 -0.1348 -0.1281 -0.2300 -0.1428 -0.7352 -0.7371 -0.0021 -0.0167 -0.0985 -0.1490 -0.7419 -2.5978 -0.0873
S-1262	Compared with biomedical treatment alone, biomedical treatment plus CHM showed significant improvement in effective rate (relative risk, 1.26; 95% confidence interval [CI], 1.19-1.34), left ventricular ejection fraction (%) (mean difference, 5.88; 95% CI, 3.92-7.85), left ventricular diastolic end diameter (mm) (mean difference, -2.78; 95% CI, -5.15 to -0.42), and other outcome measures.<unk>
T-1262	biomedical biomedical relative_risk confidence_interval left_ventricular_ejection_fraction left_ventricular_diastolic_end_diameter outcome
H-1262	-1.1247628927230835	▁bio medic al ▁treatment ▁bio medic al _ ▁treatment ▁CH m ▁left ▁vent ri cular _ e je ction ▁ fraction ▁left ▁vent ri cular _ dia sto lic _ ▁end ▁diameter
D-1262	-1.1247628927230835	biomedical treatment biomedical_ treatment CHm left ventricular_ejection fraction left ventricular_diastolic_ end diameter
P-1262	-0.0018 -0.0210 -0.0045 -3.6131 -3.1213 -0.0643 -0.0048 -3.8622 -1.2299 -3.3337 -0.7169 -4.1345 -0.5210 -0.3246 -0.6345 -0.6267 -1.8137 -0.1877 -0.0353 -1.3861 -0.0150 -4.5065 -1.7032 -0.5829 -0.2804 -0.5746 -1.2933 -0.0051 -0.0140 -0.2487 -1.5106 -0.8421 -0.9250 -0.1031
S-1114	METHODS: In this prospective, randomized, open-label crossover study with masked outcome assessments, stable heart failure patients (left ventricular ejection fraction < 40%) homozygous for the Arg16/Gln27 (n = 13) or Gly16/Glu27 haplotype (n = 8) of the β2-receptor were randomized to equipotent dosages of carvedilol or metoprolol for two 6-wk periods.<unk>
T-1114	prospective randomized crossover_study outcome stable_heart_failure patients left_ventricular_ejection_fraction homozygous haplotype β2-receptor randomized carvedilol metoprolol
H-1114	-0.7295646071434021	▁open - label _ cross over _ studie s ▁stable _ heart ▁failure ▁patients ▁ar g 16 ▁g l n 27 ▁g ly 16 / G lu 27 ▁β 2- recept or ▁car vedi lol ▁met o pro lol
D-1114	-0.7295646071434021	open-label_crossover_studies stable_heart failure patients arg16 gln27 gly16/Glu27 β2-receptor carvedilol metoprolol
P-1114	-2.1594 -0.0669 -0.0204 -1.2171 -1.6615 -0.0292 -1.8857 -0.9059 -2.6960 -2.5744 -0.3380 -1.2151 -0.8208 -1.5482 -3.2047 -0.0347 -0.2605 -0.9956 -0.6833 -0.0125 -0.3924 -0.2674 -0.4298 -0.0692 -1.6242 -1.8474 -0.2954 -0.3409 -1.3540 -0.0298 -0.0044 -0.0135 -0.3362 -0.0064 -0.0401 -0.1533 -0.0632 -0.0135 -0.0896 -0.1780 -0.0335
S-465	Of patients treated and released, low-volume ED cases exhibited higher risk of death/hospitalization/ED visit in the subsequent 7 (22.0%) and 30 days (44.9%) than medium (16.3%; aOR, 0.81 [95% CI, 0.73–0.90], and 35.3%; aOR, 0.79 [95% CI, 0.73–0.86]) or high-volume ED cases (13.0%; aOR, 0.69 [95% CI, 0.61–0.78], and 30.2%; aOR, 0.67 [95% CI, 0.61–0.74]).<unk>
T-465	patients death hospitalization aor aor aor aor
H-465	-1.5926506519317627	▁low - volu me _ ED
D-465	-1.5926506519317627	low-volume_ED
P-465	-1.6326 -0.0250 -0.0362 -0.0350 -0.5353 -4.8636 -5.4393 -0.1742
S-1625	RESULTS: At 2 years, participants offered the Health Buddy Program had 15% lower risk-adjusted all-cause mortality (hazard ratio (HR) = 0.85, 95% confidence interval (CI) = 0.74-0.98; P = .03) and had reductions in the number of quarterly inpatient admissions from baseline to the study period that were 18% greater than those of matched controls during this same time period (-0.035 vs -0.003; difference-in-differences = -0.032, 95% CI = -0.054 to -0.010, P = .005).<unk>
T-1625	health_buddy_program all-cause_mortality hazard_ratio confidence_interval inpatient admissions baseline
H-1625	-0.9756976962089539	▁risk - ad just ed _ aan - ca use _ ▁mortal ity haz ard ▁ratio ▁ci
D-1625	-0.9756976962089539	risk-adjusted_aan-cause_ mortalityhazard ratio ci
P-1625	-5.7467 -0.0413 -0.0041 -0.0060 -0.0321 -0.3068 -3.3797 -0.4041 -0.0106 -0.3042 -0.1713 -0.6530 -0.6028 -2.2907 -0.0026 -0.3684 -2.3490 -1.8174 -0.0475
S-691	Multivariable-adjusted hazard ratios were 1 (reference), 1.05 (95% CI, 0.89-1.24), 0.97 (95% CI, 0.81-1.17), and 0.85 (95% CI, 0.70-1.02) across quartiles of the Mediterranean diet score (P trend=0.08) and 1 (reference), 1.04 (95% CI, 0.89-1.21), 0.83 (95% CI, 0.70-0.98), and 0.84 (95% CI, 0.70-1.00) across quartiles of the DASH diet score (P trend=0.01).<unk>
T-691	multivariable-adjusted_hazard_ratios dash
H-691	-0.95595782995224	▁multi vari able - ad just ed _ ▁hazard ▁ratio s ▁ci
D-691	-0.95595782995224	multivariable-adjusted_ hazard ratios ci
P-691	-1.6002 -0.0293 -0.0469 -0.6188 -0.0062 -0.0174 -0.1307 -0.2445 -2.0975 -0.2060 -0.0972 -4.4956 -3.5759 -0.2172
S-287	METHODS: Using sex-specific models, we added cTnT and NT-proBNP to age and race ("laboratory report" model) and to the ARIC HF model (includes age, race, systolic blood pressure, antihypertensive medication use, current/former smoking, diabetes, body mass index, prevalent coronary heart disease, and heart rate) in 9868 participants without prevalent HF; area under the receiver operating characteristic curve (AUC), integrated discrimination improvement, net reclassification improvement (NRI), and model fit were described.<unk>
T-287	ctnt nt-probnp report aric hf systolic_blood_pressure antihypertensive_medication diabetes body_mass_index coronary_heart_disease heart_rate hf area_under_the_receiver_operating_characteristic_curve auc integrated_discrimination_improvement net_reclassification_improvement nri
H-287	-0.6652264595031738	▁c t n t ▁NT - pro b NP ▁ labora tory ▁report ▁a RIC _ HF ▁sy sto lic _ ▁blood ▁pressure ▁anti hy per tensi ve _ ▁medication ▁diabetes ▁corona ry _ heart ▁disease
D-287	-0.6652264595031738	ctnt NT-probNP laboratory report aRIC_HF systolic_ blood pressure antihypertensive_ medication diabetes coronary_heart disease
P-287	-0.0835 -0.2468 -0.1051 -0.4115 -0.6182 -0.0076 -0.0151 -0.2262 -0.0761 -3.2606 -2.2971 -0.0033 -0.8977 -0.5179 -0.1240 -0.5250 -1.3899 -2.0572 -0.0067 -0.0170 -0.2803 -0.0833 -0.1936 -0.0111 -0.3259 -0.0395 -0.1035 -0.0240 -1.3078 -0.1843 -3.9501 -1.6927 -0.0691 -0.1025 -0.8833 -0.9290 -2.1839 -0.0284
S-1222	OBJECTIVES: The study sought to investigate the safety and efficacy of eplerenone in patients at high risk for hyperkalemia or worsening renal function (WRF) in EMPHASIS-HF, a trial that enrolled patients at least 55 years old with heart failure and reduced ejection fraction (HF-REF), in New York Heart Association (NYHA) functional class II and with an estimated glomerular filtration rate (eGFR) >30 ml/min/1.73 m(2) and serum potassium <5.0 mmol/l.<unk>
T-1222	eplerenone patients hyperkalemia renal_function emphasis-hf patients heart_failure_and_reduced_ejection_fraction hf-ref new_york_heart_association nyha functional_class estimated_glomerular_filtration_rate egfr serum_potassium
H-1222	-0.73451828956604	▁e pler en one ▁hyper kal emia ▁w RF ▁EM PHA SIS - HF ▁heart ▁failure ▁reduce d _ e je ction ▁ fraction ▁NY HA ▁glo mer ular _ ▁filtr ation ▁rate ▁e G FR ▁se rum _ po tas s ium
D-1222	-0.73451828956604	eplerenone hyperkalemia wRF EMPHASIS-HF heart failure reduced_ejection fraction NYHA glomerular_ filtration rate eGFR serum_potassium
P-1222	-0.2308 -0.0506 -0.1048 -0.3747 -1.1547 -0.1505 -0.0029 -1.8055 -0.0941 -3.7540 -0.0339 -0.4624 -0.0105 -0.0336 -3.2458 -1.5754 -3.6513 -0.0081 -0.3055 -1.0804 -0.2897 -0.0143 -1.3164 -0.0306 -4.1630 -0.1991 -0.3917 -0.0769 -0.0264 -0.1950 -1.2134 -0.0499 -1.0950 -0.5342 -0.7954 -0.1756 -0.3946 -0.1513 -1.0868 -0.6217 -0.3990 -1.2117 -0.0594 -0.3866 -0.0461
S-81	Similarly, low-dose nesiritide had no significant effect on 72-hour cumulative urine volume (nesiritide, 8574 mL; 95% CI, 8014-9134 vs placebo, 8296 mL; 95% CI, 7762-8830; difference, 279 mL; 95% CI, -618 to 1176 mL; P = .49) or on the change in cystatin C level (nesiritide, 0.07 mg/L; 95% CI, 0.01-0.13 vs placebo, 0.11 mg/L; 95% CI, 0.06-0.16; difference, -0.04; 95% CI, -0.13 to 0.05; P = .36).<unk>
T-81	nesiritide nesiritide placebo change cystatin_c nesiritide placebo
H-81	-2.381122589111328	▁low - - dos e ▁nesi riti de ▁cum ul ative _ ▁urin e ▁volume
D-81	-2.381122589111328	low--dose nesiritide cumulative_ urine volume
P-81	-5.2817 -0.0750 -5.1811 -3.2394 -0.5644 -6.1250 -0.0071 -0.0842 -8.2633 -0.0280 -0.0143 -0.7755 -3.1042 -0.2317 -0.1219 -7.2086 -0.1737
S-572	RESULTS: Compared with standard care, Nordic walking led to higher functional capacity (Δ 125.6 ± 59.4 m vs Δ 57.0 ± 71.3 m travelled during 6MWT; P = 0.001), greater self-reported physical activity (Δ 158.5 ± 118.5 minutes vs Δ 155.5 ± 125.6 minutes; P = 0.049), increased right grip strength (Δ 2.3 ± 3.5 kg vs Δ 0.3 ± 3.1 kg; P = 0.026), and fewer depressive symptoms (Hospital Anxiety and Depression Scale score = Δ -1.7 ± 2.4 vs Δ -0.8 ± 3.1; P = 0.014).<unk>
T-572	walking functional_capacity 6mwt physical activity symptoms hospital_anxiety_and_depression_scale
H-572	-2.5832369327545166	▁Nordic _ ▁walking ▁functional _ ▁capacity ▁kw t
D-572	-2.5832369327545166	Nordic_ walking functional_ capacity kwt
P-572	-3.1642 -1.1640 -2.6252 -4.7138 -3.0667 -0.4114 -6.6164 -0.0908 -3.8791 -0.1009
S-1225	METHODS: This was a pre-specified analysis of subgroups of patients at high risk of hyperkalemia or WRF (patients ≥ 75 years of age, with diabetes, with eGFR <60 ml/min/1.73 m(2), and with systolic blood pressure < median of 123 mm Hg), examining the major safety measures (potassium >5.5, >6.0, and <3.5 mmol/l; hyperkalemia leading to study-drug discontinuation or hospitalization; and hospitalization for WRF) as well as the primary outcome (hospitalization for HF or cardiovascular mortality).<unk>
T-1225	patients hyperkalemia patients diabetes egfr systolic_blood_pressure potassium hyperkalemia leading hospitalization hospitalization primary_outcome hospitalization hf cardiovascular_mortality
H-1225	-0.5743923187255859	▁hyper kal emia ▁w RF ▁diabetes ▁e G FR ▁sy sto lic _ ▁blood ▁pressure
D-1225	-0.5743923187255859	hyperkalemia wRF diabetes eGFR systolic_ blood pressure
P-1225	-2.7526 -0.2056 -0.0286 -0.4438 -0.5495 -0.4785 -0.1286 -1.1384 -0.2158 -0.0396 -0.0084 -0.0904 -0.3528 -0.2936 -0.5309 -2.4738 -0.0338
S-1268	The PAF, its key biosynthetic enzymes (lyso-PAF acetyltransferase [lyso-PAF-AT] and dithiothreitol [DTT]-insensitive CDP choline: 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase [PAF-CPT]), and its catabolic isoenzymes (PAF-acetylhydrolase [PAF-AH] and lipoprotein-associated phospholipase A2 [Lp-PLA2]) were measured in serum and leukocytes of participants.<unk>
T-1268	paf biosynthetic_enzymes lyso-paf_acetyltransferase lyso-paf-at 1-alkyl-2-acetyl-sn-glycerol_cholinephosphotransferase paf-cpt catabolic_isoenzymes paf-acetylhydrolase paf-ah lipoprotein-associated_phospholipase_a2 lp-pla2 leukocytes
H-1268	-0.8881260752677917	▁PA f ▁bio syn the tic ▁enzym es lys o - pa f ▁a ce tyl transfer ase lys o - pa f - AT ▁di thi oth rei tol ▁d TT - in sensitiv e ▁CD p _ cho line ▁1- al kyl -2 - ace tyl - s n - gly cer ol - s n - gly cer ol ▁cho line phos pho transfer ase ▁p f - c pt ▁lipo prote in - as soci ated _ phos pho lipa se ▁l p - PLA 2]
D-1268	-0.8881260752677917	PAf biosynthetic enzymeslyso-paf acetyltransferaselyso-paf-AT dithiothreitol dTT-insensitive CDp_choline 1-alkyl-2-acetyl-sn-glycerol-sn-glycerol cholinephosphotransferase pf-cpt lipoprotein-associated_phospholipase lp-PLA2]
P-1268	-2.4172 -2.9379 -0.7240 -0.0050 -0.6553 -0.9876 -0.3924 -0.1677 -1.2297 -0.0861 -0.1054 -0.7656 -1.9660 -0.5477 -1.8798 -0.5732 -0.0345 -1.6613 -3.1147 -0.0215 -0.0357 -0.2501 -1.4236 -1.1103 -0.8974 -0.1143 -0.1322 -0.5801 -0.0419 -0.0825 -2.8810 -0.8933 -3.4475 -0.0423 -0.0008 -0.0080 -0.7889 -0.8407 -5.6571 -4.5882 -0.0256 -5.5548 -0.0214 -0.0278 -0.3197 -0.1804 -0.6609 -0.0438 -0.0583 -0.4270 -0.0344 -0.1646 -0.3421 -0.0479 -0.3418 -5.2921 -2.7287 -0.0166 -0.0644 -0.5742 -0.0243 -0.2302 -3.2057 -0.0867 -2.3259 -0.3717 -0.6150 -1.0582 -1.2578 -1.4040 -0.0509 -0.8381 -1.1149 -0.9656 -0.8367 -0.1068 -0.1199 -0.0157 -0.0004 -0.2016 -0.5608 -0.2637 -0.1927 -0.2595 -0.7323 -1.8105 -0.0092 -0.0526 -0.0221 -1.2914 -0.5935 -0.0743
S-1175	RESULTS: The ivabradine group demonstrated significant improvement between baseline and follow-up exercise capacity (4.2 ± 1.8 METs vs. 5.7 ± 1.9 METs, p = 0.001) and peak oxygen uptake (14.0 ± 6.1 ml/min/kg vs. 17.0 ± 3.3 ml/min/kg, p = 0.001), with simultaneous reduction in exercise-induced increase in the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity (3.1 ± 2.7 vs. 1.3 ± 2.0, p = 0.004).<unk>
T-1175	ivabradine baseline follow-up exercise_capacity mets mets peak_oxygen_uptake peak_early_diastolic_mitral_flow_velocity peak_early_diastolic_mitral_annular_velocity
H-1175	-0.9865928888320923	▁i va bra dine ▁i va bra dine _ groep ▁follow - up _ ▁exercise _ capaci
D-1175	-0.9865928888320923	ivabradine ivabradine_groep follow-up_ exercise_capaci
P-1175	-0.0095 -0.0388 -0.0291 -0.0074 -4.2040 -0.0486 -0.0393 -0.0090 -2.4719 -0.9660 -2.6871 -0.0139 -0.0018 -0.6966 -1.7195 -1.9393 -0.6919 -3.0861 -0.0854
S-1455	Multivariate analysis revealed that the odds of CHF was higher in females [Odds Ratio (OR) = 2·9, P < 0·01], individuals with pre-HCT chest radiation (OR = 4·7, P = 0·05), hypertension (OR = 2·9, P = 0·01), and with variants of genes coding for the NAD(P)H-oxidase subunit RAC2 (rs13058338, 7508T→A; OR = 2·8, P < 0·01), HFE (rs1799945, 63C→G; OR = 2·5, P = 0·05) or the doxorubicin efflux transporter ABCC2 (rs8187710, 1515G→A; OR = 4·3, P < 0·01).<unk>
T-1455	multivariate_analysis chf odds_ratio chest hypertension genes rac2 doxorubicin_efflux_transporter abcc2
H-1455	-1.4067516326904297	▁ nc _ h - oxid e _ ▁sub un it _ RAC 2 ▁do xor ubi cin _ eff lux _ ▁transporter
D-1455	-1.4067516326904297	nc_h-oxide_ subunit_RAC2 doxorubicin_efflux_ transporter
P-1455	-3.5680 -3.9898 -2.4716 -1.7261 -0.2704 -0.0673 -3.8187 -2.6161 -1.4436 -0.2013 -0.0374 -2.2839 -0.8727 -1.6425 -3.1615 -0.0459 -0.0036 -0.0598 -0.7767 -0.1622 -0.1166 -1.8860 -0.2268 -3.6076 -0.1127
S-1958	From baseline to 3 month follow-up, we recorded improvements in NYHA classification (from class III to class II in seven [78%] of nine patients, from class III to class I in one [11%] patient, and no change in one [11%] patient; p=0·0004); quality of life, as assessed by the Duke Activity Status Index (from a mean score of 13 [SD 6·2] to 24·8 [12·9]; p=0·016) and the Kansas City Cardiomyopathy Questionnaire (from a mean score of 44·3 [SD 9·8] to 79·1 [13·0]; p=0·0001); and 6 min walk test distance (from a mean of 244 m [SD 112] to 318 m [134]; p=0·016).<unk>
T-1958	baseline follow-up nyha_classification patients patient change patient quality_of_life duke_activity_status_index kansas_city_cardiomyopathy_questionnaire 6_min_walk_test
H-1958	-1.47701895236969	▁NY HA ▁classifica tion
D-1958	-1.47701895236969	NYHA classification
P-1958	-3.2955 -0.2200 -1.2919 -0.0560 -3.9320 -0.0667
S-80	RESULTS: Compared with placebo, low-dose dopamine had no significant effect on 72-hour cumulative urine volume (dopamine, 8524 mL; 95% CI, 7917-9131 vs placebo, 8296 mL; 95% CI, 7762-8830 ; difference, 229 mL; 95% CI, -714 to 1171 mL; P = .59) or on the change in cystatin C level (dopamine, 0.12 mg/L; 95% CI, 0.06-0.18 vs placebo, 0.11 mg/L; 95% CI, 0.06-0.16; difference, 0.01; 95% CI, -0.08 to 0.10; P = .72).<unk>
T-80	placebo dopamine dopamine placebo change cystatin_c dopamine placebo
H-80	-1.8875062465667725	▁low - - dos e _ ▁dop amine ▁cum ul ative _ ▁urin e ▁volume ▁dop amine
D-80	-1.8875062465667725	low--dose_ dopamine cumulative_ urine volume dopamine
P-80	-3.4700 -0.0371 -4.1641 -1.8510 -0.2958 -2.6006 -3.2551 -0.0615 -7.8577 -0.0311 -0.0154 -0.3424 -2.8890 -0.2686 -0.0824 -3.7088 -0.0088 -4.7948 -0.1285
S-66	High confidence in estimates was found for age (hazard ratio [HR], 1.45 for 10-year increase; 95% confidence interval [CI], 1.35-1.56), baseline glomerular filtration rate (HR, 1.25 for 15-mL/min decrease; 95% CI, 1.15-1.35), chronic obstructive pulmonary disease (HR, 1.54; 95% CI, 1.38-1.71), diabetes (HR, 1.56; 95% CI, 1.37-1.79), peripheral vascular disease (HR, 1.43; 95% CI, 1.2-1.72), left ventricular ejection fraction (HR, 0.77 for 10% increase; 95% CI, 0.73-0.83), and appropriate or inappropriate ICD shocks (HR, 2.34; 95% CI 1.59-3.44) New York Heart Association class, atrial fibrillation, and congestive HF were strongly associated with mortality but the confidence in estimates was low.<unk>
T-66	hazard_ratio confidence_interval baseline glomerular_filtration_rate chronic_obstructive_pulmonary_disease diabetes peripheral_vascular_disease left_ventricular_ejection_fraction icd_shocks new_york_heart_association_class atrial_fibrillation congestive_hf mortality
H-66	-1.518506646156311	▁ haz ard _ ▁ratio _ HR ▁confidence ▁interval _ CI ▁base line _ ▁glo mer ular _ ▁filtr ation _ ▁rate
D-66	-1.518506646156311	hazard_ ratio_HR confidence interval_CI baseline_ glomerular_ filtration_ rate
P-66	-4.2117 -1.8970 -0.0013 -2.2632 -0.0240 -3.9098 -2.9733 -3.9235 -0.0312 -2.4425 -1.6076 -1.8004 -0.0177 -0.4612 -0.2425 -0.0723 -0.0197 -0.2289 -1.0314 -0.0486 -3.2012 -0.1964 -5.7578 -0.0810
S-1761	At multivariable analysis, the following variables were significantly associated with primary study end point: peak oxygen uptake (% pred; P<0.001; hazard ratio [HR]=0.977; confidence interval [CI]=0.97-0.98), ventilatory efficiency slope (P=0.01; HR=1.02; CI=1.01-1.03), hemoglobin (P<0.05; HR=0.931; CI=0.87-1.00), left ventricular ejection fraction (P<0.001; HR=0.948; CI=0.94-0.96), renal function (modification of diet in renal disease; P<0.001; HR=0.990; CI=0.98-0.99), sodium (P<0.05; HR=0.967; CI=0.94-0.99), and AT nonidentification (P<0.05; HR=1.41; CI=1.06-1.89).<unk>
T-1761	multivariable_analysis end_point peak_oxygen_uptake hazard_ratio confidence_interval ventilatory_efficiency_slope hemoglobin left_ventricular_ejection_fraction renal_function renal_disease sodium
H-1761	-1.1391980648040771	▁pe ak _ ▁oxygen _ up take ▁hazard ▁ratio ▁confidence ▁interval ▁ci s ▁ventilator y _ ▁efficiency ▁s lope ▁left _ ▁vent ri cular _ ▁e je ction ▁ fraction ▁so dium
D-1761	-1.1391980648040771	peak_ oxygen_uptake hazard ratio confidence interval cis ventilatory_ efficiency slope left_ ventricular_ ejection fraction sodium
P-1761	-3.2202 -0.0047 -0.3848 -1.1801 -1.5740 -0.2545 -0.2000 -0.3122 -0.0218 -5.2800 -0.0398 -1.4582 -4.2441 -3.1804 -0.0396 -0.9479 -0.6332 -0.4271 -0.0118 -2.9541 -1.0229 -0.1597 -0.2952 -0.6262 -0.5598 -1.4302 -0.0369 -0.0246 -1.1288 -0.0250 -2.0050 -0.9664 -3.9786 -0.1050
S-1331	RESULTS: A significant improvement in 6-minute walked distance (F = 21.61, P = .001), Kansas City Cardiomyopathy Questionnaire summary (F = 8.68, P = .006), Minnesota Living with Heart Failure Questionnaire (F = 6.43, P = .017), Beck Depression Inventory (F = 6.66, P = .015), Zung (F = 6.25, P = .019), and flow-mediated dilatation diameter (F = 11.98, P = .002) was observed in the FES group compared with placebo group; B-type natriuretic peptide also declined but not significantly (F = 0.249, P = .622), and there was a tendency toward lower mitral E/e' wave ratio (F = 3.066, P = .091).<unk>
T-1331	6-minute_walked_distance kansas_city_cardiomyopathy_questionnaire minnesota_living_with_heart_failure_questionnaire beck_depression_inventory flow-mediated_dilatation fes placebo b-type_natriuretic_peptide mitral
H-1331	-0.9869692325592041	▁Kansas ▁City _ car i om yo pathy _ ▁Question naire ▁p ▁= ▁ . 006 ▁Minnesota _ ▁Living _ ▁Heart ▁Fail ure _ ▁Question naire ▁Beck _ de pression _ in ven tory ▁z ung ▁flow - media ted _ di la tation ▁diameter
D-1331	-0.9869692325592041	Kansas City_cariomyopathy_ Questionnaire p = .006 Minnesota_ Living_ Heart Failure_ Questionnaire Beck_depression_inventory zung flow-mediated_dilatation diameter
P-1331	-2.1963 -1.1398 -0.8592 -2.9580 -0.1500 -0.0162 -1.1593 -0.1867 -3.5869 -3.1590 -0.0005 -3.6482 -1.6065 -0.4926 -0.1633 -1.6013 -1.7217 -1.6148 -2.4410 -0.1371 -1.6768 -0.2993 -0.7789 -1.3948 -0.1431 -0.0009 -1.5239 -1.1522 -0.4482 -0.5238 -0.7745 -0.3091 -0.1030 -0.0152 -0.4589 -0.3198 -2.6034 -0.0314 -0.1718 -0.1244 -0.0258 -1.1524 -0.0588 -0.0047 -0.5501 -2.8384 -0.0658
2021-01-17 14:25:36 | INFO | fairseq_cli.generate | NOTE: hypothesis and token scores are output in base 2
2021-01-17 14:25:36 | INFO | fairseq_cli.generate | Translated 2,024 sentences (30,100 tokens) in 224.6s (9.01 sentences/s, 134.00 tokens/s)
2021-01-17 14:25:36 | WARNING | fairseq_cli.generate | If you are using BPE on the target side, the BLEU score is computed on BPE tokens, not on proper words.  Use --sacrebleu for standard 13a BLEU tokenization
Generate test with beam=5: BLEU4 = 20.42, 52.6/31.3/22.2/15.4 (BP=0.746, ratio=0.773, syslen=30100, reflen=38932)
